U.S. patent application number 16/914034 was filed with the patent office on 2021-03-18 for therapeutic compounds.
The applicant listed for this patent is Gilead Sciences, Inc.. Invention is credited to Zhenhong R. Cai, Hongyan Guo, Mingzhe Ji, Haolun Jin, Amy Lee, Ryan McFadden, Michael L. Mitchell, Manuel Munoz, Hyung-Jung Pyun, Lianhong Xu, Hong Yang.
Application Number | 20210078991 16/914034 |
Document ID | / |
Family ID | 1000005251312 |
Filed Date | 2021-03-18 |
![](/patent/app/20210078991/US20210078991A1-20210318-C00001.png)
![](/patent/app/20210078991/US20210078991A1-20210318-C00002.png)
![](/patent/app/20210078991/US20210078991A1-20210318-C00003.png)
![](/patent/app/20210078991/US20210078991A1-20210318-C00004.png)
![](/patent/app/20210078991/US20210078991A1-20210318-C00005.png)
![](/patent/app/20210078991/US20210078991A1-20210318-C00006.png)
![](/patent/app/20210078991/US20210078991A1-20210318-C00007.png)
![](/patent/app/20210078991/US20210078991A1-20210318-C00008.png)
![](/patent/app/20210078991/US20210078991A1-20210318-C00009.png)
![](/patent/app/20210078991/US20210078991A1-20210318-C00010.png)
![](/patent/app/20210078991/US20210078991A1-20210318-C00011.png)
View All Diagrams
United States Patent
Application |
20210078991 |
Kind Code |
A1 |
Cai; Zhenhong R. ; et
al. |
March 18, 2021 |
THERAPEUTIC COMPOUNDS
Abstract
Compounds disclosed herein including compounds of Formula I:
##STR00001## and salts thereof are provided. Pharmaceutical
compositions comprising compounds disclosed herein, processes for
preparing compounds disclosed herein, intermediates useful for
preparing compounds disclosed herein and therapeutic methods for
treating an HIV infection using compounds disclosed herein are also
provided.
Inventors: |
Cai; Zhenhong R.; (Palo
Alto, CA) ; Guo; Hongyan; (San Mateo, CA) ;
Ji; Mingzhe; (Union City, CA) ; Jin; Haolun;
(Foster City, CA) ; Lee; Amy; (Palo Alto, CA)
; McFadden; Ryan; (Foster City, CA) ; Mitchell;
Michael L.; (Castro Valley, CA) ; Munoz; Manuel;
(Vallejo, CA) ; Pyun; Hyung-Jung; (Fremont,
CA) ; Xu; Lianhong; (Palo Alto, CA) ; Yang;
Hong; (Fremont, CA) |
|
Applicant: |
Name |
City |
State |
Country |
Type |
Gilead Sciences, Inc. |
Foster City |
CA |
US |
|
|
Family ID: |
1000005251312 |
Appl. No.: |
16/914034 |
Filed: |
June 26, 2020 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
15716431 |
Sep 26, 2017 |
10800772 |
|
|
16914034 |
|
|
|
|
62436256 |
Dec 19, 2016 |
|
|
|
62401015 |
Sep 28, 2016 |
|
|
|
Current U.S.
Class: |
1/1 |
Current CPC
Class: |
A61K 31/439 20130101;
A61K 31/4985 20130101; C07D 471/08 20130101; C07D 487/04 20130101;
A61K 31/496 20130101; A61K 45/06 20130101; C07D 487/10 20130101;
C07D 491/107 20130101; A61K 31/55 20130101; A61K 31/551 20130101;
C07D 498/04 20130101; C07D 487/08 20130101; C07D 417/14 20130101;
A61K 31/5383 20130101; C07D 417/04 20130101; A61K 31/428 20130101;
A61K 31/5377 20130101; A61K 31/519 20130101; A61K 31/4545 20130101;
C07D 471/04 20130101; A61K 31/454 20130101; A61P 31/18
20180101 |
International
Class: |
C07D 417/14 20060101
C07D417/14; A61P 31/18 20060101 A61P031/18; A61K 31/428 20060101
A61K031/428; A61K 31/439 20060101 A61K031/439; A61K 31/454 20060101
A61K031/454; A61K 31/4545 20060101 A61K031/4545; A61K 31/496
20060101 A61K031/496; A61K 31/4985 20060101 A61K031/4985; A61K
31/519 20060101 A61K031/519; A61K 31/5377 20060101 A61K031/5377;
A61K 31/5383 20060101 A61K031/5383; A61K 31/55 20060101 A61K031/55;
A61K 31/551 20060101 A61K031/551; A61K 45/06 20060101 A61K045/06;
C07D 417/04 20060101 C07D417/04; C07D 471/04 20060101 C07D471/04;
C07D 471/08 20060101 C07D471/08; C07D 487/04 20060101 C07D487/04;
C07D 487/08 20060101 C07D487/08; C07D 487/10 20060101 C07D487/10;
C07D 491/107 20060101 C07D491/107; C07D 498/04 20060101
C07D498/04 |
Claims
1. A compound of Formula I: ##STR00516## or a pharmaceutically
acceptable salt thereof, wherein: R.sup.1 is H or
(C.sub.1-C.sub.6)alkyl; R.sup.2 is H or (C.sub.1-C.sub.6)alkyl;
R.sup.a is H or (C.sub.1-C.sub.6)alkyl; R.sup.3 is
O(C.sub.1-C.sub.6)alkyl or O(C.sub.1-C.sub.6)cycloalkyl; R.sup.4 is
a 3-8 membered saturated, partially unsaturated, or aryl monocyclic
ring containing 0-4 heteroatoms independently selected from
nitrogen, oxygen, or sulfur, or an 8-13 membered saturated,
partially unsaturated, or aryl bicyclic or tricyclic ring
containing 0-4 heteroatoms independently selected from nitrogen,
oxygen, or sulfur, and wherein R.sup.4 is optionally substituted
with 1-10 R.sup.f; each R.sup.f is independently halo, R.sup.X,
OR.sup.X, SR.sup.X, CN, S(O)R.sup.X, SO.sub.2R.sup.X,
OSO.sub.2R.sup.X, N(R.sup.X).sub.2, NO.sub.2, NR.sup.XC(O)R.sup.X,
NR.sup.XC(O)(CO)R.sup.X, NR.sup.XC(O)N(R.sup.X).sub.2,
NR.sup.XC(O)OR.sup.X, N(R.sup.X)S(O)R.sup.X,
N(R.sup.X)SO.sub.2R.sup.X, N(R.sup.X)SO.sub.2OR.sup.X, C(O)R.sup.X,
C(O)OR.sup.X, OC(O)R.sup.X, OC(O)OR.sup.X, C(O)N(R.sup.X).sub.2,
OC(O)N(R.sup.X).sub.2, or a 3-8 membered saturated, partially
unsaturated, or aryl monocyclic ring containing 0-4 heteroatoms
independently selected from nitrogen, oxygen, or sulfur, or two
R.sup.f on the same carbon are taken together to form an oxo group;
each R.sup.X is independently H, halo, N(R.sup.Y).sub.2,
C(O)OR.sup.Y, C.sub.1-8 aliphatic, C.sub.1-8 heteroaliphatic,
(C.sub.3-C.sub.6)cycloalkyl, 3-8 membered heterocycloalkyl
containing 1-3 heteroatoms independently selected from nitrogen,
oxygen, or sulfur, optionally substituted phenyl, or two R.sup.X on
the same nitrogen are taken together to form a 5-6 membered
saturated, partially saturated, or heteroaryl ring having 1-3
heteroatoms independently selected from nitrogen, oxygen, and
sulfur, or two R.sup.X on the same carbon or on adjacent carbons
are optionally taken together to form a
(C.sub.3-C.sub.6)cycloalkyl, or a 3-6 membered saturated fused
monocyclic ring containing 0-2 heteroatoms independently selected
from nitrogen, oxygen, and sulfur, or two R.sup.X on the same
carbon are taken together to form an oxo group; wherein the
C.sub.1-8 aliphatic, C.sub.1-8 heteroaliphatic,
(C.sub.3-C.sub.6)cycloalkyl, 3-8 membered heterocycloalkyl, or
phenyl is optionally substituted with 1-5 R.sup.z; each R.sup.z is
independently halo, C.sub.1-8 aliphatic, or C.sub.1-8
heteroaliphatic; each R.sup.Y is independently H or
(C.sub.1-C.sub.6)alkyl; R.sup.5 is ##STR00517## R.sup.b is H or
(C.sub.1-C.sub.6)alkyl; R.sup.e is H, (C.sub.1-C.sub.6)alkyl or
(C.sub.3-C.sub.6)cycloalkyl, wherein R.sup.c is optionally
substituted with 1-5 groups independently selected from halo, D,
OR.sup.X, and N(R.sup.X).sub.2; Q is a 3-10 membered saturated or
partially unsaturated monocyclic or bicyclic heterocycloalkyl
containing 1-3 heteroatoms independently selected from nitrogen,
oxygen, or sulfur, optionally substituted with 1-5 R.sup.e; each
R.sup.e is independently H, (C.sub.1-C.sub.6)alkyl,
N(R.sup.X).sub.2, C(O)R.sup.X, C(O)OR.sup.X, S(O).sub.2R.sup.X,
(C.sub.3-C.sub.6)cycloalkyl or 3-6 membered heterocycloalkyl
containing 1-2 heteroatoms independently selected from nitrogen,
oxygen, or sulfur, or two R.sup.e wherein R.sup.e on the same
carbon are taken together to form an oxo group, or two R.sup.e
wherein R.sup.e on the same carbon are taken together to form
(C.sub.3-C.sub.8)cycloalkyl or 3-4 membered heterocycloalkyl
containing 1-2 heteroatoms independently selected from nitrogen,
oxygen, or sulfur, wherein R.sup.e is optionally substituted with
1-5 R.sup.g; each R.sup.g is independently halo, R.sup.X, OR.sup.X,
N(R.sup.X).sub.2, C(O)R.sup.X, C(O)OR.sup.X, OC(O)R.sup.X,
OC(O)OR.sup.X, S(O).sub.2R.sup.X, optionally substituted 3-4
membered heterocycloalkyl containing 1-2 heteroatoms independently
selected from nitrogen, oxygen, or sulfur, or two R.sup.g on the
same carbon are taken together to form an oxo group, or two R.sup.g
on the same sulfur are optionally taken together to form an oxo
group; X.sup.1 is N or C(H); X.sup.2 is N or C(H); X.sup.3 is N or
C(H); and wherein the compound is not one of the following
structures: ##STR00518## ##STR00519##
2. The compound of claim 1, wherein Q is a 5-6 membered saturated
monocyclic heterocycloalkyl containing one heteroatom selected from
nitrogen, oxygen, or sulfur, optionally substituted with 1-2
R.sup.e.
3. The compound of claim 2, wherein Q is of the following formula:
##STR00520##
4. The compound of claim 1, of any of the following formulae:
##STR00521## ##STR00522## ##STR00523## ##STR00524## ##STR00525##
##STR00526## ##STR00527## ##STR00528##
5. The compound of claim 1, wherein R.sup.1 is H.
6. The compound of claim 1, wherein R.sup.2 is methyl.
7. The compound of claim 1, wherein R.sup.a is H.
8. The compound of claim 1, wherein R.sup.3 is selected from O-nPr,
O-iPr, O-cyclopropyl, and O-tBu.
9. The compound of claim 8, wherein R.sup.3 is O-tBu.
10. The compound of claim 1, wherein R.sup.4 is a 3-8 membered
saturated, partially unsaturated, or aryl monocyclic ring
containing 0-4 heteroatoms independently selected from nitrogen,
oxygen, or sulfur.
11. The compound of claim 10, wherein R.sup.4 is a 5-6 membered
aryl ring having 0-4 heteroatoms independently selected from
nitrogen, oxygen, or sulfur, wherein the aryl ring is optionally
substituted with 1-4 R.sup.f.
12. The compound of claim 11, wherein R.sup.4 is phenyl, optionally
substituted with with 1-4 R.sup.f.
13. The compound of claim 12, wherein R.sup.4 is phenyl optionally
substituted at the para position with one R.sup.f.
14. The compound of claim 11, wherein R.sup.4 is optionally
substituted with 1-4 R.sup.f, wherein each R.sup.f is independently
halo.
15. The compound of claim 14, wherein R.sup.4 is substituted with
one R.sup.f, wherein R.sup.f is chloro.
16. The compound of claim 15, wherein R.sup.4 is ##STR00529##
17. The compound of claim 1, wherein R.sup.b is H.
18. The compound of claim 1, wherein R.sup.c is
(C.sub.1-C.sub.6)alkyl optionally substituted with 1-5 groups
independently selected from halo, D, OR.sup.x, and
NR.sup.x.sub.2.
19. The compound of claim 18, wherein R.sup.c is methyl optionally
substituted with 1-3 groups independently selected from halo, D,
OR.sup.x, and NR.sup.x.sub.2.
20. The compound of claim 19, wherein R.sup.c is methyl substituted
with 1-3 fluoro.
21. The compound of claim 20, wherein R.sup.c is methyl substituted
with two fluoro.
22. The compound of claim 18, wherein R.sup.c is methyl.
23. The compound of claim 18, wherein R.sup.c is ethyl.
24. The compound of claim 1, wherein R.sup.c is
(C.sub.3-C.sub.6)cycloalkyl optionally substituted with 1-5 groups
independently selected from halo, D, OR.sup.x, and
NR.sup.z.sub.2.
25. The compound of claim 24, wherein R.sup.c is cyclopropyl
optionally substituted with 1-3 groups independently selected from
halo, D, OR.sup.x, and NR.sup.x.sub.2.
26. The compound of claim 24, wherein R.sup.c is cyclopropyl.
27. The compound of claim 1, wherein at least one R.sup.e is
independently a 3-6 membered heterocycloalkyl containing 1-2
heteroatoms independently selected from nitrogen, oxygen, or
sulfur.
28. The compound of claim 1, wherein Q is substituted with one
R.sup.e.
29. The compound of claim 1, wherein R.sup.e a 3-6 membered
heterocycloalkyl containing 1-2 heteroatoms independently selected
from nitrogen, oxygen, or sulfur, wherein R.sup.e is optionally
substituted with 1-5 R.sup.g.
30. The compound of claim 29, wherein R.sup.e is a 4 membered
heterocycloalkyl containing one heteroatom independently selected
from nitrogen, oxygen or sulfur, wherein R.sup.e is optionally
substituted with 1-3 R.sup.g.
31. The compound of claim 29, wherein R.sup.e is a 5 membered
heterocycloalkyl containing one heteroatom independently selected
from nitrogen, oxygen or sulfur, wherein R.sup.e is optionally
substituted with 1-3 R.sup.g.
32. The compound of claim 30, wherein R.sup.e is azetidine
optionally substituted with 1-2 R.sup.g.
33. The compound of claim 32, wherein R.sup.e is N-substituted
azetidine.
34. The compound of claim 33, wherein R.sup.e is ##STR00530##
35. The compound of claim 33, wherein R.sup.e is ##STR00531##
36. The compound of claim 30, wherein R.sup.e is oxetane optionally
substituted with 1-2 R.sup.g groups.
37. The compound of claim 36, wherein R.sup.e is ##STR00532##
38. The compound of claim 1, wherein each R.sup.gis independently
R.sup.x, OR.sup.x, C(O)R.sup.x, or C(O)OR.sup.x.
39. The compound of claim 1, wherein X.sup.1 is N.
40. The compound of claim 1, wherein X.sup.1 is C(H).
41. The compound of claim 1, wherein X.sup.2 is N.
42. The compound of claim 1, wherein X.sup.2 is C(H).
43. The compound of claim 1, wherein X.sup.3 is N.
44. The compound of claim 1, wherein X.sup.3 is C(H).
45. The compound of claim 9, wherein R.sup.3 is ##STR00533##
46. The compound of claim 1, selected from: ##STR00534##
##STR00535## ##STR00536## or a pharmaceutically acceptable salt
thereof.
47. Compound 1: ##STR00537## or a pharmaceutically acceptable salt
thereof.
48. The compound of claim 1 of formula II-e: ##STR00538## or a
pharmaceutically acceptable salt thereof, wherein: R.sup.1 is H;
R.sup.2 is (C.sub.1-C.sub.6)alkyl; R.sup.a is H; R.sup.3 is
O(C.sub.1-C.sub.6)alkyl; R.sup.4 is ##STR00539## R.sup.c is
(C.sub.1-C.sub.6)alkyl or (C.sub.3-C.sub.6)cycloalkyl, wherein
R.sup.c is optionally substituted with 1-5 groups independently
selected from halo, D, OR.sup.X, and N(R.sup.X).sub.2; R.sup.e is a
4 membered heterocycloalkyl having one heteroatom selected from N
or O, wherein R.sup.e is optionally substituted with 1-2 R.sup.g;
each R.sup.g is independently C(O)R.sup.X or C(O)OR.sup.X; and each
R.sup.X is independently C.sub.1-8 aliphatic.
49. The compound of claim 48, wherein X.sup.1 is N, X.sup.2 is
C(H), and X.sup.3 is N.
50. The compound of claim 48, wherein X.sup.1 is C(H), X.sup.2 is
C(H), and X.sup.3 is N.
51. The compound of claim 48, wherein X.sup.1 is C(H), X.sup.2 is
N, and X.sup.3 is C(H).
52. The compound of claim 48, wherein X.sup.1 is N, X.sup.2 is N,
and X.sup.3 is C(H).
53. A pharmaceutical composition comprising a compound of Formula I
as described in claim 1, or a pharmaceutically acceptable salt
thereof, and a pharmaceutically acceptable carrier.
54. A method of treating an HIV infection in a mammal comprising
administering a compound of Formula I as described in claim 1, or a
pharmaceutically acceptable salt thereof, to the mammal.
55. A method for treating an HIV infection in a mammal comprising
administering to the mammal in need thereof a therapeutically
effective amount of a compound of Formula I as described in claim
1, or a pharmaceutically acceptable salt thereof, in combination
with a therapeutically effective amount of one or more additional
therapeutic agents selected from the group consisting HIV protease
inhibiting compounds, HIV non-nucleoside inhibitors of reverse
transcriptase, HIV nucleoside inhibitors of reverse transcriptase,
HIV nucleotide inhibitors of reverse transcriptase, HIV integrase
inhibitors, gp41 inhibitors, CXCR4 inhibitors, gp120 inhibitors,
CCRS inhibitors, capsid polymerization inhibitors, maturation
inhibitors, attachment inhibitors, and other drug for treating HIV,
and combinations thereof.
56-58. (canceled)
Description
CROSS REFERENCE TO RELATED APPLICATIONS
[0001] This application claims priority to and the benefit under 35
U.S.C. 119(e) of U.S. Provisional Patent Application Ser. Nos.
62/401,015, filed Sep. 28, 2016 and 62/436,256, filed Dec. 19,
2016, the disclosures of which are hereby incorporated by reference
in their entirety.
BACKGROUND
[0002] Human immunodeficiency virus (HIV) infection and related
diseases are a major public health problem worldwide. Human
immunodeficiency virus type 1 (HIV-1) encodes three enzymes which
are required for viral replication: reverse transcriptase,
protease, and integrase. Although drugs targeting reverse
transcriptase and protease are in wide use and have shown
effectiveness, particularly when employed in combination, toxicity
and development of resistant strains have limited their usefulness
(Palella, et al N. Engl. J. Med. (1998) 338:853-860; Richman, D. D.
Nature (2001) 410:995-1001).
[0003] Accordingly, there is a need for new agents that inhibit the
replication of HIV. There is also a need for agents that are
directed against alternate sites in the viral life cycle including
agents that target the integrase enzyme. There is also a need for
new agents with appropriate levels of metabolic stability.
SUMMARY
[0004] The present invention encompasses the recognition that there
exists a need for new compounds and methods for treating HIV
infection. Accordingly, in some embodiments, the present invention
provides a compound of Formula I:
##STR00002## [0005] or a pharmaceutically acceptable salt thereof,
wherein: [0006] R.sup.1 is H or (C.sub.1-C.sub.6)alkyl; [0007]
R.sup.2 is H or (C.sub.1-C.sub.6)alkyl; [0008] R.sup.a is H or
(C.sub.1-C.sub.6)alkyl; [0009] R.sup.3 is O(C.sub.1-C.sub.6)alkyl
or O(C.sub.1-C.sub.6)cycloalkyl; [0010] R.sup.4 is a 3-8 membered
saturated, partially unsaturated, or aryl monocyclic ring
containing 0-4 heteroatoms independently selected from nitrogen,
oxygen, or sulfur, or an 8-13 membered saturated, partially
unsaturated, or aryl bicyclic or tricyclic ring containing 0-4
heteroatoms independently selected from nitrogen, oxygen, or
sulfur, and wherein R.sup.4 is optionally substituted with 1-10
R.sup.f; [0011] each R.sup.f is independently halo, R.sup.X,
OR.sup.X, SR.sup.X, CN, S(O)R.sup.X, SO.sub.2R.sup.X,
OSO.sub.2R.sup.X, N(R.sup.X).sub.2, NO.sub.2, NR.sup.XC(O)R.sup.X,
NR.sup.XC(O)(CO)R.sup.X, NR.sup.XC(O)N(R.sup.X).sub.2,
NR.sup.XC(O)OR.sup.X, N(R.sup.X)S(O)R.sup.X,
N(R.sup.X)SO.sub.2R.sup.X, N(R.sup.X)SO.sub.2OR.sup.X, C(O)R.sup.X,
C(O)OR.sup.X, OC(O)R.sup.X, OC(O)OR.sup.X, C(O)N(R.sup.X).sub.2,
OC(O)N(R.sup.X).sub.2, or a 3-8 membered saturated, partially
unsaturated, or aryl monocyclic ring containing 0-4 heteroatoms
independently selected from nitrogen, oxygen, or sulfur, or two
R.sup.f on the same carbon are taken together to form an oxo group;
[0012] each R.sup.X is independently H, halo, N(R.sup.Y).sub.2,
C(O)OR.sup.Y, C.sub.1-8 aliphatic, C.sub.1-8 heteroaliphatic,
(C.sub.3-C.sub.6)cycloalkyl, 3-8 membered heterocycloalkyl
containing 1-3 heteroatoms independently selected from nitrogen,
oxygen, or sulfur, optionally substituted phenyl, or two R.sup.X on
the same nitrogen are taken together to form a 5-6 membered
saturated, partially saturated, or heteroaryl ring having 1-3
heteroatoms independently selected from nitrogen, oxygen, and
sulfur, or two R.sup.X on the same carbon or on adjacent carbons
are optionally taken together to form a
(C.sub.3-C.sub.6)cycloalkyl, or a 3-6 membered saturated fused
monocyclic ring containing 0-2 heteroatoms independently selected
from nitrogen, oxygen, and sulfur, or two R.sup.X on the same
carbon are taken together to form an oxo group; wherein the
C.sub.1-8 aliphatic, C.sub.1-8 heteroaliphatic,
(C.sub.3-C.sub.6)cycloalkyl, 3-8 membered heterocycloalkyl, or
phenyl is optionally substituted with 1-5 R.sup.z; [0013] each
R.sup.z is independently halo, C.sub.1-8 aliphatic, or C.sub.1-8
heteroaliphatic; [0014] each R.sup.Y is independently H or
(C.sub.1-C.sub.6)alkyl; [0015] R.sup.5 is
[0015] ##STR00003## [0016] R.sup.b is H or (C.sub.1-C.sub.6)alkyl;
[0017] R.sup.c is H, (C.sub.1-C.sub.6)alkyl or
(C.sub.3-C.sub.6)cycloalkyl, wherein R.sup.c is optionally
substituted with 1-5 groups independently selected from halo, D,
OR.sup.X, and N(R.sup.X).sub.2; [0018] Q is a 3-10 membered
saturated or partially unsaturated monocyclic or bridged,
spirocyclic, or fused bicyclic heterocycloalkyl containing 1-3
heteroatoms independently selected from nitrogen, oxygen, or
sulfur, optionally substituted with 1-5 R.sup.e; [0019] each
R.sup.e is independently H, (C.sub.1-C.sub.6)alkyl,
N(R.sup.X).sub.2, C(O)R.sup.X, C(O)OR.sup.X, S(O).sub.2R.sup.X,
(C.sub.3-C.sub.6)cycloalkyl or 3-6 membered heterocycloalkyl
containing 1-2 heteroatoms independently selected from nitrogen,
oxygen, or sulfur, or two R.sup.e wherein R.sup.e on the same
carbon are taken together to form an oxo group, or two R.sup.e
wherein R.sup.e on the same carbon are taken together to form
(C.sub.3-C.sub.8)cycloalkyl or 3-4 membered heterocycloalkyl
containing 1-2 heteroatoms independently selected from nitrogen,
oxygen, or sulfur, wherein R.sup.e is optionally substituted with
1-5 R.sup.g; [0020] each R.sup.g is independently halo, R.sup.X,
OR.sup.X, N(R.sup.X).sub.2, C(O)R.sup.X, C(O)OR.sup.X,
OC(O)R.sup.X, OC(O)OR.sup.X, S(O).sub.2R.sup.X, optionally
substituted 3-4 membered heterocycloalkyl containing 1-2
heteroatoms independently selected from nitrogen, oxygen, or
sulfur, or two R.sup.g on the same carbon are taken together to
form an oxo group, or two R.sup.g on the same sulfur are optionally
taken together to form an oxo group; [0021] X.sup.1 is N or C(H);
[0022] X.sup.2 is N or C(H); [0023] X.sup.3 is N or C(H); and
[0024] wherein the compound is not one of the following
structures:
##STR00004## ##STR00005##
[0025] In some embodiments, the present invention provides a
pharmaceutical composition comprising a compound disclosed herein
(e.g., a compound of Formula I) or a pharmaceutically acceptable
salt thereof, and a pharmaceutically acceptable carrier.
[0026] In some embodiments, the present invention provides methods
for treating the proliferation of the HIV virus, treating AIDS or
delaying the onset of AIDS or ARC symptoms in a mammal (e.g., a
human), comprising administering a compound disclosed herein (e.g.,
a compound of Formula I), or a pharmaceutically acceptable salt
thereof, to the mammal.
[0027] In some embodiments, the present invention provides methods
for treating an HIV infection in a mammal (e.g., a human)
comprising administering a compound disclosed herein (e.g., a
compound of Formula I), or a pharmaceutically acceptable salt
thereof, to the mammal.
[0028] In some embodiments, the present invention provides methods
for treating an HIV infection in a mammal (e.g., a human)
comprising administering to the mammal in need thereof a
therapeutically effective amount of a compound disclosed herein
(e.g., a compound of Formula I), or a pharmaceutically acceptable
salt thereof, in combination with a therapeutically effective
amount of one or more additional therapeutic agents selected from
the group consisting of HIV protease inhibiting compounds, HIV
non-nucleoside inhibitors of reverse transcriptase, HIV nucleoside
inhibitors of reverse transcriptase, HIV nucleotide inhibitors of
reverse transcriptase, HIV integrase inhibitors, gp41 inhibitors,
CXCR4 inhibitors, gp120 inhibitors, CCR5 inhibitors, capsid
polymerization inhibitors, maturation inhibitors, attachment
inhibitors and other drugs for treating HIV, and combinations
thereof.
[0029] In some embodiments, the present invention provides a
compound disclosed herein (e.g., a compound of Formula I), or a
pharmaceutically acceptable salt thereof for use in medical therapy
(e.g., for use in treating the proliferation of the HIV virus or
AIDS or delaying the onset of AIDS or ARC symptoms in a mammal
(e.g., a human)).
[0030] In some embodiments, the present invention provides a
compound disclosed herein (e.g., a compound of Formula I), or a
pharmaceutically acceptable salt thereof for use in medical therapy
(e.g., for use in treating an HIV infection in a mammal (e.g., a
human)).
[0031] In some embodiments, the present invention provides a
compound disclosed herein (e.g., a compound of Formula I), or a
pharmaceutically acceptable salt thereof for use in the manufacture
of a medicament for treating the proliferation of the HIV virus or
AIDS or delaying the onset of AIDS or ARC symptoms in a mammal
(e.g., a human).
[0032] In some embodiments, the present invention provides a
compound disclosed herein (e.g., a compound of Formula I), or a
pharmaceutically acceptable salt thereof, for use in the
prophylactic or therapeutic treatment of the proliferation of the
HIV virus or AIDS or for use in the therapeutic treatment of
delaying the onset of AIDS or ARC symptoms.
[0033] In some embodiments, the present invention provides a
compound disclosed herein (e.g., a compound of Formula I), or a
pharmaceutically acceptable salt thereof, for the manufacture of a
medicament for treating an HIV infection in a mammal (e.g., a
human).
[0034] In some embodiments, the present invention provides a
compound disclosed herein (e.g., a compound of Formula I) or a
pharmaceutically acceptable salt thereof, for use in the
prophylactic or therapeutic treatment of an HIV infection in a
mammal (e.g., a human).
[0035] In some embodiments, the present invention provides
processes and intermediates disclosed herein that are useful for
preparing compounds disclosed herein or salts thereof.
DETAILED DESCRIPTION OF CERTAIN EMBODIMENTS
Definitions
[0036] Unless stated otherwise, the following terms and phrases as
used herein are intended to have the following meanings.
[0037] When trade names are used herein, applicants intend to
independently include the tradename product and the active
pharmaceutical ingredient(s) of the tradename product.
[0038] Unless defined otherwise, all technical and scientific terms
used herein have the same meaning as commonly understood by one of
ordinary skill in the art. A dash at the front or end of a chemical
group is a matter of convenience; chemical groups may be depicted
with or without one or more dashes without losing their ordinary
meaning. A wavy line drawn through a line in a structure indicates
a point of attachment of a group. A dashed line indicates an
optional bond. A prefix such as "C.sup.u-v" or (C.sub.u-C.sub.v)
indicates that the following group has from u to v carbon atoms.
For example, "C.sub.1-6alkyl" indicates that the alkyl group has
from 1 to 6 carbon atoms.
[0039] Aliphatic: As used herein, "aliphatic" refers to any group
derived from a linear or branched hydrocarbon, including alkyls,
alkenyls, and alkynyls. Aliphatic groups include, but are not
limited to, methyl, ethyl, propyls such as propan-1-yl, propan-2-yl
(iso-propyl), butyls such as butan-1-yl, butan-2-yl (sec-butyl),
2-methyl-propan-1-yl (iso-butyl), 2-methyl-propan-2-yl (t-butyl),
pentyls, hexyls, octyls, decyls, ethenyl (vinyl), propenyl (allyl),
1-butenyl, 1,3-butadienyl, ethynyl (--C.ident.CH), propargyl
(--CH.sub.2C.ident.CH), (E)-pent-3-en-1-ynyl, and the like. Unless
otherwise specified, an aliphatic group has from 1 to about 10
carbon atoms, for example from 1 to 10 carbon atoms, for example
from 1 to 6 carbon atoms, or from about 1 to 4 carbon atoms.
[0040] Alkyl: As used herein, the term "alkyl" refers to any group
derived from a linear or branched saturated hydrocarbon. Alkyl
groups include, but are not limited to, methyl, ethyl, propyls such
as propan-1-yl, propan-2-yl (iso-propyl), butyls such as
butan-1-yl, butan-2-yl (sec-butyl), 2-methyl-propan-1-yl
(iso-butyl), 2-methyl-propan-2-yl (t-butyl), pentyls, hexyls,
octyls, decyls, and the like. Unless otherwise specified, an alkyl
group has from 1 to about 10 carbon atoms, for example from 1 to 10
carbon atoms, for example from 1 to 6 carbon atoms, for example
from 1 to 4 carbon atoms.
[0041] Alkenyl: As used herein, "alkenyl" refers to any group
derived from a straight or branched hydrocarbon with at least one
carbon-carbon double bond. Alkenyl groups include, but are not
limited to, ethenyl (vinyl), propenyl (allyl), 1-butenyl,
1,3-butadienyl, and the like. Unless otherwise specified, an
alkenyl group has from 2 to about 10 carbon atoms, for example from
2 to 10 carbon atoms, for example from 2 to 6 carbon atoms, for
example from 2 to 4 carbon atoms.
[0042] Alkynyl: As used herein, "alkynyl" refers to any group
derived from a straight or branched hydrocarbon with at least one
carbon-carbon triple bond and includes those groups having one
triple bond and one double bond. Examples of alkynyl groups
include, but are not limited to, ethynyl (--CCH), propargyl
(-CH.sub.2C.ident.CH), (E)-pent-3-en-1-ynyl, and the like. Unless
otherwise specified, an alkynyl group has from 2 to about 10 carbon
atoms, for example from 2 to 10 carbon atoms, for example from 2 to
6 carbon atoms, for example from 2 to 4 carbon atoms.
[0043] Aryl: As used herein, the term "aryl" used alone or as part
of a larger moiety as in "aralkyl", "aralkoxy", or "aryloxyalkyl",
refers to monocyclic and bicyclic ring systems having a total of
five to fourteen ring members, wherein at least one ring in the
system is aromatic and wherein each ring in the system contains
three to seven ring members. The term "aryl" may be used
interchangeably with the term "aryl ring". In certain embodiments
of the present invention, "aryl" refers to an aromatic ring system
which includes, but not limited to, phenyl, biphenyl, naphthyl,
anthracyl and the like, which may bear one or more substituents.
Also included within the scope of the term "aryl", as it is used
herein, is a group in which an aromatic ring is fused to one or
more non-aromatic rings, such as indanyl, phthalimidyl,
naphthimidyl, phenanthridinyl, or tetrahydronaphthyl, and the
like.
[0044] Carbocycle: As used herein, the term "carbocycle" or
"carbocyclyl" refers to a saturated (i.e., cycloalkyl) or partially
unsaturated (e.g., cycloalkenyl, cycloalkadienyl, etc.) ring,
having 3 to 7 carbon atoms. In some embodiments the carbocycle is a
monocycle comprising 3-6 ring carbons (i.e.
(C.sub.3-C.sub.6)carbocycle). In some embodiments, the term
carbocycle includes multicyclic carbocyles having 7 to 12 carbon
atoms as a bicycle, and up to about 20 carbon atoms as a polycycle
provided that the largest single ring of a multicyclic carbocycle
is 7 carbon atoms.
[0045] Cycloalkyl: As used herein, the term "cycloalkyl" refers to
a cyclic alkyl group. Examples include, but are not limited to,
cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, adamantyl, and
the like.
[0046] Halo or halogen: As used herein, the term "halo" or
"halogen" refers to fluoro, chloro, bromo and iodo.
[0047] Heteroaliphatic: As used herein, the term "heteroaliphatic"
refers to an aliphatic group in which one or more of the carbon
atoms are each independently replaced with a heteroatom selected
from the group consisting of O, N, S, and Si. A heteroatom may
optionally be oxidized or alkylated. A heteroatom may be placed at
any interior position of the heteroalkyl group or at a position at
which the group is attached to the remainder of the molecule.
Examples include, but are not limited to, --CH.sub.2OCH.sub.3,
--CH.sub.2CH.sub.2NHCH.sub.3, --CH.sub.2CH.sub.2N(CH.sub.3)
--CH.sub.3, --CH.sub.2SCH.sub.2CH.sub.3, --S(O)CH.sub.3,
--CH.sub.2CH.sub.2S(O).sub.2CH.sub.3, --CHCHOCH.sub.3,
--Si(CH.sub.3).sub.3, --CH.sub.2CHNOCH.sub.3,
--CHCHN(CH.sub.3)CH.sub.3, --CH.sub.2NHOCH.sub.3 and
--CH.sub.20S(CH.sub.3).sub.3.
[0048] Heteroalkyl: As used herein, the term "heteroalkyl" refers
to an alkyl in which one or more of the carbon atoms are each
independently replaced with a heteroatom selected from the group
consisting of O, N, S, and Si. A heteroatom may optionally be
oxidized or alkylated. A heteroatom may be placed at any interior
position of the heteroalkyl group or at a position at which the
group is attached to the remainder of the molecule. Examples
include, but are not limited to, --CH.sub.2OCH.sub.3,
--CH.sub.2CH.sub.2NHCH.sub.3, --CH.sub.2CH.sub.2N(CH.sub.3)
--CH.sub.3, --CH.sub.2SCH.sub.2CH.sub.3, --S(O)CH.sub.3,
--CH.sub.2CH.sub.2S(O).sub.2CH.sub.3, --CHCHOCH.sub.3,
--Si(CH.sub.3).sub.3, --CH.sub.2CHNOCH.sub.3,
--CHCHN(CH.sub.3)CH.sub.3, --CH.sub.2NHOCH.sub.3 and
--CH.sub.20S(CH.sub.3).sub.3.
[0049] Heteroaryl: As used herein, the term "heteroaryl" refers to
an aryl group in which one or more of the carbon atoms (and any
associated hydrogen atoms) are each independently replaced with the
same or different heteroatom, as defined above. Heteroaryl groups
include, but are not limited to, groups derived from acridine,
benzoimidazole, benzothiophene, benzofuran, benzoxazole,
benzothiazole, carbazole, carboline, cinnoline, furan, imidazole,
imidazopyridine, indazole, indole, indoline, indolizine,
isobenzofuran, isochromene, isoindole, isoindoline, isoquinoline,
isothiazole, isoxazole, naphthyridine, oxadiazole, oxazole,
perimidine, phenanthridine, phenanthroline, phenazine, phthalazine,
pteridine, purine, pyran, pyrazine, pyrazole, pyridazine, pyridine,
pyrimidine, pyrrole, pyrrolizine, quinazoline, quinoline,
quinolizine, quinoxaline, tetrazole, thiadiazole, thiazole,
thiophene, triazole, xanthene, and the like. Unless otherwise
specified, a heteroaryl group has from 5 to about 20 carbon atoms,
for example from 5 to 20 carbon atoms, for example from 5 to 14
carbon atoms, for example from 5 to 10 carbon atoms.
[0050] Heteroatom: The term "heteroatom" means one or more of
oxygen, sulfur, nitrogen, phosphorus, or silicon (including, any
oxidized form of nitrogen, sulfur, phosphorus, or silicon; the
quaternized form of any basic nitrogen or; a substitutable nitrogen
of a heterocyclic ring, for example N (as in
3,4-dihydro-2H-pyrrolyl), NH (as in pyrrolidinyl) or NR.sup.+ (as
in N-substituted pyrrolidinyl)).
[0051] Heterocycle: As used herein, the terms "heterocycle,"
"heterocyclic," and "heterocyclyl" refer to a single saturated or
partially unsaturated non-aromatic ring with at least one
heteroatom, as defined above. Heterocycles include, but are not
limited to, groups derived from azetidine, aziridine,
imidazolidine, morpholine, oxirane (epoxide), oxetane, piperazine,
piperidine, pyrazolidine, piperidine, pyrrolidine, pyrrolidinone,
tetrahydrofuran, tetrahydrothiophene, dihydropyridine,
tetrahydropyridine, N-bromopyrrolidine, N-chloropiperidine, and the
like.
[0052] Optionally substituted: Compounds describedmay contain
"optionally substituted" moieties. In general, the term
"substituted," whether preceded by the term "optionally" or not,
means that one or more hydrogens of the designated moiety are
replaced with a suitable substituent. Unless otherwise indicated,
an "optionally substituted" group may have a suitable substituent
at each substitutable position of the group, and when more than one
position in any given structure may be substituted with more than
one substituent selected from a specified group, the substituent
may be either the same or different at every position. Combinations
of substituents envisioned by this invention are preferably those
that result in the formation of stable or chemically feasible
compounds. The term "stable," as used herein, refers to compounds
that are not substantially altered when subjected to conditions to
allow for their production, detection, and, in certain embodiments,
their recovery, purification, and use for one or more of the
purposes disclosed herein.
[0053] Unless otherwise indicated, suitable monovalent substituents
on a substitutable carbon atom of an "optionally substituted" group
are independently halogen; --(CH.sub.2).sub.0-4R.sup.o;
--(CH.sub.2).sub.0-4OR.sup.o; --O(CH.sub.2).sub.0-4R.sup.o,
--O--(CH.sub.2).sub.0-4C(O)OR.sup.o;
--(CH.sub.2).sub.0-4CH(OR.sup.o).sub.2;
--(CH.sub.2).sub.0-4SR.sup.o; --(CH.sub.2).sub.0-4Ph, which may be
substituted with R.sup.o; --(CH.sub.2).sub.0-4O(CH.sub.2).sub.0-1Ph
which may be substituted with R.sup.o; --CH.dbd.CHPh, which may be
substituted with R.sup.o;
--(CH.sub.2).sub.0-4O(CH.sub.2).sub.0-1-pyridyl which may be
substituted with R.sup.o; --NO.sub.2; --CN; --N.sub.3;
--(CH.sub.2).sub.0-4N(R.sup.o).sub.2;
--(CH.sub.2).sub.0-4N(R.sup.o)C(O)R.sup.o; --N(R.sup.o)C(S)R.sup.o;
--(CH.sub.2).sub.0-4N(R.sup.o)C(O)NR.sup.o.sub.2;
--N(R.sup.o)C(S)NR.sup.o.sub.2;
--(CH.sub.2).sub.0-4N(R.sup.o)C(O)OR.sup.o;
--N(R.sup.o)N(R.sup.o)C(O)R.sup.o;
--N(R.sup.o)N(R.sup.o)C(O)NR.sup.o.sub.2;
--N(R.sup.o)N(R.sup.o)C(O)OR.sup.o;
--(CH.sub.2).sub.0-4C(O)R.sup.o; --C(S)R.sup.o;
--(CH.sub.2).sub.0-4C(O)OR.sup.o; --(CH.sub.2).sub.0-4C(O)SR.sup.o;
--(CH.sub.2).sub.0-4C(O)OSiR.sup.o.sub.3;
--(CH.sub.2).sub.0-4OC(O)R.sup.o; --OC(O)(CH.sub.2).sub.0-4SR--,
SC(S)SR.sup.o; --(CH.sub.2).sub.0-4SC(O)R.sup.o;
--(CH.sub.2).sub.0-4C(O)NR.sup.o.sub.2; --C(S)NR.sup.o.sub.2;
--C(S)SR.sup.o; --SC(S)SR.sup.o,
--(CH.sub.2).sub.0-4OC(O)NR.sup.o.sub.2; --C(O)N(OR.sup.o)R.sup.o;
--C(O)C(O)R.sup.o; --C(O)CH.sub.2C(O)R.sup.o;
--C(NOR.sup.o)R.sup.o; --(CH.sub.2).sub.0-4SSR.sup.o;
--(CH.sub.2).sub.0-4S(O).sub.2R.sup.o;
--(CH.sub.2).sub.0-4S(O).sub.20R.sup.o;
--(CH.sub.2).sub.0-4OS(O).sub.2R.sup.o; --S(O).sub.2NR.sup.o.sub.2;
--(CH.sub.2).sub.0-4S(O)R.sup.o;
--N(R.sup.o)S(O).sub.2NR.sup.o.sub.2;
--N(R.sup.o)S(O).sub.2R.sup.o; --N(OR.sup.o)R.sup.o;
--C(NH)NR.sup.o.sub.2; --P(O).sub.2R.sup.o; --P(O)R.sup.o.sub.2;
--OP(O)R.sup.o.sub.2; --OP(O)(OR.sup.o).sub.2; SiR.sup.o.sub.3;
--(C.sub.1-4 straight or branched)alkylene)O--N(R.sup.o).sub.2; or
--(C.sub.1-4 straight or branched alkylene)C(O)O--N(R.sup.o).sub.2,
wherein each R.sup.o may be substituted as defined below and is
independently hydrogen, C.sub.1-6 aliphatic, --CH.sub.2Ph,
--O(CH.sub.2).sub.0-1Ph, --CH.sub.2-(5-6 membered heteroaryl ring),
or a 5-.sub.6-membered saturated, partially unsaturated, or aryl
ring having 0-4 heteroatoms independently selected from nitrogen,
oxygen, or sulfur, or, notwithstanding the definition above, two
independent occurrences of R.sup.o, taken together with their
intervening atom(s), form a 3-12-membered saturated, partially
unsaturated, or aryl mono- or bicyclic ring having 0-4 heteroatoms
independently selected from nitrogen, oxygen, or sulfur, which may
be substituted as defined below.
[0054] Unless otherwise indicated, suitable monovalent substituents
on R.sup.o (or the ring formed by taking two independent
occurrences of R.sup.o together with their intervening atoms), are
independently halogen, --(CH.sub.2).sub.0-2R.sup. , -(haloR.sup. ),
--(CH.sub.2).sub.0-2OH, --(CH.sub.2).sub.0-2OR.sup. ,
--(CH.sub.2).sub.0-2CH(OR.sup. ).sub.2; --O(haloR.sup. ), --CN,
--N.sub.3, --(CH.sub.2).sub.0-2C(O)R.sup. ,
--(CH.sub.2).sub.0-2C(O)OH, --(CH.sub.2).sub.0-2C(O)OR.sup. ,
--(CH.sub.2).sub.0-2SR.sup. , --(CH.sub.2).sub.0-2SH,
--(CH.sub.2).sub.0-2NH.sub.2, --(CH.sub.2).sub.0-2NHR.sup. ,
--(CH.sub.2).sub.0-2NR.sup. .sub.2, --NO.sub.2, --SiR.sup. .sub.3,
--OSiR.sup. .sub.3, --C(O)SR.sup. , --(C.sub.1-4 straight or
branched alkylene)C(O)OR.sup. , or --SSR.sup. wherein each R.sup.
is unsubstituted or where preceded by "halo" is substituted only
with one or more halogens, and is independently selected from
C.sub.1-4 aliphatic, --CH.sub.2Ph, --O(CH.sub.2).sub.0-1Ph, or a
5-6-membered saturated, partially unsaturated, or aryl ring having
0-4 heteroatoms independently selected from nitrogen, oxygen, or
sulfur. Suitable divalent substituents on a saturated carbon atom
of R.sup.o include .dbd.O and .dbd.S.
[0055] Unless otherwise indicated, suitable divalent substituents
on a saturated carbon atom of an "optionally substituted" group
include the following: .dbd.O, .dbd.S, .dbd.NNR*.sub.2,
.dbd.NNHC(O)R*, .dbd.NNHC(O)OR*, .dbd.NNHS(O).sub.2R*, .dbd.NR*,
.dbd.NOR*, --O(C(R*.sub.2)).sub.2-3O--, or
--S(C(R*.sub.2)).sub.2-3S--, wherein each independent occurrence of
R* is selected from hydrogen, C.sub.1-6 aliphatic which may be
substituted as defined below, or an unsubstituted 5-6-membered
saturated, partially unsaturated, or aryl ring having 0-4
heteroatoms independently selected from nitrogen, oxygen, or
sulfur. Unless otherwise indicated, suitable divalent substituents
that are bound to vicinal substitutable carbons of an "optionally
substituted" group include: --O(CR*.sub.2).sub.2-3O--, wherein each
independent occurrence of R* is selected from hydrogen, C.sub.1-6
aliphatic which may be substituted as defined below, or an
unsubstituted 5-6-membered saturated, partially unsaturated, or
aryl ring having 0-4 heteroatoms independently selected from
nitrogen, oxygen, or sulfur.
[0056] Unless otherwise indicated, suitable substituents on the
aliphatic group of R* include halogen, --R.sup. , -(haloR.sup. ),
--OH, --OR.sup. , --O(haloR.sup. ), --CN, --C(O)OH, --C(O)OR.sup. ,
--NH.sub.2, --NHR.sup. , --NR.sup. .sub.2, or --NO.sub.2, wherein
each R.sup. is unsubstituted or where preceded by "halo" is
substituted only with one or more halogens, and is independently
C.sub.1-4 aliphatic, --CH.sub.2Ph, --O(CH.sub.2).sub.0-1Ph, or a
5-6-membered saturated, partially unsaturated, or aryl ring having
0-4 heteroatoms independently selected from nitrogen, oxygen, or
sulfur.
[0057] Unless otherwise indicated, suitable substituents on a
substitutable nitrogen of an "optionally substituted" group include
--R.sup..dagger., --NR.sup..dagger..sub.2, --C(O)R.sup..dagger.,
--C(O)OR.sup..dagger., --C(O)C(O)R.sup..dagger.,
--C(O)CH.sub.2C(O)R.sup..dagger., --S(O).sub.2R.sup..dagger.,
--S(O).sub.2NR.sup..dagger..sub.2, --C(S)NR.sup..dagger..sub.2,
--C(NH)NR.sup..dagger..sub.2, or
--N(R.sup..dagger.)S(O).sub.2R.sup..dagger.; wherein each
R.sup..dagger. is independently hydrogen, C.sub.1-6 aliphatic which
may be substituted as defined below, unsubstituted --OPh, or an
unsubstituted 5-6-membered saturated, partially unsaturated, or
aryl ring having 0-4 heteroatoms independently selected from
nitrogen, oxygen, or sulfur, or, notwithstanding the definition
above, two independent occurrences of R.sup..dagger., taken
together with their intervening atom(s) form an unsubstituted
3-12-membered saturated, partially unsaturated, or aryl mono- or
bicyclic ring having 0-4 heteroatoms independently selected from
nitrogen, oxygen, or sulfur.
[0058] Unless otherwise indicated, suitable substituents on the
aliphatic group of R.sup..dagger. are independently halogen,
--R.sup. , -(haloR.sup. ), --OH, --OR.sup. , --O(haloR.sup. ),
--CN, --C(O)OH, --C(O)OR.sup. , --NH.sub.2, --NHR.sup. , --NR.sup.
.sub.2, or --NO.sub.2, wherein each R.sup. is unsubstituted or
where preceded by "halo" is substituted only with one or more
halogens, and is independently C.sub.1-4 aliphatic, --CH.sub.2Ph,
--O(CH.sub.2).sub.0-1Ph, or a 5-6-membered saturated, partially
unsaturated, or aryl ring having 0-4 heteroatoms independently
selected from nitrogen, oxygen, or sulfur.
[0059] Oxo: As used herein, the term "oxo" refers to a
double-bonded oxygen (.dbd.O). In compounds where an oxo group is
bound to an sp.sup.2 nitrogen atom, an N-oxide is indicated.
[0060] Provided compound: The term "provided compound," as used
herein, refers to a compound of Formula I:
##STR00006## [0061] or a pharmaceutically acceptable salt thereof,
wherein: [0062] R.sup.1 is H or (C.sub.1-C.sub.6)alkyl; [0063]
R.sup.2 is H or (C.sub.1-C.sub.6)alkyl; [0064] R.sup.a is H or
(C.sub.1-C.sub.6)alkyl; [0065] R.sup.3 is O(C.sub.1-C.sub.6)alkyl
or O(C.sub.1-C.sub.6)cycloalkyl; [0066] R.sup.4 is a 3-8 membered
saturated, partially unsaturated, or aryl monocyclic ring
containing 0-4 heteroatoms independently selected from nitrogen,
oxygen, or sulfur, or an 8-13 membered saturated, partially
unsaturated, or aryl bicyclic or tricyclic ring containing 0-4
heteroatoms independently selected from nitrogen, oxygen, or
sulfur, and wherein R.sup.4 is optionally substituted with 1-10
R.sup.f; [0067] each R.sup.f is independently halo, R.sup.X,
OR.sup.X, SR.sup.X, CN, S(O)R.sup.X, SO.sub.2R.sup.X,
OSO.sub.2R.sup.X, N(R.sup.X).sub.2, NO.sub.2, NR.sup.XC(O)R.sup.X,
NR.sup.XC(O)(CO)R.sup.X, NR.sup.XC(O)N(R.sup.X).sub.2,
NR.sup.XC(O)OR.sup.X, N(R.sup.X)S(O)R.sup.X,
N(R.sup.X)SO.sub.2R.sup.X, N(R.sup.X)SO.sub.2OR.sup.X, C(O)R.sup.X,
C(O)OR.sup.X, OC(O)R.sup.X, OC(O)OR.sup.X, C(O)N(R.sup.X).sub.2,
OC(O)N(R.sup.X).sub.2, or a 3-8 membered saturated, partially
unsaturated, or aryl monocyclic ring containing 0-4 heteroatoms
independently selected from nitrogen, oxygen, or sulfur, or two
R.sup.f on the same carbon are taken together to form an oxo group;
[0068] each R.sup.X is independently H, halo, N(R.sup.Y).sub.2,
C(O)OR.sup.Y, C.sub.1-8 aliphatic, C.sub.1-8 heteroaliphatic,
(C.sub.3-C.sub.6)cycloalkyl, 3-8 membered heterocycloalkyl
containing 1-3 heteroatoms independently selected from nitrogen,
oxygen, or sulfur, optionally substituted phenyl, or two R.sup.X on
the same nitrogen are taken together to form a 5-6 membered
saturated, partially saturated, or heteroaryl ring having 1-3
heteroatoms independently selected from nitrogen, oxygen, and
sulfur, or two R.sup.X on the same carbon or on adjacent carbons
are optionally taken together to form a
(C.sub.3-C.sub.6)cycloalkyl, or a 3-6 membered saturated fused
monocyclic ring containing 0-2 heteroatoms independently selected
from nitrogen, oxygen, and sulfur, or two R.sup.X on the same
carbon are taken together to form an oxo group; wherein the
C.sub.1-8 aliphatic, C.sub.1-8 heteroaliphatic,
(C.sub.3-C.sub.6)cycloalkyl, 3-8 membered heterocycloalkyl, or
phenyl is optionally substituted with 1-5 R.sup.z; [0069] each
R.sup.z is independently halo, C.sub.1-8 aliphatic, or C.sub.1-8
heteroaliphatic; [0070] each R.sup.Y is independently H or
(C.sub.1-C.sub.6)alkyl; [0071] R.sup.5 is
[0071] ##STR00007## [0072] R.sup.b is H or (C.sub.1-C.sub.6)alkyl;
[0073] R.sup.c is H, (C.sub.1-C.sub.6)alkyl or
(C.sub.3-C.sub.6)cycloalkyl, wherein R.sup.c is optionally
substituted with 1-5 groups independently selected from halo, D,
OR.sup.X, and N(R.sup.X).sub.2; [0074] Q is a 3-10 membered
saturated or partially unsaturated monocyclic or bicyclic
heterocycloalkyl containing 1-3 heteroatoms independently selected
from nitrogen, oxygen, or sulfur, optionally substituted with 1-5
R.sup.e; [0075] each R.sup.e is independently H,
(C.sub.1-C.sub.6)alkyl, N(R.sup.X).sub.2, C(O)R.sup.X,
C(O)OR.sup.X, S(O).sub.2R.sup.X, (C.sub.3-C.sub.6)cycloalkyl or 3-6
membered heterocycloalkyl containing 1-2 heteroatoms independently
selected from nitrogen, oxygen, or sulfur, or two R.sup.e wherein
R.sup.e on the same carbon are taken together to form an oxo group,
or two R.sup.e wherein R.sup.e on the same carbon are taken
together to form (C.sub.3-C.sub.8)cycloalkyl or 3-4 membered
heterocycloalkyl containing 1-2 heteroatoms independently selected
from nitrogen, oxygen, or sulfur, wherein R.sup.e is optionally
substituted with 1-5 R.sup.g; [0076] each R.sup.g is independently
halo, R.sup.X, OR.sup.X, N(R.sup.X).sub.2, C(O)R.sup.X,
C(O)OR.sup.X, OC(O)R.sup.X, OC(O)OR.sup.X, S(O).sub.2R.sup.X,
optionally substituted 3-4 membered heterocycloalkyl containing 1-2
heteroatoms independently selected from nitrogen, oxygen, or
sulfur, or two R.sup.g on the same carbon are taken together to
form an oxo group, or two R.sup.g on the same sulfur are optionally
taken together to form an oxo group; [0077] X.sup.1 is N or C(H);
[0078] X.sup.2 is N or C(H); [0079] X.sup.3 is N or C(H); and
[0080] wherein the compound is not one of the following
structures:
##STR00008## ##STR00009##
[0081] It is to be understood that one or more nitrogen atoms
included in either of the five-six fused heteroaryl rings of
Formula I can be present in an oxidized form. Accordingly, the
invention includes a compound of Formula I (as defined in the
summary of the invention) or a salt or N-oxide thereof.
Protecting Groups
[0082] In the context of the present disclosure, protecting groups
include prodrug moieties and chemical protecting groups.
[0083] Protecting group: As used herein, the phrase "protecting
group" refers to a moiety of a compound that masks or alters the
properties of a functional group or the properties of the compound
as a whole. Chemical protecting groups and strategies for
protection/deprotection are well known in the art. See e.g.,
Protective Groups in Organic Chemistry, Theodora W. Greene, John
Wiley & Sons, Inc., New York, 1991. Protecting groups are often
utilized to mask the reactivity of certain functional groups, to
assist in the efficiency of desired chemical reactions, e.g.,
making and breaking chemical bonds in an ordered and planned
fashion. Protection of functional groups of a compound alters other
physical properties besides the reactivity of the protected
functional group, such as the polarity, lipophilicity
(hydrophobicity), and other properties which can be measured by
common analytical tools. Chemically protected intermediates may
themselves be biologically active or inactive.
[0084] Protected compounds may also exhibit altered, and in some
cases, optimized properties in vitro and in vivo, such as passage
through cellular membranes and resistance to enzymatic degradation
or sequestration. In this role, protected compounds with intended
therapeutic effects may be referred to as prodrugs. Another
function of a protecting group is to convert the parental drug into
a prodrug, whereby the parental drug is released upon conversion of
the prodrug in vivo. Because active prodrugs may be absorbed more
effectively than the parental drug, prodrugs may possess greater
potency in vivo than the parental drug. Protecting groups are
removed either in vitro, in the instance of chemical intermediates,
or in vivo, in the case of prodrugs. With chemical intermediates,
it is not particularly important that the resulting products after
deprotection, e.g., alcohols, be physiologically acceptable,
although in general it is more desirable if the products are
pharmacologically innocuous.
[0085] Protecting groups are available, commonly known and used,
and are optionally used to prevent side reactions with the
protected group during synthetic procedures, i.e. routes or methods
to prepare the compounds of the invention. For the most part the
decision as to which groups to protect, when to do so, and the
nature of the chemical protecting group "PG" will be dependent upon
the chemistry of the reaction to be protected against (e.g.,
acidic, basic, oxidative, reductive or other conditions) and the
intended direction of the synthesis. Protecting groups do not need
to be, and generally are not, the same if the compound is
substituted with multiple protecting groups. In general, protecting
groups will be used to protect functional groups such as carboxyl,
hydroxyl, thio, or amino groups and to thus prevent side reactions
or to otherwise facilitate the synthetic efficiency. The order of
deprotection to yield free deprotected groups is dependent upon the
intended direction of the synthesis and the reaction conditions to
be encountered, and may occur in any order as determined by the
artisan.
[0086] Various functional groups of the compounds of the invention
may be protected. For example, protecting groups for --OH groups
(whether hydroxyl, carboxylic acid, phosphonic acid, or other
functions) include "ether- or ester-forming groups". Ether- or
ester-forming groups are capable of functioning as chemical
protecting groups in the synthetic schemes set forth herein.
However, some hydroxyl and thio protecting groups are neither
ether- nor ester-forming groups, as will be understood by those
skilled in the art, and are included with amides, discussed
below.
[0087] A very large number of hydroxyl protecting groups and
amide-forming groups and corresponding chemical cleavage reactions
are described in Protective Groups in Organic Synthesis, Theodora
W. Greene (John Wiley & Sons, Inc., New York, 1991, ISBN
0-471-62301-6) ("Greene"). See also Kocienski, Philip J.;
Protecting Groups (Georg Thieme Verlag Stuttgart, New York, 1994),
which is incorporated by reference in its entirety herein. In
particular Chapter 1, Protecting Groups: An Overview, pages 1-20,
Chapter 2, Hydroxyl Protecting Groups, pages 21-94, Chapter 3, Diol
Protecting Groups, pages 95-117, Chapter 4, Carboxyl Protecting
Groups, pages 118-154, Chapter 5, Carbonyl Protecting Groups, pages
155-184. For protecting groups for carboxylic acid, phosphonic
acid, phosphonate, sulfonic acid and other protecting groups for
acids see Greene.
Stereoisomers
[0088] Compounds of the invention may have chiral centers, e.g.,
chiral carbon or phosphorus atoms. In some embodiments, compounds
of the invention include mixtures of all stereoisomers, including
enantiomers, diastereomers, and atropisomers.
[0089] Chiral: As used herein, the term "chiral" refers to
molecules which have the property of non-superimposability of the
mirror image partner, while the term "achiral" refers to molecules
which are superimposable on their mirror image partner.
[0090] Diastereoisomer: As used herein, the term "diastereomer"
refers to a stereoisomer with two or more centers or axes of
chirality and whose molecules are not mirror images of one another.
Diastereomers typically have different physical properties, e.g.,
melting points, boiling points, spectral properties, and
reactivities. Mixtures of diastereomers may separate under high
resolution analytical procedures such as electrophoresis and
chromatography.
[0091] Enantiomer: As used herein, the term "enantiomer" refers to
two stereoisomers of a compound which are non-superimposable mirror
images of one another.
[0092] Stereoisomers: As used herein, the term "stereoisomers"
refers to compounds which have identical chemical constitution, but
differ with regard to the arrangement of the atoms or groups in
space.
[0093] In some embodiments, compounds of the present invention
exist as atropisomers. For example, atropisomers can exist when
R.sup.4 of Formula I is, e.g., phenyl, and certain substitution
patterns are present on the phenyl ring, with such chirality
occurring at the site indicated below with an asterisk:
##STR00010##
[0094] In some embodiments, chirality that results from
atropisomers (e.g., at the above-depicted asterisk position in
Formula I) may be a feature of particular compound(s) of the
invention. In some embodiments, the invention may include all
atropisomers of a particular compound. In some embodiments, the
invention may include mixtures of two or more atropisomers; in some
such embodiments, the invention may include mixtures that are
enriched in one or more particular atropisomers as compared with
one or more other atropisomers. In some embodiments, the present
invention provides a single atropisomer of particular compound(s)
described herein. In some embodiments, a particular atropisomer, or
mixture thereof, may be characterized by one or more
characteristics, properties, or activities, as described
herein.
[0095] In some embodiments, compounds of the invention are greater
than 50% a single atropisomer at the asterisk position. In some
embodiments, compounds of the invention are at least 60% a single
atropisomer at the asterisk position. In some embodiments,
compounds of the invention are at least 70% a single atropisomer at
the asterisk position. In some embodiments, compounds of the
invention are at least 80% a single atropisomer at the asterisk
position. In some embodiments, compounds of the invention are at
least 90% a single atropisomer at the asterisk position. In some
embodiments, compounds of the invention are at least 95% a single
atropisomer at the asterisk position. In some embodiments,
stereochemistry at the carbon marked with an asterisk as shown
above for compounds of the invention (e.g., compounds of Formula I)
is in the (R) configuration. In some embodiments, stereochemistry
at the carbon marked with an asterisk as shown above for compounds
of the invention (e.g., compounds of Formula I) is in the (S)
configuration.
[0096] In some embodiments, stereochemistry of compounds of the
invention occurs at the carbon bearing the R.sup.3 substituent, as
marked by an asterisk in the formula below.
##STR00011##
[0097] In some embodiments, stereochemistry at the carbon marked
with an asterisk as shown in the formula above for compounds of the
invention is in the (S) configuration. In some embodiments,
stereochemistry at the carbon marked with an asterisk as shown in
the formula above for compounds of the invention is in the (R)
configuration.
[0098] In some embodiments, compounds of the invention are greater
than 50% a single stereoisomer for the carbon at the asterisk
position. In some embodiments, compounds of the invention are at
least 60% a single stereoisomer for the carbon at the asterisk
position. In some embodiments, compounds of the invention are at
least 70% a single stereoisomer for the carbon at the asterisk
position. In some embodiments, compounds of the invention are at
least 80% a single stereoisomer for the carbon at the asterisk
position. In some embodiments, compounds of the invention are at
least 90% a single stereoisomer for the carbon at the asterisk
position. In some embodiments, compounds of the invention are at
least 95% a single stereoisomer for the carbon at the asterisk
position.
[0099] One skilled in the art will recognize that substituents and
other moieties of the compounds disclosed herein should be selected
in order to provide a compound which is sufficiently stable to
provide a pharmaceutically useful compound which can be formulated
into an acceptably stable pharmaceutical composition. Compounds
disclosed herein which have such stability are contemplated as
falling within the scope of the present invention.
[0100] It is to be understood that for compounds disclosed herein
when a bond is drawn in a non-stereochemical manner (e.g. flat) the
atom to which the bond is attached includes all stereochemical
possibilities. It is also to be understood that when a bond is
drawn in a stereochemical manner (e.g. bold, bold-wedge, dashed or
dashed-wedge) the atom to which the stereochemical bond is attached
has the stereochemistry as shown unless otherwise noted.
[0101] Stereochemical definitions and conventions used herein
generally follow S. P. Parker, Ed., McGraw-Hill Dictionary of
Chemical Terms (1984) McGraw-Hill Book Company, New York; and
Eliel, E. and Wilen, S., Stereochemistry of Organic Compounds
(1994) John Wiley & Sons, Inc., New York. Many organic
compounds exist in optically active forms, i.e., they have the
ability to rotate the plane of plane-polarized light. In describing
an optically active compound, the prefixes (D and L) or (R and S)
are used to denote the absolute configuration of the molecule about
its chiral center(s). The prefixes d and 1 or (+) and (-) are
employed to designate the sign of rotation of plane-polarized light
by the compound, with (-) or 1 meaning that the compound is
levorotatory. A compound prefixed with (+) or d is dextrorotatory.
For a given chemical structure, these stereoisomers are identical
except that they are mirror images of one another. A specific
stereoisomer may also be referred to as an enantiomer, and a
mixture of such isomers is often called an enantiomeric mixture. A
50:50 mixture of enantiomers is referred to as a racemic mixture or
a racemate, which may occur where there has been no stereoselection
or stereospecificity in a chemical reaction or process. The terms
"racemic mixture" and "racemate" refer to an equimolar mixture of
two enantiomeric species, devoid of optical activity.
[0102] In some embodiments, compounds of the invention include
enriched or resolved optical isomers at any or all asymmetric,
chiral atoms. In other words, in some embodiments, one or more
chiral centers apparent from the depictions are provided as chiral
isomers or racemic mixtures. Both racemic and diastereomeric
mixtures, as well as individual optical isomers isolated or
synthesized, substantially free of their enantiomeric or
diastereomeric partners, are all within the scope of the invention.
Racemic mixtures can be separated into individual, substantially
optically pure isomers through well-known techniques such as, for
example, separation of diastereomeric salts formed with optically
active adjuncts, e.g., acids or bases followed by conversion back
to the optically active substances. In some embodiments, a desired
optical isomer is synthesized by means of stereospecific reactions,
beginning with an appropriate stereoisomer of a desired starting
material.
[0103] In some embodiments, compounds described herein can also
exist as tautomeric isomers. Although only one delocalized
resonance structure may be depicted, all such forms are
contemplated within the scope of the invention. For example,
ene-amine tautomers can exist for purine, pyrimidine, imidazole,
guanidine, amidine, and tetrazole systems and all their possible
tautomeric forms are within the scope of the invention.
Salts and Hydrates
[0104] Pharmaceutically acceptable: As used herein, the phrase
"pharmaceutically acceptable" with respect to a substance refers to
that substance which is generally regarded as safe and suitable for
use without undue toxicity, irritation, allergic response, and the
like, commensurate with a reasonable benefit/risk ratio.
[0105] Pharmaceutically acceptable salt: In some embodiments, a
compound provided herein is used in salt form. As used herein, the
phrase "pharmaceutically acceptable salt" refers to a salt of a
compound that is pharmaceutically acceptable and that possesses (or
can be converted to a form that possesses) the desired
pharmacological activity of the parent compound. Such salts include
acid addition salts formed with inorganic acids such as
hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid,
phosphoric acid, and the like; or formed with organic acids such as
acetic acid, benzenesulfonic acid, benzoic acid, camphorsulfonic
acid, citric acid, ethanesulfonic acid, fumaric acid, glucoheptonic
acid, gluconic acid, lactic acid, maleic acid, malonic acid,
mandelic acid, methanesulfonic acid, 2-napththalenesulfonic acid,
oleic acid, palmitic acid, propionic acid, stearic acid, succinic
acid, tartaric acid, p-toluenesulfonic acid, trimethylacetic acid,
and the like, and salts formed when an acidic proton present in the
parent compound is replaced by either a metal ion, e.g., an alkali
metal ion, an alkaline earth ion, or an aluminum ion; or
coordinates with an organic base such as diethanolamine,
triethanolamine, N-methylglucamine and the like. Also included in
this definition are ammonium and substituted or quaternized
ammonium salts. Representative non-limiting lists of
pharmaceutically acceptable salts can be found in S. M. Berge et
al., J. Pharma Sci., 66(1), 1-19 (1977), and Remington: The Science
and Practice of Pharmacy, R. Hendrickson, ed., 21st edition,
Lippincott, Williams & Wilkins, Philadelphia, Pa., (2005), at
p. 732, Table 38-5, both of which are hereby incorporated by
reference herein.
[0106] Examples of pharmaceutically acceptable salts of compounds
described herein include salts derived from an appropriate base,
such as an alkali metal (for example, sodium), an alkaline earth
metal (for example, magnesium), ammonium and NX.sub.4.sup.+
(wherein X is C.sub.1-C.sub.4 alkyl). Pharmaceutically acceptable
salts of a nitrogen atom or an amino group include for example
salts of organic carboxylic acids such as acetic, benzoic, lactic,
fumaric, tartaric, maleic, malonic, malic, isethionic, lactobionic
and succinic acids; organic sulfonic acids, such as
methanesulfonic, ethanesulfonic, benzenesulfonic and
p-toluenesulfonic acids; and inorganic acids, such as hydrochloric,
hydrobromic, sulfuric, phosphoric and sulfamic acids.
Pharmaceutically acceptable salts of a compound containing a
hydroxy group include the anion of said compound in combination
with a suitable cation such as Na.sup.+ and NX.sub.4.sup.+ (wherein
X is independently selected from H or a C.sub.1-C.sub.4 alkyl
group).
[0107] For therapeutic use, salts of active ingredients of
compounds disclosed herein will typically be pharmaceutically
acceptable, i.e. they will be salts derived from a physiologically
acceptable acid or base. However, in some embodiments, salts of
acids or bases which are not pharmaceutically acceptable may also
find use, for example, in the preparation or purification of a
compound of disclosed herein. All salts, whether or not derived
from a physiologically acceptable acid or base, are within the
scope of the present invention.
[0108] Metal salts can be prepared by reacting a metal hydroxide
with a compound disclosed herein. Examples of metal salts which are
prepared in this way are salts containing Li.sup.+, Na.sup.+, and
K.sup.+. A less soluble metal salt can be precipitated from the
solution of a more soluble salt by addition of a suitable metal
compound.
[0109] In addition, salts may be formed from acid addition of
certain organic and inorganic acids, e.g., HCl, HBr,
H.sub.2SO.sub.4, H.sub.3PO.sub.4 or organic sulfonic acids, to
basic centers, such as amines. Finally, it is to be understood that
compositions herein comprise compounds disclosed herein in their
un-ionized, as well as zwitterionic form, and combinations with
water as in hydrates. In some embodiments, hydrates include a
compound disclosed herein with stoichiometric amounts of water.
[0110] Subjects: As used herein, the terms "subject" and "subjects"
"refers to humans, domestic animals (e.g., dogs and cats), farm
animals (e.g., cattle, horses, sheep, goats and pigs), laboratory
animals (e.g., mice, rats, hamsters, guinea pigs, pigs, rabbits,
dogs, and monkeys), and the like.
[0111] Therapeutically effective amount: used herein, the term
"therapeutically effective amount" means an amount of a substance
(e.g., a therapeutic agent, composition, and/or formulation) that
elicits a desired biological response when administered as part of
a therapeutic regimen. In some embodiments, a therapeutically
effective amount of a substance is an amount that is sufficient,
when administered to a subject suffering from or susceptible to a
disease, disorder, and/or condition, to treat, diagnose, prevent,
and/or delay the onset of the disease, disorder, and/or condition.
As will be appreciated by those of ordinary skill in this art, the
effective amount of a substance may vary depending on such factors
as the desired biological endpoint, the substance to be delivered,
the target cell or tissue, etc. For example, the effective amount
of compound in a formulation to treat a disease, disorder, and/or
condition is the amount that alleviates, ameliorates, relieves,
inhibits, prevents, delays onset of, reduces severity of and/or
reduces incidence of one or more symptoms or features of the
disease, disorder, and/or condition. In some embodiments, a
therapeutically effective amount is administered in a single dose;
in some embodiments, multiple unit doses are required to deliver a
therapeutically effective amount.
[0112] Treating: As used herein, the terms "treating" and
"treatment" of a disease include the following:
[0113] (1) preventing or reducing the risk of developing the
disease, i.e., causing the clinical symptoms of the disease not to
develop in a subject that may be exposed to or predisposed to the
disease but does not yet experience or display symptoms of the
disease,
[0114] (2) inhibiting the disease, i.e., arresting or reducing the
development of the disease or its clinical symptoms, or
[0115] (3) relieving the disease, i.e., causing regression of the
disease or its clinical symptoms.
Isotopes
[0116] It is understood by one skilled in the art that, in some
embodiments, this invention also includes any compound claimed that
may be enriched at any or all atoms above naturally occurring
isotopic ratios with one or more isotopes such as, but not limited
to, deuterium (.sup.2H or D). As a non-limiting example, a
--CH.sub.3 group may be substituted with --CD.sub.3.
Forms
[0117] It is contemplated that provided compounds can exist in a
variety of physical forms. For example, provided compounds can be
in solution, suspension, or in solid form. In certain embodiments,
a provided compound is in solid form. In such embodiments, a
provided compound may be amorphous, crystalline, or a mixture
thereof.
Compounds of Formula I
[0118] In some embodiments, the present invention provides a
compound of Formula [0119] I:
[0119] ##STR00012## [0120] or a pharmaceutically acceptable salt
thereof, wherein: [0121] R.sup.1 is H or (C.sub.1-C.sub.6)alkyl;
[0122] R.sup.2 is H or (C.sub.1-C.sub.6)alkyl; [0123] R.sup.a is H
or (C.sub.1-C.sub.6)alkyl; [0124] R.sup.3 is
O(C.sub.1-C.sub.6)alkyl or O(C.sub.1-C.sub.6)cycloalkyl; [0125]
R.sup.4 is a 3-8 membered saturated, partially unsaturated, or aryl
monocyclic ring containing 0-4 heteroatoms independently selected
from nitrogen, oxygen, or sulfur, or an 8-13 membered saturated,
partially unsaturated, or aryl bicyclic or tricyclic ring
containing 0-4 heteroatoms independently selected from nitrogen,
oxygen, or sulfur, and wherein R.sup.4 is optionally substituted
with 1-10 R.sup.f; [0126] each R.sup.f is independently halo,
R.sup.X, OR.sup.X, SR.sup.X, CN, S(O)R.sup.X, SO.sub.2R.sup.X,
OSO.sub.2R.sup.X, N(R.sup.X).sub.2, NO.sub.2, NR.sup.XC(O)R.sup.X,
NR.sup.XC(O)(CO)R.sup.X, NR.sup.XC(O)N(R.sup.X).sub.2,
NR.sup.XC(O)OR.sup.X, N(R.sup.X)S(O)R.sup.X,
N(R.sup.X)SO.sub.2R.sup.X, N(R.sup.X)SO.sub.2OR.sup.X, C(O)R.sup.X,
C(O)OR.sup.X, OC(O)R.sup.X, OC(O)OR.sup.X, C(O)N(R.sup.X).sub.2,
OC(O)N(R.sup.X).sub.2, or a 3-8 membered saturated, partially
unsaturated, or aryl monocyclic ring containing 0-4 heteroatoms
independently selected from nitrogen, oxygen, or sulfur, or two
R.sup.f on the same carbon are taken together to form an oxo group;
[0127] each R.sup.X is independently H, halo, N(R.sup.Y).sub.2,
C(O)OR.sup.Y, C.sub.1-8 aliphatic, C.sub.1-8 heteroaliphatic,
(C.sub.3-C.sub.6)cycloalkyl, 3-8 membered heterocycloalkyl
containing 1-3 heteroatoms independently selected from nitrogen,
oxygen, or sulfur, optionally substituted phenyl, or two R.sup.X on
the same nitrogen are taken together to form a 5-6 membered
saturated, partially saturated, or heteroaryl ring having 1-3
heteroatoms independently selected from nitrogen, oxygen, and
sulfur, or two R.sup.X on the same carbon or on adjacent carbons
are optionally taken together to form a
(C.sub.3-C.sub.6)cycloalkyl, or a 3-6 membered saturated fused
monocyclic ring containing 0-2 heteroatoms independently selected
from nitrogen, oxygen, and sulfur, or two R.sup.X on the same
carbon are taken together to form an oxo group; wherein the
C.sub.1-8 aliphatic, C.sub.1-8 heteroaliphatic,
(C.sub.3-C.sub.6)cycloalkyl, 3-8 membered heterocycloalkyl, or
phenyl is optionally substituted with 1-5 R.sup.z; [0128] each
R.sup.z is independently halo, C.sub.1-8 aliphatic, or C.sub.1-8
heteroaliphatic; [0129] each R.sup.Y is independently H or
(C.sub.1-C.sub.6)alkyl; [0130] R.sup.5 is
[0130] ##STR00013## [0131] R.sup.b is H or (C.sub.1-C.sub.6)alkyl;
[0132] R.sup.c is H, (C.sub.1-C.sub.6)alkyl or
(C.sub.3-C.sub.6)cycloalkyl, wherein R.sup.c is optionally
substituted with 1-5 groups independently selected from halo, D,
OR.sup.X, and N(R.sup.X).sub.2; [0133] Q is a 3-10 membered
saturated or partially unsaturated monocyclic or bridged,
spirocyclic, or fused bicyclic heterocycloalkyl containing 1-3
heteroatoms independently selected from nitrogen, oxygen, or
sulfur, optionally substituted with 1-5 R.sup.e; [0134] each
R.sup.e is independently H, (C.sub.1-C.sub.6)alkyl,
N(R.sup.X).sub.2, C(O)R.sup.X, C(O)OR.sup.X, S(O).sub.2R.sup.X,
(C.sub.3-C.sub.6)cycloalkyl or 3-6 membered heterocycloalkyl
containing 1-2 heteroatoms independently selected from nitrogen,
oxygen, or sulfur, or two R.sup.e wherein R.sup.e on the same
carbon are taken together to form an oxo group, or two R.sup.e
wherein R.sup.e on the same carbon are taken together to form
(C.sub.3-C.sub.8)cycloalkyl or 3-4 membered heterocycloalkyl
containing 1-2 heteroatoms independently selected from nitrogen,
oxygen, or sulfur, wherein R.sup.e is optionally substituted with
1-5 R.sup.g; [0135] each R.sup.g is independently halo, R.sup.X,
OR.sup.X, N(R.sup.X).sub.2, C(O)R.sup.X, C(O)OR.sup.X,
OC(O)R.sup.X, OC(O)OR.sup.X, S(O).sub.2R.sup.X, optionally
substituted 3-4 membered heterocycloalkyl containing 1-2
heteroatoms independently selected from nitrogen, oxygen, or
sulfur, or two R.sup.g on the same carbon are taken together to
form an oxo group, or two R.sup.g on the same sulfur are optionally
taken together to form an oxo group; [0136] X.sup.1 is N or C(H);
[0137] X.sup.2 is N or C(H); [0138] X.sup.3 is N or C(H); and
[0139] wherein the compound is not one of the following
structures:
##STR00014## ##STR00015##
[0140] In some embodiments, Q is not one of the following
formulae:
##STR00016##
[0141] In some embodiments, when Q is piperazine R.sup.e is not an
optionally substituted C.sub.1-6 alkyl group. For instance, in some
embodiments, when Q is piperazine R.sup.e is not methyl, isopropyl,
or 1,1,1-trifluoroisopropyl.
[0142] In some embodiments, when Q is piperidine R.sup.e is not an
optionally substituted C.sub.1-6 alkyl group. For instance, in some
embodiments, when Q is piperidine R.sup.e is not methyl.
[0143] In some embodiments, when Q is tetrahydropyridine R.sup.e is
not an optionally substituted C.sub.1-6 alkyl group. For instance,
in some embodiments, when Q is tetrahydropyridine R.sup.e is not
methyl.
[0144] In some embodiments, a provided compound is of either of the
following formulae:
##STR00017##
or a pharmaceutically acceptable salt thereof, wherein R.sup.1,
R.sup.2, R.sup.3, R.sup.4, R.sup.a, R.sup.b, R.sup.c, R.sup.e,
X.sup.1, X.sup.2, and X.sup.3 are as defined and described above
and herein.
[0145] In some embodiments, a provided compound is of either of the
following formulae:
##STR00018##
or a pharmaceutically acceptable salt thereof, wherein R.sup.1,
R.sup.3, R.sup.4, R.sup.a, R.sup.b, R.sup.c, R.sup.e, X.sup.1,
X.sup.2, and X.sup.3 are as defined and described above and
herein.
[0146] In some embodiments, a provided compound is of either of the
following formulae:
##STR00019##
or a pharmaceutically acceptable salt thereof, wherein R.sup.1,
R.sup.2, R.sup.3, R.sup.4, R.sup.c, R.sup.e, X.sup.1, X.sup.2, and
X.sup.3 are as defined and described above and herein.
[0147] In some embodiments, a provided compound is of either of the
following formulae:
##STR00020##
or a pharmaceutically acceptable salt thereof, wherein R.sup.1,
R.sup.2, R.sup.4, R.sup.a, R.sup.c, R.sup.e, X.sup.1, X.sup.2, and
X.sup.3 are as defined and described above and herein.
[0148] In some embodiments, a provided compound is of either of the
following formulae:
##STR00021##
or a pharmaceutically acceptable salt thereof, wherein R.sup.1,
R.sup.2, R.sup.3, R.sup.4, R.sup.a, R.sup.c, R.sup.e, X.sup.1,
X.sup.2, and X.sup.3 are as defined and described above and
herein.
[0149] In some embodiments, a provided compound is of either of the
following formulae:
##STR00022##
or a pharmaceutically acceptable salt thereof, wherein R.sup.1,
R.sup.2, R.sup.3, R.sup.4, R.sup.a, R.sup.c, R.sup.e, X.sup.1,
X.sup.2, and X.sup.3 are as defined and described above and
herein.
[0150] In some embodiments, a provided compound is of either of the
following formulae:
##STR00023##
or a pharmaceutically acceptable salt thereof, wherein R.sup.1,
R.sup.2, R.sup.3, R.sup.4, R.sup.a, R.sup.c and R.sup.e are as
defined and described above and herein.
[0151] In some embodiments, a provided compound is of either of the
following formulae:
##STR00024##
or a pharmaceutically acceptable salt thereof, wherein R.sup.1,
R.sup.2, R.sup.3, R.sup.4, R.sup.a, R.sup.c, and R.sup.e are as
defined and described above and herein.
[0152] In some embodiments, a provided compound is of either of the
following formulae:
##STR00025##
or a pharmaceutically acceptable salt thereof, wherein R.sup.1,
R.sup.2, R.sup.3, R.sup.4, R.sup.a, R.sup.c, and R.sup.e are as
defined and described above and herein.
[0153] In some embodiments, a provided compound is of either of the
following formulae:
##STR00026##
or a pharmaceutically acceptable salt thereof, wherein R.sup.1,
R.sup.2, R.sup.3, R.sup.4, R.sup.a, R.sup.c, and R.sup.e are as
defined and described above and herein.
[0154] In some embodiments, a provided compound is of either of the
following formulae:
##STR00027##
or a pharmaceutically acceptable salt thereof, wherein R.sup.4,
R.sup.c, R.sup.e, X.sup.1, X.sup.2, and X.sup.3 are as defined and
described above and herein.
[0155] In some embodiments, a provided compound is of either of the
following formulae:
##STR00028##
or a pharmaceutically acceptable salt thereof, wherein R.sup.4,
R.sup.c, R.sup.e, X.sup.1, X.sup.2, and X.sup.3 are as defined and
described above and herein.
[0156] In some embodiments, a provided compound is of either of the
following formulae:
##STR00029##
or a pharmaceutically acceptable salt thereof, wherein R.sup.4,
R.sup.c, R.sup.e, X.sup.1, X.sup.2, and X.sup.3 are as defined and
described above and herein.
[0157] In some embodiments, a provided compound is of either of the
following formulae:
##STR00030##
or a pharmaceutically acceptable salt thereof, wherein R.sup.4,
R.sup.c, R.sup.g, X.sup.1, X.sup.2, and X.sup.3 are as defined and
described above and herein.
[0158] In some embodiments, a provided compound is of either of the
following formulae:
##STR00031##
or a pharmaceutically acceptable salt thereof, wherein R.sup.1,
R.sup.2, R.sup.3, R.sup.4, R.sup.a, R.sup.c, R.sup.g, X.sup.1,
X.sup.2, and X.sup.3 are as defined and described above and
herein.
[0159] In some embodiments, a provided compound is of either of the
following formulae:
##STR00032##
or a pharmaceutically acceptable salt thereof, wherein R.sup.1,
R.sup.2, R.sup.3, R.sup.4, R.sup.a, R.sup.c, X.sup.1, X.sup.2, and
X.sup.3are as defined and described above and herein.
[0160] In some embodiments, a provided compound is of either of the
following formulae:
##STR00033##
or a pharmaceutically acceptable salt thereof, wherein R.sup.1,
R.sup.2, R.sup.3, R.sup.4, R.sup.a, R.sup.c, X.sup.1, X.sup.2, and
X.sup.3are as defined and described above and herein.
[0161] In some embodiments, a provided compound is of any of the
above depicted formulae and one or more of R.sup.1, R.sup.2,
R.sup.3, R.sup.4, R.sup.a, R.sup.b, R.sup.c, R.sup.e, X.sup.1,
X.sup.2, and X.sup.3 are as defined and described above and
herein.
[0162] In certain embodiments, a provided compound is of formula
II-e:
##STR00034##
or a pharmaceutically acceptable salt thereof, wherein X.sup.1,
X.sup.2, and X.sup.3 are as defined and described above and herein,
wherein: [0163] R.sup.1 is H; [0164] R.sup.2 is
(C.sub.1-C.sub.6)alkyl; [0165] R.sup.a is H; [0166] R.sup.3 is
O(C.sub.1-C.sub.6)alkyl; [0167] R.sup.4 is
[0167] ##STR00035## [0168] R.sup.c is (C.sub.1-C.sub.6)alkyl or
(C.sub.3-C.sub.6)cycloalkyl, wherein R.sup.c is optionally
substituted with 1-5 groups independently selected from halo, D,
OR.sup.X, and N(R.sup.X).sub.2; [0169] R.sup.e is a 4 membered
heterocycloalkyl having one heteroatom selected from N or O,
wherein R.sup.e is optionally substituted with 1-2 R.sup.g; [0170]
each R.sup.g is independently C(O)R.sup.X or C(O)OR.sup.X; and
[0171] each R.sup.X is independently C.sub.1-8 aliphatic.
[0172] In certain embodiments, a provided compound is of formula
II-e, wherein X.sup.1 is N, X.sup.2 is C(H), and X.sup.3 is N. In
certain embodiments, a provided compound is of formula II-e,
wherein X.sup.1 is C(H), X.sup.2 is C(H), and X.sup.3 is N. In
certain embodiments, a provided compound is of formula II-e,
wherein X.sup.1 is C(H), X.sup.2 is N, and X.sup.3 is C(H). In
certain embodiments, a provided compound is of formula II-e,
wherein X.sup.1 is N, X.sup.2 is N, and X.sup.3 is C(H).
[0173] In certain embodiments, a provided compound is of formula
II-e, wherein R.sup.3 is
##STR00036##
[0174] As defined generally above, R.sup.1 is H or
(C.sub.1-C.sub.6)alkyl. In some embodiments, R.sup.1 is H. In some
embodiments, R.sup.1 is (C.sub.1-C.sub.6)alkyl. In some such
embodiments, R.sup.1 is methyl, ethyl, propyl, or butyl.
[0175] As defined generally above, R.sup.2 is H or
(C.sub.1-C.sub.6)alkyl. In some embodiments, R.sup.2 is H. In some
embodiments, R.sup.2 is (C.sub.1-C.sub.6)alkyl. In some such
embodiments, R.sup.2 is methyl, ethyl, propyl, or butyl. In some
such embodiments, R.sup.2 is methyl.
[0176] As defined generally above, R.sup.a is H or
(C.sub.1-C.sub.6)alkyl. In some embodiments, R.sup.a is H. In some
embodiments, R.sup.a is (C.sub.1-C.sub.6)alkyl. In some such
embodiments, R.sup.a is methyl, ethyl, propyl, or butyl.
[0177] As defined generally above, R.sup.3 is
O(C.sub.1-C.sub.6)alkyl or O(C.sub.1-C.sub.6)cycloalkyl. In some
embodiments, R.sup.3 is OMe, OEt, O-nPr, O-iPr, O-iBu, O-nBu,
O-sBu, O-tBu, or O-cyclopropyl. In some embodiments, R.sup.3 is
O-nPr, O-iPr, or O-tBu. In certain embodiments, R.sup.3 is O-tBu.
In certain embodiments, R.sup.3 is O-cyclopropyl. In certain
embodiments, R.sup.3 is
##STR00037##
[0178] As defined generally above, R.sup.4 is a 3-8 membered
saturated, partially unsaturated, or aryl monocyclic ring
containing 0-4 heteroatoms independently selected from nitrogen,
oxygen, or sulfur, or an 8-13 membered saturated, partially
unsaturated, or aryl bicyclic or tricyclic ring containing 0-4
heteroatoms independently selected from nitrogen, oxygen, or
sulfur, and wherein R.sup.4 is optionally substituted with 1-10
R.sup.f;
[0179] In some embodiments, R.sup.4 is an optionally substituted
3-8 membered saturated monocyclic ring having 0-4 heteroatoms
independently selected from nitrogen, oxygen, or sulfur. In some
embodiments, R.sup.4 is an optionally substituted 3-6 membered
saturated monocyclic ring having 0-2 heteroatoms independently
selected from nitrogen, oxygen, or sulfur. In some embodiments,
R.sup.4 is an optionally substituted 5-6 membered saturated
monocyclic ring having 0-2 heteroatoms independently selected from
nitrogen, oxygen, or sulfur. In some embodiments, R.sup.4 is an
optionally substituted 3-8 membered saturated monocyclic
carbocycle.
[0180] In some embodiments, R.sup.4 is an optionally substituted
3-8 membered partially unsaturated monocyclic ring having 0-4
heteroatoms independently selected from nitrogen, oxygen, or
sulfur. In some embodiments, R.sup.4 is an optionally substituted
3-6 membered partially unsaturated monocyclic ring having 0-2
heteroatoms independently selected from nitrogen, oxygen, or
sulfur. In some embodiments, R.sup.4 is an optionally substituted
5-6 membered partially unsaturated monocyclic ring having 0-2
heteroatoms independently selected from nitrogen, oxygen, or
sulfur. In some embodiments, R.sup.4 is an optionally substituted
3-8 membered partially unsaturated monocyclic carbocycle.
[0181] In some embodiments, R.sup.4 is an optionally substituted
5-6 membered aryl ring having 0-4 heteroatoms independently
selected from nitrogen, oxygen, or sulfur. In some embodiments,
R.sup.4 is an optionally substituted 5-6 membered aryl ring having
0-2 heteroatoms independently selected from nitrogen, oxygen, or
sulfur. In some embodiments, R.sup.4 is an optionally substituted 5
membered heteroaryl ring having 1-3 heteroatoms independently
selected from nitrogen, oxygen, or sulfur. In some embodiments,
R.sup.4 is an optionally substituted 6 membered heteroaryl ring
having 1-3 nitrogens. In some embodiments, R.sup.4 is optionally
substituted phenyl. In certain embodiments, R.sup.4 is phenyl
substituted at the para position relative to the position of
connection to the rest of the compound.
[0182] In certain embodiments, R.sup.4 is phenyl optionally
substituted with 1-3 halo. In certain embodiments, R.sup.4 is
phenyl optionally substituted with 1-3 chloro. In certain
embodiments, R.sup.4 is phenyl substituted with one chloro. In
certain embodiments, R.sup.4 is
##STR00038##
[0183] In some embodiments, R.sup.4 is an optionally substituted
8-13 membered saturated bicyclic or tricyclic ring having 0-4
heteroatoms independently selected from nitrogen, oxygen, or
sulfur. In some embodiments, R.sup.4 is an optionally substituted
8-13 membered saturated bicyclic or tricyclic ring having 0-2
heteroatoms independently selected from nitrogen, oxygen, or
sulfur. In some embodiments, R.sup.4 is an optionally substituted
8-13 membered saturated bicyclic or tricyclic carbocycle.
[0184] In some embodiments, R.sup.4 is an optionally substituted
8-13 membered partially unsaturated bicyclic or tricyclic ring
having 0-4 heteroatoms independently selected from nitrogen,
oxygen, or sulfur. In some embodiments, R.sup.4 is an optionally
substituted 8-13 membered partially unsaturated bicyclic or
tricyclic ring having 0-3 heteroatoms independently selected from
nitrogen, oxygen, or sulfur. In some embodiments, R.sup.4 is an
optionally substituted 8-13 membered partially unsaturated bicyclic
or tricyclic ring having 1-3 heteroatoms independently selected
from nitrogen, oxygen, or sulfur. In some embodiments, R.sup.4 is
an optionally substituted 8-13 membered partially unsaturated
bicyclic or tricyclic carbocycle.
[0185] In some embodiments, R.sup.4 is an optionally substituted
8-13 membered aryl bicyclic or tricyclic ring having 0-4
heteroatoms independently selected from nitrogen, oxygen, or
sulfur. In some embodiments, R.sup.4 is an optionally substituted
8-13 membered aryl bicyclic or tricyclic ring having 0-2
heteroatoms independently selected from nitrogen, oxygen, or
sulfur. In some embodiments, R.sup.4 is an optionally substituted
10 membered aryl bicyclic ring having 0-3 heteroatoms independently
selected from nitrogen, oxygen, or sulfur.
[0186] As defined generally above, R.sup.4 is optionally
substituted with 1-10 R.sup.f. In some embodiments, R.sup.4 is
optionally substituted with 1-8 R.sup.f. In some embodiments,
R.sup.4 is optionally substituted with 1-6 R.sup.f. In some
embodiments, R.sup.4 is optionally substituted with 1-4 R.sup.f. In
some embodiments, R.sup.4 is optionally substituted with 1-2
R.sup.f. In some embodiments, R.sup.4 is optionally substituted
with one R.sup.f.
[0187] As defined generally above, each R.sup.f is independently
halo, R.sup.X, OR.sup.X, SR.sup.X, CN, S(O)R.sup.X,
SO.sub.2R.sup.X, OSO.sub.2R.sup.X, N(R.sup.X).sub.2, NO.sub.2,
NR.sup.XC(O)R.sup.X, NR.sup.XC(O)(CO)R.sup.X,
NR.sup.XC(O)N(R.sup.X).sub.2, NR.sup.XC(O)OR.sup.X,
N(R.sup.X)S(O)R.sup.X, N(R.sup.X)SO.sub.2R.sup.X,
N(R.sup.X)SO.sub.2OR.sup.X, C(O)R.sup.X, C(O)OR.sup.X,
OC(O))R.sup.X, OC(O)OR.sup.X, C(O)N(R.sup.X).sub.2,
OC(O)N(R.sup.X).sub.2, or a 3-8 membered saturated, partially
unsaturated, or aryl monocyclic ring containing 0-4 heteroatoms
independently selected from nitrogen, oxygen, or sulfur, or two
R.sup.f on the same carbon are taken together to form an oxo
group.
[0188] In some embodiments, each R.sup.f is independently halo,
R.sup.X, OR.sup.X, SR.sup.X, CN, S(O)R.sup.X, SO.sub.2R.sup.X,
OSO.sub.2R.sup.X, N(R.sup.X).sub.2, NO.sub.2, NR.sup.XC(O)R.sup.X,
NR.sup.XC(O)(CO)R.sup.X, NR.sup.XC(O)N(R.sup.X).sub.2,
NR.sup.XC(O)OR.sup.X, N(R.sup.X)S(O)R.sup.X,
N(R.sup.X)SO.sub.2R.sup.X, N(R.sup.X)SO.sub.2OR.sup.X, C(O)R.sup.X,
C(O)OR.sup.X, OC(O)R.sup.X, OC(O)OR.sup.X, C(O)N(R.sup.X).sub.2,
OC(O)N(R.sup.X).sub.2. In some embodiments, each R.sup.f is
independently halo, R.sup.X, OR.sup.X, SR.sup.X, CN, or two R.sup.f
on the same carbon are optionally taken together to form an oxo
group. In some embodiments, each R.sup.f is independently R.sup.X.
In some embodiments, each R.sup.f is independently halo. In some
embodiments, each R.sup.f is independently chloro.
[0189] In some embodiments, each R.sup.f is independently a 3-8
membered saturated, partially unsaturated, or aryl monocyclic ring
optionally containing 0-4 heteroatoms independently selected from
nitrogen, oxygen, or sulfur.
[0190] In some embodiments, R.sup.4 is phenyl substituted with 1-5
R.sup.f groups. In certain embodiments, R.sup.4 is phenyl
substituted with one R.sup.f group. In certain embodiments, R.sup.4
is phenyl substituted with two R.sup.f groups. In certain
embodiments, R.sup.4 is phenyl substituted with three R.sup.f
groups. In certain embodiments, R.sup.4 is phenyl substituted with
four R.sup.f groups. In certain embodiments, R.sup.4 is phenyl
substituted with five R.sup.f groups.
[0191] In some embodiments, R.sup.4 is an R.sup.4 moiety disclosed
in either of US Patent Publication No. 2014/0045818 or US Patent
Publication No. 2013/0281433, each of which is incorporated herein
by reference in its entirety.
[0192] As defined generally above, each R.sup.X is independently H,
halo, N(R.sup.Y).sub.2, C(O)OR.sup.Y, C.sub.1-8 aliphatic,
C.sub.1-8 heteroaliphatic, (C.sub.3-C.sub.6)cycloalkyl, 3-8
membered heterocycloalkyl containing 1-3 heteroatoms independently
selected from nitrogen, oxygen, or sulfur, optionally substituted
phenyl, or two R.sup.X on the same nitrogen are taken together to
form a 5-6 membered saturated, partially saturated, or heteroaryl
ring having 1-3 heteroatoms independently selected from nitrogen,
oxygen, and sulfur, or two R.sup.X on the same carbon or on
adjacent carbons are optionally taken together to form a
(C.sub.3-C.sub.6)cycloalkyl, or a 3-6 membered saturated fused
monocyclic ring containing 0-2 heteroatoms independently selected
from nitrogen, oxygen, and sulfur, or two R.sup.X on the same
carbon are taken together to form an oxo group, wherein the
C.sub.1-8 aliphatic, C.sub.1-8 heteroaliphatic,
(C.sub.3-C.sub.6)cycloalkyl, 3-8 membered heterocycloalkyl, or
phenyl is optionally substituted with 1-5 R.sup.z.
[0193] In some embodiments, each R.sup.X is independently H, halo,
N(R.sup.Y).sub.2, C(O)OR.sup.Y, C.sub.1-8 aliphatic, or C.sub.1-8
heteroaliphatic. In some embodiments, each R.sup.X is independently
H or C.sub.1-8 aliphatic. In some embodiments, each R.sup.X is
H.
[0194] As defined generally above, each R.sup.z is independently
halo, C.sub.1-8 aliphatic, or C.sub.1-8 heteroaliphatic.
[0195] As defined generally above, each R.sup.Y is independently H
or (C.sub.1-C.sub.6)alkyl. In some embodiments, each R.sup.y is H.
In some embodiments, each R.sup.y is independently
(C.sub.1-C.sub.6)alkyl.
[0196] As defined generally above, R.sup.5 is:
##STR00039##
[0197] In certain embodiments, R.sup.5 is
##STR00040##
In some such embodiments, X.sup.1 is N. In some such embodiments,
X.sup.2 is not N. In some such embodiments, X.sup.3 is N. In some
such embodiments, when X.sup.3 is N, X.sup.1 is also N. In some
such embodiments, when X.sup.3 is N, X.sup.2 is C(H). In certain
embodiments, when R.sup.5 is
##STR00041##
X.sup.1 is N, X.sup.2 is C(H), and X.sup.3 is N.
[0198] In some embodiments, R.sup.5 is
##STR00042##
[0199] In some embodiments, R.sup.5 is
##STR00043##
[0200] As defined above, Q is a 3-10 membered saturated or
partially unsaturated monocyclic or bridged, spirocyclic, or fused
bicyclic heterocycloalkyl containing 1-3 heteroatoms independently
selected from nitrogen, oxygen, or sulfur, wherein Q is optionally
substituted with 1-5 R.sup.e.
[0201] In some embodiments, Q is a 4-8 membered saturated
monocyclic heterocycloalkyl containing 1-2 heteroatoms
independently selected from nitrogen, oxygen, or sulfur, wherein Q
is optionally substituted with 1-2 R.sup.e. In some embodiments, Q
is a 5-6 membered saturated monocyclic heterocycloalkyl containing
one heteroatom selected from nitrogen, oxygen, or sulfur, wherein Q
is optionally substituted with 1-2 R.sup.e. In some embodiments, Q
is a 5-6 membered saturated monocyclic heterocycloalkyl containing
one nitrogen, wherein Q is optionally substituted with 1-2 R.sup.e.
In some embodiments, Q is a 5 membered saturated monocyclic
heterocycloalkyl containing one nitrogen, wherein Q is substituted
with one R.sup.e. In some such embodiments, Q is N-substituted. In
some embodiments, Q is a 6 membered saturated monocyclic
heterocycloalkyl containing one nitrogen, wherein Q is substituted
with one R.sup.e. In some such embodiments, Q is N-substituted.
[0202] In some embodiments, Q is of the following formula:
##STR00044##
[0203] In some embodiments, Q is a 6-10 membered saturated or
partially unsaturated bicyclic heterocycloalkyl containing 1-3
heteroatoms independently selected from nitrogen, oxygen, or
sulfur, wherein Q is bridged bicyclic. In some embodiments, Q is a
6-10 membered saturated or partially unsaturated bicyclic
heterocycloalkyl containing 1-3 heteroatoms independently selected
from nitrogen, oxygen, or sulfur, wherein Q is spirocyclic.
[0204] As defined generally above, R.sup.b is H or
(C.sub.1-C.sub.6)alkyl. In some embodiments, R.sup.b is H. In some
embodiments, R.sup.b is (C.sub.1-C.sub.6)alkyl. In some such
embodiments, R.sup.b is methyl, ethyl, propyl, or butyl.
[0205] As defined generally above, R.sup.c is H,
(C.sub.1-C.sub.6)alkyl or (C.sub.3-C.sub.6)cycloalkyl, wherein
R.sup.c is optionally substituted with 1-5 groups independently
selected from halo, D, OR.sup.X, and N(R.sup.X).sub.2.
[0206] In some embodiments, R.sup.c is (C.sub.1-C.sub.6)alkyl
optionally substituted with 1-5 groups independently selected from
halo, D, OR.sup.X, and N(R.sup.x).sub.2. In some embodiments,
R.sup.c is (C.sub.1-C.sub.6)alkyl optionally substituted with 1-3
groups independently selected from halo, D, OR.sup.X, and
N(R.sup.X).sub.2. In some embodiments, R.sup.c is methyl optionally
substituted with 1-3 groups independently selected from halo, D,
OR.sup.X, and N(R.sup.X).sub.2. In some embodiments, R.sup.c is
methyl. In some embodiments, R.sup.c is methyl optionally
substituted with 1-3 fluoro. In some embodiments, R.sup.c is methyl
optionally substituted with three fluoro. In some embodiments,
R.sup.c is methyl optionally substituted with two fluoro. In some
embodiments, R.sup.c is methyl optionally substituted with one
fluoro. In some embodiments, R.sup.c is ethyl optionally
substituted with 1-3 groups independently selected from halo, D,
OR.sup.X, and N(R.sup.X).sub.2. In some embodiments, R.sup.c is
ethyl. In some embodiments, R.sup.c is propyl optionally
substituted with 1-3 groups independently selected from halo, D,
OR.sup.X, and N(R.sup.X).sub.2. In some embodiments, R.sup.c is
propyl. In some embodiments, R.sup.c is cyclopropyl optionally
substituted with 1-3 groups independently selected from halo, D,
OR.sup.X, and N(R.sup.X).sub.2. In some embodiments, R.sup.c is
cyclopropyl.
[0207] As defined generally above, each R.sup.e is independently H,
(C.sub.1-C.sub.6)alkyl, N(R.sup.X).sub.2, C(O)R.sup.X,
C(O)OR.sup.X, S(O).sub.2R.sup.X, (C.sub.3-C.sub.6)cycloalkyl or 3-6
membered heterocycloalkyl containing 1-2 heteroatoms independently
selected from nitrogen, oxygen, or sulfur, or two R.sup.e on the
same carbon are taken together to form an oxo group, or two R.sup.e
on the same carbon are taken together to form a
(C.sub.3-C.sub.8)cycloalkyl or a 3-4 membered heterocycloalkyl
containing 1-2 heteroatoms independently selected from nitrogen,
oxygen, or sulfur, wherein R.sup.e is optionally substituted with
1-5 R.sub.g.
[0208] In some embodiments, one R.sup.e is independently
(C.sub.3-C.sub.6)cycloalkyl optionally substituted with 1-5
R.sup.g. In some embodiments, one R.sup.e is independently
(C.sub.3-C.sub.6)cycloalkyl optionally substituted with 1-3
R.sup.g. In some embodiments, one R.sup.e is independently
(C.sub.3-C.sub.6)cycloalkyl optionally substituted with 1-2
R.sup.g. In some embodiments, one R.sup.e is independently
unsubstituted (C.sub.3-C.sub.6)cycloalkyl.
[0209] In some embodiments, one R.sup.e is independently a 3-6
membered heterocycloalkyl containing 1-2 heteroatoms independently
selected from nitrogen, oxygen, or sulfur, wherein R.sup.e is
optionally substituted with 1-5 R.sup.g. In some embodiments, one
R.sup.e is independently a 3-6 membered heterocycloalkyl containing
1-2 heteroatoms independently selected from nitrogen, oxygen, or
sulfur, wherein R.sup.e is optionally substituted with 1-3 R.sup.g.
In some embodiments, one R.sup.e is independently a 3-6 membered
heterocycloalkyl containing 1-2 heteroatoms independently selected
from nitrogen, oxygen, or sulfur, wherein R.sup.e is optionally
substituted with 1-2 R.sup.g. In some embodiments, one R.sup.e is
independently an unsubstituted 3-6 membered heterocycloalkyl
containing 1-2 heteroatoms independently selected from nitrogen,
oxygen, or sulfur.
[0210] In some embodiments, one R.sup.e is independently a 3-6
membered heterocycloalkyl containing 1-2 heteroatoms independently
selected from nitrogen and oxygen, wherein R.sup.e is optionally
substituted with 1-5 R.sup.g. In some embodiments, one R.sup.e is
independently a 3-6 membered heterocycloalkyl containing one
heteroatom independently selected from nitrogen and oxygen, wherein
R.sup.e is optionally substituted with 1-3 R.sup.g. In some such
embodiments, one R.sup.e is independently a 3-6 membered
heterocycloalkyl containing nitrogen. In some such embodiments, one
R.sup.e is independently a 3-6 membered heterocycloalkyl containing
oxygen.
[0211] In some embodiments, one R.sup.e is independently a 4
membered heterocycloalkyl containing one heteroatom independently
selected from nitrogen, oxygen or sulfur, wherein R.sup.e is
optionally substituted with 1-5 R.sup.g. In such some embodiments,
R.sup.e is azetidine, wherein R.sup.e is optionally substituted
with 1-5 R.sup.g. In some such embodiments, R.sup.e is azetidine,
wherein R.sup.e is optionally substituted with 1-2 R.sup.g. In some
such embodiments, R.sup.e is N-substituted azetidine. In certain
embodiments, R.sup.e is
##STR00045##
In certain embodiments, R.sup.e is
##STR00046##
In some embodiments, one R.sup.e is independently oxetane, wherein
R.sup.e is optionally substituted with 1-5 R.sup.g. In some
embodiments, one R.sup.e is independently oxetane, wherein R.sup.e
is optionally substituted with 1-2 R.sup.g groups. In some
embodiments, one R.sup.e is
##STR00047##
In some embodiments, one R.sup.e is thietane, wherein R.sup.e is
optionally substituted with 1-5 R.sup.g. In some embodiments,
R.sup.e is
##STR00048##
[0212] As described above and herein, in some embodiments, each
R.sup.g independently halo, R.sup.X, OR.sup.X, N(R.sup.X).sub.2,
C(O)R.sup.X, C(O)OR.sup.X, OC(O)R.sup.X, OC(O)OR.sup.X,
S(O).sub.2R.sup.X, optionally substituted 3-4 membered
heterocycloalkyl containing 1-2 heteroatoms independently selected
from nitrogen, oxygen, or sulfur, or two R.sup.g on the same carbon
are taken together to form an oxo group, or two R.sup.g on the same
sulfur are optionally taken together to form an oxo group;
[0213] As described above and herein, in some embodiments, X.sup.1
is N or C(H). In certain embodiments, X.sup.1 is N. In certain
embodiments, X.sup.1 is C(H).
[0214] As described above and herein, in some embodiments, X.sup.2
is N or C(H). In certain embodiments, X.sup.2 is N. In certain
embodiments, X.sup.2 is C(H).
[0215] As described above and herein, in some embodiments, X.sup.3
is N or C(H). In certain embodiments, X.sup.3 is N. In certain
embodiments, X.sup.3 is C(H).
[0216] In some embodiments, a provided compound is as depicted
within any of the tables provided at Examples 124 and 125.
[0217] In certain embodiments, a provided compound is as depicted
below:
##STR00049## ##STR00050##
or a pharmaceutically acceptable salt thereof.
[0218] In some embodiments, a provided compound is as depicted
below:
##STR00051## ##STR00052##
or a pharmaceutically acceptable salt thereof.
[0219] In certain embodiments, a provided compound is as depicted
below:
##STR00053##
or a pharmaceutically acceptable salt thereof.
[0220] The compounds disclosed herein are characterized as having
antiviral activity against wildtype (WT) HIV-1 (IIIb). In some
embodiments, a provided compound is characterized by having an
EC.sub.50 of less than about 20 nM. In some embodiments, a provided
compound is characterized by having an EC.sub.50 of less than about
15 nM. In some embodiments, a provided compound is characterized by
having an EC.sub.50 of less than about 12 nM. In some embodiments,
a provided compound is characterized by having an EC.sub.50 of less
than about 11 nM. In some embodiments, a provided compound is
characterized by having an EC.sub.50 of less than about 10 nM. In
some embodiments, a provided compound is characterized by having an
EC.sub.50 of less than about 9 nM. In some embodiments, a provided
compound is characterized by having an EC.sub.50 of less than about
8 nM. In some embodiments, a provided compound is characterized by
having an EC.sub.50 of less than about 7 nM. In some embodiments, a
provided compound is characterized by having an EC.sub.50 of less
than about 6 nM. In some embodiments, a provided compound is
characterized by having an EC.sub.50 of less than about 5 nM. In
some embodiments, a provided compound is characterized by having an
EC.sub.50 of less than about 4 nM. In some embodiments, a provided
compound is characterized by having an EC.sub.50 of less than about
3 nM. In some embodiments, a provided compound is characterized by
having an EC.sub.50 of less than about 2 nM. In some embodiments, a
provided compound is characterized by having an EC.sub.50 of
between about 1 nM and about 6 nM. In some embodiments, a provided
compound is characterized by having an EC.sub.50 of between about 2
nM and about 6 nM. In some embodiments, a provided compound is
characterized by having an EC.sub.50 of between about 2 nM and
about 5 nM. In some embodiments, a provided compound is
characterized by having an EC.sub.50 of between about 3 nM and
about 4 nM.
[0221] In certain embodiments, compounds disclosed herein have
antiviral activity against mutant HIV-1 viruses. In some cases,
these viruses have been identified following development of
antiviral resistance in a subject. For example, in certain
embodiments, compounds disclosed herein are characterized as having
antiviral activity against integrase (IN) T1741 HIV-1 virus. In
some embodiments, a provided compound is characterized by having an
EC.sub.50 against IN T1741 HIV-1 of less than about 1000 nM. In
some embodiments, a provided compound is characterized by having an
EC.sub.50 against IN T1741 HIV-1 of less than about 750 nM. In some
embodiments, a provided compound is characterized by having an
EC.sub.50 against IN T1741 HIV-1 of less than about 500 nM. In some
embodiments, a provided compound is characterized by having an
EC.sub.50 against IN T1741 HIV-1 of less than about 250 nM. In some
embodiments, a provided compound is characterized by having an
EC.sub.50 against IN T1741 HIV-1 of less than about 100 nM. In some
embodiments, a provided compound is characterized by having an
EC.sub.50 against IN T1741 HIV-1 of from about 1 nM to about 1000
nM. In some embodiments, a provided compound is characterized by
having an EC.sub.50 against IN T1741 HIV-1 of from about 1 nM to
about 750 nM. In some embodiments, a provided compound is
characterized by having an EC.sub.50 against IN T1741 HIV-1 of from
about 1 nM to about 500 nM. In some embodiments, a provided
compound is characterized by having an EC.sub.50 against IN T1741
HIV-1 of from about 1 nM to about 250 nM. In some embodiments, a
provided compound is characterized by having an EC.sub.50 against
IN T1741 HIV-1 of from about 1 nM to about 100 nM.
General Synthetic Procedures
[0222] Schemes 1-19 are provided as further embodiments of the
invention and illustrate general methods which are used to prepare
compounds of the invention and which can be used to prepare
additional compounds of the invention.
##STR00054## ##STR00055##
##STR00056##
[0223] In certain embodiments, the benzothiazole intermediate 3E is
converted to the final compound 2C by the methods used to convert
2B to 1D and 1F to 1M as outlined in Scheme 1.
##STR00057##
[0224] In certain embodiments the benzothiazole intermediate 4A is
converted to the final compound 4B by the methods used to convert
2B to 1D and 1F to 1M as outlined in Scheme 1 wherein HNRR a
heterocycle (i.e., when R and R taken together with the nitrogen to
which they are attached form a ring).
##STR00058##
[0225] In certain embodiments the benzothiazoline intermediate 4V
is converted to the final compound 4W by the methods used to
convert 2B to 1M as outlined in Scheme 1.
##STR00059## ##STR00060##
[0226] In certain embodiments, an appropriately substituted phenol
6A is halogenated by the treatment of dihalide, for example
bromine, in a suitable solvent such as, for example acetic acid.
The phenol 6B is converted to a leaving group (e.g., triflate)
known to undergo cross-coupling reactions. The corresponding
activated phenol 6C undergoes a selective cross-coupling reaction
such as, for example Stille cross-coupling using a tin reagent such
as tributyl(vinyl)tin and a palladium catalyst such as
bis(triphenylphosphine) palladium(II) dichloride to give the
corresponding cross-coupled naphthalene such as styrene 6D. The
styrene is dihydroxylated to provide 6E by methods known to those
skilled in the art such as, Sharpless asymmetric dihydroxylation
using, for example, commercially available AD mix-.alpha.. The
resulting diol 6E is protected at the primary hydroxyl by suitable
protecting groups such as pivalate ester using pivaloyl chloride
and pyridine to provide 6F. The secondary hydroxyl is converted to
the corresponding ether such as tert-butyl ether using methods
known to those skilled in the art such as, tert-butyl acetate and
perchloric acid to provide 6G.
[0227] The nitro group of 6G is reduced to the corresponding
aniline 6H by catalytic hydrogenation using platinum on carbon, for
example, under a hydrogen atmosphere. Benzothiazole 6I is formed by
methods known to those skilled in the art such as potassium
thiocyanate and pyridinium perbromide, for example. The resulting
benzothiazole undergoes cross-coupling reaction such as Suzuki
cross-coupling using a boronic acid or ester and a palladium
catalyst such as tetrakis(triphenylphosphine)palladium(0) to give
the corresponding cross-coupled benzothiazole 6J. The corresponding
halobenzothiazole 6K is formed by methods known to those skilled in
the art such as tert-butyl nitrite and a copper(II) halide such as
copper(II) bromide, for example.
##STR00061##
[0228] In certain embodiments the protected primary hydroxyl 6J is
deprotected by methods known to those skilled in the art such as
the deprotection of a pivalate protecting group under basic
conditions for example, using sodium hydroxide, to give the
corresponding primary hydroxyl compound 7A. The primary hydroxyl is
oxidized to the corresponding carboxylic acid 7B by methods known
to those skilled in the art such as, for example, periodic acid and
chromium trioxide. The resulting carboxylic acid is protected by
formation of corresponding carboxylic ester 7B with treatment of,
for example, trimethylsilyldiazomethane, to form the corresponding
methyl ester.
##STR00062##
[0229] In certain embodiments the protected primary hydroxyl 6J is
deprotected by methods known to those skilled in the art such as
the deprotection of a pivalate protecting group under basic
conditions for example, using sodium hydroxide, to give the
corresponding primary hydroxyl compound 8A. The primary hydroxyl is
oxidized to the corresponding carboxylic acid 8B by periodic acid
and chromium trioxide, for example. The carboxylic acid is
protected as, for example, a methyl ester by treatment with
sulfuric acid in methanol. The tert-butyl ether is re-installed by
treating 8C with tert-butyl acetate and perchloric acid, for
example, to provide 8D. The corresponding halobenzothiazole 8E is
formed by methods known to those skilled in the art such as
tert-butyl nitrite and a copper(II)halide such as
copper(II)bromide, for example.
##STR00063## ##STR00064##
[0230] In certain embodiments chlorobenzothiazole 9A is formed from
6J by methods known to those skilled in the art such as tert-butyl
nitrite and a copper(II)halide such as copper(II)bromide, for
example. Selective palladium-catalyzed cross-coupling such as
Suzuki or Stille with protected phenol boronic acid/ester or
stannane, respectively, provides 9B. Selective deprotection of
PG.sup.2 such as catalytic hydrogenation of a benzyl ether gives
phenol 9C, which is converted to a leaving group (e.g., triflate)
known to undergo cross-coupling reactions. The corresponding
activated phenol 9D undergoes a selective cross-coupling reaction
such as, for example Suzuki cross-coupling using a boronic acid or
ester and a palladium catalyst such as
tetrakis(triphenylphosphine)palladium(0) to give the corresponding
cross-coupled benzothiazole 9E.
[0231] In certain embodiments the R.sup.4 moiety is introduced by
cross-coupling reaction such as, for example Suzuki cross-coupling
using a boronic acid or ester and a palladium catalyst such as
tetrakis(triphenylphosphine)palladium(0) to give the corresponding
cross-coupled benzothiazole 9F. The protected primary hydroxyl 9F
is deprotected by methods known to those skilled in the art such as
the deprotection of a pivalate protecting group under basic
conditions for example, using sodium hydroxide, to give the
corresponding primary hydroxyl compound 9G. The primary hydroxyl is
oxidized to the corresponding carboxylic acid 9H by periodic acid
and chromium trioxide, for example.
##STR00065##
[0232] In certain embodiments halobenzothiazole 6K undergoes
selective palladium-catalyzed cross-coupling such as Suzuki or
Stille with a boronic acid/ester or stannane that also contains a
leaving group such as for example, a chloropyridylboronic acid,
known to undergo cross-coupling reactions to give 10A. The
activated moiety 10A undergoes a cross-coupling reaction such as,
for example Suzuki or Stille cross-coupling using a boronic
acid/ester or stannane, respectively and a palladium catalyst such
as tetrakis(triphenylphosphine)palladium(0) to give the
corresponding cross-coupled benzothiazole 10B. The protected
primary hydroxyl 10B is deprotected by methods known to those
skilled in the art such as the deprotection of a pivalate
protecting group under basic conditions for example, using sodium
hydroxide, to give the corresponding primary hydroxyl compound 10C.
The primary hydroxyl is oxidized to the corresponding carboxylic
acid 10D by periodic acid and chromium trioxide, for example.
##STR00066##
[0233] In certain embodiments halobenzothiazole 6K undergoes
palladium-catalyzed cross-coupling such as Suzuki with a boronic
acid or ester; Stille with a stannane; palladium-catalyzed
carbonylation using carbon monoxide, for example in the presence of
an amine; copper(I)halide catalyzed or Buchwald-Hartwig amination;
palladium-catalyzed amidation; S.sub.NAr with an amine; to
introduce the R.sup.5 moiety in 11A. The protected primary hydroxyl
of 11A is deprotected by methods known to those skilled in the art
such as the deprotection of a pivalate protecting group under basic
conditions for example, using sodium hydroxide, to give the
corresponding primary hydroxyl compound 11B. The primary hydroxyl
is oxidized to the corresponding carboxylic acid 11C by periodic
acid and chromium trioxide, for example.
##STR00067##
[0234] In certain embodiments chlorobenzothiazole 9A undergoes
selective palladium-catalyzed cross-coupling such as Suzuki or
Stille with protected phenol boronic acid/ester or stannane,
respectively, to provide 12A. The R.sup.4 moiety is introduced by
cross-coupling reaction such as, for example Suzuki cross-coupling
using a boronic acid or ester and a palladium catalyst such as
tetrakis(triphenylphosphine)palladium(0) to give the corresponding
cross-coupled benzothiazole 12B. The protected primary hydroxyl in
12B is deprotected by methods known to those skilled in the art
such as the deprotection of a pivalate protecting group under basic
conditions for example, using sodium hydroxide, to give the
corresponding primary hydroxyl compound 12C. The primary hydroxyl
is oxidized to the corresponding carboxylic acid 12D by periodic
acid and chromium trioxide, for example.
##STR00068##
[0235] In certain embodiments halobenzothiazole 8E undergoes
selective palladium-catalyzed cross-coupling such as Suzuki or
Stille with a boronic acid/ester or stannane that also contains a
leaving group such as for example, a chloropyridylboronic acid,
known to undergo cross-coupling reactions to give 13A. The
activated moiety 13A undergoes an S.sub.NAr reaction with for
example a secondary amine, or a cross-coupling reaction such as,
for example Suzuki or Stille cross-coupling using a boronic
acid/ester or stannane, respectively and a palladium catalyst such
as tetrakis(triphenylphosphine)palladium(0) to give the
corresponding cross-coupled benzothiazole 13B. The protected
carboxylic acid 13B is deprotected by methods known to those
skilled in the art such as the deprotection of a carboxylic ester
under basic conditions for example, using sodium hydroxide, or
treatment with lithium iodide in pyridine, to give the
corresponding carboxylic acid 13C.
##STR00069##
[0236] In certain embodiments halobenzothiazole 8E undergoes
palladium-catalyzed cross-coupling such as Suzuki with a boronic
acid or ester; Stille with a stannane; palladium-catalyzed
carbonylation using carbon monoxide, for example in the presence of
an amine; copper(I)halide catalyzed or Buchwald-Hartwig amination;
palladium-catalyzed amidation; S.sub.NAr with an amine or alcohol;
to introduce the R.sup.5 moiety in 14A. The protected carboxylic
acid 14A is deprotected by methods known to those skilled in the
art such as the deprotection of a carboxylic ester under basic
conditions for example, using sodium hydroxide, or treatment with
lithium iodide in pyridine to give the corresponding carboxylic
acid 14B.
##STR00070##
[0237] In certain embodiments aminobenzothiazole 8D undergoes
reactions known to those skilled in the art such as amide formation
using carboxylic acid EDCI, for example; sulfonamide formation
using a sulfonyl chloride; urea formation using CDI in the presence
of an amine; to introduce the R.sup.5 moiety in 15A. The protected
carboxylic acid 15A is deprotected by methods known to those
skilled in the art such as the deprotection of a carboxylic ester
under basic conditions for example, using sodium hydroxide, to give
the corresponding carboxylic acid 15B.
##STR00071## ##STR00072##
[0238] In certain embodiments, ketone 16A undergoes reactions known
to those skilled in the art such as aldol condensation to give
enone 16B. Enone 16B can undergo 1,2 organometallic additions such
as Grignard additions to give tertiary alcohol 16C. Under the
action of an acid such as polyphosphoric acid, 16C is converted to
benzthiazole 16D. Reaction of 16D under basic conditions such as
lithium hexamethyldisilazane in the presence of oxaziridine such as
Davis reagent, followed oxidation with an oxidant such as
Dess-Martin periodinane can give ketoester 16E. Chiral reductions
of 16E such as CBS or Noyori can give chiral alcohol 16F. The
secondary hydroxyl is converted to the corresponding ether such as
tert-butyl ether using methods known to those skilled in the art
such as, tert-butyl acetate and perchloric acid to provide 16G. The
activated benzthiazole 16G undergoes a cross-coupling reaction such
as, for example Buchwald, Heck, Negishi, Suzuki or Stille
cross-coupling using a palladium catalyst such as
tetrakis(triphenylphosphine)palladium(0); S.sub.NAr reactions with
for example, a secondary amine; to give the corresponding
benzothiazole 16H. The protected carboxylic acid 16H is deprotected
by methods known to those skilled in the art such as the
deprotection of a carboxylic ester under basic conditions for
example, using sodium hydroxide, or treatment with lithium iodide
in pyridine to give the corresponding carboxylic acid 16I.
##STR00073##
[0239] In certain embodiments, halobenzthiazole 8E undergoes
palladium-catalyzed cross-coupling such as Suzuki with a boronic
acid or ester, for example
2-(4-fluoro-3-nitrophenyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane
to give 17A, known to those skilled in the art to undergo SnAr
reaction with nucleophiles, such as, for example methylamine, to
give 17B. Hydrogenation under platinum on carbon, for example
provides the bis-aniline 17C. Cyclization with an orthoformate,
such as triethylorthoformate in acetic acid, for example gives
benzimidazole 17D. The protected carboxylic acid 17D is deprotected
by methods known to those skilled in the art such as the
deprotection of a carboxylic ester under basic conditions for
example, using sodium hydroxide, or treatment with lithium iodide
in pyridine to give the corresponding carboxylic acid 17E.
##STR00074## ##STR00075##
[0240] In certain embodiments, halobenzthiazole 16G undergoes
palladium-catalyzed cross-coupling such as Suzuki reaction with a
boronic acid or ester, for example
(1-methyl-1H-indazol-5-yl)boronic acid) or Stille reaction with a
stannane; or a Negishi reaction with a heteroaryl halide to give
18B, known to those skilled in the art to undergo halogenation with
N-bromosucciimide for example, to give haloindazole 18C.
Palladium-catalyzed cross-coupling such as Buchwald coupling with
appropriately protected amine or amide or Suzuki reaction with
appropriately protected amino vinyl boronic acid or ester followed
by hydrogenation with rhodium on alumina, for example, furnishes
18D. Amine deprotection by conditions known to those skilled in the
art, such as hydrogen chloride in isopropanol to remove a Boc
protecting group, followed by reductive amination with an
appropriate aldehyde or acylation with an acid chloride or
chloroformate gives 18E. Saponification with an aqueous base such
as sodium hydroxide provides 18F.
##STR00076##
[0241] In some embodiments, halobenzthiazole 16G undergoes
palladium-catalyzed cross-coupling such as a Suzuki reaction with a
boronic acid or ester 19F to give 19G, Saponification with an
aqueous base such as sodium hydroxide provides 19H. Boronic acid or
ester 19F can be prepared by palladium-catalyzed borylation of 19E.
Known to those skilled in the art, aryl halide 19E can prepared
from carboxylic acid 19A via Weinreb amide formation, reaction with
metallated product of 19C and n-butyl lithium, for example, and
cyclization with a suitable hydrazine.
##STR00077##
[0242] In some embodiments, halobenzthiazole 16G undergoes
palladium-catalyzed cross-coupling such as a Negishi reaction with
a heteroaryl halide 20E to give 20F, Amine deprotection by
conditions known to those skilled in the art, such as hydrogen
chloride in isopropanol to remove a Boc protecting group, followed
by reductive amination with an appropriate aldehyde or acylation
with an acid chloride or chloroformate gives 20G. Saponification
with an aqueous base such as sodium hydroxide provides 20H. Known
to those skilled in the art, heteroaryl halide 20E can be prepared
by alkylation with a base and electrophile such as iodomethane,
Suzuki cross-coupling with vinyl boronic acid or ester 20C,
catalytic hydrogenation using rhodium on alumina.
Prodrugs
[0243] In some embodiments, a prodrug of a compound described
herein is provided. A "prodrug" is defined in the pharmaceutical
field as a biologically inactive derivative of a drug that upon
administration to the human body is converted to the biologically
active parent drug according to some chemical or enzymatic pathway.
Prodrugs include, for instance, a compound that when administered
to a biological system generates a compound of the invention that
inhibits the replication of HIV ("the active inhibitory compound").
Such a compound may be formed from the prodrug as a result of, for
example: (i) spontaneous chemical reaction(s), (ii) enzyme
catalyzed chemical reaction(s), (iii) photolysis, and/or (iv)
metabolic chemical reaction(s).
[0244] "Prodrug moiety" refers to a labile functional group which
separates from an active inhibitory compound during metabolism,
systemically, inside a cell, by hydrolysis, enzymatic cleavage, or
by some other process (Bundgaard, Hans, "Design and Application of
Prodrugs" in A Textbook of Drug Design and Development (1991), P.
Krogsgaard-Larsen and H. Bundgaard, Eds. Harwood Academic
Publishers, pp. 113-191). Enzymes which are capable of an enzymatic
activation mechanism with prodrug compounds of the invention
include, but are not limited to, amidases, esterases, microbial
enzymes, phospholipases, cholinesterases, and phosphases. Prodrug
moieties can serve to enhance solubility, absorption and
lipophilicity to optimize drug delivery, bioavailability and
efficacy. A prodrug moiety may include an active metabolite or drug
itself.
[0245] Exemplary prodrug moieties include hydrolytically sensitive
or labile acyloxymethyl esters --CH.sub.2OC(.dbd.O)R.sup.99 and
acyloxymethyl carbonates --CH.sub.2OC(.dbd.O)OR.sup.99 where
R.sup.99 is C.sub.1-C.sub.6 alkyl, C.sub.1-C.sub.6 substituted
alkyl, C.sub.6-C.sub.20 aryl or C.sub.6-C.sub.20 substituted aryl.
Acyloxyalkyl esters were first used as a prodrug strategy for
carboxylic acids and then applied to phosphates and phosphonates by
Farquhar et al. (1983) J. Pharm. Sci. 72: 24; also U.S. Pat. Nos.
4,816,570, 4,968,788, 5,663,159 and 5,792,756. Subsequently,
acyloxyalkyl esters were used to deliver phosphonic acids across
cell membranes and to enhance oral bioavailability. A close variant
of acyloxyalkyl esters, i.e., alkoxycarbonyloxyalkyl esters
(carbonates), may also enhance oral bioavailability as prodrug
moieties for use in combination with compounds of the invention. An
exemplary acyloxymethyl ester is pivaloyloxymethoxy, (POM)
--CH.sub.2OC(.dbd.O)C(CH.sub.3).sub.3. An exemplary acyloxymethyl
carbonate prodrug moiety is pivaloyloxymethylcarbonate (POC)
--CH.sub.2OC(.dbd.O)OC(CH.sub.3).sub.3.
Combination Therapy
[0246] In certain embodiments, a method for treating or preventing
an HIV infection in a human having or at risk of having the
infection is provided, comprising administering to the human a
therapeutically effective amount of a compound disclosed herein, or
a pharmaceutically acceptable salt thereof, in combination with a
therapeutically effective amount of one or more (e.g., one, two,
three, or four; or one or two; or one to three; or one to four)
additional therapeutic agents. In one embodiment, a method for
treating an HIV infection in a human having or at risk of having
the infection is provided, comprising administering to the human a
therapeutically effective amount of a compound disclosed herein, or
a pharmaceutically acceptable salt thereof, in combination with a
therapeutically effective amount of one or more (e.g., one, two,
three, or four; or one or two; or one to three; or one to four)
additional therapeutic agents.
[0247] In one embodiment, pharmaceutical compositions comprising a
compound disclosed herein, or a pharmaceutically acceptable salt
thereof, in combination with one or more (e.g., one, two, three, or
four; or one or two; or one to three; or one to four) additional
therapeutic agents, and a pharmaceutically acceptable excipient are
provided.
[0248] In certain embodiments, the present disclosure provides a
method for treating an HIV infection, comprising administering to a
subject in need thereof a therapeutically effective amount of a
compound disclosed herein, or a pharmaceutically acceptable salt
thereof, in combination with a therapeutically effective amount of
one or more additional therapeutic agents which are suitable for
treating an HIV infection.
[0249] In certain embodiments, a compound disclosed herein, or a
pharmaceutically acceptable salt thereof, is combined with one,
two, three, four, or more additional therapeutic agents. The one,
two, three, four, or more additional therapeutic agents can be
different therapeutic agents selected from the same class of
therapeutic agents, and/or they can be selected from different
classes of therapeutic agents.
Administration of HIV Combination Therapy
[0250] In certain embodiments, a compound disclosed herein, or a
pharmaceutically acceptable salt thereof, is administered with one
or more additional therapeutic agents. Co-administration of a
compound disclosed herein, or a pharmaceutically acceptable salt
thereof, with one or more additional therapeutic agents generally
refers to simultaneous or sequential administration of a compound
disclosed herein and one or more additional therapeutic agents,
such that therapeutically effective amounts of the compound
disclosed herein, or a pharmaceutically acceptable salt thereof,
and the one or more additional therapeutic agents are both present
in the body of the subject. When administered sequentially, the
combination may be administered in two or more administrations.
[0251] Co-administration includes administration of unit dosages of
the compounds disclosed herein, or pharmaceutically acceptable
salts thereof, before or after administration of unit dosages of
one or more additional therapeutic agents. For example, the
compound disclosed herein, or a pharmaceutically acceptable salt
thereof, may be administered within seconds, minutes, or hours of
the administration of the one or more additional therapeutic
agents. In some embodiments, a unit dose of a compound disclosed
herein, or a pharmaceutically acceptable salt thereof, is
administered first, followed within seconds or minutes by
administration of a unit dose of one or more additional therapeutic
agents. Alternatively, a unit dose of one or more additional
therapeutic agents is administered first, followed by
administration of a unit dose of a compound disclosed herein within
seconds or minutes. In other embodiments, a unit dose of a compound
disclosed herein is administered first, followed, after a period of
hours (e.g., 1-12 hours), by administration of a unit dose of one
or more additional therapeutic agents. In yet other embodiments, a
unit dose of one or more additional therapeutic agents is
administered first, followed, after a period of hours (e.g., 1-12
hours), by administration of a unit dose of a compound disclosed
herein.
[0252] In certain embodiments, a compound disclosed herein, or a
pharmaceutically acceptable salt thereof, is combined with one or
more additional therapeutic agents in a unitary dosage form for
simultaneous administration to a subject. In certain embodiments,
such a unitary dosage form can be administered by any route
appropriate to the condition to be treated. Suitable routes include
oral, rectal, nasal, topical (including buccal and sublingual),
transdermal, vaginal and parenteral (including subcutaneous,
intramuscular, intravenous, intradermal, intrathecal and epidural),
and the like. In certain embodiments, the compounds disclosed can
be dosed parenterally. In certain embodiments, the unitary dosage
form can be dosed intravenous, subcutaneous, or intramuscular. In
certain embodiments, the unitary dosage form is orally bioavailable
and can be dosed orally. In certain embodiments, the unitary dosage
form can be a solid dosage form for oral administration.
[0253] In certain embodiments, a compound disclosed herein, or a
pharmaceutically acceptable salt thereof, is formulated as a
tablet, which may optionally contain one or more other compounds
useful for treating HIV. In certain embodiments, the tablet can one
or more other compounds useful for treating HIV, such as HIV
protease inhibitors, HIV non-nucleoside or non-nucleotide
inhibitors of reverse transcriptase, HIV nucleoside or nucleotide
inhibitors of reverse transcriptase, HIV integrase inhibitors, HIV
non-catalytic site (or allosteric) integrase inhibitors,
pharmacokinetic enhancers, and combinations thereof.
[0254] In certain embodiments, such tablets are suitable for once
daily dosing.
HIV Combination Therapy
[0255] In the above embodiments, the additional therapeutic agent
may be an anti-HIV agent selected from the group consisting of
combination drugs for treating HIV, other drugs for treating HIV,
HIV protease inhibitors, HIV non-nucleoside or non-nucleotide
inhibitors of reverse transcriptase, HIV nucleoside or nucleotide
inhibitors of reverse transcriptase, HIV integrase inhibitors, HIV
non-catalytic site (or allosteric) integrase inhibitors, HIV entry
inhibitors, HIV maturation inhibitors, latency reversing agents,
compounds that target the HIV capsid, immune-based therapies,
phosphatidylinositol 3-kinase (PI3K) inhibitors, HIV antibodies,
bispecific antibodies and "antibody-like" therapeutic proteins, HIV
p17 matrix protein inhibitors, IL-13 antagonists, peptidyl-prolyl
cis-trans isomerase A modulators, protein disulfide isomerase
inhibitors, complement C5a receptor antagonists, DNA
methyltransferase inhibitor, HIV vif gene modulators, Vif
dimerization antagonists, HIV-1 viral infectivity factor
inhibitors, TAT protein inhibitors, HIV-1 Nef modulators, Hck
tyrosine kinase modulators, mixed lineage kinase-3 (MLK-3)
inhibitors, HIV-1 splicing inhibitors, Rev protein inhibitors,
integrin antagonists, nucleoprotein inhibitors, splicing factor
modulators, COMM domain containing protein 1 modulators, HIV
ribonuclease H inhibitors, retrocyclin modulators, CDK-9
inhibitors, dendritic ICAM-3 grabbing nonintegrin 1 inhibitors, HIV
GAG protein inhibitors, HIV POL protein inhibitors, Complement
Factor H modulators, ubiquitin ligase inhibitors, deoxycytidine
kinase inhibitors, cyclin dependent kinase inhibitors, proprotein
convertase PC9 stimulators, ATP dependent RNA helicase DDX3X
inhibitors, reverse transcriptase priming complex inhibitors, G6PD
and NADH-oxidase inhibitors, pharmacokinetic enhancers, HIV gene
therapy, HIV vaccines, and combinations thereof.
[0256] In some embodiments, the additional therapeutic agent is
selected from the group consisting of combination drugs for HIV,
other drugs for treating HIV, HIV protease inhibitors, HIV reverse
transcriptase inhibitors, HIV integrase inhibitors, HIV
non-catalytic site (or allosteric) integrase inhibitors, HIV entry
(fusion) inhibitors, HIV maturation inhibitors, latency reversing
agents, capsid inhibitors, immune-based therapies, PI3K inhibitors,
HIV antibodies, and bispecific antibodies, and "antibody-like"
therapeutic proteins, and combinations thereof.
HIV Combination Drugs
[0257] Examples of combination drugs include ATRIPLA.RTM.
(efavirenz, tenofovir disoproxil fumarate, and emtricitabine);
COMPLERA.RTM. (EVIPLERA.RTM.; rilpivirine, tenofovir disoproxil
fumarate, and emtricitabine); STRIBILD.RTM. (elvitegravir,
cobicistat, tenofovir disoproxil fumarate, and emtricitabine);
TRUVADA.RTM. (tenofovir disoproxil fumarate and emtricitabine;
TDF+FTC); DESCOVY.RTM. (tenofovir alafenamide and emtricitabine);
ODEFSEY.RTM. (tenofovir alafenamide, emtricitabine, and
rilpivirine); GENVOYA.RTM. (tenofovir alafenamide, emtricitabine,
cobicistat, and elvitegravir); darunavir, tenofovir alafenamide
hemifumarate, emtricitabine, and cobicistat; efavirenz, lamivudine,
and tenofovir disoproxil fumarate; lamivudine and tenofovir
disoproxil fumarate; tenofovir and lamivudine; tenofovir
alafenamide and emtricitabine; tenofovir alafenamide hemifumarate
and emtricitabine; tenofovir alafenamide hemifumarate,
emtricitabine, and rilpivirine; tenofovir alafenamide hemifumarate,
emtricitabine, cobicistat, and elvitegravir; COMBIVIR.RTM.
(zidovudine and lamivudine; AZT+3TC); EPZICOM.RTM. (LIVEXA.RTM.;
abacavir sulfate and lamivudine; ABC+3TC); KALETRA.RTM.
(ALUVIA.RTM.; lopinavir and ritonavir); TRIUMEQ.RTM. (dolutegravir,
abacavir, and lamivudine); TRIZIVIR.RTM. (abacavir sulfate,
zidovudine, and lamivudine; ABC+AZT+3TC); atazanavir and
cobicistat; atazanavir sulfate and cobicistat; atazanavir sulfate
and ritonavir; darunavir and cobicistat; dolutegravir and
rilpivirine; dolutegravir and rilpivirine hydrochloride;
cabotegravir and rilpivirine; cabotegravir and rilpivirine
hydrochloride; dolutegravir, abacavir sulfate, and lamivudine;
lamivudine, nevirapine, and zidovudine; raltegravir and lamivudine;
doravirine, lamivudine, and tenofovir disoproxil fumarate;
doravirine, lamivudine, and tenofovir disoproxil;
dolutegravir+lamivudine; lamivudine+abacavir+zidovudine;
lamivudine+abacavir; lamivudine+tenofovir disoproxil fumarate;
lamivudine+zidovudine+nevirapine; lopinavir+ritonavir;
lopinavir+ritonavir+abacavir+lamivudine;
lopinavir+ritonavir+zidovudine+lamivudine; tenofovir+lamivudine;
and tenofovir disoproxil fumarate+emtricitabine+rilpivirine
hydrochloride; lopinavir , ritonavir, zidovudine and lamivudine;
Vacc-4x and romidepsin; and APH-0812.
Other HIV Drugs
[0258] Examples of other drugs for treating HIV include acemannan,
alisporivir, BanLec, deferiprone, Gamimune, metenkefalin,
naltrexone, Prolastin, REP 9, RPI-MN, VSSP, H1viral, SB-728-T,
1,5-dicaffeoylquinic acid, rHIV7-shl-TAR-CCR5RZ, AAV-eCD4-Ig gene
therapy, MazF gene therapy, BlockAide, ABX-464, AG-1105, APH-0812,
BIT-225, CYT-107, HGTV-43, HPH-116, HS-10234, IMO-3100, IND-02,
MK-1376, MK-8507, MK-8591, NOV-205, PA-1050040 (PA-040), PGN-007,
SCY-635, SB-9200, SCB-719, TR-452, TEV-90110, TEV-90112, TEV-90111,
TEV-90113, RN-18, Immuglo, and VIR-576.
HIV Protease Inhibitors
[0259] Examples of HIV protease inhibitors include amprenavir,
atazanavir, brecanavir, darunavir, fosamprenavir, fosamprenavir
calcium, indinavir, indinavir sulfate, lopinavir, nelfinavir,
nelfinavir mesylate, ritonavir, saquinavir, saquinavir mesylate,
tipranavir, DG-17, TMB-657 (PPL-100), T-169, BL-008, and
TMC-310911.
HIV Reverse Transcriptase Inhibitors
[0260] Examples of HIV non-nucleoside or non-nucleotide inhibitors
of reverse transcriptase include dapivirine, delavirdine,
delavirdine mesylate, doravirine, efavirenz, etravirine, lentinan,
nevirapine, rilpivirine, AIC-292, KM-023, and VM-1500.
[0261] Examples of HIV nucleoside or nucleotide inhibitors of
reverse transcriptase include adefovir, adefovir dipivoxil,
azvudine, emtricitabine, tenofovir, tenofovir alafenamide,
tenofovir alafenamide fumarate, tenofovir alafenamide hemifumarate,
tenofovir disoproxil, tenofovir disoproxil fumarate, tenofovir
disoproxil hemifumarate, VIDEX.RTM. and VIDEX EC.RTM. (didanosine,
ddl), abacavir, abacavir sulfate, alovudine, apricitabine,
censavudine, didanosine, elvucitabine, festinavir, fosalvudine
tidoxil, CMX-157, dapivirine, doravirine, etravirine, OCR-5753,
tenofovir disoproxil orotate, fozivudine tidoxil, lamivudine,
phosphazid, stavudine, zalcitabine, zidovudine, GS-9131, GS-9148,
and KP-1461.
HIV Integrase Inhibitors
[0262] Examples of HIV integrase inhibitors include elvitegravir,
curcumin, derivatives of curcumin, chicoric acid, derivatives of
chicoric acid, 3,5-dicaffeoylquinic acid, derivatives of
3,5-dicaffeoylquinic acid, aurintricarboxylic acid, derivatives of
aurintricarboxylic acid, caffeic acid phenethyl ester, derivatives
of caffeic acid phenethyl ester, tyrphostin, derivatives of
tyrphostin, quercetin, derivatives of quercetin, raltegravir,
dolutegravir, JTK-351, bictegravir, AVX-15567, diketo quinolin-4-1
derivatives, integrase-LEDGF inhibitor, ledgins, M-522, M-532,
NSC-310217, NSC-371056, NSC-48240, NSC-642710, NSC-699171,
NSC-699172, NSC-699173, NSC-699174, stilbenedisulfonic acid, T-169
and cabotegravir.
[0263] Examples of HIV non-catalytic site, or allosteric, integrase
inhibitors (NCINI) include CX-05045, CX-05168, and CX-14442.
HIV Entry Inhibitors
[0264] Examples of HIV entry (fusion) inhibitors include
cenicriviroc, CCR5 inhibitors, gp41 inhibitors, CD4 attachment
inhibitors, gp120 inhibitors, and CXCR4 inhibitors.
[0265] Examples of CCR5 inhibitors include aplaviroc, vicriviroc,
maraviroc, cenicriviroc, PRO-140, adaptavir (RAP-101), nifeviroc
(TD-0232), anti-GP120/CD4 or CCR5 bispecific antibodies, B-07,
MB-66, polypeptide C25P, TD-0680, and vMIP (Haimipu).
[0266] Examples of gp41 inhibitors include albuvirtide,
enfuvirtide, BMS-986197, enfuvirtide biobetter, enfuvirtide
biosimilar, HIV-1 fusion inhibitors (P26-Bapc), ITV-1, ITV-2,
ITV-3, ITV-4, PIE-12 trimer and sifuvirtide.
[0267] Examples of CD4 attachment inhibitors include ibalizumab and
CADA analogs
[0268] Examples of gp120 inhibitors include Radha-108 (receptol)
3B3-PE38, BanLec, bentonite-based nanomedicine, fostemsavir
tromethamine, IQP-0831, and BMS-663068
[0269] Examples of CXCR4 inhibitors include plerixafor, ALT-1188,
N15 peptide, and vMIP (Haimipu).
HIV Maturation Inhibitors
[0270] Examples of HIV maturation inhibitors include BMS-955176 and
GSK-2838232.
Latency Reversing Agents
[0271] Examples of latency reversing agents include histone
deacetylase (HDAC) inhibitors, proteasome inhibitors such as
velcade, protein kinase C (PKC) activators, BET-bromodomain 4
(BRD4) inhibitors, ionomycin, PMA, SAHA (suberanilohydroxamic acid,
or suberoyl, anilide, and hydroxamic acid), IL-15, JQ1, disulfram,
amphotericin B, and ubiquitin inhibitors such as largazole analogs,
and GSK-343.
[0272] Examples of HDAC inhibitors include romidepsin, vorinostat,
and panobinostat.
[0273] Examples of PKC activators include indolactam, prostratin,
ingenol B, and DAG-lactones.
Capsid Inhibitors
[0274] Examples of capsid inhibitors include capsid polymerization
inhibitors or capsid disrupting compounds, HIV nucleocapsid p7
(NCp7) inhibitors such as azodicarbonamide, HIV p24 capsid protein
inhibitors, AVI-621, AVI-101, AVI-201, AVI-301, and AVI-CAN1-15
series;
Immune-Based Therapies
[0275] Examples of immune-based therapies include toll-like
receptors modulators such as tlr1, tlr2, tlr3, tlr4, tlr5, tlr6,
tlr7, tlr8, tlr9, tlr10, tlr11, tlr12, and tlr13; programmed cell
death protein 1 (Pd-1) modulators; programmed death-ligand 1
(Pd-L1) modulators; IL-15 agonists; DermaVir; interleukin-7;
plaquenil (hydroxychloroquine); proleukin (aldesleukin, IL-2);
interferon alfa; interferon alfa-2b; interferon alfa-n3; pegylated
interferon alfa; interferon gamma; hydroxyurea; mycophenolate
mofetil (MPA) and its ester derivative mycophenolate mofetil (MMF);
ribavirin; rintatolimod, polymer polyethyleneimine (PEI); gepon;
rintatolimod; IL-12; WF-10; VGV-1; MOR-22; BMS-936559; CYT-107,
interleukin-15/Fc fusion protein, normferon, peginterferon alfa-2a,
peginterferon alfa-2b, recombinant interleukin-15, RPI-MN, GS-9620,
and IR-103.
Phosphatidylinositol 3-Kinase (PI3K) Inhibitors
[0276] Examples of PI3K inhibitors include idelalisib, alpelisib,
buparlisib, CAI orotate, copanlisib, duvelisib, gedatolisib,
neratinib, panulisib, perifosine, pictilisib, pilaralisib,
puquitinib mesylate, rigosertib, rigosertib sodium, sonolisib,
taselisib, AMG-319, AZD-8186, BAY-1082439, CLR-1401, CLR-457,
CUDC-907, DS-7423, EN-3342, GSK-2126458, GSK-2269577, GSK-2636771,
INCB-040093, LY-3023414, MLN-1117, PQR-309, RG-7666, RP-6530,
RV-1729, SAR-245409, SAR-260301, SF-1126, TGR-1202, UCB-5857,
VS-5584, XL-765, and ZSTK-474.
HIV Antibodies, Bispecific Antibodies, and "Antibody-Like"
Therapeutic Proteins
[0277] Examples of HIV antibodies, bispecific antibodies, and
"antibody-like" therapeutic proteins include DARTs.RTM.,
DUOBODIES.RTM., BITES.RTM., XmAbs.RTM., TandAbs.RTM., Fab
derivatives, bnABs (broadly neutralizing HIV-1 antibodies),
BMS-936559, TMB-360, and those targeting HIV gp120 or gp41,
antibody-Recruiting Molecules targeting HIV, anti-CD63 monoclonal
antibodies , anti-GB virus C antibodies, anti-GP120/CD4, CCRS
bispecific antibodies, anti-nef single domain antibodies, anti-Rev
antibody, camelid derived anti-CD18 antibodies, camelid-derived
anti-ICAM-1 antibodies, DCVax-001, gp140 targeted antibodies,
gp41-based HIV therapeutic antibodies, human recombinant mAbs
(PGT-121), ibalizumab, Immuglo, MB-66
[0278] Examples of those targeting HIV in such a manner include
bavituximab, UB-421, C2F5, C2G12, C4E10, C2F5+C2G12+C4E10,
3-BNC-117, PGT145, PGT121, MDX010 (ipilimumab), VRC01, A32, 7B2,
10E8, VRC-07-523, VRC-HIVMAB080-00-AB, MGD-014 and VRC07.
Pharmacokinetic Enhancers
[0279] Examples of pharmacokinetic enhancers include cobicistat and
ritonavir.
Additional Therapeutic Agents
[0280] Examples of additional therapeutic agents include the
compounds disclosed in WO 2004/096286 (Gilead Sciences), WO
2006/015261 (Gilead Sciences), WO 2006/110157 (Gilead Sciences), WO
2012/003497 (Gilead Sciences), WO 2012/003498 (Gilead Sciences), WO
2012/145728 (Gilead Sciences), WO 2013/006738 (Gilead Sciences), WO
2013/159064 (Gilead Sciences), WO 2014/100323 (Gilead Sciences), US
2013/0165489 (University of Pennsylvania), US 2014/0221378 (Japan
Tobacco), US 2014/0221380 (Japan Tobacco), WO 2009/062285
(Boehringer Ingelheim), WO 2010/130034 (Boehringer Ingelheim), WO
2013/006792 (Pharma Resources), US 20140221356 (Gilead Sciences),
US 20100143301 (Gilead Sciences) and WO 2013/091096 (Boehringer
Ingelheim).
HIV Vaccines
[0281] Examples of HIV vaccines include peptide vaccines,
recombinant subunit protein vaccines, live vector vaccines, DNA
vaccines, CD4-derived peptide vaccines, vaccine combinations,
rgp120 (AIDSVAX), ALVAC HIV (vCP1521)/AIDSVAX B/E (gp120) (RV144),
monomeric gp120 HIV-1 subtype C vaccine, Remune, ITV-1, Contre Vir,
Ad5-ENVA-48, DCVax-001 (CDX-2401), Vacc-4x , Vacc-C5, VAC-3S,
multiclade DNA recombinant adenovirus-5 (rAd5), Pennvax-G,
Pennvax-GP, HIV-TriMix-mRNA vaccine, HIV-LAMP-vax, Ad35, Ad35-GRIN,
NAcGM3/VSSP ISA-51, poly-ICLC adjuvanted vaccines, TatImune,
GTU-multiHIV (FIT-06), gp140[delta]V2.TV1+MF-59, rVSVIN HIV-1 gag
vaccine, SeV-Gag vaccine, AT-20, DNK-4, ad35-Grin/ENV, TBC-M4,
HIVAX, HIVAX-2, NYVAC-HIV-PT1, NYVAC-HIV-PT4, DNA-HIV-PT123,
rAAV1-PG9DP, GOVX-B11, GOVX-B21, TVI-HIV-1, Ad-4 (Ad4-env Clade
C+Ad4-mGag), EN41-UGR7C, EN41-FPA2, PreVaxTat, AE-H, MYM-V101,
CombiHIVvac, ADVAX, MYM-V201, MVA-CMDR, DNA-Ad5 gag/pol/nef/nev
(HVTN505), MVATG-17401, ETV-01, CDX-1401, rcAD26.MOS1.HIV-Env,
Ad26.Mod.HIV vaccine, AGS-004, AVX-101, AVX-201, PEP-6409, SAV-001,
ThV-01, TL-01, TUTI-16, VGX-3300, IHV-001, and virus-like particle
vaccines such as pseudovirion vaccine, CombiVICHvac, LFn-p24 B/C
fusion vaccine, GTU-based DNA vaccine, HIV gag/pol/nef/env DNA
vaccine, anti-TAT HIV vaccine, conjugate polypeptides vaccine,
dendritic-cell vaccines, gag-based DNA vaccine, GI-2010, gp41 HIV-1
vaccine, HIV vaccine (PIKA adjuvant), I i-key/MHC class II epitope
hybrid peptide vaccines, ITV-2, ITV-3, ITV-4, LIPO-5, multiclade
Env vaccine, MVA vaccine, Pennvax-GP, pp71-deficient HCMV vector
HIV gag vaccine, recombinant peptide vaccine (HIV infection), NCI,
rgp160 HIV vaccine, RNActive HIV vaccine, SCB-703, Tat Oyi vaccine,
TBC-M4, therapeutic HIV vaccine , UBI HIV gp120,
Vacc-4x+romidepsin, variant gp120 polypeptide vaccine, rAd5 gag-pol
env A/B/C vaccine.
HIV Combination Therapy
[0282] In a particular embodiment, a compound disclosed herein, or
a pharmaceutically acceptable salt thereof, is combined with one,
two, three, four or more additional therapeutic agents selected
from ATRIPLA.RTM. (efavirenz, tenofovir disoproxil fumarate, and
emtricitabine); COMPLERA.RTM. (EVIPLERA.RTM.; rilpivirine,
tenofovir disoproxil fumarate, and emtricitabine); STRIBILD.RTM.
(elvitegravir, cobicistat, tenofovir disoproxil fumarate, and
emtricitabine); TRUVADA.RTM. (tenofovir disoproxil fumarate and
emtricitabine; TDF+FTC); DESCOVY.RTM. (tenofovir alafenamide and
emtricitabine); ODEFSEY.RTM. (tenofovir alafenamide, emtricitabine,
and rilpivirine); GENVOYA.RTM. (tenofovir alafenamide,
emtricitabine, cobicistat, and elvitegravir); adefovir; adefovir
dipivoxil; cobicistat; emtricitabine; tenofovir; tenofovir
disoproxil; tenofovir disoproxil fumarate; tenofovir alafenamide;
tenofovir alafenamide hemifumarate; TRIUMEQ.RTM. (dolutegravir,
abacavir, and lamivudine); dolutegravir, abacavir sulfate, and
lamivudine; raltegravir; raltegravir and lamivudine; maraviroc;
enfuvirtide; ALUVIA.RTM. (KALETRA.RTM.; lopinavir and ritonavir);
COMBIVIR.RTM. (zidovudine and lamivudine; AZT+3TC); EPZICOM.RTM.
(LIVEXA.RTM.; abacavir sulfate and lamivudine; ABC+3TC);
TRIZIVIR.RTM. (abacavir sulfate, zidovudine, and lamivudine;
ABC+AZT+3TC); rilpivirine; rilpivirine hydrochloride; atazanavir
sulfate and cobicistat; atazanavir and cobicistat; darunavir and
cobicistat; atazanavir; atazanavir sulfate; dolutegravir;
elvitegravir; ritonavir; atazanavir sulfate and ritonavir;
darunavir; lamivudine; prolastin; fosamprenavir; fosamprenavir
calcium efavirenz; etravirine; nelfinavir; nelfinavir mesylate;
interferon; didanosine; stavudine; indinavir; indinavir sulfate;
tenofovir and lamivudine; zidovudine; nevirapine; saquinavir;
saquinavir mesylate; aldesleukin; zalcitabine; tipranavir;
amprenavir; delavirdine; delavirdine mesylate; Radha-108
(receptol); lamivudine and tenofovir disoproxil fumarate;
efavirenz, lamivudine, and tenofovir disoproxil fumarate;
phosphazid; lamivudine, nevirapine, and zidovudine; abacavir; and
abacavir sulfate.
[0283] It will be appreciated by one of skill in the art that the
additional therapeutic agents listed above may be included in more
than one of the classes listed above. The particular classes are
not intended to limit the functionality of those compounds listed
in those classes.
[0284] In a specific embodiment, a compound disclosed herein, or a
pharmaceutically acceptable salt thereof, is combined with one or
two HIV nucleoside or nucleotide inhibitors of reverse
transcriptase. In a specific embodiment, a compound disclosed
herein, or a pharmaceutically acceptable salt thereof, is combined
with an HIV nucleoside or nucleotide inhibitor of reverse
transcriptase and an HIV non-nucleoside inhibitor of reverse
transcriptase. In another specific embodiment, a compound disclosed
herein, or a pharmaceutically acceptable salt thereof, is combined
with an HIV nucleoside or nucleotide inhibitor of reverse
transcriptase, and an HIV protease inhibiting compound. In an
additional embodiment, a compound disclosed herein, or a
pharmaceutically acceptable salt thereof, is combined with an HIV
nucleoside or nucleotide inhibitor of reverse transcriptase, an HIV
non-nucleoside inhibitor of reverse transcriptase, and a
pharmacokinetic enhancer. In certain embodiments, a compound
disclosed herein, or a pharmaceutically acceptable salt thereof, is
combined with at least one HIV nucleoside inhibitor of reverse
transcriptase, an integrase inhibitor, and a pharmacokinetic
enhancer. In another embodiment, a compound disclosed herein, or a
pharmaceutically acceptable salt thereof, is combined with two HIV
nucleoside or nucleotide inhibitors of reverse transcriptase. In
another embodiment, a compound disclosed herein, or a
pharmaceutically acceptable salt thereof, is combined with a
non-nucleoside inhibitor of reverse transcriptase. In another
embodiment, a compound disclosed herein, or a pharmaceutically
acceptable salt thereof, is combined with a non-nucleoside
inhibitor of reverse transcriptase and an integrase inhibitor.
[0285] In a particular embodiment, a compound disclosed herein, or
a pharmaceutically acceptable salt thereof, is combined with
abacavir sulfate, tenofovir, tenofovir disoproxil, tenofovir
disoproxil fumarate, tenofovir disoproxil hemifumarate, tenofovir
alafenamide, tenofovir alafenamide fumarate or tenofovir
alafenamide hemifumarate.
[0286] In a particular embodiment, a compound disclosed herein, or
a pharmaceutically acceptable salt thereof, is combined with
tenofovir, tenofovir disoproxil, tenofovir disoproxil fumarate,
tenofovir alafenamide, tenofovir alafenamide fumarate or tenofovir
alafenamide hemifumarate.
[0287] In a particular embodiment, a compound disclosed herein, or
a pharmaceutically acceptable salt thereof, is combined with a
first additional therapeutic agent selected from the group
consisting of abacavir sulfate, tenofovir, tenofovir disoproxil,
tenofovir disoproxil fumarate, tenofovir alafenamide, tenofovir
alafenamide fumarate and tenofovir alafenamide hemifumarate, and a
second additional therapeutic agent selected from the group
consisting of emtricitabine and lamivudine.
[0288] In a particular embodiment, a compound disclosed herein, or
a pharmaceutically acceptable salt thereof, is combined with a
first additional therapeutic agent selected from the group
consisting of tenofovir, tenofovir disoproxil, tenofovir disoproxil
fumarate, tenofovir alafenamide, and tenofovir alafenamide
hemifumarate, and a second additional therapeutic agent, wherein
the second additional therapeutic agent is emtricitabine. In a
particular embodiment, a compound disclosed herein, or a
pharmaceutically acceptable salt thereof, is combined with a first
additional therapeutic agent selected from the group consisting of
tenofovir alafenamide fumarate, tenofovir alafenamide, and
tenofovir alafenamide hemifumarate, and a second additional
therapeutic agent, wherein the second additional therapeutic agent
is emtricitabine. In a particular embodiment, a compound disclosed
herein, or a pharmaceutically acceptable salt thereof, is combined
with a first additional therapeutic agent selected from the group
consisting of tenofovir disoproxil fumarate, tenofovir disoproxil,
and tenofovir disoproxil hemifumarate, and a second additional
therapeutic agent, wherein the second additional therapeutic agent
is emtricitabine. In some embodiments, the compound disclosed
herein, or a pharmaceutically acceptable salt thereof, and the
first and second additional therapeutic agents as disclosed above
are administered simultaneously. Optionally, the compound disclosed
herein, or a pharmaceutically acceptable salt thereof, and the
first and second additional therapeutic agents as disclosed above
are combined in a unitary dosage form for simultaneous
administration to a subject. In other embodiments, the compound
disclosed herein, or a pharmaceutically acceptable salt thereof,
and the first and second additional therapeutic agents as disclosed
above are administered sequentially.
[0289] A compound as disclosed herein may be combined with one or
more additional therapeutic agents in any dosage amount of the
compound disclosed herein (e.g., from 1 mg to 1000 mg of
compound).
[0290] In certain embodiments, a compound disclosed herein, or a
pharmaceutically acceptable salt thereof, is combined with 5-30 mg
tenofovir alafenamide fumarate, tenofovir alafenamide hemifumarate,
or tenofovir alafenamide, and 200 mg emtricitabine. In certain
embodiments, a compound disclosed, or a pharmaceutically acceptable
salt thereof, is combined with 5-10, 5-15, 5-20, 5-25, 25-30,
20-30, 15-30, or 10-30 mg tenofovir alafenamide fumarate, tenofovir
alafenamide hemifumarate, or tenofovir alafenamide, and 200 mg
emtricitabine. In certain embodiments, a compound disclosed herein,
or a pharmaceutically acceptable salt thereof, is combined with 10
mg tenofovir alafenamide fumarate, tenofovir alafenamide
hemifumarate, or tenofovir alafenamide, and 200 mg emtricitabine.
In certain embodiments, a compound disclosed herein, or a
pharmaceutically acceptable salt thereof, is combined with 25 mg
tenofovir alafenamide fumarate, tenofovir alafenamide hemifumarate,
or tenofovir alafenamide, and 200 mg emtricitabine. A compound as
disclosed herein may be combined with the agents provided herein in
any dosage amount of the compound (e.g., from 1 mg to 1000 mg of
compound) the same as if each combination of dosages were
specifically and individually listed.
[0291] In certain embodiments, a compound disclosed herein, or a
pharmaceutically acceptable salt thereof, is combined with 200-400
mg tenofovir disoproxil fumarate, tenofovir disoproxil
hemifumarate, or tenofovir disoproxil, and 200 mg emtricitabine. In
certain embodiments, a compound disclosed herein, or a
pharmaceutically acceptable salt thereof, is combined with 300 mg
tenofovir disoproxil fumarate, tenofovir disoproxil hemifumarate,
or tenofovir disoproxil, and 200 mg emtricitabine. A compound as
disclosed herein may be combined with the agents provided herein in
any dosage amount of the compound (e.g., from 1 mg to 1000 mg of
compound) the same as if each combination of dosages were
specifically and individually listed.
[0292] In one embodiment, kits comprising a compound disclosed
herein, or a pharmaceutically acceptable salt thereof, in
combination with one or more (e.g., one, two, three, one or two, or
one to three) additional therapeutic agents are provided.
Pharmaceutical Formulations
[0293] In some embodiments, compounds described herein are
formulated with conventional carriers (e.g., inactive ingredient or
excipient material) selected in accord with ordinary practice. In
some embodiments, tablets contain excipients, including glidants,
fillers, binders and the like. In some embodiments, aqueous
formulations are prepared in sterile form. In some embodiments,
such aqueous formulations are intended for delivery by other than
oral administration and are isotonic. In some embodiments,
formulations optionally contain excipients such as those set forth
in the Handbook of Pharmaceutical Excipients (1986). Excipients
include, but are not limited to, ascorbic acid and other
antioxidants, chelating agents such as EDTA, carbohydrates such as
dextrin, hydroxyalkylcellulose, hydroxyalkylmethylcellulose,
stearic acid and the like. In some embodiments, the present
invention provides formulations in solid dosage form, for example,
in solid oral dosage form.
[0294] In some embodiments, formulations may be specially
formulated for administration in solid or liquid form, including
those adapted for the following: oral administration, for example,
drenches (aqueous or non-aqueous solutions or suspensions),
tablets, e.g., those targeted for buccal, sublingual, and systemic
absorption, boluses, powders, granules, pastes for application to
the tongue; or parenteral administration, for example, by
subcutaneous, intramuscular, intravenous or epidural injection as,
for example, a sterile solution or suspension, or sustained-release
formulation.
[0295] While it is possible for the active ingredients to be
administered alone it may be preferable to present them as
pharmaceutical formulations (compositions). The formulations, both
for veterinary and for human use, of the invention comprise at
least one active ingredient, together with one or more acceptable
carriers and optionally other therapeutic ingredients. The
carrier(s) must be "acceptable" in the sense of being compatible
with the other ingredients of the formulation and physiologically
innocuous to the recipient thereof.
[0296] Formulations include those suitable for the foregoing
administration routes. In some embodiments, formulations may
conveniently be presented in unit dosage form and may be prepared
by any of the methods well known in the art of pharmacy. Techniques
and formulations generally are found in Remington's Pharmaceutical
Sciences (Mack Publishing Co., Easton, Pa.). Such methods include
the step of bringing into association the active ingredient with
the inactive ingredients (e.g., a carrier, pharmaceutical
excipients, etc.) which constitutes one or more accessory
ingredients. In some embodiments, formulations are prepared by
uniformly and intimately bringing into association the active
ingredient with liquid carriers or finely divided solid carriers or
both, and then, if necessary, shaping the product.
[0297] In some embodiments, formulations described herein that are
suitable for oral administration are presented as discrete units
including, but not limited to, capsules, cachets or tablets each
containing a predetermined amount of the active ingredient.
[0298] In some embodiments, pharmaceutical formulations disclosed
herein comprise one or more compounds described herein together
with one or more pharmaceutically acceptable carriers or excipients
and optionally other therapeutic agents. Pharmaceutical
formulations containing the active ingredient may be in any form
suitable for the intended method of administration. When used for
oral use for example, tablets, troches, lozenges, aqueous or oil
suspensions, dispersible powders or granules, emulsions, hard or
soft capsules, syrups or elixirs may be prepared. Compositions
intended for oral use may be prepared according to any method known
to the art for the manufacture of pharmaceutical compositions and
such compositions may contain one or more agents including
sweetening agents, flavoring agents, coloring agents and preserving
agents, in order to provide a palatable preparation. Tablets
containing the active ingredient in admixture with non-toxic
pharmaceutically acceptable excipient which are suitable for
manufacture of tablets are acceptable. These excipients may be, for
example, inert diluents, such as calcium or sodium carbonate,
lactose, lactose monohydrate, croscarmellose sodium, povidone,
calcium or sodium phosphate; granulating and disintegrating agents,
such as maize starch, or alginic acid; binding agents, such as
cellulose, microcrystalline cellulose, starch, gelatin or acacia;
and lubricating agents, such as magnesium stearate, stearic acid or
talc. Tablets may be uncoated or may be coated by known techniques
including microencapsulation to delay disintegration and adsorption
in the gastrointestinal tract and thereby provide a sustained
action over a longer period. For example, a time delay material
such as glyceryl monostearate or glyceryl distearate alone or with
a wax may be employed.
[0299] The amount of active ingredient that is combined with one or
more inactive ingredients to produce a dosage form will vary
depending upon the host treated and the particular mode of
administration. For example, in some embodiments, a dosage form for
oral administration to humans contains approximately 1 to 1000 mg
of active material formulated with an appropriate amount of carrier
material (e.g., inactive ingredient or excipient material). In
certain embodiments, the carrier material varies from about 5% to
about 95% of the total composition (weight:weight).
[0300] It should be understood that, in addition to the ingredients
particularly mentioned above, formulations of this invention may
include other agents conventional in the art having regard to the
type of formulation in question, for example those suitable for
oral administration may include flavoring agents.
[0301] In some embodiments, the present invention provides
veterinary compositions comprising at least one active ingredient
as above defined together with a veterinary carrier.
[0302] Veterinary carriers are materials useful for the purpose of
administering the composition and may be solid, liquid or gaseous
materials which are otherwise inert or acceptable in the veterinary
art and are compatible with the active ingredient. These veterinary
compositions may be administered orally, parenterally or by any
other desired route.
[0303] Effective dose of active ingredient depends at least on the
nature of the condition being treated, toxicity, whether a compound
is being used prophylactically (lower doses), the method of
delivery, and the pharmaceutical formulation, and will be
determined by the clinician using conventional dose escalation
studies.
Routes of Administration
[0304] One or more compounds described herein (herein referred to
as the active ingredients) are administered by any route
appropriate to the condition to be treated. Suitable routes include
oral, rectal, nasal, topical (including buccal and sublingual),
vaginal and parenteral (including subcutaneous, intramuscular,
intravenous, intradermal, intrathecal and epidural), and the like.
It will be appreciated that a preferred route may vary with, for
example, the condition of the recipient. An advantage of the
compounds of this invention is that they are orally bioavailable
and can be dosed orally.
Identification and/or Characterization of
Compounds/Compositions
[0305] The antiviral properties of a compound of the invention may
be determined using the methods described below.
[0306] The specific pharmacological responses observed may vary
according to and depending on the particular active compound
selected or whether there are present pharmaceutical carriers, as
well as the type of formulation and mode of administration
employed, and such expected variations or differences in the
results are contemplated in accordance with practice of the present
invention. p The invention has been described with reference to
various specific and preferred embodiments and techniques. However,
it should be understood that many variations and modifications may
be made while remaining within the spirit and scope of the
invention.
[0307] The invention will now be illustrated by the following
non-limiting examples of compounds (including compounds of the
invention) and intermediates useful for preparing compounds of the
invention.
EXEMPLIFICATION
Example 1
Preparation of ethyl
(S)-2-(2-bromo-7-(4-chlorophenyl)-5-methylbenzo[d]thiazol-6-yl)-2-(tert-b-
utoxy)acetate
##STR00078## ##STR00079##
[0309] Preparation of ethyl
(E)-2-(2-bromo-5-methyl-7-oxo-4,7-dihydrobenzo[d]thiazol-6(5H)-ylidene)ac-
etate: A 3.0 L round-bottom flask was charged with
2-bromo-5-methyl-5,6-dihydrobenzo[d]thiazol-7(4H)-one (75.0 g, 305
mmol, 1.00 equiv), anhydrous THF (750 mL), and a 50% w/v solution
of ethylglyoxylate in toluene (211 mL, 1.07 mol, 3.50 equiv). The
resulting solution was placed in a water bath. Solid lithium
tert-butoxide (48.9 g, 610 mmol, 2.0 equiv) was steadily added over
a 1 min period. The reaction was capped and stirred for 4.5 h. TLC
(20% EtOAc/80% hexane indicated full consumption of
2-bromo-5-methyl-5,6-dihydrobenzo[d]thiazol-7(4H)-one). Saturated
aqueous NH.sub.4Cl (750 mL) was added quickly. The reaction was
stirred for 15 min. H.sub.2O (250 mL) was added. Most of the solids
dissolved. 1.0 M aqueous HCl (180 mL) was added over a 5 min
period. After a short time the pH of the aqueous layer was
.about.3.5. The organic phase was collected, and the aqueous layer
was extracted with EtOAc (2.times.375 mL). Combined organic layers
were washed with brine (500 mL), dried (MgSO.sub.4), filtered, and
concentrated to a minimum volume with a bath temperature of
50-60.degree. C. and 10 mmHg vacuum. DCM (40 mL) was added. The
resulting solution was transferred to a Combiflash XL solid loading
cartridge by gravity loading. The solid cartridge was assembled in
line with a 1.5 kg Combiflash XL silica gel column equilibrated
with hexane. The following gradient elution sequence was used:
[100% Hexane (5 column volumes, isocratic).fwdarw.10% EtOAc/90%
Hexane (10 column volumes, linear gradient).fwdarw.10% EtOAc/90%
Hexane (7 column volumes, isocratic)).fwdarw.100% EtOAc (8 column
volumes, isocratic)]. Fractions containing product were combined,
concentrated, and dried under high vacuum to give desired product.
LCMS-ESI.sup.+ calc'd for C.sub.12H.sub.12BrNO.sub.3S: 330.0 and
332.0 (M+H.sup.+); found: 330.0 and 332.0 (M+H.sup.+). .sup.1H NMR
(400 MHz, CDCl.sub.3): .delta. 6.77 (s, 1H), 4.60-4.53 (m, 1H),
4.30-4.21 (m, 2H), 3.23 (dd, J=17.6, 5.8 Hz, 1H), 3.07 (d, J=5.8
Hz, 1H), 1.33 (t, J=7.2 Hz, 3H), 1.23 (d, J=7.0 Hz, 3H).
[0310] Preparation of ethyl
(E)-2-(2-bromo-7-(4-chlorophenyl)-7-hydroxy-5-methyl-4,7-dihydrobenzo[d]t-
hiazol-6(5H)-ylidene)acetate: A 3-liter flask equipped with a
mechanical stirrer, addition funnel, and nitrogen inlet was charged
with ethyl
(E)-2-(2-bromo-5-methyl-7-oxo-4,7-dihydrobenzo[d]thiazol-6(5H)-ylidene)ac-
etate (24.1 g, 73 mmol, 1.0 equiv) and then diluted with THF (800
mL). To the resulting solution was added 0.6M LaCl.sub.3.2LiCl (243
mL, 146 mmol, 2.0 equiv) and then the reaction mixture was cooled
to -65.degree. C. by the aid of a dry-ice acetone bath. The
addition funnel was then charged with 1.0M 4-chlorophenylmagnesium
bromide (146 mL, 146 mmol, 2.0 equiv) and then slowly added to the
reaction mixture over a 25 minute period. Upon completion of the
addition, TLC analysis showed full consumption of the starting
material (TLC of the starting material in 20% EtOAc/Hex has
Rf=0.50; TLC of the product in 20% EtOAc/Hex has Rf=0.38), and the
reaction was quenched with saturated NH.sub.4Cl (100 mL) and then
diluted with EtOAc (1 L) and H.sub.2O (1.5 L). The cooling bath was
removed and the mixture was allowed to warm to room temperature
with stirring. The layers were separated and the aqueous extract
was washed with EtOAc (1 L). The combined organics were dried over
Na.sub.2SO.sub.4, filtered through a small plug of silica gel
eluting with EtOAc, and then concentrated in vacuo. The resulting
crude residue was chromatographed using a 330 g RediSep normal
phase silica gel cartridge (EtOAc/Hex, 5%.fwdarw.15%) on a
CombiFlash system to afford desired product. TLC (20% EtOAc/Hex)
Rf=0.38; .sup.1H NMR (400 MHz, CDCl3) .delta. 7.31 (d, J=8.6 Hz,
2H), 7.26 (d, J=8.6 Hz, 2H), 5.62 (s, 1H), 4.57-4.40 (m, 1H),
4.22-4.04 (m, 2H), 3.03 (qd, J=16.6, 3.8 Hz, 2H), 2.61 (br s, 1H),
1.38 (d, J=7.2 Hz, 3H), 1.25 (t, J=7.1 Hz, 3H).
[0311] Preparation of ethyl
2-(2-bromo-7-(4-chlorophenyl)-5-methylbenzo[d]thiazol-6-yl)acetate:
Polyphosphoric acid (PPA) (140 g) and THF (210 mL) were heated to
75.degree. C. in a 1 L recovery flask. Ethyl
(E)-2-(2-bromo-7-(4-chlorophenyl)-7-hydroxy-5-methyl-4,7-dihydrobenzo[d]t-
hiazol-6(5H)-ylidene)acetate (31.0 g, 70.0 mmol) was added via
addition funnel in THF (70 mL) over 2 min. The funnel was rinsed
with THF (20 mL). The reaction mixture was heated at 80.degree. C.
for 2.5 h. After cooling to rt, the mixture was poured onto a 1 M
K.sub.2HPO.sub.4 (1.5 L) solution followed by EtOAc (700 mL). The
layers were separated, and the organic layer was washed with brine
(500 mL). The organic layer was dried, filtered, and concentrated
in vacuo to give desired product that was used without further
purification. .sup.1H NMR (400 MHz, CDCl.sub.3): .delta. 7.81 (s,
1H), 7.45 (d, 2H, J=8 Hz), 7.29 (d, 2H, J=8 Hz), 4.13 (q, 2H, J=7
Hz), 3.57 (s, 2H), 2.45 (s, 3H), 1.23 (t, 3H, J=7 Hz).
[0312] Preparation of ethyl
2-(2-bromo-7-(4-chlorophenyl)-5-methylbenzo[d]thiazol-6-yl)-2-oxoacetate:
To a solution of the ethyl
2-(2-bromo-7-(4-chlorophenyl)-5-methylbenzo[d]thiazol-6-yl)acetate
(15.4 g, 36.4 mmol) in THF (146 mL) at -78.degree. C. was added a
solution of KHMDS (1 M in THF, 43.6 mmol, 43.6 mL) over 5 min.
After 30 min, a solution of
3-phenyl-2-(phenylsulfonyl)-1,2-oxaziridine (11.4 g, 43.6 mmol) in
THF (29 mL) was added. After 1 h, a saturated solution of
NH.sub.4Cl was added (200 mL). The reaction mixture was warmed to
rt. The layers were separated, and the aqueous layer was extracted
with EtOAc. The combined organic layers were dried, filtered, and
concentrated in vacuo and were used without further
purification.
[0313] To the above residue was added CH.sub.2Cl.sub.2 (240 mL)
followed by Dess-Martin periodinane (16.9 g, 40.0 mmol). After 2 h,
a saturated solution of Na.sub.2S.sub.2O.sub.3 (150 mL) and a
saturated solution of NaHCO.sub.3 (150 mL) and water (100 mL) were
added. The mixture was stirred at room temperature for 2 h. The
layers were separated, and the aqueous layer was extracted with
CH.sub.2Cl.sub.2. The combined organic layers were dried, filtered,
and concentrated in vacuo. A mixture of hexanes/EtOAc (9:1) was
added. The mixture was filtered, the solids were washed with
additional hex/EtOAc (9:1), and the filtrate was concentrated. The
crude oil was purified by column chromatography (5%-10% EtOAc/hex)
to give desired product. .sup.1H NMR (400 MHz, CDCl.sub.3): .delta.
7.88 (s, 1H), 7.45 (d, 2H, J=8 Hz), 7.28 (d, 2H, J=8 Hz), 3.91 (q,
2H, J=7 Hz), 2.52 (s, 3H), 1.08 (t, 3H, J=7 Hz).
[0314] Preparation of ethyl
(S)-2-(2-bromo-7-(4-chlorophenyl)-5-methylbenzo[d]thiazol-6-yl)-2-hydroxy-
acetate: Catalyst Preparation: A 25 mL flask was charged with
dichloro(pentamethylcyclopentadienyl)rhodium(III) dimer (94 mg,
0.15 mmol, 1.0 equiv) and the ligand
N-((1S,2S)-2-amino-1,2-diphenylethyl)-4-nitrobenzenesulfonamide
(153 mg, 0.39 mmol, 2.6 equiv) and sealed with a rubber septum. The
flask was purged with argon and then ACN (1.5 mL) and NEt.sub.3
(0.15 mL) were added to the flask and an additional septum was
fitted. The resulting red solution was stirred at room temperature
under argon for a minimum of 45 minutes, but not more than 6 hours,
which resulted in a heterogeneous orange suspension.
[0315] A 100 mL flask was charged with ethyl
2-(2-bromo-7-(4-chlorophenyl)-5-methylbenzo[d]thiazol-6-yl)-2-oxoacetate
(2.4 g, 5.5 mmol, 1.0 equiv) and sealed with a rubber septum. The
flask was purged with argon and to this was charged ACN (11 mL) and
NEt.sub.3 (1.9 mL, 13.6 mmol, 2.5 equiv) and stirring was
initiated. The solution was cooled to 0.degree. C. and then
HCO.sub.2H (0.63 mL, 16.7 mmol, 3.0 equiv) was added to the
solution at a rate to maintain an internal temperature not more
than 20.degree. C. Upon completion of the addition, the solution
was allowed to cool back to 0.degree. C. Argon was then bubbled
through the solution using a porous gas dispersion unit. To the
stirring solution at 0.degree. C. was charged the prepared catalyst
solution (0.5 mL, 0.05 equiv) from the catalyst preparation above.
The solution was stirred at 0.degree. C. with the bubbling of argon
through the solution until TLC indicated complete consumption of
starting material (10-18 h). The reaction was quenched with
H.sub.2O then diluted with EtOAc and allowed to warm to room
temperature. The layers were separated and the organic extract was
washed once more with H.sub.2O. The organic extract was then dried
over Na.sub.2SO.sub.4, filtered through a small pad of silica gel
eluting with EtOAc, and concentrated in vacuo. The resulting crude
residue was chromatographed using a 80 g RediSep normal phase
silica gel cartridge (EtOAc/Hex, 5%.fwdarw.20%) on a CombiFlash
system to give the desired product. TLC (20% EtOAc/Hex) Rf=0.27;
.sup.1H NMR (400 MHz, CDCl.sub.3) .delta. 7.79 (s, 1H), 7.53-7.43
(m, 2H), 7.37 (m, 2H), 5.23 (d, J=2.2 Hz, 1H), 4.19 (m, 2H), 3.29
(d, J=2.2 Hz, 1H), 2.48 (d, J=0.5 Hz, 3H), 1.21 (t, J=7.1 Hz,
3H).
[0316] Alternative preparation of ethyl
(S)-2-(2-bromo-7-(4-chlorophenyl)-5-methylbenzo[d]thiazol-6-yl)-2-hydroxy-
acetate: A solution of ethyl
2-(2-bromo-7-(4-chlorophenyl)-5-methylbenzo[d]thiazol-6-yl)-2-oxoacetate
(10.60 g, 25.0 mmol) in PhMe (100 mL) was cooled to -30.degree. C.
(R)-Me-CBS catalyst (1.39 g, 5.00 mmol) was added, followed
immediately by distilled catecholborane (4.00 mL, 37.5 mmol). At
1.2 h, additional (R)-Me-CBS catalyst (1.39 g, 5.00 mmol) was
added. After another 1 h had passed, additional (R)-Me-CBS catalyst
(700 mg, 2.50 mmol) was added. After 30 min, the reaction was
quenched with EtOAc (30 mL). Saturated aqueous NaHCO.sub.3 (50 mL)
was added, and the reaction was warmed to 23.degree. C. and stirred
for an additional 30 min. The organic phase was collected, washed
with saturated aqueous NaHCO.sub.3 (1x), dried (MgSO.sub.4),
filtered, and concentrated. Benzene was added and the resulting
solution was purified by silica gel column, eluting by 0-100% EtOAc
in hexanes to give the product. LCMS-ESI.sup.+: calc'd for
C.sub.18H.sub.15BrClNO.sub.3S: 440.0, 442.0, 440.0 (M+H.sup.+);
Found: 440.2, 442.1, 444.1 (M+H.sup.+). .sup.1H NMR (400 MHz,
CDCl.sub.3) .delta.: 7.80 (s, 1H), 7.54-7.43 (m, 2H), 7.42-7.32 (m,
2H), 5.23 (s, 1H), 4.31-4.12 (m, 2H), 2.47 (s, 3H), 1.23 (t, J=7.1
Hz, 3H).
[0317] Preparation of ethyl
(S)-2-(2-bromo-7-(4-chlorophenyl)-5-methylbenzo[d]thiazol-6-yl)-2-(tert-b-
utoxy)acetate: A suspension of ethyl
(S)-2-(2-bromo-7-(4-chlorophenyl)-5-methylbenzo[d]thiazol-6-yl)-2-hydroxy-
acetate (7.20 g, 16.9 mmol) in tert-butyl acetate (100 mL) was
cooled to 0.degree. C. in an ice bath. 70% w/v aqueous HClO.sub.4
(293 .mu.L, 3.4 mmol) was added dropwise over 5 min. The reaction
was warmed to 23.degree. C., then stirred for 2.3 h. At this point
the reaction was transferred to an addition funnel. The reaction
was added to a 23.degree. C. solution of sat aqueous NaHCO.sub.3
(400 mL) over 30 min. Once addition was complete, the reaction was
stirred for another 15 min. The resulting system was extracted with
EtOAc (2.times.150 mL). Combined organic layers were dried
(Na.sub.2SO.sub.4), filtered, and concentrated in vacuo. Some
residual tert-butyl acetate remained. Hexane (200 mL) was added and
the slurry was concentrated once more. The resulting residue
(reasonably free of tert-butyl acetate) was treated with benzene
and loaded onto a 330 g "gold" ISCO silica gel column. The
following gradient elution sequence was used: [100% Hexane (5
column volumes, isocratic) .fwdarw.10% EtOAc/90% Hexane (5 column
volumes, linear gradient .fwdarw.10% EtOAc/90% Hexane (5 column
volumes) .fwdarw.100% EtOAc (10 column volumes)].
Product-containing fractions were pooled, concentrated,
co-evarporated with Et.sub.2O (100 mL) to give desired product.
LCMS-ESI+ calc'd for C.sub.22H.sub.23BrClNO.sub.3S: 496.0, 498.0
and 500.0 (M+H+); found: 496.2, 498.2, and 500.1 (M+H+). .sup.1H
NMR (400 MHz, CDCl.sub.3): .delta. 7.77 (s, 1H), 7.48 (m, 3H), 7.37
(m, 1H), 5.12 (s, 1H), 4.20 (m, 2H), 2.57 (s, 3H), 1.24 (t, 3H, J=7
Hz), 0.96 (s, 9H).
Example 2
Preparation of ethyl
(S)-2-(2-bromo-7-(4-chlorophenyl)-5-methylbenzo[d]thiazol-6-yl)-2-cyclopr-
opoxyacetate
##STR00080## ##STR00081##
[0319] Preparation of ethyl
(R)-2-bromo-2-(2-bromo-7-(4-chlorophenyl)-5-methylbenzo[d]thiazol-6-yl)ac-
etate: Two reactions were run in parallel: To a solution of ethyl
(S)-2-(2-bromo-7-(4-chlorophenyl)-5-methylbenzo[d]thiazol-6-yl)-2-hydroxy-
acetate (23 g, 52.2 mmol, 1.0 eq) in DCM (350 mL) was added a
mixture solution of 1H-benzotriazole (6.84 g, 57.4 mmol, 1.1 eq)
and SOBr.sub.2 (11.9 g, 57.4 mmol, 1.1 eq) in DCM (50 mL) at
15.degree. C. The reaction was stirred for 2 hrs at 15.degree. C.
TLC (Petroleum ether/Ethyl acetate=5/1, Rf=0.5) showed ethyl
(S)-2-(2-bromo-7-(4-chlorophenyl)-5-methylbenzo[d]thiazol-6-yl)-2-hydroxy-
acetate was consumed completely, four new spots. Two reactions were
combined for workup. The reaction mixture was filtered,
concentrated in vacuo to remove DCM. The crude product was purified
by silica gel chromatography eluted with Petroleum ether: Ethyl
acetate (20:1) to give ethyl
(R)-2-bromo-2-(2-bromo-7-(4-chlorophenyl)-5-methylbenzo[d]thiazol-6-
-yl)acetate. LCMS-ESI.sup.+: calc'd for
C.sub.18H.sub.15Br.sub.2ClNO.sub.2S: 501.9 (M+H).sup.+; found:
502.0 (M+H).sup.+.
[0320] Preparation of ethyl
2-(2-bromo-7-(4-chlorophenyl)-5-methylbenzo[d]thiazol-6-yl)-2-cyclopropox-
yacetate: Two reactions were carried out in parallel. A mixture of
ethyl
(R)-2-bromo-2-(2-bromo-7-(4-chlorophenyl)-5-methylbenzo[d]thiazol-6-yl)ac-
etate (20 g, 39.7 mmol, 1 eq) and cyclopropanol (6.9 g, 119 mmol, 3
eq) in DCE (300 ml, freshly distilled from P.sub.2O.sub.5) was
stirred with 4 .ANG. molecular sieves (15 g) for 0.5 hr at
15.degree. C. To a suspension of AgOTf (30.6 g, 119 mmol, 3 eq) in
DCE (300 ml, freshly distilled from P.sub.2O.sub.5) was added 4
.ANG. molecular sieves (15 g). The mixture was stirred at
15.degree. C. for 0.5 hr in dark. The two mixtures were mixed
together and stirred at 80.degree. C. in dark for 1.5 hrs. LC-MS
showed the reaction was complete. Two reactions were combined for
workup. The reaction mixture was filtered, concentrated in vacuo.
The residue was purified by silica gel chromatography eluted with
Petroleum ether: Ethyl acetate (20:1) to give pure product. To the
solid was added Petroleum ether (70 mL). The mixture was stirred at
15.degree. C. for 0.5 hr. The mixture was filtered. The solid was
dried in vacuo to afford ethyl
2-(2-bromo-7-(4-chlorophenyl)-5-methylbenzo[d]thiazol-6-yl)-2-cyclopropox-
yacetate. LCMS -ESI.sup.+: calc'd for
C.sub.21H.sub.20BrClNO.sub.3S: 480.0 (M+H).sup.+; found: 480.0
(M+H).sup.+.
[0321] Individual enantiomers were separated using chiral SFC (OJ
(250 mm*30 mm, 5um); Neu-MeOH) to give ethyl
(S)-2-(2-bromo-7-(4-chlorophenyl)-5-methylbenzo[d]thiazol-6-yl)-2-cyclopr-
opoxyacetate (peak 1, [.alpha.].sub.D.sup.20 -103.59.degree. (c
1.0, CHCl.sub.3)) and ethyl
(R)-2-(2-bromo-7-(4-chlorophenyl)-5-methylbenzo[d]thiazol-6-yl)-2-cyclopr-
opoxyacetate (peak 2, [.alpha.].sub.D.sup.20 +98.22.degree. (c 1.0,
CHCl.sub.3)).
Example 3
Preparation of ethyl
(S)-2-(2-(3-bromo-1-methyl-1H-indazol-5-yl)-7-(4-chlorophenyl)-5-methylbe-
nzo[d]thiazol-6-yl)-2-(tert-butoxy)acetate
##STR00082##
[0323] Preparation of ethyl
(S)-2-(tert-butoxy)-2-(7-(4-chlorophenyl)-5-methyl-2-(1-methyl-1H-indazol-
-5-yl)benzo[d]thiazol-6-yl)acetate: A flask containing ethyl
(S)-2-(2-bromo-7-(4-chlorophenyl)-5-methylbenzo[d]thiazol-6-yl)-2-(tert-b-
utoxy)acetate (2503 mg, 5.038 mmol),
(1-methyl-1H-indazol-5-yl)boronic acid (1773 mg, 10.09 mmol),
potassium carbonate (2087 mg, 15.1 mmol), and
tetrakis(triphenylphosphine)palladium(0) (585 mg, 0.506 mmol) was
purged with Argon gas for 5 min and then added water (6 mL) and
dioxane (24 mL). After additional .about.1 min purging with Argon
gas, the flask was kept tightly with septum and heated at
95.degree. C. bath for 1.25 h. After the mixture was filtered
through celite and washed with dioxane, the filtrate and washing
were concentrated to dryness. After the residue was stirred with
dichloromethane (.about.200 mL), the solution was dried
(MgSO.sub.4) and concentrated. The residue was purified by
CombiFlash (120 g, Gold, 0-40% EtOAc/Hex) to obtain the title
product. LCMS-ESI.sup.+: calc'd for
C.sub.30H.sub.31ClN.sub.3O.sub.3S: 548.18 (M+H).sup.+; found:
548.29 (M+H).sup.+.
[0324] Preparation of ethyl
(S)-2-(2-(3-bromo-1-methyl-1H-indazol-5-yl)-7-(4-chlorophenyl)-5-methylbe-
nzo[d]thiazol-6-yl)-2-(tert-butoxy)acetate: A solution of ethyl
(S)-2-(tert-butoxy)-2-(7-(4-chlorophenyl)-5-methyl-2-(1-methyl-1H-indazol-
-5-yl)benzo[d]thiazol-6-yl)acetate (2357 mg, 4.3 mmol) in
acetonitrile (22 mL) was stirred at 0.degree. C. as
N-bromosucciimide (843 mg, 4.73 mmol) was added. After 5 min, the
mixture was stirred at rt. After 17 h, the reaction mixture was
diluted with dichloromethane (150 mL) and washed with saturated
aqueous NaHCO.sub.3 (200 mL.times.1) and water (200 mL.times.1).
After the aqueous layers were extracted with dichloromethane (100
mL.times.1), the two organic layers were combined, dried
(MgSO.sub.4), and concentrated to dryness. The residue was purified
by Combiflash (120 g, Gold, 0-35% EtOAc/Hex) to obtain the title
product. LCMS-ESI.sup.+: calc'd for
C.sub.30H.sub.30BrClN.sub.3O.sub.3S: 626.09 (M+H).sup.+; found:
626.25 (M+H).sup.+.
Method A
Example 4
Preparation of
(S)-2-(tert-butoxy)-2-(7-(4-chlorophenyl)-5-methyl-2-(1-methyl-3-(1-(oxet-
an-3-yl)piperidin-4-yl)-1H-indazol-5-yl)benzo[d]thiazol-6-yl)acetic
acid (1)
##STR00083## ##STR00084##
[0326] Preparation of tert-butyl
(S)-4-(5-(6-(1-(tert-butoxy)-2-ethoxy-2-oxoethyl)-7-(4-chlorophenyl)-5-me-
thylbenzo[d]thiazol-2-yl)-1-methyl-1H-indazol-3-yl)-3,6-dihydropyridine-1(-
2H)-carboxylate: To a microwave vial containing ethyl
(S)-2-(2-(3-bromo-1-methyl-1H-indazol-5-yl)-7-(4-chlorophenyl)-5-methylbe-
nzo[d]thiazol-6-yl)-2-(tert-butoxy)acetate (250 mg, 0.40 mmol),
tert-butyl
4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-3,6-dihydropyridine-1(2H)-
-carboxylate (185 mg, 0.60 mmol), potassium carbonate (165.3 mg,
1.2 mmol), and tetrakis(triphenylphosphine)palladium(0) (46 mg,
0.04 mmol) was added water (1 mL) and dioxane (4 mL). It was purged
with Argon gas for 10 min. The mixture was capped and microwaved at
110.degree. C. bath for 2 h. After the reaction was completed and
cooled to room temperature, the mixture was filtered through celite
and washed with ethyl acetate. The filtrate was washed with brine.
The organic phase was dried (MgSO.sub.4) and concentrated. The
residue was purified by CombiFlash (40 g, Gold, 0-50% EtOAc/Hex) to
give the desired product. LCMS-ESI+: calc'd for:
C.sub.40H.sub.46ClN.sub.4O.sub.5S; 729.3 (M+H).sup.+; found: 729.1
(M+H).sup.+.
[0327] Preparation of tert-butyl
(S)-4-(5-(6-(1-(tert-butoxy)-2-ethoxy-2-oxoethyl)-7-(4-chlorophenyl)-5-me-
thylbenzo[d]thiazol-2-yl)-1-methyl-1H-indazol-3-yl)piperidine-1-carboxylat-
e: A mixture of tert-butyl
(S)-4-(5-(6-(1-(tert-butoxy)-2-ethoxy-2-oxoethyl)-7-(4-chlorophenyl)-5-me-
thylbenzo[d]thiazol-2-yl)-1-methyl-1H-indazol-3-yl)-3,6-dihydropyridine-1(-
2H)-carboxylate (263 mg, 0.361 mmol), rhodium on alumina, 5 wt %
(111 mg, 0.054 mmol) in ethanol (40 mL) was evacuated and
back-filled with hydrogen (3.times.). Reaction mixture was stirred
overnight, filtered through a pad of Celite and concentrated to
give desired product as colorless oil. LCMS-ESI+: calc'd for
C.sub.40H.sub.48ClN.sub.4O.sub.5S; 731.3 (M+H).sup.+; found: 731.1
(M+H).sup.+.
[0328] Preparation of ethyl
(S)-2-(tert-butoxy)-2-(7-(4-chlorophenyl)-5-methyl-2-(1-methyl-3-(piperid-
in-4-yl)-1H-indazol-5-yl)benzo[d]thiazol-6-yl)acetate: A solution
of tert-butyl
(S)-4-(5-(6-(1-(tert-butoxy)-2-ethoxy-2-oxoethyl)-7-(4-chlorophenyl)-5-me-
thylbenzo[d]thiazol-2-yl)-1-methyl-1H-indazol-3-yl)piperidine-1-carboxylat-
e (214 mg, 0.293 mmol) in 1.25 HCl in isopropanol (5.0 mL) was
stirred overnight at room temperature. Reaction mixture was
quenched with saturated sodium bicarbonate solution carefully and
extracted with ethyl acetate (2.times.). Combined organic layer was
dried (MgSO.sub.4), filtered and concentrated to give crude desired
product that was used in the next step without further
purification. LCMS-ESI+: calc'd for
C.sub.35H.sub.40ClN.sub.4O.sub.3S; 631.2 (M+H).sup.+; found: 631.3
(M+H).sup.+.
[0329] Preparation of ethyl
(S)-2-(tert-butoxy)-2-(7-(4-chlorophenyl)-5-methyl-2-(1-methyl-3-(1-(oxet-
an-3-yl)piperidin-4-yl)-1H-indazol-5-yl)benzo[d]thiazol-6-yl)acetate:
A solution of
(S)-2-(tert-butoxy)-2-(7-(4-chlorophenyl)-5-methyl-2-(1-methyl-3-(piperid-
in-4-yl)-1H-indazol-5-yl)benzo[d]thiazol-6-yl)acetate (36 mg, 0.057
mmol), 3-oxetanone (41 mg, 0.57 mmol), acetic acid (2 drops) and
sodium cyanoborohydride (35.8 mg, 0.57 mmol) in methanol (1 mL) was
stirred for 18 hours at room temperature. LCMS showed complete
conversion. Reaction mixture was carried to the next step directly.
LCMS-ESI+: calc'd for C.sub.38H.sub.44ClN.sub.4O.sub.4S: 687.3
(M+H).sup.+; found: 687.4 (M+H).sup.+.
[0330] Preparation of
(S)-2-(tert-butoxy)-2-(7-(4-chlorophenyl)-5-methyl-2-(1-methyl-3-(1-(oxet-
an-3-yl)piperidin-4-yl)-1H-indazol-5-yl)benzo[d]thiazol-6-yl)acetic
acid: To above reaction mixture of ethyl
(S)-2-(tert-butoxy)-2-(7-(4-chlorophenyl)-5-methyl-2-(1-methyl-3-(1-(oxet-
an-3-yl)piperidin-4-yl)-1H-indazol-5-yl)benzo[d]thiazol-6-yl)acetate
(0.057 mmol) was added THF (1 mL), MeOH (1 mL) and 50% Sodium
hydroxide (1 mL) at rt. The mixture was stirred at 60.degree. C.
for 1.5 h. The reaction mixture was cooled by ice and acidified
with 3 N HCl. The resulting mixture was extracted with ethyl
acetate (2.times.). Combined organic layer was dried (MgSO.sub.4),
filtered and concentrated to give crude mixture which was purified
by Gilson HPLC (Phenomenex Gemini 250.times.21.2 10.mu. C18 column,
40-100% ACN/H.sub.2O+0.1% TFA) to give a yellow powder after
lyophilization. .sup.1H NMR (400 MHz, Chloroform-d) .delta.8.30 (s,
1H), 7.96 (d, J=8.5 Hz, 1H), 7.81 (s, 1H), 7.69 (d, J=8.0 Hz, 1H),
7.54-7.40 (m, 3H), 7.35 (d, J=8.9 Hz, 1H), 5.21 (s, 1H), 4.91-4.77
(m, 2H), 4.74 (t, J=7.1 Hz, 2H), 3.96 (s, 3H), 3.17 (d, J=11.2 Hz,
2H), 2.55 (s, 3H), 2.17 (s, 4H), 0.94 (s, 9H). LCMS-ESI+: calc'd
for C.sub.36H.sub.40ClN.sub.4O.sub.4S; 659.2 (M+H).sup.+; found:
659.4 (M+H).sup.+.
Method B
Example 5
(S)-2-(tert-butoxy)-2-(7-(4-chlorophenyl)-2-(3-(3-methoxyazetidin-1-yl)-1--
methyl-1H-indazol-5-yl)-5-methylbenzo[d]thiazol-6-yl)acetic acid
(2)
##STR00085##
[0332] Preparation of ethyl
(S)-2-(tert-butoxy)-2-(7-(4-chlorophenyl)-2-(3-(3-methoxyazetidin-1-yl)-1-
-methyl-1H-indazol-5-yl)-5-methylbenzo[d]thiazol-6-yl)acetate: A
microwave vial containing Tris(dibenzylideneacetone) dipalladium
(0) (6.57 mg, 7.18 .mu.mol),
2-(Dicyclohexylphosphino)-2',4',6'-triisopropylbiphenyl (3.42 mg,
7.18 .mu.mol) and cesium carbonate (78.0 mg, 239 .mu.mol) in
1,4-dioxane (1 mL) was purged with Argon for 5 min. Ethyl
(S)-2-(2-(3-bromo-1-methyl-1H-indazol-5-yl)-7-(4-chlorophenyl)-5-methylbe-
nzo[d]thiazol-6-yl)-2-(tert-butoxy)acetate (30 mg, 0.05 mmol) and
3-methoxyazetidine hydrochloride (17.74 mg, 0.14 mmol) were added
and reaction mixture was sealed and heated in a microwave reactor
at 100.degree. C. for 1 h. After cooling to room temperature, the
resulting mixture was diluted ethyl acetate. The mixture was washed
with brine, organic phase was dried (Na.sub.2SO.sub.4) and
concentrated. The residue was purified by CombiFlash (40 g, Gold,
0-50% EtOAc/Hex plus 0.1% TEA) to give desired product. LCMS-ESI+:
calc'd for: C.sub.34H.sub.37ClN.sub.4O.sub.4S; 633.2 (M+H).sup.+;
found: 633.3 (M+H).sup.+.
[0333] Preparation of
(S)-2-(tert-butoxy)-2-(7-(4-chlorophenyl)-2-(3-(3-methoxyazetidin-1-yl)-1-
-methyl-1H-indazol-5-yl)-5-methylbenzo[d]thiazol-6-yl)acetic acid:
To ethyl
(S)-2-(tert-butoxy)-2-(7-(4-chlorophenyl)-2-(3-(3-methoxyazetidin-1-
-yl)-1-methyl-1H-indazol-5-yl)-5-methylbenzo[d]thiazol-6-yl)acetate
(20 mg, 0.03 mmol) was added THF (1.5 mL), MeOH (0.2 mL) and 50%
aqueous sodium hydroxide (0.4 mL) at room temperature. The mixture
was stirred at 60.degree. C. for 2 h. The reaction mixture was
cooled by ice and acidified with 3 N HCl. The resulting mixture was
extracted with ethyl acetate (2.times.). Combined organic layer was
dried (MgSO.sub.4), filtered and concentrated to give crude mixture
which was purified by Gilson HPLC (Phenomenex Gemini 250.times.21.2
10.mu. C18 column, 40-100% ACN/H.sub.2O+0.1% TFA) to give a yellow
powder after lyophilization. .sup.1H NMR (400 MHz, Chloroform-d)
.delta. 8.16 (s, 1H), 7.95 (d, J=8.9 Hz, 1H), 7.81 (s, 1H),
7.69-7.62 (m, 1H), 7.46 (d, J=6.9 Hz, 3H), 7.16 (d, J=9.0 Hz, 1H),
5.24 (d, J=5.7 Hz, 1H), 4.49-3.96 (m, 5H), 3.83 (s, 3H), 3.29 (s,
3H), 2.50 (s, 3H), 0.94 (s, 9H). LCMS-ESI+: calc'd for
C.sub.32H.sub.33ClN.sub.4O.sub.4S; 605.2 (M+H).sup.+; found: 605.3
(M+H).sup.+.
Method C
Example 6
Preparation of
(S)-2-(tert-butoxy)-2-(7-(4-chlorophenyl)-5-methyl-2-(1-methyl-3-(2-oxoaz-
etidin-1-yl)-1H-indazol-5-yl)benzo[d]thiazol-6-yl)acetic acid
(3)
##STR00086##
[0335] Preparation of ethyl
(S)-2-(tert-butoxy)-2-(7-(4-chlorophenyl)-5-methyl-2-(1-methyl-3-(2-oxoaz-
etidin-1-yl)-1H-indazol-5-yl)benzo[d]thiazol-6-yl)acetate: A
microwave vial containing Tris(dibenzylideneacetone) dipalladium
(0) (4.4 mg, 5 .mu.mol),
2-(Dicyclohexylphosphino)-2',4',6'-triisopropylbiphenyl (2.3 mg,
5.0 .mu.mol) and cesium carbonate (52 mg, 160 .mu.mol) in
1,4-dioxane (1 mL) was purged with Argon for 5 min. Ethyl
(S)-2-(2-(3-bromo-1-methyl-1H-indazol-5-yl)-7-(4-chlorophenyl)-5-methylbe-
nzo[d]thiazol-6-yl)-2-(tert-butoxy)acetate (20 mg, 0.032 mmol) and
azetidin-2-one (6.8 mg, 0.096 mmol) were added and mixture was
sealed and heated in a microwave reactor at 100.degree. C. for 1 h.
To test the solvent effect, two additional reactions were set up
with exact same reagents and amounts in Toluene and t-BuOH
separately which gave same results. After cooling to room
temperature, the resulting three reaction mixtures were combined,
diluted ethyl acetate. The mixture was washed with brine. The
organic phase was dried (Na.sub.2SO.sub.4) and concentrated. The
residue was purified by CombiFlash (40 g, Gold, 0-10%
MeOH/CH.sub.2Cl.sub.2) to give desired product (containing impurity
from catalyst). LCMS-ESI+: calc'd for:
C.sub.33H.sub.33ClN.sub.4O.sub.4S; 617.2 (M+H).sup.+; found: 617.3
(M+H).sup.+.
[0336] Preparation of
(S)-2-(tert-butoxy)-2-(7-(4-chlorophenyl)-2-(3-(3-methoxyazetidin-1-yl)-1-
-methyl-1H-indazol-5-yl)-5-methylbenzo[d]thiazol-6-yl)acetic acid:
To ethyl
(S)-2-(tert-butoxy)-2-(7-(4-chlorophenyl)-5-methyl-2-(1-methyl-3-(2-
-oxoazetidin-1-yl)-1H-indazol-5-yl)benzo[d]thiazol-6-yl)acetate in
pyridine (1.5 ml) was added lithium iodide hydrate (240 mg, 1.58
mmol) at room temperature . The mixture was microwaved at
170.degree. C. for 3 h. The reaction mixture was cooled by ice and
acidified with 3 N HCl. The resulting mixture was extracted with
ethyl acetate. The organic layer was washed by sat'd NH.sub.4Cl,
dried (MgSO.sub.4), filtered and concentrated to give crude mixture
which was purified by Gilson HPLC (Phenomenex Gemini 250.times.21.2
10.mu. C18 column, 40-100% ACN/H.sub.2O+0.1% TFA) to give a yellow
powder after lyophilization. .sup.1H NMR (400 MHz, Chloroform-d)
.delta.9.14 (s, 1H), 8.88 (s, 1H), 8.14-8.00 (m, 1H), 7.83 (s, 1H),
7.73-7.63 (m, 1H), 7.59-7.42 (m, 3H), 7.35 (d, J=9.0 Hz, 1H), 6.51
(t, J=22.6 Hz, 6H), 5.88 (dd, J=10.4, 1.4 Hz, 1H), 5.31 (s, 1H),
3.97 (s, 3H), 2.55 (s, 3H), 1.26 (d, J=2.4 Hz, 1H), 0.99 (s, 9H).
LCMS-ESI+: calc'd for C.sub.31H.sub.29ClN.sub.4O.sub.4S; 589.2
(M+H).sup.+; found: 589.3 (M+H).sup.+.
Method D
Example 7
Preparation of
(S)-2-(tert-butoxy)-2-(7-(4-chlorophenyl)-2-(3-((S)-hexahydropyrazino[2,1-
-c][1,4]oxazin-8(1H)-yl)-1-methyl-1H-indazol-5-yl)-5-methylbenzo[d]thiazol-
-6-yl)acetic acid (4)
##STR00087##
[0338] Preparation of
(S)-2-(tert-butoxy)-2-(7-(4-chlorophenyl)-2-(3-((S)-hexahydropyrazino[2,1-
-c][1,4]oxazin-8(1H)-yl)-1-methyl-1H-indazol-5-yl)-5-methylbenzo[d]thiazol-
-6-yl)acetic acid: A mixture of ethyl
(S)-2-(2-(3-bromo-1-methyl-1H-indazol-5-yl)-7-(4-chlorophenyl)-5-methylbe-
nzo[d]thiazol-6-yl)-2-(tert-butoxy)acetate (110 mg, 0.175 mmol),
(S)-Octahydropyrazino[2,1-c][1,4]oxazine hydrochloride (87 .mu.l,
0.53 mmol), SPhos Pd G2 (24 mg, 0.035 mmol), and potassium
t-butoxide (104 mg, 1.2 mmol) in 1,2-dimethoxyethane (2 mL) was
placed in a microwave vial and reacted under microwave at
100.degree. C. for 1 h. The resulting mixture was cooled to room
temperature, diluted in methanol, filtered through a pad of Celite,
washed with EtOAc, and concentrated. To this crude mixture was
added THF (1.5 mL), MeOH (0.2 mL) and 50% aqueous sodium hydroxide
(0.4 mL). The mixture was stirred at 60.degree. C. for 2 h. The
reaction mixture was cooled by ice and acidified with 3 N HCl. The
resulting mixture was extracted with ethyl acetate (2.times.).
Combined organic layer was dried (MgSO.sub.4), filtered and
concentrated to give crude mixture which was purified by Gilson
HPLC (Phenomenex Gemini 250.times.21.2 10.mu. C18 column, 40-100%
ACN/H.sub.2O+0.1% TFA) to give a yellow powder after
lyophilization. .sup.1H NMR (400 MHz, Chloroform-d) .delta. 8.57
(s, 1H), 7.91 (s, 1H), 7.84 (d, J=8.9 Hz, 1H), 7.71 (d, J=8.1 Hz,
1H), 7.60-7.51 (m, 2H), 7.47 (d, J=7.9 Hz, 1H), 7.33 (d, J=8.9 Hz,
1H), 5.31 (s, 1H), 4.09 (q, J=12.2, 10.1 Hz, 3H), 3.93 (s, 4H),
3.66 (dt, J=28.8, 12.7 Hz, 3H), 3.45 (t, J=12.3 Hz, 1H), 3.28 (s,
1H), 3.04 (s, 1H), 2.58 (s, 3H), 1.25 (m, 2H), 1.01 (s, 9H),
0.93-0.77 (m, 3H). LCMS-ESI+: calc'd for
C.sub.35H.sub.38ClN.sub.5O.sub.4S; 660.2 (M+H).sup.+; found: 660.4
(M+H).sup.+.
Method E
Example 8
Preparation of
(S)-2-(tert-butoxy)-2-(7-(4-chlorophenyl)-2-(3-(1-(((R)-1-(methoxycarbony-
l)azetidin-2-yl)methyl)piperidin-4-yl)-1-methyl-1H-indazol-5-yl)-5-methylb-
enzo[d]thiazol-6-yl)acetic acid (5)
##STR00088## ##STR00089##
[0340] Preparation of tert-butyl
(R)-2-((4-(5-(6-((S)-1-(tert-butoxy)-2-ethoxy-2-oxoethyl)-7-(4-chlorophen-
yl)-5-methylbenzo[d]thiazol-2-yl)-1-methyl-1H-indazol-3-yl)piperidin-1-yl)-
methyl)azetidine-1-carboxylate: To a solution of ethyl
(S)-2-(tert-butoxy)-2-(7-(4-chlorophenyl)-5-methyl-2-(1-methyl-3-(piperid-
in-4-yl)-1H-indazol-5-yl)benzo[d]thiazol-6-yl)acetate (100 mg,
0.160 mmol) in acetonitrile (4.0 mL) at room temperature was added
cesium carbonate (284 mg, 0.870 mmol) and tert-butyl
(R)-2-(bromomethyl)azetidine-1-carboxylate (198 mg, 0.790 mmol) and
reaction mixture was stirred at 95.degree. C. for 3 hours. Once
complete, reaction mixture was allowed to cool to room temperature
and quenched with saturated sodium bicarbonate and extracted with
ethyl acetate (3.times.). Combined organic layer was washed with
saturated sodium chloride, dried (Na.sub.2SO.sub.4) and
concentrated. The residue was purified by CombiFlash (0-15%
MeOH/CH.sub.2Cl.sub.2) and concentrated to give desired product.
LCMS-ESI+: calc'd for C.sub.44H.sub.55ClN.sub.5O.sub.5S: 800.36
(M+H).sup.+; found: 800.39 (M+H).sup.+.
[0341] Preparation of ethyl
(S)-2-(2-(3-(1-(((R)-azetidin-2-yl)methyl)piperidin-4-yl)-1-methyl-1H-ind-
azol-5-yl)-7-(4-chlorophenyl)-5-methylbenzo[d]thiazol-6-yl)-2-(tert-butoxy-
)acetate: A solution of tert-butyl
(R)-2-((4-(5-(6((S)-1-(tert-butoxy)-2-ethoxy-2-oxoethyl)-7-(4-chloropheny-
l)-5-methylbenzo[d]thiazol-2-yl)-1-methyl-1H-indazol-3-yl)piperidin-1-yl)m-
ethyl)azetidine-1-carboxylate (88 mg, 0.011 mmol) in 1.25 M HCl in
isopropanol (5.0 mL) was stirred for 36 hours at room temperature.
Reaction mixture was quenched with saturated sodium bicarbonate and
concentrated. Residue was diluted with water and extracted with
dichloromethane (3.times.). Combined organic layer was washed with
saturated sodium chloride, dried (Na.sub.2SO.sub.4), and
concentrated to give
(S)-2-(2-(3-(1-(((R)-azetidin-2-yl)methyl)piperidin-4-yl)-1-methyl-1-
H-indazol-5-yl)-7-(4-chlorophenyl)-5-methylbenzo[d]thiazol-6-yl)-2-(tert-b-
utoxy)acetate that was used in the next step without purification.
LCMS-ESI+: calc'd for C.sub.39H.sub.47ClN.sub.5O.sub.3S: 700.31
(M+H).sup.+; found: 700.68 (M+H).sup.+.
[0342] Preparation of methyl
(R)-2-((4-(5-(6-((S)-1-(tert-butoxy)-2-ethoxy-2-oxoethyl)-7-(4-chlorophen-
yl)-5-methylbenzo[d]thiazol-2-yl)-1-methyl-1H-indazol-3-yl)piperidin-1-yl)-
methyl)azetidine-1-carboxylate: To a solution of ethyl
(S)-2-(2-(3-(1-(((R)-azetidin-2-yl)methyl)piperidin-4-yl)-1-methyl-1H-ind-
azol-5-yl)-7-(4-chlorophenyl)-5-methylbenzo[d]thiazol-6-yl)-2-(tert-butoxy-
)acetate (15 mg, 0.021 mmol) in dichloromethane (0.5 mL) was added
N,N-diisopropylethylamine (0.037 mL, 0.21 mmol) at 0.degree. C.
followed by the addition of methyl chloroformate (0.008 mL, 0.1
mmol) and stirred for 1 hour. The reaction mixture was quenched
with saturated sodium bicarbonate at 0.degree. C. and extracted
with dichloromethane (3.times.). Combined organic layer was washed
with saturated sodium chloride, dried (Na.sub.2SO.sub.4), and
concentrated. Residue was purified by CombiFlash (0-15%
MeOH/CH.sub.2Cl.sub.2) and concentrated to give desired product.
LCMS-ESI.sup.+: calc'd for C.sub.41H.sub.49ClN.sub.5O.sub.5S:
758.31 (M+H).sup.+; found: 758.66 (M+H).sup.+.
[0343] Preparation of
(S)-2-(tert-butoxy)-2-(7-(4-chlorophenyl)-2-(3-(1-(((R)-1-(methoxycarbony-
l)azetidin-2-yl)methyl)piperidin-4-yl)-1-methyl-1H-indazol-5-yl)-5-methylb-
enzo[d]thiazol-6-yl)acetic acid: A solution of
(R)-2-((4-(5-(6-((S)-1-(tert-butoxy)-2-ethoxy-2-oxoethyl)-7-(4-chlorophen-
yl)-5-methylbenzo[d]thiazol-2-yl)-1-methyl-1H-indazol-3-yl)piperidin-1-yl)-
methyl)azetidine-1-carboxylate (10 mg, 0.013 mmol) and 2.5 M sodium
hydroxide (0.040 mL, 0.11 mmol) in methanol (0.5 mL) was stirred at
50.degree. C. for one hour. Reaction mixture was concentrated,
dissolved in DMF/methanol, filtered through syringe filter and
purified by Gilson HPLC (Gemini, 5-100% ACN/H.sub.2O+0.1% TFA) to
give a yellow powder after lyophilization. .sup.1H NMR (400 MHz,
Methanol-d.sub.4) .delta. 8.46 (s, 1H), 8.12 (d, J=9.0, 1.5 Hz,
1H), 7.82 (s, 1H), 7.72-7.66 (m, 1H), 7.66-7.57 (m, 4H), 5.26 (s,
1H), 4.14-4.02 (m, 4H), 4.02-3.91 (m, 1H), 3.78-3.34 (m, 8H),
3.24-3.10 (m, 1H), 2.62 (s, 3H), 2.58-2.06 (m, 7H), 1.35-1.17 (m,
1H), 0.98 (s, 9H). LCMS-ESI.sup.+: calc'd for
C.sub.39H.sub.45ClN.sub.5O.sub.5S: 730.28 (M+H).sup.+; found:
730.71 (M+H).sup.+.
Example 9
Preparation of
(2S)-2-(tert-butoxy)-2-(7-(4-chlorophenyl)-5-methyl-2-(1-methyl-3-(1-(oxe-
tan-2-ylmethyl)piperidin-4-yl)-1H-indazol-5-yl)benzo[d]thiazol-6-yl)acetic
acid (6)
##STR00090##
[0345] Preparation of ethyl
(2S)-2-(tert-butoxy)-2-(7-(4-chlorophenyl)-5-methyl-2-(1-methyl-3-(1-(oxe-
tan-2-ylmethyl)piperidin-4-yl)-1H-indazol-5-yl)benzo[d]thiazol-6-yl)acetat-
e: To a solution of ethyl
(S)-2-(tert-butoxy)-2-(7-(4-chlorophenyl)-5-methyl-2-(1-methyl-3-(piperid-
in-4-yl)-1H-indazol-5-yl)benzo[d]thiazol-6-yl)acetate (10 mg, 0.016
mmol) and 2-(bromomethyl)oxetane (4.8 mg, 0.032 mmol) in DMF (0.5
mL) at room temperature was added cesium carbonate (11 mg, 0.035
mmol) and reaction mixture was stirred at 90.degree. C. for 3
hours. Once complete, reaction mixture was allowed to cool to room
temperature and quenched with saturated sodium bicarbonate and
concentrated. Diluted with water and extracted with ethyl acetate
(3.times.). Combined organic layer was washed with saturated sodium
chloride, dried (Na.sub.2SO.sub.4) and concentrated. Crude reaction
mixture was dissolved in DMF/methanol, filtered through syringe
filter and purified by Gilson HPLC (Gemini, 5-100%
ACN/H.sub.2O+0.1% TFA) to give a yellow powder after
lyophilization. LCMS-ESI.sup.+: calc'd for
C.sub.39H.sub.46ClN.sub.4O.sub.4S: 701.29 (M+H).sup.+; found:
701.63 (M+H).sup.+.
[0346] Preparation of
(2S)-2-(tert-butoxy)-2-(7-(4-chlorophenyl)-5-methyl-2-(1-methyl-3-(1-(oxe-
tan-2-ylmethyl)piperidin-4-yl)-1H-indazol-5-yl)benzo[d]thiazol-6-yl)acetic
acid: A solution of ethyl
(2S)-2-(tert-butoxy)-2-(7-(4-chlorophenyl)-5-methyl-2-(1-methyl-3-(1-(oxe-
tan-2-ylmethyl)piperidin-4-yl)-1H-indazol-5-yl)benzo[d]thiazol-6-yl)acetat-
e (5.9 mg, 0.0084 mmol) and 2.0 M sodium hydroxide (0.04 mL, 0.08
mmol) in methanol (0.5 mL) was stirred at 50.degree. C. for three
hours. Reaction mixture was concentrated, dissolved in
DMF/methanol, filtered through syringe filter and purified by
Gilson HPLC (Gemini, 5-100% ACN/H.sub.2O+0.1% TFA) to give a yellow
powder after lyophilization. .sup.1H NMR (400 MHz,
Methanol-d.sub.4) .delta. 8.46 (s, 1H), 8.12 (d, 1H), 7.82 (s, 1H),
7.72-7.66 (m, 1H), 7.66-7.55 (m, 4H), 5.33-5.22 (m, 2H), 4.79-4.72
(m, 1H), 4.71-4.59 (m, 1H), 4.05 (d, 3H), 3.82-3.63 (m, 3H),
3.61-3.35 (m, 3H), 3.29-3.20 (m, 1H), 2.96-2.84 (m, 1H), 2.62 (s,
3H), 2.60-2.47 (m, 1H), 2.44-2.12 (m, 4H), 0.99 (s, 9H).
LCMS-ESI.sup.+: calc'd for C.sub.37H.sub.42ClN.sub.4O.sub.4S:
673.26 (M+H).sup.+; found: 673.62 (M+H).sup.+.
Method F
Example 10
Preparation of
(S)-2-(tert-butoxy)-2-(7-(4-chlorophenyl)-5-methyl-2-(1-methyl-3-(1-(1-pr-
opionylazetidin-3-yl)piperidin-4-yl)-1H-indazol-5-yl)benzo[d]thiazol-6-yl)-
acetic acid (7)
##STR00091##
[0348] Preparation of ethyl
(S)-2-(tert-butoxy)-2-(7-(4-chlorophenyl)-5-methyl-2-(1-methyl-3-(1-(1-pr-
opionylazetidin-3-yl)piperidin-4-yl)-1H-indazol-5-yl)benzo[d]thiazol-6-yl)-
acetate: To a solution of ethyl
(S)-2-(2-(3-(1-(azetidin-3-yl)piperidin-4-yl)-1-methyl-1H-indazol-5-yl)-7-
-(4-chlorophenyl)-5-methylbenzo[d]thiazol-6-yl)-2-(tert-butoxy)acetate
(10 mg, 0.015 mmol) and N,N-Diisopropylethylamine (0.051 mL, 0.29
mmol) in methanol (0.5 mL) was added propionyl chloride (0.013 mL,
0.15 mmol) and reaction mixture was allowed to stir for one hour.
Reaction mixture was quenched with saturated sodium bicarbonate and
concentrated. Diluted with water and extracted with ethyl acetate
(3.times.). Combined organic layer was washed with saturated sodium
chloride, dried (Na.sub.2SO.sub.4) and concentrated to give ethyl
(S)-2-(tert-butoxy)-2-(7-(4-chlorophenyl)-5-methyl-2-(1-methyl-3-(1-(1-pr-
opionylazetidin-3-yl)piperidin-4-yl)-1H-indazol-5-yl)benzo[d]thiazol-6-yl)-
acetate that was used in the next step without further
purification. LCMS-ESI.sup.+: calc'd for
C.sub.41H.sub.49ClN.sub.5O.sub.4S: 742.32 (M+H).sup.+; found:
742.68 (M+H).sup.+.
[0349] Preparation of
(S)-2-(tert-butoxy)-2-(7-(4-chlorophenyl)-5-methyl-2-(1-methyl-3-(1-(1-pr-
opionylazetidin-3-yl)piperidin-4-yl)-1H-indazol-5-yl)benzo[d]thiazol-6-yl)-
acetic acid: A solution of
(S)-2-(tert-butoxy)-2-(7-(4-chlorophenyl)-5-methyl-2-(1-methyl-3-(1-(1-pr-
opionylazetidin-3-yl)piperidin-4-yl)-1H-indazol-5-yl)benzo[d]thiazol-6-yl)-
acetate (11 mg, 0.15 mmol) and 2.0 M sodium hydroxide (0.11 mL,
0.22 mmol) in methanol (0.5 mL) was stirred at 50.degree. C. for
three hours. Reaction mixture was concentrated, dissolved in
DMF/methanol, filtered through syringe filter and purified by
Gilson HPLC (Gemini, 5-100% ACN/H.sub.2O+0.1% TFA) to give a yellow
powder after lyophilization. .sup.1H NMR (400 MHz,
Methanol-d.sub.4) .delta. 8.47 (s, 1H), 8.13 (d, J=8.9 Hz, 1H),
7.82 (s, 1H), 7.73-7.56 (m, 5H), 5.26 (s, 1H), 4.63-4.53 (m, 1H),
4.49-4.40 (m, 1H), 4.37-4.30 (m, 1H), 4.25-4.15 (m, 2H), 4.06 (s,
3H), 3.77-3.47 (m, 2H), 3.27-3.08 (m, 2H), 2.62 (s, 3H), 2.46-2.17
(m, 5H), 1.36 (d, J=6.8 Hz, 1H), 1.22 (d, J=6.6 Hz, 1H), 1.13 (t,
J=7.5 Hz, 3H), 0.98 (s, 9H). LCMS-ESI.sup.+: calc'd for
C.sub.39H.sub.45ClN.sub.5O.sub.4S: 714.29 (M+H).sup.+; found:
714.66 (M+H).sup.+.
Method G
Example 11
Preparation of
(28)-2-(tert-butoxy)-2-(7-(4-chlorophenyl)-5-methyl-2-(1-methyl-3-(1-(1-(-
1,1,1-trifluoropropan-2-yl)azetidin-3-yl)piperidin-4-yl)-1H-indazol-5-yl)b-
enzo[d]thiazol-6-yl)acetic acid (8)
##STR00092##
[0351] Preparation of ethyl
(2S)-2-(tert-butoxy)-2-(7-(4-chlorophenyl)-5-methyl-2-(1-methyl-3-(1-(1-(-
1,1,1-trifluoropropan-2-yl)azetidin-3-yl)piperidin-4-yl)-1H-indazol-5-yl)b-
enzo[d]thiazol-6-yl)acetate: To a solution of ethyl
(S)-2-(2-(3-(1-(azetidin-3-yl)piperidin-4-yl)-1-methyl-1H-indazol-5-yl)-7-
-(4-chlorophenyl)-5-methylbenzo[d]thiazol-6-yl)-2-(tert-butoxy)acetate
(10 mg, 0.015 mmol) and 1,1,1-trifluoropropan-2-one (0.013 mL, 0.15
mmol) in methanol (0.5 mL) at 0.degree. C. was added sodium
cyanoborohydride (9.2 mg, 0.15 mmol) and acetic acid (0.004 mL,
0.07 mmol). Reaction mixture was allowed to stir for 5 minutes,
then removed from ice bath and stirred for one additional hour.
Reaction mixture was quenched with saturated sodium bicarbonate and
concentrated. Residue was diluted with water and extracted with
ethyl acetate (3.times.). Combined organic layer was washed with
saturated sodium chloride, dried (Na.sub.2SO.sub.4), and
concentrated to give ethyl
(2S)-2-(tert-butoxy)-2-(7-(4-chlorophenyl)-5-methyl-2-(1-methyl-3-(1-(1-(-
1,1,1-trifluoropropan-2-yl)azetidin-3-yl)piperidin-4-yl)-1H-indazol-5-yl)b-
enzo[d]thiazol-6-yl)acetate that was used in the next step without
further purification. LCMS-ESI.sup.+: calc'd for
C.sub.41H.sub.48ClF.sub.3N.sub.5O.sub.3S: 782.31 (M+H).sup.+;
found: 782.58 (M+H).sup.+.
[0352] Preparation of
(2S)-2-(tert-butoxy)-2-(7-(4-chlorophenyl)-5-methyl-2-(1-methyl-3-(1-(1-(-
1,1,1-trifluoropropan-2-yl)azetidin-3-yl)piperidin-4-yl)-1H-indazol-5-yl)b-
enzo[d]thiazol-6-yl)acetic acid: To a solution of ethyl
(2S)-2-(tert-butoxy)-2-(7-(4-chlorophenyl)-5-methyl-2-(1-methyl-3-(1-(1-(-
1,1,1-trifluoropropan-2-yl)azetidin-3-yl)piperidin-4-yl)-1H-indazol-5-yl)b-
enzo[d]thiazol-6-yl)acetate (10 mg, 0.013 mmol) in methanol (0.5
mL) was added 2.0 M sodium hydroxide (0.096 mL, 0.19 mmol) and
heated to 50.degree. C. for one hour. Reaction mixture was
concentrated, dissolved in DMF/methanol, filtered through syringe
filter and purified by Gilson HPLC (Gemini, 5-100%
ACN/H.sub.2O+0.1% TFA) to give a yellow powder after
lyophilization. .sup.1H NMR (400 MHz, Methanol-d.sub.4) .delta.
8.46 (s, 1H), 8.12 (d, J=8.7 Hz, 1H), 7.82 (s, 1H), 7.72-7.52 (m,
5H), 5.26 (s, 1H), 4.05 (s, 3H), 4.02-3.39 (m, 8H), 3.23-3.02 (m,
3H), 2.62 (s, 3H), 2.43-2.13 (m, 4H), 1.19 (d, J=6.3 Hz, 3H), 0.98
(s, 9H). LCMS-ESI.sup.+: calc'd for
C.sub.39H.sub.44ClF.sub.3N.sub.5O.sub.3S: 754.28 (M+H).sup.+;
found: 754.57 (M+H).sup.+.
Method H
Example 12
Preparation of
(S)-2-(tert-butoxy)-2-(7-(4-chlorophenyl)-5-methyl-2-(1-methyl-3-(1-((R)--
tetrahydrofuran-2-carbonyl)piperidin-4-yl)-1H-indazol-5-yl)benzo[d]thiazol-
-6-yl)acetic acid (9)
##STR00093##
[0354] Preparation of ethyl
(S)-2-(tert-butoxy)-2-(7-(4-chlorophenyl)-5-methyl-2-(1-methyl-3-(1-((R)--
tetrahydrofuran-2-carbonyl)piperidin-4-yl)-1H-indazol-5-yl)benzo[d]thiazol-
-6-yl)acetate: To a solution of (R)-tetrahydrofuran-2-carboxylic
acid (18 mg, 0.16 mmol) in DMF (1.5 mL) was added HATU (21 mg, 0.16
mmol) and reaction mixture was stirred for 30 minutes followed by
the addition of ethyl
(S)-2-(tert-butoxy)-2-(7-(4-chlorophenyl)-5-methyl-2-(1-methyl-3-(p-
iperidin-4-yl)-1H-indazol-5-yl)benzo[d]thiazol-6-yl)acetate (20 mg,
0.032 mmol) and N,N-Diisopropylethylamine (0.028 mL, 0.16 mmol) and
stirred for an additional 1 hour. Reaction mixture was quenched
with saturated sodium bicarbonate and extracted with ethyl acetate
(3.times.). Combined organic layer was washed with saturated sodium
chloride, dried (Na.sub.2SO.sub.4), and concentrated. Residue was
purified by CombiFlash (0-100% EtOAc/Hex) and concentrated to give
desired product. LCMS-ESI.sup.+: calc'd for
C.sub.40H.sub.46ClN.sub.4O.sub.5S: 729.29 (M+H).sup.+; found:
729.49 (M+H).sup.+.
[0355] Preparation of
(S)-2-(tert-butoxy)-2-(7-(4-chlorophenyl)-5-methyl-2-(1-methyl-3-(1-((R)--
tetrahydrofuran-2-carbonyl)piperidin-4-yl)-1H-indazol-5-yl)benzo[d]thiazol-
-6-yl)acetic acid: A solution of ethyl
(S)-2-(tert-butoxy)-2-(7-(4-chlorophenyl)-5-methyl-2-(1-methyl-3-(1-((R)--
tetrahydrofuran-2-carbonyl)piperidin-4-yl)-1H-indazol-5-yl)benzo[d]thiazol-
-6-yl)acetate (19 mg, 0.026 mmol) and 2.0 M sodium hydroxide (0.19
mL) in methanol (1.0 mL) was stirred at 60.degree. C. for 3 hours.
Reaction mixture was concentrated, dissolved in DMF/methanol,
filtered through syringe filter and purified by Gilson HPLC
(Gemini, 5-100% ACN/H.sub.2O+0.1% TFA) to give desired product.
.sup.1H NMR (400 MHz, Methanol-d.sub.4) .delta. 8.38 (s, 1H),
8.09-8.00 (m, 1H), 7.79 (s, 1H), 7.72-7.67 (m, 1H), 7.61-7.51 (m,
4H), 5.25 (s, 1H), 4.82-4.74 (m, 1H), 4.65-4.54 (m, 1H), 4.25-4.09
(m, 1H), 4.01-3.80 (m, 5H), 3.51-3.32 (m, 1H), 3.26 (d, J=11.5 Hz,
0H), 2.99-2.85 (m, 1H), 2.61 (s, 3H), 2.31-1.75 (m, 9H), 0.98 (s,
9H). LCMS-ESI.sup.+: calc'd for C.sub.38H.sub.42ClN.sub.4O.sub.5S:
701.26 (M+H).sup.+; found: 701.33 (M+H).sup.+.
Example 13
Preparation of
(S)-2-(tert-butoxy)-2-(7-(4-chlorophenyl)-2-(3-(1-(1,1-dioxidothietan-3-y-
l)piperidin-4-yl)-1-methyl-1H-indazol-5-yl)-5-methylbenzo[d]thiazol-6-yl)a-
cetic acid (10)
##STR00094##
[0357] Preparation of ethyl
(S)-2-(tert-butoxy)-2-(7-(4-chlorophenyl)-2-(3-(1-(1,1-dioxidothietan-3-y-
l)piperidin-4-yl)-1-methyl-1H-indazol-5-yl)-5-methylbenzo[d]thiazol-6-yl)a-
cetate: To a solution of ethyl
(S)-2-(tert-butoxy)-2-(7-(4-chlorophenyl)-5-methyl-2-(1-methyl-3-(piperid-
in-4-yl)-1H-indazol-5-yl)benzo[d]thiazol-6-yl)acetate (10 mg, 0.016
mmol) and thietan-3-one 1,1-dioxide (1.9 mg, 0.016 mmol) in
tetrahydrofuran (0.2 mL) was added titanium(IV) isopropixide (0.006
mL, 0.02 mmol) at room temperature and reaction mixture was stirred
for 1.5 hours, followed by the addition of sodium cyanoborohydride
(2.0 mg, 0.032 mmol). After one hour, reaction mixture was quenched
with saturated sodium bicarbonate and extracted with ethyl acetate
(3.times.). Combined organic layer was washed with saturated sodium
chloride, dried (Na.sub.2SO.sub.4), and concentrated. Residue was
purified by CombiFlash (0-100% EtOAc/Hex) and concentrated to give
desired product. LCMS-ESI.sup.+: calc'd for
C.sub.38H.sub.44ClN.sub.4O.sub.5S.sub.2: 735.24 (M+H).sup.+; found:
736.97 (M+H).sup.+.
[0358] Preparation of
(S)-2-(tert-butoxy)-2-(7-(4-chlorophenyl)-2-(3-(1-(1,1-dioxidothietan-3-y-
l)piperidin-4-yl)-1-methyl-1H-indazol-5-yl)-5-methylbenzo[d]thiazol-6-yl)a-
cetic acid: A solution of ethyl
(S)-2-(tert-butoxy)-2-(7-(4-chlorophenyl)-2-(3-(1-(1,1-dioxidothietan-3-y-
l)piperidin-4-yl)-1-methyl-1H-indazol-5-yl)-5-methylbenzo[d]thiazol-6-yl)a-
cetate (2.7 mg, 0.0037 mmol) and 2.0 M sodium hydroxide (0.018 mL)
in methanol (0.5 mL) was stirred at 50.degree. C. for 3 hours.
Reaction mixture was diluted with DMF/methanol, filtered through
syringe filter and purified by Gilson HPLC (Gemini, 5-100%
ACN/H.sub.2O+0.1% TFA) to give desired product. .sup.1H NMR (400
MHz, Methanol-d.sub.4) .delta. 8.47 (s, 1H), 8.12 (dd, J=8.9, 1.6
Hz, 1H), 7.82 (s, 1H), 7.72-7.58 (m, 5H), 5.26 (s, 1H), 4.54-4.39
(m, 3H), 4.05 (s, 3H), 3.57-3.36 (m, 4H), 2.91 (s, 2H), 2.62 (s,
3H), 2.34-2.12 (m, 5H), 0.98 (s, 9H). LCMS-ESI.sup.+: calc'd for
C.sub.36H.sub.40ClN.sub.4O.sub.5S.sub.2 707.21 (M+H).sup.+; found:
707.36 (M+H).sup.+.
Method I
Example 14
Preparation of
(S)-2-(2-(3-(1-((S)-1-acetylpyrrolidin-3-yl)piperidin-4-yl)-1-methyl-1H-i-
ndazol-5-yl)-7-(4-chlorophenyl)-5-methylbenzo[d]thiazol-6-yl)-2-(tert-buto-
xy)acetic acid (11)
##STR00095## ##STR00096##
[0360] Preparation of tert-butyl
(S)-3-(4-(5-(6-((S)-1-(tert-butoxy)-2-ethoxy-2-oxoethyl)-7-(4-chloropheny-
l)-5-methylbenzo[d]thiazol-2-yl)-1-methyl-1H-indazol-3-yl)piperidin-1-yl)p-
yrrolidine-1-carboxylate: To a solution of ethyl
(S)-2-(tert-butoxy)-2-(7-(4-chlorophenyl)-5-methyl-2-(1-methyl-3-(piperid-
in-4-yl)-1H-indazol-5-yl)benzo[d]thiazol-6-yl)acetate (1.0 g, 1.6
mmol), tert-butyl 3-oxopyrrolidine-1-carboxylate (2.9 g, 16 mmol),
and acetic acid (0.45 mL, 7.9 mmol) in 1,2-dichloroethane (12.0 mL)
was added sodium triacetoxyhorohydride (1.7 g, 7.9 mmol) and
reaction mixture was stirred for 90 minutes. Reaction mixture was
quenched with saturated sodium bicarbonate and extracted with
dichloromethane (3.times.). Combined organic layer was washed with
saturated sodium chloride, dried (Na.sub.2SO.sub.4) and
concentrated. The residue was purified by CombiFlash (0-20%
MeOH/DCM) to give desired product. Diastereomers were separated by
Chiralpak IC. LCMS-ESI.sup.+: calc'd for
C.sub.44H.sub.55ClN.sub.5O.sub.5S: 800.36 (M+H).sup.+; found:
800.41 (M+H).sup.+.
[0361] Preparation of ethyl
(S)-2-(tert-butoxy)-2-(7-(4-chlorophenyl)-5-methyl-2-(1-methyl-3-(1-((S)--
pyrrolidin-3-yl)piperidin-4-yl)-1H-indazol-5-yl)benzo[d]thiazol-6-yl)aceta-
te: tert-Butyl
(S)-3-(4-(5-(6-((S)-1-(tert-butoxy)-2-ethoxy-2-oxoethyl)-7-(4-chloropheny-
l)-5-methylbenzo[d]thiazol-2-yl)-1-methyl-1H-indazol-3-yl)piperidin-1-yl)p-
yrrolidine-1-carboxylate (430 mg, 0.537 mmol) was dissolved in 1.25
M HCl in isopropanol (50.0 mL) and stirred for 48 hours. Reaction
mixture was quenched with saturated sodium bicarbonate and
concentrated. Residue was diluted with water and extracted with
ethyl acetate (3.times.). Combined organic layer was washed with
saturated sodium chloride, dried (Na.sub.2SO.sub.4) and
concentrated to give ethyl
(S)-2-(tert-butoxy)-2-(7-(4-chlorophenyl)-5-methyl-2-(1-methyl-3-(1-((S)--
pyrrolidin-3-yl)piperidin-4-yl)-1H-indazol-5-yl)benzo[d]thiazol-6-yl)aceta-
te that was used in the next step without further purification.
[0362] Preparation of ethyl
(S)-2-(2-(3-(1-((S)-1-acetylpyrrolidin-3-yl)piperidin-4-yl)-1-methyl-1H-i-
ndazol-5-yl)-7-(4-chlorophenyl)-5-methylbenzo[d]thiazol-6-yl)-2-(tert-buto-
xy)acetate: To a solution of ethyl
(S)-2-(tert-butoxy)-2-(7-(4-chlorophenyl)-5-methyl-2-(1-methyl-3-(1-((S)--
pyrrolidin-3-yl)piperidin-4-yl)-1H-indazol-5-yl)benzo[d]thiazol-6-yl)aceta-
te (51 mg, 0.073 mmol) and N,N-Diisopropylethylamine (0.13 mL, 0.73
mmol) in dichloromethane (2.5 mL) was added acetyl chloride (0.03
mL, 0.4 mmol) and reaction mixture was stirred for 30 minutes.
Reaction mixture was quenched with saturated sodium bicarbonate and
extracted with dichloromethane (3.times.). Combined organic layer
was washed with saturated sodium chloride, dried (Na.sub.2SO.sub.4)
and concentrated to give ethyl
(S)-2-(2-(3-(1-((S)-1-acetylpyrrolidin-3-yl)piperidin-4-yl)-1-methyl-1H-i-
ndazol-5-yl)-7-(4-chlorophenyl)-5-methylbenzo[d]thiazol-6-yl)-2-(tert-buto-
xy)acetate that was used in the next step without further
purification.
[0363] Preparation of
(S)-2-(2-(3-(1-((S)-1-acetylpyrrolidin-3-yl)piperidin-4-yl)-1-methyl-1H-i-
ndazol-5-yl)-7-(4-chlorophenyl)-5-methylbenzo[d]thiazol-6-yl)-2-(tert-buto-
xy)acetic acid: A solution of ethyl
(S)-2-(2-(3-(1-((S)-1-acetylpyrrolidin-3-yl)piperidin-4-yl)-1-methyl-1H-i-
ndazol-5-yl)-7-(4-chlorophenyl)-5-methylbenzo[d]thiazol-6-yl)-2-(tert-buto-
xy)acetate (54 mg, 0.073 mmol) and 2.5 M sodium hydroxide (0.15 mL)
in methanol (2.0 mL) was stirred at 55.degree. C. for two hours.
Reaction mixture was diluted with DMF/methanol, filtered through
syringe filter and purified by Gilson HPLC (Gemini, 5-100%
ACN/H.sub.2O+0.1% TFA) to give desired product. .sup.1H NMR (400
MHz, Methanol-d.sub.4) .delta. 8.46 (s, 1H), 8.12 (d, J=8.9 Hz,
1H), 7.82 (s, 1H), 7.71-7.57 (m, 5H), 5.26 (s, 1H), 4.20-3.91 (m,
6H), 3.92-3.30 (m, 7H), 2.62 (s, 3H), 2.59-2.15 (m, 6H), 2.12 (d,
J=11.3 Hz, 3H), 0.98 (s, 9H). LCMS-ESI.sup.+: calc'd for
C.sub.39H.sub.45ClN.sub.5O.sub.4S: 714.29 (M+H).sup.+; found:
714.33 (M+H).sup.+.
Method J
Example 15
Preparation of
(S)-2-(2-(3-(1-((R)-1-acetylpyrrolidin-3-yl)piperidin-4-yl)-1-methyl-1H-i-
ndazol-5-yl)-7-(4-chlorophenyl)-5-methylbenzo[d]thiazol-6-yl)-2-(tert-buto-
xy)acetic acid (12)
##STR00097## ##STR00098##
[0365] Preparation of tert-butyl
(R)-3-(4-(5-(6-((S)-1-(tert-butoxy)-2-ethoxy-2-oxoethyl)-7-(4-chloropheny-
l)-5-methylbenzo[d]thiazol-2-yl)-1-methyl-1H-indazol-3-yl)piperidin-1-yl)p-
yrrolidine-1-carboxylate: To a solution of ethyl
(S)-2-(tert-butoxy)-2-(7-(4-chlorophenyl)-5-methyl-2-(1-methyl-3-(piperid-
in-4-yl)-1H-indazol-5-yl)benzo[d]thiazol-6-yl)acetate (1.0 g, 1.6
mmol), tert-butyl 3-oxopyrrolidine-1-carboxylate (2.9 g, 16 mmol),
and acetic acid (0.45 mL, 7.9 mmol) in 1,2-dichloroethane (12.0 mL)
was added sodium triacetoxyhorohydride (1.7 g, 7.9 mmol) and
reaction mixture was stirred for 90 minutes. Reaction mixture was
quenched with saturated sodium bicarbonate and extracted with
dichloromethane (3.times.). Combined organic layer was washed with
saturated sodium chloride, dried (Na.sub.2SO.sub.4) and
concentrated. The residue was purified by CombiFlash (0-20%
MeOH/DCM) to give desired product. Diastereomers were separated by
Chiralpak IC. LCMS-ESI.sup.+: calc'd for
C.sub.44H.sub.55ClN.sub.5O.sub.5S: 800.36 (M+H).sup.+; found:
800.41 (M+H).sup.+.
[0366] Preparation of ethyl
(S)-2-(tert-butoxy)-2-(7-(4-chlorophenyl)-5-methyl-2-(1-methyl-3-(1-((R)--
pyrrolidin-3-yl)piperidin-4-yl)-1H-indazol-5-yl)benzo[d]thiazol-6-yl)aceta-
te: tert-Butyl
(R)-3-(4-(5-(6-((S)-1-(tert-butoxy)-2-ethoxy-2-oxoethyl)-7-(4-chloropheny-
l)-5-methylbenzo[d]thiazol-2-yl)-1-methyl-1H-indazol-3-yl)piperidin-1-yl)p-
yrrolidine-1-carboxylate (430 mg, 0.537 mmol) was dissolved in 1.25
M HCl in isopropanol (50.0 mL) and stirred for 48 hours. Reaction
mixture was quenched with saturated sodium bicarbonate and
concentrated. Residue was diluted with water and extracted with
ethyl acetate (3.times.). Combined organic layer was washed with
saturated sodium chloride, dried (Na.sub.2SO.sub.4) and
concentrated to give ethyl
(S)-2-(tert-butoxy)-2-(7-(4-chlorophenyl)-5-methyl-2-(1-methyl-3-(1-((R)--
pyrrolidin-3-yl)piperidin-4-yl)-1H-indazol-5-yl)benzo[d]thiazol-6-yl)aceta-
te that was used in the next step without further purification.
[0367] Preparation of ethyl
(S)-2-(2-(3-(1-((R)-1-acetylpyrrolidin-3-yl)piperidin-4-yl)-1-methyl-1H-i-
ndazol-5-yl)-7-(4-chlorophenyl)-5-methylbenzo[d]thiazol-6-yl)-2-(tert-buto-
xy)acetate: To a solution of ethyl
(S)-2-(tert-butoxy)-2-(7-(4-chlorophenyl)-5-methyl-2-(1-methyl-3-(1-((R)--
pyrrolidin-3-yl)piperidin-4-yl)-1H-indazol-5-yl)benzo[d]thiazol-6-yl)aceta-
te (51 mg, 0.073 mmol) and N,N-Diisopropylethylamine (0.13 mL, 0.73
mmol) in dichloromethane (2.50 mL) was added acetyl chloride (0.03
mL, 0.4 mmol) and reaction mixture was stirred for 30 minutes.
Reaction mixture was quenched with saturated sodium bicarbonate and
extracted with dichloromethane (3.times.). Combined organic layer
was washed with saturated sodium chloride, dried (Na.sub.2SO.sub.4)
and concentrated to give ethyl
(S)-2-(2-(3-(1-((R)-1-acetylpyrrolidin-3-yl)piperidin-4-yl)-1-methyl-1H-i-
ndazol-5-yl)-7-(4-chlorophenyl)-5-methylbenzo[d]thiazol-6-yl)-2-(tert-buto-
xy)acetate that was used in the next step without further
purification.
[0368] Preparation of
(S)-2-(2-(3-(1-((R)-1-acetylpyrrolidin-3-yl)piperidin-4-yl)-1-methyl-1H-i-
ndazol-5-yl)-7-(4-chlorophenyl)-5-methylbenzo[d]thiazol-6-yl)-2-(tert-buto-
xy)acetic acid: A solution of ethyl
(S)-2-(2-(3-(1-((R)-1-acetylpyrrolidin-3-yl)piperidin-4-yl)-1-methyl-1H-i-
ndazol-5-yl)-7-(4-chlorophenyl)-5-methylbenzo[d]thiazol-6-yl)-2-(tert-buto-
xy)acetate (54 mg, 0.073 mmol) and 2.5 M sodium hydroxide (0.15 mL)
in methanol (2.0 mL) was stirred at 55.degree. C. for two hours.
Reaction mixture was diluted with DMF/methanol, filtered through
syringe filter and purified by Gilson HPLC (Gemini, 5-100%
ACN/H.sub.2O+0.1% TFA) to give desired product. .sup.1H NMR (400
MHz, Methanol-d.sub.4) .delta. 8.46 (s, 1H), 8.13 (d, J=8.9 Hz,
1H), 7.82 (d, J=0.8 Hz, 1H), 7.72-7.56 (m, 5H), 5.26 (s, 1H),
4.23-3.93 (m, 5H), 3.92-3.30 (m, 8H), 2.62 (s, 3H), 2.61-2.16 (m,
6H), 2.12 (d, J=11.3 Hz, 3H), 0.99 (s, 9H). LCMS-ESI.sup.+: calc'd
for C.sub.39H.sub.45ClN.sub.5O.sub.4S: 714.29 (M+H).sup.+; found:
714.33 (M+H).sup.+.
Method K
Example 16
Preparation of
(2S)-2-(tert-butoxy)-2-(7-(4-chlorophenyl)-5-methyl-2-(1-methyl-3-(3-(oxe-
tan-3-yl)-3,8-diazabicyclo[3.2.1]octan-8-yl)-1H-indazol-5-yl)benzo[d]thiaz-
ol-6-yl)acetic acid (13)
##STR00099## ##STR00100##
[0370] Preparation of tert-butyl
8-(5-(6-((S)-1-(tert-butoxy)-2-ethoxy-2-oxoethyl)-7-(4-chlorophenyl)-5-me-
thylbenzo[d]thiazol-2-yl)-1-methyl-1H-indazol-3-yl)-3,8-diazabicyclo[3.2.1-
]octane-3-carboxylate: A suspension of Pd.sub.2(dba).sub.3 (7 mg,
0.008 mmol), XPhos (4 mg, 0.008 mmol), and cesium carbonate (130
mg, 0.400 mmol) in dioxane (2.0 mL) was stirred for 30 minutes,
followed by the addition of ethyl
(S)-2-(2-(3-bromo-1-methyl-1H-indazol-5-yl)-7-(4-chlorophenyl)-5-methylbe-
nzo[d]thiazol-6-yl)-2-(tert-butoxy)acetate (50 mg, 0.080 mmol) and
tert-butyl 3,8-diazabicyclo[3.2.1]octane-3-carboxylate (51 mg, 0.24
mmol). Reaction mixture was sparged with argon and heated to
100.degree. C. for one hour. Reaction mixture was quenched with
saturated sodium bicarbonate and extracted with ethyl acetate
(3.times.). Combined organic layer was washed with saturated sodium
chloride, dried (Na.sub.2SO.sub.4) and concentrated. The residue
was purified by CombiFlash (0-100% EtOAc/Hex) and concentrated to
give desired product. LCMS-ESI.sup.+: calc'd for
C.sub.41H.sub.49ClN.sub.5O.sub.5S: 738.31 (M+H).sup.+; found:
757.41 (M+H).sup.+.
[0371] Preparation of ethyl
(2S)-2-(2-(3-(3,8-diazabicyclo[3.2.1]octan-8-yl)-1-methyl-1H-indazol-5-yl-
)-7-(4-chlorophenyl)-5-methylbenzo[d]thiazol-6-yl)-2-(tert-butoxy)acetate:
A solution of tert-butyl
8-(5-(6-((S)-1-(tert-butoxy)-2-ethoxy-2-oxoethyl)-7-(4-chlorophenyl)-5-me-
thylbenzo[d]thiazol-2-yl)-1-methyl-1H-indazol-3-yl)-3,8-diazabicyclo[3.2.1-
]octane-3-carboxylate (32 mg, 0.042 mmol) in 1.25 M HCl in
isopropanol (5.0 mL) was stirred for 36 hours. Reaction mixture was
quenched with saturated sedum bicarbonate and concentrated. Residue
was diluted with water and extracted with ethyl acetate (3.times.).
Combined organic layer was washed with saturated sodium chloride,
dried (Na.sub.2SO.sub.4) and concentrated. Reaction mixture was
dissolved in DMF/methanol, filtered through syringe filter and
purified by Gilson HPLC (Gemini, 5-100% ACN/H.sub.2O+0.1% TFA).
LCMS-ESI.sup.+: calc'd for C.sub.36H.sub.41ClN.sub.5O.sub.3S:
658.26 (M+H).sup.+; found: 658.54 (M+H).sup.+.
[0372] Preparation of ethyl
(2S)-2-(tert-butoxy)-2-(7-(4-chlorophenyl)-5-methyl-2-(1-methyl-3-(3-(oxe-
tan-3-yl)-3,8-diazabicyclo[3.2.1]octan-8-yl)-1H-indazol-5-yl)benzo[d]thiaz-
ol-6-yl)acetate: To a solution of ethyl
(2S)-2-(2-(3-(3,8-diazabicyclo[3.2.1]octan-8-yl)-1-methyl-1H-indazol-5-yl-
)-7-(4-chlorophenyl)-5-methylbenzo[d]thiazol-6-yl)-2-(tert-butoxy)acetate
(25 mg, 0.040 mmol) and oxetan-3-one (41 mg, 0.57 mmol) in methanol
(1.0 mL) at 0.degree. C. was added acetic acid (0.012 mL, 0.21
mmol) and sodium cyanoborohydride (24 mg, 0.38 mmol). Reaction
mixture was stirred and allowed to warm to room temperature over 16
hours. Reaction mixture was quenched with saturated sodium
bicarbonate and extracted with ethyl acetate (3.times.). Combined
organic layer was washed with saturated sodium chloride, dried
(Na.sub.2SO.sub.4) and concentrated. Residue was purified by
CombiFlash (0-100% EtOAc/Hex) to give desired product.
LCMS-ESI.sup.+: calc'd for C.sub.39H.sub.45ClN.sub.5O.sub.4S:
714.29 (M+H).sup.+; found: 714.04 (M+H).sup.+.
[0373] Preparation of
(2S)-2-(tert-butoxy)-2-(7-(4-chlorophenyl)-5-methyl-2-(1-methyl-3-(3-(oxe-
tan-3-yl)-3,8-diazabicyclo[3.2.1]octan-8-yl)-1H-indazol-5-yl)benzo[d]thiaz-
ol-6-yl)acetic acid: A solution of ethyl
(2S)-2-(tert-butoxy)-2-(7-(4-chlorophenyl)-5-methyl-2-(1-methyl-3-(3-(oxe-
tan-3-yl)-3,8-diazabicyclo[3.2.1]octan-8-yl)-1H-indazol-5-yl)benzo[d]thiaz-
ol-6-yl)acetate (15 mg, 0.022 mmol), 2.0 M sodium hydroxide (0.54
mL), and ethylene glycol (0.2 mL) in methanol (1.0 mL) was stirred
at 60.degree. C. for three hours. Reaction mixture was diluted with
DMF/methanol, filtered through syringe filter and purified by
Gilson HPLC (Gemini, 5-100% ACN/H.sub.2O+0.1% TFA) without workup
to give desired product. .sup.1H NMR (400 MHz, Methanol-d.sub.4)
.delta. 8.38 (s, 1H), 8.01 (dd, J=8.9, 1.6 Hz, 1H), 7.78 (s, 1H),
7.71-7.66 (m, 1H), 7.61-7.54 (m, 3H), 7.50 (d, J=8.9 Hz, 1H), 5.25
(s, 1H), 4.89-4.76 (m, 4H), 4.66 (s, 2H), 4.43 (p, J=6.5 Hz, 1H),
3.91 (s, 3H), 3.52 (d, J=12.8 Hz, 2H), 3.44-3.36 (m, 2H), 2.61 (s,
3H), 2.41-2.31 (m, 2H), 2.17-2.10 (m, 2H), 0.98 (s, 9H).
LCMS-ESI.sup.+: calc'd for C.sub.37H.sub.41ClN.sub.5O.sub.4S:
686.26 (M+H).sup.+; found: 686.22 (M+H).sup.+.
Method L
Example 17
Preparation of
(S)-2-(tert-butoxy)-2-(7-(4-chlorophenyl)-2-(1-(difluoromethyl)-3-(1-(1-(-
methoxycarbonyl)azetidin-3-yl)piperidin-4-yl)-1H-pyrazolo[4,3-b]pyridin-5--
yl)-5-methylbenzo[d]thiazol-6-yl)acetic acid (14)
##STR00101##
[0375] Preparation of ethyl
(2S)-2-(tert-butoxy)-2-(7-(4-chlorophenyl)-5-methyl-2-(1-(tetrahydro-2H-p-
yran-2-yl)-1H-pyrazolo[4,3-b]pyridin-5-yl)benzo[d]thiazol-6-yl)acetate:
To an oven-dried round bottom flask was charged
5-bromo-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazolo[4,3-b]pyridine
(4.09 g, 14.5 mmol, 1.80 equiv), which was then dissolved in 5:1
toluene:hexanes (48 mL). The reaction solution was then cooled to
-40.degree. C. and a solution of n-butyllithium in hexanes (2.50 M,
6.12 mL, 15.3 mmol, 1.90 equiv) was added dropwise. Upon completion
of addition, the reaction mixture was immediately cooled to
-78.degree. C. and stirred for 4.5 h. A solution of zinc chloride
in 2-methyltetrahydrofuran (1.90 M, 8.90 mL, 16.9 mmol, 2.10 equiv)
was then added, followed by 22 mL of tetrahydrofuran. After
stirring at -78.degree. C. for 25 min, the reaction mixture was
warmed to 0.degree. C. and stirred for an additional 1.5 h. The
reaction was then allowed to warm to room temperature and was
stirred for an additional 1 h. Ethyl
(S)-2-(2-bromo-7-(4-chlorophenyl)-5-methylbenzo[d]thiazol-6-yl)-2-(tert-b-
utoxy)acetate (4.00 g, 8.05 mmol, 1.00 equiv) and
Pd(PPh.sub.3).sub.4 (930 mg, 0.810 mmol, 0.10 equiv) were then
added. The reaction mixture was sparged with argon for 10 min and
subsequently heated to 60.degree. C. After stirring for 1 h, the
reaction was cooled to room temperature. 1 M hydrochloric acid was
added until all solids dissolved. Saturated aqueous NaHCO.sub.3 was
added until pH.about.7 was reached. The reaction was then diluted
with EtOAc (60 mL) and the organic and aqueous layers were
separated. The aqueous layer was extracted with additional EtOAc
(3.times.30 mL) and the organic layers were all combined, washed
with brine (50 mL), dried over anhydrous MgSO.sub.4, filtered, and
concentrated. The crude product was purified via CombiFlash (Peeke
Scientific, silica gel, gradient: 0-100% EtOAc/hex) to afford the
desired product as a pale yellow flocculent solid as a 1:1 mixture
of diastereomers. .sup.1H NMR (400 MHz, CDCl.sub.3) .delta.
8.61-8.38 (m, 2H), 8.28 (s, 2H), 8.09 (d, J=8.9 Hz, 2H), 7.93 (s,
2H), 7.51 (d, J=14.8 Hz, 8H), 5.77 (dt, J=8.3, 2.3 Hz, 2H), 5.19
(s, 2H), 4.21 (qd, J=7.1, 3.5 Hz, 4H), 4.07-3.96 (m, 2H), 3.86-3.71
(m, 2H), 2.61 (s, 6H), 2.56-2.39 (m, 2H), 2.23-2.07 (m, 4H),
1.89-1.62 (m, 6H), 1.25 (t, J=7.1 Hz, 6H), 0.99 (s, 18H).
LCMS-ESI+: calc'd for C.sub.33H.sub.36ClN.sub.4O.sub.4S: 619.21
[M+H].sup.+; found: 619.11.
[0376] Preparation of ethyl
(S)-2-(tert-butoxy)-2-(7-(4-chlorophenyl)-5-methyl-2-(1H-pyrazolo[4,3-b]p-
yridin-5-yl)benzo[d]thiazol-6-yl)acetate: To a round bottom flask
was charged ethyl
(2S)-2-(tert-butoxy)-2-(7-(4-chlorophenyl)-5-methyl-2-(1-(tetrahydro-2H-p-
yran-2-yl)-1H-pyrazolo[4,3-b]pyridin-5-yl)benzo[d]thiazol-6-yl)acetate
(2.00 g, 3.23 mmol, 1.00 equiv), followed by a solution of
hydrochloric acid in isopropanol (1.25 M, 129 mL). The reaction was
allowed to stir at room temperature for 2 days and was subsequently
quenched with saturated aqueous NaHCO.sub.3 until pH.about.7. The
reaction was concentrated in vacuo to remove all volatiles, then
diluted with EtOAc (100 mL) and water (100 mL). The organic and
aqueous layers were separated. The aqueous layer was extracted with
additional EtOAc (3.times.80 mL) and the organic layers were all
combined, washed with brine (150 mL), dried over anhydrous
MgSO.sub.4, filtered, and concentrated. The crude product was
purified via CombiFlash (Peeke Scientific, silica gel, gradient:
0-100% EtOAc/hex) to afford the desired product. .sup.1H NMR (400
MHz, CDCl.sub.3) .delta. 8.62-8.41 (m, 1H), 8.35 (s, 1H), 7.98-7.85
(m, 2H), 7.59-7.43 (m, 4H), 5.20 (s, 1H), 4.23 (qt, J=7.0, 3.5 Hz,
2H), 2.61 (s, 3H), 1.26 (t, J=7.1 Hz, 3H), 0.99 (d, J=0.9 Hz, 9H).
LCMS-ESI+: calc'd for C.sub.28H.sub.28ClN.sub.4O.sub.3S: 535.16
[M+H].sup.+; found: 535.19.
[0377] Preparation of ethyl
(S)-2-(2-(3-bromo-1H-pyrazolo[4,3-b]pyridin-5-yl)-7-(4-chlorophenyl)-5-me-
thylbenzo[d]thiazol-6-yl)-2-(tert-butoxy)acetate: To a round-bottom
flask was charged ethyl
(S)-2-(tert-butoxy)-2-(7-(4-chlorophenyl)-5-methyl-2-(1H-pyrazolo[4,3-b]p-
yridin-5-yl)benzo[d]thiazol-6-yl)acetate (1.73 g, 3.23 mmol, 1.00
equiv), which was then dissolved in dichloromethane (35 mL). The
solution was cooled to 0.degree. C., then NaHCO.sub.3 (326 mg, 3.90
mmol, 1.20 equiv) was added. A 1 M stock solution of bromine in
dichloromethane was then added dropwise (3.88 mL, 3.90 mmol, 1.20
equiv). The reaction was warmed to room temperature and stirred for
1 day. The reaction was quenched with saturated aqueous
Na.sub.2S2O.sub.3 (15 mL) and the organic and aqueous layers were
separated. The aqueous layer was extracted with additional
dichloromethane (3.times.40 mL) and the organic layers were
combined, dried over anhydrous MgSO.sub.4, filtered, and
concentrated. The crude product was purified via CombiFlash (Peeke
Scientific, silica gel, gradient: 0-100% EtOAc/hex) to afford the
desired product as a pale flocculent yellow solid. .sup.1H NMR (400
MHz, CDCl.sub.3) .delta. 11.15 (br s, 1H), 8.35 (d, J=8.9 Hz, 1H),
7.80-7.65 (m, 2H), 7.59-7.41 (m, 4H), 5.23 (s, 1H), 4.26 (qd,
J=7.1, 2.0 Hz, 2H), 2.57 (s, 3H), 1.29 (t, J=7.0 Hz, 3H), 0.99 (s,
9H). LCMS-ESI+: calc'd for C.sub.28H.sub.27BrClN.sub.4O.sub.3S:
613.07 [M+H].sup.+; found: 613.03.
[0378] Preparation of ethyl
(2S)-2-(2-(3-bromo-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazolo[4,3-b]pyridin-
-5-yl)-7-(4-chlorophenyl)-5-methylbenzo[d]thiazol-6-yl)-2-(tert-butoxy)ace-
tate: To a round bottom flask with stir bar was added ethyl
(S)-2-(2-(3-bromo-1H-pyrazolo[4,3-b]pyridin-5-yl)-7-(4-chlorophenyl)-5-me-
thylbenzo[d]thiazol-6-yl)-2-(tert-butoxy)acetate (807 mg, 1.31
mmol, 1.00 equiv), followed by dichloromethane (12 mL).
3,4-Dihydro-2H-pyran (144 .mu.L, 1.58 mmol, 1.20 equiv), and p-TsOH
(23 mg, 0.13 mmol, 0.10 equiv) were then added. The reaction
mixture was heated to 45.degree. C. and stirred for 4 h. After
cooling to room temperature, the reaction was quenched with
saturated aqueous NaHCO.sub.3. The organic and aqueous layers were
separated and the aqueous layer was extracted with additional
dichloromethane (3.times.10 mL). The organic layers were combined,
dried over anhydrous MgSO.sub.4, filtered, and concentrated. The
crude product was purified via CombiFlash (Peeke Scientific, silica
gel, gradient: 0-100% EtOAc/hex) to yield the product as a 1:1
mixture of diastereomers as a flocculent solid. .sup.1H NMR (400
MHz, CDCl.sub.3) .delta. 8.49 (d, J=8.9 Hz, 2H), 8.06 (dd, J=9.0,
2.1 Hz, 2H), 7.90 (s, 2H), 7.62-7.42 (m, 8H), 5.72 (dt, J=8.7, 2.8
Hz, 2H), 5.18 (s, 2H), 4.22 (qt, J=7.1, 3.9 Hz, 4H), 4.05-3.95 (m,
2H), 3.75 (t, J=9.4 Hz, 2H), 2.61 (s, 6H), 2.54-2.38 (m, 2H),
2.19-2.06 (m, 4H), 1.71 (td, J=16.5, 16.1, 10.3 Hz, 6H), 1.26 (t,
J=6.9 Hz, 3H), 1.25 (t, J=7.1 Hz, 3H), 0.98 (s, 18H). LCMS-ESI+:
calc'd for C.sub.33H.sub.35BrClN.sub.4O.sub.4S: 697.13 [M+H].sup.+;
found: 696.98.
[0379] Preparation of tert-butyl
4-(5-(6-((S)-1-(tert-butoxy)-2-ethoxy-2-oxoethyl)-7-(4-chlorophenyl)-5-me-
thylbenzo[d]thiazol-2-yl)-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazolo[4,3-b]p-
yridin-3-yl)-3,6-dihydropyridine-1(2H)-carboxylate: To a microwave
tube was charged ethyl
(2S)-2-(2-(3-bromo-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazolo[4,3-b]pyridin-
-5-yl)-7-(4-chlorophenyl)-5-methylbenzo[d]thiazol-6-yl)-2-(tert-butoxy)ace-
tate (900 mg, 1.29 mmol, 1.00 equiv), tert-butyl
4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-3,6-dihydropyridine-1(2H)-
-carboxylate (598 mg, 1.93 mmol, 1.50 equiv), Pd(PPh.sub.3).sub.4
(220 mg, 0.19 mmol, 0.15 equiv), and 2 M K.sub.2CO.sub.3 (1.93 mL,
3.87 mmol, 3.00 equiv). Dioxane (13 mL) was added and the reaction
mixture was sparged with argon for 10 min before sealing and
heating to 110.degree. C., followed by stirring for 4 h. After
cooling to room temperature, water (15 mL) and EtOAc (30 mL) were
added to the reaction. The organic and aqueous layers were
separated and the aqueous layer was extracted with additional EtOAc
(3.times.20 mL). The organic layers were combined, washed with
brine (50 mL), dried over anhydrous MgSO.sub.4, filtered, and
concentrated. The crude product was purified via CombiFlash (Peeke
Scientific, silica gel, gradient: 0-100% EtOAc/hex) to yield the
product as a pale yellow flocculent solid. .sup.1H NMR (400 MHz,
CDCl.sub.3) .delta. 8.41 (d, J=8.8 Hz, 2H), 8.01 (dd, J=8.9, 2.7
Hz, 2H), 7.88 (s, 2H), 7.64-7.46 (m, 8H), 7.48-7.32 (m, 2H), 5.71
(dt, J=9.2, 3.0 Hz, 2H), 5.17 (s, 2H), 4.28-4.13 (m, 8H), 4.06-3.94
(m, 2H), 3.81-3.58 (m, 8H), 2.92-2.69 (m, 4H), 2.61 (s, 6H),
2.57-2.38 (m, 2H), 2.21-2.04 (m, 4H), 1.84-1.60 (m, 4H), 1.51 (s,
18H), 1.26 (t, J=7.1 Hz, 6H), 0.98 (s, 18H). LCMS-ESI+: calc'd for
C.sub.43H.sub.51ClN.sub.5O.sub.6S: 800.32 [M+H].sup.+; found:
799.87.
[0380] Preparation of tert-butyl
4-(5-(6-((S)-1-(tert-butoxy)-2-ethoxy-2-oxoethyl)-7-(4-chlorophenyl)-5-me-
thylbenzo[d]thiazol-2-yl)-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazolo[4,3-b]p-
yridin-3-yl)piperidine-1-carboxylate: To a round-bottom flask was
added tert-butyl
4-(5-(6-((S)-1-(tert-butoxy)-2-ethoxy-2-oxoethyl)-7-(4-chlorophenyl)-5-me-
thylbenzo[d]thiazol-2-yl)-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazolo[4,3-b]p-
yridin-3-yl)-3,6-dihydropyridine-1(2H)-carboxylate (2.17 g, 2.71
mmol, 1.00 equiv), followed by EtOH (100 mL). Rhodium on alumina (5
wt. % loading, 1.67 g, 0.813 mmol, 0.30 equiv) was then added and
the reaction vessel was equipped with a hydrogen balloon.
Evacuation of the flask followed by backfilling with hydrogen gas
was conducted three times. The reaction mixture was allowed to stir
for 12 h, then an additional portion of rhodium on alumina (1.9 g)
was added. Every 3 h, the reaction vessel was charged with 2 g of
rhodium on alumina for a total of three additional portions. After
stirring for an additional 12 h, the reaction was filtered through
a pad of Celite and concentrated. The crude product was purified
via CombiFlash (Peeke Scientific, silica gel, gradient: 0-100%
EtOAc/hex) to yield the product as a flocculent solid. .sup.1H NMR
(400 MHz, CDCl.sub.3) .delta. 8.62-8.48 (m, 2H), 8.09-7.90 (m, 4H),
7.65-7.44 (m, 8H), 5.77-5.60 (m, 2H), 5.16 (s, 2H), 4.32-4.15 (m,
4H), 4.04 (d, J=11.5 Hz, 2H), 3.76 (t, J=10.5 Hz, 2H), 3.48-3.33
(m, 4H), 3.01 (t, J=12.4 Hz, 4H), 2.61 (s, 6H), 2.56-2.39 (m, 2H),
2.21-1.88 (m, 10H), 1.86-1.53 (m, 10H), 1.48 (s, 18H), 1.34-1.17
(m, 6H), 1.01-0.89 (m, 18H). LCMS-ESI+: calc'd for
C.sub.43H.sub.53ClN.sub.5O.sub.6S: 802.34 [M+H].sup.+; found:
802.03.
[0381] Preparation of ethyl
(S)-2-(tert-butoxy)-2-(7-(4-chlorophenyl)-5-methyl-2-(3-(piperidin-4-yl)--
1H-pyrazolo[4,3-b]pyridin-5-yl)benzo[d]thiazol-6-yl)acetate: To a
round bottom flask was added tert-butyl
4-(5-(6-((S)-1-(tert-butoxy)-2-ethoxy-2-oxoethyl)-7-(4-chlorophenyl)-5-me-
thylbenzo[d]thiazol-2-yl)-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazolo[4,3-b]p-
yridin-3-yl)piperidine-1-carboxylate (1.58 g, 1.97 mmol, 1.00
equiv), followed by a solution of hydrochloric acid in isopropanol
(1.25 M, 79 mL). The reaction was allowed to stir at room
temperature for 3 days and was subsequently quenched with saturated
aqueous NaHCO.sub.3 until pH.about.7. The reaction was concentrated
in vacuo to remove all volatiles, then diluted with EtOAc (100 mL)
and water (100 mL). The organic and aqueous layers were separated.
The aqueous layer was extracted with additional EtOAc (3.times.80
mL) and the organic layers were all combined, washed with brine
(150 mL), dried over anhydrous MgSO.sub.4, filtered, and
concentrated. The crude product was carried on to the next step
without further purification. .sup.1H NMR (400 MHz, CDCl.sub.3)
.delta. 8.39 (d, J=8.9 Hz, 1H), 7.91-7.77 (m, 2H), 7.62-7.44 (m,
4H), 5.17 (s, 1H), 4.23 (ddp, J=10.8, 7.1, 3.6 Hz, 2H), 3.54-3.42
(m, 1H), 3.34-3.19 (m, 2H), 2.99-2.88 (m, 2H), 2.60 (s, 3H), 2.19
(d, J=13.2 Hz, 2H), 2.04-1.87 (m, 2H), 1.26 (t, J=7.1 Hz, 3H), 0.98
(s, 9H). LCMS-ESI+: calc'd for C.sub.33H.sub.37ClN.sub.5O.sub.3S:
618.23 [M+H].sup.+; found: 618.58.
[0382] Preparation of tert-butyl
(S)-3-(4-(5-(6-(1-(tert-butoxy)-2-ethoxy-2-oxoethyl)-7-(4-chlorophenyl)-5-
-methylbenzo[d]thiazol-2-yl)-1H-pyrazolo[4,3-b]pyridin-3-yl)piperidin-1-yl-
)azetidine-1-carboxylate: To a round bottom flask was added ethyl
(S)-2-(tert-butoxy)-2-(7-(4-chlorophenyl)-5-methyl-2-(3-(piperidin-4-yl)--
1H-pyrazolo[4,3-b]pyridin-5-yl)benzo[d]thiazol-6-yl)acetate (800
mg, 1.29 mmol, 1.00 equiv) and tert-butyl
3-oxoazetidine-1-carboxylate (2.22 g, 12.9 mmol, 10.0 equiv), which
were then dissolved in dichloroethane (13 mL). Acetic acid (593
.mu.L, 10.4 mmol, 8.00 equiv), then sodium triacetoxyborohydride
(1.37 g, 6.47 mmol, 5.00 equiv), were added. The reaction was
stirred at room temperature for 6 h and was subsequently quenched
with saturated aqueous NaHCO.sub.3 (10 mL) and diluted with
dichloromethane (10 mL). The organic and aqueous layers were
separated. The aqueous layer was extracted with additional
dichloromethane (3.times.10 mL) and the organic layers were all
combined, dried over anhydrous MgSO.sub.4, filtered, and
concentrated. The crude product was purified via CombiFlash (Peeke
Scientific, silica gel, gradient: 0-100% EtOAc/hex, then 0-20%
MeOH/CH.sub.2Cl.sub.2) to yield the desired product as a flocculent
solid. .sup.1H NMR (400 MHz, CDCl.sub.3) .delta. 8.38 (d, J=8.8 Hz,
1H), 7.85 (d, J=9.7 Hz, 2H), 7.62-7.43 (m, 4H), 5.17 (s, 1H), 4.59
(d, J=8.3 Hz, 1H), 4.22 (dhept, J=10.9, 3.8 Hz, 2H), 4.04-3.93 (m,
4H), 3.38 (t, J=12.6 Hz, 1H), 3.29 (dt, J=13.5, 7.2 Hz, 1H),
3.12-2.95 (m, 2H), 2.59 (s, 3H), 2.29 (d, J=11.5 Hz, 2H), 2.22-2.06
(m, 1H), 1.44 (s, 9H), 1.25 (t, J=7.1 Hz, 3H), 0.98 (s, 9H).
LCMS-ESI+: calc'd for C.sub.41H.sub.50ClN.sub.6O.sub.5S: 773.33
[M+H].sup.+; found: 773.46.
[0383] Preparation of tert-butyl
(S)-3-(4-(5-(6-(1-(tert-butoxy)-2-ethoxy-2-oxoethyl)-7-(4-chlorophenyl)-5-
-methylbenzo[d]thiazol-2-yl)-1-(difluoromethyl)-1H-pyrazolo[4,3-b]pyridin--
3-yl)piperidin-1-yl)azetidine-1-carboxylate: To a round-bottom
flask was added tert-butyl
(S)-3-(4-(5-(6-(1-(tert-butoxy)-2-ethoxy-2-oxoethyl)-7-(4-chlorophenyl)-5-
-methylbenzo[d]thiazol-2-yl)-1H-pyrazolo[4,3-b]pyridin-3-yl)piperidin-1-yl-
)azetidine-1-carboxylate (128 mg, 0.166 mmol, 1.00 equiv) and DMF
(2 mL). The solution was cooled to 0.degree. C. and sodium hydride
(60% dispersion in mineral oil, 33.0 mg, 0.828 mmol, 5.00 equiv)
was added. After stirring at 0.degree. C. for 30 min, a solution of
difluoroiodomethane in THF (10 wt. %, 982 .mu.L, 1.33 mmol, 8.00
equiv) was added. The reaction was stirred for an additional 20 min
before adding saturated aqueous NH.sub.4Cl and diluting with EtOAc
(5 mL). The organic and aqueous layers were separated. The aqueous
layer was extracted with additional EtOAc (3.times.5 mL) and the
organic layers were all combined, washed with brine (20 mL), dried
over anhydrous MgSO.sub.4, filtered, and concentrated. The crude
product was purified via Gilson HPLC (Gemini, 5-100%
MeCN/H.sub.2O+0.1% TFA) to afford a pale yellow solid after
concentration. .sup.1H NMR (400 MHz, CD.sub.3OD) .delta. 8.58 (d,
J=8.9 Hz, 1H), 8.38 (d, J=8.8 Hz, 1H), 8.01-7.66 (m, 2H), 7.66-7.47
(m, 4H), 5.24 (s, 1H), 4.38-4.01 (m, 7H), 3.80-3.58 (m, 3H),
3.27-3.07 (m, 2H), 2.60 (s, 3H), 2.56 (d, J=9.8 Hz, 2H), 2.36-2.12
(m, 2H), 1.47 (s, 9H), 1.25 (t, J=7.1 Hz, 3H), 0.99 (s, 9H).
LCMS-ESI+: calc'd for C.sub.42H.sub.50ClF.sub.2N.sub.6O.sub.5S:
823.32 [M+H].sup.+; found: 823.19.
[0384] Preparation of ethyl
(S)-2-(2-(3-(1-(azetidin-3-yl)piperidin-4-yl)-1-(difluoromethyl)-1H-pyraz-
olo[4,3-b]pyridin-5-yl)-7-(4-chlorophenyl)-5-methylbenzo[d]thiazol-6-yl)-2-
-(tert-butoxy)acetate: To a round-bottom flask with stir bar was
added tert-butyl
(S)-3-(4-(5-(6-(1-(tert-butoxy)-2-ethoxy-2-oxoethyl)-7-(4-chlorophenyl)-5-
-methylbenzo[d]thiazol-2-yl)-1-(difluoromethyl)-1H-pyrazolo[4,3-b]pyridin--
3-yl)piperidin-1-yl)azetidine-1-carboxylate (52.0 mg, 0.0630 mmol,
1.00 equiv), followed by a solution of hydrochloric acid in
isopropanol (1.25 M, 2.5 mL). The reaction was allowed to stir at
room temperature for 2 days and was subsequently quenched with
saturated aqueous NaHCO.sub.3 until pH>10. The reaction was
concentrated in vacuo to remove all volatiles, then diluted with
EtOAc (5 mL) and water (5 mL). The organic and aqueous layers were
separated. The aqueous layer was extracted with additional EtOAc
(3.times.5 mL) and dichloromethane (3.times.5 mL), and the organic
layers were all combined, washed with brine (10 mL), dried over
anhydrous MgSO.sub.4, filtered, and rotavapped. The crude product
was carried on to the next step without further purification.
LCMS-ESI+: calc'd for C.sub.37H.sub.42ClF.sub.2N.sub.6O.sub.3S:
723.27 [M+H].sup.+; found: 723.58.
[0385] Preparation of methyl
(S)-3-(4-(5-(6-(1-(tert-butoxy)-2-ethoxy-2-oxoethyl)-7-(4-chlorophenyl)-5-
-methylbenzo[d]thiazol-2-yl)-1-(difluoromethyl)-1H-pyrazolo[4,3-b]pyridin--
3-yl)piperidin-1-yl)azetidine-1-carboxylate: To a vial with stir
bar was added ethyl
(S)-2-(2-(3-(1-(azetidin-3-yl)piperidin-4-yl)-1-(difluoromethyl)-1H-pyraz-
olo[4,3-b]pyridin-5-yl)-7-(4-chlorophenyl)-5-methylbenzo[d]thiazol-6-yl)-2-
-(tert-butoxy)acetate (13.5 mg, 0.0187 mmol, 1.00 equiv) and
dichloromethane (500 .mu.L). N,N-Diisopropylethylamine (32.5 .mu.L,
0.187 mmol, 10.0 equiv), followed by methyl chloroformate (7.2
.mu.L, 0.093 mmol, 5.0 equiv), were then added. After stirring for
40 min, water (1 mL) and EtOAc (1 mL) were added to the reaction
mixture. The organic and aqueous layers were separated. The aqueous
layer was extracted with additional EtOAc (3.times.1 mL) and the
organic layers were all combined, washed with brine (2 mL), dried
over anhydrous MgSO.sub.4, filtered, and concentrated. The crude
product was carried on to the next step without further
purification. LCMS-ESI+: calc'd for
C.sub.39H.sub.44ClF.sub.2N.sub.6O.sub.5S: 781.28 [M+H].sup.+;
found: 781.59.
[0386] Preparation of
(S)-2-(tert-butoxy)-2-(7-(4-chlorophenyl)-2-(1-(difluoromethyl)-3-(1-(1-(-
methoxycarbonyl)azetidin-3-yl)piperidin-4-yl)-1H-pyrazolo[4,3-b]pyridin-5--
yl)-5-methylbenzo[d]thiazol-6-yl)acetic acid: To a vial with stir
bar was added crude methyl
(S)-3-(4-(5-(6-(1-(tert-butoxy)-2-ethoxy-2-oxoethyl)-7-(4-chlorophenyl)-5-
-methylbenzo[d]thiazol-2-yl)-1-(difluoromethyl)-1H-pyrazolo[4,3-b]pyridin--
3-yl)piperidin-1-yl)azetidine-1-carboxylate (14.6 mg, 0.0187 mmol,
1.00 equiv), THF (1 mL), and three drops of methanol. An aqueous
2.5 M NaOH solution (23 .mu.L, 0.056 mmol, 3.0 equiv) was then
added and the reaction was heated to 60.degree. C. for 20 min.
After cooling to room temperature, the reaction mixture was
filtered and purified directly by Gilson HPLC (Gemini, 5-100%
MeCN/H.sub.2O+0.1% TFA) to afford a pale yellow solid after
lyophilization. .sup.1H NMR (400 MHz, CD.sub.3OD) .delta. 8.58 (d,
J=8.9 Hz, 1H), 8.38 (d, J=8.9 Hz, 1H), 8.03-7.65 (m, 3H), 7.65-7.52
(m, 3H), 5.25 (s, 1H), 4.42-4.27 (m, 2H), 4.27-4.17 (m, 2H),
4.17-4.07 (m, 1H), 3.72 (s, 3H), 3.70-3.59 (m, 3H), 3.25-3.08 (m,
2H), 2.61 (s, 3H), 2.60-2.50 (m, 2H), 2.34-2.13 (m, 2H), 0.98 (s,
9H). LCMS-ESI+: calc'd for
C.sub.37H.sub.40ClF.sub.2N.sub.6O.sub.5S: 753.24 [M+H].sup.+;
found: 753.91.
Method M
Example 18
Preparation of
(S)-2-(tert-butoxy)-2-(7-(4-chlorophenyl)-5-methyl-2-(1-methyl-3-(4-(oxet-
an-3-yl)piperazin-1-yl)-1H-pyrazolo[4,3-b
]pyridin-5-yl)benzo[d]thiazol-6-yl)acetic acid (15)
##STR00102##
[0388] Preparation of ethyl
(S)-2-(tert-butoxy)-2-(7-(4-chlorophenyl)-5-methyl-2-(1-methyl-1H-pyrazol-
o[4,3-b]pyridin-5-yl)benzo[d]thiazol-6-yl)acetate: To an oven-dried
round bottom flask was charged
5-bromo-1-methyl-1H-pyrazolo[4,3-b]pyridine (1.71 g, 8.06 mmol,
2.00 equiv), which was then dissolved in 5:1 toluene:hexanes (32
mL). The reaction solution was then cooled to -40.degree. C. and a
solution of n-butyllithium in hexanes (2.50 M, 3.54 mL, 8.86 mmol,
2.20 equiv) was added dropwise. Upon completion of addition, the
reaction mixture was immediately cooled to -78.degree. C. and
stirred for 3 h. A solution of zinc chloride in
2-methyltetrahydrofuran (1.90 M, 4.87 mL, 9.23 mmol, 2.30 equiv)
was then added, followed by 14 mL of tetrahydrofuran. After
stirring at -78.degree. C. for 10 min, the reaction mixture was
warmed to 0.degree. C. and stirred for an additional 30 min. The
reaction was then allowed to warm to room temperature and was
stirred for an additional 35 min. Ethyl
(S)-2-(2-bromo-7-(4-chlorophenyl)-5-methylbenzo[d]thiazol-6-yl)-2-(tert-b-
utoxy)acetate (2.00 g, 4.03 mmol, 1.00 equiv) and
Pd(PPh.sub.3).sub.4 (465 mg, 0.403 mmol, 0.10 equiv) were then
added. The reaction mixture was sparged with argon for 10 min and
subsequently heated to 60.degree. C. After stirring for 1 h, the
reaction was cooled to room temperature. 1 M hydrochloric acid was
added until all solids dissolved. Saturated aqueous NaHCO.sub.3 was
added until pH.about.7 was reached. The reaction was then diluted
with EtOAc (60 mL) and the organic and aqueous layers were
separated. The aqueous layer was extracted with additional EtOAc
(3.times.30 mL) and the organic layers were all combined, washed
with brine (50 mL), dried over anhydrous MgSO.sub.4, filtered, and
concentrated. The crude product was purified via CombiFlash (Peeke
Scientific, silica gel, gradient: 0-100% EtOAc/hex) to afford the
desired product as a pale yellow flocculent solid. LCMS-ESI+:
calc'd for C.sub.29H.sub.30ClN.sub.4O.sub.3S: 549.17 [M+H].sup.+;
found: 549.30.
[0389] Preparation of ethyl
(S)-2-(2-(3-bromo-1-methyl-1H-pyrazolo[4,3-b]pyridin-5-yl)-7-(4-chlorophe-
nyl)-5-methylbenzo[d]thiazol-6-yl)-2-(tert-butoxy)acetate: To a
round bottom flask with stir bar was added ethyl
(S)-2-(tert-butoxy)-2-(7-(4-chlorophenyl)-5-methyl-2-(1-methyl-1H-pyrazol-
o[4,3-b]pyridin-5-yl)benzo[d]thiazol-6-yl)acetate (931 mg, 1.70
mmol, 1.00 equiv) and acetonitrile (18 mL). The solution was cooled
to 0.degree. C. and 2,6-lutidine (711 .mu.L, 6.10 mmol, 3.60
equiv), followed by a 1 M stock solution of bromine in acetonitrile
(6.10 mL, 6.10 mmol, 3.60 equiv), were added. The reaction was
allowed to warm to room temperature and was stirred for 7 h before
additional 2,6-lutidine (180 .mu.L) and 1 M bromine in acetonitrile
(1.5 mL) were added. After stirring for 12 h, the reaction was
quenched with saturated aqueous NaHCO.sub.3 and saturated aqueous
Na.sub.2S.sub.2O.sub.3, followed by dilution with EtOAc (30 mL).
The organic and aqueous layers were separated. The aqueous layer
was extracted with additional EtOAc (3.times.25 mL) and the organic
layers were combined, washed with brine (50 mL), dried over
anhydrous MgSO.sub.4, filtered, and concentrated. The crude product
was purified via CombiFlash (Peeke Scientific, silica gel,
gradient: 0-100% EtOAc/hex) to afford the desired product as a pale
yellow flocculent solid. LCMS-ESI+: calc'd for
C.sub.29H.sub.29BrClN.sub.4O.sub.3S: 627.08 [M+H].sup.+; found:
627.14.
[0390] Preparation of tert-butyl
(S)-4-(5-(6-(1-(tert-butoxy)-2-ethoxy-2-oxoethyl)-7-(4-chlorophenyl)-5-me-
thylbenzo[d]thiazol-2-yl)-1-methyl-1H-pyrazolo[4,3-b]pyridin-3-yl)piperazi-
ne-1-carboxylate: To a microwave tube was charged ethyl
(S)-2-(2-(3-bromo-1-methyl-1H-pyrazolo[4,3-b]pyridin-5-yl)-7-(4-chlorophe-
nyl)-5-methylbenzo[d]thiazol-6-yl)-2-(tert-butoxy)acetate (99.0 mg,
0.158 mmol, 1.00 equiv), tert-butyl piperazine-1-carboxylate (88.1
mg, 0.473 mmol, 3.00 equiv),
tris(dibenzylideneacetone)dipalladium(0) (28.9 mg, 0.0315 mmol,
0.20 equiv), 2-dicyclohexylphosphino-2',4',6'-triisopropylbiphenyl
(15.0 mg, 0.0315 mmol, 0.20 equiv), cesium carbonate (257 mg, 0.788
mmol, 5.00 equiv), and dioxane (4 mL). The reaction mixture was
sparged with argon for 10 min and then heated to 100.degree. C. for
3 h. After cooling to room temperature, saturated aqueous
NaHCO.sub.3 (2 mL) and EtOAc (8 mL) were added to the reaction
mixture. The organic and aqueous layers were separated. The aqueous
layer was extracted with additional EtOAc (3.times.5 mL) and the
organic layers were combined, washed with brine (10 mL), dried over
anhydrous MgSO.sub.4, filtered, and concentrated. The crude product
was purified via CombiFlash (Peeke Scientific, silica gel,
gradient: 0-100% EtOAc/hex) to afford the desired product.
LCMS-ESI+: calc'd for C.sub.38H.sub.46ClN.sub.6O.sub.5S: 733.29
[M+H].sup.+; found: 732.65.
[0391] Preparation of ethyl
(S)-2-(tert-butoxy)-2-(7-(4-chlorophenyl)-5-methyl-2-(1-methyl-3-(piperaz-
in-1-yl)-1H-pyrazolo[4,3-b]pyridin-5-yl)benzo[d]thiazol-6-yl)acetate:
To a round-bottom flask with stir bar was added tert-butyl
(S)-4-(5-(6-(1-(tert-butoxy)-2-ethoxy-2-oxoethyl)-7-(4-chlorophenyl)-5-me-
thylbenzo[d]thiazol-2-yl)-1-methyl-1H-pyrazolo[4,3-b]pyridin-3-yl)piperazi-
ne-1-carboxylate and a solution of hydrochloric acid in isopropanol
(1.25 M, 4.1 mL). The reaction was allowed to stir at room
temperature for 2 days and was subsequently quenched with saturated
aqueous NaHCO.sub.3 until pH>10. The reaction was concentrated
in vacuo to remove all volatiles, then diluted with EtOAc (5 mL)
and water (5 mL). The organic and aqueous layers were separated.
The aqueous layer was extracted with additional EtOAc (3.times.5
mL) and the organic layers were all combined, washed with brine (10
mL), dried over anhydrous MgSO.sub.4, filtered, and concentrated.
The crude product was carried on to the next step without further
purification. LCMS-ESI+: calc'd for
C.sub.33H.sub.38ClN.sub.6O.sub.3S: 633.24 [M+H].sup.+; found:
633.50.
[0392] Preparation of ethyl
(S)-2-(tert-butoxy)-2-(7-(4-chlorophenyl)-5-methyl-2-(1-methyl-3-(4-(oxet-
an-3-yl)piperazin-1-yl)-1H-pyrazolo[4,3-b]pyridin-5-yl)benzo[d]thiazol-6-y-
l)acetate: To a vial with stir bar was added ethyl
(S)-2-(tert-butoxy)-2-(7-(4-chlorophenyl)-5-methyl-2-(1-methyl-3-(piperaz-
in-1-yl)-1H-pyrazolo[4,3-b]pyridin-5-yl)benzo[d]thiazol-6-yl)acetate
(9.0 mg, 0.014 mmol, 1.0 equiv), 3-oxetanone (9.0 .mu.L, 0.14 mmol,
10 equiv), and methanol (500 .mu.L). The reaction was cooled to
0.degree. C., then acetic acid (4.5 .mu.L, 0.078 mmol, 5.5 equiv)
and sodium cyanoborohydride (8.9 mg, 0.14 mmol, 10 equiv) were
added. The reaction was warmed to room temperature and stirred for
8 h before quenching with saturated aqueous NaHCO.sub.3 until
pH>10. The reaction was concentrated in vacuo to remove all
volatiles, then diluted with EtOAc (2 mL) and water (2 mL). The
organic and aqueous layers were separated. The aqueous layer was
extracted with additional EtOAc (3.times.2 mL) and the organic
layers were all combined, washed with brine (5 mL), dried over
anhydrous MgSO.sub.4, filtered, and rotavapped. The crude product
was purified via CombiFlash (Peeke Scientific, silica gel,
gradient: 0-100% EtOAc/hex, then 0-20% MeOH/CH.sub.2Cl.sub.2) to
afford the desired product as a pale yellow solid. LCMS-ESI+:
calc'd for C.sub.36H.sub.42ClN.sub.6O.sub.4S: 689.27 [M+H].sup.+;
found: 689.41.
[0393] Preparation of
(S)-2-(tert-butoxy)-2-(7-(4-chlorophenyl)-5-methyl-2-(1-methyl-3-(4-(oxet-
an-3-yl)piperazin-1-yl)-1H-pyrazolo[4,3-b]pyridin-5-yl)benzo[d]thiazol-6-y-
l)acetic acid: To a vial with stir bar was added ethyl
(S)-2-(tert-butoxy)-2-(7-(4-chlorophenyl)-5-methyl-2-(1-methyl-3-(4-(oxet-
an-3-yl)piperazin-1-yl)-1H-pyrazolo[4,3-b]pyridin-5-yl)benzo[d]thiazol-6-y-
l)acetate (7.3 mg, 0.011 mmol, 1.0 equiv), THF (500 .mu.L), and
three drops of methanol. An aqueous 25% NaOH solution (53 .mu.L,
0.11 mmol, 10 equiv) was then added and the reaction was heated to
60.degree. C. for 3 h. Additional 50% NaOH solution (100 .mu.L) was
added before heating for 3 h. After cooling to room temperature,
the reaction mixture was filtered and purified directly by Gilson
HPLC (Gemini, 5-100% MeCN/H.sub.2O+0.1% TFA) to afford a pale
yellow solid after lyophilization. .sup.1H NMR (400 MHz,
CD.sub.3OD) .delta. 8.36 (d, J=9.0 Hz, 1H), 8.00 (d, J=9.0 Hz, 1H),
7.86 (s, 1H), 7.73-7.63 (m, 1H), 7.63-7.50 (m, 3H), 5.22 (s, 1H),
4.96-4.86 (m, 2H), 4.84-4.76 (m, 2H), 4.44 (p, J=6.3 Hz, 1H), 3.94
(s, 3H), 3.55-3.31 (m, 8H), 2.61 (s, 3H), 0.97 (s, 9H). LCMS-ESI+:
calc'd for C.sub.34H.sub.38ClN.sub.6O.sub.5S.sub.2:
661.24[M+H].sup.+; found: 662.11.
Method N
Example 19
Preparation of
(S)-2-(tert-butoxy)-2-(7-(4-chlorophenyl)-5-methyl-2-(5-methyl-7-(1-(oxet-
an-3-yl)piperidin-4-yl)-5H-pyrrolo[2,3-b]pyrazin-2-yl)benzo[d]thiazol-6-yl-
)acetic acid (16)
##STR00103##
[0395] Preparation of ethyl
(S)-2-(tert-butoxy)-2-(7-(4-chlorophenyl)-5-methyl-2-(5-methyl-5H-pyrrolo-
[2,3-b]pyrazin-2-yl)benzo[d]thiazol-6-yl)acetate: To an oven-dried
round bottom flask was charged
2-bromo-5-methyl-5H-pyrrolo[2,3-b]pyrazine (896 mg, 4.23 mmol, 2.00
equiv), which was then dissolved in 3:1 toluene:hexanes (12 mL).
The reaction solution was then cooled to -78.degree. C. and a
solution of n-butyllithium in hexanes (2.50 M, 1.86 mL, 4.65 mmol,
2.20 equiv) was added dropwise. After stirring for 1.5 h, a
solution of zinc chloride in 2-methyltetrahydrofuran (1.90 M, 2.56
mL, 4.86 mmol, 2.30 equiv) was then added, followed by 10 mL of
tetrahydrofuran. After stirring at -78.degree. C. for 25 min, the
reaction mixture was warmed to 0.degree. C. and stirred for an
additional 35 min. The reaction was then allowed to warm to room
temperature and was stirred for an additional 2 h. Ethyl
(S)-2-(2-bromo-7-(4-chlorophenyl)-5-methylbenzo[d]thiazol-6-yl)-2-(tert-b-
utoxy)acetate (1.05 g, 2.11 mmol, 1.00 equiv) and
Pd(PPh.sub.3).sub.4 (244 mg, 0.211 mmol, 0.10 equiv) were then
added. The reaction mixture was sparged with argon for 10 min and
subsequently heated to 60.degree. C. After stirring for 3 h, the
reaction was cooled to room temperature. 1 M hydrochloric acid was
added until all solids dissolved. Saturated aqueous NaHCO.sub.3 was
added until pH.about.7 was reached. The reaction was then diluted
with EtOAc (30 mL) and the organic and aqueous layers were
separated. The aqueous layer was extracted with additional EtOAc
(3.times.15 mL) and the organic layers were all combined, washed
with brine (30 mL), dried over anhydrous MgSO.sub.4, filtered, and
concentrated. The crude product was purified via CombiFlash (Peeke
Scientific, silica gel, gradient: 0-100% EtOAc/hex) to afford the
desired product as a pale yellow flocculent solid. LCMS-ESI+:
calc'd for C.sub.29H.sub.30ClN.sub.4O.sub.3S: 549.17 [M+H].sup.+;
found: 549.19.
[0396] Preparation of ethyl
(S)-2-(2-(7-bromo-5-methyl-5H-pyrrolo[2,3-b]pyrazin-2-yl)-7-(4-chlorophen-
yl)-5-methylbenzo[d]thiazol-6-yl)-2-(tert-butoxy)acetate: To a
round bottom flask with stir bar was added ethyl
(S)-2-(tert-butoxy)-2-(7-(4-chlorophenyl)-5-methyl-2-(5-methyl-5H-pyrrolo-
[2,3-b]pyrazin-2-yl)benzo[d]thiazol-6-yl)acetate (1.18 g, 2.15
mmol, 1.00 equiv) and acetonitrile (25 mL). The solution was cooled
to 0.degree. C. and N-bromosuccinimide (421 mg, 2.36 mmol, 1.10
equiv) was added. The reaction was allowed to warm to room
temperature and was stirred for 25 min before quenching with
saturated aqueous NaHCO.sub.3 (10 mL) and diluting with EtOAc (50
mL). The aqueous layer was extracted with additional EtOAc
(3.times.25 mL) and the organic layers were combined, washed with
brine (70 mL), dried over anhydrous MgSO.sub.4, filtered, and
concentrated. The crude product was purified via CombiFlash (Peeke
Scientific, silica gel, gradient: 0-100% EtOAc/hex) to afford the
desired product as a pale yellow flocculent solid. LCMS-ESI+:
calc'd for C.sub.29H.sub.29BrClN.sub.4O.sub.3S: 627.08 [M+H].sup.+;
found: 627.06.
[0397] Preparation of tert-butyl
(S)-4-(2-(6-(1-(tert-butoxy)-2-ethoxy-2-oxoethyl)-7-(4-chlorophenyl)-5-me-
thylbenzo[d]thiazol-2-yl)-5-methyl-5H-pyrrolo[2,3-b]pyrazin-7-yl)-3,6-dihy-
dropyridine-1(2H)-carboxylate: To a microwave tube was charged
ethyl
(S)-2-(2-(7-bromo-5-methyl-5H-pyrrolo[2,3-b]pyrazin-2-yl)-7-(4-chlorophen-
yl)-5-methylbenzo[d]thiazol-6-yl)-2-(tert-butoxy)acetate (820 mg,
1.31 mmol, 1.00 equiv), tert-butyl
4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-3,6-dihydropyridine-1(2H)-
-carboxylate (606 mg, 1.96 mmol, 1.50 equiv), Pd(PPh.sub.3).sub.4
(226 mg, 0.196 mmol, 0.15 equiv), and 2 M K.sub.2CO.sub.3 (1.95 mL,
3.92 mmol, 3.00 equiv). Dioxane (18 mL) was added and the reaction
mixture was sparged with argon for 10 min before sealing and
heating to 110.degree. C. and stirring for 2.5 h. After cooling to
room temperature, water (15 mL) and EtOAc (40 mL) were added to the
reaction. The organic and aqueous layers were separated and the
aqueous layer was extracted with additional EtOAc (3.times.20 mL).
The organic layers were combined, washed with brine (50 mL), dried
over anhydrous MgSO.sub.4, filtered, and concentrated. The crude
product was purified via CombiFlash (Peeke Scientific, silica gel,
gradient: 0-100% EtOAc/hex) to yield the product as a pale yellow
flocculent solid. LCMS-ESI+: calc'd for
C.sub.39H.sub.45ClN.sub.5O.sub.5S: 730.28 [M+H].sup.+; found:
729.77.
[0398] Preparation of tert-butyl
(S)-4-(2-(6-(1-(tert-butoxy)-2-ethoxy-2-oxoethyl)-7-(4-chlorophenyl)-5-me-
thylbenzo[d]thiazol-2-yl)-5-methyl-5H-pyrrolo[2,3-b]pyrazin-7-yl)piperidin-
e-1-carboxylate: To a round bottom flask was added tert-butyl
(S)-4-(2-(6-(1-(tert-butoxy)-2-ethoxy-2-oxoethyl)-7-(4-chlorophenyl)-5-me-
thylbenzo[d]thiazol-2-yl)-5-methyl-5H-pyrrolo[2,3-b]pyrazin-7-yl)-3,6-dihy-
dropyridine-1(2H)-carboxylate (933 mg, 1.28 mmol, 1.00 equiv),
followed by EtOH (50 mL). Rhodium on alumina (5 wt. % loading, 394
mg, 0.192 mmol, 0.15 equiv) was then added and the reaction vessel
was equipped with a hydrogen balloon. Evacuation of the flask
followed by backfilling with hydrogen gas was conducted three
times. The reaction mixture was allowed to stir for 12 h, then an
additional portion of rhodium on alumina (200 mg) was added. After
stirring for an additional 24 h, the reaction was filtered through
a pad of Celite and concentrated. The crude product was purified
via CombiFlash (Peeke Scientific, silica gel, gradient: 0-100%
EtOAc/hex) to yield the product as a flocculent solid. LCMS-ESI+:
calc'd for C.sub.39H.sub.47ClN.sub.5O.sub.5S: 732.30 [M+H].sup.+;
found: 731.87.
[0399] Preparation of ethyl
(S)-2-(tert-butoxy)-2-(7-(4-chlorophenyl)-5-methyl-2-(5-methyl-7-(piperid-
in-4-yl)-5H-pyrrolo[2,3-b]pyrazin-2-yl)benzo[d]thiazol-6-yl)acetate:
To a round bottom flask was added tert-butyl
(S)-4-(2-(6-(1-(tert-butoxy)-2-ethoxy-2-oxoethyl)-7-(4-chlorophenyl)-5-me-
thylbenzo[d]thiazol-2-yl)-5-methyl-5H-pyrrolo[2,3-b]pyrazin-7-yl)piperidin-
e-1-carboxylate (819 mg, 1.12 mmol, 1.00 equiv), followed by a
solution of hydrochloric acid in isopropanol (1.25 M, 27 mL). The
reaction was allowed to stir at room temperature for 2 days and was
subsequently quenched with saturated aqueous NaHCO.sub.3 until
pH>10. The reaction was concentrated in vacuo to remove all
volatiles, then diluted with EtOAc (50 mL) and water (50 mL). The
organic and aqueous layers were separated. The aqueous layer was
extracted with additional EtOAc (3.times.20 mL) and the organic
layers were all combined, washed with brine (50 mL), dried over
anhydrous MgSO.sub.4, filtered, and concentrated. The crude product
was carried on to the next step without further purification.
LCMS-ESI+: calc'd for C.sub.34H.sub.39ClN.sub.5O.sub.3S: 632.25
[M+H].sup.+; found: 632.47.
[0400] Preparation of ethyl
(S)-2-(tert-butoxy)-2-(7-(4-chlorophenyl)-5-methyl-2-(5-methyl-7-(1-(oxet-
an-3-yl)piperidin-4-yl)-5H-pyrrolo[2,3-b]pyrazin-2-yl)benzo[d]thiazol-6-yl-
)acetate: To a vial with stir bar was added ethyl
(S)-2-(tert-butoxy)-2-(7-(4-chlorophenyl)-5-methyl-2-(5-methyl-7-(piperid-
in-4-yl)-5H-pyrrolo[2,3-b]pyrazin-2-yl)benzo[d]thiazol-6-yl)acetate
(70.0 mg, 0.111 mmol, 1.00 equiv), 3-oxetanone (71 .mu.L, 1.1 mmol,
10 equiv), and methanol (1 mL). The reaction was cooled to
0.degree. C., then acetic acid (35 .mu.L, 0.61 mmol, 5.5 equiv) and
sodium cyanoborohydride (70.0 mg, 1.11 mmol, 10.0 equiv) were
added. The reaction was warmed to room temperature and stirred for
12 h before additional 3-oxetanone (70 .mu.L), acetic acid (30
.mu.L), and sodium cyanoborohydride (55 mg) were added. After
stirring for an additional 12 h, saturated aqueous NaHCO.sub.3 was
added until pH>10. The reaction was concentrated in vacuo to
remove all volatiles, then diluted with EtOAc (2 mL) and water (2
mL). The organic and aqueous layers were separated. The aqueous
layer was extracted with additional EtOAc (3.times.2 mL) and the
organic layers were all combined, washed with brine (5 mL), dried
over anhydrous MgSO.sub.4, filtered, and concentrated. The crude
product was purified via CombiFlash (Peeke Scientific, silica gel,
gradient: 0-100% EtOAc/hex, then 0-20% MeOH/CH.sub.2Cl.sub.2) to
afford the desired product as a pale yellow solid. LCMS-ESI+:
calc'd for C.sub.37H.sub.43ClN.sub.5O.sub.4S: 688.27 [M+H].sup.+;
found: 688.60.
[0401] Preparation of
(S)-2-(tert-butoxy)-2-(7-(4-chlorophenyl)-5-methyl-2-(5-methyl-7-(1-(oxet-
an-3-yl)piperidin-4-yl)-5H-pyrrolo[2,3-b]pyrazin-2-yl)benzo[d]thiazol-6-yl-
)acetic acid: To a vial with stir bar was added ethyl
(S)-2-(tert-butoxy)-2-(7-(4-chlorophenyl)-5-methyl-2-(5-methyl-7-(1-(oxet-
an-3-yl)piperidin-4-yl)-5H-pyrrolo[2,3-b]pyrazin-2-yl)benzo[d]thiazol-6-yl-
)acetate (52.3 mg, 0.0760 mmol, 1.00 equiv), THF (600 .mu.L), and
three drops of methanol. An aqueous 2.5 M NaOH solution (152 .mu.L,
0.380 mmol, 5.00 equiv) was then added and the reaction was heated
to 60.degree. C. for 2 h. After cooling to room temperature, the
reaction mixture was filtered and purified directly by Gilson HPLC
(Gemini, 5-100% MeCN/H.sub.2O+0.1% TFA) to afford a pale yellow
solid after lyophilization. .sup.1H NMR (400 MHz, CD.sub.3OD)
.delta. 9.07 (s, 1H), 7.78 (s, 1H), 7.73-7.64 (m, 1H), 7.61 (d,
J=8.2 Hz, 4H), 5.25 (s, 1H), 4.89-4.64 (m, 4H), 4.55-4.32 (m, 1H),
3.76 (s, 3H), 3.69-3.43 (m, 2H), 3.30-3.16 (m, 1H), 3.16-2.91 (m,
2H), 2.62 (s, 3H), 2.53-2.23 (m, 2H), 2.21-1.90 (m, 2H), 0.98 (s,
9H). LCMS-ESI+: calc'd for C.sub.35H.sub.39ClN.sub.5O.sub.4S:
660.24 [M+H].sup.+; found: 660.59.
Method O
Example 20
Preparation of
(S)-2-(tert-butoxy)-2-(7-(4-chlorophenyl)-5-methyl-2-(1-methyl-3-(1-(oxet-
an-3-yl)piperidin-4-yl)-1H-pyrrolo[2,3-b]pyridin-5-yl)benzo[d]thiazol-6-yl-
)acetic acid (17)
##STR00104## ##STR00105##
[0403] Preparation of
5-bromo-3-iodo-1-methyl-1H-pyrrolo[2,3-b]pyridine: To a solution of
5-bromo-3-iodo-1H-pyrrolo[2,3-b]pyridine (4.23 g, 13.1 mmol) in
anhydrous DMF (100 mL) at 0.degree. C. was added 60% sodium hydride
(0.629 g, 15.7 mmol) and reaction mixture was stirred for 15
minutes. Iodomethane (0.98 mL, 15.7 mmol) was added and reaction
mixture was stirred at 0.degree. C. for 1.5 hours. Reaction was
complete by LCMS analysis. Reaction mixture was concentrated,
suspended in EtOAc/CH.sub.2Cl.sub.2) and washed with saturated
ammonium chloride (2.times.). Organic layer was dried (MgSO.sub.4),
filtered, concentrated and purified by CombiFlash (120 g, Gold,
0-20% EtOAc/Hex) to give a yellow solid. LCMS-ESI.sup.+: calc'd for
C.sub.8H.sub.7BrIN.sub.2: 338.9 (M+H)+; found: 339.1
(M+H).sup.+.
[0404] Preparation of tert-butyl
4-(5-bromo-1-methyl-1H-pyrrolo[2,3-b]pyridin-3-yl)-5,6-dihydropyridine-1(-
2H)-carboxylate: A 100 mL round bottom flask was charged with
5-bromo-3-iodo-1-methyl-1H-pyrrolo[2,3-b]pyridine (2.44 g,7 .24
mmol), tert-butyl
4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-5,6-dihydropyridine-1(2H)-
-carboxylate (2.46 g, 7.97 mmol), dichloro
1,1-bis(diphenylphosphino)ferrocene palladium(II) dichloromethane
(591 mg, 0.724 mmol) and potassium phosphate (7.7 g, 36 mmol). The
flask was flushed with nitrogen for 5 minutes, then anhydrous
dioxane (50 mL) was added and flask was placed into an oil bath
pre-heated to 70.degree. C. Reaction mixture was stirred for 5
hours. LCMS shows multiple reaction products in addition to desired
product. Reaction mixture was filtered through a pad of Celite,
concentrated and purified by CombiFlash (120 g, 0-30% EtOAc/Hex) to
give impure product. Repurification by CombiFlash (120 g Gold,
5-20% EtOAc/Hex) gave desire product. LCMS-ESI.sup.+: calc'd for
C.sub.18H.sub.23BrN.sub.3O.sub.2: 392.1 (M+H).sup.+; found: 392.1
(M+H).sup.+.
[0405] Preparation of tert-butyl
4-(5-bromo-1-methyl-1H-pyrrolo[2,3-b]pyridin-3-yl)piperidine-1-carboxylat-
e: A flask containing a mixture of tert-butyl
4-(5-bromo-1-methyl-1H-pyrrolo[2,3-b]pyridin-3-yl)-5,6-dihydropyridine-1(-
2H)-carboxylate (135 mg, 0.344 mmol), rhodium on alumina, 5 wt %
(130 mg, 0.063 mmol) in ethanol (5 mL) was evacuated and
back-filled with hydrogen (3.times.). Reaction mixture was stirred
overnight, filtered through a pad of Celite and concentrated. The
colorless residue was purified by CombiFlash (12 g, Gold, 2-25%
EtOAc/Hex) to give a colorless oil. LCMS-ESI+: calc'd for
C.sub.18H.sub.25BrN.sub.3O.sub.2: 394.1 (M+H).sup.+; found: 394.1
(M+H).sup.+.
[0406] Preparation of tert-butyl
(S)-4-(5-(6-(1-(tert-butoxy)-2-ethoxy-2-oxoethyl)-7-(4-chlorophenyl)-5-me-
thylbenzo[d]thiazol-2-yl)-1-methyl-1H-pyrrolo[2,3-b]pyridin-3-yl)piperidin-
e-1-carboxylate: A 25 mL round bottom flash was charged with the
tert-butyl
4-(5-bromo-1-methyl-1H-pyrrolo[2,3-b]pyridin-3-yl)piperidine-1-carboxylat-
e (71 mg, 0.18 mmol), bis(neopentyl glycolato)diboron (53 mg, 0.234
mmol), PdCl.sub.2(Amphos).sub.2 (13 mg, 0.018 mmol) and potassium
propionate (91 mg, 0.81 mmol) and flushed with nitrogen. De-gassed
dioxane (2.0 mL) was added under a nitrogen atmosphere and reaction
mixture was heated to 80.degree. C. for 2h. The reaction turned to
a heterogeneous yellow color. LCMS showed mass corresponding to
(3-(1-(tert-butoxycarbonyl)piperidin-4-yl)-1-methyl-1H-pyrrolo[2,3-b]pyri-
din-5-yl)boronic acid (.about.33%) and dimer mass (.about.66%).
Reaction mixture was cooled to .about.50.degree. C. Potassium
carbonate (2M, 0.223 mL, 0.446 mmol) and ethyl
(S)-2-(2-bromo-7-(4-chlorophenyl)-5-methylbenzo[d]thiazol-6-yl)-2-(tert-b-
utoxy)acetate (59 mg, 0.119 mmol) were added and the reaction
heated to 80.degree. C. After 2 h, LCMS showed desired product
mass. Reaction was cooled to room temperature, filtered through a
pad of Celite and concentrated. The residue was purified by
CombiFlash (12 g Gold, 0-100% EtOAc/Hex) and concentrated to give
impure product. Repurified by CombiFlash (12 g Gold, 10-40%
EtOAc/Hex) and concentrated to desired product with some impurity.
LCMS-ESI+: calc'd for C.sub.40H.sub.48ClN.sub.4O.sub.5S: 731.3
(M+H).sup.+; found: 731.1 (M+H).sup.+.
[0407] Preparation of ethyl
(S)-2-(tert-butoxy)-2-(7-(4-chlorophenyl)-5-methyl-2-(1-methyl-3-(1-(oxet-
an-3-yl)piperidin-4-yl)-1H-pyrrolo[2,3-b]pyridin-5-yl)benzo[d]thiazol-6-yl-
)acetate: A solution of tert-butyl
(S)-4-(5-(6-(1-(tert-butoxy)-2-ethoxy-2-oxoethyl)-7-(4-chlorophenyl)-5-me-
thylbenzo[d]thiazol-2-yl)-1-methyl-1H-pyrrolo[2,3-b]pyridin-3-yl)piperidin-
e-1-carboxylate (7.5 mg, 0.010 mmol) in 1.25 HCl in isopropanol
(1.0 mL) was stirred overnight at room temperature. Reaction
mixture was quenched with saturated sodium bicarbonate solution and
extracted with ethyl acetate (2.times.). Combined organic layer was
dried (MgSO4), filtered and concentrated to give ethyl
(S)-2-(tert-butoxy)-2-(7-(4-chlorophenyl)-5-methyl-2-(1-methyl-3-(piperid-
in-4-yl)-1H-pyrrolo[2,3-b]pyridin-5-yl)benzo[d]thiazol-6-yl)acetate
that was used in the next step without further purification.
[0408] A solution of ethyl
(S)-2-(tert-butoxy)-2-(7-(4-chlorophenyl)-5-methyl-2-(1-methyl-3-(piperid-
in-4-yl)-1H-pyrrolo[2,3-b]pyridin-5-yl)benzo[d]thiazol-6-yl)acetate
(6.6 mg, 0.01 mmol), 3-oxetanone (6.7 .mu.L, 0.105 mmol), acetic
acid (3.0 .mu.L, 0.052 mmol) and sodium cyanoborohydride (6.6 mg,
0.105 mmol) in ethanol was stirred for 8 hours at room temperature.
LCMS showed about 50% conversion. Added 3-oxetanone (6.7 .mu.L,
0.105 mmol), acetic acid (3.0 .mu.L, 0.052 mmol) and sodium
cyanoborohydride (6.6 mg, 0.105 mmol) and stirred overnight. LCMS
showed complete conversion. Reaction was quenched with saturated
sodium bicarbonate solution and brine and stirred for 1.5 hours.
The mixture was extracted with ethyl acetate (2.times.) and
combined organic layer was dried (MgSO.sub.4), filtered and
concentrated. The residue was purified by CombiFlash (4 g, Gold,
0-10% MeOH/CH.sub.2Cl.sub.2) to give a colorless film. LCMS-ESI+:
calc'd for C.sub.38H.sub.44ClN.sub.4O.sub.4S: 687.3 (M+H).sup.+;
found: 687.3 (M+H).sup.+.
[0409] Preparation of
(S)-2-(tert-butoxy)-2-(7-(4-chlorophenyl)-5-methyl-2-(1-methyl-3-(1-(oxet-
an-3-yl)piperidin-4-yl)-1H-pyrrolo[2,3-b]pyridin-5-yl)benzo[d]thiazol-6-yl-
)acetic acid: A solution of ethyl
(S)-2-(tert-butoxy)-2-(7-(4-chlorophenyl)-5-methyl-2-(1-methyl-3-(1-(oxet-
an-3-yl)piperidin-4-yl)-1H-pyrrolo[2,3-b]pyridin-5-yl)benzo[d]thiazol-6-yl-
)acetate (3.4 mg, 0.005 mmol) and 5M sodium hydroxide (10 .mu.L,
0.050 mmol) in THF (0.5 mL) and methanol (0.1 mL) was stirred at
45.degree. C. for 4 hours. Additional 5M sodium hydroxide (5 .mu.L,
0.025 mmol) was added and reaction mixture was stirred for 2 hours.
Reaction mixture was concentrated, dissolved in DMF/methanol,
filtered through syringe filter and purified by Gilson HPLC
(Gemini, 5-100% ACN/H.sub.2O+0.1% TFA) to give a yellow powder
after lyophilization.
[0410] .sup.1H NMR (400 MHz, Methanol-d.sub.4) .delta. 8.95 (d,
J=2.0 Hz, 1H), 8.64 (d, J=2.0 Hz, 1H), 7.83 (s, 1H), 7.72-7.65 (m,
1H), 7.60 (dd, J=7.0, 1.5 Hz, 3H), 7.37 (s, 1H), 5.26 (s, 1H), 4.94
(t, J=7.7 Hz, 2H), 4.45 (s, 1H), 3.87 (s, 3H), 3.62 (d, J=13.5 Hz,
2H), 3.25 (d, J=11.0 Hz, 1H), 3.16-3.01 (m, 2H), 2.62 (s, 3H), 2.36
(d, J=14.1 Hz, 2H), 2.17-1.99 (m, 2H), 0.98 (s, 9H).
LCMS-ESI.sup.+: calc'd for C.sub.36H.sub.40ClN.sub.4O.sub.4S: 659.2
(M+H).sup.+; found: 659.2 (M+H).sup.+.
Example 21
Preparation of
(S)-2-(tert-butoxy)-2-(7-(4-chlorophenyl)-2-(3-(3,6-dihydro-2H-pyran-4-yl-
)-1-methyl-1H-indazol-5-yl)-5-methylbenzo[d]thiazol-6-yl)acetic
acid (18)
##STR00106##
[0412] Preparation of ethyl
(S)-2-(tert-butoxy)-2-(7-(4-chlorophenyl)-2-(3-(3,6-dihydro-2H-pyran-4-yl-
)-1-methyl-1H-indazol-5-yl)-5-methylbenzo[d]thiazol-6-yl)acetate: A
mixture of ethyl
(S)-2-(2-(3-bromo-1-methyl-1H-indazol-5-yl)-7-(4-chlorophenyl)-5-methylbe-
nzo[d]thiazol-6-yl)-2-(tert-butoxy)acetate (70.3 mg, 0.112 mmol),
2-(3,6-dihydro-2H-pyran-4-yl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane
(42.1 mg, 0.200 mmol), tetrakis(triphenylphosphine)palladium(0)
(13.43 mg, 0.012 mmol), and potassium carbonate (46.94 mg, 0.340
mmol) in a microwave vial was purged with argon gas for .about.3
min and water (0.3 mL) and dioxane (1.2 mL) were added. The
resulting mixture was reacted in a microwave reactor for 20 min at
110.degree. C. To the reaction mixture was added water (0.5 mL) and
the resulting mixture was again reacted in a microwave reactor for
20 min at 110.degree. C. After the reaction mixture was diluted
with ethyl acetate and washed with water (.times.2), and the
aqueous layer was extracted with ethyl acetate (.times.1), the
organic layers were combined and concentrated. The residue was
purified by Combiflash (12 g, Gold, 0-60% EtOAc/Hex) to obtain the
title product. LCMS-ESI.sup.+: calc'd for
C.sub.35H.sub.37ClN.sub.3O.sub.4S: 630.22 (M+H).sup.+; found:
630.36 (M+H).sup.+.
[0413] Preparation of
(S)-2-(tert-butoxy)-2-(7-(4-chlorophenyl)-2-(3-(3,6-dihydro-2H-pyran-4-yl-
)-1-methyl-1H-indazol-5-yl)-5-methylbenzo[d]thiazol-6-yl)acetic
acid: To a solution of ethyl
(S)-2-(tert-butoxy)-2-(7-(4-chlorophenyl)-2-(3-(3,6-dihydro-2H-pyran-4-yl-
)-1-methyl-1H-indazol-5-yl)-5-methylbenzo[d]thiazol-6-yl)acetate
(28.5 mg, 0.045 mmol) in THF (1 mL) and MeOH (1 mL) was added 2 N
NaOH (1 mL) at room temperature and kept tightly before the mixture
was stirred at 70.degree. C. for 1.5 h. The reaction mixture was
concentrated to remove organic solvent and acidified with 2 N HCl.
The resulting mixture was dissolved with DMF and MeCN (total
.about.5 mL), filtered through syringe filter, and purified by
Gilson HPLC (Phenomenex Gemini, 60-100% ACN/H.sub.2O+0.1% TFA) to
obtain the title product after lyophilization. .sup.1H NMR (400
MHz, Acetonitrile-d.sub.3) .delta. 8.48 (dd, J=1.6, 0.8 Hz, 1H),
8.08 (dd, J=8.9, 1.6 Hz, 1H), 7.83 (d, J=1.0 Hz, 1H), 7.70-7.63 (m,
1H), 7.63-7.57 (m, 3H), 7.54 (dd, J=8.8, 0.8 Hz, 1H), 6.59 (dt,
J=3.0, 1.5 Hz, 1H), 5.28 (s, 1H), 4.35 (q, J=2.8 Hz, 2H), 4.00 (s,
3H), 3.91 (t, J=5.5 Hz, 2H), 2.69 (dq, J=5.4, 2.9 Hz, 2H), 2.58 (d,
J=0.9 Hz, 3H), 0.99 (s, 9H). LCMS-ESI.sup.+: calc'd for
C.sub.33H.sub.33ClN.sub.3O.sub.4S: 602.19 (M+H).sup.+; found:
602.28 (M+H).sup.+.
Example 22
Preparation of
(S)-2-(tert-butoxy)-2-(7-(4-chlorophenyl)-5-methyl-2-(1-methyl-3-(tetrahy-
dro-2H-pyran-4-yl)-1H-indazol-5-yl)benzo[d]thiazol-6-yl)acetic acid
(19)
##STR00107##
[0415] Preparation of ethyl
(S)-2-(tert-butoxy)-2-(7-(4-chlorophenyl)-5-methyl-2-(1-methyl-3-(tetrahy-
dro-2H-pyran-4-yl)-1H-indazol-5-yl)benzo[d]thiazol-6-yl)acetate: A
mixture of ethyl
(S)-2-(tert-butoxy)-2-(7-(4-chlorophenyl)-2-(3-(3,6-dihydro-2H-p-
yran-4-yl)-1-methyl-1H-indazol-5-yl)-5-methylbenzo[d]thiazol-6-yl)acetate
(29.3 mg, 0.046 mmol) and 5% Rhodium on alumina (22 mg) in ethanol
(3 mL) was stirred under H.sub.2 atmosphere for 5 h. The reaction
mixture was filtered through celite pad and the filtrate was
concentrated to dryness to get the crude title product.
LCMS-ESI.sup.+: calc'd for C.sub.35H.sub.39ClN.sub.3O.sub.4S:
632.23 (M+H).sup.+; found: 632.38 (M+H).sup.+.
[0416] Preparation of
(S)-2-(tert-butoxy)-2-(7-(4-chlorophenyl)-5-methyl-2-(1-methyl-3-(tetrahy-
dro-2H-pyran-4-yl)-1H-indazol-5-yl)benzo[d]thiazol-6-yl)acetic
acid: To a solution of the above crude ethyl
(S)-2-(tert-butoxy)-2-(7-(4-chlorophenyl)-5-methyl-2-(1-methyl-3-(tetrahy-
dro-2H-pyran-4-yl)-1H-indazol-5-yl)benzo[d]thiazol-6-yl)acetate in
THF (1 mL) and MeOH (1 mL) was added 2 N NaOH (1 mL) at room
temperature and kept tightly before the mixture was stirred at
70.degree. C. for 1.5 h. The reaction mixture was concentrated to
remove organic solvent and acidified with 2 N HCl. The resulting
mixture was dissolved with DMF and MeCN (total 6 mL), filtered
through syringe filter, and purified by Gilson HPLC (Phenomenex
Gemini, 60-100% ACN/H.sub.2O+0.1% TFA) to obtain the title product
after lyophilization. .sup.1H NMR (400 MHz, Acetonitrile-d.sub.3)
.delta. 8.40 (dd, J=1.6, 0.9 Hz, 1H), 8.07 (dt, J=8.9, 1.4 Hz, 1H),
7.85 (d, J=1.2 Hz, 1H), 7.69-7.64 (m, 1H), 7.63-7.56 (m, 3H), 7.53
(dt, J=8.9, 0.9 Hz, 1H), 5.29 (s, 1H), 4.02 (dp, J=8.9, 2.6 Hz,
2H), 3.98 (d, J=0.9 Hz, 3H), 3.65-3.52 (m, 2H), 3.39 (ddd, J=15.6,
10.2, 6.3 Hz, 1H), 2.58 (d, J=0.8 Hz, 3H), 2.06-1.87 (m, 4H), 0.99
(s, 9H). LCMS-ESI.sup.+: calc'd for
C.sub.33H.sub.35ClN.sub.3O.sub.4S: 604.20 (M+H).sup.+; found:
604.31 (M+H).sup.+.
Example 23
Preparation of
(S)-2-(tert-butoxy)-2-(7-(4-chlorophenyl)-5-methyl-2-(1-methyl-3-(1-(3-me-
thyloxetan-3-yl)piperidin-4-yl)-1H-indazol-5-yl)benzo[d]thiazol-6-yl)aceti-
c acid (20)
##STR00108## ##STR00109##
[0418] Preparation of 1-(3-methyloxetan-3-yl)piperidin-4-ol : A
solution of 3-(phenylsulfonylmethylene)oxetane (2.1 g, 10 mmol) and
piperidin-4-ol (1.11 g, 11 mmol) in methanol (100 mL) was stirred
at 50.degree. C. for 5 hours. LCMS shows desired product, trace
starting material. Reaction mixture was telescoped into next
reaction. Magnesium turnings (1.2 g, 50 mmol) were treated with
chloro trimethylsilane (0.5 mL), followed by anhydrous methanol (5
mL). The mixture was gently swirled resulting in vigorous bubbling.
After 30 seconds, mixture was decanted, anhydrous methanol (5 mL)
was added, swirled for 30 seconds and decanted. The activated
magnesium was added to above reaction mixture and stirred at
50.degree. C. for 12h. LCMS shows desired product mass. Reaction
mixture was diluted with methanol, filtered through a pad of Celite
and the filtrate concentrated. Crude
1-(3-methyloxetan-3-yl)piperidin-4-ol was dissolved in methanol and
was applied to a Amberlite column. The column was washed with
methanol and product was eluted off using 2M ammonia in methanol.
Product containing fractions were concentrated and dried under
house vacuum to give a yellow residue. LCMS-ESI+: calc'd for
C.sub.9H.sub.18NO.sub.2: 172.1 (M+H).sup.+; found: 172.2
(M+H).sup.+.
[0419] Preparation of 1-(3-methyloxetan-3-yl)piperidin-4-one: To a
solution of oxalyl chloride (0.24 mL, 2.84 mmol) in dichloromethane
(10 mL) at -78.degree. C. was added dropwise DMSO (0.37 mL, 5.20
mmol). Reaction mixture was stirred for 15 minutes, and then a
solution of 1-(3-methyloxetan-3-yl)piperidin-4-ol (0.41 g, 2.37
mmol) in dichloromethane (1.5 mL) was added dropwise. Reaction
mixture was stirred for 5 minutes, and then triethylamine (1.65 mL,
11.8 mmol) was added. Reaction mixture was stirred at -78.degree.
for 30 minutes, then warmed to room temperature over 1 hour.
Reaction mixture was filtered and filtrate was concentrated and
stored in the freezer over the weekend. Purified by CombiFlash (24
g Gold, 0-20% MeOH/EtOAc, staining with DNP) to give a yellow
residue. LCMS-ESI+: calc'd for C.sub.9H.sub.16NO.sub.2: 170.1
(M+H).sup.+; found: 170.1 (M+H).sup.+.
[0420] Preparation of
1-(3-methyloxetan-3-yl)-1,2,3,6-tetrahydropyridin-4-yl
trifluoromethanesulfonate: To a solution of 1.0M lithium
hexamethyldisilazide in THF (2.0 mL) in THF (2 mL) at -78.degree.
C. was added a solution of 1-(3-methyloxetan-3-yl)piperidin-4-one
(0.221 g, 1.30 mmol) in THF (2 mL) over 5 minutes. Reaction mixture
was warmed to room temperature over 2 hours, then cooled to
-78.degree. C. n-Phenyltrifluoromethanesulfonimide (0.56 g, 1.56
mmol) was added and reaction mixture was warmed to room temperature
over 2 hours. The reaction mixture was quenched with ammonium
chloride and stirred for 20 minutes. The organic component was
removed by rotovap and the white mixture was extracted with ethyl
acetate (2.times.). Combined organic layer was dried (MgSO.sub.4),
filtered and concentrated. The yellow residue was purified by
CombiFlash (12 g Gold, 10-60-100% EtOAc/Hex) to give desired
product plus 1-(3-methyloxetan-3-yl)piperidin-4-one. LCMS-ESI+:
calc'd for C.sub.10H.sub.15F.sub.3NO.sub.4S: 302.1 (M+H).sup.+;
found: 302.0 (M+H).sup.+.
[0421] Preparation of ethyl
(S)-2-(tert-butoxy)-2-(7-(4-chlorophenyl)-5-methyl-2-(1-methyl-3-(1-(3-me-
thyloxetan-3-yl)-1,2,3,6-tetrahydropyridin-4-yl)-1H-indazol-5-yl)benzo[d]t-
hiazol-6-yl)acetate: A mixture of
1-(3-methyloxetan-3-yl)-1,2,3,6-tetrahydropyridin-4-yl
trifluoromethanesulfonate (250 mg, 0.830 mmol),
bis(pinacolato)diboron (309 mg, 3.15 mmol),
[1,1'-bis(diphenylphosphino)ferrocene]dichloropalladium(II),
complex with dichloromethane (19 mg, 0.027 mmol), and
1,1'-bis(diphenylphosphino)ferrocene (15 mg, 0.027 mmol) in dioxane
(8.0 mL) was sparged with nitrogen for 20 minutes. Reaction mixture
was heated at 80.degree. C. for 3 hours. LCMS shows some desired
product mass, majority is dimer. Cooled to room temperature and
stored in freezer over the weekend.
[0422] The mixture was allowed to thaw for 1 hour. 2M Potassium
carbonate (0.48 mL, 0.96 mmol) was added and reaction mixture was
sparged with nitrogen for 5 minutes. PdCl.sub.2(Amphos).sub.2 (11
mg, 0.016 mmol) and ethyl
(S)-2-(2-(3-bromo-1-methyl-1H-indazol-5-yl)-7-(4-chlorophenyl)-5-me-
thylbenzo[d]thiazol-6-yl)-2-(tert-butoxy)acetate (59 mg, 0.119
mmol) (100 mg, 0.129 mmol) were added and reaction mixture was
heated at 80.degree. C. for 4 hours. LCMS showed desired product
mass. Reaction mixture was cooled to room temperature, diluted with
ethyl acetate and washed with brine. The aqueous layer was
back-extracted and combined organic layer was dried (MgSO.sub.4),
filtered and concentrated to give a dark brown residue.
Purification by CombiFlash (12 g, Gold, 0-100% EtOAc/hex) gave a
yellow film. LCMS-ESI+: calc'd for
C.sub.39H.sub.44ClN.sub.4O.sub.4S: 699.3 (M+H).sup.+; found: 699.2
(M+H).sup.+.
[0423] Preparation of ethyl
(S)-2-(tert-butoxy)-2-(7-(4-chlorophenyl)-5-methyl-2-(1-methyl-3-(1-(3-me-
thyloxetan-3-yl)piperidin-4-yl)-1H-indazol-5-yl)benzo[d]thiazol-6-yl)aceta-
te: A mixture of ethyl
(S)-2-(tert-butoxy)-2-(7-(4-chlorophenyl)-5-methyl-2-(1-methyl-3-(1-(3-me-
thyloxetan-3-yl)-1,2,3,6-tetrahydropyridin-4-yl)-1H-indazol-5-yl)benzo[d]t-
hiazol-6-yl)acetate (46 mg, 0.066 mmol) and 5% rhodium on alumina
(40 mg, 0.019 mmol) in ethanol (4.0 mL) was stirred under hydrogen
atmosphere for 36 hours. LCMS showed reaction was complete.
Reaction mixture was filtered through a pad of Celite, concentrated
and purified by CombiFlash (4 g, Gold, 0-70% Hex/(20% MeOH in
EtOAc)) to give a colorless film. LCMS-ESI+: calc'd for
C.sub.39H.sub.46ClN.sub.4O.sub.4S: 701.3 (M+H).sup.+; found: 701.3
(M+H).sup.+.
[0424] Preparation of
(S)-2-(tert-butoxy)-2-(7-(4-chlorophenyl)-5-methyl-2-(1-methyl-3-(1-(3-me-
thyloxetan-3-yl)piperidin-4-yl)-1H-indazol-5-yl)benzo[d]thiazol-6-yl)aceti-
c acid: A solution of ethyl
(S)-2-(tert-butoxy)-2-(7-(4-chlorophenyl)-5-methyl-2-(1-methyl-3-(1-(3-me-
thyloxetan-3-yl)piperidin-4-yl)-1H-indazol-5-yl)benzo[d]thiazol-6-yl)aceta-
te (25 mg, 0.036 mmol) and 5M sodium hydroxide (36 .mu.L, 0.18
mmol) in THF (1.0 mL) and MeOH (0.1 mL) was stirred at 60.degree.
C. for 3 hours. Reaction mixture was cooled to room temperature,
diluted with DMF (0.5 mL), concentrated to .about.0.5 mL, diluted
with methanol, filtered through a syringe filter and purified by
Gilson HPLC (Gemini, 5-100% ACN/H.sub.2O+0.1% TFA). Product was
lyophilized to give a yellow powder. .sup.1H NMR (400 MHz,
Methanol-d.sub.4) .delta. 8.46 (s, 1H), 8.13 (d, J=8.9 Hz, 1H),
7.82 (s, 1H), 7.75-7.48 (m, 5H), 5.25 (s, 1H), 4.89 (d, J=7.9 Hz,
2H), 4.54 (d, J=7.8 Hz, 2H), 4.05 (s, 3H), 3.64-3.32 (m, 4H), 2.61
(s, 3H), 2.48-2.14 (m, 4H), 1.81 (s, 3H), 0.98 (s, 9H). LCMS-ESI+:
calc'd for C.sub.37H.sub.42ClN.sub.4O.sub.4S: 673.3 (M+H).sup.+;
found: 673.2 (M+H).sup.+.
Example 24
Preparation of
(S)-2-(7-(4-chlorophenyl)-5-methyl-2-(1-methyl-3-(1-(oxetan-3-yl)piperidi-
n-4-yl)-1H-indazol-5-yl)benzo[d]thiazol-6-yl)-24(2-(methyl-d.sub.3)propan--
2-yl-1,1,1,3,3,3-d.sub.6)oxy)acetic acid (21)
##STR00110##
[0426] Preparation of tert-butyl
4-(5-chloro-1-methyl-1H-indazol-3-yl)-5,6-dihydropyridine-1(2H)-carboxyla-
te: A 100 mL round bottom flask was charged with
3-bromo-5-chloro-1-methyl-1H-indazole (2.00 g, 8.15 mmol),
tert-butyl
4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-5,6-dihydropyridine-1(2H)-
-carboxylate (3.02 mg, 9.78 mmol), dichloro
1,1-bis(diphenylphosphino)ferrocene palladium(II) dichloromethane
(665 mg, 0.815 mmol) and potassium phosphate 8.65 g, 40.7 mmol) .
The flask was flushed with nitrogen for 5 minutes, then anhydrous
dioxane (40 mL) was added and flask was placed into an oil bath
pre-heated to 90.degree. C. Reaction mixture was stirred for 5
hours. LCMS shows nearly complete conversion. Reaction mixture was
filtered through a pad of Celite, concentrated and purified by
CombiFlash (120 g, 10-25% EtOAc/Hex) to give a yellow residue.
LCMS-ESI+: calc'd for C.sub.14H.sub.15ClN.sub.3O.sub.2: 292.1
(M-tBu+H).sup.+; found: 292.2(M-tBu+H).sup.+.
[0427] Preparation of tert-butyl
4-(5-chloro-1-methyl-1H-indazol-3-yl)piperidine-1-carboxylate: A
mixture of tert-butyl
4-(5-chloro-1-methyl-1H-indazol-3-yl)-5,6-dihydropyridine-1(2H)-carboxyla-
te (2.61 g, 7.50 mmol), rhodium on alumina (5%, 2.01 g, 0.977 mmol)
in ethanol (40 mL) was stirred under a hydrogen atmosphere for 8
hours. Reaction mixture was filtered through Celite and the
filtrate was concentrated. The residue was purified by CombiFlash
(120 g, Gold, 0-25% EtOAc/Hex) to give a colorless oil. LCMS-ESI+:
calc'd for C.sub.14H.sub.17ClN.sub.3O.sub.2: 294.1 (M-tBu+H).sup.+;
found: 294.1 (M+H).sup.+.
[0428] Preparation of
5-chloro-1-methyl-3-(piperidin-4-yl)-1H-indazole: To a solution of
tert-butyl
4-(5-chloro-1-methyl-1H-indazol-3-yl)piperidine-1-carboxylate
(0.495 g, 1.42 mmol) in dichloromethane (4.0 mL) was added
trifluoroacetic acid (1.0 mL). The reaction mixture turned orange
immediately. Reaction mixture was stirred for 1 hour, then
concentrated. The residue was suspended in 10% dichloromethane in
hexane, resulting solid collected by filtration and dried on house
vacuum to give desired product as a TFA salt. LCMS-ESI+: calc'd for
C.sub.13H.sub.18ClN.sub.3: 250.1 (M+H).sup.+; found: 250.2
(M+H).sup.+.
[0429] Preparation of
5-chloro-1-methyl-3-(1-(oxetan-3-yl)piperidin-4-yl)-1H-indazole: A
solution of 5-chloro-1-methyl-3-(piperidin-4-yl)-1H-indazole TFA
salt (291 mg, 0.80 mmol), oxetan-3-one (0.37 mL, 5.834 mmol),
acetic acid (0.334 mL, 5.83 mmol), and sodium triacetoxyborohydride
(1.24 g, 5.83 mmol) in DMF (3.0 mL) was stirred at 60.degree. C.
for 1 hour. LCMS show no starting material. Reaction mixture was
quenched with saturated sodium bicarbonate, and extracted with
EtOAc. Organic layer was washed with 5% lithium chloride solution
(3.times.), brine and dried (MgSO.sub.4). Concentration and
purification by CombiFlash (12 g, Gold, 0-5% MeOH/EtOAc) gave
desired product. The aqueous layer was back-extracted with ethyl
acetate (3.times.), dried (MgSO.sub.4), filtered and concentrated.
The residue was dried over the weekend under house vacuum and
purified by CombiFlash (12 g, Gold, 0-5% MeOH/EtOAc) to give
additional product. LCMS-ESI+: calc'd for
C.sub.16H.sub.21ClN.sub.3O: 306.1 (M+H).sup.+; found: 306.2
(M+H).sup.+.
[0430] Preparation of ethyl
(S)-2-(2-bromo-7-(4-chlorophenyl)-5-methylbenzo[d]thiazol-6-yl)-2-((2-(me-
thyl-d.sub.3)propan-2-yl-1,1,1,3,3,3-d.sub.6)oxy)acetate: Two
parallel reactions: to a solution of ethyl
(S)-2-(2-bromo-7-(4-chlorophenyl)-5-methylbenzo[d]thiazol-6-yl)-2-hydroxy-
acetate (1.10 g, 2.50 mmol) in tert-butanol, d.sub.10 (11 mL) and
dichloromethane (2.2 mL)at -10.degree. C. was added
trifluoromethanesulfonic anhydride (5 g, 17.7 mmol) over 5 minutes.
The internal temperature rose to 37.degree. C. but cooled back down
to below 0.degree. C. Reaction mixture was stirred at this
temperature for 1 hour, then quenched with triethylamine (4.5 mL)
and stirred for 10 minutes. Reaction mixture was diluted with ethyl
acetate, poured into 5M NaOH and washed with brine (2.times.). The
organic layers from both reactions were combined, dried
(MgSO.sub.4) and concentrated to give a white paste that was
adsorbed onto silica gel using dichloromethane and methanol.
Purification by CombiFlash (40 g, Gold, 0-25% EtOAc/Hex) gave the
desired product. LCMS-ESI+: calc'd for
C.sub.22H.sub.15D.sub.9BrClNO.sub.3S: 505.1 (M+H).sup.+; found:
505.1 (M+H).sup.+.
[0431] Preparation of ethyl
(S)-2-(7-(4-chlorophenyl)-5-methyl-2-(1-methyl-3-(1-(oxetan-3-yl)piperidi-
n-4-yl)-1H-indazol-5-yl)benzo[d]thiazol-6-yl)-2-((2-(methyl-d.sub.3)propan-
-2-yl-1,1,1,3,3,3-d.sub.6)oxy)acetate: A 10 mL round bottom flash
was charged with the
5-chloro-1-methyl-3-(1-(oxetan-3-yl)piperidin-4-yl)-1H-indazole
(105 mg, 0.343 mmol), bis(neopentyl glycolato)diboron (101 mg,
0.446 mmol), PdCl.sub.2(Amphos).sub.2 (24 mg, 0.034 mmol) and
potassium propionate (173 mg, 1.55 mmol) and flushed with nitrogen.
De-gassed dioxane (3.0 mL) was added under a nitrogen atmosphere
and reaction mixture was heated to 80.degree. C. for 2h. The
reaction turned from a heterogeneous yellow color to a dark brown
color. To the above reaction mixture, 2M potassium carbonate (1.28
mL, 2.56 mmol) and ethyl
(S)-2-(2-bromo-7-(4-chlorophenyl)-5-methylbenzo[d]thiazol-6-yl)-2-((2-(me-
thyl-d.sub.3)propan-2-yl-1,1,1,3,3,3-d.sub.6)oxy)acetate (262 mg,
0.342 mmol) were added and the reaction heated to 80.degree. C.
After 2 h, LCMS showed desired product mass. Reaction was cooled to
room temperature, filtered through a pad of Celite, concentrated.
The residue was purified by CombiFlash (4 g Gold, 5-40% EtOAc/Hex)
and concentrated to give a white film. LCMS-ESI+: calc'd for
C.sub.38H.sub.35D.sub.9ClN.sub.4O.sub.4S: 696.3 (M+H).sup.+; found:
696.5 (M+H).sup.+.
[0432] Preparation of
(S)-2-(7-(4-chlorophenyl)-5-methyl-2-(1-methyl-3-(1-(oxetan-3-yl)piperidi-
n-4-yl)-1H-indazol-5-yl)benzo[d]thiazol-6-yl)-2-((2-(methyl-d.sub.3)propan-
-2-yl-1,1,1,3,3,3-d.sub.6)oxy)acetic acid: A solution of ethyl
(S)-2-(7-(4-chlorophenyl)-5-methyl-2-(1-methyl-3-(1-(oxetan-3-yl)piperidi-
n-4-yl)-1H-indazol-5-yl)benzo[d]thiazol-6-yl)-2-((2-(methyl-d.sub.3)propan-
-2-yl-1,1,1,3,3,3-d.sub.6)oxy)acetate (131 mg, 0.139 mmol) and 5M
sodium hydroxide (0.278 mL, 1.39 mmol) in THF (3.0 mL) and MeOH
(0.5 mL) was heated at 50.degree. C. for 3 hours. Reaction mixture
was diluted with ethyl acetate, washed with brine, dried
(MgSO.sub.4), filtered and concentrated. Residue was dissolved in
methanol and purified by Gilson HPLC (5-100% ACN/H.sub.2O) and
product-containing fractions were lyophilized to give a yellow
powder. .sup.1H NMR (400 MHz, Methanol-d.sub.4) .delta. 8.46 (s,
1H), 8.12 (d, J=8.7 Hz, 1H), 7.81 (s, 1H), 7.73-7.56 (m, 5H), 5.24
(s, 1H), 4.98-4.89 (m, 3H), 4.86-4.79 (m, 3H), 4.47 (s, 1H), 4.05
(s, 3H), 3.65 (d, J=9.8 Hz, 2H), 3.50 (d, J=19.5 Hz, 1H), 3.21-3.03
(m, 2H), 2.61 (s, 3H), 2.39 (d, J=12.9 Hz, 2H), 2.33-2.14 (m, 2H).
LCMS-ESI+: calc'd for C.sub.36H.sub.31D.sub.9ClN.sub.4O.sub.4S:
668.3 (M+H).sup.+; found: 668.3 (M+H).sup.+.
Example 25
Preparation of
(S)-2-(7-(4-chlorophenyl)-5-methyl-2-(1-methyl-3-(1-(oxetan-3-yl)piperidi-
n-4-yl)-1H-indazol-5-yl)benzo[d]thiazol-6-yl)-2-cyclopropoxyacetic
acid (22)
##STR00111##
[0434] Preparation of
(S)-2-(7-(4-chlorophenyl)-5-methyl-2-(1-methyl-3-(1-(oxetan-3-yl)piperidi-
n-4-yl)-1H-indazol-5-yl)benzo[d]thiazol-6-yl)-2-cyclopropoxyacetic
acid: Prepared in a similar manner as
(S)-2-(7-(4-chlorophenyl)-5-methyl-2-(1-methyl-3-(1-(oxetan-3-yl)piperidi-
n-4-yl)-1H-indazol-5-yl)benzo[d]thiazol-6-yl)-2-((2-(methyl-d.sub.3)propan-
-2-yl-1,1,1,3,3,3-d.sub.6)oxy)acetic acid, except using
bis(pinacolato) diboron instead of bis(neopentyl glycolato)diboron.
.sup.1H NMR (400 MHz, Methanol-d4) .delta. 8.39 (s, 1H), 8.04 (dd,
J=8.9, 1.6 Hz, 1H), 7.79 (s, 1H), 7.60-7.44 (m, 5H), 5.15 (s, 1H),
4.96-4.81 (m, 4H), 4.48 (p, J=6.6 Hz, 1H), 4.00 (s, 3H), 3.60 (s,
1H), 3.50 (s, 1H), 3.26 (m, 1H), 3.12 (m, 2H), 2.65 (m, 1H), 2.54
(s, 3H), 2.40-2.20 (m, 4H), 0.46-0.21 (m, 4H).
Example 26
Preparation of
(S)-2-(tert-butoxy)-2-(2-(3-(1-(tert-butoxycarbonyl)piperidin-4-yl)-1-met-
hyl-1H-indazol-5-yl)-7-(4-chlorophenyl)-5-methylbenzo[d]thiazol-6-yl)aceti-
c acid (23)
##STR00112##
[0436] Preparation of
(S)-2-(tert-butoxy)-2-(2-(3-(1-(tert-butoxycarbonyl)piperidin-4-yl)-1-met-
hyl-1H-indazol-5-yl)-7-(4-chlorophenyl)-5-methylbenzo[d]thiazol-6-yl)aceti-
c acid: To tert-butyl
(S)-4-(5-(6-(1-(tert-butoxy)-2-ethoxy-2-oxoethyl)-7-(4-chlorophenyl)-5-me-
thylbenzo[d]thiazol-2-yl)-1-methyl-1H-indazol-3-yl)piperidine-1-carboxylat-
e (20 mg, 0.027 mmol) was added THF (1 mL), MeOH (0.2 mL) and 50%
Sodium hydroxide (0.2 mL) at rt. The mixture was stirred at
60.degree. C. for 1 h. The reaction mixture was cooled by ice and
acidified with 2 N HCl. The resulting mixture was extracted with
ethyl acetate (2.times.). Combined organic layer was dried
(MgSO.sub.4), filtered and concentrated to give crude mixture which
was purified by Gilson HPLC (Phenomenex Gemini 250.times.21.2
10.mu. C18 column, 40-100% ACN/H.sub.2O+0.1% TFA) to give a yellow
powder after lyophilization. .sup.1H NMR (400 MHz, Chloroform-d)
.delta. 8.32 (s, 1H), 8.04 (d, J=8.0 Hz, 1H), 7.84 (s, 1H),
7.63-7.31 (m, 3H), 5.27 (s, 1H), 4.25 (s, 2H), 4.02 (s, 3H), 3.24
(t, J=11.2 Hz, 1H), 2.93 (s, 2H), 2.54 (s, 3H), 2.02-1.82 (m, 4H),
1.48 (s, 9H), 0.96 (s, 9H). LCMS-ESI+: calc'd for
C.sub.38H.sub.44ClN.sub.4O.sub.5S; 703.2 (M+H).sup.+; found: 703.0
(M+H).sup.+.
Example 27
Preparation of
(S)-2-(tert-butoxy)-2-(2-(3-(1-(tert-butoxycarbonyl)piperidin-4-yl)-1-met-
hyl-1H-indazol-5-yl)-7-(4-chlorophenyl)-5-methylbenzo[d]thiazol-6-yl)aceti-
c acid (24)
##STR00113##
[0438] Preparation of ethyl
(S)-4-(5-(6-(1-(tert-butoxy)-2-ethoxy-2-oxoethyl)-7-(4-chlorophenyl)-5-me-
thylbenzo[d]thiazol-2-yl)-1-methyl-1H-indazol-3-yl)piperidine-1-carboxylat-
e: To a flask containing ethyl
(S)-2-(tert-butoxy)-2-(7-(4-chlorophenyl)-5-methyl-2-(1-methyl-3-(piperid-
in-4-yl)-1H-indazol-5-yl)benzo[d]thiazol-6-yl)acetate (36 mg, 0.057
mmol) in THF (1 mL) and 1N sodium hydroxide (0.5 mL) was added
Ethyl chloroformate (20 .mu.l, 0.21 mmol). The mixture was stirred
at room temperature for 18 h. The reaction was completed and
carried to the next step directly. LCMS-ESI+: calc'd for:
C.sub.38H.sub.44ClN.sub.4O.sub.5S; 703.3 (M+H).sup.+; found: 703.5
(M+H).sup.+.
[0439] Preparation of
(S)-2-(tert-butoxy)-2-(2-(3-(1-(tert-butoxycarbonyl)piperidin-4-yl)-1-met-
hyl-1H-indazol-5-yl)-7-(4-chlorophenyl)-5-methylbenzo[d]thiazol-6-yl)aceti-
c acid: To above reaction mixture containing crude ethyl
(S)-4-(5-(6-(1-(tert-butoxy)-2-ethoxy-2-oxoethyl)-7-(4-chlorophenyl)-5-me-
thylbenzo[d]thiazol-2-yl)-1-methyl-1H-indazol-3-yl)piperidine-1-carboxylat-
e (0.057 mmol) was added MeOH (0.5 mL) and 50% Sodium hydroxide
(0.2 mL) at rt. The mixture was stirred at 60.degree. C. for 1 h.
The reaction mixture was cooled by ice bath and acidified with 3N
HCl. The resulting mixture was extracted with ethyl acetate
(2.times.). Combined organic layer was dried (MgSO.sub.4), filtered
and concentrated to give crude mixture which was purified by Gilson
HPLC (Phenomenex Gemini 250.times.21.2 10.mu. C18 column, 40-100%
ACN/H.sub.2O+0.1% TFA) to give a yellow powder after
lyophilization. .sup.1H NMR (400 MHz, Chloroform-d) d 8.36 (d,
J=1.6 Hz, 1H), 8.03 (dd, J=8.8, 1.5 Hz, 1H), 7.89 (s, 1H), 7.72 (d,
J=8.1 Hz, 1H), 7.59-7.47 (m, 3H), 7.39 (d, J=8.8 Hz, 1H), 5.32 (s,
1H), 4.30 (s, 2H), 4.17 (q, J=7.1 Hz, 2H), 4.03 (s, 3H), 3.36-3.16
(m, 1H), 3.00 (t, J=12.4 Hz, 2H), 2.59 (s, 3H), 2.14-1.82 (m, 4H),
1.29 (t, J=7.1 Hz, H), 1.01 (s, 9H). LCMS-ESI+: calc'd for
C.sub.36H.sub.40ClN.sub.4O.sub.5S; 675.4 (M+H).sup.+; found: 675.3
(M+H).sup.+.
Example 28
Preparation of
(S)-2-(tert-butoxy)-2-(2-(3-(1-(tert-butoxycarbonyl)piperidin-4-yl)-1-met-
hyl-1H-indazol-5-yl)-7-(4-chlorophenyl)-5-methylbenzo[d]thiazol-6-yl)aceti-
c acid (25)
##STR00114##
[0441] Preparation of ethyl
(S)-2-(tert-butoxy)-2-(7-(4-chlorophenyl)-5-methyl-2-(1-methyl-3-(1-(meth-
ylsulfonyl)piperidin-4-yl)-1H-indazol-5-yl)benzo[d]thiazol-6-yl)acetate:
To a flask containing ethyl
(S)-2-(tert-butoxy)-2-(7-(4-chlorophenyl)-5-methyl-2-(1-methyl-3-(piperid-
in-4-yl)-1H-indazol-5-yl)benzo[d]thiazol-6-yl)acetate (40 mg, 0.063
mmol) in dichloromethane (2 mL) and Triethylamine (70.66 .mu.l,
506.95 .mu.mol) was added Methanesulfonyl chloride (7.36 .mu.l,
95.05 .mu.mol) at 0.degree. C. It was stirred and warmed to room
tempeture overnight (18 h). The reaction was complete and carried
to the next step directly. LCMS-ESI+: calc'd for:
C.sub.36H.sub.42ClN.sub.4O.sub.5S.sub.2; 709.2 (M+H).sup.+; found:
709.4 (M+H).sup.+.
[0442] Preparation of
(S)-2-(tert-butoxy)-2-(7-(4-chlorophenyl)-5-methyl-2-(1-methyl-3-(1-(meth-
ylsulfonyl)piperidin-4-yl)-1H-indazol-5-yl)benzo[d]thiazol-6-yl)acetic
acid: To above reaction mixture containing crude ethyl
(S)-2-(tert-butoxy)-2-(7-(4-chlorophenyl)-5-methyl-2-(1-methyl-3-(1-(meth-
ylsulfonyl)piperidin-4-yl)-1H-indazol-5-yl)benzo[d]thiazol-6-yl)acetate
(0.063 mmol) was added THF (2 mL), MeOH (0.5 mL) and 50% Sodium
hydroxide (0.5 mL) at rt. The mixture was stirred at 60.degree. C.
for 2 h. The reaction mixture was cooled by ice and acidified with
3 N HCl. The resulting mixture was extracted with ethyl acetate
(2.times.). Combined organic layer was dried (MgSO.sub.4), filtered
and concentrated to give crude mixture which was purified by Gilson
HPLC (Phenomenex Gemini 250.times.21.2 10.mu. C18 column, 40-100%
ACN/H.sub.2O+0.1% TFA) to give a yellow powder after
lyophilization. .sup.1H NMR (400 MHz, Chloroform-d) .delta. 8.42
(s, 1H), 8.06-7.88 (m, 2H), 7.73 (d, J=8.2 Hz, 1H), 7.62-7.47 (m,
3H), 7.41 (d, J=8.8 Hz, 1H), 5.33 (s, 1H), 4.04 (s, 3H), 3.95 (d,
J=11.9 Hz, 2H), 3.23 (dd, J=10.2, 4.8 Hz, 1H), 3.01-2.87 (m, 2H),
2.86 (s, 3H), 2.59 (s, 3H), 2.16 (p, J=3.9 Hz, 4H), 1.02 (s, 9H).
LCMS-ESI+: calc'd for C.sub.34H.sub.38ClN.sub.4O.sub.5S.sub.2;
681.2 (M+H).sup.+; found: 681.4 (M+H).sup.+.
Example 29
Preparation of
(S)-2-(tert-butoxy)-2-(7-(4-chlorophenyl)-5-methyl-2-(1-methyl-3-(1-((S)--
tetrahydrofuran-3-yl)piperidin-4-yl)-1H-indazol-5-yl)benzo[d]thiazol-6-yl)-
acetic acid (26)
##STR00115##
[0444] Preparation of ethyl
(S)-2-(tert-butoxy)-2-(7-(4-chlorophenyl)-5-methyl-2-(1-methyl-3-(1-((S)--
tetrahydrofuran-3-yl)piperidin-4-yl)-1H-indazol-5-yl)benzo[d]thiazol-6-yl)-
acetate: To a microwave vial containing ethyl
(S)-2-(tert-butoxy)-2-(7-(4-chlorophenyl)-5-methyl-2-(1-methyl-3-(piperid-
in-4-yl)-1H-indazol-5-yl)benzo[d]thiazol-6-yl)acetate (50 mg, 0.079
mmol) in acetonitrile (2 mL) was added (S)-tetrahydrofuran-3-yl
methanesulfonate (40 mg, 0.241 mmol) and Potassium carbonate (30
mg, 475 .mu.mol). The mixture was microwaved at 100.degree. C. for
1 h. Additional cesium carbonate (63.17 mg, 475 mmol), 40 mg of
(S)-tetrahydrofuran-3-yl methanesulfonate were added and mixture
was microwaved at 100.degree. C. for another 2 h. The reaction was
complete and carried to the next step directly after cooled to room
temperature. LCMS-ESI+: calc'd for:
C.sub.39H.sub.46ClN.sub.4O.sub.4S; 701.3 (M+H).sup.+; found: 701.4
(M+H).sup.+.
[0445] Preparation of
(S)-2-(tert-butoxy)-2-(7-(4-chlorophenyl)-5-methyl-2-(1-methyl-3-(1-((S)--
tetrahydrofuran-3-yl)piperidin-4-yl)-1H-indazol-5-yl)benzo[d]thiazol-6-yl)-
acetic acid: To above reaction mixture containing crude ethyl
(S)-2-(tert-butoxy)-2-(7-(4-chlorophenyl)-5-methyl-2-(1-methyl-3-(1-(meth-
ylsulfonyl)piperidin-4-yl)-1H-indazol-5-yl)benzo[d]thiazol-6-yl)acetate
(0.079 mmol) was added THF (2 mL), MeOH (0.5 mL) and 50% Sodium
hydroxide (0.5 mL) at rt. The mixture was stirred at 60.degree. C.
for 2 h. The reaction mixture was cooled by ice and acidified with
3 N HCl. The resulting mixture was extracted with ethyl acetate
(2.times.). Combined organic layer was dried (MgSO.sub.4), filtered
and concentrated to give crude mixture which was purified by Gilson
HPLC (Phenomenex Gemini 250.times.21.2 10.mu. C18 column, 40-100%
ACN/H.sub.2O+0.1% TFA) to give a yellow powder after
lyophilization. .sup.1H NMR (400 MHz, Chloroform-d) .delta. 8.24
(d, J=35.9 Hz, 1H), 7.96 (dd, J=36.3, 8.8 Hz, 1H), 7.78 (s, 1H),
7.70-7.57 (m, 1H), 7.52-7.37 (m, 3H), 7.33 (t, J=10.1 Hz, 1H),
5.33-5.10 (m, 1H), 4.18 (t, J=8.9 Hz, 1H), 4.06-3.80 (m, 3H),
3.80-2.72 (m, 8H), 2.49 (s, 3H), 2.35-2.03 (m, 6H), 1.28-1.05 (m,
1H), 0.93 (s, 9H). LCMS-ESI+: calc'd for
C.sub.37H.sub.42ClN.sub.4O.sub.4S; 673.3(M+H).sup.+; found:
673.3(M+H).sup.+.
Example 30
Preparation of
(S)-2-(tert-butoxy)-2-(7-(4-chlorophenyl)-5-methyl-2-(1-methyl-3-(1-((R)--
tetrahydrofuran-3-yl)piperidin-4-yl)-1H-indazol-5-yl)benzo[d]thiazol-6-yl)-
acetic acid (27)
##STR00116##
[0447] Preparation of ethyl
(S)-2-(tert-butoxy)-2-(7-(4-chlorophenyl)-5-methyl-2-(1-methyl-3-(1-((R)--
tetrahydrofuran-3-yl)piperidin-4-yl)-1H-indazol-5-yl)benzo[d]thiazol-6-yl)-
acetate: To a microwave vial containing ethyl
(S)-2-(tert-butoxy)-2-(7-(4-chlorophenyl)-5-methyl-2-(1-methyl-3-(piperid-
in-4-yl)-1H-indazol-5-yl)benzo[d]thiazol-6-yl)acetate (50 mg, 0.079
mmol) in acetonitrile (2 mL) was added (R)-tetrahydrofuran-3-yl
methanesulfonate (40 mg, 0.241 mmol) and Cesium carbonate (63.17
mg, 475 mmol). The mixture was microwaved at 100.degree. C. for 4
h. The reaction was completed and carried to the next step directly
after cooled to room temperature. LCMS-ESI+: calc'd for:
C.sub.39H.sub.46ClN.sub.4O.sub.4S; 701.3 (M+H).sup.+; found: 701.4
(M+H).sup.+.
[0448] Preparation of
(S)-2-(tert-butoxy)-2-(7-(4-chlorophenyl)-5-methyl-2-(1-methyl-3-(1-((R)--
tetrahydrofuran-3-yl)piperidin-4-yl)-1H-indazol-5-yl)benzo[d]thiazol-6-yl)-
acetic acid: To above reaction mixture containing crude ethyl
(S)-2-(tert-butoxy)-2-(7-(4-chlorophenyl)-5-methyl-2-(1-methyl-3-(1-((R)--
tetrahydrofuran-3-yl)piperidin-4-yl)-1H-indazol-5-yl)benzo[d]thiazol-6-yl)-
acetate (0.079 mmol) was added THF (2 mL), MeOH (0.5 mL) and 50%
Sodium hydroxide (0.5 mL) at rt. The mixture was stirred at
60.degree. C. for 2 h. The reaction mixture was cooled by ice and
acidified with 3 N HCl. The resulting mixture was extracted with
ethyl acetate (2.times.). Combined organic layer was dried
(MgSO.sub.4), filtered and concentrated to give crude mixture which
was purified by Gilson HPLC (Phenomenex Gemini 250.times.21.2
10.mu. C18 column, 40-100% ACN/H.sub.2O+0.1% TFA) to give a yellow
powder after lyophilization. .sup.1H NMR (400 MHz, Chloroform-d)
.delta. 8.23 (d, J=24.7 Hz, 1H), 7.97 (dd, J=30.7, 8.8 Hz, 1H),
7.79 (s, 1H), 7.64 (d, J=8.1 Hz, 1H), 7.51-7.39 (m, 3H), 7.33 (t,
J=9.5 Hz, 1H), 5.24 (s, 1H), 4.20 (d, J=10.0 Hz, 1H), 3.96 (d,
J=15.5 Hz, 3H), 3.81-3.48 (m, 6H), 3.40 (m, 2H), 3.23 (d, J=33.5
Hz, 2H), 2.84 (d, J=11.8 Hz, 1H), 2.50 (s, 3H), 2.36-2.02 (m, 4H),
0.93 (s, 9H). LCMS-ESI+: calc'd for
C.sub.37H.sub.42ClN.sub.4O.sub.4S; 673.3 (M+H).sup.+; found: 673.4
(M+H).sup.+.
Example 31
Preparation of
(S)-2-(tert-butoxy)-2-(2-(3-(1-(1-(tert-butoxycarbonyl)azetidin-3-yl)pipe-
ridin-4-yl)-1-methyl-1H-indazol-5-yl)-7-(4-chlorophenyl)-5-methylbenzo[d]t-
hiazol-6-yl)acetic acid (28)
##STR00117##
[0450] Preparation of tert-butyl
(S)-3-(4-(5-(6-(1-(tert-butoxy)-2-ethoxy-2-oxoethyl)-7-(4-chlorophenyl)-5-
-methylbenzo[d]thiazol-2-yl)-1-methyl-1H-indazol-3-yl)piperidin-1-yl)azeti-
dine-1-carboxylate: A solution of
(S)-2-(tert-butoxy)-2-(7-(4-chlorophenyl)-5-methyl-2-(1-methyl-3-(piperid-
in-4-yl)-1H-indazol-5-yl)benzo[d]thiazol-6-yl)acetate (260 mg,
0.412 mmol), N-Boc-3-oxoazetidine (380 mg, 2.22 mmol), acetic acid
(0.2 mL, 3.5 mmol)) and sodium cyanoborohydride (300 mg, 4.77 mmol)
in methanol (10 mL) was stirred for 24 hours at room temperature.
Reaction was quenched with saturated sodium bicarbonate solution
and brine. The mixture was extracted with ethyl acetate (2.times.)
and combined organic layer was dried (MgSO.sub.4), filtered and
concentrated. The residue was purified by CombiFlash (40 g, Gold,
0-10% MeOH/CH.sub.2Cl.sub.2) to give the desired product. .sup.1H
NMR (400 MHz, Chloroform-d) .delta. 8.35-8.27 (m, 1H), 8.06 (dd,
J=8.9, 1.6 Hz, 1H), 7.85 (d, J=1.0 Hz, 1H), 7.59-7.44 (m, 4H),
7.44-7.34 (m, 1H), 5.16 (s, 1H), 4.21 (tq, J=7.1, 3.5 Hz, 2H), 4.02
(s, 3H), 3.96-3.57 (m, 7H), 3.51-3.28 (m, 3H), 3.08 (q, J=7.3 Hz,
1H), 3.00-2.67 (m, 4H), 2.60 (s, 3H), 2.42-2.18 (m, 4H), 1.43 (s,
1H), 1.35 (td, J=7.3, 2.9 Hz, 5H), 1.25 (t, J=7.1 Hz, 5H), 0.98 (s,
9H). LCMS-ESI+: calc'd for C.sub.43H.sub.53ClN.sub.5O.sub.5S: 786.3
(M+H).sup.+; found: 786.2 (M+H).sup.+.
[0451] Preparation of
(S)-2-(tert-butoxy)-2-(2-(3-(1-(1-(tert-butoxycarbonyl)azetidin-3-yl)pipe-
ridin-4-yl)-1-methyl-1H-indazol-5-yl)-7-(4-chlorophenyl)-5-methylbenzo[d]t-
hiazol-6-yl)acetic acid: To a flask containing tert-butyl
(S)-3-(4-(5-(6-(1-(tert-butoxy)-2-ethoxy-2-oxoethyl)-7-(4-chlorophenyl)-5-
-methylbenzo[d]thiazol-2-yl)-1-methyl-1H-indazol-3-yl)piperidin-1-yl)azeti-
dine-1-carboxylate (10 mg, 0.013 mmol) was added THF (1 mL), MeOH
(0.2 mL) and 50% Sodium hydroxide (0.2 mL) at rt. The mixture was
stirred at 60.degree. C. for 2 h. The reaction mixture was cooled
by ice bath and acidified with 2 N HCl. The resulting mixture was
extracted with ethyl acetate (2.times.). Combined organic layer was
dried (MgSO.sub.4), filtered and concentrated to give crude mixture
which was purified by Gilson HPLC (Phenomenex Gemini 250.times.21.2
10.mu. C18 column, 40-100% ACN/H.sub.2O+0.1% TFA) to a yellow
powder after lyophilization. .sup.1H NMR (400 MHz, Chloroform-d)
.delta. 8.38 (s, 1H), 8.05 (d, J=9.0 Hz, 1H), 7.87 (s, 1H), 7.72
(d, J=8.1 Hz, 1H), 7.53 (dd, J=10.9, 3.3 Hz, 3H), 7.39 (d, J=8.5
Hz, 1H), 5.32 (s, 1H), 4.30-4.08 (m, 1H), 4.03 (s, 3H), 3.99-3.77
(m, 2H), 3.76-3.53 (m, 2H), 3.09 (d, J=81.1 Hz, 1H), 2.58 (s, 3H),
2.28-1.92 (m, 6H), 1.72-1.53 (m, 2H), 1.45 (s, 9H), 1.01 (s, 9H).
LCMS-ESI+: calc'd for C.sub.41H.sub.49ClN.sub.5O.sub.5S;
758.3(M+H).sup.+; found: 758.1(M+H).sup.+.
Example 32
Preparation of
(S)-2-(2-(3-(1-(azetidin-3-yl)piperidin-4-yl)-1-methyl-1H-indazol-5-yl)-7-
-(4-chlorophenyl)-5-methylbenzo[d]thiazol-6-yl)-2-(tert-butoxy)acetic
acid (29)
##STR00118##
[0453] Preparation of ethyl
(S)-2-(2-(3-(1-(azetidin-3-yl)piperidin-4-yl)-1-methyl-1H-indazol-5-yl)-7-
-(4-chlorophenyl)-5-methylbenzo[d]thiazol-6-yl)-2-(tert-butoxy)acetate:
A solution tert-butyl
(S)-3-(4-(5-(6-(1-(tert-butoxy)-2-ethoxy-2-oxoethyl)-7-(4-chlorophenyl)-5-
-methylbenzo[d]thiazol-2-yl)-1-methyl-1H-indazol-3-yl)piperidin-1-yl)azeti-
dine-1-carboxylate (95 mg, 0.121 mmol) in 1.25 HCl in isopropanol
(5.0 mL) (not well soluble) was stirred overnight at room
temperature. The reaction had only 33% conversion. Additional MeOH
(2 mL), 1.25M HCl/iPrOH (5 mL) and CH.sub.2Cl.sub.2 (5 mL) were
added so the reaction solution became clear. The reaction was
stirred for another 18h. Reaction mixture was quenched with
saturated sodium bicarbonate solution carefully and extracted with
ethyl acetate (2.times.). Combined organic layer was dried
(MgSO.sub.4), filtered and concentrated to give crude desired
product that was used in the next step without further
purification. LCMS-ESI+: calc'd for
C.sub.38H.sub.45ClN.sub.5O.sub.3S; 686.3 (M+H).sup.+; found: 686.2
(M+H).sup.+.
[0454] Preparation of
(S)-2-(2-(3-(1-(azetidin-3-yl)piperidin-4-yl)-1-methyl-1H-indazol-5-yl)-7-
-(4-chlorophenyl)-5-methylbenzo[d]thiazol-6-yl)-2-(tert-butoxy)acetic
acid: To a flask containing of ethyl
(S)-2-(2-(3-(1-(azetidin-3-yl)piperidin-4-yl)-1-methyl-1H-indazol-5-yl)-7-
-(4-chlorophenyl)-5-methylbenzo[d]thiazol-6-yl)-2-(tert-butoxy)acetate
(15 mg, 0.022 mmol) was added THF (1 mL), MeOH (0.2 mL) and 50%
Sodium hydroxide (0.2 mL) at rt. The mixture was stirred at
60.degree. C. for 2 h. The reaction mixture was cooled by ice and
acidified with 2 N HCl. The resulting mixture was extracted with
ethyl acetate (2.times.). Combined organic layer was dried
(MgSO.sub.4), filtered and concentrated to give crude mixture which
was purified by Gilson HPLC (Phenomenex Gemini 250.times.21.2
10.mu. C18 column, 40-100% ACN/H.sub.2O+0.1% TFA) to give a yellow
powder after lyophilization. .sup.1H NMR (400 MHz, Chloroform-d)
.delta. 8.27 (s, 1H), 7.92 (dd, J=9.0, 1.5 Hz, 1H), 7.75 (s, 1H),
7.59 (dd, J=8.5, 2.0 Hz, 1H), 7.44 (td, J=6.0, 2.9 Hz, 3H), 7.36
(d, J=8.9 Hz, 1H), 5.16 (s, 1H), 4.43 (d, J=65.3 Hz, 4H), 3.95 (s,
3H), 3.48-2.89 (m, 7H), 2.54 (d, J=13.0 Hz, 6H), 2.39-2.16 (m, 3H),
0.90 (s, 9H). LCMS-ESI+: calc'd for
C.sub.36H.sub.41ClN.sub.5O.sub.3S; 658.3(M+H).sup.+; found:
658.3(M+H).sup.+.
Example 33
Preparation of
(S)-2-(2-(3-(1-(1-acetylazetidin-3-yl)piperidin-4-yl)-1-methyl-1H-indazol-
-5-yl)-7-(4-chlorophenyl)-5-methylbenzo[d]thiazol-6-yl)-2-(tert-butoxy)ace-
tic acid (30)
##STR00119##
[0456] Preparation of ethyl
(S)-2-(2-(3-(1-(1-acetylazetidin-3-yl)piperidin-4-yl)-1-methyl-1H-indazol-
-5-yl)-7-(4-chlorophenyl)-5-methylbenzo[d]thiazol-6-yl)-2-(tert-butoxy)ace-
tate: To a flask containing ethyl
(S)-2-(2-(3-(1-(azetidin-3-yl)piperidin-4-yl)-1-methyl-1H-indazol-5-yl)-7-
-(4-chlorophenyl)-5-methylbenzo[d]thiazol-6-yl)-2-(tert-butoxy)acetate
(20 mg, 0.029 mmol) in THF (2 mL) were added
N-Ethyldiisopropylamine (101.52 .mu.l, 582.83 .mu.mol) and Acetyl
chloride (20.72 .mu.l, 291.42 .mu.mol). The mixture was stirred at
room temperature overnight. The reaction was complete and carried
to the next step directly. LCMS-ESI+: calc'd for:
C.sub.40H.sub.47ClN.sub.5O.sub.4S; 728.3 (M+H).sup.+; found: 728.3
(M+H).sup.+.
[0457] Preparation of
(S)-2-(2-(3-(1-(1-acetylazetidin-3-yl)piperidin-4-yl)-1-methyl-1H-indazol-
-5-yl)-7-(4-chlorophenyl)-5-methylbenzo[d]thiazol-6-yl)-2-(tert-butoxy)ace-
tic acid: To above reaction mixture containing crude ethyl
(S)-2-(2-(3-(1-(1-acetylazetidin-3-yl)piperidin-4-yl)-1-methyl-1H-indazol-
-5-yl)-7-(4-chlorophenyl)-5-methylbenzo[d]thiazol-6-yl)-2-(tert-butoxy)ace-
tate (0.029 mmol) was added MeOH (0.5 mL) and 50% Sodium hydroxide
(0.5 mL) at rt. The mixture was stirred at 60.degree. C. for 2 h.
The reaction mixture was cooled by ice and acidified with 3 N HCl.
The resulting mixture was extracted with ethyl acetate (2.times.).
Combined organic layer was dried (MgSO.sub.4), filtered and
concentrated to give crude mixture which was purified by Gilson
HPLC (Phenomenex Gemini 250.times.21.2 10.mu. C18 column, 40-100%
ACN/H.sub.2O+0.1% TFA) to give a yellow powder after
lyophilization. .sup.1H NMR (400 MHz, Chloroform-d) .delta. 8.24
(s, 1H), 7.95 (d, J=8.8 Hz, 1H), 7.76 (s, 1H), 7.63-7.55 (m, 1H),
7.50-7.39 (m, 3H), 7.35 (d, J=8.8 Hz, 1H), 5.18 (s, 1H), 4.75-4.06
(m, 4H), 3.96 (s, 3H), 3.86 (d, J=8.1 Hz, 1H), 3.45 (s, 4H),
3.13-2.94 (m, 2H), 2.53 (s, 3H), 2.29 (d, J=23.0 Hz, 4H), 1.82 (s,
3H), 1.19 (d, J=11.8 Hz, 1H), 0.91 (s, 9H). LCMS-ESI+: calc'd for
C.sub.38H.sub.43ClN.sub.5O.sub.4S; 700.3 (M+H).sup.+; found: 700.3
(M+H).sup.+.
Example 34
Preparation of
(S)-2-(tert-butoxy)-2-(7-(4-chlorophenyl)-5-methyl-2-(1-methyl-3-(1-(1-me-
thylazetidin-3-yl)piperidin-4-yl)-1H-indazol-5-yl)benzo[d]thiazol-6-yl)ace-
tic acid (31)
##STR00120##
[0459] Preparation of ethyl
(S)-2-(tert-butoxy)-2-(7-(4-chlorophenyl)-5-methyl-2-(1-methyl-3-(1-(1-me-
thylazetidin-3-yl)piperidin-4-yl)-1H-indazol-5-yl)benzo[d]thiazol-6-yl)ace-
tate: A solution of ethyl
(S)-2-(2-(3-(1-(azetidin-3-yl)piperidin-4-yl)-1-methyl-1H-indazol-5-yl)-7-
-(4-chlorophenyl)-5-methylbenzo[d]thiazol-6-yl)-2-(tert-butoxy)acetate
(44 mg, 0.064 mmol) in acetonitrile (2 mL) was stirred at 0.degree.
C. bath as 37% formaldehyde (0.175 mL, 2.36 mmol), and sodium
cyanoborohydride (88 mg, 1.4 mmol) were added. To the reaction
mixture was added .about.2 drops of acetic acid. After 1 h, the
reaction was completed and carried to the next step directly.
LCMS-ESI+: calc'd for: C.sub.39H.sub.47ClN.sub.5O.sub.3S; 700.3
(M+H).sup.+; found: 700.2 (M+H).sup.+.
[0460] Preparation of
(S)-2-(tert-butoxy)-2-(7-(4-chlorophenyl)-5-methyl-2-(1-methyl-3-(1-(1-me-
thylazetidin-3-yl)piperidin-4-yl)-1H-indazol-5-yl)benzo[d]thiazol-6-yl)ace-
tic acid: To above reaction mixture containing ethyl
(S)-2-(tert-butoxy)-2-(7-(4-chlorophenyl)-5-methyl-2-(1-methyl-3-(1-(1-me-
thylazetidin-3-yl)piperidin-4-yl)-1H-indazol-5-yl)benzo[d]thiazol-6-yl)ace-
tate (0.064 mmol) were added THF (2 mL), MeOH (0.5 mL) and 50%
Sodium hydroxide (0.5 mL) at rt. The mixture was stirred at
60.degree. C. for 2 h. The reaction mixture was cooled by ice bath
and acidified with 3 N HCl. The resulting mixture was extracted
with ethyl acetate (2.times.). Combined organic layer was dried
(MgSO.sub.4), filtered and concentrated to give crude mixture which
was purified by Gilson HPLC (Phenomenex Gemini 250.times.21.2
10.mu. C18 column, 40-100% ACN/H.sub.2O+0.1% TFA) to give a yellow
powder after lyophilization. .sup.1H NMR (400 MHz, Chloroform-d)
.delta. 8.33-8.19 (m, 1H), 7.95 (dd, J=8.8, 1.6 Hz, 1H), 7.78 (s,
1H), 7.61 (dd, J=8.6, 2.1 Hz, 1H), 7.46 (td, J=5.9, 2.9 Hz, 3H),
7.37 (d, J=8.9 Hz, 1H), 5.19 (s, 1H), 4.48 (dt, J=18.0, 9.1 Hz,
4H), 4.28-4.10 (m, 1H), 3.97 (s, 3H), 3.36-3.07 (m, 4H), 2.92 (s+m,
4H), 2.54 (s, 3H), 2.26 (ddd, J=19.8, 9.9, 4.8 Hz, 4H), 0.92 (s,
9H). LCMS-ESI+: calc'd for C.sub.37H.sub.43ClN.sub.5O.sub.3S; 672.3
(M+H).sup.+; found: 772.3 (M+H).sup.+.
Example 35
(S)-2-(tert-butoxy)-2-(7-(4-chlorophenyl)-2-(1-(2-(dimethylamino)ethyl)-3--
(1-(oxetan-3-yl)piperidin-4-yl)-1H-pyrrolo[2,3-b]pyridin-5-yl)-5-methylben-
zo[d]thiazol-6-yl)acetic acid (32)
##STR00121## ##STR00122##
[0462] Preparation of
2-(3-bromo-5-chloro-1H-indazol-1-yl)-N,N-dimethylethan-1-amine
(isomer a): To a solution of 3-bromo-5-chloro-1H-indazole (1 g,
4.32 mmol) in anhydrous DMF (10 mL) at room temperature was added
cesium carbonate (3.66 g, 11.23 mmol), followed by
2-dimethylamino-ethyl chloride hydrochloride (0.81 g, 5.62 mmol).
The reaction was heated to 100.degree. C. for 18h. It was diluted
with water (10 mL) and 3% LiCl (50 mL), then extracted with EtOAc.
The organic layer was washed with brine, dried over sodium sulfate,
and concentrated. The crude mixture was purified by CombiFlash (40
g, Gold, 0-20% MeOH/CH.sub.2Cl.sub.2) to give an oily material
(isomer ratio=6:1 by NMR). 1H NMR (400 MHz, Chloroform-d) .delta.
7.58 (dd, J=1.6, 0.9 Hz, 1H), 7.36 (dd, J=2.1, 1.3 Hz, 2H), 4.42
(t, J=6.9 Hz, 2H), 2.81 (t, J=6.9 Hz, 2H), 2.29 (s, 6H).
LCMS-ESI.sup.+: calc'd for C.sub.11H.sub.14BrClN.sub.3: 302.0
(M+H)+; found: 303.9 (M+H).sup.+.
[0463] Preparation of tert-butyl
4-(5-chloro-1-(2-(dimethylamino)ethyl)-1H-indazol-3-yl)-3,6-dihydropyridi-
ne-1(2H)-carboxylate: A 20 mL microwave vial was charged with
2-(3-bromo-5-chloro-1H-indazol-1-yl)-N,N-dimethylethan-1-amine (0.5
g,1.65 mmol), tert-butyl
4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-5,6-dihydropyridine-1(2H)-
-carboxylate (766.4 mg, 2.45 mmol), Palladium (0)
tetrakis(triphenylphosphine) (190.94 mg, 0.17 mmol), and Potassium
carbonate (685.09 mg, 4.96 mmol) in water (2 mL) and dioxane (8
mL). It was flushed with nitrogen for 5 minutes, then microwaved at
100.degree. C. for 60 min. Reaction mixture was filtered through a
pad of Celite, concentrated and purified by CombiFlash (40 g, 0-20%
MeOH/CH.sub.2Cl.sub.2) to give desire product. The above reaction
was repeated 3 times to generate enough material for the next step.
LCMS-ESI.sup.+: calc'd for C.sub.21H.sub.30ClN.sub.4O.sub.2: 405.2
(M+H).sup.+; found: 405.2 (M+H).sup.+.
[0464] Preparation of tert-butyl
4-(1-(2-(dimethylamino)ethyl)-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-
-yl)-1H-indazol-3-yl)-3,6-dihydropyridine-1(2H)-carboxylate and
tert-butyl
4-(2-(2-(dimethylamino)ethyl)-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-
-yl)-2H-indazol-3-yl)-3,6-dihydropyridine-1(2H)-carboxylate: To a
flask charged with tert-butyl
4-(5-chloro-1-(2-(dimethylamino)ethyl)-1H-indazol-3-yl)-3,6-dihydropyridi-
ne-1(2H)-carboxylate (1.76 g, 4.35 mmol) were added [Bis
(Pinacolato) Diboron (3.22 g, 13.4 mmol), potassium acetate (1.28
g, 13.04 mmol), Palladium acetate trimer (48.79 mg, 0.22 mmol) and
2-(Dicyclohexylphosphino)-2',4',6'-triisopropylbiphenyl (207.2 mg,
0.43 mmol). 1,4-Dioxane (20 mL) was added and the mixture was
flushed with nitrogen for 10 min. The reaction mixture was heated
to 100.degree. C. for 4 h under a nitrogen atmosphere. It was
cooled to room temperature, filtered through a pad of Celite and
concentrated. The residue was purified by CombiFlash (80 g Gold,
0-20% MeOH/CH.sub.2Cl.sub.2 (twice). It was still black colored and
treated with Activated Carbon to remove the black palladium
residues.
[0465] tert-Butyl
4-(1-(2-(dimethylamino)ethyl)-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-
-yl)-1H-indazol-3-yl)-3,6-dihydropyridine-1(2H)-carboxylate:
.sup.1H NMR (400 MHz, Chloroform-d) .delta. 8.44-8.27 (m, 1H), 7.80
(dd, J=8.5, 0.9 Hz, 1H), 7.40 (d, J=8.4 Hz, 1H), 6.50 (s, 1H),
4.59-4.37 (m, 2H), 4.20 (d, J=4.0 Hz, 2H), 3.68 (t, J=5.7 Hz, 2H),
2.94 (t, J=7.3 Hz, 2H), 2.77 (d, J=6.2 Hz, 2H), 2.35 (s, 6H), 1.52
(d, J=8.6 Hz, 9H), 1.36 (d, J=3.9 Hz, 12H). LCMS-ESI+: calc'd for
C.sub.27H.sub.42BN.sub.4O.sub.4: 497.3 (M+H).sup.+; found: 497.3
(M+H).sup.+.
[0466] tert-Butyl
4-(2-(2-(dimethylamino)ethyl)-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-
-yl)-2H-indazol-3-yl)-3,6-dihydropyridine-1(2H)-carboxylate:
.sup.1H NMR (400 MHz, Chloroform-d) .delta. 8.36 (d, J=0.9 Hz, 1H),
7.78 (dd, J=8.5, 0.9 Hz, 1H), 7.37 (dd, J=8.4, 0.9 Hz, 1H), 6.50
(s, 1H), 4.44 (dd, J=8.4, 6.0 Hz, 2H), 4.33-4.07 (m, 2H), 3.68 (t,
J=5.7 Hz, 2H), 2.89-2.63 (m, 4H), 2.30 (s, 6H), 1.50 (s, 9H), 1.37
(s, 12H). LCMS-ESI+: calc'd for C.sub.27H.sub.42BN.sub.4O.sub.4:
497.3 (M+H).sup.+; found: 497.3 (M+H).sup.+.
[0467] Preparation of tert-butyl
(S)-4-(5-(6-(1-(tert-butoxy)-2-ethoxy-2-oxoethyl)-7-(4-chlorophenyl)-5-me-
thylbenzo[d]thiazol-2-yl)-1-(2-(dimethylamino)ethyl)-1H-indazol-3-yl)-3,6--
dihydropyridine-1(2H)-carboxylate: A 100 mL round bottom flask was
charged with ethyl
(S)-2-(2-bromo-7-(4-chlorophenyl)-5-methylbenzo[d]thiazol-6-yl)-2-(tert-b-
utoxy)acetate (0.65 g, 1.31 mmol), tert-butyl
4-(1-(2-(dimethylamino)ethyl)-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-
-yl)-1H-indazol-3-yl)-3,6-dihydropyridine-1(2H)-carboxylate (0.8 g,
1.61 mmol), Pd(PPh.sub.3).sub.4 (200 mg, 0.17 mmol) and potassium
phosphate (0.545 g, 2 mmol). Then 1,4-dioxane (15 mL) and water
(3ML) were added and the flask was flushed with nitrogen for 10
minutes. The flask was placed into a pre-heated heating block to
100.degree. C. and stirred for 3 hours. Cooled to rt, it was
diluted with EtOAc, washed with brine. The organic phase was dried
over Na.sub.2SO.sub.4 and concentrated. The crude residue was
purification by CombiFlash (80 g Gold, 0-10% MeOH/CH.sub.2Cl.sub.2)
gave the desire product. .sup.1H NMR (400 MHz, Chloroform-d)
.delta. 8.48 (s, 1H), 8.08 (d, J=8.8 Hz, 1H), 7.86 (s, 1H),
7.61-7.45 (m, 4H), 6.49 (s, 1H), 5.16 (d, J=2.4 Hz, 1H), 4.53 (s,
2H), 4.21 (dq, J=7.2, 3.6 Hz, 4H), 3.70 (d, J=7.7 Hz, 2H), 2.78 (s,
1H), 2.65-2.52 (m, 2H), 2.37 (s, 6H), 1.91 (s, 1H), 1.53 (d, J=7.2
Hz, 3H), 1.24 (s, 9H), 0.98 (d, J=1.4 Hz, 9H). LCMS-ESI.sup.+:
calc'd for C.sub.43H.sub.53ClN.sub.5O.sub.5S: 786.3 (M+H).sup.+;
found: 786.3 (M+H).sup.+.
[0468] Preparation of tert-butyl
(S)-4-(5-(6-(1-(tert-butoxy)-2-ethoxy-2-oxoethyl)-7-(4-chlorophenyl)-5-me-
thylbenzo[d]thiazol-2-yl)-1-(2-(dimethylamino)ethyl)-1H-indazol-3-yl)piper-
idine-1-carboxylate: A flask containing a mixture of tert-butyl
(S)-4-(5-(6-(1-(tert-butoxy)-2-ethoxy-2-oxoethyl)-7-(4-chlorophenyl)-5-me-
thylbenzo[d]thiazol-2-yl)-1-(2-(dimethylamino)ethyl)-1H-indazol-3-yl)-3,6--
dihydropyridine-1(2H)-carboxylate (1000 mg, 1.272 mmol), rhodium on
alumina, 5 wt % (400 mg, 0.194 mmol) in ethanol (200 mL) was
evacuated and back-filled with hydrogen (3.times.). Reaction
mixture was stirred overnight under hydrogen atmosphere vigorously;
.sup.1H NMR showed that the product was about 50% formed. It was
filtered through a pad of Celite and added 500 mg of fresh
catalyst. The resulting mixture was stirred under hydrogen
atmosphere vigorously over the weekend. LCMS showed mostly the
desired product with a very small amount of de-chlorinated product
peak. The mixture was filtered through a pad of Celite and
concentrated. The residue was purified by CombiFlash (120 g, Gold,
0-22% MeOH/CH.sub.2Cl.sub.2) gave the desire product. LCMS-ESI+:
calc'd for C.sub.43H.sub.55ClN.sub.5O.sub.5S: 788.3 (M+H).sup.+;
found: 788.1 (M+H).sup.+.
[0469] Preparation of ethyl
(S)-2-(tert-butoxy)-2-(7-(4-chlorophenyl)-2-(1-(2-(dimethylamino)ethyl)-3-
-(piperidin-4-yl)-1H-indazol-5-yl)-5-methylbenzo[d]thiazol-6-yl)acetate:
A solution of tert-butyl
(S)-4-(5-(6-(1-(tert-butoxy)-2-ethoxy-2-oxoethyl)-7-(4-chlorophenyl)-5-me-
thylbenzo[d]thiazol-2-yl)-1-(2-(dimethylamino)ethyl)-1H-indazol-3-yl)piper-
idine-1-carboxylate (800 mg, 1.015 mmol) in 1.25 HCl in isopropanol
(20 mL) was stirred overnight at room temperature. Reaction mixture
was quenched with saturated sodium bicarbonate solution and
extracted with ethyl acetate (2.times.). Combined organic layer was
dried over sodium sulfate, filtered and concentrated to give the
desire product that was used in the next step without further
purification. LCMS-ESI+: calc'd for
C.sub.38H.sub.47ClN.sub.5O.sub.3S: 688.3 (M+H).sup.+; found: 688.1
(M+H).sup.+.
[0470] Preparation of ethyl
(S)-2-(tert-butoxy)-2-(7-(4-chlorophenyl)-2-(1-(2-(dimethylamino)ethyl)-3-
-(1-(oxetan-3-yl)piperidin-4-yl)-1H-indazol-5-yl)-5-methylbenzo[d]thiazol--
6-yl)acetate: A solution of ethyl
(S)-2-(tert-butoxy)-2-(7-(4-chlorophenyl)-2-(1-(2-(dimethylamino)ethyl)-3-
-(piperidin-4-yl)-1H-indazol-5-yl)-5-methylbenzo[d]thiazol-6-yl)acetate
(250 mg, 0.363 mmol), 3-Oxetanone (350 .mu.l, 5.46 mmol), acetic
acid (100 .mu.L, 1.75 mmol) and sodium cyanoborohydride (456.5 mg,
7.26 mmol) in methanol (5 mL) was stirred for 5 hours at room
temperature. LCMS showed complete conversion. Reaction was quenched
with saturated sodium bicarbonate solution and brine and stirred
for 1.5 hours. The mixture was extracted with ethyl acetate
(2.times.) and combined organic layer was dried (MgSO.sub.4),
filtered and concentrated. The residue was purified by CombiFlash
(40 g, Gold, 0-10% MeOH/CH.sub.2Cl.sub.2) to give the desire
product. LCMS-ESI+: calc'd for C.sub.4H.sub.51ClN.sub.5O.sub.4S:
744.3 (M+H).sup.+; found: 744.4 (M+H).sup.+.
[0471] Preparation of
(S)-2-(tert-butoxy)-2-(7-(4-chlorophenyl)-2-(1-(2-(dimethylamino)ethyl)-3-
-(1-(oxetan-3-yl)piperidin-4-yl)-1H-indazol-5-yl)-5-methylbenzo[d]thiazol--
6-yl)acetic acid: To ethyl
(S)-2-(tert-butoxy)-2-(7-(4-chlorophenyl)-2-(1-(2-(dimethylamino)ethyl)-3-
-(1-(oxetan-3-yl)piperidin-4-yl)-1H-indazol-5-yl)-5-methylbenzo[d]thiazol--
6-yl)acetate (200 mg, 0.269 mmol) was added THF (2 mL), MeOH (0.5
mL) and 50% Sodium hydroxide (0.5 mL) at room temperature. The
mixture was stirred at 60.degree. C. for 2 h. The reaction mixture
was cooled by ice and acidified with 3 N HCl. The resulting mixture
was extracted with ethyl acetate (2.times.). Combined organic layer
was dried (MgSO.sub.4), filtered and concentrated to give crude
mixture which was purified by Gilson HPLC (Phenomenex Gemini
250.times.21.2 10.mu. C18 column, 40-100% ACN/H.sub.2O+0.1% TFA) to
give a yellow powder after lyophilization. .sup.1H NMR (400 MHz,
Chloroform-d) .delta. 8.30 (s, 1H), 8.01 (d, J=8.8 Hz, 1H), 7.81
(s, 1H), 7.68 (d, J=8.2 Hz, 1H), 7.53 (q, J=9.0 Hz, 4H), 5.28 (s,
1H), 5.10 (t, J=7.0 Hz, 2H), 4.78 (dt, J=13.1, 6.9 Hz, 4H), 4.28
(s, 1H), 3.80-3.18 (m, 5H), 2.83 (s, 6H), 2.57 (s, 3H), 2.34 (m,
4H), 0.98 (s, 9H). LCMS-ESI+: calc'd for
C.sub.39H.sub.47ClN.sub.5O.sub.4S; 716.3 (M+H).sup.+; found: 716.2
(M+H).sup.+.
Example 36
Preparation of
(S)-2-(2-(3-(1-(1-acetylazetidin-3-yl)piperidin-4-yl)-1-(2-(dimethylamino-
)ethyl)-1H-pyrrolo[2,3-1]pyridin-5-yl)-7-(4-chlorophenyl)-5-methylbenzo[d]-
thiazol-6-yl)-2-(tert-butoxy)acetic acid (33)
##STR00123## ##STR00124##
[0473] Preparation of tert-butyl
(S)-3-(4-(5-(6-(1-(tert-butoxy)-2-ethoxy-2-oxoethyl)-7-(4-chlorophenyl)-5-
-methylbenzo[d]thiazol-2-yl)-1-(2-(dimethylamino)ethyl)-1H-indazol-3-yl)pi-
peridin-1-yl)azetidine-1-carboxylate: A solution of ethyl
(S)-2-(tert-butoxy)-2-(7-(4-chlorophenyl)-2-(1-(2-(dimethylamino)ethyl)-3-
-(piperidin-4-yl)-1H-indazol-5-yl)-5-methylbenzo[d]thiazol-6-yl)acetate
(250 mg, 363.2 .mu.mol), 1-Boc-3-azetidinone (186.53 mg, 1.01
mmol), acetic acid (0.1 mL, 1.75 mmol)) and sodium cyanoborohydride
(228 mg, 3.63 mmol) in methanol (5 mL) was stirred for 24 hours at
room temperature. Reaction was quenched with saturated sodium
bicarbonate solution and brine. The mixture was extracted with
ethyl acetate (2.times.) and combined organic layer was dried
(MgSO.sub.4), filtered and concentrated. The residue was purified
by CombiFlash (40 g, Gold, 0-10% MeOH/CH.sub.2Cl.sub.2) to give
impure product. LCMS-ESI+: calc'd for
C.sub.46H.sub.60ClN.sub.6O.sub.5S: 843.4 (M+H).sup.+; found: 843.1
(M+H).sup.+.
[0474] Preparation of
(S)-2-(2-(3-(1-(azetidin-3-yl)piperidin-4-yl)-1-(2-(dimethylamino)ethyl)--
1H-indazol-5-yl)-7-(4-chlorophenyl)-5-methylbenzo[d]thiazol-6-yl)-2-(tert--
butoxy)acetic acid: A solution of tert-butyl
(S)-3-(4-(5-(6-(1-(tert-butoxy)-2-ethoxy-2-oxoethyl)-7-(4-chlorophenyl)-5-
-methylbenzo[d]thiazol-2-yl)-1-(2-(dimethylamino)ethyl)-1H-indazol-3-yl)pi-
peridin-1-yl)azetidine-1-carboxylate (600 mg, from previous step)
in 1.25 HCl in isopropanol (10 mL) (not well soluble) was stirred
overnight at room temperature. Reaction mixture was quenched with
saturated sodium bicarbonate solution carefully and extracted with
ethyl acetate (2.times.). Combined organic layer was dried
(MgSO.sub.4), filtered and concentrated to give 264 mg of crude
product as borate-chelate as shown by LCMS. This material was added
THF (5 mL), MeOH (10 mL), ethylene glycol (5 ml) and 50% Sodium
hydroxide (4 mL). The mixture was stirred at 60.degree. C. for 3 h,
then room temperature overnight to break the borate complex.
Reaction mixture was concentrated down, and then
DMF/MeOH/CH.sub.3CN were added, producing a gel-like solid. After
filtration and concentration, the residue was purified by Gilson
HPLC (Phenomenex Gemini 250.times.21.2 10 u C18 column, 40-100%
ACN/H.sub.2O+0.1% TFA) to give a yellow powder after
lyophilization. LCMS-ESI+: calc'd for
C.sub.39H.sub.48ClN.sub.6O.sub.3S; 715.3 (M+H).sup.+; found: 715.2
(M+H).sup.+.
[0475] Preparation of
(S)-2-(2-(3-(1-(1-acetylazetidin-3-yl)piperidin-4-yl)-1-(2-(dimethylamino-
)ethyl)-1H-indazol-5-yl)-7-(4-chlorophenyl)-5-methylbenzo[d]thiazol-6-yl)--
2-(tert-butoxy)acetic acid: To a flask containing
(S)-2-(2-(3-(1-(azetidin-3-yl)piperidin-4-yl)-1-(2-(dimethylamino)ethyl)--
1H-indazol-5-yl)-7-(4-chlorophenyl)-5-methylbenzo[d]thiazol-6-yl)-2-(tert--
butoxy)acetic acid (22 mg, 0.024 mmol) in THF (2 mL) were added
N-Ethyldiisopropylamine (200 .mu.l, 1.15 mmol) and Acetyl chloride
(35 .mu.l, 0.49 mmol). The mixture was stirred at room temperature
for 1 h. The reaction mixture was cooled to 0.degree. C., acidified
with 3N HCl, and concentrated to remove the organic solvent. The
residue was purified by Gilson HPLC (Phenomenex Gemini
250.times.21.2 10 u C18 column, 40-100% ACN/H.sub.2O+0.1% TFA) to
give a yellow powder after lyophilization. LCMS-ESI+: calc'd for
C.sub.4H.sub.50ClN.sub.6O.sub.4S; 757.3 (M+H).sup.+; found: 757.3
(M+H).sup.+.
Example 37
(S)-2-(tert-butoxy)-2-(7-(4-chlorophenyl)-5-methyl-2-(3-(1-(oxetan-3-yl)pi-
peridin-4-yl)-1H-indazol-5-yl)benzo[d]thiazol-6-yl)acetic acid
(34)
##STR00125## ##STR00126##
[0477] Preparation of
3-bromo-5-chloro-1-(tetrahydro-2H-pyran-2-yl)-1H-indazole: To a
solution of 3-bromo-5-chloro-1H-indazole (3 g, 12.96 mmol)
dissolved in EtOAc (25 mL) were added a catalytic amount of
p-Toluenesulfonic acid (0.22 g, 1.3 mmol) and 3,4-Dihydro-2H-pyran
(2.36 ml, 25.92 mmol). The reaction mixture was heated to reflux
(100.degree. C.) for 2 h. LC-MS indicates the reaction was done. It
was cooled to RT, quenched with sat'd NaHCO.sub.3 (50 mL), then
extracted with EtOAc. The organic extracts were washed with brine,
dried over sodium sulfate, concentrated. The crude mixture was
purified by CombiFlash (120 g, Gold, 0-5% MeOH/CH.sub.2Cl.sub.2) to
give a white solid (isomer ratio=1:1 by NMR). .sup.1H NMR (400 MHz,
Chloroform-d) .delta. 7.59 (dd, J=2.0, 0.7 Hz, 1H), 7.52 (dd,
J=8.9, 0.7 Hz, 1H), 7.38 (dd, J=8.9, 1.9 Hz, 1H), 5.65 (dd, J=9.0,
2.8 Hz, 1H), 3.99 (dtd, J=11.5, 3.7, 1.5 Hz, 1H), 3.80-3.61 (m,
1H), 2.50 (dddd, J=13.4, 11.0, 8.9, 4.1 Hz, 1H), 2.26-1.95 (m, 2H),
1.87-1.59 (m, 3H). LCMS-ESI.sup.+: calc'd for
C.sub.12H.sub.13BrClN.sub.2O: 316.6 (M+H)+; found: 316.7
(M+H).sup.+.
[0478] Preparation of tert-butyl
4-(5-chloro-1-(tetrahydro-2H-pyran-2-yl)-1H-indazol-3-yl)-3,6-dihydropyri-
dine-1(2H)-carboxylate: A solution of
3-bromo-5-chloro-1-(tetrahydro-2H-pyran-2-yl)-1H-indazole (4 g,
12.67 mmol), tert-butyl
4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-3,6-dihydropyridine-1(2H)-
-carboxylate (6 g, 19.4 mmol), Palladium (0)
tetrakis(triphenylphosphine) (2 g, 1.73 mmol), Potassium carbonate
(6 g, 43.4 mmol) in water (10 mL) and 1,4-dioxane (40 mL) in a 500
mL RBF was flushed with argon for 10 minutes, then sealed, and
heated to 100.degree. C. for 3 h. Reaction mixture was cooled to
room temperature, filtered through a pad of Celite, concentrated
and purified by CombiFlash (220 g, using 0-30% EtOAc/Hexane) to
give desired product as isomer mixture. LCMS-ESI.sup.+: calc'd for
C.sub.22H.sub.29ClN.sub.3O.sub.3: 417.2 (M+H).sup.+; found: 417.9
(M+H).sup.+.
[0479] Preparation of tert-butyl
4-(1-(tetrahydro-2H-pyran-2-yl)-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-
-2-yl)-1H-indazol-3-yl)-3,6-dihydropyridine-1(2H)-carboxylate: To a
flask with tert-butyl
4-(5-chloro-1-(tetrahydro-2H-pyran-2-yl)-1H-indazol-3-yl)-3,6-dihydropyri-
dine-1(2H)-carboxylate (4.0 g, 9.57 mmol) in1,4-Dioxane (60 ml)
were added Bis (Pinacolato) Diboron (5.4 g, 21.26 mmol), potassium
acetate (2.8 g, 28.7 mmol), Palladium acetate trimer (215 mg, 0.96
mmol) and 2-(Dicyclohexylphosphino)-2',4',6'-triisopropylbiphenyl
(913 mg, 1.91 mmol). The mixture was flushed with nitrogen for 10
min, and heated to 100.degree. C. for 3 h under a nitrogen
atmosphere. It was cooled to room temperature, filtered through a
pad of Celite and concentrated. The residue was purified by
CombiFlash (80 g Gold, 0 to 50% EtOAc/Hex) to give desired product
as isomer mixture. LCMS-ESI.sup.+: calc'd for
C.sub.28H.sub.41BN.sub.3O.sub.5: 510.5 (M+H).sup.+; found: 510.1
(M+H).sup.+.
[0480] Preparation of tert-butyl
4-(5-(6-((S)-1-(tert-butoxy)-2-ethoxy-2-oxoethyl)-7-(4-chlorophenyl)-5-me-
thylbenzo[d]thiazol-2-yl)-1-(tetrahydro-2H-pyran-2-yl)-1H-indazol-3-yl)-3,-
6-dihydropyridine-1(2H)-carboxylate: A flask was charged with ethyl
(S)-2-(2-bromo-7-(4-chlorophenyl)-5-methylbenzo[d]thiazol-6-yl)-2-(tert-b-
utoxy)acetate (2.6 g, 5.23 mmol), tert-butyl
4-(1-(tetrahydro-2H-pyran-2-yl)-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-
-2-yl)-1H-indazol-3-yl)-3,6-dihydropyridine-1(2H)-carboxylate (3.2
g, 6.28 mmol), Pd(PPh.sub.3).sub.4 (605 mg, 0.523 mmol) and
potassium phosphate (2.17 g, 15.7 mmol). Then 1,4-dioxane (50 mL)
and water (10 mL) were added. The mixture was flushed with nitrogen
for 10 minutes. It was heated to 100.degree. C. for 4 hours. Cooled
to rt, it was diluted with EtOAc, washed with brine. The organic
phase was dried over Na.sub.2SO.sub.4 and concentrated. The crude
residue was purification by CombiFlash (80 g Gold, 0-10%
MeOH/CH.sub.2Cl.sub.2) gave the desire product as regioisomeric
mixture. .sup.1H NMR (400 MHz, Chloroform-d) .delta. 8.52 (s, 1H),
8.07 (d, J=8.8 Hz, 1H), 7.88 (s, 1H), 7.61 (d, J=8.8 Hz, 1H),
7.59-7.46 (m, 4H), 6.52 (s, 1H), 5.71 (dd, J=9.2, 2.8 Hz, 1H), 5.16
(s, 1H), 4.21 (dd, J=7.1, 2.9 Hz, 3H), 4.03 (d, J=11.3 Hz, 1H),
3.81-3.58 (m, 3H), 2.81 (d, J=17.3 Hz, 2H), 2.60 (d, J=0.8 Hz, 3H),
2.57-2.41 (m, 1H), 2.24-2.05 (m, 1H), 1.85-1.60 (m, 3H), 1.52 (s,
9H), 1.26 (td, J=7.1, 2.0 Hz, 4H), 0.98 (s, 9H). LCMS-ESI.sup.+:
calc'd for C.sub.44H.sub.52ClN.sub.406S: 799.4 (M+H).sup.+; found:
799.1 (M+H).sup.+.
[0481] Preparation of tert-butyl
4-(5-(6-((S)-1-(tert-butoxy)-2-ethoxy-2-oxoethyl)-7-(4-chlorophenyl)-5-me-
thylbenzo[d]thiazol-2-yl)-1-(tetrahydro-2H-pyran-2-yl)-1H-indazol-3-yl)pip-
eridine-1-carboxylate: A flask containing a mixture of tert-butyl
4-(5-(6-((S)-1-(tert-butoxy)-2-ethoxy-2-oxoethyl)-7-(4-chlorophenyl)-5-me-
thylbenzo[d]thiazol-2-yl)-1-(tetrahydro-2H-pyran-2-yl)-1H-indazol-3-yl)-3,-
6-dihydropyridine-1(2H)-carboxylate (2.27 g, 2.84 mmol), rhodium on
alumina (5 wt %, 2 g, 0.972 mmol) in ethanol (200 mL) was evacuated
and back-filled with hydrogen (3.times.). Reaction mixture was
stirred under hydrogen atmosphere vigorously for 3 days. LCMS
showed mostly the desired product with a very small amount of
de-chlorinated by-product peak. The mixture was filtered through a
pad of Celite and concentrated. The residue was purified by
CombiFlash (120 g, Gold, 0-22% MeOH/CH.sub.2Cl.sub.2) to give the
desire product. 1H NMR (400 MHz, Chloroform-d) .delta. 8.42 (s,
1H), 8.07 (d, J=8.6 Hz, 1H), 7.92 (s, 1H), 7.62-7.42 (m, 5H), 5.66
(dd, J=9.5, 2.7 Hz, 1H), 5.16 (s, 1H), 4.21 (dd, J=7.1, 2.5 Hz,
2H), 4.05 (d, J=11.6 Hz, 1H), 3.76 (d, J=9.9 Hz, 1H), 3.26 (d,
J=11.0 Hz, 1H), 2.96 (s, 2H), 2.60 (s, 3H), 2.51 (m, 1H), 2.15 (s,
1H), 2.08-1.86 (m, 4H), 1.70 (d, J=43.6 Hz, 2H), 1.49 (s, 9H), 1.25
(td, J=7.1, 2.5 Hz, 4H), 0.98 (s, 9H). LCMS-ESI+: calc'd for
C.sub.44H.sub.54ClN.sub.4O.sub.6S: 801.4 (M+H).sup.+; found: 801.2
(M+H).sup.+.
[0482] Preparation of ethyl
(S)-2-(tert-butoxy)-2-(7-(4-chlorophenyl)-5-methyl-2-(3-(piperidin-4-yl)--
1H-indazol-5-yl)benzo[d]thiazol-6-yl)acetate: A solution of
tert-butyl
4-(5-(6-((S)-1-(tert-butoxy)-2-ethoxy-2-oxoethyl)-7-(4-chlorophenyl)-5-me-
thylbenzo[d]thiazol-2-yl)-1-(tetrahydro-2H-pyran-2-yl)-1H-indazol-3-yl)pip-
eridine-1-carboxylate (2.15 g, 2.68 mmol) in 1.25 HCl in
isopropanol (150 mL) was stirred at room temperature for 48 h.
Reaction was quenched carefully with 1N Sodium hydroxide at
0.degree. C. to pH>8. It was extracted with ethyl acetate
(2.times.). Combined organic layer was dried over sodium sulfate,
filtered and concentrated to give the desired product as a solid.
It was used in the next step without further purification. An
analytical sample was prepared by HPLC purification to give the
bis-TFA salt. .sup.1H NMR (400 MHz, Chloroform-d) .delta. 10.28 (s,
1H), 9.02 (s, 1H), 8.34 (s, 1H), 7.91 (d, J=8.7 Hz, 1H), 7.76 (s,
1H), 7.53-7.32 (m, 5H), 5.09 (s, 1H), 4.14 (qt, J=6.9, 3.6 Hz, 2H),
3.57 (m, 2H), 3.48 (m, 1H), 3.20 (m, 2H), 2.52 (s, 3H), 2.27 (m,
4H), 1.18 (t, J=7.1 Hz, 3H), 0.90 (s, 9H). LCMS-ESI+: calc'd for
C.sub.34H.sub.38ClN.sub.4O.sub.3S: 617.2 (M+H).sup.+; found: 617.4
(M+H).sup.+.
[0483] Preparation of ethyl
(S)-2-(tert-butoxy)-2-(7-(4-chlorophenyl)-5-methyl-2-(3-(1-(oxetan-3-yl)p-
iperidin-4-yl)-1H-indazol-5-yl)benzo[d]thiazol-6-yl)acetate: A
solution of ethyl
(S)-2-(tert-butoxy)-2-(7-(4-chlorophenyl)-5-methyl-2-(3-(piperidin--
4-yl)-1H-indazol-5-yl)benzo[d]thiazol-6-yl)acetate (1 g, 1.62
mmol), 3-Oxetanone (1.04 ml, 16.2 mmol), acetic acid (600 .mu.L)
and sodium cyanoborohydride (2.04 g, 32.4 mmol) in methanol (14 mL)
was stirred for 24 hours at room temperature. LCMS showed complete
conversion. Reaction was quenched with saturated sodium bicarbonate
solution and brine and stirred for 1.5 hours. The mixture was
extracted with ethyl acetate (2.times.) and combined organic layer
was dried (MgSO.sub.4), filtered and concentrated. The residue was
purified by crude mixture which was purified by Gilson HPLC
(Phenomenex Gemini 250.times.21.2 10.mu. C18 column, 40-100%
ACN/H.sub.2O+0.1% TFA) to give the desired product. .sup.1H NMR
(400 MHz, Chloroform-d) .delta. 8.38 (s, 1H), 8.04 (d, J=11.0 Hz,
1H), 7.84 (d, J=8.0 Hz, 1H), 7.60-7.37 (m, 5H), 5.15 (d, J=3.7 Hz,
1H), 4.69 (d, J=4.7 Hz, 3H), 4.20 (d, J=6.6 Hz, 2H), 3.70-2.70 (d,
J=86.9 Hz, 3H), 2.59 (d, J=4.6 Hz, 3H), 2.09 (s, 6H), 1.24 (q,
J=6.8 Hz, 3H), 0.97 (d, J=4.1 Hz, 9H). LCMS-ESI+: calc'd for
C.sub.37H.sub.42ClN.sub.4O.sub.4S: 673.3(M+H).sup.+; found: 673.3
(M+H).sup.+.
[0484] Preparation of
(S)-2-(tert-butoxy)-2-(7-(4-chlorophenyl)-5-methyl-2-(3-(1-(oxetan-3-yl)p-
iperidin-4-yl)-1H-indazol-5-yl)benzo[d]thiazol-6-yl)acetic acid: To
ethyl
(S)-2-(tert-butoxy)-2-(7-(4-chlorophenyl)-5-methyl-2-(3-(1-(oxetan-3-yl)p-
iperidin-4-yl)-1H-indazol-5-yl)benzo[d]thiazol-6-yl)acetate (50 mg,
0.074 mmol) was added DMF (2 mL), MeOH (0.5 mL) and 50% Sodium
hydroxide (0.5 mL) at room temperature. The mixture was stirred at
60.degree. C. for 2 h. The reaction mixture was cooled by ice and
acidified with 3 N HCl. The resulting mixture was extracted with
ethyl acetate (2.times.). Combined organic layer was dried
(MgSO.sub.4), filtered and concentrated to give crude mixture which
was purified by Gilson HPLC (Phenomenex Gemini 250.times.21.2
10.mu. C18 column, 40-100% ACN/H.sub.2O+0.1% TFA) to give a yellow
powder after lyophilization. .sup.1H NMR (400 MHz, Chloroform-d) 6
8.37 (d, J=1.5 Hz, 1H), 8.19 (s, 2H), 8.01 (dd, J=8.8, 1.6 Hz, 1H),
7.89-7.79 (m, 1H), 7.72 (d, J=8.2 Hz, 1H), 7.60-7.45 (m, 4H), 5.32
(s, 1H), 5.05 (t, J=6.8 Hz, 2H), 4.79 (t, J=7.2 Hz, 2H), 4.03 (t,
J=6.7 Hz, 1H), 3.36 (m, 3H), 2.96-2.85 (m, 1H), 2.58 (s, 3H), 2.50
(d, J=29.6 Hz, 2H), 2.33 (s, 1H), 1.25 (d, J=3.5 Hz, 1H), 1.01 (s,
9H), 0.87 (d, J=11.2 Hz, 1H). LCMS-ESI+: calc'd for
C.sub.35H.sub.38ClN.sub.4O.sub.4S; 645.2(M+H).sup.+; found:
645.3(M+H).sup.+.
Example 38A and 38B
Preparation of
(S)-2-(tert-butoxy)-2-(7-(4-chlorophenyl)-2-(1-ethyl-3-(1-(oxetan-3-yl)pi-
peridin-4-yl)-1H-indazol-5-yl)-5-methylbenzo[d]thiazol-6-yl)acetic
acid (35) and ethyl
(S)-2-(tert-butoxy)-2-(7-(4-chlorophenyl)-2-(2-ethyl-3-(1-(oxetan-3-yl)pi-
peridin-4-yl)-2H-indazol-5-yl)-5-methylbenzo[d]thiazol-6-yl)acetate
(36)
##STR00127## ##STR00128##
[0486] Preparation of
(S)-2-(tert-butoxy)-2-(7-(4-chlorophenyl)-2-(1-ethyl-3-(1-(oxetan-3-yl)pi-
peridin-4-yl)-1H-indazol-5-yl)-5-methylbenzo[d]thiazol-6-yl)acetic
acid and
(S)-2-(tert-butoxy)-2-(7-(4-chlorophenyl)-2-(2-ethyl-3-(1-(oxetan-3-y-
l)piperidin-4-yl)-2H-indazol-5-yl)-5-methylbenzo[d]thiazol-6-yl)acetic
acid: To a solution of ethyl
(S)-2-(tert-butoxy)-2-(7-(4-chlorophenyl)-5-methyl-2-(3-(1-(oxetan-3-yl)p-
iperidin-4-yl)-1H-indazol-5-yl)benzo[d]thiazol-6-yl)acetate (600
mg, 0.891 mmol) in anhydrous DMF (10 mL) was added sodium hydride
(60% disp. in oil. 106.93 mg, 2.67 mmol) and stirred for 20 min at
to 0.degree. C. under argon. Iodoethane (500 .mu.l, 6.2 mmol) was
added. The reaction mixture was kept at 0.degree. C. for 20 min,
then at room temperature for 1 h. Reaction was complete by LCMS
analysis and used in next step directly. LCMS-ESI.sup.+: calc'd for
C.sub.39H.sub.46ClN.sub.4O.sub.4S: 701.3(M+H).sup.+; found:
701.4(M+H).sup.+.
[0487] To above reaction mixture was added MeOH (10 mL) and 50%
Sodium hydroxide (5 mL) at room temperature. The mixture was
stirred at 60.degree. C. for 1 h. The reaction mixture was cooled
by ice and acidified with 3 N HCl. The resulting mixture was
extracted with ethyl acetate (2.times.). Combined organic layer was
dried (MgSO.sub.4), filtered and concentrated to give crude mixture
which was purified by Gilson HPLC (Phenomenex Gemini 250.times.21.2
10.mu. C18 column, 40-100% ACN/H.sub.2O+0.1% TFA)
[0488]
(S)-2-(tert-butoxy)-2-(7-(4-chlorophenyl)-2-(1-ethyl-3-(1-(oxetan-3-
-yl)piperidin-4-yl)-1H-indazol-5-yl)-5-methylbenzo[d]thiazol-6-yl)acetic
acid: .sup.1H NMR (400 MHz, Chloroform-d) .delta. 8.27 (s, 1H),
8.00 (d, J=9.0 Hz, 1H), 7.82 (s, 1H), 7.65 (d, J=8.6 Hz, 1H),
7.53-7.44 (m, 3H), 7.41 (d, J=8.9 Hz, 1H), 5.24 (s, 1H), 5.08 (d,
J=6.7 Hz, 2H), 4.78 (t, J=7.2 Hz, 2H), 4.34 (t, J=7.2 Hz, 2H), 4.27
(s, 1H), 3.61-2.83 (m, 5H), 2.58 (s, Hz, 3H), 2.41 (d, J=38.9 Hz,
4H), 1.47 (t, J=7.2 Hz, 3H), 0.96 (s, 9H). LCMS-ESI+: calc'd for
C.sub.37H.sub.42BN.sub.4O.sub.4 S: 673.3 (M+H).sup.+; found: 673.4
(M+H).sup.+.
[0489]
(S)-2-(tert-butoxy)-2-(7-(4-chlorophenyl)-2-(2-ethyl-3-(1-(oxetan-3-
-yl)piperidin-4-yl)-2H-indazol-5-yl)-5-methylbenzo[d]thiazol-6-yl)acetic
acid: .sup.1H NMR (400 MHz, Chloroform-d) .delta. 8.60 (s, 1H),
7.91 (s, 1H), 7.82 (d, J=9.1 Hz, 1H), 7.71 (d, J=9.1 Hz, 1H), 7.53
(dd, J=10.6, 2.9 Hz, 4H), 5.33 (s, 1H), 5.13 (m, 2H), 4.85 (t,
J=7.2 Hz, 2H), 4.53 (d, J=7.3 Hz, 2H), 4.29 (m, 1H), 3.62 (d, J=9.5
Hz, 3H), 3.01-2.77 (m, 1H), 2.59 (s, 3H), 3.00-2.15 (br, 2H), 2.14
(d, J=13.2 Hz, 2H), 1.60 (t, J=6.9 Hz, 3H), 1.23 (d, J=17.9 Hz,
1H), 1.01 (s, 9H). LCMS-ESI+: calc'd for C.sub.37H.sub.42BN.sub.404
S: 673.3 (M+H).sup.+; found: 673.4 (M+H).sup.+.
Example 39
Preparation of
(S)-2-(tert-butoxy)-2-(7-(4-chlorophenyl)-2-(1-(2-hydroxyethyl)-3-(1-(oxe-
tan-3-yl)piperidin-4-yl)-1H-indazol-5-yl)-5-methylbenzo[d]thiazol-6-yl)ace-
tic acid (37)
##STR00129##
[0491] Preparation of ethyl
(S)-2-(tert-butoxy)-2-(2-(1-(2-((tert-butyldimethylsilyl)oxy)ethyl)-3-(1--
(oxetan-3-yl)piperidin-4-yl)-1H-indazol-5-yl)-7-(4-chlorophenyl)-5-methylb-
enzo[d]thiazol-6-yl)acetate: To a solution of ethyl
(S)-2-(tert-butoxy)-2-(7-(4-chlorophenyl)-5-methyl-2-(3-(1-(oxetan-3-yl)p-
iperidin-4-yl)-1H-indazol-5-yl)benzo[d]thiazol-6-yl)acetate (50 mg,
0.074 mmol) in anhydrous DMF (10 mL) was added sodium hydride (60%
disp. in oil, 10 mg, 0.417 mmol) and stirred for 20 min at to
0.degree. C. under argon. (2-Bromoethoxy)-tert-butyldimethylsilane
(50 .mu., 233.04 .mu.mol) was added. The reaction mixture was kept
at 0.degree. C. for 20 min, then at room temperature for 16 h.
Reaction was complete by LCMS analysis and used in the next step
directly. LCMS-ESI.sup.+: calc'd for
C.sub.45H.sub.60ClN.sub.4O.sub.5SSi: 831.6 (M+H)+; found:
831.4(M+H).sup.+.
[0492] Preparation of
(S)-2-(tert-butoxy)-2-(7-(4-chlorophenyl)-2-(1-(2-hydroxyethyl)-3-(1-(oxe-
tan-3-yl)piperidin-4-yl)-1H-indazol-5-yl)-5-methylbenzo[d]thiazol-6-yl)ace-
tic acid: To above reaction mixture was added MeOH (1 mL) and 50%
Sodium hydroxide (0.5 mL) at room temperature. The mixture was
stirred at 60.degree. C. for 1 h. The reaction mixture was cooled
by ice and acidified with 3 N HCl. The resulting mixture was
extracted with ethyl acetate (2.times.). Combined organic layer was
dried (MgSO.sub.4), filtered and concentrated to give crude mixture
which was purified by Gilson HPLC (Phenomenex Gemini 250.times.21.2
10.mu. C18 column, 40-100% ACN/H.sub.2O+0.1% TFA) to give a yellow
powder after lyophilization. .sup.1H NMR (400 MHz, Chloroform-d)
.delta. 8.03 (s, 1H), 7.87 (s, 1H), 7.71 (s, 1H), 7.51 (dd, J=16.9,
8.7 Hz, 3H), 5.33 (s, 1H), 5.13 (d, J=7.1 Hz, 2H), 4.81 (d, J=7.7
Hz, 2H), 4.46 (s, 2H), 4.25 (d, J=6.6 Hz, 1H), 4.13 (t, J=4.9 Hz,
2H), 2.59 (s, 3H), 2.6-1.9 (br, 8H) 1.01 (s, 9H). LCMS-ESI+: calc'd
for C.sub.37H.sub.42ClN.sub.4O.sub.5S; 689.3(M+H).sup.+; found:
689.3(M+H).sup.+.
Example 40
Preparation of
(S)-2-(tert-butoxy)-2-(7-(4-chlorophenyl)-2-(1-cyclopropyl-3-(1-(oxetan-3-
-yl)piperidin-4-yl)-1H-indazol-5-yl)-5-methylbenzo[d]thiazol-6-yl)acetic
acid (38)
##STR00130##
[0494] Preparation of ethyl
(S)-2-(tert-butoxy)-2-(7-(4-chlorophenyl)-2-(1-cyclopropyl-3-(1-(oxetan-3-
-yl)piperidin-4-yl)-1H-indazol-5-yl)-5-methylbenzo[d]thiazol-6-yl)acetate:
To a microwave vial with ethyl
(S)-2-(tert-butoxy)-2-(7-(4-chlorophenyl)-5-methyl-2-(3-(1-(oxetan-3-yl)p-
iperidin-4-yl)-1H-indazol-5-yl)benzo[d]thiazol-6-yl)acetate (95 mg,
141.1 .mu.mol) in THF (3 mL) was added Cyclopropylboronic acid
(60.6 mg, 705.5 .mu.mol), anhydrous cupric acetate, (76.9 mg,
423.35 .mu.mol), triethylamine (0.12 ml, 847 .mu.mol) and pyridine
(0.09 ml, 1129 .mu.mol). The mixture was heated in microwave at
140.degree. C. for 30 min. The reaction mixture was cooled to room
temperature and used as is for the next step. LCMS-ESI.sup.+:
calc'd for C.sub.40H.sub.46ClN.sub.4O.sub.4S: 713.3(M+H)+; found:
713.4 (M+H).sup.+.
[0495] Preparation of
(S)-2-(tert-butoxy)-2-(7-(4-chlorophenyl)-2-(1-cyclopropyl-3-(1-(oxetan-3-
-yl)piperidin-4-yl)-1H-indazol-5-yl)-5-methylbenzo[d]thiazol-6-yl)acetic
acid: To above reaction mixture was added MeOH (1 mL) and 50%
Sodium hydroxide (0.5 mL) at room temperature. The mixture was
stirred at 60.degree. C. for 1 h. The reaction mixture was cooled
by ice and acidified with 3 N HCl. The resulting mixture was
extracted with ethyl acetate (2.times.). Combined organic layer was
dried (MgSO.sub.4), filtered and concentrated to give crude mixture
which was purified by Gilson HPLC (Phenomenex Gemini 250.times.21.2
10.mu. C18 column, 40-100% ACN/H.sub.2O+0.1% TFA) to give a yellow
powder after lyophilization. .sup.1H NMR (400 MHz, Chloroform-d)
.delta. 8.40 (dd, J=72.4, 34.3 Hz, 1H), 8.12-7.90 (m, 1H), 7.89 (s,
1H), 7.72 (d, J=8.1 Hz, 1H), 7.62 (d, J=8.8 Hz, 1H), 7.58-7.43 (m,
2H), 5.32 (s, 1H), 5.11 (t, J=7.1 Hz, 2H), 4.81 (t, J=7.6 Hz, 2H),
4.28 (t, J=6.8 Hz, 1H), 3.85-2.66 (m, 5H), 2.58 (s, 3H), 2.53-2.13
(m, 5H), 1.20 (s, 4H), 1.01 (s, 9H). LCMS-ESI+: calc'd for
C.sub.38H.sub.42ClN.sub.4O.sub.4S; 685.3(M+H).sup.+; found:
685.3(M+H).sup.+.
Example 41
Preparation of
(S)-2-(tert-butoxy)-2-(7-(4-chlorophenyl)-2-(1-(difluoromethyl)-3-(1-(oxe-
tan-3-yl)piperidin-4-yl)-1H-indazol-5-yl)-5-methylbenzo[d]thiazol-6-yl)ace-
tic acid (39)
##STR00131##
[0497] Preparation of ethyl
(S)-2-(tert-butoxy)-2-(7-(4-chlorophenyl)-2-(1-(difluoromethyl)-3-(1-(oxe-
tan-3-yl)piperidin-4-yl)-1H-indazol-5-yl)-5-methylbenzo[d]thiazol-6-yl)ace-
tate: To a 50 mL pressure vessel with a stir bar was added ethyl
(S)-2-(tert-butoxy)-2-(7-(4-chlorophenyl)-5-methyl-2-(3-(1-(oxetan-3-yl)p-
iperidin-4-yl)-1H-indazol-5-yl)benzo[d]thiazol-6-yl)acetate (77 mg,
0.114 mmol), difluoroiodomethane (430.65 .mu.l, 0.23 mmol) in THF
(2 ml) and cesium carbonate (111.79 mg, 0.34 mmol). The vessel was
sealed and heated to 40.degree. C. for 24 h. LCMS showed little
desired product was formed. Additional difluoroiodomethane (430.65
.mu.l, 0.23 mmol) and cesium carbonate (111.79 mg, 0.34 mmol) were
added and mixture heated at 40.degree. C. for another 24 h.
Additional product formed, but still greater than half of SM
remained by LCMS analysis. The reaction mixture was cooled room
temperature. It was taken to the next step directly.
LCMS-ESI.sup.+: calc'd for
C.sub.38H.sub.42ClF.sub.2N.sub.4O.sub.4S: 723.3(M+H)+; found:
723.4(M+H).sup.+.
[0498] Preparation of
(S)-2-(tert-butoxy)-2-(7-(4-chlorophenyl)-2-(1-(difluoromethyl)-3-(1-(oxe-
tan-3-yl)piperidin-4-yl)-1H-indazol-5-yl)-5-methylbenzo[d]thiazol-6-yl)ace-
tic acid: To above reaction mixture was added MeOH (1 mL) and 50%
Sodium hydroxide (0.5 mL) at room temperature. The mixture was
stirred at 60.degree. C. for 1 h. The reaction mixture was cooled
by ice and acidified with 3 N HCl. The resulting mixture was
extracted with ethyl acetate (2.times.). Combined organic layer was
dried (MgSO.sub.4), filtered and concentrated to give crude mixture
which was purified by Gilson HPLC (Phenomenex Gemini 250.times.21.2
10.mu. C18 column, 40-100% ACN/H.sub.2O+0.1% TFA) to give a yellow
powder after lyophilization. .sup.1H NMR (400 MHz, Chloroform-d)
.delta. 8.39 (d, J=7.0 Hz, 1H), 8.10 (dd, J=28.7, 8.8 Hz, 1H), 7.88
(s, 1H), 7.80 (dd, J=8.8, 5.7 Hz, 1H), 7.72 (d, J=8.2 Hz, 1H),
7.60-7.35 (m, 4H), 5.33 (s, 1H), 5.11 (t, J=7.0 Hz, 2H), 4.80 (t,
J=7.6 Hz, 2H), 4.33-4.16 (m, 1H), 3.80-3.04 (m, 4H), 2.58 (s, 3H),
2.38 (d, J=36.9 Hz, 4H), 1.01 (d, J=1.8 Hz, 9H). 19F NMR (376 MHz,
Chloroform-d) .delta. -76.25, -95.25 (d, J=58.9 Hz). LCMS-ESI+:
calc'd for C.sub.36H.sub.38ClF.sub.2N.sub.4O.sub.4S;
695.2(M+H).sup.+; found: 695.3(M+H).sup.+.
Example 42
Preparation of
(S)-2-(tert-butoxy)-2-(7-(4-chlorophenyl)-2-(1-(2-hydroxyethyl)-3-(1-(oxe-
tan-3-yl)piperidin-4-yl)-1H-indazol-5-yl)-5-methylbenzo[d]thiazol-6-yl)ace-
tic acid (40)
##STR00132##
[0500] Preparation of ethyl
(S)-2-(tert-butoxy)-2-(7-(4-chlorophenyl)-5-methyl-2-(1-(methyl-d3)-3-(1--
(oxetan-3-yl)piperidin-4-yl)-1H-indazol-5-yl)benzo[d]thiazol-6-yl)acetate:
To a solution of ethyl
(S)-2-(tert-butoxy)-2-(7-(4-chlorophenyl)-5-methyl-2-(3-(1-(oxetan-3-yl)p-
iperidin-4-yl)-1H-indazol-5-yl)benzo[d]thiazol-6-yl)acetate (33 mg,
0.049 mmol) in anhydrous THF(1 mL) was added sodium hydride (60%
disp. in oil, 10 mg, 0.417 mmol) and stirred for 20 min at to
0.degree. C. under argon. Iodomethane-d3 (21.3 mg, 0.147 mmol) was
added. The reaction mixture was kept at 0.degree. C. for 20 min,
then at room temperature for 1 h. Reaction was complete by LCMS
analysis and used in the next step directly. LCMS-ESI.sup.+: calc'd
for C.sub.45H.sub.60ClN.sub.4O.sub.5SSi: 831.6 (M+H)+; found:
690.4(M+H).sup.+.
[0501] Preparation of
(S)-2-(tert-butoxy)-2-(7-(4-chlorophenyl)-5-methyl-2-(1-(methyl-d.sub.3)--
3-(1-(oxetan-3-yl)piperidin-4-yl)-1H-indazol-5-yl)benzo[d]thiazol-6-yl)ace-
tic acid: To above reaction mixture was added MeOH (1 mL) and 50%
Sodium hydroxide (0.5 mL) at room temperature. The mixture was
stirred at 60.degree. C. for 1 h. The reaction mixture was cooled
by ice and acidified with 3 N HCl. The resulting mixture was
extracted with ethyl acetate (2.times.). Combined organic layer was
dried (MgSO.sub.4), filtered and concentrated to give crude mixture
which was purified by Gilson HPLC (Phenomenex Gemini 250.times.21.2
10.mu. C18 column, 40-100% ACN/H.sub.2O+0.1% TFA) to give a yellow
powder after lyophilization. .sup.1H NMR (400 MHz, Chloroform-d)
.delta. 8.24 (s, 1H), 7.98 (s, 1H), 7.79 (s, 1H), 7.63 (s, 1H),
7.45 (d, J=8.6 Hz, 3H), 7.33 (d, J=8.6 Hz, 1H), 5.24 (s, 1H), 5.06
(t, J=7.1 Hz, 2H), 4.71 (t, J=7.6 Hz, 2H), 4.18 (s, 1H), 2.50 (s,
3H), 2.45 (d, J=14.7 Hz, 2H), 2.30 (s, 6H), 0.93 (s, 9H).
LCMS-ESI+: calc'd for C.sub.36H.sub.37 D.sub.3ClN.sub.4O.sub.4S;
662.3 (M+H).sup.+; found: 662.3(M+H).sup.+.
Example 43
Preparation of
(S)-2-(tert-butoxy)-2-(7-(4-chlorophenyl)-5-methyl-2-(3-(1-(oxetan-3-yl)p-
iperidin-4-yl)-1-(2,2,2-trifluoroethyl)-1H-indazol-5-yl)benzo[d]thiazol-6--
yl)acetic acid (41)
##STR00133##
[0503] Preparation of
(S)-2-(tert-butoxy)-2-(7-(4-chlorophenyl)-5-methyl-2-(3-(1-(oxetan-3-yl)p-
iperidin-4-yl)-1-(2,2,2-trifluoroethyl)-1H-indazol-5-yl)benzo[d]thiazol-6--
yl)acetic acid: To a solution of
(S)-2-(tert-butoxy)-2-(7-(4-chlorophenyl)-5-methyl-2-(3-(1-(oxetan-3-yl)p-
iperidin-4-yl)-1H-indazol-5-yl)benzo[d]thiazol-6-yl)acetic acid (26
mg, 0.040 mmol) in anhydrous DMF(1 mL) was added sodium hydride
(60% disp. in oil, 3.2 mg, 0.08 mmol) and stirred for 20 min at to
0.degree. C. under argon. 2,2,2-Trifluoroethyl
trifluoromethanesulfonate (11.61 .mu.l, 0.080 mmol) was added. The
reaction mixture was kept at 0.degree. C. for 20 min, then at room
temperature for 1 h. Reaction was complete by LCMS analysis. The
reaction mixture was cooled to 0.degree. C., acidified with 3N HCl,
extracted with EtOAc, washed with 3% LiCl and brine. After drying
over MgSO4, organic layer was concentrated to remove the organic
solvent. The residue was purified by HPLC purified by Gilson HPLC
(Phenomenex Gemini 250.times.21.2 10.mu. C18 column, 40-100%
ACN/H.sub.2O+0.1% TFA) to give a yellow powder after
lyophilization. .sup.1H NMR (400 MHz, Chloroform-d) .delta. 7.88
(s, 1H), 7.45 (d, J=14.2 Hz, 7H), 5.23 (s, 1H), 4.82 (m, 2H), 4.59
(dd, J=12.9, 7.8 Hz, 3H), 4.46-4.24 (m, 1H), 4.04 (t, J=7.0 Hz,
1H), 3.68 (m, 1H), 2.77 (m, 1H), 2.46 (s, 3H), 2.12 (d, J=17.3 Hz,
5H), 1.30-1.09 (m, 1H), 0.97 (s, 9H). 19F NMR (377 MHz,
Chloroform-d) .delta. -74.15 (t, J=8.5 Hz), -75.73. LCMS-ESI+:
calc'd for C.sub.37H.sub.39ClF.sub.3N.sub.4O.sub.4S;
727.2(M+H).sup.+; found: 727.4(M+H).sup.+.
Example 44
Preparation of
(S)-2-(tert-butoxy)-2-(7-(4-chlorophenyl)-2-(1-(2,2-difluoroethyl)-3-(1-(-
oxetan-3-yl)piperidin-4-yl)-1H-indazol-5-yl)-5-methylbenzo[d]thiazol-6-yl)-
acetic acid (42)
##STR00134##
[0505] Preparation of
(S)-2-(tert-butoxy)-2-(7-(4-chlorophenyl)-2-(1-(2,2-difluoroethyl)-3-(1-(-
oxetan-3-yl)piperidin-4-yl)-1H-indazol-5-yl)-5-methylbenzo[d]thiazol-6-yl)-
acetic acid: To a flask with a stir bar was added
(S)-2-(tert-butoxy)-2-(7-(4-chlorophenyl)-5-methyl-2-(3-(1-(oxetan-3-yl)p-
iperidin-4-yl)-1H-indazol-5-yl)benzo[d]thiazol-6-yl)acetic acid (25
mg, 0.03 mmol) in DMF (1 mL), 2,2-Difluoroethyl
trifluoromethanesulfonate (31.89 mg, 0.15 mmol) and cesium
carbonate (97.06 mg, 0.3 mmol). The mixture was stirred at
80.degree. C. for 5 h. The reaction mixture was cooled to 0.degree.
C., acidified with 3N HCl. It was extracted with EtOAc, washed with
3% LiCl and brine. After dried over MgSO.sub.4, it was concentrated
to remove the organic solvent. The residue was purified by HPLC
purified by Gilson HPLC (Phenomenex Gemini 250.times.21.2 10.mu.
C18 column, 40-100% ACN/H.sub.2O+0.1% TFA) to give a yellow powder
after lyophilization. .sup.1H NMR (400 MHz, Chloroform-d) .delta.
7.82 (m, 2H), 7.43 (d, J=17.9 Hz, 6H), 6.10-5.60 (m, 1H), 5.19 (s,
1H), 4.87 (m, 2H), 4.63 (m, 2H), 4.44-3.92 (m, 3H), 3.62-2.61 (m,
5H), 2.48 (s, 3H), 2.18 (s, 4H), 0.94 (s, 9H). 19F NMR (377 MHz,
Chloroform-d) .delta. -76.02, -126.24 (ddt, J=56.5, 28.6, 13.8 Hz).
LCMS-ESI+: calc'd for C.sub.37H.sub.40ClF.sub.2N.sub.4O.sub.4S;
709.3(M+H).sup.+; found: 709.4(M+H).sup.+.
Example 45
(S)-2-(2-(3-(1-(1-acetylazetidin-3-yl)piperidin-4-yl)-1-(difluoromethyl)-1-
H-indazol-5-yl)-7-(4-chlorophenyl)-5-methylbenzo[d]thiazol-6-yl)-2-(tert-b-
utoxy)acetic acid (43)
##STR00135##
[0507] Preparation of tert-butyl
(S)-4-(5-(6-(1-(tert-butoxy)-2-ethoxy-2-oxoethyl)-7-(4-chlorophenyl)-5-me-
thylbenzo[d]thiazol-2-yl)-1H-indazol-3-yl)piperidine-1-carboxylate:
To a solution of ethyl
(S)-2-(tert-butoxy)-2-(7-(4-chlorophenyl)-5-methyl-2-(3-(piperidin-4-yl)--
1H-indazol-5-yl)benzo[d]thiazol-6-yl)acetate (0.7 g, 1.13 mmol) in
dichloromethane (14 mL) was added Di-tert-butyl dicarbonate (0.37
g, 1.7 mmol) and N,N-Diisopropylethylamine (0.6 ml). The reaction
mixture was kept at room temperature for 18 h. Reaction was
complete by LCMS analysis. The reaction mixture was quenched with
sat'd NaHCO3, extracted with EtOAc, dried (MgSO4) and concentrated
to give desired product. LCMS-ESI+: calc'd for
C.sub.39H.sub.46ClN.sub.4O.sub.5S; 717.32(M+H).sup.+; found:
717.1(M+H).sup.+.
[0508] Preparation of tert-butyl
(S)-4-(5-(6-(1-(tert-butoxy)-2-ethoxy-2-oxoethyl)-7-(4-chlorophenyl)-5-me-
thylbenzo[d]thiazol-2-yl)-1-(difluoromethyl)-1H-indazol-3-yl)piperidine-1--
carboxylate: To a solution of tert-butyl
(S)-4-(5-(6-(1-(tert-butoxy)-2-ethoxy-2-oxoethyl)-7-(4-chlorophenyl)-5-me-
thylbenzo[d]thiazol-2-yl)-1H-indazol-3-yl)piperidine-1-carboxylate
(325 mg, 0.453 mmol) in anhydrous DMF(5 mL) was added sodium
hydride (60% disp. in oil, 21.75 mg, 0.91 mmol) and stirred for 20
min at to 0.degree. C. under argon. Difluoroiodomethane (1279.55
.mu.l, 0.68 mmol) in THF was added. The reaction mixture was kept
at 0.degree. C. for 20 min, then at room temperature for 2 h. LCMS
showed about 1/3 of starting material remained. The reaction
mixture was cooled to 0.degree. C. under argon again, and
additional NaH (60% disp. in oil, 21.75 mg, 0.91 mmol) was added,
followed by difluoroiodomethane (1279.55 .mu.l, 0.68 mmol) as
before. After another 2 h at RT, the reaction was completed. The
reaction mixture was cooled to 0.degree. C., then added 1N HCl
until pH about 7. It was extracted with EtOAc, washed with 3% LiCl
and brine. The organic layer was dried over Na.sub.2SO.sub.4 and
concentrated. The residue was purified by CombiFlash (40 g, Gold,
0-100% EtOAc/Hexane) gave the desired regioisomer product (faster
runner on TLC). .sup.1H NMR (400 MHz, Chloroform-d) .delta. 8.39
(dd, J=1.6, 0.8 Hz, 1H), 8.14 (dd, J=8.8, 1.6 Hz, 1H), 7.89 (d,
J=0.9 Hz, 1H), 7.77 (d, J=8.7 Hz, 1H), 7.60-7.35 (m, 5H), 5.16 (s,
1H), 4.22 (tt, J=7.1, 3.6 Hz, 4H), 4.12 (q, J=7.1 Hz, 2H), 3.25
(tt, J=11.6, 3.9 Hz, 1H), 2.97 (t, J=12.7 Hz, 2H), 2.61 (d, J=0.7
Hz, 3H), 1.92 (qd, J=12.1, 4.4 Hz, 2H), 1.49 (s, 9H), 1.26 (t,
J=7.1 Hz, 3H), 0.99 (s, 9H). LCMS-ESI+: calc'd for
C.sub.40H.sub.46ClF.sub.2N.sub.4O.sub.5S: 767.3 (M+H).sup.+; found:
767.1 (M+H).sup.+.
[0509] Preparation of ethyl
(S)-2-(tert-butoxy)-2-(7-(4-chlorophenyl)-2-(1-(difluoromethyl)-3-(piperi-
din-4-yl)-1H-indazol-5-yl)-5-methylbenzo[d]thiazol-6-yl)acetate: A
solution of tert-butyl
(S)-4-(5-(6-(1-(tert-butoxy)-2-ethoxy-2-oxoethyl)-7-(4-chlorophenyl)-5-me-
thylbenzo[d]thiazol-2-yl)-1-(difluoromethyl)-1H-indazol-3-yl)piperidine-1--
carboxylate (100 mg, 0.13 mmol) in 1.25 HCl in isopropanol (3 mL)
was stirred at room temperature for 16 h. Reaction was quenched
carefully with 1N sodium hydroxide at 0.degree. C. to pH>8. It
was extracted with ethyl acetate (2.times.). Combined organic layer
was dried over sodium sulfate, filtered and concentrated to give
desire product. It was used in the next step without further
purification. LCMS-ESI+: calc'd for
C.sub.35H.sub.38ClF.sub.2N.sub.4O.sub.3S: 667.2 (M+H).sup.+; found:
667.4 (M+H).sup.+.
[0510] Preparation of tert-butyl
(S)-3-(4-(5-(6-(1-(tert-butoxy)-2-ethoxy-2-oxoethyl)-7-(4-chlorophenyl)-5-
-methylbenzo[d]thiazol-2-yl)-1-(difluoromethyl)-1H-indazol-3-yl)piperidin--
1-yl)azetidine-1-carboxylate: A solution of ethyl
(S)-2-(tert-butoxy)-2-(7-(4-chlorophenyl)-2-(1-(difluoromethyl)-3-(piperi-
din-4-yl)-1H-indazol-5-yl)-5-methylbenzo[d]thiazol-6-yl)acetate (40
mg, 60 .mu.mol), 1-Boc-3-azetidinone (102 mg, 0.6 mmol), acetic
acid (2 drops) and sodium cyanoborohydride (64 mg, 0.3 mmol) in
methanol (5 mL) was stirred for 5 hours at room temperature.
Reaction was quenched with saturated sodium bicarbonate solution
and brine. The mixture was extracted with ethyl acetate (2.times.)
and combined organic layer was dried (MgSO.sub.4), filtered and
concentrated. The residue was purified by CombiFlash (40 g, Gold,
0-10% MeOH/CH.sub.2Cl.sub.2) to give desired product. LCMS-ESI+:
calc'd for C.sub.43H.sub.51ClF.sub.2N.sub.5O.sub.5S:
822.4(M+H).sup.+; found: 822.1 (M+H).sup.+.
[0511] Preparation of ethyl
(S)-2-(2-(3-(1-(azetidin-3-yl)piperidin-4-yl)-1-(difluoromethyl)-1H-indaz-
ol-5-yl)-7-(4-chlorophenyl)-5-methylbenzo[d]thiazol-6-yl)-2-(tert-butoxy)a-
cetate: A solution of tert-butyl
(S)-3-(4-(5-(6-(1-(tert-butoxy)-2-ethoxy-2-oxoethyl)-7-(4-chlorophenyl)-5-
-methylbenzo[d]thiazol-2-yl)-1-(difluoromethyl)-1H-indazol-3-yl)piperidin--
1-yl)azetidine-1-carboxylate (49 mg, 0.06 mmol) in 1.25 HCl in
isopropanol (3 mL) was stirred at room temperature for 16 h.
Reaction was quenched carefully with 1N sodium hydroxide at
0.degree. C. to pH>8. It was extracted with ethyl acetate
(2.times.). Combined organic layer was dried over sodium sulfate,
filtered and concentrated to give desire product. It was used in
the next step without further purification. LCMS-ESI+: calc'd for
C.sub.38H.sub.43ClF.sub.2N.sub.5O.sub.3S: 722.3 (M+H).sup.+; found:
722.2 (M+H).sup.+.
[0512] Preparation of
(S)-2-(2-(3-(1-(azetidin-3-yl)piperidin-4-yl)-1-(difluoromethyl)-1H-indaz-
ol-5-yl)-7-(4-chlorophenyl)-5-methylbenzo[d]thiazol-6-yl)-2-(tert-butoxy)a-
cetic acid: To the ethyl
(S)-2-(2-(3-(1-(azetidin-3-yl)piperidin-4-yl)-1-(difluoromethyl)-1H-indaz-
ol-5-yl)-7-(4-chlorophenyl)-5-methylbenzo[d]thiazol-6-yl)-2-(tert-butoxy)a-
cetate (15 mg, 0.020 mmol) was added THF (2 mL), MeOH (1 mL) and
50% sodium hydroxide (0.5 mL) at room temperature. The mixture was
stirred at 60.degree. C. for 1 h. The reaction mixture was cooled
by ice and acidified with 3N HCl to pH=6. It was concentrated to
remove the organic solvent. Used as is in next step. LCMS-ESI+:
calc'd for C.sub.36H.sub.38ClF.sub.2N.sub.5O.sub.3S; 694.2
(M+H).sup.+; found: 694.2(M+H).sup.+.
[0513] Preparation of
(S)-2-(2-(3-(1-(1-acetylazetidin-3-yl)piperidin-4-yl)-1-(difluoromethyl)--
1H-indazol-5-yl)-7-(4-chlorophenyl)-5-methylbenzo[d]thiazol-6-yl)-2-(tert--
butoxy)acetic acid: To a flask containing
(S)-2-(2-(3-(1-(azetidin-3-yl)piperidin-4-yl)-1-(difluoromethyl)-1H-indaz-
ol-5-yl)-7-(4-chlorophenyl)-5-methylbenzo[d]thiazol-6-yl)-2-(tert-butoxy)a-
cetic acid (14 mg, 0.020 mmol) in dichloromethane (10 mL) and water
(5 mL) were added, followed by Sodium carbonate (62.02 mg, 2 mol)
and Acetyl chloride (14.22 .mu.l, 200 .mu.mol). The mixture was
stirred at room temperature for 20 h. The desired acid product LCMS
[m+1]=736.27 was formed as major, along with the corresponding
mixed anhydride side-product (LCMS[m+1]=778.02). The layers were
separated and the organic layer was dried (MgSO.sub.4), and
concentrated. To the residue was added MeOH (1 mL), THF (2 mL) and
1N Sodium hydroxide (0.1 mL), stirred at RT for 1 h to hydrolyze
corresponding mixed anhydride side-product. After the completion,
the reaction mixture was cooled to 0.degree. C., acidified with 3N
HCl to pH=4. The mixture was then concentrated to give crude
mixture which was purified by Gilson HPLC (Phenomenex Gemini
250.times.21.2 10.mu. C18 column, 40-100% ACN/H.sub.2O+0.1% TFA) to
give a yellow powder after lyophilization. .sup.1H NMR (400 MHz,
Chloroform-d) .delta. 8.39 (d, J=7.0 Hz, 1H), 8.10 (dd, J=28.7, 8.8
Hz, 1H), 7.88 (s, 1H), 7.80 (dd, J=8.8, 5.7 Hz, 1H), 7.72 (d, J=8.2
Hz, 1H), 7.60-7.35 (m, 4H), 5.33 (s, 1H), 5.11 (t, J=7.0 Hz, 2H),
4.80 (t, J=7.6 Hz, 2H), 4.33-4.16 (m, 1H), 3.80-3.04 (m, 4H), 2.58
(s, 3H), 2.38 (d, J=36.9 Hz, 4H), 1.01 (d, J=1.8 Hz, 9H). 19F NMR
(376 MHz, Chloroform-d) .delta. -76.25, -95.25 (d, J=58.9 Hz). 19F
NMR (376 MHz, Chloroform-d) .delta. -76.48, -95.40 (d, J=58.0 Hz).
LCMS-ESI+: calc'd for C.sub.38H.sub.41ClF.sub.2N.sub.5O.sub.4S;
736.3 (M+H).sup.+; found: 736.2(M+H).sup.+.
Example 46
(S)-2-(tert-butoxy)-2-(7-(4-chlorophenyl)-2-(1-(difluoromethyl)-3-(1-(1-(m-
ethoxycarbonyl)azetidin-3-yl)piperidin-4-yl)-1H-indazol-5-yl)-5-methylbenz-
o[d]thiazol-6-yl)acetic acid (44)
##STR00136##
[0515] Preparation of
(S)-2-(2-(3-(1-(azetidin-3-yl)piperidin-4-yl)-1-(difluoromethyl)-1H-indaz-
ol-5-yl)-7-(4-chlorophenyl)-5-methylbenzo[d]thiazol-6-yl)-2-(tert-butoxy)a-
cetic acid: To the ethyl
(S)-2-(2-(3-(1-(azetidin-3-yl)piperidin-4-yl)-1-(difluoromethyl)-1H-indaz-
ol-5-yl)-7-(4-chlorophenyl)-5-methylbenzo[d]thiazol-6-yl)-2-(tert-butoxy)a-
cetate (15 mg, 0.020 mmol) was added THF (2 mL), MeOH (1 mL) and
50% Sodium hydroxide (0.5 mL) at room temperature. The mixture was
stirred at 60.degree. C. for 1 h. The reaction mixture was cooled
by ice and acidified with 3N HCl to pH=6. It was concentrated to
remove the organic solvent and used as is in next step. LCMS-ESI+:
calc'd for C.sub.36H.sub.38ClF.sub.2N.sub.5O.sub.3S; 694.2
(M+H).sup.+; found: 694.2(M+H).sup.+.
[0516] Preparation of
(S)-2-(tert-butoxy)-2-(7-(4-chlorophenyl)-2-(1-(difluoromethyl)-3-(1-(1-(-
methoxycarbonyl)azetidin-3-yl)piperidin-4-yl)-1H-indazol-5-yl)-5-methylben-
zo[d]thiazol-6-yl)acetic acid: To a flask containing crude
(S)-2-(2-(3-(1-(azetidin-3-yl)piperidin-4-yl)-1-(difluoromethyl)-1H-indaz-
ol-5-yl)-7-(4-chlorophenyl)-5-methylbenzo[d]thiazol-6-yl)-2-(tert-butoxy)a-
cetic acid (14 mg, 0.020 mmol) in dichloromethane (10 mL) and water
(5 mL) were added Sodium carbonate (100 mg, 3 mmol) and Methyl
chloroformate (50 .mu.l, 647.11 .mu.mol). The mixture was stirred
at room temperature for 20 h. The corresponding mixed anhydride
by-product (LCMS[m+1]=810.15) was major. The biphasic layers were
separated, the organic layer was dried over MgSO.sub.4, and
concentrated. To the residue was added MeOH (1 mL) and THF (2 mL)
and 1N Sodium hydroxide (0.1 mL), stirred at RT for 1 h to
hydrolyze the mixed anhydride by-product. After the completion, the
reaction mixture was cooled to 0.degree. C., acidified with 3N HCl
to pH=4. The mixture was then concentrated to give crude mixture
which was purified by Gilson HPLC (Phenomenex Gemini 250.times.21.2
10.mu. C.sub.18 column, 40-100% ACN/H.sub.2O+0.1% TFA) to give a
yellow powder after lyophilization. .sup.1H NMR (400 MHz,
Chloroform-d) .delta. 8.89 (s, 1H), 8.03-7.79 (m, 3H), 7.71 (s,
1H), 7.65-7.39 (m, 4H), 5.34 (s, 1H), 4.50 (s, 2H), 4.30 (s, 2H),
3.95 (m, 1H), 3.81 (m, 2H), 3.73 (s, 3H), 3.68-3.20 (m, 2H), 2.99
(s, 1H), 2.63 (s, 3H), 2.40 (d, J=7.1 Hz, 4H), 1.02 (s, 9H),
1.00-0.83 (m, 3H). 19F NMR (376 MHz, Chloroform-d) .delta. -76.39,
-95.49 (d, J=58.9 Hz). LCMS-ESI+: calc'd for
C.sub.38H.sub.41ClF.sub.2N.sub.5O.sub.5S; 752.3 (M+H).sup.+; found:
752.2(M+H).sup.+.
Example 47
Preparation of
(S)-2-(2-(3-(1-(1-acetylazetidin-3-yl)piperidin-4-yl)-1-cyclopropyl-1H-in-
dazol-5-yl)-7-(4-chlorophenyl)-5-methylbenzo[d]thiazol-6-yl)-2-(tert-butox-
y)acetic acid (45)
##STR00137##
[0518] Preparation of tert-butyl
(S)-4-(5-(6-(1-(tert-butoxy)-2-ethoxy-2-oxoethyl)-7-(4-chlorophenyl)-5-me-
thylbenzo[d]thiazol-2-yl)-1-cyclopropyl-1H-indazol-3-yl)piperidine-1-carbo-
xylate: To a microwave vial with tert-butyl
(S)-4-(5-(6-(1-(tert-butoxy)-2-ethoxy-2-oxoethyl)-7-(4-chlorophenyl)-5-me-
thylbenzo[d]thiazol-2-yl)-1H-indazol-3-yl)piperidine-1-carboxylate
(170 mg, 237 .mu.mol) in THF (3 mL) was added Cyclopropylboronic
acid (101.79 mg, 1185 .mu.mol), anhydrous Cupric acetate, (129 mg,
711 .mu.mol), Triethylamine (198 .mu.l, 1422 .mu.mol) and pyridine
(153 .mu.l, 1896 .mu.mol). The mixture was heated in microwave at
140.degree. C. for 30 min. The reaction mixture was cooled to room
temperature, filtered through a pad of Celite and concentrated. The
residue was purified by CombiFlash (40 g, Gold, 0-100%
EtOAc/Hexane) to give desired product. LCMS-ESI.sup.+: calc'd for
C.sub.42H.sub.49ClN.sub.4O.sub.5S: 757.4(M+H)+; found: 757.2
(M+H).sup.+.
[0519] Preparation of ethyl
(S)-2-(tert-butoxy)-2-(7-(4-chlorophenyl)-2-(1-cyclopropyl-3-(piperidin-4-
-yl)-1H-indazol-5-yl)-5-methylbenzo[d]thiazol-6-yl)acetate: A
solution of tert-butyl
(S)-4-(5-(6-(1-(tert-butoxy)-2-ethoxy-2-oxoethyl)-7-(4-chlorophenyl)-5-me-
thylbenzo[d]thiazol-2-yl)-1-cyclopropyl-1H-indazol-3-yl)piperidine-1-carbo-
xylate (132 mg, 0.174 mmol) in 1.25 HCl in isopropanol (4 mL) was
stirred at room temperature for 16 h. Reaction was quenched
carefully with sat'd NaHCO.sub.3. It was extracted with ethyl
acetate (2.times.). Combined organic layer was dried over sodium
sulfate, filtered and concentrated to give desired product. It was
used in the next step without further purification. LCMS-ESI+:
calc'd for C.sub.37H.sub.41ClN.sub.4O.sub.3S: 657.3 (M+H).sup.+;
found: 657.4 (M+H).sup.+.
[0520] Preparation of ethyl
(S)-2-(2-(3-(1-(azetidin-3-yl)piperidin-4-yl)-1-cyclopropyl-1H-indazol-5--
yl)-7-(4-chlorophenyl)-5-methylbenzo[d]thiazol-6-yl)-2-(tert-butoxy)acetat-
e: It was made by the same conditions and procedures as for
(S)-2-(2-(3-(1-(1-acetylazetidin-3-yl)piperidin-4-yl)-1-(difluoromethyl)--
1H-indazol-5-yl)-7-(4-chlorophenyl)-5-methylbenzo[d]thiazol-6-yl)-2-(tert--
butoxy)acetic acid. Reductive animation of ethyl
(S)-2-(tert-butoxy)-2-(7-(4-chlorophenyl)-2-(1-cyclopropyl-3-(piperidin-4-
-yl)-1H-indazol-5-yl)-5-methylbenzo[d]thiazol-6-yl)acetate with
1-Boc-3-azetidinone followed by de-Boc in 1.25 HCl in isopropanol
to give desired product. LCMS-ESI+: calc'd for
C.sub.40H.sub.46ClN.sub.5O.sub.3S: 712.4(M+H).sup.+; found: 712.3
(M+H).sup.+.
[0521] Preparation of ethyl
(S)-2-(2-(3-(1-(1-acetylazetidin-3-yl)piperidin-4-yl)-1-cyclopropyl-1H-in-
dazol-5-yl)-7-(4-chlorophenyl)-5-methylbenzo[d]thiazol-6-yl)-2-(tert-butox-
y)acetic acid: It was prepared using similar procedure as for
(S)-2-(2-(3-(1-(1-acetylazetidin-3-yl)piperidin-4-yl)-1-(difluoromethyl)--
1H-indazol-5-yl)-7-(4-chlorophenyl)-5-methylbenzo[d]thiazol-6-yl)-2-(tert--
butoxy)acetic acid. .sup.1H NMR (400 MHz, DMSO-d6) .delta. 8.44 (s,
1H), 8.15 (d, J=8.9 Hz, 1H), 7.85 (s, 1H), 7.77 (d, J=8.8 Hz, 1H),
7.73-7.52 (m, 4H), 5.05 (s, 1H), 4.51-3.68 (m, 5H), 3.55 (s, 3H),
3.03 (s, 1H), 2.53 (s, 3H), 2.16 (t, J=7.4 Hz, 4H), 1.80 (s, 3H),
1.45 (d, J=7.4 Hz, 4H), 1.16-1.01 (m, 4H), 0.89 (s, 9H), 0.87-0.78
(m, 6H). LCMS-ESI+: calc'd for C.sub.40H.sub.44ClN.sub.5O.sub.4S;
726.3 (M+H).sup.+; found: 726.3(M+H).sup.+.
Example 48
(S)-2-(tert-butoxy)-2-(7-(4-chlorophenyl)-2-(1-cyclopropyl-3-(1-(1-(methox-
ycarbonyl)azetidin-3-yl)piperidin-4-yl)-1H-indazol-5-yl)-5-methylbenzo[d]t-
hiazol-6-yl)acetic acid (46)
##STR00138##
[0523] Preparation of
(S)-2-(tert-butoxy)-2-(7-(4-chlorophenyl)-2-(1-cyclopropyl-3-(1-(1-(metho-
xycarbonyl)azetidin-3-yl)piperidin-4-yl)-1H-indazol-5-yl)-5-methylbenzo[d]-
thiazol-6-yl)acetic acid: It was prepared using similar procedure
as for
(S)-2-(2-(3-(1-(1-acetylazetidin-3-yl)piperidin-4-yl)-1-(difluoromethyl)--
1H-indazol-5-yl)-7-(4-chlorophenyl)-5-methylbenzo[d]thiazol-6-yl)-2-(tert--
butoxy)acetic acid. .sup.1H NMR (400 MHz, DMSO-d6) .delta. 8.44 (d,
J=1.5 Hz, 1H), 8.20-8.06 (m, 1H), 7.85 (s, 1H), 7.76 (d, J=8.9 Hz,
1H), 7.73-7.51 (m, 4H), 5.05 (s, 1H), 4.18 (s, 4H), 3.74 (d, J=4.1
Hz, 1H), 3.60 (s, 3H), 3.55 (s, 3H), 3.00 (m, 1H), 2.53 (s, 3H),
2.16 (t, J=7.4 Hz, 4H), 2.04 (m, 1H), 1.46 (t, J=7.2 Hz, 4H),
1.16-0.99 (m, 4H), 0.89 (s, 9H), 0.86-0.80 (m, 6H). LCMS-ESI+:
calc'd for C.sub.40H.sub.44ClN.sub.5O.sub.5S; 742.3 (M+H).sup.+;
found: 742.24(M+H).sup.+.
Example 49
Preparation of
(S)-2-(2-(3-(1-(1-acetylazetidin-3-yl)piperidin-4-yl)-1-ethyl-1H-indazol--
5-yl)-7-(4-chlorophenyl)-5-methylbenzo[d]thiazol-6-yl)-2-(tert-butoxy)acet-
ic acid (47)
##STR00139##
[0525] Preparation of tert-butyl
(S)-4-(5-(6-(1-(tert-butoxy)-2-ethoxy-2-oxoethyl)-7-(4-chlorophenyl)-5-me-
thylbenzo[d]thiazol-2-yl)-1-ethyl-1H-indazol-3-yl)piperidine-1-carboxylate-
: To a solution of tert-butyl
(S)-4-(5-(6-(1-(tert-butoxy)-2-ethoxy-2-oxoethyl)-7-(4-chlorophenyl)-5-me-
thylbenzo[d]thiazol-2-yl)-1H-indazol-3-yl)piperidine-1-carboxylate
(180 mg, 0.25 mmol) in anhydrous DMF (3 mL) was added sodium
hydride (60% disp. in oil, 30 mg, 0.75 mmol) and stirred for 20 min
at to 0.degree. C. under argon. Iodoethane (121 .mu.l, 1.5 mmol)
was added. The reaction mixture was kept at 0.degree. C. for 20
min, then at room temperature for 1 h. Reaction was complete by
LCMS analysis. 1N HCl was added to adjust pH to 7-8, then it was
extracted with EtOAc. The organic layer was washed with 3% LiCl and
dried over MgSO.sub.4 and concentrated. The residue was purified by
CombiFlash (40 g, Gold, 0-100% EtOAc/Hexane) to give desired major
isomer product. .sup.1H NMR (400 MHz, Chloroform-d) .delta. 8.31
(dd, J=1.6, 0.7 Hz, 1H), 8.03 (dd, J=8.8, 1.6 Hz, 1H), 7.84 (d,
J=0.9 Hz, 1H), 7.59-7.41 (m, 4H), 7.37 (dd, J=8.8, 0.7 Hz, 1H),
5.14 (s, 1H), 4.35 (q, J=7.3 Hz, 2H), 4.19 (dq, J=7.2, 3.6 Hz, 2H),
3.32-3.12 (m, 1H), 2.92 (s, 2H), 2.58 (d, J=0.8 Hz, 3H), 1.99-1.83
(m, 3H), 1.47 (s+m, 12H), 1.23 (td, J=7.1, 0.7 Hz, 4H), 0.96 (s,
9H). LCMS-ESI.sup.+: calc'd for C.sub.41H.sub.49ClN.sub.4O.sub.5S:
745.4(M+H).sup.+; found: 745.2 (M+H).sup.+.
[0526] Minor regioisomer. .sup.1H NMR (400 MHz, Chloroform-d)
.delta. 8.30 (d, J=1.3 Hz, 1H), 7.93 (dd, J=9.0, 1.6 Hz, 1H), 7.84
(d, J=0.9 Hz, 1H), 7.67 (dd, J=9.1, 0.8 Hz, 1H), 7.58-7.40 (m, 4H),
5.14 (s, 1H), 4.52-4.04 (m, 6H), 3.30-3.01 (m, 1H), 2.86 (t, J=13.0
Hz, 2H), 2.58 (d, J=0.8 Hz, 3H), 2.16 (dt, J=13.1, 5.3 Hz, 2H),
1.88 (d, J=13.2 Hz, 2H), 1.66 (s, 2H), 1.56 (t, J=7.3 Hz, 3H), 1.51
(s, 9H), 1.23 (t, J=7.1 Hz, 3H), 0.97 (s, 9H).
[0527] Preparation of ethyl
(S)-2-(tert-butoxy)-2-(7-(4-chlorophenyl)-2-(1-ethyl-3-(piperidin-4-yl)-1-
H-indazol-5-yl)-5-methylbenzo[d]thiazol-6-yl)acetate: A solution of
tert-butyl
(S)-4-(5-(6-(1-(tert-butoxy)-2-ethoxy-2-oxoethyl)-7-(4-chlorophenyl)-5-me-
thylbenzo[d]thiazol-2-yl)-1-ethyl-1H-indazol-3-yl)piperidine-1-carboxylate
(126 mg, 0.169 mmol) in 1.25 HCl in isopropanol (4 mL) was stirred
at room temperature for 16 h. Reaction was quenched carefully with
sat'd NaHCO.sub.3 and extracted with ethyl acetate (2.times.).
Combined organic layer was dried over sodium sulfate, filtered and
concentrated to give desired product. It was used in the next step
without further purification. LCMS-ESI+: calc'd for
C.sub.36H.sub.41ClN.sub.4O.sub.3S: 645.3 (M+H).sup.+; found: 645.4
(M+H).sup.+.
[0528] Preparation of
(S)-2-(2-(3-(1-(azetidin-3-yl)piperidin-4-yl)-1-ethyl-1H-indazol-5-yl)-7--
(4-chlorophenyl)-5-methylbenzo[d]thiazol-6-yl)-2-(tert-butoxy)acetic
acid: Prepared using similar procedure as for
(S)-2-(2-(3-(1-(1-acetylazetidin-3-yl)piperidin-4-yl)-1-(difluoromethyl)--
1H-indazol-5-yl)-7-(4-chlorophenyl)-5-methylbenzo[d]thiazol-6-yl)-2-(tert--
butoxy)acetic acid. Reductive animation of ethyl
(S)-2-(tert-butoxy)-2-(7-(4-chlorophenyl)-2-(1-ethyl-3-(piperidin-4-yl)-1-
H-indazol-5-yl)-5-methylbenzo[d]thiazol-6-yl)acetate with
1-Boc-3-azetidinone followed by de-Boc in 1.25 HCl in isopropanol
and hydrolysis with 50% Sodium hydroxide to give desired product.
LCMS-ESI+: calc'd for C.sub.37H.sub.42ClN.sub.5O.sub.3S:
672.3(M+H).sup.+; found: 672.3 (M+H).sup.+.
[0529] Preparation of
(S)-2-(2-(3-(1-(1-acetylazetidin-3-yl)piperidin-4-yl)-1-ethyl-1H-indazol--
5-yl)-7-(4-chlorophenyl)-5-methylbenzo[d]thiazol-6-yl)-2-(tert-butoxy)acet-
ic acid: To a flask containing
(S)-2-(2-(3-(1-(azetidin-3-yl)piperidin-4-yl)-1-ethyl-1H-indazol-5-yl)-7--
(4-chlorophenyl)-5-methylbenzo[d]thiazol-6-yl)-2-(tert-butoxy)acetic
acid (67 mg, 0.1 mmol) in DMF (2 mL) and EtOAc (10 mL) were added
sat'd aq. sodium bicarbonate (10 mL) and Acetyl chloride (200
.mu.l, 2.8 mmol). The mixture was stirred at room temperature for
20 h. LCMS analysis indicated that only the desired acid product
was formed. The reaction mixture was cooled to 0.degree. C.,
acidified with 3N HCl to pH=4 and extracted with EtOAc. The organic
layer was concentrated to give crude mixture which was purified by
Gilson HPLC (Phenomenex Gemini 250.times.21.2 10.mu. C18 column,
40-100% ACN/H.sub.2O+0.1% TFA) to give a yellow powder after
lyophilization. 1H NMR (400 MHz, Chloroform-d) .delta. 8.24 (s,
1H), 7.95 (d, J=9.3 Hz, 1H), 7.78 (s, 1H), 7.63 (d, J=8.2 Hz, 1H),
7.44 (d, J=8.4 Hz, 3H), 7.35 (d, J=8.9 Hz, 1H), 5.24 (s, 1H), 4.72
(dd, J=9.9, 5.2 Hz, 1H), 4.42-4.06 (m, 5H), 3.59 (d, J=135.5 Hz,
6H), 2.50 (s, 3H), 2.28 (d, J=22.2 Hz, 3H), 1.81 (s, 3H), 1.43 (t,
J=7.2 Hz, 3H), 1.15 (d, J=17.4 Hz, 1H), 0.93 (s, 9H). LCMS-ESI+:
calc'd for C.sub.39H.sub.44ClN.sub.5O.sub.4S; 714.3 (M+H).sup.+;
found: 714.3(M+H).sup.+.
Example 50
Preparation of
(S)-2-(tert-butoxy)-2-(7-(4-chlorophenyl)-2-(1-ethyl-3-(1-(1-(methoxycarb-
onyl)azetidin-3-yl)piperidin-4-yl)-1H-indazol-5-yl)-5-methylbenzo[d]thiazo-
l-6-yl)acetic acid (48)
##STR00140##
[0531] Preparation of
(S)-2-(tert-butoxy)-2-(7-(4-chlorophenyl)-2-(1-ethyl-3-(1-(1-(methoxycarb-
onyl)azetidin-3-yl)piperidin-4-yl)-1H-indazol-5-yl)-5-methylbenzo[d]thiazo-
l-6-yl)acetic acid: To a flask containing
(S)-2-(2-(3-(1-(azetidin-3-yl)piperidin-4-yl)-1-ethyl-1H-indazol-5-yl)-7--
(4-chlorophenyl)-5-methylbenzo[d]thiazol-6-yl)-2-(tert-butoxy)acetic
acid (67 mg, 0.1 mmol) in DMF (2 mL) and EtOAc (10 mL) were added
sat'd aq. sodium bicarbonate (10 mL) and Methyl chloroformate (100
.mu.l, 1.29 mmol). The mixture was stirred at room temperature for
20 h. LCMS analysis indicated that only the desired acid product
was formed. The reaction mixture was cooled to 0.degree. C.,
acidified with 3N HCl to pH=4 and extracted with EtOAc. The organic
layer was concentrated to give crude mixture which was purified by
Gilson HPLC (Phenomenex Gemini 250.times.21.2 10.mu. C18 column,
40-100% ACN/H.sub.2O+0.1% TFA) to give a yellow powder after
lyophilization. .sup.1H NMR (400 MHz, Chloroform-d) .delta. 8.32
(s, 1H), 8.03 (s, 1H), 7.86 (s, 1H), 7.71 (d, J=8.1 Hz, 1H),
7.58-7.47 (m, 3H), 7.43 (d, J=8.9 Hz, 1H), 5.31 (s, 1H), 4.48 (s,
2H), 4.38 (q, J=7.2 Hz, 2H), 4.19 (t, J=8.9 Hz, 2H), 4.04-3.92 (m,
3H), 3.85 (s, 1H), 3.68 (d, J=1.8 Hz, 3H), 3.43 (d, J=50.1 Hz, 3H),
2.76 (s, 1H), 2.57 (s, 3H), 2.34 (m, 3H), 1.50 (t, J=7.2 Hz, 3H),
1.20 (d, J=6.2 Hz, 5H), 1.00 (s, 9H). LCMS-ESI+: calc'd for
C.sub.39H.sub.44ClN.sub.5O.sub.5S; 730.3 (M+H).sup.+; found:
730.4(M+H).sup.+.
Example 51
(S)-2-(tert-butoxy)-2-(7-(4-chlorophenyl)-2-(1-ethyl-3-(1-((S)-1-(methoxyc-
arbonyl)pyrrolidin-3-yl)piperidin-4-yl)-1H-indazol-5-yl)-5-methylbenzo[d]t-
hiazol-6-yl)acetic acid (49)
##STR00141##
[0533] Preparation of tert-butyl
3-(4-(5-(6-((S)-1-(tert-butoxy)-2-ethoxy-2-oxoethyl)-7-(4-chlorophenyl)-5-
-methylbenzo[d]thiazol-2-yl)-1H-indazol-3-yl)piperidin-1-yl)pyrrolidine-1--
carboxylate: A solution of ethyl
(S)-2-(tert-butoxy)-2-(7-(4-chlorophenyl)-5-methyl-2-(3-(piperidin-4-yl)--
1H-indazol-5-yl)benzo[d]thiazol-6-yl)acetate (1.56 g, 2.53 mmol),
N-Boc-3-pyrrolidinone (4.68 g, 25.3 mmol), Acetic acid (0.72 ml,
12.6 mmol) Sodium triacetoxyborohydride (2.68 g, 12.6 mmol) in
dichloroethane (50 mL) was stirred for 5 hours at room temperature.
Reaction was quenched with saturated sodium bicarbonate solution
and brine. The mixture was extracted with dichloromathane
(2.times.) and combined organic layer was dried (MgSO.sub.4),
filtered and concentrated. The residue was purified by CombiFlash
(120 g, Gold, 0-20% MeOH/CH.sub.2Cl.sub.2) to give desired product
as two diasteriomers. LCMS-ESI+: calc'd for
C.sub.43H.sub.52ClN.sub.5O.sub.5S: 786.43 (M+H).sup.+; found:
786.65 (M+H).sup.+.
[0534] Preparation of tert-butyl
(S)-3-(4-(5-(6-((S)-1-(tert-butoxy)-2-ethoxy-2-oxoethyl)-7-(4-chloropheny-
l)-5-methylbenzo[d]thiazol-2-yl)-1-ethyl-1H-indazol-3-yl)piperidin-1-yl)py-
rrolidine-1-carboxylate and tert-butyl
(R)-3-(4-(5-(6-((S)-1-(tert-butoxy)-2-ethoxy-2-oxoethyl)-7-(4-chloropheny-
l)-5-methylbenzo[d]thiazol-2-yl)-1-ethyl-1H-indazol-3-yl)piperidin-1-yl)py-
rrolidine-1-carboxylate: To a solution of tert-butyl
3-(4-(5-(6-((S)-1-(tert-butoxy)-2-ethoxy-2-oxoethyl)-7-(4-chlorophenyl)-5-
-methylbenzo[d]thiazol-2-yl)-1H-indazol-3-yl)piperidin-1-yl)pyrrolidine-1--
carboxylate (995 mg, 1.27 mmol) in anhydrous DMF (10 mL) was added
Sodium hydride (60% disp. in oil, 152 mg, 3.80 mmol) and stirred
for 20 min at to 0.degree. C. under argon. Iodoethane (610 .mu.l,
7.59 mmol) was added. The reaction mixture was kept at 0.degree. C.
for 3 h, then at room temperature for 1 h. Reaction was complete by
LCMS analysis. Reaction mixture was neutralized using 1N HCl to pH
to 7-8, and extracted with EtOAc. The organic layer was washed with
3% LiCl, dried over MgSO.sub.4 and concentrated. The residue was
purified by CombiFlash (80 g, Gold, 50-100% EtOAc/Hexane) to give
the diastereomeric mixture which was further separated by chiral
column separation (AD-H 4.6.times.100 mm column, 30% EtOH as
co-solvent)
[0535] tert-butyl
(S)-3-(4-(5-(6-((S)-1-(tert-butoxy)-2-ethoxy-2-oxoethyl)-7-(4-chloropheny-
l)-5-methylbenzo[d]thiazol-2-yl)-1-ethyl-1H-indazol-3-yl)piperidin-1-yl)py-
rrolidine-1-carboxylate, Rt=1.74 min, (S,S)-diastereomer: .sup.1H
NMR (400 MHz, Chloroform-d) .delta. 8.37 (s, 1H), 8.04 (dd, J=9.0,
1.5 Hz, 1H), 7.85 (s, 1H), 7.60-7.45 (m, 4H), 7.39 (d, J=8.8 Hz,
1H), 5.16 (s, 1H), 4.37 (q, J=7.2 Hz, 2H), 4.21 (qq, J=7.2, 3.7 Hz,
2H), 3.84-2.71 (m, 9H), 2.60 (s, 3H), 2.37-1.95 (m, 7H), 1.83 (s,
1H), 1.62 (s, 3H), 1.48 (d, J=6.0 Hz, 12H), 1.25 (t, J=7.1 Hz, 3H),
0.98 (s, 9H). LCMS-ESI+: calc'd for
C.sub.45H.sub.56ClN.sub.5O.sub.5S; 814.5 (M+H).sup.+; found:
814.3(M+H).sup.+.
[0536] tert-butyl
(R)-3-(4-(5-(6-((S)-1-(tert-butoxy)-2-ethoxy-2-oxoethyl)-7-(4-chloropheny-
l)-5-methylbenzo[d]thiazol-2-yl)-1-ethyl-1H-indazol-3-yl)piperidin-1-yl)py-
rrolidine-1-carboxylate, Rt=2.37 min, (R, S)-diastereomer: .sup.1H
NMR (400 MHz, Chloroform-d) .delta. 8.37 (s, 1H), 8.04 (d, J=8.8
Hz, 1H), 7.85 (s, 1H), 7.61-7.45 (m, 4H), 7.39 (d, J=8.9 Hz, 1H),
5.16 (s, 1H), 4.37 (q, J=7.2 Hz, 2H), 4.21 (tq, J=7.0, 3.5 Hz, 2H),
3.87-2.71 (m, 9H), 2.60 (s, 3H), 2.40-1.93 (m, 7H), 1.82 (s, 1H),
1.62 (s, 3H), 1.48 (d, J=5.6 Hz, 12H), 1.25 (t, J=7.1 Hz, 3H), 0.98
(s, 9H). LCMS-ESI+: calc'd for C.sub.45H.sub.56ClN.sub.5O.sub.5S;
814.5 (M+H).sup.+; found: 814.4(M+H).sup.+.
[0537] Preparation of ethyl
(S)-2-(tert-butoxy)-2-(7-(4-chlorophenyl)-2-(1-ethyl-3-(1-((S)-pyrrolidin-
-3-yl)piperidin-4-yl)-1H-indazol-5-yl)-5-methylbenzo[d]thiazol-6-yl)acetat-
e: A solution of tert-butyl
(S)-3-(4-(5-(6-((S)-1-(tert-butoxy)-2-ethoxy-2-oxoethyl)-7-(4-chloropheny-
l)-5-methylbenzo[d]thiazol-2-yl)-1-ethyl-1H-indazol-3-yl)piperidin-1-yl)py-
rrolidine-1-carboxylate (339 mg, 0.416 mmol) in 1.25 HCl in
isopropanol (20 mL) was stirred at room temperature for 24 h. The
solvent was removed by vacuum. The residue was added
dichloromethane (50 mL) then evaporated to dryness again. Used as
is the next step. LCMS-ESI+: calc'd for
C.sub.40H.sub.48ClN.sub.5O.sub.3S: 714.4 (M+H).sup.+; found: 714.4
(M+H).sup.+.
[0538] Preparation of
(S)-2-(tert-butoxy)-2-(7-(4-chlorophenyl)-2-(1-ethyl-3-(1-((S)-pyrrolidin-
-3-yl)piperidin-4-yl)-1H-indazol-5-yl)-5-methylbenzo[d]thiazol-6-yl)acetic
acid: To the above crude mixture (0.416 mmol) was added THF (10 mL)
MeOH (4 mL) and 50% Sodium hydroxide (4 mL) at room temperature.
The resulting mixture was stirred at room temperature for 16 h. The
reaction mixture was concentrated to remove the organic solvent.
Toluene was added and evaporated again to only aqueous layer
remained. Used as is for the next step. LCMS-ESI+: calc'd for
C.sub.38H.sub.44ClN.sub.5O.sub.3S; 686.3 (M+H).sup.+; found:
686.4(M+H).sup.+.
[0539] Preparation of
(S)-2-(tert-butoxy)-2-(7-(4-chlorophenyl)-2-(1-ethyl-3-(1-((S)-1-(methoxy-
carbonyl)pyrrolidin-3-yl)piperidin-4-yl)-1H-indazol-5-yl)-5-methylbenzo[d]-
thiazol-6-yl)acetic acid: To above crude mixture containing
(S)-2-(tert-butoxy)-2-(7-(4-chlorophenyl)-2-(1-ethyl-3-(1-((S)-pyrrolidin-
-3-yl)piperidin-4-yl)-1H-indazol-5-yl)-5-methylbenzo[d]thiazol-6-yl)acetic
acid (0.416 mmol) were added dichloromethane (80 mL), sat'd sodium
bicarbonate (40 mL) and Methyl chloroformate (1000 .mu.l, 1.3
mmol). The mixture was stirred at room temperature for 20 h. The
reaction mixture was cooled to 0.degree. C., acidified with 3N HCl
to pH=4. The layers were separated and the aqueous phase was
extracted with 25% CH3Cl/i-PrOH mixture (2.times.). The organic
phases were combined and concentrated to give crude mixture which
was purified by Gilson HPLC (Phenomenex Gemini 250.times.21.2
10.mu. C18 column, 40-100% ACN/H.sub.2O+0.1% TFA) to give a yellow
powder after lyophilization. .sup.1H NMR (400 MHz, Chloroform-d)
.delta. 8.71 & 8.30 (s, s, 1H), 8.10-8.03-7.84 (m, 2H), 7.72
(d, J=8.2 Hz, 1H), 7.54 (t, J=10.6 Hz, 3H), 7.47-7.38 (m, 1H), 5.33
(s, 1H), 4.39 (dd, J=12.5, 6.9 Hz, 2H), 3.89 (br, 2H), 3.72 (d,
J=10.5 Hz, 6H), 3.50 (d, J=32.3 Hz, 4H), 3.03 (m, 1H), 2.67 (m,
2H), 2.59 (s, 3H), 2.49-2.14 (m, 4H), 1.52 (dt, J=12.7, 7.2 Hz,
3H), 1.25 (br, 5H), 1.01 (s, 9H), 0.92-0.81 (m, 1H). LCMS-ESI+:
calc'd for C.sub.40H.sub.46ClN.sub.5O.sub.5S; 744.4 (M+H).sup.+;
found: 744.5(M+H).sup.+.
Example 52
(S)-2-(tert-butoxy)-2-(7-(4-chlorophenyl)-2-(1-ethyl-3-(1-((R)-1-(methoxyc-
arbonyl)pyrrolidin-3-yl)piperidin-4-yl)-1H-indazol-5-yl)-5-methylbenzo[d]t-
hiazol-6-yl)acetic acid (50)
##STR00142## ##STR00143##
[0541] Preparation of
(S)-2-(tert-butoxy)-2-(7-(4-chlorophenyl)-2-(1-ethyl-3-(1-((R)-1-(methoxy-
carbonyl)pyrrolidin-3-yl)piperidin-4-yl)-1H-indazol-5-yl)-5-methylbenzo[d]-
thiazol-6-yl)acetic acid: Prepared using similar procedures as for
(S)-2-(2-(3-(1-(1-acetylazetidin-3-yl)piperidin-4-yl)-1-(difluoromethyl)--
1H-indazol-5-yl)-7-(4-chlorophenyl)-5-methylbenzo[d]thiazol-6-yl)-2-(tert--
butoxy)acetic acid. Starting from tert-butyl
(R)-3-(4-(5-(6-((S)-1-(tert-butoxy)-2-ethoxy-2-oxoethyl)-7-(4-chloropheny-
l)-5-methylbenzo[d]thiazol-2-yl)-1-ethyl-1H-indazol-3-yl)piperidin-1-yl)py-
rrolidine-1-carboxylate, it was de-Boc in 1.25 HCl in isopropanol
and then saponification with 50% Sodium hydroxide followed by the
reaction with Methyl chloroformate. The crude mixture was purified
by Gilson HPLC (Phenomenex Gemini 250.times.21.2 10.mu. 18 column,
40-100% ACN/H.sub.2O+0.1% TFA) to give a yellow powder after
lyophilization. .sup.1H NMR (400 MHz, Chloroform-d) .delta. 8.49
(d, J=145.1 Hz, 1H), 8.14-7.65 (m, 3H), 7.65-7.38 (m, 4H), 5.33 (s,
1H), 4.39 (dd, J=11.4, 7.6 Hz, 2H), 3.90 (br s, 2H), 3.72 (d,
J=12.1 Hz, 5H), 3.48 (d, J=37.2 Hz, 2H), 3.12-2.62 (m, 3H), 2.59
(d, J=3.4 Hz, 3H), 2.47-2.14 (m, 2H), 1.52 (dt, J=11.7, 7.2 Hz,
3H), 1.25 (s, 5H), 1.01 (d, J=2.3 Hz, 9H), 0.91-0.81 (m, 1H).
LCMS-ESI+: calc'd for C.sub.40H.sub.46ClN.sub.5O.sub.5S; 744.4
(M+H).sup.+; found: 744.5(M+H).sup.+.
Example 53
Preparation of
(S)-2-(tert-butoxy)-2-(7-(4-chlorophenyl)-2-(3-(2,5-dihydrofuran-3-yl)-1--
methyl-1H-indazol-5-yl)-5-methylbenzo[d]thiazol-6-yl)acetic acid
(51)
##STR00144##
[0543] Preparation of ethyl
(S)-2-(tert-butoxy)-2-(7-(4-chlorophenyl)-2-(3-(2,5-dihydrofuran-3-yl)-1--
methyl-1H-indazol-5-yl)-5-methylbenzo[d]thiazol-6-yl)acetate: A
mixture of ethyl
(S)-2-(2-(3-bromo-1-methyl-1H-indazol-5-yl)-7-(4-chlorophenyl)-5-me-
thylbenzo[d]thiazol-6-yl)-2-(tert-butoxy)acetate (29.6 mg, 0.047
mmol),
2-(2,5-dihydrofuran-3-yl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane
(13.4 mg, 0.068 mmol), tetrakis(triphenylphosphine)palladium(0)
(5.4 mg, 0.005 mmol), and potassium carbonate (21.1 mg, 0.152 mmol)
in a microwave vial was purged with argon gas for .about.3 min and
water (0.25 mL) and dioxane (1 mL) were added. The resulting
mixture was reacted in a microwave reactor for 30 min at
110.degree. C. After the reaction mixture was diluted with ethyl
acetate and washed with water (.times.2), and the aqueous fractions
were extracted with ethyl acetate (.times.1), the organic fractions
were combined, dried (Na.sub.2SO.sub.4), and concentrated. The
residue was purified by Combiflash (12 g, Gold, 0-100% EtOAc/Hex)
to get 23.3 mg of impure product, which was further purified by
Gilson HPLC (Phenomenex Gemini 250.times.21.2 10 u C18 column,
60-100% ACN/H.sub.2O+0.1% TFA). The collected fraction was
neutralized with saturated aqueous NaHCO.sub.3 and concentrated to
dryness. The residue was dissolved in dichloromethane, washed with
water, dried (Na.sub.2SO.sub.4), and concentrated to obtain the
title product. LCMS-ESI.sup.+: calc'd for
C.sub.35H.sub.37ClN.sub.3O.sub.4S: 616.20 (M+H).sup.+; found:
616.31 (M+H).sup.+.
[0544] Preparation of
(S)-2-(tert-butoxy)-2-(7-(4-chlorophenyl)-2-(3-(2,5-dihydrofuran-3-yl)-1--
methyl-1H-indazol-5-yl)-5-methylbenzo[d]thiazol-6-yl)acetic acid:
To a solution of ethyl
(S)-2-(tert-butoxy)-2-(7-(4-chlorophenyl)-2-(3-(2,5-dihydrofuran-3-yl)-1--
methyl-1H-indazol-5-yl)-5-methylbenzo[d]thiazol-6-yl)acetate (5.0
mg, 0.008 mmol) in THF (0.5 mL) and MeOH (0.5 mL) was added 2 N
NaOH (0.15 mL) at room temperature and kept tightly before the
mixture was stirred at 70.degree. C. for 1.5 h. The reaction
mixture was concentrated to remove organic solvent and acidified
with 2 N HCl. The resulting mixture was dissolved with DMF and MeCN
(total .about.3 mL), filtered through syringe filter, and purified
by Gilson HPLC (Phenomenex Gemini, 60-100% ACN/H.sub.2O+0.1% TFA)
to obtain the title product after lyophilization. .sup.1H NMR (400
MHz, Acetonitrile-d.sub.3) .delta. 8.48 (dd, J=1.5, 0.8 Hz, 1H),
8.13 (dd, J=8.9, 1.6 Hz, 1H), 7.86 (d, J=1.0 Hz, 1H), 7.71-7.64 (m,
1H), 7.64-7.54 (m, 4H), 6.67 (p, J=2.0 Hz, 1H), 5.29 (s, 1H), 5.06
(td, J=4.7, 2.1 Hz, 2H), 4.86 (td, J=4.8, 4.3, 1.7 Hz, 2H), 4.03
(s, 3H), 2.59 (d, J=0.8 Hz, 3H), 1.00 (s, 9H). LCMS-ESI.sup.+:
calc'd for C.sub.32H.sub.31ClN.sub.3O.sub.4S: 588.17(M+H).sup.+;
found: 588.27 (M+H).sup.+.
Example 54
Preparation of
(2S)-2-(tert-butoxy)-2-(7-(4-chlorophenyl)-5-methyl-2-(1-methyl-3-(tetrah-
ydrofuran-3-yl)-1H-indazol-5-yl)benzo[d]thiazol-6-yl)acetic acid
(52)
##STR00145##
[0546] Preparation of ethyl
(2S)-2-(tert-butoxy)-2-(7-(4-chlorophenyl)-5-methyl-2-(1-methyl-3-(tetrah-
ydrofuran-3-yl)-1H-indazol-5-yl)benzo[d]thiazol-6-yl)acetate: A
mixture of ethyl
(S)-2-(tert-butoxy)-2-(7-(4-chlorophenyl)-2-(3-(2,5-dihydrofuran-3--
yl)-1-methyl-1H-indazol-5-yl)-5-methylbenzo[d]thiazol-6-yl)acetate
(12.0 mg, 0.019 mmol) and 5% Rhodium on alumina (9.7 mg) in ethanol
(2 mL) was stirred under H.sub.2 atmosphere for 4 h. The reaction
mixture was filtered through celite pad and the filtrate was
concentrated to dryness to get the crude product. LCMS-ESI.sup.+:
calc'd for C.sub.34H.sub.37ClN.sub.3O.sub.4S: 618.22 (M+H).sup.+;
found: 618.37 (M+H).sup.+.
[0547] Preparation of
(2S)-2-(tert-butoxy)-2-(7-(4-chlorophenyl)-5-methyl-2-(1-methyl-3-(tetrah-
ydrofuran-3-yl)-1H-indazol-5-yl)benzo[d]thiazol-6-yl)acetic acid:
To a solution of the above crude ethyl
(2S)-2-(tert-butoxy)-2-(7-(4-chlorophenyl)-5-methyl-2-(1-methyl-3-(tetrah-
ydrofuran-3-yl)-1H-indazol-5-yl)benzo[d]thiazol-6-yl)acetate in THF
(0.5 mL) and MeOH (0.5 mL) was added 2 N NaOH (0.2 mL) at room
temperature and kept tightly before the mixture was stirred at
70.degree. C. for 1.5 h. The reaction mixture was concentrated to
remove organic solvent and acidified with 2 N HCl. The resulting
mixture was dissolved with DMF and MeCN (total 6 mL), filtered
through syringe filter, and purified by Gilson HPLC (Phenomenex
Gemini, 60-100% ACN/H.sub.2O+0.1% TFA) to obtain the title product
after lyophilization. .sup.1H NMR (400 MHz, Acetonitrile-d.sub.3)
.delta. 8.41 (two d, J=0.8 Hz, 1H), 8.09-8.06 (m, 0.48H), 8.05 (t,
J=1.4 Hz, 0.52H), 7.86 (two s, 1H), 7.67 (two d, J=8.9 Hz, 1H),
7.64-7.57 (m, 3H), 7.55 (two d, J=8.9 Hz, 1H), 5.29 (s, 1H),
4.21-4.12 (m, 1H), 4.05 (two t, J=8.2 Hz, 1H), 3.99 (s, 3H),
4.01-3.85 (m, 3H), 2.58 (d, J=0.8 Hz, 3H), 2.51-2.39 (m, 1H),
2.32-2.20 (m, 1H), 0.99 (s, 9H). LCMS-ESI.sup.+: calc'd for
C.sub.32H.sub.33ClN.sub.3O.sub.4S: 590.19 (M+H).sup.+; found:
590.29 (M+H).sup.+.
Example 55
(S)-2-(tert-butoxy)-2-(2-(3-(1-(tert-butoxycarbonyl)azetidin-3-yl)-1-methy-
l-1H-indazol-5-yl)-7-(4-chlorophenyl)-5-methylbenzo[d]thiazol-6-yl)acetic
acid (53)
##STR00146##
[0549] Preparation of tert-butyl
(S)-3-(5-(6-(1-(tert-butoxy)-2-ethoxy-2-oxoethyl)-7-(4-chlorophenyl)-5-me-
thylbenzo[d]thiazol-2-yl)-1-methyl-1H-indazol-3-yl)azetidine-1-carboxylate-
: A mixture of ethyl
(S)-2-(2-(3-bromo-1-methyl-1H-indazol-5-yl)-7-(4-chlorophenyl)-5-methylbe-
nzo[d]thiazol-6-yl)-2-(tert-butoxy)acetate (47.1 mg, 0.047 mmol),
potassium
[1-[(1,1-dimethylethoxy)carbonyl]-3-azetidinyl]trifluoro-borate
(29.9 mg, 0.114 mmol), tetrakis(triphenylphosphine)palladium(0)
(9.6 mg, 0.008 mmol), and potassium carbonate (32.2 mg, 0.233
mmol), water (0.3 mL), and dioxane (1.2 mL) was placed in a
microwave vial and the resulting mixture was reacted in a microwave
reactor at 110.degree. C. for 30 min followed by at 150.degree. C.
for 2.5 h. The resulting mixture was diluted in methanol, filtered
through syringe filter, and purified by Gilson HPLC (Phenomenex
Gemini, 700-100% ACN/H.sub.2O+0.1% TFA) to obtain the title product
after lyophilization. LCMS-ESI.sup.+: calc'd for
C.sub.38H.sub.44ClN.sub.4O.sub.5S: 703.27 (M+H).sup.+; found:
703.04 (M+H).sup.+.
[0550] Preparation of
(S)-2-(tert-butoxy)-2-(2-(3-(1-(tert-butoxycarbonyl)azetidin-3-yl)-1-meth-
yl-1H-indazol-5-yl)-7-(4-chlorophenyl)-5-methylbenzo[d]thiazol-6-yl)acetic
acid: To a solution of tert-butyl
(S)-3-(5-(6-(1-(tert-butoxy)-2-ethoxy-2-oxoethyl)-7-(4-chlorophenyl)-5-me-
thylbenzo[d]thiazol-2-yl)-1-methyl-1H-indazol-3-yl)azetidine-1-carboxylate
(4.4 mg, 0.005 mmol) in THF (0.5 mL) and MeOH (0.5 mL) was added 2
N NaOH (0.1 mL) at room temperature and kept tightly before the
mixture was stirred at 50.degree. C. for 23.5 h. The reaction
mixture was concentrated to remove organic solvent and acidified
with 2 N HCl. The resulting mixture was dissolved with DMF and MeCN
(total .about.3 mL), filtered through syringe filter, and purified
by Gilson HPLC (Phenomenex Gemini, 40-100% ACN/H.sub.2O+0.1% TFA)
to obtain the title product after lyophilization. .sup.1H NMR (400
MHz, Acetonitrile-d.sub.3) .delta. 8.41-8.35 (m, 1H), 8.17 (dd,
J=8.9, 1.6 Hz, 1H), 7.86 (s, 1H), 7.66 (dd, J=7.8, 2.4 Hz, 1H),
7.63-7.56 (m, 4H), 5.28 (s, 1H), 4.39 (d, J=7.1 Hz, 2H), 4.20 (dd,
J=12.7, 5.5 Hz, 3H), 4.04 (s, 3H), 2.58 (s, 3H), 1.44 (s, 9H), 0.99
(s, 9H). LCMS-ESI.sup.+: calc'd for
C.sub.36H.sub.40ClN.sub.4O.sub.5S: 675.24 (M+H).sup.+; found:
674.98 (M+H).sup.+.
Example 56
Preparation of
(S)-2-(tert-butoxy)-2-(7-(4-chlorophenyl)-2-(3-(1-isopropylazetidin-3-yl)-
-1-methyl-1H-indazol-5-yl)-5-methylbenzo[d]thiazol-6-yl)acetic acid
(54)
##STR00147##
[0552] Preparation of ethyl
(S)-2-(2-(3-(azetidin-3-yl)-1-methyl-1H-indazol-5-yl)-7-(4-chlorophenyl)--
5-methylbenzo[d]thiazol-6-yl)-2-(tert-butoxy)acetate: To a flask
containing tert-butyl
(S)-3-(5-(6-(1-(tert-butoxy)-2-ethoxy-2-oxoethyl)-7-(4-chlorophenyl)-5-me-
thylbenzo[d]thiazol-2-yl)-1-methyl-1H-indazol-3-yl)azetidine-1-carboxylate
(16.0 mg, 0.023 mmol) was added 1.25 M HCl in isopropanol (3 mL)
and the resulting mixture was stirred at room temperature for 24 h.
After the reaction mixture was concentrated, the residue was
co-evaporated with acetonitrile (.times.1) and dried to obtain the
crude title product, which was used for the next reaction.
LCMS-ESI.sup.+: calc'd for C.sub.33H.sub.36ClN.sub.4O.sub.3S:
603.22 (M+H).sup.+; found: 603.28 (M+H).sup.+.
[0553] Preparation of
(S)-2-(tert-butoxy)-2-(7-(4-chlorophenyl)-2-(3-(1-isopropylazetidin-3-yl)-
-1-methyl-1H-indazol-5-yl)-5-methylbenzo[d]thiazol-6-yl)acetic
acid: A solution of crude ethyl
(S)-2-(2-(3-(azetidin-3-yl)-1-methyl-1H-indazol-5-yl)-7-(4-chlorophenyl)--
5-methylbenzo[d]thiazol-6-yl)-2-(tert-butoxy)acetate (14.6 mg,
0.023 mmol) in acetonitrile (2 mL) and acetone (0.5 mL) was stirred
at 0.degree. C. bath as sodium cyanoborohydride (.about.30 mg,
0.477 mmol) and acetic acid (2 drops) were added. To the reaction
mixture was added. After 30 min, the reaction mixture was quenched
with saturated NaHCO.sub.3 solution and the product was extracted
with dichloromethane (.times.2). The combined extracts were dried
(Na.sub.2SO.sub.4) and concentrated to get crude isopropylated
product with impurities. LCMS-ESI.sup.+: calc'd for
C.sub.36H.sub.342ClN.sub.4O.sub.3S: 645.27 (M+H).sup.+; found:
645.32 (M+H).sup.+.
[0554] The crude isopropylated product was dissolved in THF (0.5
mL) and MeOH (0.5 mL) was added 2 N NaOH (0.2 mL) at room
temperature and kept tightly before the mixture was stirred at
70.degree. C. for 1.5 h. The reaction mixture was acidified with 2
N HCl (.about.0.22 mL) and concentrated to remove organic solvent.
The resulting mixture was dissolved with methanol, filtered through
syringe filter (total 3 mL), and purified by Gilson HPLC
(Phenomenex Gemini, 30-100% ACN/H.sub.2O+0.1% TFA) to obtain the
title product after lyophilization. .sup.1H NMR (400 MHz,
Acetonitrile-d.sub.3) .delta. 11.15 (s, 1H), 8.33 (s, 1H),
8.21-8.13 (m, 1H), 7.86 (s, 1H), 7.67 (dd, J=8.0, 2.1 Hz, 1H), 7.61
(d, J=8.4 Hz, 4H), 5.28 (s, 1H), 4.70-4.50 (m, 2H), 4.24 (m, 2H),
4.08 (s, 3H), 3.44 (hep, J=6.7 Hz, 1H), 2.58 (s, 3H), 1.28 (d,
J=6.7 Hz, 6H), 0.99 (s, 9H). LCMS-ESI.sup.+: calc'd for
C.sub.34H.sub.38ClN.sub.4O.sub.3S: 617.24 (M+H).sup.+; found:
617.29 (M+H).sup.+.
Example 57
Preparation of
(S)-2-(7-(4-chlorophenyl)-2-(3-(1-isopropylazetidin-3-yl)-1-methyl-1H-ind-
azol-5-yl)-5-methylbenzo[d]thiazol-6-yl)-2-cyclopropoxyacetic acid
(55)
##STR00148## ##STR00149##
[0556] Preparation of tert-butyl
3-((5-bromo-2-fluorophenyl)(hydroxy)methyl)azetidine-1-carboxylate:
A solution of 4-bromo-1-fluoro2-iodobenzene (3.196 g, 10.62 mmol)
in 2-Me-THF (22 mL) was stirred in dry ice--acetone bath while 2.5
M n-BuLi in hexane (from Aldrich, 4.25 mL, 10.63 mmol) was added
dropwise. After 15 min, A solution of
1-Boc-3-azetidinecarboxaldehyde (1.971 g, 10.64 mmol) in 2-Me-THF
(4 mL) was added slowly. After 1 h, the reaction mixture was
quenched with saturated aqueous NH.sub.4Cl solution at the cold
temperature and warmed to rt. The product was extracted with ethyl
acetate (.about.100 mL.times.2), and the extracts were washed with
water (.times.2) before combining, drying (Na.sub.2SO.sub.4), and
concentration. The concentrated residue was purified by CombiFlash
(120 g, Gold, 0-40% EtOAc/Hex) to obtain the title product.
LCMS-ESI.sup.+: calc'd for C.sub.11H.sub.12BrFNO.sub.3: 304.00
(M+H-C.sub.4H.sub.8).sup.+; found: 303.87
(M+H-C.sub.4H.sub.8).sup.+.
[0557] Preparation of tert-butyl
3-(5-bromo-2-fluorobenzoyl)azetidine-1-carboxylate: A solution of
tert-butyl
3-((5-bromo-2-fluorophenyl)(hydroxy)methyl)azetidine-1-carboxylate
(2.499 g, 6.937 mmol) in dichloromethane (50 mL) was stirred at
0.degree. C. as Dess-Martin Periodinane (3.537 g, 8.339 mmol) was
added. After 1.5 h, the mixture was filtered through celite pad.
The filtrate was washed with saturated aqueous NaHCO.sub.3 solution
(.times.1) and water (.times.1). After the aqueous fractions were
extracted with dichloromethane (.times.1), the organic fractions
were combined, dried (Na.sub.2SO.sub.4), and concentrated. The
residue was purified by CombiFlash (120 g, Gold, 0-40% EtOAc/Hex)
to obtain the title product. LCMS-ESI.sup.+: calc'd for
C.sub.11H.sub.10BrFNO.sub.3: 301.98 (M+H-C.sub.4H.sub.8).sup.+;
found: 301.90 (M+H-C.sub.4H.sub.8).sup.+.
[0558] Preparation of tert-butyl
3-(5-bromo-1-methyl-1H-indazol-3-yl)azetidine-1-carboxylate: To a
solution of tert-butyl
3-(5-bromo-2-fluorobenzoyl)azetidine-1-carboxylate (1.586 g, 4.428
mmol), p-toluenesulfonic acid hydtate (59 mg, 342.62 umol) in
dioxane (16 mL) was added methylhydrazine (1.6 mL, 30.39 mmol) and
the mixture was reacted in microwave reactor at 150.degree. C. for
1 h. The reaction mixture was transferred to a RBF and
concentrated. The concentrated residue was purified by CombiFlash
(120 g, Gold, 0-60% EtOAc/Hex) to obtain the title product.
LCMS-ESI.sup.+: calc'd for C.sub.12H.sub.13BrN.sub.3O.sub.2: 310.02
(M+H-C.sub.4H.sub.8).sup.+; found: 310.01
(M+H-C.sub.4H.sub.8).sup.+.
[0559] Preparation of tert-butyl
3-(1-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-indazol-3--
yl)azetidine-1-carboxylate: To a flask containing tert-butyl
3-(5-bromo-1-methyl-1H-indazol-3-yl)azetidine-1-carboxylate (604
mg, 1.649 mmol) were added bis(pinacolato)diboron (512.3 mg, 2.017
mmol), dichloro 1,1'-bis(diphenylphosphino)ferrocene palladium (II)
dichloromethane (144 mg, 0.176 mmol), and potassium acetate (500.2
mg, 5.097 mmol) and the resulting flask was purged with argon gas.
To the flask was added degassed 1,4-dioxane (bubbled with Ar for 1
h, 10 mL) and the resulting mixture was kept tightly and stirred at
95.degree. C. for 1 h and at 100.degree. C. for 30 min. The
reaction mixture was diluted with EA, dried (Na.sub.2SO.sub.4) and
concentrated. The residue was purified by CombiFlash (80 g, Gold,
25-45% EtOAc/Hex) using hexanes--EA as eluents to obtain the title
product. LCMS-ESI.sup.+: calc'd for
C.sub.22H.sub.33BN.sub.3O.sub.4: 414.26 (M+H)+; found: 413.77
(M+H).sup.+.
[0560] Preparation of tert-butyl
(S)-3-(5-(7-(4-chlorophenyl)-6-(1-cyclopropoxy-2-ethoxy-2-oxoethyl)-5-met-
hylbenzo[d]thiazol-2-yl)-1-methyl-1H-indazol-3-yl)azetidine-1-carboxylate:
To a vial containing ethyl
(S)-2-(2-bromo-7-(4-chlorophenyl)-5-methylbenzo[d]thiazol-6-yl)-2-cyclopr-
opoxyacetate (35 mg, 0.073 mmol), tert-butyl
3-(1-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-indazol-3--
yl)azetidine-1-carboxylate (32.1 mg, 0.088 mmol), K.sub.2CO.sub.3
(34.0 mg, 0.246 mmol), and tetrakis(triphenylphosphine)palladium(0)
(9.72 mg, 0.008 mmol) in water (0.25 mL) and 1,4-dioxane (1 mL) was
purged with Ar and then kept tightly before heating at 95.degree.
C. bath for 45 min. The reaction mixture was diluted with ethyl
acetate, dried (Na.sub.2SO.sub.4), and concentrated. The residue
was purified by CombiFlash (12 g, Gold, 25-70% EtOAc/Hex) to obtain
the title product. LCMS-ESI.sup.+: calc'd for
C.sub.37H.sub.40ClN.sub.4O.sub.5S: 687.24 (M+H).sup.+; found:
687.01 (M+H).sup.+.
[0561] Preparation of ethyl
(S)-2-(2-(3-(azetidin-3-yl)-1-methyl-1H-indazol-5-yl)-7-(4-chlorophenyl)--
5-methylbenzo[d]thiazol-6-yl)-2-cyclopropoxyacetate: To a flask
containing tert-butyl
(S)-3-(5-(7-(4-chlorophenyl)-6-(1-cyclopropoxy-2-ethoxy-2-oxoethyl)-5-met-
hylbenzo[d]thiazol-2-yl)-1-methyl-1H-indazol-3-yl)azetidine-1-carboxylate
(47.4 mg, 0.069 mmol) was added 1.25 M HCl in isopropanol (2 mL,
2.5 mmol) and the resulting solution was stirred at rt. After 20 h,
the reaction mixture was concentrated at 20.degree. C. bath and
dried in vacuum for 30 min to get crude ethyl
(S)-2-(2-(3-(azetidin-3-yl)-1-methyl-1H-indazol-5-yl)-7-(4-chlorophenyl)--
5-methylbenzo[d]thiazol-6-yl)-2-cyclopropoxyacetate which contained
some isopropanol. LCMS-ESI.sup.+: calc'd for
C.sub.32H.sub.32ClN.sub.4O.sub.3S: 587.19 (M+H).sup.+; found:
587.26 (M+H).sup.+.
[0562] Preparation of
(S)-2-(7-(4-chlorophenyl)-2-(3-(1-isopropylazetidin-3-yl)-1-methyl-1H-ind-
azol-5-yl)-5-methylbenzo[d]thiazol-6-yl)-2-cyclopropoxyacetic acid:
To a flask containing the above crude ethyl
(S)-2-(2-(3-(azetidin-3-yl)-1-methyl-1H-indazol-5-yl)-7-(4-chlorophenyl)--
5-methylbenzo[d]thiazol-6-yl)-2-cyclopropoxyacetate were added
methanol (3 mL) and acetone (0.15 mL) and stirred at 0.degree. C.
bath as sodium cyanoborohydride (50 mg, 0.796 mmol) and AcOH (1
drop) were added. After 1.5 h, the reaction mixture was diluted
with saturated NaHCO.sub.3, and the product was extracted with
ethyl acetate (.times.3). The extracts were combined dried
(MgSO.sub.4), concentrated, and dried in vacuum for 30 min.
LCMS-ESI.sup.+: calc'd for C.sub.35H.sub.38ClN.sub.4O.sub.3S:
629.24 (M+H).sup.+; found: 629.33 (M+H).sup.+.
[0563] The above residue was dissolved in THF (1 mL) and MeOH (1
mL) before 2 N NaOH (1 mL) was added. The resulting mixture was
stirred at 70.degree. C. preheated bath. After 1 h, the reaction
mixture was acidified with 2 N HCl (.about.1.05 mL) and
concentrated to almost dryness. The residue was triturated with
MeOH (.about.1.5 mL) and the suspension was filtered through
syringe filter. The resulting filtrate was purified by Gilson HPLC
(Phenomenex Gemini, 30-50% ACN/H.sub.2O+0.1% TFA) to obtain the
title product after lyophilization. .sup.1H NMR (400 MHz,
Acetonitrile-d.sub.3) .delta. 9.08 (br, 1H), 8.32 (dt, J=2.4, 1.2
Hz, 1H), 8.17 (ddd, J=10.4, 9.0, 1.6 Hz, 1H), 7.87 (d, J=6.4 Hz,
1H), 7.66-7.56 (m, 3H), 7.52 (dd, J=8.6, 2.1 Hz, 1H), 7.47 (dd,
J=8.5, 2.1 Hz, 1H), 5.17 (s, 1H), 4.68-4.36 (m, 4H), 4.36-4.22 (m,
1H), 4.09 (s, 1.2H), 4.06 (s, 1.8H), 3.66-3.53 (m, 0.4H), 3.48 (dq,
J=8.8, 6.4 Hz, 0.6H), 3.26 (tt, J=6.0, 3.0 Hz, 1H), 2.57-2.47 (m,
3H), 1.28 (t, J=6.8 Hz, 6H), 0.48-0.24 (m, 4H). LCMS-ESI.sup.+:
calc'd for C.sub.33H.sub.34ClN.sub.4O.sub.3S: 601.20 (M+H).sup.+;
found: 601.31 (M+H).sup.+.
Example 58
Preparation of
(S)-2-(tert-butoxy)-2-(7-(4-chlorophenyl)-2-(3-(1-(2-methoxyethyl)azetidi-
n-3-yl)-1-methyl-1H-indazol-5-yl)-5-methylbenzo[d]thiazol-6-yl)acetic
acid (56)
##STR00150## ##STR00151##
[0565] Preparation of tert-butyl
(S)-3-(5-(6-(1-(tert-butoxy)-2-ethoxy-2-oxoethyl)-7-(4-chlorophenyl)-5-me-
thylbenzo[d]thiazol-2-yl)-1-methyl-1H-indazol-3-yl)azetidine-1-carboxylate-
: A microwave reaction vial containing ethyl
(S)-2-(2-bromo-7-(4-chlorophenyl)-5-methylbenzo[d]thiazol-6-yl)-2-(tert-b-
utoxy)acetate (98.2 mg, 0.198 mmol), tert-butyl
3-(1-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-indazol-3--
yl)azetidine-1-carboxylate (99.3 mg, 0.240 mmol), potassium
carbonate (85.2 mg, 0.616 mmol), and
tetrakis(triphenylphosphine)palladium(0) (23.2 mg, 0.020 mmol) in
water (0.4 mL) and 1,4-dioxane (1.6 mL) was purged with Ar for 5
min and then kept tightly before heating at 95.degree. C. bath for
5 h. The reaction mixture was diluted with EA, dried
(Na.sub.2SO.sub.4), and concentrated. The residue was purified by
CombiFlash (24 g, Gold, 0-80% EtOAc/Hex) to get impure product. The
impure product was purified again by CombiFlash (24 g, Gold, 30-65%
EtOAc/Hex) to obtain the title product. LCMS-ESI.sup.+: calc'd for
C.sub.38H.sub.44ClN.sub.4O.sub.5S: 703.27 (M+H).sup.+; found:
703.03 (M+H).sup.+.
[0566] Preparation of ethyl
(S)-2-(2-(3-(azetidin-3-yl)-1-methyl-1H-indazol-5-yl)-7-(4-chlorophenyl)--
5-methylbenzo[d]thiazol-6-yl)-2-(tert-butoxy)acetate: To a flask
containing tert-butyl
(S)-3-(5-(6-(1-(tert-butoxy)-2-ethoxy-2-oxoethyl)-7-(4-chlorophenyl)-5-me-
thylbenzo[d]thiazol-2-yl)-1-methyl-1H-indazol-3-yl)azetidine-1-carboxylate
(94.7 mg, 0.135 mmol) was added 1.25 M HCl in isopropanol (3.5 mL,
4.375 mmol) and the resulting solution was stirred at rt. After 20
h, the reaction mixture was concentrated and dried in vacuum for 5
h to get crude ethyl
(S)-2-(2-(3-(azetidin-3-yl)-1-methyl-1H-indazol-5-yl)-7-(4-chlorophenyl)--
5-methylbenzo[d]thiazol-6-yl)-2-(tert-butoxy)acetate. LCMS
-ESI.sup.+: calc'd for C.sub.33H.sub.36ClN.sub.4O.sub.3S: 603.22
(M+H).sup.+; found: 603.29 (M+H).sup.+.
[0567] Preparation of
(S)-2-(tert-butoxy)-2-(7-(4-chlorophenyl)-2-(3-(1-(2-methoxyethyl)azetidi-
n-3-yl)-1-methyl-1H-indazol-5-yl)-5-methylbenzo[d]thiazol-6-yl)acetic
acid: To a flask containing 1/4 of the above crude ethyl
(S)-2-(2-(3-(azetidin-3-yl)-1-methyl-1H-indazol-5-yl)-7-(4-chlorophenyl)--
5-methylbenzo[d]thiazol-6-yl)-2-(tert-butoxy)acetate were added
methanol (2 mL), methoxyacetaldehyde (0.1 mL, 1.357 mmol) and
stirred at 0.degree. C. bath as sodium cyanoborohydride (30 mg,
0.477 mmol) and acetic acid (1 drop). After 30 min, the reaction
mixture was diluted with saturated aqueous NaHCO.sub.3, and the
product was extracted with ethyl acetate (.times.3). The extracts
were combined dried (MgSO.sub.4), concentrated, and dried in vacuum
for 30 min. LCMS-ESI.sup.+: calc'd for
C.sub.36H.sub.42ClN.sub.4O.sub.4S: 661.26 (M+H).sup.+; found:
661.37 (M+H).sup.+.
[0568] The above residue was dissolved in THF (1 mL) and MeOH (1
mL) before 2 N NaOH (1 mL) was added. The resulting mixture was
stirred at 70.degree. C. preheated bath for 2 h and the reaction
mixture was acidified with 2 N HCl (.about.1.05 mL) and
concentrated to almost dryness. The residue was triturated with
MeOH (.about.1.5 mL) and the suspension was filtered through
syringe filter. The resulting filtrate was purified by Gilson HPLC
(Phenomenex Gemini, 30-50% ACN/H.sub.2O+0.1% TFA) to obtain the
title product after lyophilization. .sup.1H NMR (400 MHz,
Acetonitrile-d.sub.3) .delta. 8.31 (s, 1H), 8.19-8.11 (m, 1H), 7.85
(d, J=2.6 Hz, 1H), 7.67 (dd, J=7.8, 2.4 Hz, 1H), 7.64-7.55 (m, 4H),
5.28 (s, 1H), 4.75 (t, J=9.6 Hz, 1H), 4.60 (m, 2H), 4.47 (m, 1H),
4.35 (br, 1H), 4.07 (two s, 3H), 3.68-3.58 (m, 2H), 3.56-3.50 (m,
1H), 3.47 (m, 1H), 3.36 (two s, 3H), 2.58 (two s, 3H), 0.99 (s,
9H). LCMS-ESI.sup.+: calc'd for C.sub.34H.sub.38ClN.sub.4O.sub.4S:
633.23 (M+H).sup.+; found: 633.32 (M+H).sup.+.
Example 59
Preparation of
(S)-2-(tert-butoxy)-2-(7-(4-chlorophenyl)-5-methyl-2-(1-methyl-3-(1-methy-
lazetidin-3-yl)-1H-indazol-5-yl)benzo[d]thiazol-6-yl)acetic acid
(57)
##STR00152##
[0570] Preparation of
(S)-2-(tert-butoxy)-2-(7-(4-chlorophenyl)-5-methyl-2-(1-methyl-3-(1-methy-
lazetidin-3-yl)-1H-indazol-5-yl)benzo[d]thiazol-6-yl)acetic acid:
To a flask containing 1/8 of the above crude ethyl
(S)-2-(2-(3-(azetidin-3-yl)-1-methyl-1H-indazol-5-yl)-7-(4-chlorophenyl)--
5-methylbenzo[d]thiazol-6-yl)-2-(tert-butoxy)acetate were added
methanol (1 mL), 37% formaldehyde (0.1 mL, 1.343 mmol) and stirred
at 0.degree. C. bath as sodium cyanoborohydride (30 mg, 0.477 mmol)
and acetic acid (1 drop). After 30 min, the reaction mixture was
diluted with saturated aqueous NaHCO.sub.3, and the product was
extracted with ethyl acetate (.times.3). The extracts were combined
dried (MgSO.sub.4), concentrated, and dried in vacuum for 30 min.
LCMS-ESI.sup.+: calc'd for C.sub.34H.sub.38ClN.sub.4O.sub.3S:
617.24 (M+H).sup.+; found: 617.33 (M+H).sup.+.
[0571] The above residue was dissolved in THF (1 mL) and MeOH (1
mL) before 2 N NaOH (1 mL) was added. The resulting mixture was
stirred at 70.degree. C. preheated bath for 2 h and the reaction
mixture was acidified with 2 N HCl (.about.1.05 mL) and
concentrated to almost dryness. The residue was triturated with
MeOH (.about.1.5 mL) and the suspension was filtered through
syringe filter. The resulting filtrate was purified by Gilson HPLC
(Phenomenex Gemini, 30-60% ACN/H.sub.2O+0.1% TFA) to obtain the
title product after lyophilization. .sup.1H NMR (400 MHz,
Acetonitrile-d.sub.3) .delta. 8.30-8.24 (m, 1H), 8.13 (dd, J=8.9,
1.6 Hz, 1H), 7.82 (s, 1H), 7.67 (dd, J=7.8, 2.5 Hz, 1H), 7.64-7.49
(m, 4H), 5.27 (s, 1H), 4.87-4.44 (m, 3H), 4.16 (s, 2H), 4.06 (s,
3H), 2.95 (s, 3H), 2.57 (s, 3H), 0.98 (s, 9H). LCMS-ESI.sup.+:
calc'd for C.sub.32H.sub.34ClN.sub.4O.sub.3S: 589.20 (M+H).sup.+;
found: 589.29 (M+H).sup.+.
Example 60
Preparation of
(S)-2-(tert-butoxy)-2-(7-(4-chlorophenyl)-2-(3-(1-ethylazetidin-3-yl)-1-m-
ethyl-1H-indazol-5-yl)-5-methylbenzo[d]thiazol-6-yl)acetic acid
(58)
##STR00153##
[0573] Preparation of
(S)-2-(tert-butoxy)-2-(7-(4-chlorophenyl)-2-(3-(1-ethylazetidin-3-yl)-1-m-
ethyl-1H-indazol-5-yl)-5-methylbenzo[d]thiazol-6-yl)acetic acid: To
a flask containing 1/8 of the above crude ethyl
(S)-2-(2-(3-(azetidin-3-yl)-1-methyl-1H-indazol-5-yl)-7-(4-chlorophenyl)--
5-methylbenzo[d]thiazol-6-yl)-2-(tert-butoxy)acetate were added
methanol (1 mL), acetaldehyde (0.015 mL, 0.267 mmol) and stirred at
0.degree. C. bath as sodium cyanoborohydride (30 mg, 0.477 mmol)
and acetic acid (1 drop). After 30 min, the reaction mixture was
diluted with saturated aqueous NaHCO.sub.3, and the product was
extracted with ethyl acetate (.times.3). The extracts were combined
dried (MgSO.sub.4), concentrated, and dried in vacuum for 30 min.
LCMS-ESI.sup.+: calc'd for C.sub.35H.sub.40ClN.sub.4O.sub.3S:
631.25 (M+H).sup.+; found: 631.29 (M+H).sup.+.
[0574] The above residue was dissolved in THF (1 mL) and MeOH (1
mL) before 2 N NaOH (1 mL) was added. The resulting mixture was
stirred at 70.degree. C. preheated bath for 2 h and the reaction
mixture was acidified with 2 N HCl (.about.1.05 mL) and
concentrated to almost dryness. The residue was triturated with
MeOH (.about.1.5 mL) and the suspension was filtered through
syringe filter. The resulting filtrate was purified by Gilson HPLC
(Phenomenex Gemini, 30-60% ACN/H.sub.2O+0.1% TFA) to obtain the
title product after lyophilization. .sup.1H NMR (400 MHz,
Acetonitrile-d.sub.3) .delta. 8.27 (s, 1H), 8.13 (dd, J=8.9, 1.6
Hz, 1H), 7.82 (s, 1H), 7.66 (dd, J=7.9, 2.3 Hz, 1H), 7.64-7.53 (m,
4H), 5.27 (s, 1H), 4.65 (m, 3H), 4.36-4.21 (m, 1H), 4.17 (d, J=9.0
Hz, 1H), 4.06 (s, 3H), 3.27 (d, J=8.2 Hz, 2H), 2.57 (d, J=6.5 Hz,
3H), 1.22 (t, J=7.1 Hz, 3H), 0.99 (s, 9H). LCMS-ESI.sup.+: calc'd
for C.sub.33H.sub.36ClN.sub.4O.sub.3S: 603.22 (M+H).sup.+; found:
603.33 (M+H).sup.+.
Example 61
Preparation of
(S)-2-(tert-butoxy)-2-(7-(4-chlorophenyl)-5-methyl-2-(1-methyl-3-(1-(oxet-
an-3-yl)azetidin-3-yl)-1H-indazol-5-yl)benzo[d]thiazol-6-yl)acetic
acid (59)
##STR00154##
[0576] Preparation of (S)-ethyl
2-(tert-butoxy)-2-(7-(4-chlorophenyl)-5-methyl-2-(1-methyl-3-(1-(oxetan-3-
-yl)azetidin-3-yl)-1H-indazol-5-yl)benzo[d]thiazol-6-yl)acetate: In
a 50 mL round-bottom flask, ethyl
(S)-2-(2-(3-(azetidin-3-yl)-1-methyl-1H-indazol-5-yl)-7-(4-chlorophenyl)--
5-methylbenzo[d]thiazol-6-yl)-2-(tert-butoxy)acetate (0.010 g,
0.015 mmol) was dissolved in MeOH (1 mL). Oxetan-3-one (0.011 g,
0.15 mmol) was added to the reaction mixture. NaBH.sub.3CN (0.01 g,
0.15 mmol) and one drop of acetic acid were added to the reaction
mixture. The reaction mixture was stirred at room temperature for
half an hour. After concentration, the residue was dissolved in
EtOAc, washed with brine and dried over Na.sub.2SO.sub.4. After
concentration, the crude was used for next step without further
purification.
[0577] Preparation of
(S)-2-(tert-butoxy)-2-(7-(4-chlorophenyl)-5-methyl-2-(1-methyl-3-(1-(oxet-
an-3-yl)azetidin-3-yl)-1H-indazol-5-yl)benzo[d]thiazol-6-yl)acetic
acid: Prepared in a manner similar to
(S)-2-(tert-butoxy)-2-(7-(4-chlorophenyl)-5-methyl-2-(1-methyl-3-(2-oxa-6-
-azaspiro[3.3
]heptan-6-yl)-1H-indazol-5-yl)benzo[d]thiazol-6-yl)acetic acid
except using (S)-ethyl
2-(tert-butoxy)-2-(7-(4-chlorophenyl)-5-methyl-2-(1-methyl-3-(1-(oxetan-3-
-yl)azetidin-3-yl)-1H-indazol-5-yl)benzo[d]thiazol-6-yl)acetate
instead of (S)-ethyl
2-(tert-butoxy)-2-(7-(4-chlorophenyl)-5-methyl-2-(1-methyl-3-(2-
-oxa-6-azaspiro[3.3]heptan-6-yl)-1H-indazol-5-yl)benzo[d]thiazol-6-yl)acet-
ate. .sup.1H NMR (400 MHz, Chloroform-d) 6 1H NMR (400 MHz,
Acetonitrile-d3) .delta. 8.36 (s, 1H), 8.31-8.10 (m, 1H), 7.88 (d,
J=1.0 Hz, 1H), 7.73-7.52 (m, 5H), 5.29 (s, 1H), 5.05-4.36 (m, 4H),
4.17-4.04 (m, 4H), 3.02 (dd, J=8.6, 5.5 Hz, 1H), 2.59 (d, J=0.8 Hz,
4H), 1.00 (s, 9H).
Example 62
Preparation of
(S)-2-(2-(3-(1-(tert-butyl)azetidin-3-yl)-1-methyl-1H-indazol-5-yl)-7-(4--
chlorophenyl)-5-methylbenzo[d]thiazol-6-yl)-2-cyclopropoxyacetic
acid (60)
##STR00155## ##STR00156##
[0579] Preparation of
1-(tert-butyl)-N-methoxy-N-methylazetidine-3-carboxamide:
1-(tert-butyl)azetidine-3-carboxylic acid (0.50 g, 3.18 mmol) was
dissolved in 2-methyltetrahyrdofuran (5 ml) then treated with
carbonyl diimidazole (0.618 g, 3.82) and diisopropylethylamine (1.2
ml, 7.0 mmol). The reaction stirred for 30 minutes at room
temperature then the N,O-dimethylhydroxylamine hydrochloride (0.213
g, 3.50 mmol) was added. The reaction continued for 15 hours at
room temperature. The reaction mixture was concentrated and
suspended in ethyl ether and washed with saturated sodium
bicarbonate solution. The aqueous layer was back-extracted with
ethyl ether (6.times.), combined organic layer was dried
(MgSO.sub.4), filtered and concentrated to give desired product
with imidazole contamination. .sup.1H NMR (400 MHz, Chloroform-d)
.delta. 3.63 (s, 3H), 3.60-3.51 (m, 1H), 3.46 (t, J=7.2 Hz, 2H),
3.38 (t, J=7.6 Hz, 2H), 3.16 (s, 3H), 0.97 (s, 9H).
[0580] Preparation of
(5-bromo-2-fluorophenyl)(1-(tert-butyl)azetidin-3-yl)methanone: A
solution of 4-bromo-1-fluoro-2-iodobenzene (1.50 g, 4.99 mmol) in
2-Me-THF (12 mL) was stirred in dry ice-acetone bath while 1.6 M
n-BuLi in hex(3.4 mL, 5.49 mmol) was added dropwise over .about.2
min. After 20 min, a solution of
1-(tert-butyl)-N-methoxy-N-methylazetidine-3-carboxamide (333 mg,
1.66 mmol) in 2-Me-THF (3 mL) was added slowly. Reaction mixture
was stirred at -78.degree. C. for 2 hours. LCMS and TLC show
desired product. Reaction was quenched with brine, extracted with
ethyl acetate (2.times.), dried (MgSO.sub.4), filtered,
concentrated and purified by CombiFlash (40 g Gold, 0-8%
MeOH/CH.sub.2Cl.sub.2) to give a yellow oil. LCMS-ESI+: calc'd for
C.sub.14H.sub.18BrFNO: 314.1 (M+H).sup.+; found: 314.0
(M+H).sup.+.
[0581] Preparation of
5-bromo-3-(1-(tert-butyl)azetidin-3-yl)-1-methyl-1H-indazole: To a
solution of the
(5-bromo-2-fluorophenyl)(1-(tert-butyl)azetidin-3-yl)methanone (279
mg, 0.889 mmol), p-toluenesulfonic acid monohydrate (13 mg, 0.075
mmol) in dioxane (3.3 mL) was added methylhydrazine (0.32 mL, 6.1
mmol) and the reaction mixture was heated in the microwave at
150.degree. C. for 1 hour. Reaction mixture was cooled,
concentrated and purified by CombiFlash (24 g Gold, 0-10%
MeOH/CH.sub.2Cl.sub.2) to give an off-white film. LCMS-ESI+: calc'd
for C.sub.15H.sub.21BrN.sub.3: 322.1 (M+H).sup.+; found: 322.1
(M+H).sup.+.
[0582] Preparation of ethyl
(S)-2-(2-(3-(1-(tert-butyl)azetidin-3-yl)-1-methyl-1H-indazol-5-yl)-7-(4--
chlorophenyl)-5-methylbenzo[d]thiazol-6-yl)-2-cyclopropoxyacetate:
A 10 mL round bottom flash was charged with
5-bromo-3-(1-(tert-butyl)azetidin-3-yl)-1-methyl-1H-indazole (52
mg, 0.161 mmol), bis(neopentyl glycolato)diboron (47 mg, 0.210
mmol) , PdCl.sub.2(Amphos).sub.2 (11 mg, 0.016 mmol) and potassium
propionate (812 mg, 0.726 mmol) and flushed with nitrogen.
De-gassed dioxane (1.0 mL) was added under a nitrogen atmosphere
and reaction mixture was heated to 80.degree. C. for 2 h, then
cooled to .about.50.degree. C.
[0583] To the above reaction mixture, 2M potassium carbonate (0.40
mL, 0.806 mmol) and ethyl
(S)-2-(2-bromo-7-(4-chlorophenyl)-5-methylbenzo[d]thiazol-6-yl)-2-cyclopr-
opoxyacetate (25 mg, 0.052 mmol) were added and the reaction heated
to 80.degree. C. After 2 h, LCMS showed desired product mass.
Reaction was cooled to room temperature, diluted with ethyl
acetate, washed with brine, dried (MgSO.sub.4), filtered and
concentrated. The resulting residue was dissolved in DMF (1.8 mL),
filtered through a syringe filter and purified by Gilson HPLC
(Gemini, 5-100% ACN/H.sub.2O+0.1% TFA). Product was lyophilized
overnight to give a yellow powder. LCMS-ESI+: calc'd for
C.sub.36H.sub.40ClN.sub.4O.sub.3S: 643.2 (M+H).sup.+; found: 643.3
(M+H).sup.+.
[0584] Preparation of
(S)-2-(2-(3-(1-(tert-butyl)azetidin-3-yl)-1-methyl-1H-indazol-5-yl)-7-(4--
chlorophenyl)-5-methylbenzo[d]thiazol-6-yl)-2-cyclopropoxyacetic
acid: A solution of ethyl
(S)-2-(2-(3-(1-(tert-butyl)azetidin-3-yl)-1-methyl-1H-indazol-5-yl)-7-(4--
chlorophenyl)-5-methylbenzo[d]thiazol-6-yl)-2-cyclopropoxyacetate
(5.2 mg, 0.008 mmol), sodium hydroxide (5M, 16 .mu.L, 0.08 mmol) in
MeOH (0.2 mL) and THF (1.0 mL) was heated at 45.degree. C. for 2
hours. Reaction mixture was concentrated, dissolved in DMF (1.5
mL), filtered through a syringe filter and purified by Gilson HPLC
(Gemini, 5-100% ACN/H.sub.2O+0.1% TFA). Product was lyophilized to
give an off-white powder. .sup.1H NMR (400 MHz, Methanol-d.sub.4)
.delta. 8.40 (d, J=13.1 Hz, 1H), 8.21-8.12 (m, 1H), 7.86 (s, 1H),
7.69 (t, J=8.4 Hz, 1H), 7.64-7.48 (m, 4H), 5.17 (s, 1H), 4.75-4.55
(m, 2H), 4.50-4.38 (m, 2H), 4.16-4.09 (m, 3H), 3.27 (m, 1H), 2.57
(s, 3H), 1.45-1.36 (m, 9H), 0.44-0.25 (m, 4H). LCMS-ESI+: calc'd
for C.sub.34H.sub.35ClN.sub.4O.sub.3S (M+H).sup.+: 615.2; found:
615.2 (M+H).sup.+.
Example 63
Preparation of
(S)-2-(tert-butoxy)-2-(7-(4-chlorophenyl)-2-(3-(1-(1,3-dimethoxypropan-2--
yl)azetidin-3-yl)-1-methyl-1H-indazol-5-yl)-5-methylbenzo[d]thiazol-6-yl)a-
cetic acid (61)
##STR00157##
[0586] Preparation of (S)-ethyl
2-(tert-butoxy)-2-(7-(4-chlorophenyl)-2-(3-(1-(1,3-dimethoxypropan-2-yl)a-
zetidin-3-yl)-1-methyl-1H-indazol-5-yl)-5-methylbenzo[d]thiazol-6-yl)aceta-
te: In a 50 mL round-bottom flask, (S)-ethyl
2-(2-(3-(azetidin-3-yl)-1-methyl-1H-indazol-5-yl)-7-(4-chlorophenyl)-5-me-
thylbenzo[d]thiazol-6-yl)-2-(tert-butoxy)acetate (0.010 g, 0.015
mmol) was dissolved in MeOH (1 mL). 1,3-Dimethoxypropan-2-one
(0.018 g, 0.15 mmol) was added to the reaction mixture.
NaBH.sub.3CN (0.01 g, 0.15 mmol) and one drop of acetic acid were
added to the reaction mixture. The reaction mixture was stirred at
room temperature for half an hour. After concentration, the residue
was dissolved in EtOAc, washed with brine and dried over
Na.sub.2SO.sub.4. After concentration, the crude was used for next
step without further purification.
[0587] Preparation of
(S)-2-(tert-butoxy)-2-(7-(4-chlorophenyl)-2-(3-(1-(1,3-dimethoxypropan-2--
yl)azetidin-3-yl)-1-methyl-1H-indazol-5-yl)-5-methylbenzo[d]thiazol-6-yl)a-
cetic acid: Prepared in a manner similar to
(S)-2-(tert-butoxy)-2-(7-(4-chlorophenyl)-5-methyl-2-(1-methyl-3-(2-oxa-6-
-azaspiro[3.3]heptan-6-yl)-1H-indazol-5-yl)benzo[d]thiazol-6-yl)acetic
acid except using (S)-ethyl
2-(tert-butoxy)-2-(7-(4-chlorophenyl)-2-(3-(1-(1,3-dimethoxypropan-2-yl)a-
zetidin-3-yl)-1-methyl-1H-indazol-5-yl)-5-methylbenzo[d]thiazol-6-yl)aceta-
te instead of (S)-ethyl
2-(tert-butoxy)-2-(7-(4-chlorophenyl)-5-methyl-2-(1-methyl-3-(2-oxa-6-aza-
spiro[3.3
]heptan-6-yl)-1H-indazol-5-yl)benzo[d]thiazol-6-yl)acetate. .sup.1H
NMR (400 MHz, Acetonitrile-d3) .delta. 8.33 (s, 1H), 8.17 (d, J=8.7
Hz, 1H), 7.87 (d, J=1.0 Hz, 1H), 7.75-7.55 (m, 5H), 5.29 (s, 1H),
4.62 (d, J=23.4 Hz, 4H), 4.08 (s, 3H), 3.65 (s, 5H), 3.36 (d, J=1.1
Hz, 6H), 3.01 (s, 2H), 2.59 (s, 3H), 1.00 (s, 9H).
Example 64
(2S)-2-(tert-butoxy)-2-(2-(3-(1-(tert-butoxycarbonyl)pyrrolidin-3-yl)-1-me-
thyl-1H-indazol-5-yl)-7-(4-chlorophenyl)-5-methylbenzo[d]thiazol-6-yl)acet-
ic acid (62)
##STR00158## ##STR00159##
[0589] Preparation of tert-butyl
(S)-3-(5-(6-(1-(tert-butoxy)-2-ethoxy-2-oxoethyl)-7-(4-chlorophenyl)-5-me-
thylbenzo[d]thiazol-2-yl)-1-methyl-1H-indazol-3-yl)-2,5-dihydro-1H-pyrrole-
-1-carboxylate: A mixture of ethyl
(S)-2-(2-(3-bromo-1-methyl-1H-indazol-5-yl)-7-(4-chlorophenyl)-5-methylbe-
nzo[d]thiazol-6-yl)-2-(tert-butoxy)acetate (203.7 mg, 0.325 mmol),
tert-butyl
3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-2,5-dihydro-1H-pyrrole-1--
carboxylate (155.9 mg, 0.528 mmol),
tetrakis(triphenylphosphine)palladium(0) (38.6 mg, 0.033 mmol), and
potassium carbonate (135.3 mg, 0.979 mmol), water (1 mL), and
dioxane (4 mL) was placed in a microwave vial and the resulting
mixture was reacted in a microwave reactor at 110.degree. C. for 30
min After the reaction mixture was diluted with ethyl acetate and
washed with water (.times.2), and the aqueous fractions were
extracted with ethyl acetate (.times.1), the organic fractions were
combined, dried (Na.sub.2SO.sub.4), and concentrated. The residue
was purified by Combiflash (40 g, Gold, 0-80% EtOAc/Hex) to obtain
the title product. LCMS-ESI.sup.+: calc'd for
C.sub.39H.sub.44ClN.sub.4O.sub.5S: 715.27 (M+H).sup.+; found:
715.06 (M+H).sup.+.
[0590] Preparation of tert-butyl
3-(5-(6-((S)-1-(tert-butoxy)-2-ethoxy-2-oxoethyl)-7-(4-chlorophenyl)-5-me-
thylbenzo[d]thiazol-2-yl)-1-methyl-1H-indazol-3-yl)pyrrolidine-1-carboxyla-
te: A mixture of tert-butyl
(S)-3-(5-(6-(1-(tert-butoxy)-2-ethoxy-2-oxoethyl)-7-(4-chlorophenyl)-5-me-
thylbenzo[d]thiazol-2-yl)-1-methyl-1H-indazol-3-yl)-2,5-dihydro-1H-pyrrole-
-1-carboxylate (213.8 mg, 0.299 mmol) and 5% Rhodium on alumina
(43.7 mg) in ethanol (10 mL) was stirred under H.sub.2 atmosphere
for 3 h. The reaction mixture was filtered through celite pad and
the filtrate was concentrated to dryness. The residue and 5%
Rhodium on alumina (103 mg) in ethanol (10 mL) was again stirred
under H.sub.2 atmosphere for 18 h. The reaction mixture was
filtered through celite pad and the filtrate was concentrated to
dryness to obtain the crude title product, which was used for the
next reaction. LCMS-ESI.sup.+: calc'd for
C.sub.39H.sub.46ClN.sub.4O.sub.5S: 717.29 (M+H).sup.+; found:
717.08 (M+H).sup.+.
[0591] Preparation of
(2S)-2-(tert-butoxy)-2-(2-(3-(1-(tert-butoxycarbonyl)pyrrolidin-3-yl)-1-m-
ethyl-1H-indazol-5-yl)-7-(4-chlorophenyl)-5-methylbenzo[d]thiazol-6-yl)ace-
tic acid: To a solution of crude tert-butyl
3-(5-(6-((S)-1-(tert-butoxy)-2-ethoxy-2-oxoethyl)-7-(4-chlorophenyl)-5-me-
thylbenzo[d]thiazol-2-yl)-1-methyl-1H-indazol-3-yl)pyrrolidine-1-carboxyla-
te (10.2 mg, 0.014 mmol) in THF (0.5 mL) and MeOH (0.5 mL) was
added 2 N NaOH (0.2 mL) at room temperature and kept tightly before
the mixture was stirred at 50.degree. C. for 30 h. The reaction
mixture was concentrated to remove organic solvent and acidified
with 2 N HCl. The resulting mixture was dissolved with DMF and MeCN
(total .about.3 mL), filtered through syringe filter, and purified
by Gilson HPLC (Phenomenex Gemini, 60-100% ACN/H.sub.2O+0.1% TFA)
to obtain the title product after lyophilization. .sup.1H NMR (400
MHz, Acetonitrile-d.sub.3) .delta. 8.39 (s, 1H), 8.14 (d, J=9.0 Hz,
1H), 7.87 (s, 1H), 7.67 (d, J=8.4 Hz, 1H), 7.64-7.54 (m, 4H), 5.28
(s, 1H), 4.02 (s, 3H), 3.84 (m, 1H), 3.72-3.48 (m, 3H), 3.43 (m,
1H), 2.59 (s, 3H), 2.40 (s, 1H), 2.26 (d, J=7.6 Hz, 1H), 1.50-1.41
(m, 9H), 0.99 (s, 9H). LCMS-ESI.sup.+: calc'd for
C.sub.37H.sub.42ClN.sub.4O.sub.5S: 689.26 (M+H).sup.+; found:
689.02 (M+H).sup.+.
Example 65
Preparation of
(2S)-2-(tert-butoxy)-2-(7-(4-chlorophenyl)-5-methyl-2-(1-methyl-3-(1-meth-
ylpyrrolidin-3-yl)-1H-indazol-5-yl)benzo[d]thiazol-6-yl)acetic acid
(63)
##STR00160##
[0593] Preparation of ethyl
(2S)-2-(tert-butoxy)-2-(7-(4-chlorophenyl)-5-methyl-2-(1-methyl-3-(pyrrol-
idin-3-yl)-1H-indazol-5-yl)benzo[d]thiazol-6-yl)acetate: To a flask
containing crude tert-butyl
3-(5-(6-((S)-1-(tert-butoxy)-2-ethoxy-2-oxoethyl)-7-(4-chlorophenyl)-5-me-
thylbenzo[d]thiazol-2-yl)-1-methyl-1H-indazol-3-yl)pyrrolidine-1-carboxyla-
te (202.6 mg, 0.282 mmol) was added 1.25 M HCl in isopropanol (15
mL) and the resulting mixture was stirred at room temperature for
24 h. The reaction mixture was concentrated and dried to obtain the
crude title product, which was used for the next reaction.
LCMS-ESI.sup.+: calc'd for C.sub.34H.sub.38ClN.sub.4O.sub.3S:
617.24 (M+H).sup.+; found: 617.39 (M+H).sup.+.
[0594] Preparation of
(2S)-2-(tert-butoxy)-2-(7-(4-chlorophenyl)-5-methyl-2-(1-methyl-3-(1-meth-
ylpyrrolidin-3-yl)-1H-indazol-5-yl)benzo[d]thiazol-6-yl)acetic
acid: A solution of crude ethyl
(2S)-2-(tert-butoxy)-2-(7-(4-chlorophenyl)-5-methyl-2-(1-methyl-3-(pyrrol-
idin-3-yl)-1H-indazol-5-yl)benzo[d]thiazol-6-yl)acetate (30.5 mg,
0.047 mmol) in acetonitrile (2 mL) was stirred at 0.degree. C. bath
as 37% formaldehyde (0.1 mL, 1.343 mmol), and sodium
cyanoborohydride (.about.30 mg, 0.477 mmol) were added. To the
reaction mixture was added .about.2 drops of acetic acid. After 1
h, the reaction mixture was quenched with saturated NaHCO.sub.3
solution and the product was extracted with dichloromethane
(.times.2). The combined extracts were dried (Na.sub.2SO.sub.4) and
concentrated to get crude methylated product with impurities.
LCMS-ESI.sup.+: calc'd for C.sub.35H.sub.40ClN.sub.4O.sub.3S:
631.25 (M+H).sup.+; found: 631.40 (M+H).sup.+.
[0595] The crude methylated product was dissolved in THF (0.5 mL)
and MeOH (0.5 mL) was added 2 N NaOH (0.2 mL) at room temperature
and kept tightly before the mixture was stirred at 70.degree. C.
for 2 h. The reaction mixture was concentrated to remove organic
solvent and acidified with 2 N HCl. The resulting mixture was
dissolved with DMF and MeCN (total 3 mL), filtered through syringe
filter, and purified by Gilson HPLC (Phenomenex Gemini, 60-100%
ACN/H.sub.2O+0.1% TFA) to give a mixture of two diastereomers of
(2S)-2-(tert-butoxy)-2-(7-(4-chlorophenyl)-5-methyl-2-(1-methyl-3-(1-meth-
ylpyrrolidin-3-yl)-1H-indazol-5-yl)benzo[d]thiazol-6-yl)acetic acid
after lyophilization. .sup.1H NMR (400 MHz, Acetonitrile-d.sub.3)
.delta. 10.28 (s, 0.5H), 9.29-9.02 (m, 0.5H), 8.37 and 8.31 (two s,
1H), 8.19-8.05 (m, 1H), 7.84 and 7.82 (two s, 1H), 7.72-7.64 (m,
1H), 7.64-7.51 (m, 4H), 5.28 (s, 1H), 4.25 (q, J=6.2 Hz, 0.5H),
4.14 (m, 1H), 4.01 and 4.00 (two s, 3H), 3.97 (m, 0.5H), 3.93-3.74
(m, 1H), 3.46 (m, 1H), 3.25 (m, 1H), 2.99 and 2.97 (two s, 3H),
2.67 (m, 1H), 2.58 and 2.57 (two s, 3H), 2.45-2.23 (m, 1H), 0.99
(s, 9H). LCMS-ESI.sup.+: calc'd for
C.sub.33H.sub.36ClN.sub.4O.sub.3S: 590.19 (M+H).sup.+; found:
603.32 (M+H).sup.+.
Example 66
Preparation of
(2S)-2-(tert-butoxy)-2-(7-(4-chlorophenyl)-2-(3-(1-ethylpyrrolidin-3-yl)--
1-methyl-1H-indazol-5-yl)-5-methylbenzo[d]thiazol-6-yl)acetic acid
(64)
##STR00161##
[0597] Preparation of
(2S)-2-(tert-butoxy)-2-(7-(4-chlorophenyl)-2-(3-(1-ethylpyrrolidin-3-yl)--
1-methyl-1H-indazol-5-yl)-5-methylbenzo[d]thiazol-6-yl)acetic acid:
A solution of crude ethyl
(2S)-2-(tert-butoxy)-2-(7-(4-chlorophenyl)-5-methyl-2-(1-methyl-3-(pyrrol-
idin-3-yl)-1H-indazol-5-yl)benzo[d]thiazol-6-yl)acetate (30.1 mg,
0.046 mmol) in acetonitrile (2 mL) was stirred at 0.degree. C. bath
as acetaldehyde (0.05 mL, 0.89 mmol), and sodium cyanoborohydride
(.about.30 mg, 0.477 mmol) were added. To the reaction mixture was
added .about.2 drops of acetic acid. After 15 min, the reaction
mixture was quenched with saturated NaHCO.sub.3 solution and the
product was extracted with dichloromethane (.times.2). The combined
extracts were dried (Na.sub.2SO.sub.4) and concentrated to get
crude ethylated product with impurities. LCMS-ESI.sup.+: calc'd for
C.sub.36H.sub.42ClN.sub.4O.sub.3S: 645.27 (M+H).sup.+; found:
645.42 (M+H).sup.+.
[0598] The crude ethylated product was dissolved in THF (0.5 mL)
and MeOH (0.5 mL) was added 2 N NaOH (0.2 mL) at room temperature
and kept tightly before the mixture was stirred at 70.degree. C.
for 2 h. The reaction mixture was acidified with 2 N HCl
(.about.0.25 mL), and concentrated to remove organic solvent. The
resulting mixture was dissolved with methanol, filtered through
syringe filter (total 3 mL), and purified by Gilson HPLC
(Phenomenex Gemini, 30-70% ACN/H.sub.2O+0.1% TFA) to give a
.about.2:3 mixture of two diastereomers of
(2S)-2-(tert-butoxy)-2-(7-(4-chlorophenyl)-2-(3-(1-ethylpyrrolidin-3-yl)--
1-methyl-1H-indazol-5-yl)-5-methylbenzo[d]thiazol-6-yl)acetic acid
after lyophilization. .sup.1H NMR (400 MHz, Acetonitrile-d.sub.3)
.delta. 8.38 (d, J=11.3 Hz, 1H), 8.16 (dt, J=8.9, 1.7 Hz, 1H), 7.85
(d, J=4.2 Hz, 1H), 7.67 (d, J=8.6 Hz, 1H), 7.59 (m, 4H), 5.28 (s,
1H), 4.50-4.05 (m, 1H), 4.03 (s, 3H), 4.05-3.45 (m, 1H), 3.58-3.13
(m, 5H), 2.70-2.55 (m, 1H), 2.58 (s, 3H), 2.45-2.25 (m, 1H), 1.35
(td, J=7.3, 1.7 Hz, 3H), 0.99 (s, 9H). LCMS-ESI.sup.+: calc'd for
C.sub.34H.sub.38ClN.sub.4O.sub.3S: 590.19 (M+H).sup.+; found:
617.33 (M+H).sup.+.
Example 67
Preparation of
(2S)-2-(tert-butoxy)-2-(7-(4-chlorophenyl)-2-(3-(1-(2-methoxyethyl)pyrrol-
idin-3-yl)-1-methyl-1H-indazol-5-yl)-5-methylbenzo[d]thiazol-6-yl)acetic
acid (65)
##STR00162##
[0600] Preparation of
(2S)-2-(tert-butoxy)-2-(7-(4-chlorophenyl)-2-(3-(1-(2-methoxyethyl)pyrrol-
idin-3-yl)-1-methyl-1H-indazol-5-yl)-5-methylbenzo[d]thiazol-6-yl)acetic
acid: A solution of crude ethyl
(2S)-2-(tert-butoxy)-2-(7-(4-chlorophenyl)-5-methyl-2-(1-methyl-3-(pyrrol-
idin-3-yl)-1H-indazol-5-yl)benzo[d]thiazol-6-yl)acetate (30.7 mg,
0.049 mmol) in acetonitrile (2 mL) was stirred at 0.degree. C. bath
as 2-methoxyacetaldehyde (55 mg, 0.742 mmol), and sodium
cyanoborohydride (.about.30 mg, 0.477 mmol) were added. To the
reaction mixture was added .about.2 drops of acetic acid. After 25
min, the reaction mixture was quenched with saturated NaHCO.sub.3
solution and the product was extracted with dichloromethane
(.times.2). The combined extracts were dried (Na.sub.2SO.sub.4) and
concentrated to get crude methoxyethylated product with impurities.
LCMS-ESI.sup.+: calc'd for C.sub.37H.sub.44ClN.sub.4O.sub.4S:
675.28 (M+H).sup.+; found: 675.47 (M+H).sup.+.
[0601] The crude methoxyethylated product was dissolved in THF (0.5
mL) and MeOH (0.5 mL) was added 2 N NaOH (0.2 mL) at room
temperature and kept tightly before the mixture was stirred at
70.degree. C. for 2 h. The reaction mixture acidified with acetic
acid (4.about.5 drops), and concentrated to remove organic solvent.
The resulting mixture was dissolved with methanol, filtered through
syringe filter (total 3 mL), and purified by Gilson HPLC
(Phenomenex Gemini, 30-70% ACN/H.sub.2O+0.1% TFA) to give a
.about.2:3 mixture of two diastereomers of
(2S)-2-(tert-butoxy)-2-(7-(4-chlorophenyl)-2-(3-(1-(2-methoxyethyl)pyrrol-
idin-3-yl)-1-methyl-1H-indazol-5-yl)-5-methylbenzo[d]thiazol-6-yl)acetic
acid after lyophilization. .sup.1H NMR (400 MHz,
Acetonitrile-d.sub.3) .delta. 9.18 (s, 0.6H), 8.64 (s, 0.4H), 8.36
(d, J=18.0 Hz, 1H), 8.14 (t, J=8.6 Hz, 1H), 7.84 (d, J=6.6 Hz, 1H),
7.67 (dd, J=7.9, 2.4 Hz, 1H), 7.59 (d, J=7.3 Hz, 4H), 5.28 (s, 1H),
4.31-3.96 (m, 2H), 4.02 (two s, 3H), 3.93-3.77 (m, 1H), 3.75-3.67
(m, 2H), 3.65-3.54 (s, 1H), 3.53-3.43 (m, 3H), 3.40 (two s, 3H),
3.34 (m, 1H), 2.58 (two s, 3H), 2.48-2.19 (m, 1H), 0.99 (s, 9H).
LCMS-ESI.sup.+: calc'd for C.sub.35H.sub.40ClN.sub.4O.sub.4S:
647.25 (M+H).sup.+; found: 647.35 (M+H).sup.+.
Example 68
Preparation of (S)-ethyl
2-(tert-butoxy)-2-(7-(4-chlorophenyl)-5-methyl-2-(1-methyl-3-((S)-pyrroli-
din-3-yl)-1H-indazol-5-yl)benzo[d]thiazol-6-yl)acetate (66) and
(S)-ethyl
2-(tert-butoxy)-2-(7-(4-chlorophenyl)-5-methyl-2-(1-methyl-3-((R)-pyrroli-
din-3-yl)-1H-indazol-5-yl)benzo[d]thiazol-6-yl)acetate (67)
##STR00163##
[0603] Resolution of tert-butyl
(S)-3-(5-(6-((S)-1-(tert-butoxy)-2-ethoxy-2-oxoethyl)-7-(4-chlorophenyl)--
5-methylbenzo[d]thiazol-2-yl)-1-methyl-1H-indazol-3-yl)pyrrolidine-1-carbo-
xylate and tert-butyl
(R)-3-(5-(6-((S)-1-(tert-butoxy)-2-ethoxy-2-oxoethyl)-7-(4-chlorophenyl)--
5-methylbenzo[d]thiazol-2-yl)-1-methyl-1H-indazol-3-yl)pyrrolidine-1-carbo-
xylate: The crude tert-butyl
3-(5-(6-((S)-1-(tert-butoxy)-2-ethoxy-2-oxoethyl)-7-(4-chlorophenyl)-5-me-
thylbenzo[d]thiazol-2-yl)-1-methyl-1H-indazol-3-yl)pyrrolidine-1-carboxyla-
te (908.7 mg, 1.270 mmol) was purified by Combiflash (120 g, Gold,
20-50% EtOAc/Hex) to get 760.1 mg (83%) of purified tert-butyl
3-(5-(6-((S)-1-(tert-butoxy)-2-ethoxy-2-oxoethyl)-7-(4-chlorophenyl)-5-me-
thylbenzo[d]thiazol-2-yl)-1-methyl-1H-indazol-3-yl)pyrrolidine-1-carboxyla-
te. tert-butyl
3-(5-(6-((S)-1-(tert-butoxy)-2-ethoxy-2-oxoethyl)-7-(4-chlorophenyl)-5-me-
thylbenzo[d]thiazol-2-yl)-1-methyl-1H-indazol-3-yl)pyrrolidine-1-carboxyla-
te (200 mg) was separated on chiral HPLC purification (Chiralpak
ID, 150.times.4.6 mm, 5 micron; eluent: heptane/iPA (70/30), flow
rate32 1 mL/min for 15 min) to obtain diasteromer A (Rt=6.87 min)
and diastereomer B (Rt=9.12 min). Stereochemistry was arbitrarily
assigned. Diastereomer A assigned as tert-butyl
(S)-3-(5-(6-((S)-1-(tert-butoxy)-2-ethoxy-2-oxoethyl)-7-(4-chlorophenyl)--
5-methylbenzo[d]thiazol-2-yl)-1-methyl-1H-indazol-3-yl)pyrrolidine-1-carbo-
xylate and tert-butyl
(S)-3-(5-(6-((S)-1-(tert-butoxy)-2-ethoxy-2-oxoethyl)-7-(4-chlorophenyl)--
5-methylbenzo[d]thiazol-2-yl)-1-methyl-1H-indazol-3-yl)pyrrolidine-1-carbo-
xylate diastereomer B assigned as tert-butyl
(R)-3-(5-(6-((S)-1-(tert-butoxy)-2-ethoxy-2-oxoethyl)-7-(4-chlorophenyl)--
5-methylbenzo[d]thiazol-2-yl)-1-methyl-1H-indazol-3-yl)pyrrolidine-1-carbo-
xylate. Diastereomer A: LCMS -ESI.sup.+: calc'd for
C.sub.39H.sub.46ClN.sub.4O.sub.5S: 717.29 (M+H).sup.+; found:
717.10 (M+H).sup.+. Diastereomer B: LCMS-ESI.sup.+: calc'd for
C.sub.39H.sub.46ClN.sub.4O.sub.5S: 717.29 (M+H).sup.+; found:
717.10 (M+H).sup.+.
[0604] Preparation of (S)-ethyl
2-(tert-butoxy)-2-(7-(4-chlorophenyl)-5-methyl-2-(1-methyl-3-((S)-pyrroli-
din-3-yl)-1H-indazol-5-yl)benzo[d]thiazol-6-yl)acetate and
(S)-ethyl
2-(tert-butoxy)-2-(7-(4-chlorophenyl)-5-methyl-2-(1-methyl-3-((R)-pyrroli-
din-3-yl)-1H-indazol-5-yl)benzo[d]thiazol-6-yl)acetate: Separately,
diastereomer A (92.0 mg, 0.128 mmol) and diastereomer B (87.8 mg,
0.122 mmol) were each dissolved in 1.25 M hydrochloric acid in
isopropanol (6.5 mL and 6.0 mL, respectively) and stirred at rt for
21 h. The reaction mixtures were separately concentrated to get the
crude products that were used without further purification.
Stereochemistry was arbitrarily assigned. Diastereomer A assigned
as (S)-ethyl
2-(tert-butoxy)-2-(7-(4-chlorophenyl)-5-methyl-2-(1-methyl-3-((S)-pyrroli-
din-3-yl)-1H-indazol-5-yl)benzo[d]thiazol-6-yl)acetate and
diastereomer B assigned as (S)-ethyl
2-(tert-butoxy)-2-(7-(4-chlorophenyl)-5-methyl-2-(1-methyl-3-((R)-pyrroli-
din-3-yl)-1H-indazol-5-yl)benzo[d]thiazol-6-yl)acetate,
respectively. Diastereomer A: LCMS-ESI.sup.+: calc'd for
C.sub.34H.sub.38ClN.sub.4O.sub.3S: 617.24 (M+H).sup.+; found:
617.37 (M+H).sup.+. Diastereomer B: LCMS-ESI.sup.+: calc'd for
C.sub.34H.sub.38ClN.sub.4O.sub.3S: 617.24 (M+H).sup.+; found:
617.38 (M+H).sup.+.
Example 69
Preparation of
(S)-2-(tert-butoxy)-2-(7-(4-chlorophenyl)-2-(3-((S)-1-(2-methoxyethyl)pyr-
rolidin-3-yl)-1-methyl-1H-indazol-5-yl)-5-methylbenzo[d]thiazol-6-yl)aceti-
c acid (68)
##STR00164##
[0606] Preparation of (S)-ethyl
2-(tert-butoxy)-2-(7-(4-chlorophenyl)-2-(3-((S)-1-(2-methoxyethyl)pyrroli-
din-3-yl)-1-methyl-1H-indazol-5-yl)-5-methylbenzo[d]thiazol-6-yl)acetate:
Prepared in a manner similar to (2S)-ethyl
2-(tert-butoxy)-2-(7-(4-chlorophenyl)-5-methyl-2-(1-methyl-3-(1-(oxetan-3-
-yl)pyrrolidin-3-yl)-1H-indazol-5-yl)benzo[d]thiazol-6-yl)acetate
except using (S)-ethyl
2-(tert-butoxy)-2-(7-(4-chlorophenyl)-5-methyl-2-(1-methyl-3-((S)-pyrroli-
din-3-yl)-1H-indazol-5-yl)benzo[d]thiazol-6-yl)acetate and
2-methoxyacetaldehyde instead of (2S)-ethyl
2-(tert-butoxy)-2-(7-(4-chlorophenyl)-5-methyl-2-(1-methyl-3-(pyrrolidin--
3-yl)-1H-indazol-5-yl)benzo[d]thiazol-6-yl)acetate and
oxetan-3-one.
[0607] Preparation of
(S)-2-(tert-butoxy)-2-(7-(4-chlorophenyl)-2-(3-((S)-1-(2-methoxyethyl)pyr-
rolidin-3-yl)-1-methyl-1H-indazol-5-yl)-5-methylbenzo[d]thiazol-6-yl)aceti-
c acid: Prepared in a manner similar to
(S)-2-(tert-butoxy)-2-(7-(4-chlorophenyl)-5-methyl-2-(1-methyl-3-(2-oxa-6-
-azaspiro[3.3]heptan-6-yl)-1H-indazol-5-yl)benzo[d]thiazol-6-yl)acetic
acid except using (S)-ethyl
2-(tert-butoxy)-2-(7-(4-chlorophenyl)-2-(3-((S)-1-(2-methoxyethyl)pyrroli-
din-3-yl)-1-methyl-1H-indazol-5-yl)-5-methylbenzo[d]thiazol-6-yl)acetate
instead of (S)-ethyl
2-(tert-butoxy)-2-(7-(4-chlorophenyl)-5-methyl-2-(1-methyl-3-(2-oxa-6-aza-
spiro[3.3
]heptan-6-yl)-1H-indazol-5-yl)benzo[d]thiazol-6-yl)acetate. .sup.1H
NMR (400 MHz, Chloroform-d) .delta. 1H NMR (400 MHz,
Acetonitrile-d3) .delta. 8.39 (d, J=12.0 Hz, 1H), 8.17 (d, J=9.0
Hz, 1H), 7.86 (s, 1H), 7.67 (dd, J=8.0, 2.2 Hz, 1H), 7.60 (d, J=8.5
Hz, 4H), 5.28 (s, 1H), 4.39-4.10 (m, 2H), 4.04 (s, 3H), 3.96-3.79
(m, 1H), 3.72 (t, J=5.0 Hz, 2H), 3.48 (s, 3H), 3.43-3.35 (m, 3H),
3.34 (s, 1H), 2.59 (s, 4H), 2.37 (s, 1H), 1.00 (s, 9H).
Example 70
Preparation of
(S)-2-(tert-butoxy)-2-(7-(4-chlorophenyl)-2-(3-((R)-1-(2-methoxyethyl)pyr-
rolidin-3-yl)-1-methyl-1H-indazol-5-yl)-5-methylbenzo[d]thiazol-6-yl)aceti-
c acid (69)
##STR00165##
[0609] Preparation of (S)-ethyl
2-(tert-butoxy)-2-(7-(4-chlorophenyl)-2-(3-((R)-1-(2-methoxyethyl)pyrroli-
din-3-yl)-1-methyl-1H-indazol-5-yl)-5-methylbenzo[d]thiazol-6-yl)acetate:
Prepared in a manner similar to (2S)-ethyl
2-(tert-butoxy)-2-(7-(4-chlorophenyl)-5-methyl-2-(1-methyl-3-(1-(oxetan-3-
-yl)pyrrolidin-3-yl)-1H-indazol-5-yl)benzo[d]thiazol-6-yl)acetic
except using (S)-ethyl
2-(tert-butoxy)-2-(7-(4-chlorophenyl)-5-methyl-2-(1-methyl-3-((R)-pyrroli-
din-3-yl)-1H-indazol-5-yl)benzo[d]thiazol-6-yl)acetate and
2-methoxyacetaldehyde instead of (2S)-ethyl
2-(tert-butoxy)-2-(7-(4-chlorophenyl)-5-methyl-2-(1-methyl-3-(pyrrolidin--
3-yl)-1H-indazol-5-yl)benzo[d]thiazol-6-yl)acetate and
oxetan-3-one.
[0610] Preparation of
(S)-2-(tert-butoxy)-2-(7-(4-chlorophenyl)-2-(3-((R)-1-(2-methoxyethyl)pyr-
rolidin-3-yl)-1-methyl-1H-indazol-5-yl)-5-methylbenzo[d]thiazol-6-yl)aceti-
c acid: Prepared in a manner similar to
(S)-2-(tert-butoxy)-2-(7-(4-chlorophenyl)-5-methyl-2-(1-methyl-3-(2-oxa-6-
-azaspiro[3.3]heptan-6-yl)-1H-indazol-5-yl)benzo[d]thiazol-6-yl)acetic
acid except using (S)-ethyl
2-(tert-butoxy)-2-(7-(4-chlorophenyl)-2-(3-((R)-1-(2-methoxyethyl)pyrroli-
din-3-yl)-1-methyl-1H-indazol-5-yl)-5-methylbenzo[d]thiazol-6-yl)acetate
instead of (S)-ethyl
2-(tert-butoxy)-2-(7-(4-chlorophenyl)-5-methyl-2-(1-methyl-3-(2-oxa-6-aza-
spiro[3.3
]heptan-6-yl)-1H-indazol-5-yl)benzo[d]thiazol-6-yl)acetate. .sup.1H
NMR (400 MHz, Acetonitrile-d3) .delta. 8.38 (d, J=5.9 Hz, 1H), 8.17
(d, J=8.9 Hz, 1H), 7.87 (s, 1H), 7.74-7.52 (m, 5H), 5.28 (s, 1H),
4.17 (s, 1H), 4.04 (s, 3H), 3.85 (s, 3H), 3.78-3.65 (m, 4H),
3.63-3.23 (m, 4H), 2.59 (s, 3H), 2.34 (d, J=19.2 Hz, 2H), 1.00 (s,
9H).
Example 71
Preparation of
(2S)-2-(tert-butoxy)-2-(7-(4-chlorophenyl)-5-methyl-2-(1-methyl-3-(1-(oxe-
tan-3-yl)pyrrolidin-3-yl)-1H-indazol-5-yl)benzo[d]thiazol-6-yl)acetic
acid (70)
##STR00166##
[0612] Preparation of (2S)-ethyl
2-(tert-butoxy)-2-(7-(4-chlorophenyl)-5-methyl-2-(1-methyl-3-(1-(oxetan-3-
-yl)pyrrolidin-3-yl)-1H-indazol-5-yl)benzo[d]thiazol-6-yl)acetate:
In a 50 mL round-bottom flask, (2S)-ethyl
2-(tert-butoxy)-2-(7-(4-chlorophenyl)-5-methyl-2-(1-methyl-3-(pyrrolidin--
3-yl)-1H-indazol-5-yl)benzo[d]thiazol-6-yl)acetate (0.010 g, 0.015
mmol) was dissolved in MeOH (1 mL). Oxetan-3-one (0.011 g, 0.15
mmol) was added to the reaction mixture. NaBH.sub.3CN (0.01 g, 0.15
mmol) and one drop of acetic acid were added to the reaction
mixture. The reaction mixture was stirred at room temperature for
half an hour. After concentration, the residue was dissolved in
EtOAc, washed with brine and dried over Na.sub.2SO.sub.4. After
concentration, the crude was used for next step without further
purification.
[0613] Preparation of
(2S)-2-(tert-butoxy)-2-(7-(4-chlorophenyl)-5-methyl-2-(1-methyl-3-(1-(oxe-
tan-3-yl)pyrrolidin-3-yl)-1H-indazol-5-yl)benzo[d]thiazol-6-yl)acetic
acid: Prepared in a manner similar to
(S)-2-(tert-butoxy)-2-(7-(4-chlorophenyl)-5-methyl-2-(1-methyl-3-(2-oxa-6-
-azaspiro[3.3
]heptan-6-yl)-1H-indazol-5-yl)benzo[d]thiazol-6-yl)acetic acid
except using (2S)-ethyl
2-(tert-butoxy)-2-(7-(4-chlorophenyl)-5-methyl-2-(1-methyl-3-(1-(oxetan-3-
-yl)pyrrolidin-3-yl)-1H-indazol-5-yl)benzo[d]thiazol-6-yl)acetate
instead of (S)-ethyl
2-(tert-butoxy)-2-(7-(4-chlorophenyl)-5-methyl-2-(1-methyl-3-(2-oxa-6-aza-
spiro[3.3]heptan-6-yl)-1H-indazol-5-yl)benzo[d]thiazol-6-yl)acetate.
.sup.1H NMR (400 MHz, Acetonitrile-d3) .delta. 8.42 (s, 1H), 8.18
(dt, J=9.0, 1.8 Hz, 1H), 7.87 (s, 1H), 7.77-7.50 (m, 5H), 5.29 (s,
1H), 5.01-4.82 (m, 2H), 4.76 (d, J=11.0 Hz, 2H), 4.62 (s, 1H), 4.26
(s, 1H), 4.05 (d, J=5.6 Hz, 3H), 3.25 (m, 5H), 2.68 (d, J=12.8 Hz,
1H), 2.59 (s, 3H), 2.39 (dt, J=14.1, 7.3 Hz, 1H), 1.39-1.11 (m,
1H), 1.00 (s, 9H).
Example 72
Preparation of
(2S)-2-(tert-butoxy)-2-(7-(4-chlorophenyl)-2-(3-(1-cyclobutylpyrrolidin-3-
-yl)-1-methyl-1H-indazol-5-yl)-5-methylbenzo[d]thiazol-6-yl)acetic
acid (71)
##STR00167##
[0615] Preparation of (2S)-ethyl
2-(tert-butoxy)-2-(7-(4-chlorophenyl)-2-(3-(1-cyclobutylpyrrolidin-3-yl)--
1-methyl-1H-indazol-5-yl)-5-methylbenzo[d]thiazol-6-yl)acetate:
Prepared in a manner similar to (2S)-ethyl
2-(tert-butoxy)-2-(7-(4-chlorophenyl)-5-methyl-2-(1-methyl-3-(1-(oxetan-3-
-yl)pyrrolidin-3-yl)-1H-indazol-5-yl)benzo[d]thiazol-6-yl)acetate
except using cyclobutanone instead of Oxetan-3-one.
[0616] Preparation of
(2S)-2-(tert-butoxy)-2-(7-(4-chlorophenyl)-2-(3-(1-cyclobutylpyrrolidin-3-
-yl)-1-methyl-1H-indazol-5-yl)-5-methylbenzo[d]thiazol-6-yl)acetic
acid: Prepared in a manner similar to
(S)-2-(tert-butoxy)-2-(7-(4-chlorophenyl)-5-methyl-2-(1-methyl-3-(2-oxa-6-
-azaspiro[3.3]heptan-6-yl)-1H-indazol-5-yl)benzo[d]thiazol-6-yl)acetic
acid except using (2S)-ethyl
2-(tert-butoxy)-2-(7-(4-chlorophenyl)-2-(3-(1-cyclobutylpyrrolidin-3-yl)--
1-methyl-1H-indazol-5-yl)-5-methylbenzo[d]thiazol-6-yl)acetate
instead of (S)-ethyl
2-(tert-butoxy)-2-(7-(4-chlorophenyl)-5-methyl-2-(1-methyl-3-(2-
-oxa-6-azaspiro[3.3]heptan-6-yl)-1H-indazol-5-yl)benzo[d]thiazol-6-yl)acet-
ate. .sup.1H NMR (400 MHz, Acetonitrile-d3) .delta. 8.40 (dd,
J=11.8, 1.6 Hz, 1H), 8.18 (ddt, J=8.9, 4.0, 1.6 Hz, 1H), 7.98-7.78
(m, 1H), 7.73-7.52 (m, 5H), 5.29 (s, 1H), 4.28-4.07 (m, 1H), 4.05
(d, J=3.1 Hz, 3H), 3.91 (p, J=9.4, 8.7 Hz, 1H), 3.70 (s, 1H),
3.56-3.33 (m, 1H), 3.24-3.13 (m, 1H), 2.91 (m, 5H), 2.59 (s, 3H),
2.34 (dq, J=8.1, 4.5, 3.2 Hz, 5H), 1.00 (s, 9H).
Example 73
Preparation of
(2S)-2-(tert-butoxy)-2-(7-(4-chlorophenyl)-2-(3-(1-(methoxycarbonyl)pyrro-
lidin-3-yl)-1-methyl-1H-indazol-5-yl)-5-methylbenzo[d]thiazol-6-yl)acetic
acid (72)
##STR00168##
[0618] Preparation of
(2S)-2-(tert-butoxy)-2-(7-(4-chlorophenyl)-5-methyl-2-(1-methyl-3-(pyrrol-
idin-3-yl)-1H-indazol-5-yl)benzo[d]thiazol-6-yl)acetic acid
Prepared in a manner similar to
(S)-2-(tert-butoxy)-2-(7-(4-chlorophenyl)-5-methyl-2-(1-methyl-3-(2-oxa-6-
-azaspiro[3.3]heptan-6-yl)-1H-indazol-5-yl)benzo[d]thiazol-6-yl)acetic
acid except using (2S)-ethyl
2-(tert-butoxy)-2-(7-(4-chlorophenyl)-5-methyl-2-(1-methyl-3-(pyrrolidin--
3-yl)-1H-indazol-5-yl)benzo[d]thiazol-6-yl)acetate instead of
(S)-ethyl
2-(tert-butoxy)-2-(7-(4-chlorophenyl)-5-methyl-2-(1-methyl-3-(2-oxa-6-aza-
spiro[3.3]heptan-6-yl)-1H-indazol-5-yl)benzo[d]thiazol-6-yl)acetate.
[0619] Preparation of
(2S)-2-(tert-butoxy)-2-(7-(4-chlorophenyl)-2-(3-(1-(methoxycarbonyl)pyrro-
lidin-3-yl)-1-methyl-1H-indazol-5-yl)-5-methylbenzo[d]thiazol-6-yl)acetic
acid: in a 50 mL round-bottom flask,
(2S)-2-(tert-butoxy)-2-(7-(4-chlorophenyl)-5-methyl-2-(1-methyl-3-(pyrrol-
idin-3-yl)-1H-indazol-5-yl)benzo[d]thiazol-6-yl)acetic acid (0.02
g, 0.034 mmol) was dissolved in THF (0.5 mL). 2 N NaOH (0.5 mL) was
added to reaction mixture followed by methyl chloroformate (0.004
g, 0.037 mmol). The reaction mixture was stirred at room
temperature for 1 hour. The solution was concentrated and the
residue was purified by HPLC to give of desired product. .sup.1H
NMR (400 MHz, Acetonitrile-d3) .delta. 8.38 (s, 1H), 8.13 (dd,
J=8.9, 1.6 Hz, 1H), 7.93-7.76 (m, 1H), 7.74-7.42 (m, 4H), 5.29 (s,
1H), 4.01 (s, 3H), 3.89 (d, J=9.7 Hz, 2H), 3.65 (s, 4H), 3.60-3.53
(m, 1H), 3.48 (dt, J=10.4, 7.6 Hz, 1H), 2.59 (d, J=0.9 Hz, 3H),
2.41 (d, J=10.3 Hz, 1H), 2.33-2.11 (m, 1H), 1.00 (s, 9H).
Example 74
Preparation of
(2S)-2-(tert-butoxy)-2-(7-(4-chlorophenyl)-2-(3-(1-((2-methoxyethoxy)carb-
onyl)pyrrolidin-3-yl)-1-methyl-1H-indazol-5-yl)-5-methylbenzo[d]thiazol-6--
yl)acetic acid (73)
##STR00169##
[0621] Preparation of
(2S)-2-(tert-butoxy)-2-(7-(4-chlorophenyl)-2-(3-(1-((2-methoxyethoxy)carb-
onyl)pyrrolidin-3-yl)-1-methyl-1H-indazol-5-yl)-5-methylbenzo[d]thiazol-6--
yl)acetic acid: Prepared in a manner similar to
(2S)-2-(tert-butoxy)-2-(7-(4-chlorophenyl)-2-(3-(1-(methoxycarbonyl)pyrro-
lidin-3-yl)-1-methyl-1H-indazol-5-yl)-5-methylbenzo[d]thiazol-6-yl)acetic
acid except using 2-methoxyethyl carbonochloridate instead of
methyl chloroformate. .sup.1H NMR (400 MHz, Acetonitrile-d3)
.delta. 8.37 (dd, J=1.7, 0.8 Hz, 1H), 8.13 (dd, J=8.9, 1.6 Hz, 1H),
7.86 (d, J=1.0 Hz, 1H), 7.73-7.50 (m, 5H), 5.29 (s, 1H), 4.27-4.07
(m, 2H), 4.01 (s, 3H), 3.99-3.79 (m, 2H), 3.76-3.43 (m, 5H),
3.37-3.22 (m, 3H), 2.97 (s, 1H), 2.59 (d, J=0.9 Hz, 3H), 2.42 (s,
1H), 2.24 (s, 1H), 1.00 (s, 9H).
Example 75
Preparation of
(2S)-2-(2-(3-(1-acetylpyrrolidin-3-yl)-1-methyl-1H-indazol-5-yl)-7-(4-chl-
orophenyl)-5-methylbenzo[d]thiazol-6-yl)-2-(tert-butoxy)acetic acid
(74)
##STR00170##
[0623] Preparation of
(2S)-2-(2-(3-(1-acetylpyrrolidin-3-yl)-1-methyl-1H-indazol-5-yl)-7-(4-chl-
orophenyl)-5-methylbenzo[d]thiazol-6-yl)-2-(tert-butoxy)acetic
acid: Prepared in a manner similar to
(2S)-2-(tert-butoxy)-2-(7-(4-chlorophenyl)-2-(3-(1-(methoxycarbonyl)pyrro-
lidin-3-yl)-1-methyl-1H-indazol-5-yl)-5-methylbenzo[d]thiazol-6-yl)acetic
acid except using acetyl chloride instead of methyl chloroformate.
.sup.1H NMR (400 MHz, Acetonitrile-d3) .delta. 8.53-8.28 (m, 1H),
8.23-8.00 (m, 1H), 7.92-7.79 (m, 1H), 7.72-7.47 (m, 5H), 5.39-5.22
(m, 1H), 3.99 (d, J=4.5 Hz, 4H), 3.94-3.43 (m, 4H), 2.71-2.52 (m,
3H), 2.53-2.19 (m, 2H), 2.19-2.08 (m, 3H), 1.13-0.87 (m, 9H).
Example 76 and 77
Preparation of
(S)-2-(tert-butoxy)-2-(7-(4-chlorophenyl)-2-(3-((R)-1-(2-methoxyacetyl)py-
rrolidin-3-yl)-1-methyl-1H-indazol-5-yl)-5-methylbenzo[d]thiazol-6-yl)acet-
ic acid (75) and
(S)-2-(tert-butoxy)-2-(7-(4-chlorophenyl)-2-(3-((S)-1-(2-methoxyacetyl)py-
rrolidin-3-yl)-1-methyl-1H-indazol-5-yl)-5-methylbenzo[d]thiazol-6-yl)acet-
ic acid (76)
##STR00171##
[0625] Preparation of
(S)-2-(tert-butoxy)-2-(7-(4-chlorophenyl)-2-(3-((R)-1-(2-methoxyacetyl)py-
rrolidin-3-yl)-1-methyl-1H-indazol-5-yl)-5-methylbenzo[d]thiazol-6-yl)acet-
ic acid &
(S)-2-(tert-butoxy)-2-(7-(4-chlorophenyl)-2-(3-((S)-1-(2-methoxy-
acetyl)pyrrolidin-3-yl)-1-methyl-1H-indazol-5-yl)-5-methylbenzo[d]thiazol--
6-yl)acetic acid: Prepared in a manner similar to
(2S)-2-(tert-butoxy)-2-(7-(4-chlorophenyl)-2-(3-(1-(methoxycarbonyl)pyrro-
lidin-3-yl)-1-methyl-1H-indazol-5-yl)-5-methylbenzo[d]thiazol-6-yl)acetic
acid except using 2-methoxyacetyl chloride instead of methyl
chloroformate. The two diastereoisomers were separated by prep
HPLC.
(S)-2-(tert-butoxy)-2-(7-(4-chlorophenyl)-2-(3-((R)-1-(2-methoxyacetyl)py-
rrolidin-3-yl)-1-methyl-1H-indazol-5-yl)-5-methylbenzo[d]thiazol-6-yl)acet-
ic acid: .sup.1H NMR (400 MHz, Acetonitrile-d3) .delta. 8.51-8.28
(m, 1H), 8.22-7.98 (m, 1H), 7.98-7.80 (m, 1H), 7.71-7.47 (m, 5H),
5.28 (s, 1H), 4.15-4.03 (m, 2H), 4.03-3.95 (m, 4H), 3.96-3.46 (m,
5H), 3.45-3.27 (m, 3H), 2.72-2.52 (m, 3H), 2.47-2.09 (m, 2H), 0.99
(d, J=0.9 Hz, 9H).
(S)-2-(tert-butoxy)-2-(7-(4-chlorophenyl)-2-(3-((S)-1-(2-methoxyacetyl)py-
rrolidin-3-yl)-1-methyl-1H-indazol-5-yl)-5-methylbenzo[d]thiazol-6-yl)acet-
ic acid: .sup.1H NMR (400 MHz, Acetonitrile-d3) .delta. 8.47-8.25
(m, 1H), 8.17-8.00 (m, 1H), 7.85 (d, J=5.6 Hz, 1H), 7.72-7.46 (m,
6H), 5.28 (s, 1H), 4.22-4.04 (m, 2H), 4.03-3.93 (m, 4H), 3.78-3.57
(m, 2H), 3.54 (dt, J=17.6, 8.8 Hz, 1H), 3.48-3.29 (m, 3H),
2.70-2.56 (m, 3H), 2.51-2.15 (m, 1H), 1.23 (d, J=6.9 Hz, 1H), 0.99
(d, J=1.1 Hz, 9H).
Example 78
Preparation of
(2S)-2-(tert-butoxy)-2-(7-(4-chlorophenyl)-2-(3-(1-(2-methoxyethyl)piperi-
din-3-yl)-1-methyl-1H-indazol-5-yl)-5-methylbenzo[d]thiazol-6-yl)acetic
acid (77)
##STR00172## ##STR00173##
[0627] Preparation of (S)-tert-butyl
3-(5-(6-(1-(tert-butoxy)-2-ethoxy-2-oxoethyl)-7-(4-chlorophenyl)-5-methyl-
benzo[d]thiazol-2-yl)-1-methyl-1H-indazol-3-yl)-5,6-dihydropyridine-1(2H)--
carboxylate: A 50 mL round-bottom flask was charged with (S)-ethyl
2-(2-(3-bromo-1-methyl-1H-indazol-5-yl)-7-(4-chlorophenyl)-5-methylbenzo[-
d]thiazol-6-yl)-2-(tert-butoxy)acetate (200 mg, 0.32 mmol),
tert-butyl
3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-5,6-dihydropyridine-1(2H)-
-carboxylate (148 mg, 0.48 mmol), Pd(PPh.sub.3).sub.4 (37 mg, 0.032
mmol), K.sub.2CO.sub.3 (132 mg, 0.96 mmol) in dioxane (16 mL) and
water (4 mL). The reaction mixture was heated to 100.degree. C. for
1 h. The reaction was cooled to room temperature and diluted with
ethyl acetate (50 mL), washed with 1N HCl and dried over
Na.sub.2SO.sub.4. After concentration, the crude was purified by
column chromatography on silica gel with hexane-EtOAc to obtain
desired product.
[0628] Preparation of tert-butyl
3-(5-(6-((S)-1-(tert-butoxy)-2-ethoxy-2-oxoethyl)-7-(4-chlorophenyl)-5-me-
thylbenzo[d]thiazol-2-yl)-1-methyl-1H-indazol-3-yl)piperidine-1-carboxylat-
e: A flask was charged with 5% w/w Rh/Al.sub.2O.sub.3 (93 mg, 0.045
mmol), (S)-tert-butyl
3-(5-(6-(1-(tert-butoxy)-2-ethoxy-2-oxoethyl)-7-(4-chlorophenyl)-5-methyl-
benzo[d]thiazol-2-yl)-1-methyl-1H-indazol-3-yl)-5,6-dihydropyridine-1(2H)--
carboxylate (220 mg), and EtOH (absolute, 10 mL). The reaction was
evacuated (vacuum) and backfilled from a balloon of H.sub.2, then
stirred vigorously at 23.degree. C. for 2.5 h. The reaction mixture
was filtered through celite, and the filtrate was concentrated. The
residue was purified by CombiFlash (40 g column) using
hexane--ethyl acetate as eluents to give desired product.
[0629] Preparation of (2S)-ethyl
2-(tert-butoxy)-2-(7-(4-chlorophenyl)-5-methyl-2-(1-methyl-3-(piperidin-3-
-yl)-1H-indazol-5-yl)benzo[d]thiazol-6-yl)acetate: tert-butyl
3-(5-(6-((S)-1-(tert-butoxy)-2-ethoxy-2-oxoethyl)-7-(4-chlorophenyl)-5-me-
thylbenzo[d]thiazol-2-yl)-1-methyl-1H-indazol-3-yl)piperidine-1-carboxylat-
e (220 mg, 0.30 mmol) was dissolved in 1.25 M HCl in 2-propanol (15
mL) in a 50 ml round-bottom flask. The reaction mixture was stirred
at room temperature for overnight. After concentration, the HCl
salt of desired product was obtained.
[0630] Preparation of (2S)-ethyl
2-(tert-butoxy)-2-(7-(4-chlorophenyl)-2-(3-(1-(2-methoxyethyl)piperidin-3-
-yl)-1-methyl-1H-indazol-5-yl)-5-methylbenzo[d]thiazol-6-yl)acetate:
In a 50 mL round-bottom flask, (2S)-ethyl
2-(tert-butoxy)-2-(7-(4-chlorophenyl)-5-methyl-2-(1-methyl-3-(piperidin-3-
-yl)-1H-indazol-5-yl)benzo[d]thiazol-6-yl)acetate (0.010 g, 0.016
mmol) was dissolved in MeOH (1 mL). 2-methoxyacetaldehyde (0.012 g,
0.16 mmol) was added to the reaction mixture. NaBH.sub.3CN (0.01 g,
0.15 mmol) and one drop of acetic acid were added to the reaction
mixture. The reaction mixture was stirred at room temperature for
half an hour. After concentration, the residue was dissolved in
EtOAc, washed with brine and dried over Na.sub.2SO.sub.4. After
concentration, the crude was used for next step without further
purification.
[0631] Preparation of
(2S)-2-(tert-butoxy)-2-(7-(4-chlorophenyl)-2-(3-(1-(2-methoxyethyl)piperi-
din-3-yl)-1-methyl-1H-indazol-5-yl)-5-methylbenzo[d]thiazol-6-yl)acetic
acid: Prepared in a manner similar to
(S)-2-(tert-butoxy)-2-(7-(4-chlorophenyl)-5-methyl-2-(1-methyl-3-(2-oxa-6-
-azaspiro[3.3
]heptan-6-yl)-1H-indazol-5-yl)benzo[d]thiazol-6-yl)acetic acid
except using (2S)-ethyl
2-(tert-butoxy)-2-(7-(4-chlorophenyl)-2-(3-(1-(2-methoxyethyl)piperidin-3-
-yl)-1-methyl-1H-indazol-5-yl)-5-methylbenzo[d]thiazol-6-yl)acetate
instead of (S)-ethyl
2-(tert-butoxy)-2-(7-(4-chlorophenyl)-5-methyl-2-(1-methyl-3-(2-oxa-6-aza-
spiro[3.3
]heptan-6-yl)-1H-indazol-5-yl)benzo[d]thiazol-6-yl)acetate. .sup.1H
NMR (400 MHz, Acetonitrile-d3) .delta. 8.43 (dd, J=6.5, 1.5 Hz,
1H), 8.21 (t, J=10.2 Hz, 1H), 7.94-7.75 (m, 1H), 7.78-7.48 (m, 5H),
5.28 (s, 1H), 4.09 (s, 3H), 4.03 (s, 3H), 3.92-3.52 (m, 6H), 3.46
(d, J=1.4 Hz, 1H), 3.34 (d, J=7.8 Hz, 2H), 2.65-2.48 (m, 3H), 2.15
(d, J=56.1 Hz, 2H), 1.84-1.71 (m, 1H), 0.99 (d, J=1.7 Hz, 9H).
Example 79
Preparation of
(S)-2-(tert-butoxy)-2-(7-(4-chlorophenyl)-5-methyl-2-(1-methyl-3-(2-oxoim-
idazolidin-1-yl)-1H-indazol-5-yl) benzo[d]thiazol-6-yl) acetic acid
(78)
##STR00174##
[0633] Preparation of (S)-ethyl
2-(tert-butoxy)-2-(7-(4-chlorophenyl)-5-methyl-2-(1-methyl-3-(2oxoimidazo-
lidin-1-yl)-1H-indazol-5-yl)benzo[d]thiazol-6-yl)acetate: In a 5 mL
microwave vial, (S)-ethyl
2-(2-(3-bromo-1-methyl-1H-indazol-5-yl)-7-(4-chlorophenyl)-5-methylbenzo[-
d]thiazol-6-yl)-2-(tert-butoxy)acetate (0.025 g, 0.29 mmol),
imidazolidin-2-one (0.10 g, 0.15 mmol), CuI (0.015 g, 0.079 mmol),
and N,N-dimethyl cyclohexane (0.011 g, 0.079 mmol) in dioxane (1
mL) was heated to 100.degree. C. under MW for one hour. The
reaction mixture was diluted with ethyl acetate (50 mL), washed
with 1N HCl and dried over Na.sub.2SO.sub.4. After concentration,
the crude was purified by column chromatography on silica gel with
hexane-EtOAc to obtain (S)-ethyl
2-(tert-butoxy)-2-(7-(4-chlorophenyl)-5-methyl-2-(1-methyl-3-(2oxoimidazo-
lidin-1-yl)-1H-indazol-5-yl)benzo[d]thiazol-6-yl)acetate.
[0634] Preparation of
(S)-2-(tert-butoxy)-2-(7-(4-chlorophenyl)-5-methyl-2-(1-methyl-3-(2-oxoim-
idazolidin-1-yl)-1H-indazol-5-yl)benzo[d]thiazol-6-yl)acetic acid:
In a 5 mL microwave vial, (S)-ethyl
2-(tert-butoxy)-2-(7-(4-chlorophenyl)-5-methyl-2-(1-methyl-3-(2oxoimidazo-
lidin-1-yl)-1H-indazol-5-yl)benzo[d]thiazol-6-yl)acetate (0.017 g,
0.027 mmol), lithium iodide (0.08 g, 0.60 mmol) in pyridine (0.5
mL) was heated to 170.degree. C. under MW for two hours. The
solution was concentrated and the residue was purified by HPLC to
give desired product. .sup.1H NMR (400 MHz, Chloroform-d) .delta.
9.00-8.79 (m, 1H), 8.11 (dd, J=9.0, 1.6 Hz, 1H), 7.77 (s, 1H),
7.75-7.63 (m, 1H), 7.64-7.54 (m, 3H), 7.48 (d, J=9.0 Hz, 1H), 5.24
(s, 1H), 4.26-4.02 (m, 2H), 3.94 (s, 3H), 3.64 (t, J=8.0 Hz, 2H),
2.60 (s, 3H), 0.97 (s, 9H).
Example 80
Preparation of
(S)-2-(tert-butoxy)-2-(7-(4-chlorophenyl)-2-(3-(3-(2-methoxyethyl)-2-oxoi-
midazolidin-1-yl)-1-methyl-1H-indazol-5-yl)-5-methylbenzo[d]thiazol-6-yl)a-
cetic acid (79)
##STR00175##
[0636] Preparation of (S)-ethyl
2-(tert-butoxy)-2-(7-(4-chlorophenyl)-2-(3-(3-(2-methoxyethyl)-2-oxoimida-
zolidin-1-yl)-1-methyl-1H-indazol-5-yl)-5-methylbenzo[d]thiazol-6-yl)aceta-
te: A 50-mL 1-neck round-bottom flask was charged with reactant
(S)-ethyl
2-(tert-butoxy)-2-(7-(4-chlorophenyl)-5-methyl-2-(1-methyl-3-(2-oxoimidaz-
olidin-1-yl)-1H-indazol-5-yl)benzo[d]thiazol-6-yl)acetate (0.015 g,
0.024 mmol) in DMF (2 ml). Sodium hydride (60%, 0.003 g, 0.075
mmol) was added to the reaction mixture at room temperature.
2-bromoethyl methyl ether (0.014 g, 0.048 mmol) was added in. The
reaction mixture was stirred at room temperature for 1 hour. Two
drops of water were added to quench the reaction. The reaction
mixture was diluted with MeOH (2 mL) and purified by HPLC to afford
desired product.
[0637] Preparation of
(S)-2-(tert-butoxy)-2-(7-(4-chlorophenyl)-2-(3-(3-(2-methoxyethyl)-2-oxoi-
midazolidin-1-yl)-1-methyl-1H-indazol-5-yl)-5-methylbenzo[d]thiazol-6-yl)a-
cetic acid: In a 5 mL microwave vial, (S)-ethyl
2-(tert-butoxy)-2-(7-(4-chlorophenyl)-2-(3-(3-(2-methoxyethyl)-2-oxoimida-
zolidin-1-yl)-1-methyl-1H-indazol-5-yl)-5-methylbenzo[d]thiazol-6-yl)aceta-
te (0.014 g, 0.020 mmol), lithium iodide (0.08 g, 0.60 mmol) in
pyridine (0.5 mL) was heated to 170.degree. C. under MW for two
hours. The solution was concentrated and the residue was purified
by HPLC to give desired product. .sup.1H NMR (400 MHz,
Chloroform-d) .delta. 8.88 (d, J=1.7 Hz, 1H), 8.10 (dd, J=8.9, 1.8
Hz, 1H), 7.76 (s, 1H), 7.71-7.59 (m, 1H), 7.55 (dt, J=4.9, 2.5 Hz,
4H), 7.49 (d, J=9.0 Hz, 1H), 5.20 (s, 1H), 4.06-3.87 (m, 6H), 3.69
(dd, J=9.2, 6.8 Hz, 2H), 3.57 (t, J=5.0 Hz, 2H), 3.47 (t, J=5.1 Hz,
2H), 3.35 (d, J=2.6 Hz, 3H), 2.56 (s, 2H), 0.94 (d, J=2.4 Hz,
9H).
Example 81
Preparation of
(S)-2-(tert-butoxy)-2-(7-(4-chlorophenyl)-5-methyl-2-(1-methyl-3-(3-methy-
l-2-oxoimidazolidin-1-yl)-1H-indazol-5-yl)benzo[d]thiazol-6-yl)acetic
acid (80)
##STR00176##
[0639] Preparation of (S)-ethyl
2-(tert-butoxy)-2-(7-(4-chlorophenyl)-5-methyl-2-(1-methyl-3-(3-methyl-2--
oxoimidazolidin-1-yl)-1H-indazol-5-yl)benzo[d]thiazol-6-yl)acetate:
Prepared in a manner similar to (S)-ethyl
2-(tert-butoxy)-2-(7-(4-chlorophenyl)-2-(3-(3-(2-methoxyethyl)-2-oxoimida-
zolidin-1-yl)-1-methyl-1H-indazol-5-yl)-5-methylbenzo[d]thiazol-6-yl)aceta-
te except using methyl iodide instead of 2-bromoethyl methyl
ether.
[0640] Preparation of
(S)-2-(tert-butoxy)-2-(7-(4-chlorophenyl)-5-methyl-2-(1-methyl-3-(3-methy-
l-2-oxoimidazolidin-1-yl)-1H-indazol-5-yl)
benzo[d]thiazol-6-yl)acetic acid: Prepared in a manner similar to
(S)-2-(tert-butoxy)-2-(7-(4-chlorophenyl)-2-(3-(3-(2-methoxyethyl)-2-oxoi-
midazolidin-1-yl)-1-methyl-1H-indazol-5-yl)-5-methylbenzo[d]thiazol-6-yl)a-
cetic acid except using (S)-ethyl
2-(tert-butoxy)-2-(7-(4-chlorophenyl)-5-methyl-2-(1-methyl-3-(3-methyl-2--
oxoimidazolidin-1-yl)-1H-indazol-5-yl)benzo[d]thiazol-6-yl)acetate
instead of (S)-ethyl
2-(tert-butoxy)-2-(7-(4-chlorophenyl)-2-(3-(3-(2-methoxyethyl)-2-oxoimida-
zolidin-1-yl)-1-methyl-1H-indazol-5-yl)-5-methylbenzo[d]thiazol-6-yl)aceta-
te. .sup.1H NMR (400 MHz, Chloroform-d) .delta. 9.01-8.79 (m, 1H),
8.07 (dd, J=8.9, 1.7 Hz, 1H), 7.77 (s, 1H), 7.69 (dd, J=8.6, 2.0
Hz, 1H), 7.58 (dt, J=5.8, 2.2 Hz, 3H), 7.45 (d, J=9.0 Hz, 1H), 5.24
(s, 1H), 4.10-3.83 (m, 6H), 3.59 (dd, J=9.1, 7.0 Hz, 2H), 2.89 (s,
3H), 2.60 (s, 3H), 0.97 (s, 9H).
Example 82
Preparation of
(S)-2-(2-(3-(3-((1,3-dioxolan-2-yl)methyl)-2-oxoimidazolidin-1-yl)-1-meth-
yl-1H-indazol-5-yl)-7-(4-chlorophenyl)-5-methylbenzo[d]thiazol-6-yl)-2-(te-
rt-butoxy)acetic acid (81)
##STR00177##
[0642] Preparation of (S)-ethyl
2-(2-(3-(3-((1,3-dioxolan-2-yl)methyl)-2-oxoimidazolidin-1-yl)-1-methyl-1-
H-indazol-5-yl)-7-(4-chlorophenyl)-5-methylbenzo[d]thiazol-6-yl)-2-(tert-b-
utoxy)acetate: Prepared in a manner similar to (S)-ethyl
2-(tert-butoxy)-2-(7-(4-chlorophenyl)-2-(3-(3-(2-methoxyethyl)-2-oxoimida-
zolidin-1-yl)-1-methyl-1H-indazol-5-yl)-5-methylbenzo[d]thiazol-6-yl)aceta-
te except using 2-Bromomethyl-1,3-dioxolane instead of 2-bromoethyl
methyl ether.
[0643] Preparation of
(S)-2-(2-(3-(3-((1,3-dioxolan-2-yl)methyl)-2-oxoimidazolidin-1-yl)-1-meth-
yl-1H-indazol-5-yl)-7-(4-chlorophenyl)-5-methylbenzo[d]thiazol-6-yl)-2-(te-
rt-butoxy)acetic acid: Prepared in a manner similar to
(S)-2-(tert-butoxy)-2-(7-(4-chlorophenyl)-2-(3-(3-(2-methoxyethyl)-2-oxoi-
midazolidin-1-yl)-1-methyl-1H-indazol-5-yl)-5-methylbenzo[d]thiazol-6-yl)a-
cetic acid except using (S)-ethyl
2-(2-(3-(3-((1,3-dioxolan-2-yl)methyl)-2-oxoimidazolidin-1-yl)-1-methyl-1-
H-indazol-5-yl)-7-(4-chlorophenyl)-5-methylbenzo[d]thiazol-6-yl)-2-(tert-b-
utoxy)acetate instead of (S)-ethyl
2-(tert-butoxy)-2-(7-(4-chlorophenyl)-2-(3-(3-(2-methoxyethyl)-2-oxoimida-
zolidin-1-yl)-1-methyl-1H-indazol-5-yl)-5-methylbenzo[d]thiazol-6-yl)aceta-
te. .sup.1H NMR (400 MHz, Chloroform-d) .delta. 9.09-8.84 (m, 1H),
8.19-8.04 (m, 1H), 7.79 (d, J=2.7 Hz, 1H), 7.68 (dd, J=8.4, 1.9 Hz,
1H), 7.62-7.54 (m, 4H), 7.52 (dd, J=8.9, 1.1 Hz, 1H), 5.25 (d,
J=6.7 Hz, 1H), 5.05 (s, 1H), 4.20-4.05 (m, 2H), 4.04-3.99 (m, 2H),
3.97 (d, J=2.7 Hz, 3H), 3.95-3.84 (m, 1H), 3.84-3.69 (m, 3H), 3.48
(d, J=4.2 Hz, 1H), 2.60 (d, J=0.9 Hz, 2H), 0.97 (s, 9H).
Example 83
Preparation of
(S)-2-(tert-butoxy)-2-(7-(4-chlorophenyl)-2-(3-(3-ethyl-2-oxoimidazolidin-
-1-yl)-1-methyl-1H-indazol-5-yl)-5-methylbenzo[d]thiazol-6-yl)acetic
acid (82)
##STR00178##
[0645] Preparation of (S)-ethyl
2-(tert-butoxy)-2-(7-(4-chlorophenyl)-2-(3-(3-ethyl-2-oxoimidazolidin-1-y-
l)-1-methyl-1H-indazol-5-yl)-5-methylbenzo[d]thiazol-6-yl)acetate:
Prepared in a manner similar to (S)-ethyl
2-(tert-butoxy)-2-(7-(4-chlorophenyl)-2-(3-(3-(2-methoxyethyl)-2-oxoimida-
zolidin-1-yl)-1-methyl-1H-indazol-5-yl)-5-methylbenzo[d]thiazol-6-yl)aceta-
te except using ethyl iodide instead of 2-bromoethyl methyl
ether.
[0646] Preparation of
(S)-2-(tert-butoxy)-2-(7-(4-chlorophenyl)-2-(3-(3-ethyl-2-oxoimidazolidin-
-1-yl)-1-methyl-1H-indazol-5-yl)-5-methylbenzo[d]thiazol-6-yl)acetic
acid: Prepared in a manner similar to
(S)-2-(tert-butoxy)-2-(7-(4-chlorophenyl)-2-(3-(3-(2-methoxyethyl)-2-oxoi-
midazolidin-1-yl)-1-methyl-1H-indazol-5-yl)-5-methylbenzo[d]thiazol-6-yl)a-
cetic acid except using (S)-ethyl
2-(tert-butoxy)-2-(7-(4-chlorophenyl)-2-(3-(3-ethyl-2-oxoimidazolidin-1-y-
l)-1-methyl-1H-indazol-5-yl)-5-methylbenzo[d]thiazol-6-yl)acetate
instead of (S)-ethyl
2-(tert-butoxy)-2-(7-(4-chlorophenyl)-2-(3-(3-(2-methoxyethyl)-2-oxoimida-
zolidin-1-yl)-1-methyl-1H-indazol-5-yl)-5-methylbenzo[d]thiazol-6-yl)aceta-
te. .sup.1H NMR (400 MHz, Chloroform-d) .delta. 8.92 (dd, J=1.7,
0.7 Hz, 1H), 8.09 (dd, J=9.0, 1.7 Hz, 1H), 7.78 (d, J=0.9 Hz, 1H),
7.72-7.62 (m, 1H), 7.62-7.53 (m, 3H), 7.48 (dd, J=9.0, 0.7 Hz, 1H),
5.24 (s, 1H), 4.06-3.96 (m, 2H), 3.94 (s, 3H), 3.63 (dd, J=8.8, 7.3
Hz, 2H), 3.37 (q, J=7.2 Hz, 3H), 2.60 (d, J=0.8 Hz, 3H), 1.21 (t,
J=7.2 Hz, 3H), 0.97 (s, 9H).
Example 84
Preparation of
(S)-2-(tert-butoxy)-2-(7-(4-chlorophenyl)-5-methyl-2-(1-methyl-3-(3-(2-mo-
rpholinoethyl)-2-oxoimidazolidin-1-yl)-1H-indazol-5-yl)benzo[d]thiazol-6-y-
l)acetic acid (83)
##STR00179##
[0648] Preparation of (S)-ethyl
2-(tert-butoxy)-2-(7-(4-chlorophenyl)-5-methyl-2-(1-methyl-3-(3-(2-morpho-
linoethyl)-2-oxoimidazolidin-1-yl)-1H-indazol-5-yl)benzo[d]thiazol-6-yl)ac-
etate: Prepared in a manner similar to (S)-ethyl
2-(tert-butoxy)-2-(7-(4-chlorophenyl)-2-(3-(3-(2-methoxyethyl)-2-oxoimida-
zolidin-1-yl)-1-methyl-1H-indazol-5-yl)-5-methylbenzo[d]thiazol-6-yl)aceta-
te except using 4-(2-bromoethyl) morpholine instead of 2-bromoethyl
methyl ether.
[0649] Preparation of
(S)-2-(tert-butoxy)-2-(7-(4-chlorophenyl)-5-methyl-2-(1-methyl-3-(3-(2-mo-
rpholinoethyl)-2-oxoimidazolidin-1-yl)-1H-indazol-5-yl)benzo[d]thiazol-6-y-
l)acetic acid: Prepared in a manner similar to
(S)-2-(tert-butoxy)-2-(7-(4-chlorophenyl)-2-(3-(3-(2-methoxyethyl)-2-oxoi-
midazolidin-1-yl)-1-methyl-1H-indazol-5-yl)-5-methylbenzo[d]thiazol-6-yl)a-
cetic acid except using (S)-ethyl
2-(tert-butoxy)-2-(7-(4-chlorophenyl)-5-methyl-2-(1-methyl-3-(3-(2-morpho-
linoethyl)-2-oxoimidazolidin-1-yl)-1H-indazol-5-yl)benzo[d]thiazol-6-yl)ac-
etate instead of (S)-ethyl
2-(tert-butoxy)-2-(7-(4-chlorophenyl)-2-(3-(3-(2-methoxyethyl)-2-oxoimida-
zolidin-1-yl)-1-methyl-1H-indazol-5-yl)-5-methylbenzo[d]thiazol-6-yl)aceta-
te. .sup.1H NMR (400 MHz, Acetonitrile-d3) .delta. 9.04 (s, 1H),
8.85-8.70 (m, 2H), 8.60-8.46 (m, 2H), 8.14 (dd, J=8.9, 1.7 Hz, 1H),
8.01 (dd, J=7.9, 6.1 Hz, 2H), 7.86 (d, J=1.0 Hz, 1H), 7.73-7.60 (m,
4H), 7.52 (d, J=9.0 Hz, 1H), 5.27 (s, 1H), 4.07 (dd, J=9.1, 7.0 Hz,
2H), 3.97 (s, 3H), 3.84-3.59 (m, 4H), 3.35 (t, J=5.2 Hz, 2H), 3.12
(s, 2H), 2.58 (s, 3H), 0.99 (s, 9H). LCMS-ESI.sup.+: calc'd for
C.sub.37H.sub.41ClN.sub.6O.sub.5S: 716.2, 718.2 (M+H.sup.+); Found:
716.2, 718.2 (M+H.sup.+).
Example 85
Preparation of
(S)-2-(tert-butoxy)-2-(7-(4-chlorophenyl)-2-(3-(4-ethyl-3-oxopiperazin-1--
yl)-1-methyl-1H-indazol-5-yl)-5-methylbenzo[d]thiazol-6-yl)acetic
acid (84)
##STR00180##
[0651] Preparation of
(S)-2-(tert-butoxy)-2-(7-(4-chlorophenyl)-2-(3-(4-ethyl-3-oxopiperazin-1--
yl)-1-methyl-1H-indazol-5-yl)-5-methylbenzo[d]thiazol-6-yl)acetic
acid:
(S)-2-(tert-butoxy)-2-(7-(4-chlorophenyl)-2-(3-(4-ethyl-3-oxopiperazin-1--
yl)-1-methyl-1H-indazol-5-yl)-5-methylbenzo[d]thiazol-6-yl)acetic
acid was prepared in a similar manner as
(S)-2-(tert-butoxy)-2-(7-(4-chlorophenyl)-2-(3-(3-(2-methoxyethyl)-2-oxoi-
midazolidin-1-yl)-1-methyl-1H-indazol-5-yl)-5-methylbenzo[d]thiazol-6-yl)a-
cetic acid. .sup.1H NMR (400 MHz, Methanol-d4) .delta. 8.46-8.39
(m, 1H), 8.07-7.97 (m, 1H), 7.79 (s, 1H), 7.72-7.65 (m, 1H), 7.58
(m, 3H), 7.49 (t, J=9.0 Hz, 1H), 5.24 (s, 1H), 4.07 (m, 1H), 3.91
(m, 4H), 3.76 (m, 2H), 3.63-3.47 (m, 4H), 2.61 (s, 3H), 1.19 (td,
J=7.2, 3.0 Hz, 3H), 0.97 (s, 9H); LCMS-ESI+: calc'd for
C.sub.34H.sub.37ClN.sub.5O.sub.4S: 646.22 (M+H+); Found: 646.3
(M+H+).
Example 86
Preparation of
(S)-2-(tert-butoxy)-2-(7-(4-chlorophenyl)-5-methyl-2-(1-methyl-3-(4-methy-
l-3-oxopiperazin-1-yl)-1H-indazol-5-yl)benzo[d]thiazol-6-yl)acetic
acid (85)
##STR00181##
[0653] Preparation of
(S)-2-(tert-butoxy)-2-(7-(4-chlorophenyl)-5-methyl-2-(1-methyl-3-(4-methy-
l-3-oxopiperazin-1-yl)-1H-indazol-5-yl)benzo[d]thiazol-6-yl)acetic
acid:
(S)-2-(tert-butoxy)-2-(7-(4-chlorophenyl)-5-methyl-2-(1-methyl-3-(4-methy-
l-3-oxopiperazin-1-yl)-1H-indazol-5-yl)benzo[d]thiazol-6-yl)acetic
acid was prepared in a similar manner as
(S)-2-(tert-butoxy)-2-(7-(4-chlorophenyl)-2-(3-(3-(2-methoxyethyl)-2-oxoi-
midazolidin-1-yl)-1-methyl-1H-indazol-5-yl)-5-methylbenzo[d]thiazol-6-yl)a-
cetic acid. .sup.1H NMR (400 MHz, Methanol-d4) .delta. 8.37 (s,
1H), 8.03-7.96 (m, 1H), 7.80-7.76 (m, 1H), 7.74-7.64 (m, 2H), 7.59
(m, 1H), 7.54-7.40 (m, 2H), 5.24 (s, 1H), 4.07 (s, 2H), 3.90 (d,
J=8.4 Hz, 3H), 3.76 (s, 2H), 3.58 (t, J=5.4 Hz, 2H), 3.03 (s, 3H),
2.60 (s, 3H), 0.97 (s, 9H); LCMS-ESI+: calc'd for
C.sub.33H.sub.35ClN.sub.5O.sub.4S: 632.20 (M+H+); Found: 632.3
(M+H+).
Example 87
Preparation of
(S)-2-(tert-butoxy)-2-(7-(4-chlorophenyl)-2-(3-(4-ethyl-2-oxopiperazin-1--
yl)-1-methyl-1H-indazol-5-yl)-5-methylbenzo[d]thiazol-6-yl)acetic
acid (86)
##STR00182##
[0655] Preparation of
(S)-2-(tert-butoxy)-2-(7-(4-chlorophenyl)-2-(3-(4-ethyl-2-oxopiperazin-1--
yl)-1-methyl-1H-indazol-5-yl)-5-methylbenzo[d]thiazol-6-yl)acetic
acid:
(S)-2-(tert-butoxy)-2-(7-(4-chlorophenyl)-2-(3-(4-ethyl-2-oxopiperazin-1--
yl)-1-methyl-1H-indazol-5-yl)-5-methylbenzo[d]thiazol-6-yl)acetic
acid was prepared in a similar manner as
(S)-2-(tert-butoxy)-2-(7-(4-chlorophenyl)-2-(3-(3-(2-methoxyethyl)-2-oxoi-
midazolidin-1-yl)-1-methyl-1H-indazol-5-yl)-5-methylbenzo[d]thiazol-6-yl)a-
cetic acid. .sup.1H NMR (400 MHz, Methanol-d4) .delta. 8.34 (s,
1H), 8.19 (d, J=9.0, 1H), 7.81 (d, J=0.9 Hz, 1H), 7.72-7.64 (m,
2H), 7.63-7.52 (m, 3H), 5.24 (s, 1H), 4.29-4.20 (m, 4H), 4.08 (s,
3H), 3.82 (t, J=5.6 Hz, 2H), 3.43 (q, J=7.3 Hz, 2H), 2.61 (s, 3H),
1.45 (t, J=7.3 Hz, 3H), 0.97 (s, 9H); LCMS-ESI+: calc'd for
C.sub.34H.sub.37ClN.sub.5O.sub.4S:646.22 (M+H+); Found: 646.3
(M+H+).
Example 88
Preparation
(S)-2-(tert-butoxy)-2-(7-(4-chlorophenyl)-5-methyl-2-(1-methyl-3-(4-methy-
l-2-oxopiperazin-1-yl)-1H-indazol-5-yl)benzo[d]thiazol-6-yl)acetic
acid (87)
##STR00183##
[0657] Preparation of
(S)-2-(tert-butoxy)-2-(7-(4-chlorophenyl)-5-methyl-2-(1-methyl-3-(4-methy-
l-2-oxopiperazin-1-yl)-1H-indazol-5-yl)benzo[d]thiazol-6-yl)acetic
acid:
(S)-2-(tert-butoxy)-2-(7-(4-chlorophenyl)-5-methyl-2-(1-methyl-3-(4-methy-
l-2-oxopiperazin-1-yl)-1H-indazol-5-yl)benzo[d]thiazol-6-yl)acetic
acid was prepared in a similar manner as
(S)-2-(tert-butoxy)-2-(7-(4-chlorophenyl)-2-(3-(3-(2-methoxyethyl)-2-oxoi-
midazolidin-1-yl)-1-methyl-1H-indazol-5-yl)-5-methylbenzo[d]thiazol-6-yl)a-
cetic acid. .sup.1H NMR (400 MHz, CD3OD) .delta. 8.33 (dd, J=1.7,
0.8 Hz, 1H), 8.18 (dd, J=9.0, 1.7 Hz, 1H), 7.81 (d, J=0.9 Hz, 1H),
7.72-7.64 (m, 2H), 7.63-7.52 (m, 3H), 5.25 (s, 1H), 4.24 (d, J=2.3
Hz, 4H), 4.07 (s, 3H), 3.80 (t, J=5.6 Hz, 2H), 3.11 (s, 3H), 2.61
(d, J=0.8 Hz, 3H), 0.97 (s, 9H); LCMS-ESI+: calc'd for
C.sub.33H.sub.35ClN.sub.5O.sub.4S: 632.20 (M+H+); Found: 632.3
(M+H+).
Example 89
Preparation of
(S)-2-(tert-butoxy)-2-(7-(4-chlorophenyl)-5-methyl-2-(1-methyl-3-(3-morph-
olinoazetidin-1-yl)-1H-indazol-5-yl)benzo[d]thiazol-6-yl)acetic
acid (88)
##STR00184##
[0659] Preparation of
(S)-2-(tert-butoxy)-2-(7-(4-chlorophenyl)-5-methyl-2-(1-methyl-3-(3-morph-
olinoazetidin-1-yl)-1H-indazol-5-yl)benzo[d]thiazol-6-yl)acetic
acid: A mixture of ethyl
(S)-2-(2-(3-bromo-1-methyl-1H-indazol-5-yl)-7-(4-chlorophenyl)-5-methylbe-
nzo[d]thiazol-6-yl)-2-(tert-butoxy)acetate (51.1 mg, 0.081 mmol),
4-(azetidin-3-yl)morpholine dihydrochloride (52.6 mg, 0.244 mmol),
SPhos Pd G2 (11.9 mg, 0.017 mmol), and potassium t-butoxide (77.0
mg, 0.686 mmol) in 1,2-dimethoxyethane (1.5 mL) was placed in a
microwave vial and reacted in a microwave reactor at 110.degree. C.
for 1 h. The resulting mixture was diluted in methanol, acidified
with acetic acid (7-8 drops), filtered, and concentrated. The
residue was dissolved in methanol (3 mL), filtered through syringe
filter, and purified by Gilson HPLC (Phenomenex Gemini, 30-70%
ACN/H.sub.2O+0.1% TFA) to obtain the title product after
lyophilization. .sup.1H NMR (400 MHz, Acetonitrile-d.sub.3) .delta.
8.16-8.10 (m, 1H), 8.07 (dd, J=9.0, 1.6 Hz, 1H), 7.83 (s, 1H), 7.66
(dd, J=7.8, 2.0 Hz, 1H), 7.63-7.56 (m, 3H), 7.42 (dd, J=9.0, 0.6
Hz, 1H), 5.27 (s, 1H), 4.50-4.36 (m, 4H), 4.08 (d, J=7.2 Hz, 1H),
3.92 (br, 4H), 3.86 (s, 3H), 3.16 (br, 4H), 2.58 (s, 3H), 0.99 (s,
9H). LCMS-ESI.sup.+: calc'd for C.sub.35H.sub.39ClN.sub.5O.sub.4S:
660.24 (M+H).sup.+; found: 660.34 (M+H).sup.+.
Example 90
Preparation of
(S)-2-(tert-butoxy)-2-(7-(4-chlorophenyl)-5-methyl-2-(1-methyl-3-(6-methy-
l-2,6-diazaspiro[3.3]heptan-2-yl)-1H-indazol-5-yl)benzo[d]thiazol-6-yl)ace-
tic acid (89)
##STR00185##
[0661] Preparation of
(S)-2-(tert-butoxy)-2-(7-(4-chlorophenyl)-5-methyl-2-(1-methyl-3-(6-methy-
l-2,6-diazaspiro[3.3]heptan-2-yl)-1H-indazol-5-yl)benzo[d]thiazol-6-yl)ace-
tic acid: A mixture of ethyl
(S)-2-(2-(3-bromo-1-methyl-1H-indazol-5-yl)-7-(4-chlorophenyl)-5-methylbe-
nzo[d]thiazol-6-yl)-2-(tert-butoxy)acetate (101.9 mg, 0.162 mmol),
2-methyl-2,6-diazaspiro[3.3]heptane (55.2 mg, 0.492 mmol), SPhos Pd
G2 (24.9 mg, 0.035 mmol), and potassium t-butoxide (36.6 mg, 0.326
mmol) in 1,2-dimethoxyethane (3 mL) was placed in a microwave vial
and reacted in a microwave reactor at 110.degree. C. for 1 h. The
resulting mixture was diluted in methanol, acidified with acetic
acid (0.05 mL), filtered, and concentrated. The residue was
dissolved in methanol--water mixture (9 mL), filtered through
syringe filter, and purified by Gilson HPLC (Phenomenex Gemini,
40-55% ACN/H.sub.2O+0.1% TFA). The collected fractions were
neutralized with 2 N NaOH, and concentrated and lyophilized. The
residue was dissolved in methanol--water mixture, filtered through
syringe filter, and purified again by Waters HPLC (Phenomenex
Gemini-NX, 10-100% ACN) to obtain the title product after
lyophilization. .sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta. 8.10
(d, J=1.6 Hz, 1H), 8.00 (dd, J=8.9, 1.6 Hz, 1H), 7.83 (s, 1H), 7.73
(d, J=8.2 Hz, 1H), 7.70-7.64 (m, 2H), 7.61 (d, J=7.3 Hz, 1H), 7.53
(d, J=9.0 Hz, 1H), 5.00 (s, 1H), 4.19 (s, 4H), 3.84 (s, 3H), 3.41
(s, 4H), 2.54 (s, 3H), 2.25 (s, 3H), 0.88 (s, 9H). LCMS-ESI.sup.+:
calc'd for C.sub.34H.sub.37ClN.sub.5O.sub.3S: 630.23 (M+H).sup.+;
found: 630.25 (M+H).sup.+.
Example 91
(S)-2-(tert-butoxy)-2-(7-(4-chlorophenyl)-2-(3-(3-(dimethylamino)azetidin--
1-yl)-1-methyl-1H-indazol-5-yl)-5-methylbenzo[d]thiazol-6-yl)acetic
acid (90)
##STR00186##
[0663] Preparation of
(2S)-2-(tert-butoxy)-2-(7-(4-chlorophenyl)-5-methyl-2-(1-methyl-3-(tetrah-
ydrofuran-3-yl)-1H-indazol-5-yl)benzo[d]thiazol-6-yl)acetic acid: A
mixture of ethyl
(S)-2-(2-(3-bromo-1-methyl-1H-indazol-5-yl)-7-(4-chlorophenyl)-5-methylbe-
nzo[d]thiazol-6-yl)-2-(tert-butoxy)acetate (49.5 mg, 0.079 mmol),
N,N-dimethylazetidin-3-amine dihydrochloride (41.3 mg, 0.239 mmol),
SPhos Pd G2 (11.4 mg, 0.016 mmol), and potassium t-butoxide (72.4
mg, 0.646 mmol) in 1,2-dimethoxyethane (1.5 mL) was placed in a
microwave vial and reacted in a microwave reactor at 110.degree. C.
for 2.5 h. The resulting mixture was diluted in methanol, filtered
through syringe filter, and purified by Gilson HPLC (Phenomenex
Gemini, 50-100% ACN/H.sub.2O+0.1% TFA) to obtain the title product
after lyophilization. .sup.1H NMR (400 MHz, Acetonitrile-d.sub.3)
.delta. 8.15-8.10 (m, 1H), 8.06 (dd, J=9.0, 1.6 Hz, 1H), 7.82 (s,
1H), 7.66 (dd, J=7.8, 2.2 Hz, 1H), 7.59 (d, J=7.9 Hz, 3H), 7.41 (d,
J=8.9 Hz, 1H), 5.27 (s, 1H), 4.49-4.29 (m, 4H), 4.17 (dq, J=12.9,
6.0 Hz, 1H), 3.86 (s, 3H), 2.84 (s, 6H), 2.57 (s, 3H), 0.99 (s,
9H). LCMS-ESI.sup.+: calc'd for C.sub.33H.sub.37ClN.sub.5O.sub.3S:
618.23 (M+H).sup.+; found: 618.24 (M+H).sup.+.
Example 92
Preparation of
(S)-2-(tert-butoxy)-2-(7-(4-chlorophenyl)-5-methyl-2-(1-methyl-3-(2-oxa-6-
-azaspiro[3.3]heptan-6-yl)-1H-indazol-5-yl)benzo[d]thiazol-6-yl)acetic
acid (91)
##STR00187##
[0665] Preparation of (S)-ethyl
2-(tert-butoxy)-2-(7-(4-chlorophenyl)-5-methyl-2-(1-methyl-3-(2-oxa-6-aza-
spiro[3.3]heptan-6-yl)-1H-indazol-5-yl)benzo[d]thiazol-6-yl)acetate:
In a 5 mL microwave vial, (S)-ethyl
2-(2-(3-bromo-1-methyl-1H-indazol-5-yl)-7-(4-chlorophenyl)-5-methylbenzo[-
d]thiazol-6-yl)-2-(tert-butoxy)acetate (0.020 g, 0.032 mmol),
2-oxa-6-azaspiro[3.3]heptane (0.01 g, 0.096 mmol),
Pd.sub.2(dba).sub.3 (0.004 g, 0.0044 mmol),
2-(Dicyclohexylphosphino)-2',4',6'-triisopropylbiphenyl (0.002 g,
0.0048 mmol) and Cs.sub.2CO.sub.3 (0.052 g, 0.16 mmol) in dioxane
(1 mL) was heated to 100.degree. C. under MW for one hour. The
reaction mixture was diluted with ethyl acetate (50 mL), washed
with 1N HCl and dried over Na.sub.2SO.sub.4. After concentration,
the crude was purified by column chromatography on silica gel with
hexane-EtOAc to obtain desired product.
[0666] Preparation of
(S)-2-(tert-butoxy)-2-(7-(4-chlorophenyl)-5-methyl-2-(1-methyl-3-(2-oxa-6-
-azaspiro[3.3]heptan-6-yl)-1H-indazol-5-yl)benzo[d]thiazol-6-yl)acetic
acid: In a 50 mL round-bottom flask, (S)-ethyl
2-(tert-butoxy)-2-(7-(4-chlorophenyl)-5-methyl-2-(1-methyl-3-(2-oxa-6-aza-
spiro[3.3]heptan-6-yl)-1H-indazol-5-yl)benzo[d]thiazol-6-yl)acetate
(0.014 g, 0.022 mmol) was treated with THF (1 mL), and 5 M aq NaOH
(1 mL), then heated to 100.degree. C. for 30 min. The reaction was
cooled to 23.degree. C., and filtered (0.45 micron teflon syringe
filter). The filtrate was purified by reverse phase HPLC, eluting
by 5-100% acetonitrile in H.sub.2O with 0.1% TFA to give desired
product. .sup.1H NMR (400 MHz, Acetonitrile-d3) .delta. 8.16 (dd,
J=1.6, 0.8 Hz, 1H), 8.02 (d, J=8.8 Hz, 1H), 7.82 (s, 1H), 7.74-7.62
(m, 1H), 7.62-7.52 (m, 3H), 5.28 (s, 1H), 4.80 (s, 4H), 3.88-3.52
(m, 8H), 2.57 (d, J=0.8 Hz, 3H), 0.99 (s, 9H).
Example 93
Preparation of
(S)-2-(tert-butoxy)-2-(7-(4-chlorophenyl)-2-(3-((R)-3-(dimethylamino)pyrr-
olidin-1-yl)-1-methyl-1H-indazol-5-yl)-5-methylbenzo[d]thiazol-6-yl)acetic
acid (92)
##STR00188##
[0668] Preparation of (S)-ethyl
2-(tert-butoxy)-2-(7-(4-chlorophenyl)-2-(3-((R)-3-(dimethylamino)pyrrolid-
in-1-yl)-1-methyl-1H-indazol-5-yl)-5-methylbenzo[d]thiazol-6-yl)acetate:
Prepared in a manner similar to (S)-ethyl
2-(tert-butoxy)-2-(7-(4-chlorophenyl)-5-methyl-2-(1-methyl-3-(2-oxa-6-aza-
spiro[3.3]heptan-6-yl)-1H-indazol-5-yl)benzo[d]thiazol-6-yl)acetate
except using (R)-N,N-dimethylpyrrolidin-3-amine and tripotassium
phosphate instead of 2-oxa-6-azaspiro[3.3]heptane and
Cs.sub.2CO.sub.3.
[0669] Preparation of
(S)-2-(tert-butoxy)-2-(7-(4-chlorophenyl)-2-(3-((R)-3-(dimethylamino)pyrr-
olidin-1-yl)-1-methyl-1H-indazol-5-yl)-5-methylbenzo[d]thiazol-6-yl)acetic
acid: Prepared in a manner similar to
(S)-2-(tert-butoxy)-2-(7-(4-chlorophenyl)-5-methyl-2-(1-methyl-3-(2-oxa-6-
-azaspiro[3.3]heptan-6-yl)-1H-indazol-5-yl)benzo[d]thiazol-6-yl)acetic
acid except using (S)-ethyl
2-(tert-butoxy)-2-(7-(4-chlorophenyl)-2-(3-((R)-3-(dimethylamino)pyrrolid-
in-1-yl)-1-methyl-1H-indazol-5-yl)-5-methylbenzo[d]thiazol-6-yl)acetate
instead of (S)-ethyl
2-(tert-butoxy)-2-(7-(4-chlorophenyl)-5-methyl-2-(1-methyl-3-(2-oxa-6-aza-
spiro[3.3]heptan-6-yl)-1H-indazol-5-yl)benzo[d]thiazol-6-yl)acetate.
.sup.1H NMR (400 MHz, Acetonitrile-d3) .delta. 8.50-8.37 (m, 1H),
8.02 (dd, J=9.0, 1.6 Hz, 1H), 7.85 (s, 1H), 7.67 (dd, J=8.7, 1.8
Hz, 1H), 7.61 (q, J=3.8, 2.9 Hz, 3H), 7.41 (d, J=9.0 Hz, 1H), 5.28
(s, 1H), 4.80 (s, 3H), 4.08-3.91 (m, 2H), 3.87 (d, J=6.7 Hz, 2H),
3.67 (td, J=8.5, 7.0 Hz, 1H), 2.92 (s, 3H), 2.59 (d, J=0.8 Hz, 3H),
2.58-2.45 (m, 3H), 2.35 (dq, J=14.4, 7.3 Hz, 3H), 0.99 (s, 9H).
Example 94
Preparation of
(S)-2-(tert-butoxy)-2-(7-(4-chlorophenyl)-2-(3-((S)-3-(dimethylamino)pyrr-
olidin-1-yl)-1-methyl-1H-indazol-5-yl)-5-methylbenzo[d]thiazol-6-yl)acetic
acid (93)
##STR00189##
[0671] Preparation of (S)-ethyl
2-(tert-butoxy)-2-(7-(4-chlorophenyl)-2-(3-((S)-3-(dimethylamino)pyrrolid-
in-1-yl)-1-methyl-1H-indazol-5-yl)-5-methylbenzo[d]thiazol-6-yl)acetate:
Prepared in a manner similar to (S)-ethyl
2-(tert-butoxy)-2-(7-(4-chlorophenyl)-5-methyl-2-(1-methyl-3-(2-oxa-6-aza-
spiro[3.3
]heptan-6-yl)-1H-indazol-5-yl)benzo[d]thiazol-6-yl)acetate except
using (S)-N,N-dimethylpyrrolidin-3-amine and tripotassium phosphate
instead of 2-oxa-6-azaspiro[3.3]heptane and Cs.sub.2CO.sub.3.
[0672] Preparation of
(S)-2-(tert-butoxy)-2-(7-(4-chlorophenyl)-2-(3-((S)-3-(dimethylamino)pyrr-
olidin-1-yl)-1-methyl-1H-indazol-5-yl)-5-methylbenzo[d]thiazol-6-yl)acetic
acid: Prepared in a manner similar to
(S)-2-(tert-butoxy)-2-(7-(4-chlorophenyl)-5-methyl-2-(1-methyl-3-(2-oxa-6-
-azaspiro[3.3
]heptan-6-yl)-1H-indazol-5-yl)benzo[d]thiazol-6-yl)acetic acid
except using (S)-ethyl
2-(tert-butoxy)-2-(7-(4-chlorophenyl)-2-(3-((S)-3-(dimethylamino)pyrrolid-
in-1-yl)-1-methyl-1H-indazol-5-yl)-5-methylbenzo[d]thiazol-6-yl)acetate
instead of (S)-ethyl
2-(tert-butoxy)-2-(7-(4-chlorophenyl)-5-methyl-2-(1-methyl-3-(2-oxa-6-aza-
spiro[3.3
]heptan-6-yl)-1H-indazol-5-yl)benzo[d]thiazol-6-yl)acetate. .sup.1H
NMR (400 MHz, Acetonitrile-d3) .delta. 8.37 (dd, J=1.6, 0.7 Hz,
1H), 8.01 (dd, J=8.9, 1.6 Hz, 1H), 7.83 (d, J=0.9 Hz, 1H),
7.75-7.64 (m, 1H), 7.60 (d, J=8.3 Hz, 2H), 7.45-7.31 (m, 1H), 5.27
(s, 1H), 4.08 (q, J=7.1 Hz, 1H), 4.04-3.89 (m, 2H), 3.90-3.74 (m,
5H), 3.67 (d, J=8.5 Hz, 1H), 3.49 (d, J=11.1 Hz, 1H), 3.27-3.03 (m,
4H), 2.86 (s, 3H), 2.58 (d, J=0.8 Hz, 4H), 0.99 (s, 9H).
Example 95
Preparation of
(S)-2-(tert-butoxy)-2-(7-(4-chlorophenyl)-2-(3-((S)-3-(dimethylamino)pyrr-
olidin-1-yl)-1-methyl-1H-indazol-5-yl)-5-methylbenzo[d]thiazol-6-yl)acetic
acid (94)
##STR00190##
[0674] Preparation of (S)-ethyl
2-(tert-butoxy)-2-(2-(3-((S)-3-((tert-butoxycarbonyl)
(methyl)amino)pyrrolidin-1-yl)-1-methyl-1H-indazol-5-yl)-7-(4-chloropheny-
l)-5-methylbenzo[d]thiazol-6-yl)acetate: Prepared in a manner
similar to (S)-ethyl
2-(tert-butoxy)-2-(7-(4-chlorophenyl)-5-methyl-2-(1-methyl-3-(2-
-oxa-6-azaspiro[3.3]heptan-6-yl)-1H-indazol-5-yl)benzo[d]thiazol-6-yl)acet-
ate except using (S)-tert-butyl methyl(pyrrolidin-3-yl)carbamate,
2-(Di-t-butylphosphino)biphenyl and tripotassium phosphate instead
of 2-oxa-6-azaspiro[3.3]heptane,
2-(Dicyclohexylphosphino)-2',4',6'-triisopropylbiphenyl and
Cs.sub.2CO.sub.3.
[0675] Preparation of (S)-ethyl
2-(tert-butoxy)-2-(7-(4-chlorophenyl)-5-methyl-2-(1-methyl-3-((S)-3-(meth-
ylamino)pyrrolidin-1-yl)-1H-indazol-5-yl)benzo[d]thiazol-6-yl)acetate:
(S)-ethyl 2-(tert-butoxy)-2-(2-(3-((S)-3-((tert-butoxycarbonyl)
(methyl)amino)pyrrolidin-1-yl)-1-methyl-1H-indazol-5-yl)-7-(4-chloropheny-
l)-5-methylbenzo[d]thiazol-6-yl)acetate (14 mg, 0.018 mmol) was
dissolved in 1.25 M HCl in 2-propanol (3 mL) in a 50 ml
round-bottom flask. The reaction mixture was stirred at room
temperature for overnight. After concentration, the HCl salt of the
desired product was obtained.
[0676] Preparation of
(S)-2-(tert-butoxy)-2-(7-(4-chlorophenyl)-5-methyl-2-(1-methyl-3-((S)-3-(-
methylamino)pyrrolidin-1-yl)-1H-indazol-5-yl)benzo[d]thiazol-6-yl)acetic
acid: Prepared in a manner similar to
(S)-2-(tert-butoxy)-2-(7-(4-chlorophenyl)-5-methyl-2-(1-methyl-3-(2-oxa-6-
-azaspiro[3.3]heptan-6-yl)-1H-indazol-5-yl)benzo[d]thiazol-6-yl)acetic
acid except using (S)-ethyl
2-(tert-butoxy)-2-(7-(4-chlorophenyl)-5-methyl-2-(1-methyl-3-((S)-3-(meth-
ylamino)pyrrolidin-1-yl)-1H-indazol-5-yl)benzo[d]thiazol-6-yl)acetate
instead of (S)-ethyl
2-(tert-butoxy)-2-(7-(4-chlorophenyl)-5-methyl-2-(1-methyl-3-(2-oxa-6-aza-
spiro[3.3]heptan-6-yl)-1H-indazol-5-yl)benzo[d]thiazol-6-yl)acetate.
.sup.1H NMR (400 MHz, Acetonitrile-d3) .delta. 8.38 (d, J=1.6 Hz,
1H), 8.00 (dd, J=9.0, 1.6 Hz, 1H), 7.82 (s, 1H), 7.72-7.45 (m, 3H),
7.38 (d, J=8.9 Hz, 1H), 5.28 (s, 1H), 3.92 (dd, J=9.0, 6.5 Hz, 2H),
3.85 (s, 4H), 3.76 (dd, J=11.6, 5.9 Hz, 1H), 3.63 (td, J=9.2, 5.3
Hz, 1H), 3.44 (s, 3H), 2.76 (s, 3H), 2.58 (s, 3H), 2.56-2.37 (m,
1H), 2.30 (dt, J=9.8, 4.4 Hz, 1H), 0.99 (s, 9H).
Example 96
Preparation of
(S)-2-(tert-butoxy)-2-(7-(4-chlorophenyl)-2-(3-((R)-3-(dimethylamino)pyrr-
olidin-1-yl)-1-methyl-1H-indazol-5-yl)-5-methylbenzo[d]thiazol-6-yl)acetic
acid (95)
##STR00191##
[0678] Preparation of (S)-ethyl
2-(tert-butoxy)-2-(2-(3-((R)-3-((tert-butoxycarbonyl)
(methyl)amino)pyrrolidin-1-yl)-1-methyl-1H-indazol-5-yl)-7-(4-chloropheny-
l)-5-methylbenzo[d]thiazol-6-yl)acetate: Prepared in a manner
similar to (S)-ethyl
2-(tert-butoxy)-2-(7-(4-chlorophenyl)-5-methyl-2-(1-methyl-3-(2-
-oxa-6-azaspiro[3.3]heptan-6-yl)-1H-indazol-5-yl)benzo[d]thiazol-6-yl)acet-
ate except using (R)-tert-butyl methyl(pyrrolidin-3-yl)carbamate,
2-(Di-t-butylphosphino)biphenyl and tripotassium phosphate instead
of 2-oxa-6-azaspiro[3.3]heptane,
2-(Dicyclohexylphosphino)-2',4',6'-triisopropylbiphenyl and
Cs.sub.2CO.sub.3.
[0679] Preparation of (S)-ethyl
2-(tert-butoxy)-2-(7-(4-chlorophenyl)-5-methyl-2-(1-methyl-3-((R)-3-(meth-
ylamino)pyrrolidin-1-yl)-1H-indazol-5-yl)benzo[d]thiazol-6-yl)acetate:
(S)-ethyl 2-(tert-butoxy)-2-(2-(3-((R)-3-((tert-butoxycarbonyl)
(methyl)amino)pyrrolidin-1-yl)-1-methyl-1H-indazol-5-yl)-7-(4-chloropheny-
l)-5-methylbenzo[d]thiazol-6-yl)acetate (14 mg, 0.018 mmol) was
dissolved in 1.25 M HCl in 2-propanol (3 mL) in a 50 ml
round-bottom flask. The reaction mixture was stirred at room
temperature for overnight. After concentration, the HCl salt of the
desired product was obtained.
[0680] Preparation of
(S)-2-(tert-butoxy)-2-(7-(4-chlorophenyl)-5-methyl-2-(1-methyl-3-((R)-3-(-
methylamino)pyrrolidin-1-yl)-1H-indazol-5-yl)benzo[d]thiazol-6-yl)acetic
acid: Prepared in a manner similar to
(S)-2-(tert-butoxy)-2-(7-(4-chlorophenyl)-5-methyl-2-(1-methyl-3-(2-oxa-6-
-azaspiro[3.3]heptan-6-yl)-1H-indazol-5-yl)benzo[d]thiazol-6-yl)acetic
acid except using (S)-ethyl
2-(tert-butoxy)-2-(7-(4-chlorophenyl)-5-methyl-2-(1-methyl-3-((R)-3-(meth-
ylamino)pyrrolidin-1-yl)-1H-indazol-5-yl)benzo[d]thiazol-6-yl)acetate
instead of (S)-ethyl
2-(tert-butoxy)-2-(7-(4-chlorophenyl)-5-methyl-2-(1-methyl-3-(2-oxa-6-aza-
spiro[3.3]heptan-6-yl)-1H-indazol-5-yl)benzo[d]thiazol-6-yl)acetate.
.sup.1H NMR (400 MHz, Chloroform-d) 1H NMR (400 MHz,
Acetonitrile-d3) .delta. 8.48-8.22 (m, 1H), 8.12-7.90 (m, 2H), 7.79
(s, 1H), 7.66 (dd, J=7.8, 2.0 Hz, 1H), 7.58 (d, J=8.2 Hz, 3H), 7.35
(d, J=9.0 Hz, 1H), 5.27 (s, 1H), 4.13 (s, 3H), 3.87 (d, J=24.9 Hz,
3H), 3.62 (s, 1H), 2.75 (d, J=2.9 Hz, 3H), 2.64-2.53 (m, 3H),
2.52-2.34 (m, 1H), 2.33-2.18 (m, 1H), 0.99 (s, 9H).
Example 97
Preparation of
(S)-2-(tert-butoxy)-2-(7-(4-chlorophenyl)-5-methyl-2-(1-methyl-3-(2-azasp-
iro[3.4]octan-2-yl)-1H-indazol-5-yl)benzo[d]thiazol-6-yl)acetic
acid (96)
##STR00192##
[0682] Preparation of (S)-ethyl
2-(tert-butoxy)-2-(7-(4-chlorophenyl)-5-methyl-2-(1-methyl-3-(2-azaspiro[-
3.4]octan-2-yl)-1H-indazol-5-yl)benzo[d]thiazol-6-yl)acetate:
Prepared in a manner similar to (S)-ethyl
2-(tert-butoxy)-2-(7-(4-chlorophenyl)-5-methyl-2-(1-methyl-3-(2-oxa-6-aza-
spiro[3.3]heptan-6-yl)-1H-indazol-5-yl)benzo[d]thiazol-6-yl)acetate
except using 2-azaspiro[3.4]octane instead of
2-oxa-6-azaspiro[3.3]heptane.
[0683] Preparation of
(S)-2-(tert-butoxy)-2-(7-(4-chlorophenyl)-5-methyl-2-(1-methyl-3-(2-azasp-
iro[3.4]octan-2-yl)-1H-indazol-5-yl)benzo[d]thiazol-6-yl)acetic
acid: Prepared in a manner similar to
(S)-2-(tert-butoxy)-2-(7-(4-chlorophenyl)-5-methyl-2-(1-methyl-3-(2-oxa-6-
-azaspiro[3.3]heptan-6-yl)-1H-indazol-5-yl)benzo[d]thiazol-6-yl)acetic
acid except using (S)-ethyl
2-(tert-butoxy)-2-(7-(4-chlorophenyl)-5-methyl-2-(1-methyl-3-(2-azaspiro[-
3.4]octan-2-yl)-1H-indazol-5-yl)benzo[d]thiazol-6-yl)acetate
instead of (S)-ethyl
2-(tert-butoxy)-2-(7-(4-chlorophenyl)-5-methyl-2-(1-methyl-3-(2-
-oxa-6-azaspiro[3.3]heptan-6-yl)-1H-indazol-5-yl)benzo[d]thiazol-6-yl)acet-
ate. .sup.1H NMR (400 MHz, Acetonitrile-d3) .delta. 8.33-8.18 (m,
1H), 8.12 (s, 1H), 7.82 (s, 1H), 7.72-7.62 (m, 1H), 7.60 (dtd,
J=5.7, 2.7, 1.1 Hz, 3H), 5.24 (m, 10H), 2.56 (d, J=0.8 Hz, 3H),
1.78-1.61 (m, 4H), 0.98 (s, 9H).
Example 98
Preparation of
(S)-2-(tert-butoxy)-2-(7-(4-chlorophenyl)-5-methyl-2-(1-methyl-3-(2-azasp-
iro[3.5]nonan-2-yl)-1H-indazol-5-yl)benzo[d]thiazol-6-yl)acetic
acid (97)
##STR00193##
[0685] Preparation of (S)-ethyl
2-(tert-butoxy)-2-(7-(4-chlorophenyl)-5-methyl-2-(1-methyl-3-(2-azaspiro[-
3.5]nonan-2-yl)-1H-indazol-5-yl)benzo[d]thiazol-6-yl)acetate:
Prepared in a manner similar to (S)-ethyl
2-(tert-butoxy)-2-(7-(4-chlorophenyl)-5-methyl-2-(1-methyl-3-(2-oxa-6-aza-
spiro[3.3
]heptan-6-yl)-1H-indazol-5-yl)benzo[d]thiazol-6-yl)acetate except
using 2-azaspiro[3.5]nonane instead of
2-oxa-6-azaspiro[3.3]heptane.
[0686] Preparation of
(S)-2-(tert-butoxy)-2-(7-(4-chlorophenyl)-5-methyl-2-(1-methyl-3-(2-azasp-
iro[3.5]nonan-2-yl)-1H-indazol-5-yl)benzo[d]thiazol-6-yl)acetic
acid: Prepared in a manner similar to
(S)-2-(tert-butoxy)-2-(7-(4-chlorophenyl)-5-methyl-2-(1-methyl-3-(2-oxa-6-
-azaspiro[3.3
]heptan-6-yl)-1H-indazol-5-yl)benzo[d]thiazol-6-yl)acetic acid
except using (S)-ethyl
2-(tert-butoxy)-2-(7-(4-chlorophenyl)-5-methyl-2-(1-methyl-3-(2-azaspiro[-
3.5]nonan-2-yl)-1H-indazol-5-yl)benzo[d]thiazol-6-yl)acetate
instead of (S)-ethyl
2-(tert-butoxy)-2-(7-(4-chlorophenyl)-5-methyl-2-(1-methyl-3-(2-
-oxa-6-azaspiro[3.3
]heptan-6-yl)-1H-indazol-5-yl)benzo[d]thiazol-6-yl)acetate. .sup.1H
NMR (400 MHz, Acetonitrile-d3) .delta. 8.23 (d, J=1.6 Hz, 1H), 8.13
(s, 1H), 7.82 (s, 1H), 7.66 (dd, J=8.9, 2.2 Hz, 1H), 7.59 (q,
J=3.6, 2.9 Hz, 3H), 7.03 (s, 1H), 5.28 (s, 1H), 5.00 (m, 8H), 2.57
(s, 3H), 2.06-1.86 (m, 2H), 1.79 (t, J=5.7 Hz, 2H), 1.64-1.37 (m,
2H), 1.34-1.17 (m, 4H), 0.99(s, 9H).
Example 99
Preparation of
(S)-2-(tert-butoxy)-2-(7-(4-chlorophenyl)-2-(3-(4-(2-methoxyethyl)piperaz-
in-1-yl)-1-methyl-1H-indazol-5-yl)-5-methylbenzo[d]thiazol-6-yl)acetic
acid (98)
##STR00194##
[0688] Preparation of
(S)-2-(tert-butoxy)-2-(7-(4-chlorophenyl)-2-(3-(4-(2-methoxyethyl)piperaz-
in-1-yl)-1-methyl-1H-indazol-5-yl)-5-methylbenzo[d]thiazol-6-yl)acetic
acid: A mixture of ethyl
(S)-2-(2-(3-bromo-1-methyl-1H-indazol-5-yl)-7-(4-chlorophenyl)-5-methylbe-
nzo[d]thiazol-6-yl)-2-(tert-butoxy)acetate (50.4 mg, 0.080 mmol),
1-(2-methoxyethyl)piperazine (36.0 mg, 0.250 mmol), SPhos Pd G2
(11.8 mg, 0.016 mmol), and potassium t-butoxide (18.3 mg, 0.163
mmol) in 1,2-dimethoxyethane (1.5 mL) was placed in a microwave
vial and reacted in a microwave reactor at 110.degree. C. for 2 h.
The resulting mixture was diluted in methanol, filtered, and
concentrated. The residue was dissolved in THF (0.5 mL), methanol
(0.5 mL), and 2 N NaOH (0.2 mL) at room temperature and kept
tightly before the mixture was stirred at 70.degree. C. for 3 h.
The reaction mixture was acidified with acetic acid (0.05 mL) and
concentrated to remove organic solvent. The resulting mixture was
dissolved in methanol (3 mL), filtered through syringe filter, and
purified by Gilson HPLC (Phenomenex Gemini, 30-70%
ACN/H.sub.2O+0.1% TFA) to obtain the title product after
lyophilization. .sup.1H NMR (400 MHz, Acetonitrile-d.sub.3) .delta.
8.33-8.26 (m, 1H), 8.10 (dd, J=9.0, 1.5 Hz, 1H), 7.83 (s, 1H),
7.71-7.63 (m, 1H), 7.63-7.54 (m, 3H), 7.47 (d, J=8.9 Hz, 1H), 5.27
(s, 1H), 3.89 (s, 3H), 3.81-3.73 (m, 2H), 3.73-3.57 (m, 4H),
3.55-3.39 (m, 4H), 3.36 (s, 3H), 3.30 (t, J=5.0 Hz, 2H), 2.58 (s,
3H), 0.99 (s, 9H). LCMS-ESI.sup.+: calc'd for
C.sub.35H.sub.41ClN.sub.5O.sub.4S: 662.26 (M+H).sup.+; found:
662.32 (M+H).sup.+.
Example 100
Preparation of
(S)-2-(tert-butoxy)-2-(7-(4-chlorophenyl)-2-(3-(4-(2-ethoxyethyl)piperazi-
n-1-yl)-1-methyl-1H-indazol-5-yl)-5-methylbenzo[d]thiazol-6-yl)acetic
acid (99)
##STR00195##
[0690] Preparation of
(S)-2-(tert-butoxy)-2-(7-(4-chlorophenyl)-2-(3-(4-(2-ethoxyethyl)piperazi-
n-1-yl)-1-methyl-1H-indazol-f5-yl)-5-methylbenzo[d]thiazol-6-yl)acetic
acid: A mixture of ethyl
(S)-2-(2-(3-bromo-1-methyl-1H-indazol-5-yl)-7-(4-chlorophenyl)-5-methylbe-
nzo[d]thiazol-6-yl)-2-(tert-butoxy)acetate (102.2 mg, 0.163 mmol),
1-(2-ethoxyethyl)piperazine (78.2 mg, 0.494 mmol), SPhos Pd G2
(24.2 mg, 0.034 mmol), and potassium t-butoxide (37.5 mg, 0.334
mmol) in 1,2-dimethoxyethane (3 mL) was placed in a microwave vial
and reacted in a microwave reactor at 110.degree. C. for 2 h. The
resulting mixture was diluted in methanol, filtered, and
concentrated. The residue was dissolved in THF (1 mL), methanol (1
mL), and 2 N NaOH (0.4 mL) at room temperature and kept tightly
before the mixture was stirred at 70.degree. C. for 3 h. The
reaction mixture was acidified with acetic acid (0.10 mL) and
concentrated to remove organic solvent. The resulting mixture was
dissolved in methanol (6 mL), filtered through syringe filter, and
purified by Gilson HPLC (Phenomenex Gemini, 40-75%
ACN/H.sub.2O+0.1% TFA) to obtain the title product after
lyophilization. .sup.1H NMR (400 MHz, Acetonitrile-d.sub.3) .delta.
8.33 (dd, J=1.6, 0.8 Hz, 1H), 8.13 (dd, J=9.0, 1.6 Hz, 1H), 7.85
(d, J=0.8 Hz, 1H), 7.67 (dd, J=8.0, 2.2 Hz, 1H), 7.60 (d, J=8.3 Hz,
3H), 7.50 (dd, J=8.9, 0.8 Hz, 1H), 5.28 (s, 1H), 4.01 (d, J=11.4
Hz, 2H), 3.91 (s, 3H), 3.81-3.74 (m, 2H), 3.68 (d, J=10.0 Hz, 2H),
3.58 (q, J=7.0 Hz, 2H), 3.48-3.29 (m, 6H), 2.58 (d, J=0.8 Hz, 3H),
1.23 (t, J=7.0 Hz, 3H), 0.99 (s, 9H). LCMS-ESI.sup.+: calc'd for
C.sub.36H.sub.43ClN.sub.5O.sub.4S: 676.27 (M+H).sup.+; found:
676.41 (M+H).sup.+.
Example 101
Preparation of
(S)-2-(tert-butoxy)-2-(7-(4-chlorophenyl)-2-(3-(4-(cyclopropylmethyl)pipe-
razin-1-yl)-1-methyl-1H-indazol-5-yl)-5-methylbenzo[d]thiazol-6-yl)acetic
acid (100)
##STR00196##
[0692] Preparation of (S)-ethyl
2-(tert-butoxy)-2-(7-(4-chlorophenyl)-2-(3-(4-(cyclopropylmethyl)piperazi-
n-1-yl)-1-methyl-1H-indazol-5-yl)-5-methylbenzo[d]thiazol-6-yl)acetate:
Prepared in a manner similar to (S)-ethyl
2-(tert-butoxy)-2-(7-(4-chlorophenyl)-5-methyl-2-(1-methyl-3-(2-oxa-6-aza-
spiro[3.3
]heptan-6-yl)-1H-indazol-5-yl)benzo[d]thiazol-6-yl)acetate except
using 1-(cyclopropylmethyl)piperazine HBr salt, SPhos Pd G2 and
potassium tert-butoxide instead of 2-oxa-6-azaspiro[3.3]heptane,
Pd.sub.2(dba).sub.3,
2-(Dicyclohexylphosphino)-2',4',6'-triisopropylbiphenyl and
Cs.sub.2CO.sub.3.
[0693] Preparation of
(S)-2-(tert-butoxy)-2-(7-(4-chlorophenyl)-2-(3-(4-(cyclopropylmethyl)pipe-
razin-1-yl)-1-methyl-1H-indazol-5-yl)-5-methylbenzo[d]thiazol-6-yl)acetic
acid: Prepared in a manner similar to
(S)-2-(tert-butoxy)-2-(7-(4-chlorophenyl)-5-methyl-2-(1-methyl-3-(2-oxa-6-
-azaspiro[3.3
]heptan-6-yl)-1H-indazol-5-yl)benzo[d]thiazol-6-yl)acetic acid
except using (S)-ethyl
2-(tert-butoxy)-2-(7-(4-chlorophenyl)-2-(3-(4-(cyclopropylmethyl)piperazi-
n-1-yl)-1-methyl-1H-indazol-5-yl)-5-methylbenzo[d]thiazol-6-yl)acetate
instead of (S)-ethyl
2-(tert-butoxy)-2-(7-(4-chlorophenyl)-5-methyl-2-(1-methyl-3-(2-oxa-6-aza-
spiro[3.3
]heptan-6-yl)-1H-indazol-5-yl)benzo[d]thiazol-6-yl)acetate. .sup.1H
NMR (400 MHz, Acetonitrile-d3) .delta. 8.43-8.28 (m, 1H), 8.14 (dd,
J=8.9, 1.6 Hz, 1H), 7.85 (s, 1H), 7.69-7.64 (m, 1H), 7.61 (d, J=8.0
Hz, 3H), 7.50 (dd, J=8.9, 0.7 Hz, 1H), 5.28 (s, 1H), 4.09 (s, 1H),
4.01 (d, J=13.6 Hz, 2H), 3.92 (s, 3H), 3.72 (d, J=7.3 Hz, 2H), 3.40
(d, J=12.3 Hz, 1H), 3.34-3.18 (m, 3H), 3.06 (d, J=7.1 Hz, 3H),
2.69-2.34 (m, 2H), 0.99 (s, 9H), 0.95 (s, 1H), 0.83-0.67 (m, 2H),
0.45 (dt, J=6.3, 4.6 Hz, 2H).
Example 102
Preparation of
(2S)-2-(tert-butoxy)-2-(7-(4-chlorophenyl)-5-methyl-2-(1-methyl-3-(6-meth-
yl-3,6-diazabicyclo[3.1.1]heptan-3-yl)-1H-indazol-5-yl)benzo[d]thiazol-6-y-
l)acetic acid (101).
##STR00197##
[0695] Preparation of tert-butyl
3-(5-(6-((S)-1-(tert-butoxy)-2-ethoxy-2-oxoethyl)-7-(4-chlorophenyl)-5-me-
thylbenzo[d]thiazol-2-yl)-1-methyl-1H-indazol-3-yl)-3,6-diazabicyclo[3.1.1-
]heptane-6-carboxylate: A microwave vial containing
Tris(dibenzylideneacetone) dipalladium (0) (14.6 mg, 16 .mu.mol),
2-(Dicyclohexylphosphino)-2',4',6'-triisopropylbiphenyl (7.6 mg, 16
.mu.mol) and cesium carbonate (130 mg, 400 .mu.mol) in 1,4-dioxane
(1 mL) was purged with Argon for 5 min. Ethyl
(S)-2-(2-(3-bromo-1-methyl-1H-indazol-5-yl)-7-(4-chlorophenyl)-5-methylbe-
nzo[d]thiazol-6-yl)-2-(tert-butoxy)acetate (50 mg, 80 .mu.mol) and
tert-butyl 3,6-diazabicyclo[3.1.1]heptane-6-carboxylate
hydrochloride (56 mg, 240 .mu.mol) were added and reaction mixture
was sealed and heated in a microwave reactor at 100.degree. C.
After 1.5 h, half of the Ethyl
(S)-2-(2-(3-bromo-1-methyl-1H-indazol-5-yl)-7-(4-chlorophenyl)-5-methylbe-
nzo[d]thiazol-6-yl)-2-(tert-butoxy)acetate remained. Reaction
mixture was re-subjected to microwave at 100.degree. C. for 1.5 h,
resulting in a third of the ethyl
(S)-2-(2-(3-bromo-1-methyl-1H-indazol-5-yl)-7-(4-chlorophenyl)-5-methylbe-
nzo[d]thiazol-6-yl)-2-(tert-butoxy)acetate remaining. The reaction
mixture was transferred into a new reaction vial with the same
amount of reagents and repeated above procedure. After cooling to
room temperature, the resulting mixture was diluted ethyl acetate.
The mixture was washed with brine. The organic phase was dried
(Na.sub.2SO.sub.4) and concentrated. The residue was purified by
CombiFlash (40 g, Gold, 0-50% EtOAc/Hex plus 0.1% TEA) to give
desired product. LCMS-ESI+: calc'd for:
C.sub.40H.sub.46ClN.sub.5O.sub.5S; 744.4 (M+H).sup.+; found: 744.2
(M+H).sup.+.
[0696] Preparation of ethyl
(2S)-2-(2-(3-(3,6-diazabicyclo[3.1.1]heptan-3-yl)-1-methyl-1H-indazol-5-y-
l)-7-(4-chlorophenyl)-5-methylbenzo[d]thiazol-6-yl)-2-(tert-butoxy)acetate-
: A solution tert-butyl
3-(5-(6-((S)-1-(tert-butoxy)-2-ethoxy-2-oxoethyl)-7-(4-chlorophenyl)-5-me-
thylbenzo[d]thiazol-2-yl)-1-methyl-1H-indazol-3-yl)-3,6-diazabicyclo[3.1.1-
]heptane-6-carboxylate (20 mg, 0.027 mmol) in 1.25 HCl in
isopropanol (4.0 mL) was stirred for 22 h at room temperature.
Reaction mixture was quenched with saturated sodium bicarbonate
solution carefully and extracted with ethyl acetate (2.times.).
Combined organic layer was dried (MgSO.sub.4), filtered and
concentrated to give crude desired product that was used in the
next step without further purification. LCMS-ESI+: calc'd for
C.sub.35H.sub.38ClN.sub.5O.sub.3S; 644.2 (M+H).sup.+; found: 644.4
(M+H).sup.+.
[0697] Preparation of ethyl
(2S)-2-(tert-butoxy)-2-(7-(4-chlorophenyl)-5-methyl-2-(1-methyl-3-(6-meth-
yl-3,6-diazabicyclo[3.1.1]heptan-3-yl)-1H-indazol-5-yl)benzo[d]thiazol-6-y-
l)acetate: A solution of ethyl
(2S)-2-(2-(3-(3,6-diazabicyclo[3.1.1]heptan-3-yl)-1-methyl-1H-indazol-5-y-
l)-7-(4-chlorophenyl)-5-methylbenzo[d]thiazol-6-yl)-2-(tert-butoxy)acetate
(from above reaction, 0.027 mmol) in acetonitrile (2 mL) was
stirred at 0.degree. C. bath as 37% formaldehyde (0.08 mL, 0.8
mmol), and sodium cyanoborohydride (20 mg, 0.3 mmol) were added. To
the reaction mixture was added .about.2 drops of acetic acid. After
1 h, the reaction was completed and carried to the next step
directly. LCMS-ESI+: calc'd for: C.sub.36H.sub.40ClN.sub.5O.sub.3S;
658.3 (M+H).sup.+; found: 658.3 (M+H).sup.+.
[0698] Preparation of
(2S)-2-(tert-butoxy)-2-(7-(4-chlorophenyl)-5-methyl-2-(1-methyl-3-(6-meth-
yl-3,6-diazabicyclo[3.1.1]heptan-3-yl)-1H-indazol-5-yl)benzo[d]thiazol-6-y-
l)acetic acid: Above reaction mixture containing ethyl
(2S)-2-(tert-butoxy)-2-(7-(4-chlorophenyl)-5-methyl-2-(1-methyl-3-(6-meth-
yl-3,6-diazabicyclo[3.1.1]heptan-3-yl)-1H-indazol-5-yl)benzo[d]thiazol-6-y-
l)acetate (0.027 mmol) was added THF (2 mL), MeOH (0.5 mL) and 50%
aqueous sodium hydroxide (0.5 mL) at room temperature . The mixture
was stirred at 60.degree. C. for 2 h. The reaction mixture was
cooled by ice and acidified with 3 N HCl. The resulting mixture was
extracted with ethyl acetate (2.times.). Combined organic layer was
dried (MgSO.sub.4), filtered and concentrated to give crude mixture
which was purified by Gilson HPLC (Phenomenex Gemini 250.times.21.2
10 .mu. C18 column, 40-100% ACN/H.sub.2O+0.1% TFA) to give a yellow
powder after lyophilization. .sup.1H NMR (400 MHz, Chloroform-d)
.delta. 8.51 (s, 1H), 7.96 (d, J=8.9 Hz, 1H), 7.78 (d, J=28.3 Hz,
2H), 7.51 (d, J=5.0 Hz, 4H), 7.22 (s, 1H), 5.27 (s, 1H), 4.20-3.75
(m, 9H), 2.91 (s, 1H), 2.59 (s, 3H), 2.38 (s, 3H), 1.64-1.35 (m,
2H), 0.99 (s, 9H). LCMS-ESI+: calc'd for
C.sub.34H.sub.36ClN.sub.5O.sub.3S; 630.2 (M+H).sup.+; found: 630.4
(M+H).sup.+.
Example 103
Preparation of
(S)-2-(tert-butoxy)-2-(7-(4-chlorophenyl)-2-(3-(3-((methoxycarbonyl)(meth-
ypamino)azetidin-1-yl)-1-methyl-1H-indazol-5-yl)-5-methylbenzo[d]thiazol-6-
-yl)acetic acid (102).
##STR00198##
[0700] Preparation of ethyl
(S)-2-(tert-butoxy)-2-(2-(3-(3-((tert-butoxycarbonyl)(methyl)amino)azetid-
in-1-yl)-1-methyl-1H-indazol-5-yl)-7-(4-chlorophenyl)-5-methylbenzo[d]thia-
zol-6-yl)acetate: A microwave vial containing
Tris(dibenzylideneacetone) dipalladium (0) (14.6 mg, 16 .mu.mol),
2-(Dicyclohexylphosphino)-2',4',6'-triisopropylbiphenyl (7.6 mg, 16
.mu.mol) and potassium phosphate tribasic (84.6 mg, 399 .mu.mol) in
1,4-dioxane (1 mL) was purged with Argon for 5 min. Ethyl
(S)-2-(2-(3-bromo-1-methyl-1H-indazol-5-yl)-7-(4-chlorophenyl)-5-methylbe-
nzo[d]thiazol-6-yl)-2-(tert-butoxy)acetate (50 mg, 80 .mu.mol) and
tert-butyl azetidin-3-yl(methyl)carbamate hydrochloride (53 mg, 240
.mu.mol). The mixture was sealed and reacted in a microwave reactor
at 110.degree. C. for 1 h. After cooling to room temperature, the
resulting mixture was diluted ethyl acetate. The mixture was washed
with brine. The organic phase was dried (Na.sub.2SO.sub.4) and
concentrated. The residue was purified by CombiFlash (40 g, Gold,
0-50% EtOAc/Hex plus 0.1% TEA) to give desired product. LCMS-ESI+:
calc'd for: C.sub.39H.sub.46ClN.sub.5O.sub.5S; 732.3 (M+H).sup.+;
found: 732.0 (M+H).sup.+.
[0701] Preparation of
(S)-(1-(5-(6-(1-(tert-butoxy)-2-ethoxy-2-oxoethyl)-7-(4-chlorophenyl)-5-m-
ethylbenzo[d]thiazol-2-yl)-1-methyl-1H-indazol-3-yl)azetidin-3-yl)(methyl)-
carbamic acid: A solution ethyl
(S)-2-(tert-butoxy)-2-(2-(3-(3-((tert-butoxycarbonyl)(methyl)amino)azetid-
in-1-yl)-1-methyl-1H-indazol-5-yl)-7-(4-chlorophenyl)-5-methylbenzo[d]thia-
zol-6-yl)acetate (20 mg, 0.027 mmol) in 1.25 HCl in isopropanol
(4.0 mL) was stirred for 2h at room temperature. Reaction mixture
was quenched with saturated sodium bicarbonate solution carefully
and extracted with ethyl acetate (2.times.). Combined organic layer
was dried (MgSO.sub.4), filtered and concentrated to give crude
desired product that was used in the next step without further
purification. LCMS-ESI+: calc'd for
C.sub.35H.sub.38ClN.sub.5O.sub.5S; 676.2 (M+H).sup.+; found: 676.3
(M+H).sup.+.
[0702] Preparation of
(S)-2-(tert-butoxy)-2-(7-(4-chlorophenyl)-2-(3-(3-((methoxycarbonyl)(meth-
yl)amino)azetidin-1-yl)-1-methyl-1H-indazol-5-yl)-5-methylbenzo[d]thiazol--
6-yl)acetic acid: A solution of
(S)-(1-(5-(6-(1-(tert-butoxy)-2-ethoxy-2-oxoethyl)-7-(4-chlorophenyl)-5-m-
ethylbenzo[d]thiazol-2-yl)-1-methyl-1H-indazol-3-yl)azetidin-3-yl)(methyl)-
carbamic acid (from above reaction, 0.029 mmol) in DMF(1 mL) was
stirred at 0.degree. C. bath as NaH (60%, 3.6 mg, 0.09 mmol), and
iodomethane (13 mg, 0.09 mmol) were added. The reaction mixture was
stirred at room temperature for 18 h. The reaction mixture was
cooled by ice and acidified with 3 N HCl. The resulting mixture was
extracted with ethyl acetate (2.times.). Combined organic layer was
dried (MgSO.sub.4), filtered and concentrated to give crude mixture
which was purified by Gilson HPLC (Phenomenex Gemini 250.times.21.2
10 .mu. C18 column, 40-100% ACN/H.sub.2O+0.1% TFA) to give a yellow
powder after lyophilization. .sup.1H NMR (400 MHz, Chloroform-d)
.delta. 8.49 (d, J=1.7 Hz, 1H), 7.97-7.85 (m, 2H), 7.72 (d, J=8.1
Hz, 1H), 7.53 (td, J=7.4, 5.7 Hz, 3H), 7.26 (m, 1H), 5.32 (s, 1H),
4.40 (t, J=8.6 Hz, 1H), 4.24-4.06 (m, 2H), 3.88 (s, 3H), 3.86-3.78
(m, 1H), 3.52 (dt, J=13.0, 6.0 Hz, 2H), 3.32 (d, J=1.0 Hz, 3H),
2.99 (s, 3H), 2.59 (s, 3H), 1.26 (s, 1H), 1.01 (s, 9H). LCMS-ESI+:
calc'd for C.sub.34H.sub.36ClN.sub.5O.sub.5S; 662.2 (M+H).sup.+;
found: 662.3 (M+H).sup.+.
Example 104
(S)-2-(7-(4-chlorophenyl)-5-methyl-2-(1-methyl-3-(4-methylpiperazin-1-yl)--
1H-indazol-5-yl)benzo[d]thiazol-6-yl)-2-cyclopropoxyacetic acid
(103)
##STR00199##
[0704] Preparation of
5-bromo-1-methyl-3-(4-methylpiperazin-1-yl)-1H-indazole: A
microwave vial containing 5-bromo-1-methyl-1H-indazol-3-amine (700
mg, 3.1 mmol), 2-chloro-N-(2-chloroethyl)-N-methylethan-1-amine
hydrochloride (655.7 mg, 3.41 mmol), tetrabutylammonium iodide
(114.37 mg, 0.31 mmol) and N-Ethyldiisopropylamine (1780 .mu.l,
10.22 mmol) in anhydrous DMF (3 mL) was sealed and heated in a
microwave reactor at 200.degree. C. for 1 h. After cooling to room
temperature, the resulting mixture was diluted ethyl acetate. The
mixture was washed with 3%v LiCl aq. Solution. The organic phase
was dried (Na.sub.2SO.sub.4) and concentrated. The residue was
purified by CombiFlash (40 g, Gold, 0-20% MeOH/DCM.) to give
desired product. .sup.1H NMR (400 MHz, Methanol-d4) .delta. 7.84
(dd, J=1.9, 0.7 Hz, 1H), 7.41 (dd, J=9.0, 1.8 Hz, 1H), 7.28 (dd,
J=9.0, 0.7 Hz, 1H), 3.84 (s, 3H), 3.46-3.33 (m, 4H), 2.73-2.62 (m,
4H), 2.38 (s, 3H). LCMS-ESI+: calc'd for:
C.sub.13H.sub.17BrN.sub.4; 309.2 (M+H).sup.+; found: 309.2
(M+H).sup.+.
[0705] Preparation of ethyl
(S)-2-(7-(4-chlorophenyl)-5-methyl-2-(1-methyl-3-(4-methylpiperazin-1-yl)-
-1H-indazol-5-yl)benzo[d]thiazol-6-yl)-2-cyclopropoxyacetate: A
microwave tube containing
5-bromo-1-methyl-3-(4-methylpiperazin-1-yl)-1H-indazole (40 mg, 129
.mu.mol), Bis (Pinacolato) Diboron (36 mg, 142 .mu.mol), potassium
acetate (56 mg, 569 .mu.mol), and PdCl2(dppf)-DCM (10.6 mg, 13
.mu.mol) in 1,4-dioxane (2 mL) was added a drop of AcOH. The
mixture was purged with Argon gas for 5 min, then sealed and
reacted in a microwave reactor at 100.degree. C. for 1.5 h. LCMS
showed full conversion to the boronate ester. LCMS-ESI+: calc'd
for: C.sub.19H.sub.29BN.sub.4O.sub.2; 257.3 (M+H).sup.+; found:
357.34 (M+H).sup.+.
[0706] After cooling to room temperature, ethyl
(S)-2-(2-bromo-7-(4-chlorophenyl)-5-methylbenzo[d]thiazol-6-yl)-2-cyclopr-
opoxyacetate (15 mg, 31.2 .mu.mol),
tetrakis(triphenylphosphine)nickel (3.61 mg, 3.12 .mu.mol) and 2M
aq K.sub.2CO.sub.3 (1 ml) were added. The mixture was purged with
Argon gas for 5 min, then sealed and heated in a microwave reactor
at 100.degree. C. for 1 h. LCMS showed the reaction was completed.
The reaction mixture was cooled to room temperature, diluted ethyl
acetate, washed with sat'd NaHCO.sub.3, and brine. The organic
phase was dried (Na.sub.2SO.sub.4) and concentrated. The residue
was purified by CombiFlash (40 g, Gold, 0-20% MeOH/DCM) to give the
product. LCMS-ESI+: calc'd for: C.sub.34H.sub.36ClN.sub.5O.sub.3S;
630.2 (M+H).sup.+; found: 630.4 (M+H).sup.+.
[0707] Preparation of
(S)-2-(7-(4-chlorophenyl)-5-methyl-2-(1-methyl-3-(4-methylpiperazin-1-yl)-
-1H-indazol-5-yl)benzo[d]thiazol-6-yl)-2-cyclopropoxyacetic acid:
To ethyl
(S)-2-(7-(4-chlorophenyl)-5-methyl-2-(1-methyl-3-(4-methylpiperazin-1-yl)-
-1H-indazol-5-yl)benzo[d]thiazol-6-yl)-2-cyclopropoxyacetate (20
mg) was added THF (1.5 mL), MeOH (0.2 mL) and 50% aqueous sodium
hydroxide (0.4 mL) at room temperature . The mixture was stirred at
60.degree. C. for 2 h. The reaction mixture was cooled by ice and
acidified with 3 N HCl. The resulting mixture was extracted with
ethyl acetate (2.times.) and combined organic layer was dried
(MgSO.sub.4), filtered and concentrated to give crude mixture which
was purified by Gilson HPLC (Phenomenex Gemini 250.times.21.2
10.mu. C18 column, 40-100% ACN/H.sub.2O+0.1% TFA) to give a yellow
powder after lyophilization. .sup.1H NMR (400 MHz, Chloroform-d)
.delta. 8.32 (d, J=1.6 Hz, 1H), 7.98 (dd, J=8.9, 1.5 Hz, 1H),
7.91-7.84 (m, 1H), 7.55-7.46 (m, 3H), 7.43 (dd, J=8.2, 1.9 Hz, 1H),
7.35-7.28 (m, 1H), 5.22 (s, 1H), 4.02 (d, J=13.9 Hz, 1H), 3.92 (s,
3H), 3.77-3.51 (m, 4H), 3.27-3.09 (m, 4H), 2.90 (s, 3H), 2.68, 2.55
(s, 3H), 0.57-0.16 (m, 4H). LCMS-ESI+: calc'd for
C.sub.32H.sub.32ClN.sub.5O.sub.3S; 602.2 (M+H).sup.+; found: 602.4
(M+H).sup.+.
Example 105
(S)-2-(tert-butoxy)-2-(7-(4-chlorophenyl)-5-methyl-2-(1-methyl-3-(4-(oxeta-
n-3-yl)piperazin-1-yl)-1H-indazol-5-yl)benzo[d]thiazol-6-yl)acetic
acid (104)
##STR00200##
[0709] Preparation of
(S)-2-(tert-butoxy)-2-(7-(4-chlorophenyl)-5-methyl-2-(1-methyl-3-(4-(oxet-
an-3-yl)piperazin-1-yl)-1H-indazol-5-yl)benzo[d]thiazol-6-yl)acetic
acid: Prepared in a manner similar to
(S)-2-(7-(4-chlorophenyl)-5-methyl-2-(1-methyl-3-(4-methylpiperazin-1-yl)-
-1H-indazol-5-yl)benzo[d]thiazol-6-yl)-2-cyclopropoxyacetic acid.
.sup.1H NMR (400 MHz, Chloroform-d) .delta. 8.33 (d, J=1.6 Hz, 1H),
7.96 (dd, J=8.8, 1.4 Hz, 1H), 7.85 (s, 1H), 7.71 (d, J=8.8 Hz, 1H),
7.58-7.45 (m, 3H), 7.32 (d, J=8.9 Hz, 1H), 5.30 (s, 1H), 5.09 (dd,
J=7.9, 6.1 Hz, 2H), 4.82 (t, J=7.6 Hz, 2H), 4.25 (t, J=6.7 Hz, 1H),
3.92 (s, 3H), 3.89-3.67 (m, 4H), 3.35 (s, 4H), 2.57 (s, 3H), 1.01
(s, 9H); LCMS-ESI+: calc'd for C.sub.35H.sub.39ClN.sub.5O.sub.4S;
660.2 (M+H).sup.+; found: 660.4 (M+H).sup.+.
Example 106A and 106B
Preparation of
(S)-2-(tert-butoxy)-2-(7-(4-chlorophenyl)-5-methyl-2-(1-methyl-3-(1-methy-
l-1,2,3,6-tetrahydropyridin-4-yl)-1H-pyrrolo[2,3-b]pyridin-5-yl)benzo[d]th-
iazol-6-yl)acetic acid (105) and
(S)-2-(tert-butoxy)-2-(7-(4-chlorophenyl)-5-methyl-2-(1-methyl-3-(1-methy-
lpiperidin-4-yl)-1H-pyrrolo[2,3-b]pyridin-5-yl)benzo[d]thiazol-6-yl)acetic
acid (106)
##STR00201##
[0711] Preparation of
5-bromo-1-methyl-3-(1-methyl-1,2,3,6-tetrahydropyridin-4-yl)-1H-pyrrolo-[-
2,3-b]pyridine: To a solution of
5-bromo-3-iodo-1-methyl-1H-pyrrolo[2,3-b]pyridine (180 mg, 0.534
mmol) and 1-methyl-1,2,3,6-tetrahydropyridin-4-boronic acid (155
mg, 0.694 mmol) in dioxane (5.4 mL, degassed) was added
tetrakis(triphenylphosphine)palladium(0) (75 mg, 0.064 mmol),
K.sub.2CO.sub.3 (369 mg, 2.67 mmol) and water (1.8 mL, degassed).
The reaction mixture was heated at 40.degree. C. for 15 h, cooled
and partitioned between ethyl acetate and brine. The organic layer
was separated, dried over Na.sub.2SO.sub.4, filtered and
concentrated to give crude which was purified by chromatographic
column to afford the desired product (106 mg, 65%). LCMS-ESI+:
calc'd for C.sub.14H.sub.17BrN.sub.3: 306.1 (M+H+); Found:
306.2(M+H+).
[0712] Preparation of ethyl
(S)-2-(tert-butoxy)-2-(7-(4-chlorophenyl)-5-methyl-2-(1-methyl-3-(1-methy-
l-1,2,3,6-tetrahydropyridin-4-yl)-1H-pyrrolo[2,3-b]pyridin-5-yl)benzo[d]th-
iazol-6-yl)acetate: The title compound was synthesized in a manner
analogous for tert-butyl
(S)-4-(5-(6-(1-(tert-butoxy)-2-ethoxy-2-oxoethyl)-7-(4-chlorophenyl)-5-me-
thylbenzo[d]thiazol-2-yl)-1-methyl-1H-pyrrolo[2,3-b]pyridin-3-yl)piperidin-
e-1-carboxylate, using
5-bromo-1-methyl-3-(1-methyl-1,2,3,6-tetrahydropyridin-4-yl)-1H-pyrrolo-[-
2,3-b]pyridine instead of tert-butyl
4-(5-bromo-1-methyl-1H-pyrrolo[2,3-b]pyridin-3-yl)piperidine-1-carboxylat-
e. LCMS-ESI+: calc'd for C.sub.36H.sub.40ClN.sub.4O.sub.3S: 643.2
(M+H+); Found: 643.2 (M+H+).
[0713] Preparation of
(S)-2-(tert-butoxy)-2-(7-(4-chlorophenyl)-5-methyl-2-(1-methyl-3-(1-methy-
l-1,2,3,6-tetrahydropyridin-4-yl)-1H-pyrrolo[2,3-b]pyridin-5-yl)benzo[d]th-
iazol-6-yl)acetic acid: To a solution of ethyl
(S)-2-(tert-butoxy)-2-(7-(4-chlorophenyl)-5-methyl-2-(1-methyl-3-(1-methy-
l-1,2,3,6-tetrahydropyridin-4-yl)-1H-pyrrolo[2,3-b]pyridin-5-yl)benzo[d]th-
iazol-6-yl)acetate: (25 mg, 0.039 mmol) in THF/CH.sub.3OH (1.0
ml/1.0 ml) was added 2N NaOH (0.2 m1, 0.39 mmol). The reaction
mixture was heated at 50.degree. C. for 2 h and the crude was
purified by reverse phase HPLC, eluting by 0-100% acetonitrile in
H.sub.2O with 0.1% TFA to give the product as TFA salt. .sup.1H NMR
(400 MHz, CD.sub.3OD) .delta. 8.97-8.84 (m, 2H), 7.85 (s, 1H),
7.71-7.60 (m, 5H), 6.31 (s, 1H), 5.25 (s, 1H), 4.11-3.74(m, 6H),
3.13-2.95 (m, 6H), 2.62 (s, 3H), 0.98 (s, 9H). LCMS-ESI+: calc'd
for C.sub.34H.sub.36ClN.sub.4O.sub.3S: 615.2 (M+H+); Found 615.2
(M+H+).
[0714] Preparation of
(S)-2-(tert-butoxy)-2-(7-(4-chlorophenyl)-5-methyl-2-(1-methyl-3-(1-methy-
lpiperidin-4-yl)-1H-pyrrolo[2,3-b]pyridin-5-yl)benzo[d]thiazol-6-yl)acetic
acid: A mixture of
(S)-2-(tert-butoxy)-2-(7-(4-chlorophenyl)-5-methyl-2-(1-methyl-3-(1-methy-
l-1,2,3,6-tetrahydropyridin-4-yl)-1H-pyrrolo[2,3-b]pyridin-5-yl)benzo[d]th-
iazol-6-yl)acetic acid (5.2 mg, 0.008 mmol), rhodium on alumina (8
mg, 0.004 mmol) in ethanol (1.5 mL) under hydrogen atmosphere.
After stirring for 8 hours, Celite was added and the mixture was
filtered through a pad of Celite. Concentration and purification by
Gilson HPLC (Gemini, 5-100% ACN/H.sub.2O+0.1% TFA) gave a white
powder after lyophilization. .sup.1H NMR (400 MHz,
Methanol-d.sub.4) .delta. 8.94 (d, J=2.0 Hz, 1H), 8.64 (d, J=2.1
Hz, 1H), 7.83 (s, 1H), 7.73-7.66 (m, 1H), 7.60 (d, J=6.5 Hz, 3H),
7.35 (s, 1H), 5.26 (s, 1H), 3.86 (s, 3H), 3.64 (d, J=12.7 Hz, 2H),
3.22 (t, J=12.3 Hz, 3H), 2.95 (s, 3H), 2.62 (s, 3H), 2.33 (d,
J=14.5 Hz, 2H), 2.09-1.94 (m, 2H), 0.98 (s, 9H). LCMS-ESI+: calc'd
for C.sub.34H.sub.38ClN.sub.4O.sub.3S: 617.2 (M+H).sup.+; found:
617.5 (M+H).sup.+.
Example 107
Preparation of
(S)-2-(tert-butoxy)-2-(7-(4-chlorophenyl)-5-methyl-2-(1-methyl-3-(4-methy-
lpiperazin-1-yl)-1H-pyrrolo[2,3-b]pyridin-5-yl)benzo[d]thiazol-6-yl)acetic
acid (107)
##STR00202##
[0716] Preparation of
5-bromo-1-methyl-3-(4-methylpiperazin-1-yl)-1H-pyrrolo[2,3-b]pyridine:
A solution of 5-bromo-3-iodo-1-methyl-1H-pyrrolo[2,3-b]pyridine
(150 mg, 0.445 mmol), 1-methylpiperazine (356.7 mg, 3.56 mmol),
copper(I) iodide (84.8 mg, 0.445 mmol), K.sub.3PO.sub.4 (378 mg,
1.78 mmol), 1,2-ethanediol (138 mg, 2.23 mmol) in isopropyl alcohol
(5 ml) in a sealed tubes was heated at 70.degree. C. for 2 days.
After cooling to room temperature, the reaction mixture was
filtered through Celite. The filtrate was concentrated in vacuo.
The residue was taken up in EtOAc and the solution was washed with
saturated NaHCO.sub.3, dried (Na.sub.2SO.sub.4) and concentrated.
Purification by flash chromatography afforded title compound.
LCMS-ESI+: calc'd for C.sub.13H.sub.18BrN.sub.4: 309.1 (M+H+);
Found: 309.1 (M+H+).
[0717] Preparation of ethyl
(S)-2-(tert-butoxy)-2-(7-(4-chlorophenyl)-5-methyl-2-(1-methyl-3-(4-methy-
lpiperazin-1-yl)-1H-pyrrolo[2,3-b]pyridin-5-yl)benzo[d]thiazol-6-yl)acetat-
e: The title compound was synthesized in a manner analogous for
tert-butyl
(S)-4-(5-(6-(1-(tert-butoxy)-2-ethoxy-2-oxoethyl)-7-(4-chlorophenyl)-5-me-
thylbenzo[d]thiazol-2-yl)-1-methyl-1H-pyrrolo[2,3-b]pyridin-3-yl)piperidin-
e-1-carboxylate, using
5-bromo-1-methyl-3-(4-methylpiperazin-1-yl)-1H-pyrrolo[2,3-b]pyridine
instead of tert-butyl
4-(5-bromo-1-methyl-1H-pyrrolo[2,3-b]pyridin-3-yl)piperidine-1-carboxylat-
e. LCMS -ESI+: calc'd for C.sub.35H.sub.41ClN.sub.5O.sub.3S: 646.3
(M+H+); Found: 646.3 (M+H+).
[0718] Preparation of
(S)-2-(tert-butoxy)-2-(7-(4-chlorophenyl)-5-methyl-2-(1-methyl-3-(4-methy-
lpiperazin-1-yl)-1H-pyrrolo[2,3-b]pyridin-5-yl)benzo[d]thiazol-6-yl)acetic
acid: To a solution of ethyl
(S)-2-(tert-butoxy)-2-(7-(4-chlorophenyl)-5-methyl-2-(1-methyl-3-(4-methy-
lpiperazin-1-yl)-1H-pyrrolo[2,3-b]pyridin-5-yl)benzo[d]thiazol-6-yl)acetat-
e (57 mg, 0.088 mmol) in THF/CH.sub.3OH (1.0 ml/1.0 ml) was added
2N NaOH (0.44 ml, 0.88 mmol). The reaction mixture was heated at
50.degree. C. for 2 h and the crude was purified by reverse phase
HPLC, eluting by 0-100% acetonitrile/H.sub.2O with 0.1% TFA to give
the desired product. .sup.1H NMR (400 MHz, CD.sub.3OD) .delta. 8.92
(s, 1H), 8.61 (d, J=2 Hz, 1H), 7.70-7.60(m, 4H), 7.16 (s, 1H), 5.25
(s, 1H), 3.84 (s, 3H), 3.80-3.10 (m, 8H), 3.01 (s, 3H), 2.62 (s,
3H), 0.98 (s, 9H). LCMS-ESI+: calc'd for
C.sub.33H.sub.37ClN.sub.5O.sub.3S: 618.2 (M+H+); Found 618.2
(M+H+).
Example 108
Preparation of
(S)-2-(tert-butoxy)-2-(7-(4-chlorophenyl)-5-methyl-2-(1-methyl-3-(1-(oxet-
an-3-yl)piperidin-4-yl)-1H-pyrrolo[3,2-b]pyridin-5-yl)benzo[d]thiazol-6-yl-
)acetic acid (108)
##STR00203##
[0720] Preparation of 5-bromo-1-methyl-1H-pyrrolo[3,2-b]pyridine:
To a solution of 5-bromo-1H-pyrrolo[3,2-b]pyridine (1.02 g, 5.2
mmol) in DMF (10 mL) at 0.degree. C. was added sodium hydride (60%,
0.21 g, 5.2 mmol) and stirred for 10 minutes. Iodomethane (322
.mu.L, 5.2 mmol) was added and reaction mixture was stirred for one
hour. Reaction mixture was quenched with saturated sodium
bicarbonate solution and extracted with ethyl acetate (3.times.).
Combined organic layer was dried (MgSO.sub.4), filtered,
concentrated and purified by CombiFlash (ethyl acetate/hexanes) to
give desired product. LCMS-ESI+: calc'd for
C.sub.8H.sub.8BrN.sub.2: 211.0 (M+H+); Found 211.2 (M+H+).
[0721] Preparation of ethyl
(S)-2-(tert-butoxy)-2-(7-(4-chlorophenyl)-5-methyl-2-(1-methyl-1H-pyrrolo-
[3,2-b]pyridin-5-yl)benzo[d]thiazol-6-yl)acetate: To a solution of
5-bromo-1-methyl-1H-pyrrolo[3,2-b]pyridine (489 mg, 0.84 mmol),
Pd(PPh.sub.3).sub.4 (73 mg, 0.063 mmol), copper(I) iodide (40.2 mg,
0.21 mmol), and hexa-n-butylditin (0.425 mL, 0.84 mmol) in toluene
(0.5 mL) at 110.degree. C. was added ethyl
(S)-2-(2-bromo-7-(4-chlorophenyl)-5-methylbenzo[d]thiazol-6-yl)-2-(tert-b-
utoxy)acetate (0.210 g, 0.42 mmol) in toluene (3 mL) over 30
minutes. Reaction mixture was stirred overnight at 110.degree. C.,
cooled to room temperature and purified by CombiFlash (ethyl
acetate/hexanes) to give desired product. LCMS-ESI+: calc'd for
C.sub.30H.sub.31ClN.sub.3O.sub.3S: 548.2 (M+H+); Found 548.2
(M+H+).
[0722] Preparation of ethyl
(S)-2-(2-(3-bromo-1-methyl-1H-pyrrolo[3,2-b]pyridin-5-yl)-7-(4-chlorophen-
yl)-5-methylbenzo[d]thiazol-6-yl)-2-(tert-butoxy)acetate: To a
solution of ethyl
(S)-2-(tert-butoxy)-2-(7-(4-chlorophenyl)-5-methyl-2-(1-methyl-1H-p-
yrrolo[3,2-b]pyridin-5-yl)benzo[d]thiazol-6-yl)acetate (67 mg, 0.12
mmol) in DMF at 0.degree. C. was added N-bromosuccinimide (22 mg,
0.12 mmol) and reaction mixture was stirred for one hour. Reaction
mixture was partitioned between ethyl acetate and saturated sodium
bicarbonate solution and organic layer was concentrated and
purified by CombiFlash (ethyl aceate/hexanes) to give desired
product. LCMS-ESI+: calc'd for C.sub.30H.sub.30BrClN.sub.3O.sub.3S:
626.1 (M+H+); Found 626.1 (M+H+).
[0723] Preparation of tert-butyl
(S)-4-(5-(6-(1-(tert-butoxy)-2-ethoxy-2-oxoethyl)-7-(4-chlorophenyl)-5-me-
thylbenzo[d]thiazol-2-yl)-1-methyl-1H-pyrrolo[3,2-b]pyridin-3-yl)-3,6-dihy-
dropyridine-1(2H)-carboxylate: A mixture of ethyl
(S)-2-(2-(3-bromo-1-methyl-1H-pyrrolo[3,2-b]pyridin-5-yl)-7-(4-chlorophen-
yl)-5-methylbenzo[d]thiazol-6-yl)-2-(tert-butoxy)acetate (0.047 g,
0.075 mmol), tert-butyl
4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-3,6-dihydropyridine-1(2H)-
-carboxylate (25 mg, 0.083 mmol), Pd(PPh.sub.3).sub.4 (9 mg, 0.008
mmol), and 2M sodium carbonate solution (0.11 mL, 0.22 mmol) in
dioxane (1.0 mL) was heated at 90.degree. C. for one hour. LCMS
showed reaction was incomplete. Additional tert-butyl
4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-3,6-dihydropyridine-1(2H)-
-carboxylate (25 mg, 0.083 mmol) and Pd(PPh.sub.3).sub.4 (9 mg,
0.008 mmol) were added and reaction continued for 0.5 hour.
Reaction mixture was portioned between ethyl acetate and saturated
sodium bicarbonate solution, organic layer dried (MgSO.sub.4),
filtered, concentrated and purified by CombiFlash (ethyl
acetate/hexanes) to give desired product. LCMS-ESI+: calc'd for
C.sub.40H.sub.46ClN.sub.4O.sub.5S: 729.3 (M+H).sup.+; found:
729.1.
[0724] Preparation of tert-butyl
(S)-4-(5-(6-(1-(tert-butoxy)-2-ethoxy-2-oxoethyl)-7-(4-chlorophenyl)-5-me-
thylbenzo[d]thiazol-2-yl)-1-methyl-1H-pyrrolo[3,2-b]pyridin-3-yl)piperidin-
e-1-carboxylate: A mixture of tert-butyl
(S)-4-(5-(6-(1-(tert-butoxy)-2-ethoxy-2-oxoethyl)-7-(4-chlorophenyl)-5-me-
thylbenzo[d]thiazol-2-yl)-1-methyl-1H-pyrrolo[3,2-b]pyridin-3-yl)-3,6-dihy-
dropyridine-1(2H)-carboxylate (22 mg, 0.030 mmol) and 5% rhodium on
alumina (22 mg) in ethanol (20 mL) was stirred under hydrogen
atmosphere overnight. Reaction mixture was filtered, concentrated
and used in the next step without further purification. LCMS-ESI+:
calc'd for C.sub.40H.sub.48ClN.sub.4O.sub.5S: 731.3 (M+H).sup.+;
found: 731.2.
[0725] Preparation of ethyl
(S)-2-(tert-butoxy)-2-(7-(4-chlorophenyl)-5-methyl-2-(1-methyl-3-(1-(oxet-
an-3-yl)piperidin-4-yl)-1H-pyrrolo[3,2-b]pyridin-5-yl)benzo[d]thiazol-6-yl-
)acetate: To tert-butyl
(S)-4-(5-(6-(1-(tert-butoxy)-2-ethoxy-2-oxoethyl)-7-(4-chlorophenyl)-5-me-
thylbenzo[d]thiazol-2-yl)-1-methyl-1H-pyrrolo[3,2-b]pyridin-3-yl)piperidin-
e-1-carboxylate (17 mg, 0.023 mmol) was added 1.25 N hydrochloric
acid in isopropanol. Reaction mixture was stirred for 20 hours. The
pH was adjusted to pH 8 using 1M sodium hydroxide, extracted with
ethyl acetate (2.times.), 15% methanol in dichloromethane
(2.times.). The combined organic layer was, dried (MgSO.sub.4),
filtered, concentrated and used in the next step without further
purification. LCMS-ESI+: calc'd for
C.sub.35H.sub.40ClN.sub.4O.sub.3S: 631.2 (M+H).sup.+; found:
631.3.
[0726] A solution of free amine (85 mg, 0.14), oxetan-3-one (10 mg,
0.14 mmol), acetic acid (2 .mu.L, 0.03 mmol) and sodium
cyanoborohydride (8.0 mg, 0.14 mmol) in methanol (1.0 mL) was
stirred overnight. Reaction mixture was concentrated and used in
the next step without further purification. LCMS-ESI+: calc'd for
C.sub.37H.sub.43ClN.sub.5O.sub.4S: 688.3 (M+H).sup.+; found:
687.4.
[0727] Preparation of
(S)-2-(tert-butoxy)-2-(7-(4-chlorophenyl)-5-methyl-2-(1-methyl-3-(1-(oxet-
an-3-yl)piperidin-4-yl)-1H-pyrrolo[3,2-b]pyridin-5-yl)benzo[d]thiazol-6-yl-
)acetic acid: A solution of ethyl
(S)-2-(tert-butoxy)-2-(7-(4-chlorophenyl)-5-methyl-2-(1-methyl-3-(1-(oxet-
an-3-yl)piperidin-4-yl)-1H-pyrrolo[3,2-b]pyridin-5-yl)benzo[d]thiazol-6-yl-
)acetate and 2M sodium hydroxide in THF/Ethanol was stirred at
60.degree. C. for one hour. Reaction mixture was filtered through a
syringe filter and purified by Gilson HPLC (Gemini, 5-100%
ACN/H.sub.2O+0.1% TFA). Product was lyophilized to give an
off-white powder. .sup.1H NMR (400 MHz, Methanol-d4) .delta. 8.18
(d, J=8.6 Hz, 1H), 7.90 (d, J=8.6 Hz, 1H), 7.82 s, 1H), 7.72-7.52
(m, 4H), 7.42 (s, 1H), 5.22 (s, 1H), 4.82 (m, 4H), 4.42 (m, 1H),
3.84 (s, 3H), 3.57 (m, 2H), 3.38 (m, 1H), 3.09 (m, 2H), 2.61 (s,
3H), 2.49 (m, 2H), 2.04 (m, 2H), 0.97 (s, 9H); LCMS-ESI+: calc'd
for C.sub.36H.sub.40ClN.sub.4O.sub.4S: 659.2 (M+H).sup.+; found:
659.3.
Example 109
Preparation of
(S)-2-(tert-butoxy)-2-(7-(4-chlorophenyl)-5-methyl-2-(3-(1-(oxetan-3-yl)p-
iperidin-4-yl)pyrazolo[1,5-a]pyrimidin-5-yl)benzo[d]thiazol-6-yl)acetic
acid (109)
##STR00204##
[0729] Preparation of ethyl
(S)-2-(tert-butoxy)-2-(7-(4-chlorophenyl)-5-methyl-2-(pyrazolo[1,5-a]pyri-
midin-5-yl)benzo[d]thiazol-6-yl)acetate: To a solution of
5-bromopyrazolo[1,5-a]pyrimidine (200 mg, 1.00 mmol),
Pd(PPh.sub.3).sub.4 (117 mg, 0.101 mmol), copper(I) iodide (96 mg,
0.101 mmol), and hexa-n-butylditin (0.51 mL, 1.0 mmol) in toluene
(0.5 mL) at 110.degree. C. was added ethyl
(S)-2-(2-bromo-7-(4-chlorophenyl)-5-methylbenzo[d]thiazol-6-yl)-2-(tert-b-
utoxy)acetate (0.50 g, 1.0 mmol) in toluene (3 mL) over 30 minutes.
Reaction mixture was stirred nine hours at 110.degree. C., cooled
to room temperature. Ethyl acetate and lithium chloride were added
and stirred over the weekend. Reaction mixture was filtered,
concentrated and purified by CombiFlash (ethyl acetate/hexanes) to
give desired product. LCMS-ESI+: calc'd for
C.sub.28H.sub.28ClN.sub.4O.sub.3S: 535.2 (M+H+); Found 535.2
(M+H+).
[0730] Preparation of ethyl
(S)-2-(2-(3-bromopyrazolo[1,5-a]pyrimidin-5-yl)-7-(4-chlorophenyl)-5-meth-
ylbenzo[d]thiazol-6-yl)-2-(tert-butoxy)acetate: To a solution of
ethyl
(S)-2-(tert-butoxy)-2-(7-(4-chlorophenyl)-5-methyl-2-(pyrazolo[1,5-a]pyri-
midin-5-yl)benzo[d]thiazol-6-yl)acetate (343 mg, 0.641 mmol) in
dichloromethane at -78.degree. C. was added N-bromosuccinimide (114
mg, 0.641 mmol) and reaction mixture was stirred for one hour.
Reaction mixture was warmed to room temperature and after 0.5
hours, reaction mixture was partitioned between ethyl acetate and
saturated sodium bicarbonate solution and organic layer was
concentrated and purified by CombiFlash (ethyl aceate/hexanes) to
give desired product. LCMS-ESI+: calc'd for
C.sub.28H.sub.27BrClN.sub.4O.sub.3S: 613.1 (M+H+); Found 613.1
(M+H+).
[0731] Preparation of tert-butyl
(S)-4-(5-(6-(1-(tert-butoxy)-2-ethoxy-2-oxoethyl)-7-(4-chlorophenyl)-5-me-
thylbenzo[d]thiazol-2-yl)pyrazolo[1,5-a]pyrimidin-3-yl)-3,6-dihydropyridin-
e-1(2H)-carboxylate: A mixture of ethyl
(S)-2-(2-(3-bromopyrazolo[1,5-a]pyrimidin-5-yl)-7-(4-chlorophenyl)-5-meth-
ylbenzo[d]thiazol-6-yl)-2-(tert-butoxy)acetate (0.343 g, 0.559
mmol), tert-butyl
4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-3,6-dihydropyridine-1(2H)-
-carboxylate (190 mg, 0.615 mmol), Pd(PPh.sub.3).sub.4 (5 mg, 0.048
mmol), and 2M sodium carbonate solution (0.84 mL, 2.0 mmol) in
dioxane (10 mL) was heated at 90.degree. C. for four hours.
Reaction mixture was portioned between ethyl acetate and saturated
sodium bicarbonate solution, organic layer dried (MgSO.sub.4),
filtered, concentrated and purified by CombiFlash (ethyl
acetate/hexanes) to give desired product. LCMS-ESI+: calc'd for
C.sub.38H.sub.43ClN.sub.5O.sub.5S: 716.3 (M+H).sup.+; found:
716.0.
[0732] Preparation of tert-butyl
(S)-4-(5-(6-(1-(tert-butoxy)-2-ethoxy-2-oxoethyl)-7-(4-chlorophenyl)-5-me-
thylbenzo[d]thiazol-2-yl)pyrazolo[1,5-a]pyrimidin-3-yl)piperidine-1-carbox-
ylate: A mixture of tert-butyl
(S)-4-(5-(6-(1-(tert-butoxy)-2-ethoxy-2-oxoethyl)-7-(4-chlorophenyl)-5-me-
thylbenzo[d]thiazol-2-yl)pyrazolo[1,5-a]pyrimidin-3-yl)-3,6-dihydropyridin-
e-1(2H)-carboxylate (96 mg, 0.13 mmol) and 10% platinum on carbon
(50 mg) in ethanol (10 mL) and ethyl acetate (20 mL) containing a
few drops of acetic acid was stirred under hydrogen atmosphere for
one day. Additional 10% platinum on carbon (50 mg) was added and
reaction stirred for three days. Reaction mixture was filtered,
concentrated and used in the next step without further
purification. LCMS-ESI+: calc'd for
C.sub.38H.sub.45ClN.sub.5O.sub.5S: 717.3 (M+H).sup.+; found:
714.0.
[0733] Preparation of ethyl
(S)-2-(tert-butoxy)-2-(7-(4-chlorophenyl)-5-methyl-2-(3-(1-(oxetan-3-yl)p-
iperidin-4-yl)pyrazolo[1,5-a]pyrimidin-5-yl)benzo[d]thiazol-6-yl)acetate:
To tert-butyl
(S)-4-(5-(6-(1-(tert-butoxy)-2-ethoxy-2-oxoethyl)-7-(4-chlorophenyl)-5-me-
thylbenzo[d]thiazol-2-yl)pyrazolo[1,5-a]pyrimidin-3-yl)piperidine-1-carbox-
ylate (18 mg, 0.025 mmol) was added 1.25 N hydrochloric acid in
isopropanol (1 mL). Reaction mixture was stirred for 48 hours. The
reaction was quenched with saturated sodium bicarbonate solution,
pH was adjusted to pH 7 using 2M sodium hydroxide, extracted with
ethyl acetate (2.times.), 10% methanol in ethyl acetate (2.times.).
The combined organic layer was, dried (MgSO.sub.4), filtered,
concentrated and used in the next step without further
purification. LCMS-ESI+: calc'd for
C.sub.33H.sub.37ClN.sub.5O.sub.3S: 618.2 (M+H).sup.+; found:
618.3.
[0734] A solution of free amine (16 mg, 0.026), oxetan-3-one (19
mg, 0.26 mmol), acetic acid (one drop) and sodium cyanoborohydride
(8.0 mg, 0.13 mmol) in methanol (1.0 mL) was stirred overnight.
Reaction mixture was concentrated and purified by Gilson HPLC
(Gemini, 5-100% ACN/H.sub.2O+0.1% TFA). Product was lyophilized to
give desired product. LCMS-ESI+: calc'd for
C.sub.36H.sub.41ClN.sub.5O.sub.4S: 674.3 (M+H).sup.+; found:
674.3.
[0735] Preparation of
(S)-2-(tert-butoxy)-2-(7-(4-chlorophenyl)-5-methyl-2-(3-(1-(oxetan-3-yl)p-
iperidin-4-yl)pyrazolo[1,5-a]pyrimidin-5-yl)benzo[d]thiazol-6-yl)acetic
acid: A solution of ethyl
(S)-2-(tert-butoxy)-2-(7-(4-chlorophenyl)-5-methyl-2-(3-(1-(oxetan-3-yl)p-
iperidin-4-yl)pyrazolo[1,5-a]pyrimidin-5-yl)benzo[d]thiazol-6-yl)acetate
and 2M sodium hydroxide in THF/Ethanol was stirred at 60.degree. C.
for two hours. Reaction mixture was filtered through a syringe
filter and purified by Gilson HPLC (Gemini, 5-100%
ACN/H.sub.2O+0.1% TFA). Product was lyophilized to give an
off-white powder. .sup.1H NMR (400 MHz, Methanol-d4) .delta. 8.92
(s, 1H), 8.15 (s, 1H), 7.82 (m, 2H), 7.62 (m, 1H), 7.57 (m, 3H),
5.26 (s, 1H), 4.79 (m, 4H), 4.38 (m, 1H), 3.52 (m, 2H), 3.32 (m,
1H), 3.05 (m, 2H), 2.58 (s, 3H), 2.32 (m, 2H), 2.09 (m, 2H), 0.98
(s, 9H); LCMS-ESI+: calc'd for C.sub.34H.sub.37ClN.sub.5O.sub.4S:
646.2 (M+H).sup.+; found: 646.2.
Example 110
Preparation of
(S)-2-(tert-butoxy)-2-(7-(4-chlorophenyl)-5-methyl-2-(3-(1-(oxetan-3-yl)p-
iperidin-4-yl)pyrazolo[1,5-a]pyrimidin-5-yl)benzo[d]thiazol-6-yl)acetic
acid (110)
##STR00205##
[0737] Preparation of
(S)-2-(tert-butoxy)-2-(7-(4-chlorophenyl)-2-(3-(1-(1-(methoxycarbonyl)aze-
tidin-3-yl)piperidin-4-yl)pyrazolo[1,5-a]pyrimidin-5-yl)-5-methylbenzo[d]t-
hiazol-6-yl)acetic acid: Prepared in a manner similar to
(S)-2-(tert-butoxy)-2-(7-(4-chlorophenyl)-5-methyl-2-(3-(1-(oxetan-3-yl)p-
iperidin-4-yl)pyrazolo[1,5-a]pyrimidin-5-yl)benzo[d]thiazol-6-yl)acetic
acid. .sup.1H NMR (400 MHz, Methanol-d4) .delta. 8.91 (dd, J=7.3,
1.3 Hz, 1H), 8.08 (s, 1H), 7.87-7.77 (m, 2H), 7.68 (dd, J=8.5, 2.1
Hz, 1H), 7.64-7.51 (m, 3H), 5.24 (s, 1H), 4.37-4.20 (m, 4H),
4.15-4.06 (m, 1H), 3.71 (s, 3H), 3.62 (s, 1H), 3.13 (s, 1H), 2.61
(s, 3H), 2.35 (d, J=14.1 Hz, 2H), 2.13 (s, 1H), 0.98 (s, 9H);
LCMS-ESI+: calc'd for C.sub.34H.sub.37ClN.sub.5O.sub.4S: 703.2
(M+H).sup.+; found: 703.3.
Example 111
Preparation of
(S)-2-(tert-butoxy)-2-(7-(4-chlorophenyl)-2-(3-(4-isopropylpiperazin-1-yl-
)-1-methyl-1H-pyrazolo[3,4-b]pyridin-5-yl)-5-methylbenzo[d]thiazol-6-yl)ac-
etic acid (111)
##STR00206## ##STR00207##
[0739] Preparation of
1-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazolo[3,4--
b]pyridine: A mixture of
5-bromo-1-methyl-1H-pyrazolo[3,4-b]pyridine (3.04 g, 14.0 mmol),
bis(pinacolato)diboron (4.37 g, 17.0 mmol), PdCl.sub.2(dppf) (0.992
g, 1 mmol), and potassium acetate (3.52 g, 36 mmol) in dioxane was
heated at 100.degree. C. for 1 hour. Reaction mixture was portioned
between ethyl acetate and saturated sodium bicarbonate solution,
organic layer dried (MgSO.sub.4), filtered, concentrated and
purified by CombiFlash (ethyl acetate/hexanes) to give desired
product. LCMS-ESI+: calc'd for C.sub.13H.sub.19BN.sub.3O.sub.2:
260.2 (M+H).sup.+; found: 260.2 (M+H).sup.+.
[0740] Preparation of ethyl
(S)-2-(tert-butoxy)-2-(7-(4-chlorophenyl)-5-methyl-2-(1-methyl-1H-pyrazol-
o[3,4-b]pyridin-5-yl)benzo[d]thiazol-6-yl)acetate: A mixture of
ethyl
(S)-2-(2-bromo-7-(4-chlorophenyl)-5-methylbenzo[d]thiazol-6-yl)-2-(tert-b-
utoxy)acetate (3.84 g, 8.0 mmol),
1-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazolo[3,4--
b]pyridine (2.0 g, 8.0 mmol), Pd(PPh.sub.3).sub.4 (0.446 g, 0.39
mmol) in 2M potassium carbonate solution (7.72 mL, 15 mmol) and
dioxane (40 mL) was heated at 100.degree. C. for 1 hour. Reaction
was stopped, reaction mixture was portioned between ethyl acetate
and saturated sodium bicarbonate solution, organic layer dried
(MgSO.sub.4), filtered, concentrated and purified by CombiFlash
(ethyl acetate/hexanes) to give desired product. LCMS-ESI+: calc'd
for C.sub.29H.sub.30ClN.sub.4O.sub.3S: 549.2 (M+H).sup.+; found:
549.2.
[0741] Preparation of ethyl
(S)-2-(2-(3-bromo-1-methyl-1H-pyrazolo[3,4-b]pyridin-5-yl)-7-(4-chlorophe-
nyl)-5-methylbenzo[d]thiazol-6-yl)-2-(tert-butoxy)acetate: To a
solution of ethyl
(S)-2-(tert-butoxy)-2-(7-(4-chlorophenyl)-5-methyl-2-(1-methyl-1-
H-pyrazolo[3,4-b]pyridin-5-yl)benzo[d]thiazol-6-yl)acetate (450 mg,
0.82 mmol) in acetonitrile (1.0 mL) was added 2,9-lutidine (286
.mu.L, 2.5 mmol), followed by bromine (393 mg, 2.5 mmol). Reaction
mixture was stirred overnight, quenched with saturated sodium
bicarbonate solution, extracted with ethyl acetate (2.times.),
organic layer dried (MgSO.sub.4), filtered, concentrated and
purified by CombiFlash (ethyl acetate/hexanes) to give desired
product. LCMS-ESI+: calc'd for C.sub.29H.sub.29BrClN.sub.4O.sub.3S:
627.1 (M+H).sup.+; found: 627.12.
[0742] Preparation of ethyl
(S)-2-(tert-butoxy)-2-(7-(4-chlorophenyl)-2-(3-(4-isopropylpiperazin-1-yl-
)-1-methyl-1H-pyrazolo[3,4-b]pyridin-5-yl)-5-methylbenzo[d]thiazol-6-yl)ac-
etate: A mixture of ethyl (S)-2-(2-(3-bromo-1-methyl-1
H-pyrazolo[3,4-b]pyridin-5-yl)-7-(4-chlorophenyl)-5-methylbenzo[d]thiazol-
-6-yl)-2-(tert-butoxy)acetate (17 mg, 0.027 mmol),
N-isopropylpiperazine (10 mg, 0.078 mmol),
Tris(dibenzylideneacetone)dipalladium(0) (2 mg, 0.0027 mmol),
4,5-Bis(diphenylphosphino)-9,9-dimethylxanthene (3 mg, 0.0054 mmol)
and cesium carbonate (26 mg, 0.081 mmol) in dioxane (1 mL) was
heated at 100.degree. C. overnight. Reaction mixture was portioned
between ethyl acetate and saturated sodium bicarbonate solution,
organic layer dried (MgSO.sub.4), filtered, concentrated and
purified by CombiFlash (ethyl acetate/hexanes to 20% methanol in
ethyl acetate) to give desired product. LCMS-ESI+: calc'd for
C.sub.36H.sub.44ClN.sub.6O.sub.3S: 675.3 (M+H).sup.+; found:
675.3.
[0743] Preparation of
(S)-2-(tert-butoxy)-2-(7-(4-chlorophenyl)-2-(3-(4-isopropylpiperazin-1-yl-
)-1-methyl-1H-pyrazolo[3,4-b]pyridin-5-yl)-5-methylbenzo[d]thiazol-6-yl)ac-
etic acid: A solution of ethyl
(S)-2-(tert-butoxy)-2-(7-(4-chlorophenyl)-2-(3-(4-isopropylpiperazin-1-yl-
)-1-methyl-1H-pyrazolo[3,4-b]pyridin-5-yl)-5-methylbenzo[d]thiazol-6-yl)ac-
etate (8 mg, 0.11 mmol) and 2M sodium hydroxide in THF/ethanol (1
mL) was stirred at 60.degree. C. for one hour. Reaction mixture was
filtered through a syringe filter and purified by Gilson HPLC
(Gemini, 5-100% ACN/H.sub.2O+0.1% TFA). Product was lyophilized to
give an off-white powder. .sup.1H NMR (400 MHz, Methanol-d4)
.delta. 9.15 (s, 1H), 8.79 (s, 1H), 7.84 (s, 1H), 7.72-7.65 (m,
1H), 7.63-7.56 (m, 3H), 5.25 (s, 1H), 4.22 (m, 2H), 3.97 (s, 3H),
3.62 (m, 3H), 3.42 (m, 6H), 2.62 (s, 3H), 1.44 (d, J=6.6 Hz, 6H),
0.98 (s, 9H); LCMS-ESI+: calc'd for
C.sub.34H.sub.40ClN.sub.6O.sub.3S: 675.3 (M+H).sup.+; found:
647.3.
Example 112. Preparation of
(S)-2-(tert-butoxy)-2-(7-(4-chlorophenyl)-5-methyl-2-(1-methyl-3-(4-(oxet-
an-3-yl)piperazin-1-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)benzo[d]thiazol-6-y-
l)acetic acid (112)
##STR00208##
[0745] Preparation of
(S)-2-(tert-butoxy)-2-(7-(4-chlorophenyl)-5-methyl-2-(1-methyl-3-(4-(oxet-
an-3-yl)piperazin-1-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)benzo[d]thiazol-6-y-
l)acetic acid: Prepared in a similar manner as
(S)-2-(tert-butoxy)-2-(7-(4-chlorophenyl)-2-(3-(4-isopropylpiperazin-1-yl-
)-1-methyl-1H-pyrazolo[3,4-b]pyridin-5-yl)-5-methylbenzo[d]thiazol-6-yl)ac-
etic acid. .sup.1H NMR (400 MHz, Methanol-d4) .delta. 9.12 (s, 1H),
8.75 (s, 1H), 7.82 (s, 1H), 7.72-7.64 (m, 1H), 7.62-7.53 (m, 3H),
5.25 (s, 1H), 4.98-4.81 (m, 4H), 4.50-4.40 (m, 1H), 3.96 (s, 3H),
3.78 (m, 4H), 3.40 (m, 4H), 2.61 (s, 3H), 0.97 (s, 9H); LCMS-ESI+:
calc'd for C.sub.34H.sub.38ClN.sub.6O.sub.4S: 661.2 (M+H).sup.+;
found: 661.2.
Example 113
Preparation of
(S)-2-(tert-butoxy)-2-(7-(4-chlorophenyl)-5-methyl-2-(1-methyl-3-(1-(oxet-
an-3-yl)piperidin-4-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)benzo[d]thiazol-6-y-
l)acetic acid (113)
##STR00209## ##STR00210##
[0747] Preparation of tert-butyl
(S)-4-(5-(6-(1-(tert-butoxy)-2-ethoxy-2-oxoethyl)-7-(4-chlorophenyl)-5-me-
thylbenzo[d]thiazol-2-yl)-1-methyl-1H-pyrazolo[3,4-b]pyridin-3-yl)-3,6-dih-
ydropyridine-1(2H)-carboxylate: A mixture of ethyl
(S)-2-(2-(3-bromo-1-methyl-1H-pyrazolo[3,4-b]pyridin-5-yl)-7-(4-chlorophe-
nyl)-5-methylbenzo[d]thiazol-6-yl)-2-(tert-butoxy)acetate (0.114 g,
0.18 mmol), tert-butyl
4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-3,6-dihydropyridine-1(2H)-
-carboxylate (67 mg, 0.22 mmol), Pd(PPh.sub.3).sub.4 (0.446 g, 0.39
mmol), and 2M sodium carbonate solution (0.27 mL, 0.55 mmol) in
dioxane (1.0 mL) was heated at 100.degree. C. for two hours.
Reaction mixture was portioned between ethyl acetate and saturated
sodium bicarbonate solution, organic layer dried (MgSO.sub.4),
filtered, concentrated and purified by CombiFlash (ethyl
acetate/hexanes) to give desired product. LCMS-ESI+: calc'd for
C.sub.39H.sub.45ClN.sub.5O.sub.5S: 730.3 (M+H).sup.+; found:
730.0.
[0748] Preparation of tert-butyl
(S)-4-(5-(6-(1-(tert-butoxy)-2-ethoxy-2-oxoethyl)-7-(4-chlorophenyl)-5-me-
thylbenzo[d]thiazol-2-yl)-1-methyl-1H-pyrazolo[3,4-b]pyridin-3-yl)piperidi-
ne-1-carboxylate: A mixture of tert-butyl
(S)-4-(5-(6-(1-(tert-butoxy)-2-ethoxy-2-oxoethyl)-7-(4-chlorophenyl)-5-me-
thylbenzo[d]thiazol-2-yl)-1-methyl-1H-pyrazolo[3,4-b]pyridin-3-yl)-3,6-dih-
ydropyridine-1(2H)-carboxylate (0.840 g, 1.15 mmol) and 5% rhodium
on alumina (400 mg) in ethanol was stirred under hydrogen
atmosphere overnight. Additional 5% rhodium on alumina (400 mg) was
added and reaction continued for one day. Reaction mixture was
filtered, concentrated and used in the next step without further
purification. LCMS-ESI+: calc'd for
C.sub.39H.sub.47ClN.sub.5O.sub.5S: 632.2 (M-Boc+H).sup.+; found:
632.3.
[0749] Preparation of ethyl
(S)-2-(tert-butoxy)-2-(7-(4-chlorophenyl)-5-methyl-2-(1-methyl-3-(piperid-
in-4-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)benzo[d]thiazol-6-yl)acetate:
To tert-butyl
(S)-4-(5-(6-(1-(tert-butoxy)-2-ethoxy-2-oxoethyl)-7-(4-chlorophenyl)-5-me-
thylbenzo[d]thiazol-2-yl)-1-methyl-1H-pyrazolo[3,4-b]pyridin-3-yl)piperidi-
ne-1-carboxylate (72 mg, 0.98 mmol) was added 1.25 N hydrochloric
acid in isopropanol. Reaction mixture was stirred for 28 hours. The
pH was adjusted to pH 7 using 1M sodium hydroxide, extracted with
ethyl acetate (2.times.), 15% methanol in dichloromethane
(2.times.). The combined organic layer was washed with saturated
sodium bicarbonate solution, dried (MgSO.sub.4), filtered,
concentrated and used in the next step without further
purification. LCMS-ESI+: calc'd for
C.sub.39H.sub.47ClN.sub.5O.sub.5S: 632.2 (M+H).sup.+; found:
632.3.
[0750] Preparation of ethyl
(S)-2-(tert-butoxy)-2-(7-(4-chlorophenyl)-5-methyl-2-(1-methyl-3-(1-(oxet-
an-3-yl)piperidin-4-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)benzo[d]thiazol-6-y-
l)acetate: A solution of ethyl
(S)-2-(tert-butoxy)-2-(7-(4-chlorophenyl)-5-methyl-2-(1-methyl-3-(piperid-
in-4-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)benzo[d]thiazol-6-yl)acetate
(28 mg, 0.040 mmol), oxetan-3-one (25 mg, 0.40 mmol), acetic acid
(5 .mu.L, 0.08 mmol) and sodium cyanoborohydride (12 mg, 0.2 mmol)
in methanol (1.0 mL) was stirred overnight. Reaction mixture was
quenched with saturated sodium bicarbonate solution and extracted
with ethyl acetate (2.times.), 15% methanol in dichloromethane
(2.times.). The combined organic layer was dried (MgSO.sub.4),
filtered, concentrated and purified by CombiFlash (ethyl
acetate/hexanes to 20% methanol in ethyl acetate) to give desired
product. LCMS-ESI+: calc'd for C.sub.37H.sub.43ClN.sub.5O.sub.4S:
688.3 (M+H).sup.+; found: 688.3.
[0751] Preparation of
(S)-2-(tert-butoxy)-2-(7-(4-chlorophenyl)-5-methyl-2-(1-methyl-3-(1-(oxet-
an-3-yl)piperidin-4-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)benzo[d]thiazol-6-y-
l)acetic acid: A solution of ethyl
(S)-2-(tert-butoxy)-2-(7-(4-chlorophenyl)-5-methyl-2-(1-methyl-3-(1-(oxet-
an-3-yl)piperidin-4-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)benzo[d]thiazol-6-y-
l)acetate and 2M sodium hydroxide in THF/Ethanol was stirred at
40.degree. C. overnight. Reaction mixture was filtered through a
syringe filter and purified by Gilson HPLC (Gemini, 5-100%
ACN/H.sub.2O+0.1% TFA). Product was lyophilized to give an
off-white powder. .sup.1H NMR (400 MHz, Methanol-d.sub.4) .delta.
9.22 (s, 1H), 8.82 (s, 1H), 7.85 (s, 1H), 7.72-7.65 (m, 1H),
7.63-7.54 (m, 3H), 5.26 (s, 1H), 4.93 (m, 2H), 4.84 (m, 2H), 4.48
(m, 1H), 4.09 (s, 3H), 3.64-3.50 (m, 3H), 2.62 (s, 3H), 2.42 (m,
2H), 2.24 (m, 2H), 0.98 (s, 9H); LCMS-ESI+: calc'd for
C.sub.35H.sub.39ClN.sub.5O.sub.4S: 660.2 (M+H).sup.+; found:
660.3.
Example 114A and 114B
Preparation of
(S)-2-(tert-butoxy)-2-(7-(4-chlorophenyl)-2-(3-(1-(1-(methoxycarbonyl)aze-
tidin-3-yl)piperidin-4-yl)-1-methyl-1H-pyrazolo[3,4-b]pyridin-5-yl)-5-meth-
ylbenzo[d]thiazol-6-yl)acetic acid (114) and
(S)-2-(tert-butoxy)-2-(7-(4-chlorophenyl)-2-(3-(1-(1-(ethoxycarbonyl)azet-
idin-3-yl)piperidin-4-yl)-1-methyl-1H-pyrazolo[3,4-b]pyridin-5-yl)-5-methy-
lbenzo[d]thiazol-6-yl)acetic acid (115)
##STR00211## ##STR00212##
[0753] Preparation of tert-butyl
(S)-3-(4-(5-(6-(1-(tert-butoxy)-2-ethoxy-2-oxoethyl)-7-(4-chlorophenyl)-5-
-methylbenzo[d]thiazol-2-yl)-1-methyl-1H-pyrazolo[3,4-b]pyridin-3-yl)piper-
idin-1-yl)azetidine-1-carboxylate: ethyl
(S)-2-(tert-butoxy)-2-(7-(4-chlorophenyl)-5-methyl-2-(1-methyl-3-(piperid-
in-4-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)benzo[d]thiazol-6-yl)acetate
(70 mg, 0.11 mmol), tert-butyl 3-oxoazetidine-1-carboxylate (95 mg,
0.55 mmol), acetic acid (6 .mu.L, 0.11 mmol) and sodium
cyanoborohydride (35 mg, 0.55 mmol) in methanol (1.0 mL) was
stirred overnight. Reaction mixture was quenched with saturated
sodium bicarbonate solution and extracted with ethyl acetate
(2.times.), 15% methanol in dichloromethane (2.times.). The
combined organic layer was dried (MgSO.sub.4), filtered,
concentrated and used in next step without further purification.
LCMS-ESI+: calc'd for C.sub.42H.sub.52ClN.sub.6O.sub.5S: 787.3
(M+H).sup.+; found: 787.1.
[0754] Preparation of ethyl
(S)-2-(2-(3-(1-(azetidin-3-yl)piperidin-4-yl)-1-methyl-1H-pyrazolo[3,4-b]-
pyridin-5-yl)-7-(4-chlorophenyl)-5-methylbenzo[d]thiazol-6-yl)-2-(tert-but-
oxy)acetate: tert-butyl
(S)-3-(4-(5-(6-(1-(tert-butoxy)-2-ethoxy-2-oxoethyl)-7-(4-chlorophenyl)-5-
-methylbenzo[d]thiazol-2-yl)-1-methyl-1H-pyrazolo[3,4-b]pyridin-3-yl)piper-
idin-1-yl)azetidine-1-carboxylate (47 mg, 0.060 mmol) in 1.25 N
hydrochloric acid in isopropanol was stirred for two days. The pH
was adjusted to pH 9 with 2M sodium hydroxide. Purification by
Gilson HPLC (Gemini, 5-100% ACN/H.sub.2O+0.1% TFA) gave desired
product. LCMS-ESI+: calc'd for C.sub.37H.sub.44ClN.sub.6O.sub.3S:
687.3 (M+H).sup.+; found: 687.4.
[0755] Preparation of methyl
(S)-3-(4-(5-(6-(1-(tert-butoxy)-2-ethoxy-2-oxoethyl)-7-(4-chlorophenyl)-5-
-methylbenzo[d]thiazol-2-yl)-1-methyl-1H-pyrazolo[3,4-b]pyridin-3-yl)piper-
idin-1-yl)azetidine-1-carboxylate: To a solution of ethyl
(S)-2-(2-(3-(1-(azetidin-3-yl)piperidin-4-yl)-1-methyl-1H-pyrazolo[3,4-b]-
pyridin-5-yl)-7-(4-chlorophenyl)-5-methylbenzo[d]thiazol-6-yl)-2-(tert-but-
oxy)acetate (15 mg, 0.022 mmol) in dichloromethane (1.0 mL) at
.degree. C. was added NN-diisopropylethylamine (15 .mu.L, 0.088
mmol), followed by methyl chloroformate (3 .mu.L, 0.044 mmol).
Reaction mixture was stirred for five minutes, then purified by
Gilson HPLC (Gemini, 5-100% ACN/H.sub.2O+0.1% TFA) gave desired
product. LCMS-ESI+: calc'd for C.sub.39H.sub.46ClN.sub.6O.sub.5S:
745.3 (M+H).sup.+; found: 745.3.
[0756] Preparation of
(S)-2-(tert-butoxy)-2-(7-(4-chlorophenyl)-2-(3-(1-(1-(methoxycarbonyl)aze-
tidin-3-yl)piperidin-4-yl)-1-methyl-1H-pyrazolo[3,4-b]pyridin-5-yl)-5-meth-
ylbenzo[d]thiazol-6-yl)acetic acid and
(S)-2-(tert-butoxy)-2-(7-(4-chlorophenyl)-2-(3-(1-(1-(ethoxycarbonyl)azet-
idin-3-yl)piperidin-4-yl)-1-methyl-1H-pyrazolo[3,4-b]pyridin-5-yl)-5-methy-
lbenzo[d]thiazol-6-yl)acetic acid: A solution of methyl
(S)-3-(4-(5-(6-(1-(tert-butoxy)-2-ethoxy-2-oxoethyl)-7-(4-chlorophenyl)-5-
-methylbenzo[d]thiazol-2-yl)-1-methyl-1H-pyrazolo[3,4-b]pyridin-3-yl)piper-
idin-1-yl)azetidine-1-carboxylate (10 mg, 0.013 mmol) and 2N sodium
hydroxide (67 .mu.L, 0.13 mmol) in THF/EtOH (1.0 mL) was heated at
60.degree. C. for one hour. Reaction mixture was filtered through a
syringe filter and purified by Gilson HPLC (Gemini, 5-100%
ACN/H.sub.2O+0.1% TFA). Product was lyophilized to give an
off-white powder.
[0757]
(S)-2-(tert-butoxy)-2-(7-(4-chlorophenyl)-2-(3-(1-(1-(methoxycarbon-
yl)azetidin-3-yl)piperidin-4-yl)-1-methyl-1H-pyrazolo[3,4-b]pyridin-5-yl)--
5-methylbenzo[d]thiazol-6-yl)acetic acid: .sup.1H NMR (400 MHz,
Methanol-d4) .delta. 9.23 (m, 1H), 8.82 (s, 1H), 7.86 (s, 1H),
7.73-7.54 (m, 4H), 5.26 (s, 1H), 4.36 (t, J=9.0 Hz, 2H), 4.27-4.12
(m, 3H), 4.09 (s, 3H), 3.72 (s, 3H), 3.62 (m, 3H), 3.18 (m, 2H),
2.62 (s, 3H), 2.42-2.22 (m, 4H), 0.98 (s, 9H); LCMS-ESI+: calc'd
for C.sub.37H.sub.42ClN.sub.6O.sub.5S: 717.3 (M+H).sup.+; found:
717.3.
[0758]
(S)-2-(tert-butoxy)-2-(7-(4-chlorophenyl)-2-(3-(1-(1-(ethoxycarbony-
l)azetidin-3-yl)piperidin-4-yl)-1-methyl-1H-pyrazolo[3,4-b]pyridin-5-yl)-5-
-methylbenzo[d]thiazol-6-yl)acetic acid: .sup.1H NMR (400 MHz,
Methanol-d4) .delta. 9.24 (s, 1H), 8.83 (s, 1H), 7.86 (s, 1H),
7.73-7.57 (m, 4H), 5.26 (s, 1H), 4.37 (m, 2H), 4.25-4.07 (m, 5H),
4.05 (s, 3H), 3.71-3.50 (m, 3H), 3.20 (m, 2H), 2.62 (s, 3H), 2.42
(m, 2H), 2.21 (m, 2H), 1.27 (t, J=7.1 Hz, 3H), 0.98 (s, 9H);
LCMS-ESI+: calc'd for C.sub.38H.sub.44ClN.sub.6O.sub.5S: 731.3
(M+H).sup.+; found: 731.3
Example 115
Preparation of
(S)-2-(tert-butoxy)-2-(2-(3-(1-(1-(tert-butoxycarbonyl)azetidin-3-yl)pipe-
ridin-4-yl)-1-methyl-1H-pyrazolo[3,4-b]pyridin-5-yl)-7-(4-chlorophenyl)-5--
methylbenzo[d]thiazol-6-yl)acetic acid (116)
##STR00213##
[0760] Preparation of
(S)-2-(tert-butoxy)-2-(2-(3-(1-(1-(tert-butoxycarbonyl)azetidin-3-yl)pipe-
ridin-4-yl)-1-methyl-1H-pyrazolo[3,4-b]pyridin-5-yl)-7-(4-chlorophenyl)-5--
methylbenzo[d]thiazol-6-yl)acetic acid: Prepared in a similar
manner as
(S)-2-(tert-butoxy)-2-(7-(4-chlorophenyl)-2-(3-(1-(1-(methoxycarbonyl)aze-
tidin-3-yl)piperidin-4-yl)-1-methyl-1H-pyrazolo[3,4-b]pyridin-5-yl)-5-meth-
ylbenzo[d]thiazol-6-yl)acetic acid. .sup.1H NMR (400 MHz,
Methanol-d4) .delta. 9.24 (s, 1H), 8.84 (s, 1H), 7.86 (s, 1H),
7.73-7.57 (m, 4H), 5.26 (s, 1H), 4.30 (m, 2H), 4.15 (m, 3H), 4.08
(s, 3H), 3.71 (m, 2H), 3.51 (m, 1H), 3.18 (m, 2H), 2.62 (s, 3H),
2.41 (m, 2H), 2.20 (m, 2H), 1.47 (s, 9H), 1.28 (s, 1H), 0.98 (s,
9H); LCMS-ESI+: calc'd for C.sub.40H.sub.48ClN.sub.6O.sub.5S: 759.3
(M+H).sup.+; found: 759.1.
Example 116
Preparation of
(S)-2-(2-(3-(1-(1-acetylazetidin-3-yl)piperidin-4-yl)-1-methyl-1H-pyrazol-
o[3,4-b]pyridin-5-yl)-7-(4-chlorophenyl)-5-methylbenzo[d]thiazol-6-yl)-2-(-
tert-butoxy)acetic acid (117)
##STR00214##
[0762] Preparation of
(S)-2-(2-(3-(1-(1-acetylazetidin-3-yl)piperidin-4-yl)-1-methyl-1H-pyrazol-
o[3,4-b]pyridin-5-yl)-7-(4-chlorophenyl)-5-methylbenzo[d]thiazol-6-yl)-2-(-
tert-butoxy)acetic acid: Prepared in a similar manner as
(S)-2-(tert-butoxy)-2-(7-(4-chlorophenyl)-2-(3-(1-(1-(methoxycarbonyl)aze-
tidin-3-yl)piperidin-4-yl)-1-methyl-1H-pyrazolo[3,4-b]pyridin-5-yl)-5-meth-
ylbenzo[d]thiazol-6-yl)acetic acid. .sup.1H NMR (400 MHz,
Methanol-d.sub.4) .delta. 9.23 (d, J=2.0 Hz, 2H), 8.84 (d, J=2.0
Hz, 2H), 7.86 (d, J=0.9 Hz, 2H), 7.73-7.65 (m, 2H), 7.64-7.57 (m,
4H), 5.26 (s, 2H), 4.63-4.54 (m, 3H), 4.45 (dd, J=11.0, 4.2 Hz,
3H), 4.39-4.28 (m, 3H), 4.24-4.15 (m, 3H), 4.10 (s, 4H), 3.70 (s,
2H), 3.56 (s, 1H), 3.19 (s, 2H), 2.62 (s, 4H), 2.44 (d, J=14.6 Hz,
4H), 2.24 (s, 2H), 1.94 (s, 4H), 0.98 (s, 9H); LCMS-ESI+: calc'd
for C.sub.37H.sub.42ClN.sub.6O.sub.4S: 701.3 (M+H).sup.+; found:
701.3.
Example 117
Preparation of
(S)-2-(tert-butoxy)-2-(7-(4-chlorophenyl)-5-methyl-2-(1-methyl-3-(1-(oxet-
an-3-yl)piperidin-4-yl)-1H-pyrazolo[3,4-b]pyrazin-5-yl)benzo[d]thiazol-6-y-
l)acetic acid (118)
##STR00215## ##STR00216##
[0764] Preparation of
5-chloro-1-methyl-1H-pyrazolo[3,4-b]pyrazin-3-amine: To a solution
of 3,6-dichloropyrazine-2-carbonitrile (1.088 g, 6.25 mmol) in
toluene (12 mL) at 0.degree. C. was added dropwise methyl hydrazine
(362 .mu.L, 6.88 mmol). Reaction mixture was stirred for 3 hours at
0.degree. C. LCMS shows no starting material. Reaction mixture was
concentrated and purified by CombiFlash (120 g Gold, 10-45%
EtOAc/Hex) to give impure product. Crystallized from hot
acetone/hexane to give two crops of
5-chloro-1-methyl-1H-pyrazolo[3,4-b]pyrazin-3-amine. LCMS-ESI+:
calc'd for C.sub.6H.sub.7ClN.sub.5: 184.0 (M+H).sup.+; found: 184.2
(M+H).sup.+.
[0765] Preparation of ethyl
(S)-2-(2-(3-amino-1-methyl-1H-pyrazolo[3,4-b]pyrazin-5-yl)-7-(4-chlorophe-
nyl)-5-methylbenzo[d]thiazol-6-yl)-2-(tert-butoxy)acetate: A 50 mL
round bottom flask was charged with
5-chloro-1-methyl-1H-pyrazolo[3,4-b]pyrazin-3-amine (100 mg, 0.545
mmol), bis(pinacolato)diboron (160 mg, 0.708 mmol) ,
PdCl.sub.2(Amphos).sub.2 (39 mg, 0.054 mmol) and potassium
propionate (274 mg, 2.45 mmol) and flushed with nitrogen. De-gassed
dioxane (5.0 mL) was added under a nitrogen atmosphere and reaction
mixture was sparged for 5 minutes, then heated to 85.degree. C. for
3 h. LCMS showed desired product mass for
5-(5,5-dimethyl-1,3,2-dioxaborinan-2-yl)-1-methyl-1H-pyrazolo[3,4-b]pyraz-
in-3-amine. Reaction mixture was cooled to .about.50.degree. C.
[0766] To the above reaction mixture, 2M potassium carbonate (1.7
mL, 3.36 mmol) and ethyl
(S)-2-(2-bromo-7-(4-chlorophenyl)-5-methylbenzo[d]thiazol-6-yl)-2-(tert-b-
utoxy)acetate (222 mg, 0.447 mmol) were added and the reaction
heated to 70.degree. C. After 2 h, LCMS showed desired product
mass. Reaction was cooled to room temperature and partitioned
between EtOAc/brine. Organic layer was dried (MgSO.sub.4),
filtered, concentrated and purified by CombiFlash (12 g Gold, 0-50%
EtOAc/hex) to a yellow film. LCMS-ESI+: calc'd for
C.sub.28H.sub.30ClN.sub.6O.sub.3S: 565.2 (M+H).sup.+; found: 565.2
(M+H).sup.+.
[0767] Preparation of ethyl
(S)-2-(2-(3-bromo-1-methyl-1H-pyrazolo[3,4-b]pyrazin-5-yl)-7-(4-chlorophe-
nyl)-5-methylbenzo[d]thiazol-6-yl)-2-(tert-butoxy)acetate: To a
solution ethyl
(S)-2-(2-(3-amino-1-methyl-1H-pyrazolo[3,4-b]pyrazin-5-yl)-7-(4-chl-
orophenyl)-5-methylbenzo[d]thiazol-6-yl)-2-(tert-butoxy)acetate
(136 mg, 0.240 mmol) in acetonitrile (5 mL) was added cupric
bromide (64 mg, 0.29 mmol), followed by tert-butyl nitrite (43
.mu.L, 0.36 mmol) at 0.degree. C. Reaction mixture was warmed to
room temperature over 3 hours. LCMS shows almost complete
conversion. Reaction mixture was diluted with ethyl acetate, washed
with brine/sodium sulfite, dried (MgSO4), filtered and
concentrated. Residue was purified by CombiFlash (12 Gold, 0-30%
EtOAc/Hex) to give a yellow solid. LCMS-ESI+: calc'd for
C.sub.28H.sub.28BrClN.sub.5O.sub.3S: 628.1 (M+H).sup.+; found:
628.2 (M+H).sup.+.
[0768] Preparation of tert-butyl
(S)-4-(5-(6-(1-(tert-butoxy)-2-ethoxy-2-oxoethyl)-7-(4-chlorophenyl)-5-me-
thylbenzo[d]thiazol-2-yl)-1-methyl-1H-pyrazolo[3,4-b]pyrazin-3-yl)-3,6-dih-
ydropyridine-1(2H)-carboxylate: A mixture of ethyl
(S)-2-(2-(3-bromo-1-methyl-1H-pyrazolo[3,4-b]pyrazin-5-yl)-7-(4-chlorophe-
nyl)-5-methylbenzo[d]thiazol-6-yl)-2-(tert-butoxy)acetate (110 mg,
0.176 mmol), tert-butyl
4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-5,6-dihydropyridine-1(2H)-
-carboxylate (81 mg, 0.264 mmol) and palladium (0)
tetrakis(triphenylphosphine) (30 mg, 0.026 mmol) in 2M potassium
carbonate (0.26 mL, 0.53 mmol) and dioxane (2.0 mL) was sparged
with nitrogren for 5 minutes, then heated at 80.degree. C. After 4
hours, additional tert-butyl
4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-5,6-dihydropyridine-1(2H)-
-carboxylate (81 mg, 0.264 mmol) and 2M potassium carbonate (0.26
mL, 0.53 mmol) were added and reaction mixture was heated to
100.degree. C. After 1 hour, reaction was complete. Reaction
mixture was cooled to room temperature, diluted with ethyl acetate
and washed with brine. Organic layer was dried (MgSO.sub.4),
filtered, concentrated and purified by CombiFlash (12 g, Gold,
0-30% EtOAc/Hex) to give a yellow foam. LCMS-ESI+: calc'd for
C.sub.38H.sub.44ClN.sub.6O.sub.5S: 731.3 (M+H).sup.+; found: 731.0
(M+H).sup.+.
[0769] Preparation of tert-butyl
(S)-4-(5-(6-(1-(tert-butoxy)-2-ethoxy-2-oxoethyl)-7-(4-chlorophenyl)-5-me-
thylbenzo[d]thiazol-2-yl)-1-methyl-1H-pyrazolo[3,4-b]pyrazin-3-yl)piperidi-
ne-1-carboxylate: A mixture of tert-butyl
(S)-4-(5-(6-(1-(tert-butoxy)-2-ethoxy-2-oxoethyl)-7-(4-chlorophenyl)-5-me-
thylbenzo[d]thiazol-2-yl)-1-methyl-1H-pyrazolo[3,4-b]pyrazin-3-yl)-3,6-dih-
ydropyridine-1(2H)-carboxylate (90% purity, 133 mg, 0.164 mmol) and
rhodium on alumina (130 mg, 0.063 mmol) in ethanol (5.0 mL) was
stirred under hydrogen atmosphere for 8 hours. Reaction mixture was
filtered through a pad of Celite, concentrated and purified by
CombiFlash (12 g, Gold, 0-30% EtOAc/Hex) to give a yellow film.
LCMS-ESI+: calc'd for C.sub.38H.sub.46ClN.sub.6O.sub.5S: 733.3
(M+H).sup.+; found: 733.1 (M+H).sup.+.
[0770] Preparation of ethyl
(S)-2-(tert-butoxy)-2-(7-(4-chlorophenyl)-5-methyl-2-(1-methyl-3-(1-(oxet-
an-3-yl)piperidin-4-yl)-1H-pyrazolo[3,4-b]pyrazin-5-yl)benzo[d]thiazol-6-y-
l)acetate: A solution of tert-butyl
(S)-4-(5-(6-(1-(tert-butoxy)-2-ethoxy-2-oxoethyl)-7-(4-chlorophenyl)-5-me-
thylbenzo[d]thiazol-2-yl)-1-methyl-1H-pyrazolo[3,4-b]pyrazin-3-yl)piperidi-
ne-1-carboxylate (80 mg, 0.11 mmol) in 1.25 HCl in isopropanol (4.4
mL) was stirred at room temperature for 6 hours. HPLC showed
.about.50% completion. Reaction mixture was quenched with saturated
sodium bicarbonate solution and extracted with ethyl acetate
(2.times.). Combined organic layer was dried (MgSO4), filtered and
concentrated to give ethyl
(S)-2-(tert-butoxy)-2-(7-(4-chlorophenyl)-5-methyl-2-(1-methyl-3-(1-(oxet-
an-3-yl)piperidin-4-yl)-1H-pyrazolo[3,4-b]pyrazin-5-yl)benzo[d]thiazol-6-y-
l)acetate plus tert-butyl
(S)-4-(5-(6-(1-(tert-butoxy)-2-ethoxy-2-oxoethyl)-7-(4-chlorophenyl)-5-me-
thylbenzo[d]thiazol-2-yl)-1-methyl-1H-pyrazolo[3,4-b]pyrazin-3-yl)piperidi-
ne-1-carboxylate. Mixture was used in next step without further
purification.
[0771] The above mixture was dissolved in ethanol (1.5 mL), and
3-oxetanone (36 .mu.L, 0.57 mmol), acetic acid (16 .mu.L, 0.28
mmol) and sodium cyanoborohydride (36 mg, 0.57 mmol) were added.
Reaction mixture was stirred for 3 hours. LCMS showed nearly
complete conversion. Reaction was quenched with saturated sodium
bicarbonate solution and brine. The mixture was extracted with
ethyl acetate (2.times.) and combined organic layer was dried
(MgSO4), filtered and concentrated. The residue was purified by
CombiFlash (4 g, Gold, 0-20% MeOH/EtOAc) to give pure desired
product. LCMS-ESI+: calc'd for C.sub.36H.sub.42ClN.sub.6O.sub.4S:
689.3 (M+H).sup.+; found: 689.3 (M+H).sup.+.
[0772] Preparation of
(S)-2-(tert-butoxy)-2-(7-(4-chlorophenyl)-5-methyl-2-(1-methyl-3-(1-(oxet-
an-3-yl)piperidin-4-yl)-1
H-pyrazolo[3,4-b]pyrazin-5-yl)benzo[d]thiazol-6-yl)acetic acid: A
solution of ethyl
(S)-2-(tert-butoxy)-2-(7-(4-chlorophenyl)-5-methyl-2-(1-methyl-3-(1-(oxet-
an-3-yl)piperidin-4-yl)-1
H-pyrazolo[3,4-b]pyrazin-5-yl)benzo[d]thiazol-6-yl)acetate (31.7
mg, 0.046 mmol) and 5M sodium hydroxide (92 .mu.L, 0.46 mmol) in
tetrahydrofuran (1.2 mL) and methanol (0.2 mL) was stirred at
50.degree. C. for 4 hours. LCMS showed incomplete conversion. Added
more 5M sodium hydroxide (92 .mu.L, 0.46 mmol) and stirred for 45
minutes. Reaction mixture was cooled to room temperature, diluted
with DMF (0.5 mL) and concentrated to .about.0.7 mL. The resulting
mixture was diluted with methanol, filtered through a syringe
filter and purified by Gilson HPLC (Gemini, 5-100%
ACN/H.sub.2O+0.1% TFA). Product was lyophilized to give an
off-white powder. .sup.1H NMR (400 MHz, Methanol-d.sub.4) .delta.
9.56 (s, 1H), 7.96 (s, 1H), 7.79-7.49 (m, 4H), 5.29 (s, 1H), 4.86
(d, J=6.0 Hz, 4H), 4.54-4.40 (m, 1H), 4.17 (s, 3H), 3.77-3.53 (m,
2H), 3.16 (s, 2H), 2.67 (s, 3H), 2.55 (s, 2H), 2.33 (d, J=14.3 Hz,
2H), 1.02 (s, 9H). LCMS-ESI+: calc'd for
C.sub.34H.sub.38ClN.sub.6O.sub.4S: 661.2 (M+H).sup.+; found: 661.2
(M+H).sup.+.
Example 118
Preparation of
(S)-2-(tert-butoxy)-2-(7-(4-chlorophenyl)-2-(3-(1-(1-(methoxycarbonyl)aze-
tidin-3-yl)piperidin-4-yl)-1-methyl-1H-pyrazolo[3,4-b]pyrazin-5-yl)-5-meth-
ylbenzo[d]thiazol-6-yl)acetic acid (119)
##STR00217## ##STR00218##
[0774] Preparation of tert-butyl
(S)-3-(4-(5-(6-(1-(tert-butoxy)-2-ethoxy-2-oxoethyl)-7-(4-chlorophenyl)-5-
-methylbenzo[d]thiazol-2-yl)-1-methyl-1H-pyrazolo[3,4-b]pyrazin-3-yl)piper-
idin-1-yl)azetidine-1-carboxylate: A solution of tert-butyl
(S)-4-(5-(6-(1-(tert-butoxy)-2-ethoxy-2-oxoethyl)-7-(4-chlorophenyl)-5-me-
thylbenzo[d]thiazol-2-yl)-1-methyl-1H-pyrazolo[3,4-b]pyrazin-3-yl)piperidi-
ne-1-carboxylate (47 mg, 0.064 mmol) in 1.25 HCl in isopropanol
(2.5 mL) was stirred at room temperature for 2 days. Reaction
mixture was quenched with saturated sodium bicarbonate solution and
extracted with ethyl acetate (2.times.). Combined organic layer was
dried (MgSO4), filtered and concentrated to give a crude mixture
that was used in next step without further purification.
[0775] The above mixture was dissolved in ethanol (1.5 mL), and
N-Boc 3-oxoazetidine (102 mg, 0.59 mmol), acetic acid (17 .mu.L,
0.297 mmol) and sodium cyanoborohydride (37 mg, 0.59 mmol) were
added. Reaction mixture was stirred for 3 hours. LCMS showed nearly
complete conversion. Reaction was quenched with saturated sodium
bicarbonate solution and brine. The mixture was extracted with
ethyl acetate (2.times.) and combined organic layer was dried
(MgSO4), filtered and concentrated. The residue was purified by
CombiFlash (4 g, Gold, 0-20% MeOH/EtOAc) to give pure desired
product. LCMS-ESI+: calc'd for C.sub.41H.sub.51ClN.sub.7O.sub.5S:
788.3 (M+H).sup.+; found: 788.1 (M+H).sup.+.
[0776] Preparation of ethyl
(S)-2-(2-(3-(1-(azetidin-3-yl)piperidin-4-yl)-1-methyl-1H-pyrazolo[3,4-b]-
pyrazin-5-yl)-7-(4-chlorophenyl)-5-methylbenzo[d]thiazol-6-yl)-2-(tert-but-
oxy)acetate: To a flask containing tert-butyl
(S)-3-(4-(5-(6-(1-(tert-butoxy)-2-ethoxy-2-oxoethyl)-7-(4-chlorophenyl)-5-
-methylbenzo[d]thiazol-2-yl)-1-methyl-1H-pyrazolo[3,4-b]pyrazin-3-yl)piper-
idin-1-yl)azetidine-1-carboxylate (25 mg, 0.032 mmol) was added
1.25M hydrogen chloride in isopropanol (1.2 mL, 1.5 mmol). Reaction
mixture was stirred overnight to give a yellow mixture. LCMS shows
-50% completion. Dichloromethane (1.2 mL) was added and reaction
mixture was continued for 8 hours. Additional 1.25M hydrogen
chloride in isopropanol (1.2 mL, 1.5 mmol) was added and reaction
was stirred overnight. HPLC showed .about.80% completion. Reaction
was quenched with solid sodium bicarbonate and stirred for 5
minutes. Water was added and reaction mixture was partioned between
dichloromethane and brine. Aqueous layer was back extracted with
dichloromethane (2.times.) and combined organic layer was dried
(MgSO.sub.4), filtered, dried under vacuum and used in next step
without further purification. LCMS-ESI+: calc'd for
C.sub.36H.sub.43ClN.sub.7O.sub.3S: 688.3 (M+H).sup.+; found: 688.3
(M+H).sup.+.
[0777] Preparation of methyl
(S)-3-(4-(5-(6-(1-(tert-butoxy)-2-ethoxy-2-oxoethyl)-7-(4-chlorophenyl)-5-
-methylbenzo[d]thiazol-2-yl)-1-methyl-1H-pyrazolo[3,4-b]pyrazin-3-yl)piper-
idin-1-yl)azetidine-1-carboxylate: To a solution of ethyl
(S)-2-(2-(3-(1-(azetidin-3-yl)piperidin-4-yl)-1-methyl-1H-pyrazolo[3,4-b]-
pyrazin-5-yl)-7-(4-chlorophenyl)-5-methylbenzo[d]thiazol-6-yl)-2-(tert-but-
oxy)acetate (11 mg, 0.012 mmol) in dichloromethane (1.0 mL) was
added diisopropylethylamine (21 .mu.L, 0.12 mmol), followed by
methyl chloroformate (5 .mu.L, 0.062 mmol). Reaction mixture was
stirred for 1 hour, then quenched with saturated sodium bicarbonate
solution. Mixture was extracted with dichloromethane (2.times.),
dried (MgSO.sub.4), filtered and concentrated. Residue was purified
by CombiFlash (4 g, Gold, 0-40% Hex/(20% MeOH/EtOAc) to give a
yellow film, plus an impurity. The mixture was purified by Gilson
HPLC (Gemini, 5-100% ACN/H.sub.2O+0.1% TFA) and product-containing
fractions were concentrated to remove organics, basified with
saturated sodium bicarbonate solution and extracted with ethyl
acetate (2.times.). Combined organic layer was dried (MgSO4),
filtered and dried to give a colorless film. LCMS-ESI+: calc'd for
C.sub.38H.sub.45ClN.sub.7O.sub.5S: 746.3 (M+H).sup.+; found: 746.3
(M+H).sup.+.
[0778] Preparation of
(S)-2-(tert-butoxy)-2-(7-(4-chlorophenyl)-2-(3-(1-(1-(methoxycarbonyl)aze-
tidin-3-yl)piperidin-4-yl)-1-methyl-1H-pyrazolo[3,4-b]pyrazin-5-yl)-5-meth-
ylbenzo[d]thiazol-6-yl)acetic acid: methyl
(S)-3-(4-(5-(6-(1-(tert-butoxy)-2-ethoxy-2-oxoethyl)-7-(4-chlorophenyl)-5-
-methylbenzo[d]thiazol-2-yl)-1-methyl-1H-pyrazolo[3,4-b]pyrazin-3-yl)piper-
idin-1-yl)azetidine-1-carboxylate (5.9 mg, 0.01 mmol) and 5M sodium
hydroxide (10 .mu.L, 0.05 mmol) in THF (1.0 mL) and MeOH (0.1 mL)
were stirred at 60.degree. C. for 2.5 hours. Reaction mixture was
diluted with DMF (0.5 mL) and concentrated to .about.0.5 mL,
filtered through a syringe filter and purified by Gilson HPLC
(Gemini, 5-100% ACN/H.sub.2O+0.1% TFA). Product was lyophilized to
give an off-white powder. .sup.1H NMR (400 MHz, Methanol-d.sub.4)
.delta. 9.53 (s, 1H), 7.93 (s, 1H), 7.72-7.66 (m, 1H), 7.64-7.53
(m, 3H), 5.24 (s, 1H), 4.33 (s, 2H), 4.27-4.16 (m, 2H), 4.14 (s,
4H), 3.72 (s, 4H), 3.59 (br s, 1H), 3.15 (br s, 2H), 2.63 (s, 3H),
2.51 (br s, 2H), 2.29 (br s, 1H), 0.98 (s, 9H). LCMS-ESI+: calc'd
for C.sub.36H.sub.41ClN.sub.7O.sub.5S: 718.3 (M+H).sup.+; found:
718.2 (M+H).sup.+.
Example 119
Preparation of
(S)-2-(2-(3-(1-(1-acetylazetidin-3-yl)piperidin-4-yl)-1-methyl-1H-pyrazol-
o[3,4-b]pyrazin-5-yl)-7-(4-chlorophenyl)-5-methylbenzo[d]thiazol-6-yl)-2-(-
tert-butoxy)acetic acid (120)
##STR00219##
[0780] Preparation of ethyl
(S)-2-(2-(3-(1-(1-acetylazetidin-3-yl)piperidin-4-yl)-1-methyl-1H-pyrazol-
o[3,4-b]pyrazin-5-yl)-7-(4-chlorophenyl)-5-methylbenzo[d]thiazol-6-yl)-2-(-
tert-butoxy)acetate: To a solution of ethyl
(S)-2-(2-(3-(1-(azetidin-3-yl)piperidin-4-yl)-1-methyl-1H-pyrazolo[3,4-b]-
pyrazin-5-yl)-7-(4-chlorophenyl)-5-methylbenzo[d]thiazol-6-yl)-2-(tert-but-
oxy)acetate (11 mg, 0.012 mmol) in dichloromethane (1.0 mL) was
added diisopropylethylamine (21 .mu.L, 0.12 mmol), followed by
acetyl chloride (4 .mu.L, 0.062 mmol). Reaction mixture was stirred
for 1 hour, then quenched with saturated sodium bicarbonate
solution. Mixture was extracted with dichloromethane (2.times.),
dried (MgSO.sub.4), filtered and concentrated. Residue was purified
by CombiFlash (4 g, Gold, 0-40% Hex/(20% MeOH/EtOAc) to give a
yellow film. LCMS-ESI+: calc'd for
C.sub.38H.sub.45ClN.sub.7O.sub.4S: 730.3 (M+H).sup.+; found: 730.4
(M+H).sup.+.
[0781] Preparation of
(S)-2-(2-(3-(1-(1-acetylazetidin-3-yl)piperidin-4-yl)-1-methyl-1H-pyrazol-
o[3,4-b]pyrazin-5-yl)-7-(4-chlorophenyl)-5-methylbenzo[d]thiazol-6-yl)-2-(-
tert-butoxy)acetic acid: ethyl
(S)-2-(2-(3-(1-(1-acetylazetidin-3-yl)piperidin-4-yl)-1-methyl-1H-pyrazol-
o[3,4-b]pyrazin-5-yl)-7-(4-chlorophenyl)-5-methylbenzo[d]thiazol-6-yl)-2-(-
tert-butoxy)acetate (7.5 mg, 0.01 mmol) and 5M sodium hydroxide (10
.mu.L, 0.05 mmol) in THF (1.0 mL) and MeOH (0.1 mL) were stirred at
60.degree. C. for 1.5 hours. Reaction mixture was diluted with DMF
(0.5 mL) and concentrated to .about.0.5 mL, filtered through a
syringe filter and purified by Gilson HPLC (Gemini, 5-100%
ACN/H.sub.2O+0.1% TFA). Product was lyophilized to give an
off-white powder. .sup.1H NMR (400 MHz, Methanol-d.sub.4) .delta.
9.53 (s, 1H), 7.93 (s, 1H), 7.75-7.65 (m, 1H), 7.65-7.46 (m, 3H),
5.25 (s, 1H), 4.65-4.50 (m, 1H), 4.49-4.39 (m, 1H), 4.38-4.23 (m,
1H), 4.23-4.04 (m, 5H), 3.86-3.50 (m, 3H), 3.20 (s, 2H), 2.63 (s,
3H), 2.52 (br s, 2H), 2.30 (br s, 1H), 1.94 (s, 3H), 0.98 (s, 9H).
LCMS-ESI+: calc'd for C.sub.36H.sub.41ClN.sub.7O.sub.4S: 702.3
(M+H).sup.+; found: 702.2 (M+H).sup.+
Example 120
Preparation of
(S)-2-(tert-butoxy)-2-(7-(4-chlorophenyl)-2-(3-(4,4-dimethyl-2-oxoimidazo-
lidin-1-yl)-1-methyl-1H-indazol-5-yl)-5-methylbenzo[d]thiazol-6-yl)acetic
acid (121)
##STR00220##
[0783] Preparation of (S)-ethyl
2-(tert-butoxy)-2-(7-(4-chlorophenyl)-2-(3-(4,4-dimethyl-2-oxoimidazolidi-
n-1-yl)-1-methyl-1H-indazol-5-yl)-5-methylbenzo[d]thiazol-6-yl)acetate:
Prepared in a manner similar to (S)-ethyl
2-(tert-butoxy)-2-(7-(4-chlorophenyl)-5-methyl-2-(1-methyl-3-(2oxoimidazo-
lidin-1-yl)-1H-indazol-5-yl)benzo[d]thiazol-6-yl)acetate except
using 4,4-dimethylimidazolidin-2-one instead of
imidazolidin-2-one.
[0784] Preparation of
(S)-2-(tert-butoxy)-2-(7-(4-chlorophenyl)-2-(3-(4,4-dimethyl-2-oxoimidazo-
lidin-1-yl)-1-methyl-1H-indazol-5-yl)-5-methylbenzo[d]thiazol-6-yl)acetic
acid: Prepared in a manner similar to
(S)-2-(tert-butoxy)-2-(7-(4-chlorophenyl)-5-methyl-2-(1-methyl-3-(2-oxoim-
idazolidin-1-yl)-1H-indazol-5-yl)benzo[d]thiazol-6-yl)acetic acid
except using (S)-ethyl
2-(tert-butoxy)-2-(7-(4-chlorophenyl)-2-(3-(4,4-dimethyl-2-oxoimidazolidi-
n-1-yl)-1-methyl-1H-indazol-5-yl)-5-methylbenzo[d]thiazol-6-yl)acetate
instead of (S)-ethyl
2-(tert-butoxy)-2-(7-(4-chlorophenyl)-5-methyl-2-(1-methyl-3-(2oxoimidazo-
lidin-1-yl)-1H-indazol-5-yl)benzo[d]thiazol-6-yl)acetate. .sup.1H
NMR (400 MHz, Acetonitrile-d3) .delta. 9.08 (d, J=1.7 Hz, 1H), 8.11
(dd, J=9.0, 1.7 Hz, 1H), 7.85 (s, 1H), 7.74-7.51 (m, 4H), 7.47 (dd,
J=8.9, 0.8 Hz, 1H), 5.28 (s, 1H), 3.94 (s, 3H), 3.80 (d, J=1.0 Hz,
2H), 2.79-2.45 (m, 3H), 1.52-1.30 (m, 6H), 0.99 (s, 9H).
Example 121
Preparation of
(S)-2-(tert-butoxy)-2-(7-(4-chlorophenyl)-5-methyl-2-(1-methyl-3-(3,4,4-t-
rimethyl-2-oxoimidazolidin-1-yl)-1H-indazol-5-yl)benzo[d]thiazol-6-yl)acet-
ic acid (122)
##STR00221##
[0786] Preparation of (S)-ethyl
2-(tert-butoxy)-2-(7-(4-chlorophenyl)-5-methyl-2-(1-methyl-3-(3,4,4-trime-
thyl-2-oxoimidazolidin-1-yl)-1H-indazol-5-yl)benzo[d]thiazol-6-yl)acetate:
Prepared in a manner similar to (S)-ethyl
2-(tert-butoxy)-2-(7-(4-chlorophenyl)-5-methyl-2-(1-methyl-3-(3-methyl-2--
oxoimidazolidin-1-yl)-1H-indazol-5-yl)benzo[d]thiazol-6-yl)acetate
except using (S)-ethyl
2-(tert-butoxy)-2-(7-(4-chlorophenyl)-2-(3-(4,4-dimethyl-2-oxoimidazolidi-
n-1-yl)-1-methyl-1H-indazol-5-yl)-5-methylbenzo[d]thiazol-6-yl)acetate
instead of (S)-ethyl
2-(tert-butoxy)-2-(7-(4-chlorophenyl)-5-methyl-2-(1-methyl-3-(2-oxoimidaz-
olidin-1-yl)-1H-indazol-5-yl)benzo[d]thiazol-6-yl)acetate.
[0787] Preparation of
(S)-2-(tert-butoxy)-2-(7-(4-chlorophenyl)-5-methyl-2-(1-methyl-3-(3,4,4-t-
rimethyl-2-oxoimidazolidin-1-yl)-1H-indazol-5-yl)benzo[d]thiazol-6-yl)acet-
ic acid: Prepared in a manner similar to
(S)-2-(tert-butoxy)-2-(7-(4-chlorophenyl)-2-(3-(3-(2-methoxyethyl)-2-oxoi-
midazolidin-1-yl)-1-methyl-1H-indazol-5-yl)-5-methylbenzo[d]thiazol-6-yl)a-
cetic acid except using (S)-ethyl
2-(tert-butoxy)-2-(7-(4-chlorophenyl)-5-methyl-2-(1-methyl-3-(3,4,4-trime-
thyl-2-oxoimidazolidin-1-yl)-1H-indazol-5-yl)benzo[d]thiazol-6-yl)acetate
instead of (S)-ethyl
2-(tert-butoxy)-2-(7-(4-chlorophenyl)-2-(3-(3-(2-methoxyethyl)-2-oxoimida-
zolidin-1-yl)-1-methyl-1H-indazol-5-yl)-5-methylbenzo[d]thiazol-6-yl)aceta-
te. .sup.1H NMR (400 MHz, Acetonitrile-d3) .delta. 9.14 (s, 1H),
8.12 (dd, J=9.0, 1.7 Hz, 1H), 7.85 (s, 1H), 7.74-7.55 (m, 3H),
7.51-7.41 (m, 1H), 5.28 (s, 1H), 3.94 (s, 3H), 3.75 (s, 3H), 2.83
(s, 3H), 2.58 (d, J=0.9 Hz, 3H), 1.38 (d, J=1.9 Hz, 6H), 1.00 (s,
9H).
Example 122
Preparation of
(S)-2-(tert-butoxy)-2-(7-(4-chlorophenyl)-2-(3-(3-(2-methoxyethyl)-4,4-di-
methyl-2-oxoimidazolidin-1-yl)-1-methyl-1H-indazol-5-yl)-5-methylbenzo[d]t-
hiazol-6-yl)acetic acid (123)
##STR00222##
[0789] Preparation of
(S)-2-(tert-butoxy)-2-(7-(4-chlorophenyl)-2-(3-(3-(2-methoxyethyl)-4,4-di-
methyl-2-oxoimidazolidin-1-yl)-1-methyl-1H-indazol-5-yl)-5-methylbenzo[d]t-
hiazol-6-yl)acetic acid: Prepared in a manner similar to
(S)-2-(tert-butoxy)-2-(7-(4-chlorophenyl)-2-(3-(3-(2-methoxyethyl)-2-oxoi-
midazolidin-1-yl)-1-methyl-1H-indazol-5-yl)-5-methylbenzo[d]thiazol-6-yl)a-
cetic acid except using (S)-ethyl
2-(tert-butoxy)-2-(7-(4-chlorophenyl)-2-(3-(4,4-dimethyl-2-oxoimidazolidi-
n-1-yl)-1-methyl-1H-indazol-5-yl)-5-methylbenzo[d]thiazol-6-yl)acetate
instead of (S)-ethyl
2-(tert-butoxy)-2-(7-(4-chlorophenyl)-2-(3-(3-(2-methoxyethyl)-2-oxoimida-
zolidin-1-yl)-1-methyl-1H-indazol-5-yl)-5-methylbenzo[d]thiazol-6-yl)aceta-
te. .sup.1H NMR (400 MHz, Acetonitrile-d3) .delta. 9.08 (dd, J=1.7,
0.8 Hz, 1H), 8.08 (dd, J=9.0, 1.7 Hz, 1H), 7.82 (d, J=1.0 Hz, 1H),
7.71-7.52 (m, 3H), 7.46-7.34 (m, 1H), 5.26 (s, 1H), 3.91 (s, 3H),
3.72 (d, J=1.2 Hz, 2H), 3.53 (d, J=6.2 Hz, 2H), 3.37 (d, J=17.6 Hz,
6H), 2.55 (d, J=0.8 Hz, 3H), 1.38 (d, J=1.9 Hz, 6H), 0.99 (s,
9H).
Example 123
Preparation of
(2S)-2-(tert-butoxy)-2-(7-(4-chlorophenyl)-2-(3-(1-(1-methoxypropan-2-yl)-
azetidin-3-yl)-1-methyl-1H-indazol-5-yl)-5-methylbenzo[d]thiazol-6-yl)acet-
ic acid (124)
##STR00223##
[0791] Preparation of
(2S)-2-(tert-butoxy)-2-(7-(4-chlorophenyl)-2-(3-(1-(1-methoxypropan-2-yl)-
azetidin-3-yl)-1-methyl-1H-indazol-5-yl)-5-methylbenzo[d]thiazol-6-yl)acet-
ic acid: To a flask containing 1/4 of the above crude ethyl
(S)-2-(2-(3-(azetidin-3-yl)-1-methyl-1H-indazol-5-yl)-7-(4-chlorophenyl)--
5-methylbenzo[d]thiazol-6-yl)-2-(tert-butoxy)acetate were added
methanol (2 mL), methoxyacetone (0.1 mL, 1.077 mmol) and stirred at
0.degree. C. bath as sodium cyanoborohydride (30 mg, 0.477 mmol)
and acetic acid (1 drop). After 30 min, the reaction mixture was
diluted with saturated aqueous NaHCO.sub.3, and the product was
extracted with ethyl acetate (.times.3). The extracts were combined
dried (MgSO.sub.4), concentrated, and dried in vacuum for 30 min.
LCMS-ESI.sup.+: calc'd for C.sub.37H.sub.44ClN.sub.4O.sub.4S:
675.28 (M+H).sup.+; found: 675.39 (M+H).sup.+.
[0792] The above residue was dissolved in THF (1 mL) and MeOH (1
mL) before 2 N NaOH (1 mL) was added. The resulting mixture was
stirred at 70.degree. C. preheated bath for 2 h and the reaction
mixture was acidified with 2 N HCl (.about.1.05 mL) and
concentrated to almost dryness. The residue was triturated with
MeOH (.about.1.5 mL) and the suspension was filtered through
syringe filter. The resulting filtrate was purified by Gilson HPLC
(Phenomenex Gemini 250.times.21.2 10 u C18 column, 30-60%
ACN/H.sub.2O+0.1% TFA) to give a diastereomeric mixture of
(2S)-2-(tert-butoxy)-2-(7-(4-chlorophenyl)-2-(3-(1-(1-methoxypropan-2-yl)-
azetidin-3-yl)-1-methyl-1H-indazol-5-yl)-5-methylbenzo[d]thiazol-6-yl)acet-
ic acid after lyophilization. .sup.1H NMR (400 MHz,
Acetonitrile-d.sub.3) .delta. 9.10 (s, 1H), 8.28 (d, J=1.7 Hz, 1H),
8.19-8.10 (m, 1H), 7.84 (d, J=6.0 Hz, 1H), 7.70-7.64 (m, 1H),
7.64-7.52 (m, 4H), 5.28 (s, 1H), 4.69-4.33 (m, 5H), 4.08 (s, 1H),
4.05 (s, 2H), 3.77-3.42 (m, 3H), 3.37 (four s, 3H), 2.57 (two s,
3H), 1.28 (four d, J=6.7 Hz, 3H), 0.99 (s, 9H). LCMS-ESI.sup.+:
calc'd for C.sub.35H.sub.40ClN.sub.4O.sub.4S: 647.25 (M+H).sup.+;
found: 647.35 (M+H).sup.+.
Example 124
Exemplary Compound Characterization
TABLE-US-00001 [0793] ES/MS Structure Cmpd# Chemical Name m/z 1H
HMR Method ##STR00224## 125 (S)-2-(tert-butoxy)-2-(7-(4-
chlorophenyl)-2-(3-(1-(2- methoxyethyl)piperidin-
4-yl)-1-methyl-1H- indazol-5-yl)-5- methylbenzo[d]thiazol-6-
yl)acetic acid 661.3 (M + H)+ 1H NMR (400 MHz, Chloroform-d) d 8.28
(s, 1H), 7.96 (s, 1H), 7.83 (s, 2H), 7.59-7.42 (m, 3H), 7.37 (d, J
= 8.8 Hz, 1H), 5.27 (s, 1H), 4.00 (s, 3H), 3.79 (t, J = 4.7 Hz,
2H), 3.48 (s, 0H), 3.36 (s, 3H), 3.23 (s, 2H), 2.60 (s, 3H),
2.48-2.08 (m, 4H), 1.37-1.09 A (m, 6H), 0.99 (s, 9H), 0.85 (t, J =
9.5 Hz, 4H). ##STR00225## 126 (S)-2-(tert-butoxy)-2-(7-(4-
chlorophenyl)-2-(3-(1- ethylpiperidin-4-yl)-1-
methyl-1H-indazol-5-yl)- 5-methylbenzo[d]thiazol- 6-yl)acetic acid
631.4 (M + H)+ 1H NMR (400 MHz, Chloroform d) d 8.34-8.17 (m, 1H),
8.05-7.90 (m, 1H), 7.80 (s, 1H), 7.64 (d, J = 7.9 Hz, 1H), 7.45 (d,
J = 8.2 Hz, 3H), 7.37-7.28 (m, 1H), 5.25 (d, J = 2.7 Hz, 1H), 3.96
(d, J = 8.1 Hz, 3H), 3.83- A 2.65 (m, 6H), 2.50 (s, 3H), 2.23 (d, J
= 16.6 Hz, 4H), 1.34 (dt, J = 15.3, 7.2 Hz, 3H), 0.93 (s, 9H)
##STR00226## 127 (S)-2-(tert-butoxy)-2-(7-(4-
chlorophenyl)-2-(3-(1- isopropylpiperidin-4-yl)-1-
methyl-1H-indazol-5-yl)-5- methylbenzo[d]thiazol-6-yl) acetic acid
645.4 (M + H)+ 1H NMR (400 MHz, Chloroform-d) d 11.64 (d, J = 220.5
Hz, 1H), 8.42-8.20 (m, 1H), 8.06 (ddd, J = 30.3, 8.8, 1.5 Hz, 1H),
7.87 (d, J = 1.0 Hz, 1H), 7.72 (d, J = 8.2 Hz, 1H), 7.61- 7.46 (m,
3H), 7.46-7.33 (m, 1H), 5.32 (d, J = A 3.9 Hz, 1H), 4.04 (d, J =
9.0 Hz, 3H), 3.81-2.85 (m, 6H), 2.79- 2.60 (m, 2H), 2.58 (s, 3H),
2.39- 2.17 (m, 2H), 2.01 (dd, J = 99.3, 1.3 Hz, 1H), 1.40 (dd, J =
16.3, 6.6 Hz, 6H), 1.26 (s, 2H), 1.01 (s, 9H). ##STR00227## 128
(S)-2-(tert-butoxy)-2-(7-(4- chlorophenyl)-2-(3-(1-
cyclopropylpiperidin-4-yl)- 1-methyl-1H-indazol-5-yl)-
5-methylbenzo[d]thiazol- 6-yl)acetic acid 643.44 (M + H)+ .sup.1H
NMR (400 MHz, Methanol- d.sub.4) .delta. 8.45 (s, 1 H), 8.11 (dd, J
= 8.8, 1.6 Hz, 1 H), 7.81 (s, 1 H), 7.74- 7.65 (m, 1 H), 7.67-7.52
(m, 4 H), 5.26 (s, 1 H), 4.03 (s, 3 H), 3.81 (d, J = 12.4 Hz, 2 H),
3.42 (t, J = 12.8 Hz, 2 H), 2.90 (dt, J = 12.2, 6.2 Hz, 1 H), 2.61
(s, 3 H), 2.36 (d, A J = 14.5 Hz, 2 H), 2.17 (q, J = 12.5 Hz, 2 H),
1.09- 0.98 (m, 4 H), 0.98 (s, 9 H) ##STR00228## 129
(S)-2-(tert-butoxy)-2-(7-(4- chlorophenyl)-2-(3-(1-
cyclobutylpiperidin-4-yl)-1- methyl-1H-indazol-5-yl)-5-
methylbenzo[d]thiazol-6-yl) acetic acid 657.49 (M + H)+ .sup.1H NMR
(400 MHz, Methanol- d.sub.4) .delta. 8.46 (dd, J = 1.7, 0.8 Hz, 1
H), 8.13 (dd, J = 8.9, 1.6 Hz, 1 H), 7.82 (s, 1 H), 7.72- 7.67 (m,
1 H), 7.66-7.58 (m, 4 H), 5.26 (s, 1 H), 4.05 (s, 3 H), 3.74 (p, J
= 8.1 Hz, 1 H), 3.64 (d, J = 12.4 Hz, 2 H), 3.56-3.42 (m, 1 H),
3.02 (t, J = A 12.8 Hz, 2 H), 2.62 (s, 3 H), 2.47- 2.31 (m, 4 H),
2.31-2.07 (m, 4 H), 2.00-1.80 (m, 2 H), 0.98 (d, J = 1.9 Hz, 9 H)
##STR00229## 130 (S)-2-(tert-butoxy)-2-(7-(4-
chlorophenyl)-2-(3-(1-(2- (dimethylamino)ethyl)
piperidin-4-yl)-1-methyl- 1H-indazol-5-yl)-5-
methylbenzo[d]thiazol-6- yl)acetic acid 673.54 (M + H)+ .sup.1H NMR
(400 MHz, Methanol- d.sub.4) .delta. 8.47-8.45 (m, 1 H), 8.11 (dd,
J = 8.9, 1.6 Hz, 1 H), 7.82 (d, J = 0.9 Hz, 1 H), 7.72-7.66 (m, 1
H), 7.66-7.56 (m, 4 H), 5.26 (s, 1 H), 4.06 (s, 3 H), 3.75 (d, J =
12.0 Hz, 2 H), 3.67 (s, 4 H), 3.63- 3.49 (m, 1 H), 3.42-3.31 (m, 2
H), 3.01 (s, 6 H), A 2.62 (s, 3 H), 2.46- 2.36 (m, 2 H), 2.38-2.22
(m, 2 H), 0.98 (s, 9 H) ##STR00230## 131
(S)-2-(tert-butoxy)-2-(7-(4- chlorophenyl)-2-(3-(3-
methoxy-3-methylazetidin- 1-yl)-1-methyl-1H-indazol-
5-yl)-5-methylbenzo [d]thiazol-6-yl)acetic acid 619.3 (M + H)+ 1H
NMR (400 MHz, Chloroform-d) .delta. 8.28 (d, J = 1.8 Hz, 1H), 8.00
(dd, J = 9.0, 1.8 Hz, 1H), 7.90 (s, 1H), 7.71 (d, J = 7.7 Hz, 1H),
7.61- 7.40 (m, 3H), 7.29 (s, 1H), 5.31 (s, 1H), 4.46- 4.08 (m, 4H),
3.91 (s, 3H), 3.32 B (s, 3H), 2.57 (s, 3H), 1.63 (s, 3H), 1.25 (s,
9H), 1.00 (s, 9H), 0.86 (dt, J = 13.7, 4.1 Hz, 3H) ##STR00231## 132
(S)-2-(tert-butoxy)-2-(7-(4- chlorophenyl)-5-methyl-2-
(1-methyl-3-(4-methyl-1,4- diazepan-1-yl)-1H-indazol-
5-yl)benzo[d]thiazol-6- yl)acetic acid 632.2 (M + H)+ 1H NMR (400
MHz, Chloroform-d) d 8.38 (d, J = 5.3 Hz, 1H), 7.88 (d, J = 6.2 Hz,
2H), 7.72 (d, J = 8.2 Hz, 1H), 7.60- 7.45 (m, 3H), 7.24 (s, 1H),
5.31 (s, 1H), 4.20 (d, J = 16.8 Hz, 1H), 3.87 (s, 5H), 3.77 (m,
1H), 3.63 (m, B 1H), 3.33 (m, 2H), 3.14 (m, 2H), 2.92 (s, 3H), 2.58
(s, 3H), 2.35 (m, 1H), 1.25 (m, 4H), 1.01 (s, 10H), 0.90 (d, J =
19.8 Hz, 1H). ##STR00232## 133 (S)-2-(tert-butoxy)-2-(7-(4-
chlorophenyl)-2-(3-(4- ethylpiperazin-1-yl)-1-
methyl-1H-indazol-5-yl)-5- methylbenzo[d]thiazol-6-yl) acetic acid
632.2 (M + H+) 1H NMR (400 MHz, CD3OD) .delta. 8.42-8.37 (m, 1H),
8.03 (dd, J = 8.9, 1.6 Hz, 1H), 7.79 (d, J = 0.9 Hz, 1H), 7.72-
7.64 (m, 1H), 7.63-7.48 (m, 4H), 5.24 (s, 1H), 4.11 (d, J = 11.7
Hz, 2H), 3.92 (s, 3H), 3.68 (s, 1H), 3.37-3.25 (m, B 10H), 2.61 (d,
J = 0.7 Hz, 3H), 1.41 (t, J = 7.3 Hz, 3H), 0.97 (s, 9H)
##STR00233## 134 (S)-2-(tert-butoxy)-2-(7-(4-
chlorophenyl)-2-(3-(3-(2- methoxyethoxy)azetidin-1-
yl)-1-methyl-1H-indazol-5- yl)-5-methylbenzo[d] thiazol-6-yl)acetic
acid 649.2 (M + H)+ 1H NMR (400 MHz, Chloroform-d) .delta. 8.24 (s,
1H), 8.03 (d, J = 8.7 Hz, 1H), 7.88 (s, 1H), 7.71 (s, 1H), 7.52 (d,
J = 7.5 Hz, 5H), 7.22 (s, 2H), 5.31 (d, J = 6.9 Hz, 3H), 4.51 (s,
3H), 4.16 (d, J = 24.0 Hz, 2H), 3.88 (d, J = 9.9 Hz, 5H), 3.68- D
3.52 (m, 5H), 3.40 (s, 4H), 2.59 (d, J = 17.5 Hz, 6H), 1.14 (s,
3H), 1.01 (s, 16H), 0.86 (d, J = 17.0 Hz, ##STR00234## 135
(S)-2-(tert-butoxy)-2-(7-(4- chlorophenyl)-2-(3-((R)-
hexahydropyrazino[2,1-c] [1,4]oxazin-8(1H)-yl)-1-
methyl-1H-indazol-5-yl)- 5-methylbenzo[d]thiazol- 6-yl)acetic acid
660.2 (M + H)+ 1H NMR (400 MHz, Chloroform-d) .delta. 8.45 (d, J =
1.6 Hz, 1H), 7.94- 7.83 (m, 2H), 7.72 (d, J = 8.1 Hz, 1H), 7.60-
7.42 (m, 3H), 7.34 (d, J = 8.9 Hz, 1H), 5.32 (s, 1H), 4.05 (dd, J =
12.3, 4.9 Hz, 4H), 3.93 (s + m, 4H), 3.65 (tt, J = 22.1, D 12.0 Hz,
4H), 3.49-3.36 (m, 1H), 3.25 (t, J = 12.4 Hz, 1H), 3.04 (dd, J =
12.1, 7.7 Hz, 1H), 2.59 (s, 3H), 1.01 (s, 9H), 0.88 (t, J = 7.3 Hz,
1H). ##STR00235## 136 (S)-2-(2-(3-(4-(azetidin-1-
yl)piperidin-1-yl)-1-methyl- 1H-indazol-5-yl)-7-(4-
chlorophenyl)-5- methylbenzo[d]thiazol- 6-yl)-2-(tert-butoxy)
acetic acid 658.32 (M + H)+ D ##STR00236## 137
(S)-2-(tert-butoxy)-2-(7-(4- chlorophenyl)-2-(3-(4-
(dimethylcarbamoyl)-4- methylpiperidin-1-yl)-1-
methyl-1H-indazol-5-yl)-5- methylbenzo[d]thiazol-6- yl)acetic acid
688.20 (M + H)+ .sup.1H NMR (400 MHz, Methanol- d.sub.4) .delta.
8.43 (d, J = 1.0 Hz, 1 H), 8.11- 7.92 (m, 1 H), 7.80 (s, 1 H),
7.73- 7.65 (m, 1 H), 7.65-7.51 (m, 4 H), 5.25 (s, 1 H), 4.30-3.37
(m, 7 H), 3.10 (s, 6 H), 2.61 (s, 3 H), 2.52- 2.29 (m, 2 H),
1.93-1.66 (m, 2 H), 1.39 (s, 3 H), 0.98 (s, 9 H) D ##STR00237## 138
(S)-2-(tert-butoxy)-2-(7-(4- chlorophenyl)-5-methyl-2-
(1-methyl-3-((S)-4- oxohexahydropyrazino [2,1-c][1,4]oxazin-8(1H)-
yl)-1H-indazol-5-yl)benzo [d]thiazol-6-yl)acetic acid 674.27 (M +
H)+ .sup.1H NMR (400 MHz, Methanol- d.sub.4) .delta. 8.44 (s, 1H),
7.98 (d, 1H), 7.80 (s, 1H), 7.72- 7.67 (m, 1H), 7.63-7.42 (m, 4H),
5.25 (s, 1H), 4.64 (d, J = 12.9 Hz, 1H), 4.21- 4.10 (m, 3H),
4.03-3.84 (m, 6H), 3.71 (dd, J = 12.0, 7.3 Hz, 1H), 3.16-3.05 (m, D
1H), 3.05-2.81 (m, 2H), 2.61 (s, 3H), 0.98 (s, 9H) ##STR00238## 139
(S)-2-(tert-butoxy)-2-(7-(4- chlorophenyl)-2-(3-((S)-3-
methoxypyrrolidin-1-yl)-1- methyl-1H-indazol-5-yl)-5-
methylbenzo[d]thiazol- 6-yl)acetic acid 619.2 (M + H)+ 1H NMR (400
MHz, Acetonitrile-d3) .delta. 8.42-8.35 (m, 1H), 8.11 (s, 0H), 7.99
(dd, J = 9.0, 1.6 Hz, 1H), 7.81 (s, 1H), 7.70- 7.64 (m, 1H), 7.60
(s, 3H), 7.33 (d, J = 8.9 Hz, 1H), 5.26 (s, 1H), 4.19-4.10 (m, 1H),
3.82 (s, 3H), 3.77-3.56 (m, D 4H), 3.35 (s, 3H), 2.58 (s, 3H), 2.27
(t, J = 7.4 Hz, 1H), 2.20-2.06 (m, 3H), 1.12 (d, J = 6.1 Hz, 2H),
0.98 (s, 9H), 0.90 (t, J = 6.8 Hz, 2H). ##STR00239## 140
(S)-2-(tert-butoxy)-2-(7-(4- chlorophenyl)-2-(3-((R)-3-
methoxypyrrolidin-1-yl)-1- methyl-1H-indazol-5-yl)-5-
methylbenzo[d]thiazol- 6-yl)acetic acid 619.2 (M + H)+ 1H NMR (400
MHz, Acetonitrile-d3) .delta. 8.44-8.37 (m, 1H), 8.09 (d, J = 8.3
Hz, 1H), 7.83 (s, 1H), 7.71- 7.54 (m, 4H), 5.28 (s, 1H), 4.17 (d, J
= 5.6 Hz, 1H), 3.35 (s, 3H), 2.65 (s, 1H), 2.58 (d, J = 0.8 Hz,
3H), 2.27 (t, J = 7.5 Hz, 1H), 2.14 D (d, J = 26.3 Hz, 2H),
1.65-1.48 (m, 1H), 0.99 (s, 9H), 0.94-0.81 (m, 3H). ##STR00240##
141 (2S)-2-(2-(3-(8-oxa-3- azabicyclo[3.2.1]octan-3-
yl)-1-methyl-1H-indazol-5- yl)-7-(4-chlorophenyl)-5-
methylbenzo[d]thiazol- 6-yl)-2-(tert-butoxy) acetic acid 631.3 (M +
H)+ 1H NMR (400 MHz, Chloroform-d) .delta. 8.02-7.86 (m, 2H), 7.73
(s, 1H), 7.61-7.45 (m, 4H), 7.23 (s, 1H), 5.31 (s, 1H), 4.54 (s,
2H), 3.90 (s, 3H), 3.81-3.69 (m, 3H), 3.37 (d, J = 11.8 Hz, 2H),
2.58 (s, 3H), 2.41- B 2.26 (m, 2H), 2.18-1.97 (m, 3H), 1.01 (s,
9H), 0.88 (t, J = 6.7 Hz, 2H). ##STR00241## 142
(S)-2-(tert-butoxy)-2-(7-(4- chlorophenyl)-2-(3-(4-
methoxypiperidin-1-yl)-1- methyl-1H-indazol-5-yl)-5-
methylbenzo[d]thiazol- 6-yl)acetic acid 633.3 (M + H)+ 1H NMR (400
MHz, Chloroform-d) .delta. 8.37-8.29 (m, 1H), 8.00 (dd, J = 8.9,
1.5 Hz, 1H), 7.84 (s, 1H), 7.72 (d, J = 8.3 Hz, 1H), 7.52 (d, J =
8.4 Hz, 3H), 7.24 (s, 1H), 5.31 (s, 1H), 3.89 (s, 3H), 3.86-3.70
(m, 2H), 3.41 (s, 3H), 3.16 (ddt, J = B 13.0, 9.8, 3.5 Hz, 2H),
2.56 (s, 3H), 2.18-1.64 (m, 4H), 1.25 (s, 1H), 1.00 (s, 9H).
##STR00242## 143 (2S)-2-(2-(3-(6-oxa-3- azabicyclo[3.1.1]heptan-3-
yl)-1-methyl-1H-indazol-5- yl)-7-(4-chlorophenyl)-5-
methylbenzo[d]thiazol-6- yl)-2-(tert-butoxy) acetic acid 617.3 (M +
H)+ 1H NMR (400 MHz, Chloroform-d) .delta. 8.66 (s, 1H), 7.97- 7.86
(m, 2H), 7.78-7.67 (m, 1H), 7.59-7.41 (m, 3H), 7.23 (s, 1H), 5.30
(s, 1H), 4.84 (d, J = 6.5 Hz, 2H), 4.04 (s, 4H), 3.92 (s, 3H),
3.43-3.24 (m, B 1H), 2.58 (s, 4H), 2.16 (d, J = 8.9 Hz, 1H), 1.01
(s, 9H). ##STR00243## 144 (S)-2-(tert-butoxy)-2-(7-(4-
chlorophenyl)-5-methyl-2-
(1-methyl-3-morpholino- 1H-indazol-5-yl)benzo[d]
thiazol-6-yl)acetic acid 605.3 (M + H)+ 1H NMR (400 MHz,
Chloroform-d) .delta. 8.53 (d, J = 1.9 Hz, 1H), 7.97- 7.86 (m, 2H),
7.72 (d, J = 7.8 Hz, 1H), 7.64- 7.52 (m, 2H), 7.51-7.42 (m, 1H),
7.34 (d, J = 8.9 Hz, 1H), 5.31 (s, 1H), 4.06- B 3.83 (m, 6H), 3.55
(t, J = 3.8 Hz, 4H), 2.59 (s, 3H), 2.01 (s, 1H), 1.01 (s, 9H).
##STR00244## 145 (S)-2-(tert-butoxy)-2-(7-(4-
chlorophenyl)-2-(3-(3-((2- methoxyethyl)(methyl)
amino)azetidin-1-yl)-1- methyl-1H-indazol-5-yl)-
5-methylbenzo[d]thiazol- 6-yl)acetic acid 662.3 (M + H)+ 1H NMR
(400 MHz, Chloroform-d) .delta. 8.10-8.00 (m, 1H), 7.82 (dd, J =
9.0, 1.6 Hz, 1H), 7.69 (s, 1H), 7.54 (dd, J = 8.7, 2.1 Hz, 1H),
7.45- 7.31 (m, 3H), 7.16 (d, J = 8.9 Hz, 1H), 5.11 (s, 1H),
4.40-4.26 (m, 4H), 3.75 (s, 3H), 3.64 (dd, J = D 5.6, 3.6 Hz, 2H),
3.28 (s, 3H), 3.26- 3.18 (m, 1H), 2.87 (s, 3H), 2.48 (s, 3H), 1.89
(s, 2H), 0.85 (s, 9H). ##STR00245## 146
(S)-2-(tert-butoxy)-2-(7-(4- chlorophenyl)-5-methyl-2-
(1-methyl-3-(4-(oxetan- 3-yl)piperidin-1-yl)-1H-
indazol-5-yl)benzo[d] thiazol-6-yl)acetic acid 659.3 (M + H)+ 1H
NMR (400 MHz, Chloroform-d) .delta. 8.40 (d, J = 1.5 Hz, 1H), 8.04
(dd, J = 8.8, 1.5 Hz, 1H), 7.87 (s, 1H), 7.72 (d, J = 7.9 Hz, 1H),
7.58- 7.45 (m, 4H), 7.31 (d, J = 8.9 Hz, 1H), 5.32 (s, 1H), 4.84
(dd, J = 7.9, 6.1 Hz, 2H), 4.56 (t, J = 6.3 Hz, 2H), 4.00 (d, J =
12.2 Hz, 2H), D 3.93 (s, 3H), 3.20- 2.95 (m, 2H), 2.87 (q, J = 8.0
Hz, 1H), 2.56 (s, 3H), 2.03-1.85 (m, 1H), 1.81 (d, J = 12.5 Hz,
2H), 1.52 (dd, J = 16.3, 9.2 Hz, 2H), 1.00 (s, 9H). ##STR00246##
147 (S)-2-(2-(3-(1-(((R)-1- acetylazetidin-2-yl)methyl)
piperidin-4-yl)-1-methyl- 1H-indazol-5-yl)-7-(4- chlorophenyl)-5-
methylbenzo[d]thiazol-6- yl)-2-(tert-butoxy)acetic acid 686.81 (M +
H)+ .sup.1H NMR (400 MHz, Chloroform-d) .delta. 8.44 (s, 1H), 8.07
(dd, J = 8.9, 1.6 Hz, 1H), 7.81 (s, 1H), 7.74-7.68 (m, 1H), 7.66-
7.53 (m, 4H), 5.25 (s, 1H), 4.29- 4.15 (m, 1H), 4.04 (s, 4H), 3.75-
3.36 (m, 5H), 3.18-2.96 (m, 5H), 2.77-2.66 (m, 1H), 2.62 (s, 3H),
2.59-2.45 (m, 1H), 2.26 (dp, E J = 23.5, 11.9 Hz, 5H), 0.98 (s, 9H)
##STR00247## 148 (S)-2-(2-(3-(1-(((R)-1-
acetylazetidin-2-yl)methyl) piperidin-4-yl)-1-methyl-
1H-indazol-5-yl)-7-(4- chlorophenyl)-5- methylbenzo[d]thiazol-6-
yl)-2-(tert-butoxy)acetic acid 714.66 (M + H)+ .sup.1H NMR (400
MHz, Methanol- d.sub.4) .delta. 8.47-8.42 (m, 1H), 8.12 (d, J =
8.8, 1.6 Hz, 1H), 7.82 (s, 1H), 7.69 (d, J = 8.6, 2.1 Hz, 1H),
7.67-7.56 (m, 4H), 5.25 (s, 1H), 5.07-4.95 (m, 2H), 4.31- 4.15 (m,
2H), 4.14-4.00 (m, 4H), 3.85-3.34 (m, 5H), 3.22- 3.11 (m, 1H), 2.62
(s, 3H), 2.58- 2.10 (m, 5H), 1.97-1.89 (m, E 3H), 0.98 (s, 9H)
##STR00248## 149 (S)-2-(tert-butoxy)-2-(7-(4-
chlorophenyl)-5-methyl-2- (1-methyl-3-(1-(((S)-1-
methylazetidin-2-yl)methyl) piperidin-4-yl)-1H-indazol-
5-yl)benzo[d]thiazol-6-yl) acetic acid 686.43 (M + H)+ .sup.1H NMR
(400 MHz, Methanol- d.sub.4) .delta. 8.45 (s, 1H), 8.10 (d, J =
8.9, 1.6 Hz, 1H), 7.82 (s, 1H), 7.72- 7.57 (m, 5H), 5.26 (s, 1H),
4.24 (s, 1H), 4.05 (s, 3H), 3.74 (dd, 1H), 3.63-3.40 (m, 5H), 3.25-
3.05 (m, 2H), 3.02 (s, 3H), 2.73 (tt, 1H), 2.62 (s, 3H), 2.55 (t, J
= 10.4 Hz, 1H), 2.38-2.17 (m, E 5H), 0.98 (s, 9H) ##STR00249## 150
(S)-2-(tert-butoxy)-2-(7-(4- chlorophenyl)-2-(3-(1-
(((S)-1-(methoxycarbonyl) azetidin-2-yl)methyl)
piperidin-4-yl)-1-methyl- 1H-indazol-5-yl)-5-
methylbenzo[d]thiazol-6- yl)acetic acid 730.68 (M + H)+ .sup.1H NMR
(400 MHz, Methanol- d.sub.4) .delta. 8.46 (s, 1H), 8.12 (d, 1H),
7.82 (s, 1H), 7.72- 7.56 (m, 5H), 5.26 (s, 1H), 4.06 (s, 3H), 3.97
(tt, J = 8.0, 7.4 Hz, 1H), 3.75 (s, 3H), 3.72- 3.36 (m, 6H), 3.17
(dd, J = 22.9, 10.7 Hz, 1H), 2.62 (s, 3H), 2.57- 2.47 (m, 2H), 2.40
(t, J = 15.3 Hz, 2H), 2.33- 2.06 (m, 4H), 0.98 (s, 9H) E
##STR00250## 151 (S)-2-(2-(3-(1-(((S)-1-
acetylazetidin-2-yl)methyl) piperidin-4-yl)-1-methyl-
1H-indazol-5-yl)-7-(4- chlorophenyl)-5- methylbenzo[d]thiazol-
6-yl)-2-(tert-butoxy) acetic acid 714.68 (M + H)+ .sup.1H NMR (400
MHz, Methanol- d.sub.4) .delta. 8.45 (s, 1H), 8.13 (d, J = 8.9, 1.6
Hz, 1H), 7.82 (s, 1H), 7.69 (d, 1H), 7.66-7.56 (m, 4H), 5.25 (s,
1H), 5.00 (q, J = 9.0 Hz, 1H), 4.30- 4.14 (m, 2H), 4.06 (d, J =
12.5 Hz, 3H), 3.73- 3.35 (m, 4H), 3.16 (t, 1H), 2.62 (s, 3H), 2.59-
2.46 (m, 1H), 2.48-2.31 (m, 3H), 2.31-2.08 (m, 4H), 1.94 (d, E J =
11.4 Hz, 3H), 0.98 (s, 9H) ##STR00251## 152
(S)-2-(tert-butoxy)-2-(7-(4- chlorophenyl)-2-(3-(1-(1-
(cyclopropanecarbonyl) azetidin-3-yl)piperidin-4-
yl)-1-methyl-1H-indazol- 5-yl)-5-methylbenzo [d]thiazol-6-yl)acetic
acid 726.68 (M + H)+ .sup.1H NMR (400 MHz, Methanol- d.sub.4)
.delta. 8.47 (s, 1H), 8.13 (d, 1H), 7.82 (s, 1H), 7.72- 7.56 (m,
5H), 5.26 (s, 1H), 4.78- 4.68 (m, 1H), 4.64-4.54 (m, 1H), 4.40-4.29
(m, 1H), 4.29- 4.15 (m, 2H), 4.06 (s, 3H), 3.83- 3.47 (m, 3H),
3.26-3.10 (m, 2H), 2.62 (s, 3H), 2.48-2.36 (m, 2H), 2.34-2.15 (m,
2H), 1.67- 1.56 (m, 1H), F 0.99 (s, 9H), 0.95- 0.86 (m, 4H)
##STR00252## 153 (S)-2-(tert-butoxy)-2-(7-(4-
chlorophenyl)-2-(3-(1-(1- (methoxycarbonyl)azetidin-
3-yl)piperidin-4-yl)-1- methyl-1H-indazol-5-yl)-5-
methylbenzo[d]thiazol-6- yl)acetic acid 716.52 (M + H)+ .sup.1H NMR
(400 MHz, Methanol- d.sub.4) .delta. 8.46 (s, 1H), 8.13 (d, J = 8.9
Hz, 1H), 7.82 (s, 1H), 7.73-7.53 (m, 5H), 5.25 (s, 1H), 4.46-4.11
(m, 6H), 4.06 (s, 3H), 3.73 (s, 4H), 3.60-3.45 (m, 1H), 3.22-3.06
(m, 2H), 2.62 (s, 3H), 2.48-2.33 (m, 2H), 2.31- 2.11 (m, 2H), 0.98
(s, 9H) F ##STR00253## 154 (S)-2-(tert-butoxy)-2-(7-(4-
chlorophenyl)-5-methyl-2- (1-methyl-3-(1-(1-
(methylsulfonyl)azetidin-3- yl)piperidin-4-yl)-1H-
indazol-5-yl)benzo[d] thiazol-6-yl)acetic acid 736.56 (M + H)+
.sup.1H NMR (400 MHz, Methanol- d.sub.4) .delta. 8.47-8.44 (m, 1H),
8.11 (dd, J = 8.9, 1.6 Hz, 1H), 7.82 (d, J = 0.8 Hz, 1H), 7.72-
7.66 (m, 1H), 7.65-7.57 (m, 4H), 5.26 (s, 1H), 4.29-4.19 (m, 5H),
4.05 (s, 3H), 3.76-3.45 (m, 4H), 3.30-3.11 (m, 1H), 3.03 (s, 3H),
2.62 (s, 3H), 2.46-2.18 (m, 4H), 0.98 (s, 9H) F ##STR00254## 155
(S)-2-(tert-butoxy)-2-(7-(4- chlorophenyl)-2-(3-(1-(3,3-
difluorocyclobutyl) piperidin-4-yl)-1-methyl- 1H-indazol-5-yl)-5-
methylbenzo[d]thiazol-6- yl)acetic acid 693.7 (M + H)+ .sup.1H NMR
(400 MHz, Methanol- d.sub.4) .delta. 8.45 (s, 1H), 8.11 (dd, J =
8.9, 1.6 Hz, 1H), 7.82 (s, 1H), 7.72- 7.66 (m, 1H), 7.66-7.52 (m,
4H), 5.26 (s, 1H), 4.05 (s, 3H), 3.91- 3.62 (m, 3H), 3.62-3.43 (m,
(m, 6H), 2.62 (s, 3H), 2.45-2.33 (m, 2H), 2.28- 2.12 (m, 2H), 0.98
(s, 9H) G ##STR00255## 156 (S)-2-(tert-butoxy)-2-(7-(4-
chlorophenyl)-2-(3-(1- ((1s,3s)-3- hydroxycyclobutyl)
piperidin-4-yl)-1-methyl- 1H-indazol-5-yl)-5-
methylbenzo[d]thiazol- 6-yl)acetic acid 673.95 (M + H)+ .sup.1H NMR
(400 MHz, Methanol- d.sub.4) .delta. 8.39 (s, 1H), 8.07 (dd, J =
8.9, 1.6 Hz, 1H), 7.79 (s, 1H), 7.71- 7.67 (m, 1H), 7.61-7.56 (m,
4H), 5.25 (s, 1H), 4.11 (p, J = 7.2 Hz, 1H), 4.00 (s, 3H),
3.96-3.69 (m, 1H), 3.64 (d, J = 12.2 Hz, 2H), 3.45 (ddt, J = 12.3,
8.5, 4.0 Hz, 1H), 3.39-3.21 (m, 2H), 3.09- 2.95 (m, 2H), G
2.87-2.70 (m, 1H), 2.60 (s, 3H), 2.42-2.05 (m, 6H), 0.98 (s, 9H)
##STR00256## 157 (S)-2-(tert-butoxy)-2-(7-(4-
chlorophenyl)-5-methyl-2- (1-methyl-3-(1-((S)-
tetrahydrofuran-2-carbonyl) piperidin-4-yl)-1H-indazol-
5-yl)benzo[d]thiazol-6-yl) acetic acid 701.33 (M + H)+ .sup.1H NMR
(400 MHz, Methanol- d.sub.4) .delta. 8.38 (s, 1H), 8.04 (dd, J =
8.9, 1.6 Hz, 1H), 7.79 (s, 1H), 7.72- 7.66 (m, 1H), 7.61-7.52 (m,
5H), 5.25 (s, 1H), 4.79 (t, J = 7.8, 5.9 Hz, 1H), 4.64- 4.54 (m,
1H), 4.24-4.06 (m, 1H), 3.98 (s, 3H), 3.97-3.80 (m, 2H), 3.49-3.35
(m, 1H), 3.36- H 3.21 (m, 1H), 3.00-2.84 (m, 1H), 2.61 (s, 3H),
2.30-1.75 (m, 7H), 0.98 (s, 9H) ##STR00257## 158
(2S)-2-(tert-butoxy)-2-(7- (4-chlorophenyl)-5-methyl-
2-(1-methyl-3-(1-(2- methyltetrahydrofuran-2-
carbonyl)piperidin-4-yl)- 1H-indazol-5-yl)benzo[d]
thiazol-6-yl)acetic acid 715.18 (M + H)+ .sup.1H NMR (400 MHz,
Methanol- d.sub.4) .delta. 8.35 (s, 1H), 8.08-8.01 (m, 1H), 7.78
(s, 1H), 7.73-7.66 (m, 1H), 7.61-7.51 (m, 4H), 5.25 (s, 1H), 4.61
(s, 1H), 4.00-3.90 (m, 4H), 3.90-3.73 (m, 1H), 3.46- 3.33 (m, 1H),
3.25-3.08 (m, 1H), 3.01-2.64 (m, 2H), 2.61 (s, H 3H), 2.12-1.61 (m,
8H), 1.49 (d, J = 1.5 Hz, 3H), 0.98 (s, 9H). ##STR00258## 159
(2S)-2-(tert-butoxy)-2-(7- (4-chlorophenyl)-5-methyl-
2-(1-methyl-3-(1-(oxetane- 2-carbonyl)piperidin-4-
yl)-1H-indazol-5-yl)benzo [d]thiazol-6-yl)acetic acid 687.27 (M +
H)+ .sup.1H NMR (400 MHz, Methanol- d.sub.4) .delta. 8.47-8.41 (m,
1H), 8.11- 8.04 (m, 1H), 7.81 (s, 1H), 7.71- 7.65 (m, 1H),
7.63-7.52 (m, 5H), 5.54 (dt, 1H), 5.26 (s, 1H), 4.77-4.46 (m, 3H),
4.05-4.00 (m, 4H), 3.84- 3.70 (m, 1H), 3.50-3.36 (m, 1H), 3.05-2.82
H (m, 3H), 2.61 (s, 3H), 2.21-1.79 (m, 3H), 0.98 (s, 9H)
##STR00259## 160 (S)-2-(tert-butoxy)-2-(7-(4-
chlorophenyl)-5-methyl-2- (1-methyl-3-(1-(3-
methyloxetane-3-carbonyl) piperidin-4-yl)-1H-indazol-
5-yl)benzo[d]thiazol-6-yl) acetic acid 701.29 (M + H)+ .sup.1H NMR
(400 MHz, Methanol- d.sub.4) .delta. 8.37 (s, 1H), 8.01 (d, 1H),
7.78 (s, 1H), 7.72- 7.66 (m, 1H), 7.60-7.50 (m, 4H), 5.25 (s, 1H),
4.98 (t, J = 5.5 Hz, 2H), 4.63-4.53 (m, 1H), 4.38 (d, J = 5.9 Hz,
2H), 3.97 (s, 3H), 3.45- 3.34 (m, 1H), 3.27-3.16 (m, 2H), 2.96-2.85
H (m, 1H), 2.60 (s, 3H), 2.13-2.04 (m, 3H), 1.96- 1.74 (m, 1H),
1.69 (s, 3H), 0.97 (s, 9H) ##STR00260## 161
(S)-2-(tert-butoxy)-2-(7-(4- chlorophenyl)-5-methyl-2-
(1-methyl-3-(1-(oxetane-3- carbonyl)piperidin-4-yl)-
1H-indazol-5-yl)benzo[d] thiazol-6-yl)acetic acid 687.28 (M + H)+
.sup.1H NMR (400 MHz, Methanol- d.sub.4) .delta. 8.43 (s, 1H), 8.05
(dt, J = 8.9, 1.6 Hz, 1H), 7.81 (s, 1H), 7.72- 7.66 (m, 1H),
7.64-7.54 (m, 4H), 5.26 (s, 1H), 4.93-4.89 (m, 2H), 4.86-4.83 (m,
2H), 4.67- 4.57 (m, 1H), 4.31-4.20 (m, 1H), 4.01 (s, 3H), 3.62 (d,
J = 13.8 H Hz, 1H), 3.50- 3.37 (m, 1H), 3.29-3.19 (m, 1H),
3.01-2.90 (m, 1H), 2.61 (s, 3H), 2.15-2.04 (m, 2H), 1.92- 1.78 (m,
2H), 0.98 (s, 9H) ##STR00261## 162 (S)-2-(tert-butoxy)-2-(7-(4-
chlorophenyl)-2-(3-(1-((S)- 1-(methoxycarbonyl) pyrrolidin-3-yl)
piperidin-4-yl)-1- methyl-1H-indazol-5-yl)-5- methylbenzo[d]
thiazol-6-yl)acetic acid 730.36 (M + H)+ .sup.1H NMR (400 MHz,
Methanol- d.sub.4) .delta. 8.46 (s, 1H), 8.13 (d, J = 8.9 Hz, 1H),
7.82 (s, 1H), 7.73-7.52 (m, 5H), 5.26 (s, 1H), 4.08-3.92 (m, 5H),
3.86- 3.34 (m, 10H), 2.65-2.07 (m, 10H), 0.99 (s, 9H). I
##STR00262## 163 (S)-2-(tert-butoxy)-2-(7-(4-
chlorophenyl)-5-methyl-2- (1-methyl-3-(1-((S)-1-
methylpyrrolidin-3-yl) piperidin-4-yl)-1H-indazol-
5-yl)benzo[d]thiazol-6-yl) acetic acid 686.59 (M + H)+ .sup.1H NMR
(400 MHz, Methanol- d.sub.4) .delta. 8.45 (d, 1H), 8.13-8.04 (m,
1H), 7.82 (d, J = 3.1 Hz, 1H), 7.75-7.68 (m, 1H), 7.67-7.55 (m,
4H), 7.23 (dq, J = 10.4, 5.9, 5.3 Hz, 1H), 6.92- 6.83 (m, 1H), 5.26
(s, 1H), 4.18- 4.08 (m, 1H), 4.05 (d, J = 6.1 Hz, 3H), 3.97- 3.37
(m, 4H), I 3.27-3.16 (m, 2H), 3.02 (s, 3H), 2.68-2.60 (m, 4H),
2.48-2.20 (m, 5H), 1.89- 1.79 (m, 1H), 0.98 (s, 9H) ##STR00263##
164 (S)-2-(tert-butoxy)-2-(7-(4- chlorophenyl)-5-methyl-2-
(1-methyl-3-(1-((R)-1- methylpyrrolidin-3-yl)
piperidin-4-yl)-1H-indazol- 5-yl)benzo[d]thiazol-6-yl) acetic acid
686.59 (M + H)+ .sup.1H NMR (400 MHz, Methanol- d.sub.4) .delta.
8.44 (t, J = 2.2 Hz, 1H), 8.09 (ddd, J = 8.8, 7.1, 1.6 Hz, 1H),
7.84- 7.79 (m, 1H), 7.74-7.67 (m, 1H), 7.66-7.54 (m, 5H), 7.27-
7.16 (m, 1H), 6.91-6.81 (m, 1H), 5.26 (s, 1H), 4.23 (p, J = 7.9 Hz,
1H), 4.05 (d, J = 3.1 Hz, 3H), 4.00-3.33 (m, I 5H), 3.04 (s, 3H),
2.76-2.64 (m, 1H), 2.62 (d, J = 0.7 Hz, 3H), 2.53- 2.19 (m, 5H),
1.88-1.77 (m, 1H), 0.98 (s, 9H)
##STR00264## 165 (S)-2-(tert-butoxy)-2-(7-(4-
chlorophenyl)-2-(3-(1-((R)- 1-(methoxycarbonyl)
pyrrolidin-3-yl)piperidin- 4-yl)-1-methyl-1H-indazol-
5-yl)-5-methylbenzo[d] thiazol-6-yl)acetic acid 730.74 (M + H)+
.sup.1H NMR (400 MHz, Methanol- d.sub.4) .delta. 8.46 (s, 1H), 8.13
(d, J = 8.9 Hz, 1H), 7.82 (s, 1H), 7.73-7.52 (m, 5H), 5.26 (s, 1H),
4.15-3.91 (m, 6H), 3.74 (s, 9H), 2.62 (s, 3H), 2.59-2.05 (m, 7H),
0.99 (s, 9H). I ##STR00265## 166 (2S)-2-(tert-butoxy)-2-(7-
(4-chlorophenyl)-5-methyl- 2-(1-methyl-3-(3-(oxetan-
3-yl)-3,6-diazabicyclo [3.1.1]heptan-6-yl)-1H-
indazol-5-yl)benzo[d] thiazol-6-yl)acetic acid 672.42 (M + H)+
.sup.1H NMR (400 MHz, Methanol- d.sub.4) .delta. 8.24 (s, 1H), 8.05
(dd, J = 9.0, 1.6 Hz, 1H), 7.80 (s, 1H), 7.70- 7.65 (m, 1H),
7.63-7.54 (m, 4H), 5.24 (s, 1H), 4.76 (t, J = 7.7 Hz, 6.2 Hz, 2H),
4.61- 4.51 (m, 2H), 4.34-4.21 (m, 1H), 3.97 (s, 3H), 3.95-3.68 (m,
4H), 3.25-3.16 K (m, 1H), 2.61 (s, 3H), 2.15 (d, J = 10.0 Hz, 1H),
0.98 (s, 9H) ##STR00266## 167 (S)-2-(tert-butoxy)-2-(7-(4-
chlorophenyl)-2-(3-(1-(1- (methoxycarbonyl)azetidin-
3-yl)piperidin-4-yl)-1- methyl-1H-pyrazolo[4,3-b] pyridin-5-yl)-5-
methylbenzo[d]thiazol-6- yl)acetic acid 717.55 (M + H)+ .sup.1H NMR
(400 MHz, Methanol- d.sub.4) .delta. 8.41 (d, J = 8.9 Hz, 1 H),
8.13 (d, J = 8.9 Hz, 1 H), 7.88 (d, J = 0.9 Hz, 1 H), 7.73- 7.65
(m, 1 H), 7.65-7.48 (m, 3 H), 5.24 (s, 1 H), 4.43-4.26 (m, 2 H),
4.28-4.16 (m, 3 H), 4.13 (td, J = 7.4, 4.7 Hz, 1 H), 4.09 (s, 3 H),
3.72 (s, 3 H), 3.70- 3.51 (m, 2 H), 3.28-3.06 (m, 2 H), 2.62 (s, 3
H), 2.59-2.38 (m, 2 H), 2.35-2.13 L (m, 2 H), 0.98 (s, 9 H)
##STR00267## 168 (S)-2-(tert-butoxy)-2-(7-(4-
chlorophenyl)-2-(3-(1-(1- (isopropoxycarbonyl)
azetidin-3-yl)piperidin-4- yl)-1-methyl-1H- pyrazolo[4,3-b]pyridin-
5-yl)-5-methylbenzo [d]thiazol-6-yl)acetic acid 745.55 (M + H)+
.sup.1H NMR (400 MHz, Methanol- d.sub.4) .delta. 8.41 (d, J = 8.9
Hz, 1 H), 8.14 (d, J = 9.0 Hz, 1 H), 7.88 (s, 1 H), 7.69 (dd, J =
8.7, 2.1 Hz, 1 H), 7.66 5.24 (s, 1 H), 4.40- 4.25 (m, 2 H),
4.25-4.15 (m, 2 H), 4.15-4.01 (m, 5 H), 3.79- 3.54 (m, 2 H),
3.24-3.06 (m, 1 H), 2.62 (s, 3 H), 2.58-2.44 (m, 2 H), 2.35-2.14
(m, 2 H), 1.27 (d, J = 6.3 Hz, 6 H), 0.98 (s, 9 H) L ##STR00268##
169 (S)-2-(2-(3-(1-((R)-1- acetylpyrrolidin-3-yl)
piperidin-4-yl)-1-methyl- 1H-pyrazolo[4,3-b] pyridin-5-yl)-7-(4-
chlorophenyl)-5- methylbenzo[d]thiazol-6- yl)-2-(tert-butoxy)
acetic acid 715.69 (M + H)+ .sup.1H NMR (400 MHz, Methanol-
d.sub.4) .delta. 8.27 (dd, J = 8.9, 3.0 Hz, 1 H), 7.99 (dd, J =
8.9, 3.3 Hz, 1 H), 7.81 (s, 1 H), 7.73- 7.66 (m, 1 H), 7.64-7.51
(m, 3 H), 5.24 (s, 1 H), 4.18-3.89 (m, 3 H), 3.91-3.46 (m, 5 H),
3.48- 3.31 (m, 3 H), 2.62 (s, 3 H), 2.56- 2.37 (m, 3 H), 2.38-2.15
(m, 5 H), 2.16-1.98 (m, 3 H), 0.98 (s, 9 H) L ##STR00269## 170
(S)-2-(2-(3-(1-((S)-1- acetylpyrrolidin-3-yl)
piperidin-4-yl)-1-methyl- 1H-pyrazolo[4,3-b]pyridin-
5-yl)-7-(4-chlorophenyl)- 5-methylbenzo[d]thiazol-
6-yl)-2-(tert-butoxy) acetic acid 715.63 (M + H)+ .sup.1H NMR (400
MHz, Methanol- d.sub.4) .delta. 8.41 (dd, J = 9.0, 1.1 Hz, 1 H),
8.14 (d, J = 9.0 Hz, 1 H), 7.88 (s, 1 H), 7.70 (dd, J = 8.8, 2.1
Hz, 1 H), 7.65-7.54 (m, 3 H), 5.24 (s, 1 H), 4.09 (s, 3 H), 4.06-
3.90 (m, 2 H), 3.89-3.74 (m, 2 H), 3.74-3.34 (m, 5 H), 2.62 (s, 3
H), 2.58-2.45 (m, 3 H), 2.33- 2.17 (m, 3 H), 2.17-1.99 (m, 4 H),
0.98 (s, 9 H) L ##STR00270## 171 (S)-2-(tert-butoxy)-2-(7-(4-
chlorophenyl)-5-methyl-2- (1-methyl-3-(1-((R)-1-
methylpyrrolidin-3-yl) piperidin-4-yl)-1H-pyrazolo
[4,3-b]pyridin-5-yl)benzo[d] thiazol-6-yl)acetic acid 687.29 (M +
H)+ .sup.1H NMR (400 MHz, Methanol- d.sub.4) .delta. 8.42 (d, J =
8.9 Hz, 1 H), 8.15 (d, J = 9.0 Hz, 1 H), 7.89 (s, 1 H), 7.75-7.66
(m, 1 H), 7.66-7.50 (m, 3 H), 5.24 (s, 1 H), 4.27-4.12 (m, 1 H),
4.10 (s, 3 H), 3.94-3.76 (m, 2 H), 3.76- 3.58 (m, 5 H), 3.03 (s,
3H), 2.71- 2.64 (m, 1 H), 2.63 (s, 3 H), 2.60- L 2.15 (m, 7 H),
0.98 (s, 9 H) ##STR00271## 172 (S)-2-(tert-butoxy)-2-(7-(4-
chlorophenyl)-5-methyl-2- (1-methyl-3-(1-((S)-1-
methylpyrrolidin-3-yl) piperidin-4-yl)-1H-
pyrazolo[4,3-b]pyridin-5- yl)benzo[d]thiazol-6- yl)acetic acid
687.59 (M + H)+ .sup.1H NMR (400 MHz, Methanol- d.sub.4) .delta.
8.41 (d, J = 8.9 Hz, 1 H), 8.13 (d, J = 8.9 Hz, 1 H), 7.88 (s, 1
H), 7.74-7.65 (m, 1 H), 7.65-7.49 (m, 3 H), 5.25 (s, 1 H),
4.30-4.15 (m, 1 H), 4.09 (s, 3 H), 4.01-3.55 (m, 7 H), 3.53- 3.32
(m, 2 H), 3.02 (s, 3 H), 2.74- 2.63 (m, 1 H), 2.62 (s, 3 H), 2.61-
L 2.31 (m, 5 H), 0.98 (s, 9 H) ##STR00272## 173
(S)-2-(tert-butoxy)-2-(7-(4- chlorophenyl)-2-(3-(1-(2-
(dimethylamino)ethyl) piperidin-4-yl)-1-methyl-
1H-pyrazolo[4,3-b]pyridin- 5-yl)-5-methylbenzo[d]
thiazol-6-yl)acetic acid 675.29 (M + H)+ .sup.1H NMR (400 MHz,
Methanol- d.sub.4) .delta. 8.41 (d, J = 8.9 Hz, 1 H), 8.13 (d, J =
9.0 Hz, 1 H), 7.66-7.45 (m, 3 H), 5.24 (s, 1 H), 4.09 (s, 3 H),
3.76-3.46 (m, 9 H), 2.98 (s, 6 H), 2.63 (s, 3 H), 2.56-2.37 (m, 2
H), 2.43- 2.25 (m, 2 H), 0.98 (s, 9 H) L ##STR00273## 174
(S)-2-(tert-butoxy)-2-(7-(4- chlorophenyl)-5-methyl-2-
(3-(1-(oxetan-3-yl) piperidin-4-yl)-1H- pyrazolo[4,3-b]
pyridin-5-yl)benzo[d] thiazol-6-yl)acetic acid 646.67 (M + H)+
.sup.1H NMR (400 MHz, Methanol- d.sub.4) .delta. 8.40 (d, J = 8.8
Hz, 1 H), 8.08 (d, J = 8.8 Hz, 1 H), 7.87 (s, 1 H), 7.74-7.65 (m, 1
H), 7.66-7.48 (m, 3 H), 5.24 (s, 1 H), 4.86-4.73 (m, 4 H), 4.45
(dt, J = 13.4, 6.9 Hz, 1 H), 3.74-3.52 (m, 3 H), 3.23- 3.01 (m, 2
H), 2.62 (s, 3 H), 2.59- 2.41 (m, 2 H), L 2.41-2.11 (m, 2 H), 0.98
(s, 9 H) ##STR00274## 175 (S)-2-(tert-butoxy)-2-(7-(4-
chlorophenyl)-5-methyl-2- (1-methyl-3-(1-(oxetan-3-
yl)piperidin-4-yl)-1H- pyrazolo[4,3-b]pyridin-
5-yl)benzo[d]thiazol-6-yl) acetic acid 660.53 (M + H)+ .sup.1H NMR
(400 MHz, Methanol- d.sub.4) .delta. 8.37 (d, J = 8.9 Hz, 1 H),
8.10 (d, J = 8.9 Hz, 1 H), 7.86, (d, J = 0.9 Hz, 1 H), 7.69 (dt, J
= 7.4, 1.9 Hz, 1 H), 7.65- 7.48 (m, 3 H), 5.24 (s, 1 H), 4.88- 4.67
(m, 4 H), 4.45 (p, J = 6.4 Hz, 1 H), 4.06 (s, 3 H), 3.72-3.50 (m, 3
H), 3.21- L 2.98 (m, 2 H), 2.62 (d, J = 0.8 Hz, 3 H), 2.58- 2.38
(m, 2 H), 2.36-2.12 (m, 2 H), 0.98 (s, 9 H). ##STR00275## 176
(S)-2-(tert-butoxy)-2-(7-(4- chlorophenyl)-5-methyl-2-
(1-(methyl-d3)-3-(1- (oxetan-3-yl)piperidin-4-
yl)-1H-pyrazolo[4,3-b] pyridin-5-yl)benzo[d] thiazol-6-yl)acetic
acid 663.73 (M + H)+ .sup.1H NMR (400 MHz, Methanol- d.sub.4)
.delta. 8.36 (d, J = 8.9 Hz, 1 H), 8.10 (d, J = 8.9 Hz, 1 H), 7.85
(s, 1 H), 7.69 (dt, J = 7.7, 1.9 Hz, 1H), 7.66 5.24 (s, 1 H), 4.88-
4.66 (m, 4 H), Hz, 1 H), 3.76- 3.47 (m, 3 H), 3.23-3.01 (m, 2 H),
2.62 (s, 3 H), 2.56-2.38 (m, 2 H), 2.38-2.13 (m, 2 H), 0.98 (s, L
9H). ##STR00276## 177 (S)-2-(tert-butoxy)-2-(7-(4-
chlorophenyl)-2-(1-ethyl-3- (1-(oxetan-3-yl)piperidin-
4-yl)-1H-pyrazolo[4,3-b] pyridin-5-yl)-5- methylbenzo[d]thiazol-6-
yl)acetic acid 674.68 (M + H)+ .sup.1H NMR (400 MHz, Methanol-
d.sub.4) .delta. 8.35 (d, J = 8.9 Hz, 1 H), 8.12 (d, J = 8.9 Hz, 1
H), 7.85 (s, 1 H), 7.73-7.65 (m, 1 H), 7.65-7.49 (m, 3 H), 5.24 (s,
1 H), 4.88-4.77 (m, 4 H), 4.51- 4.37 (m, 4 H), 3.71-3.51 (m, 2 H),
3.21-3.03 (m, 2 H), 2.62 (s, 3 H), 2.56-2.39 (m, 2 H), 2.37- L 2.14
(m, 2 H), 1.49 (t, J = 7.2 Hz, 3 H), 0.97 (s, 9 H) ##STR00277## 178
(S)-2-(tert-butoxy)-2-(7-(4- chlorophenyl)-2-(1-
cyclopropyl-3-(1-(oxetan- 3-yl)piperidin-4-yl)-1H-
pyrazolo[4,3-b]pyridin-5- yl)-5-methylbenzo[d] thiazol-6-yl)acetic
acid 686.50 (M + H)+ .sup.1H NMR (400 MHz, Methanol- d.sub.4)
.delta. 8.37 (dt, J = 8.9, 1.7 Hz, 1 H), 8.19 (dt, J = 8.7, 1.6 Hz,
1 H), 7.86 (s, 1 H), 7.75- 7.64 (m, 1 H), 7.64-7.48 (m, 3 H), 5.24
(s, 1 H), 4.89-4.73 (m, 4 H), 4.53-4.35 (m, 1 H), 3.80- 3.43 (m, 4
H), 3.24-2.98 (m, 2 H), 2.62 (s, 3 H), 2.56-2.35 (m, 2 L H),
2.37-2.15 (m, 2 H), 1.26- 1.14 (m, 4 H), 0.98 (s, 9 H) ##STR00278##
179 (S)-2-(tert-butoxy)-2-(7-(4- chlorophenyl)-2-(1-ethyl-3-
(1-(1-(methoxycarbonyl) azetidin-3-yl)piperidin-4-
yl)-1H-pyrazolo[4,3-b] pyridin-5-yl)-5- methylbenzo[d]thiazol-6-
yl)acetic acid 731.60 (M + H)+ .sup.1H NMR (400 MHz, Methanol-
d.sub.4) .delta. 8.41 (d, J = 8.9 Hz, 1 H), 8.18 (d, J = 8.9 Hz, 1
H), 7.88 (s, 1 H), 7.75-7.65 (m, 1 H), 7.65-7.47 (m, 3 H), 5.24 (s,
1 H), 4.48 (q, J = 7.2 Hz, 2 H), 4.42- 4.27 (m, 2 H), 4.28-4.13 (m,
2 H), 4.17-4.06 (m, 1 H), 3.77- 3.66 (m, 4 H), 3.66-3.54 (m, 2 H),
3.24-3.06 (m, 2 H), 2.62 (s, 3 H), 2.61-2.41 (m, 2 H), 2.39- L 2.09
(m, 2 H), 1.50 (t, J = 7.2 Hz, 3 H), 0.98 (s, 9 H) ##STR00279## 180
(S)-2-(tert-butoxy)-2-(7-(4- chlorophenyl)-2-(1- cyclopropyl-
3-(1-(1-(methoxycarbonyl) azetidin-3-yl)piperidin-4-
yl)-1H-pyrazolo[4,3-b] pyridin-5-yl)-5- methylbenzo[d]thiazol-
6-yl)acetic acid 744.04 (M + H)+ .sup.1H NMR (400 MHz, Methanol-
d.sub.4) .delta. 8.44 (d, J = 8.8 Hz, 1 H), 8.26 (d, J = 8.9 Hz, 1
H), 7.89 (s, 1 H), 7.75-7.65 (m, 1 H), 7.65-7.52 (m, 3 H), 5.24 (s,
1 H), 4.46-4.28 (m, 2 H), 4.28- 4.08 (m, 2 H), 4.17-4.03 (m, 2 H),
1.29-1.11 (m, 5 H), 3.65- 3.55 (m, 1 H), 3.25-3.07 (m, 2 H), 2.63
(s, 3 H), 2.57-2.41 (m, 2 H), 2.33-2.14 (m, 2 H), 1.29- 1.11 (m, 4
H), L 0.98 (s, 9 H) ##STR00280## 181 (S)-2-(2-(3-(1-(1-
acetylazetidin-3-yl) piperidin-4-yl)-1-ethyl- 1H-pyrazolo
[4,3-b]pyridin-5-yl)-7- (4-chlorophenyl)-5- methylbenzo[d]thiazol-
6-yl)-2-(tert-butoxy) acetic acid 715.57 (M + H)+ .sup.1H NMR (400
MHz, Methanol- d.sub.4) .delta. 8.40 (dt, J = 8.9, 1.5 Hz, 1 H),
8.17 (d, J = 9.1 Hz, 1 H), 7.88 (s, 1 H), 7.76-7.66 (m, 1 H), 7.66-
7.43 (m, 3 H), 5.24 (s, 1 H), 4.63- 4.52 (m, 1 H), 4.47 (q, J = 7.3
Hz, 2 H), 4.38- 4.26 (m, 1 H), 4.24-4.07 (m, 3 H), 3.82-3.49 (m, 3
H), 3.28- 3.05 (m, 2 H), 2.62 (s, 3 H), 2.61- 2.44 (m, 2 H), L
2.38-2.13 (m, 2 H), 1.94 (s, 3 H), 1.50 (t, J = 7.2 Hz, 3 H), 0.98
(s, 9 H) ##STR00281## 182 (S)-2-(2-(3-(1-(1- acetylazetidin-3-yl)
piperidin-4-yl)-1- cyclopropyl-1H-pyrazolo [4,3-b]pyridin-5-yl)-
7-(4-chlorophenyl)-5- methylbenzo[d]thiazol-6- yl)-2-(tert-butoxy)
acetic acid 727.59 (M + H)+ .sup.1H NMR (400 MHz, Methanol-
d.sub.4) .delta. 8.44 (d, J = 8.9 Hz, 1 H), 8.25 (d, J = 8.8 Hz, 1
H), 7.88 (s, 1 H), 7.69 (d, J = 8.1 Hz, 1 H), 7.65- 7.48 (m, 3 H),
5.23 (s, 1 H), 4.65- 4.51 (m, 1 H), 4.51-4.34 (m, 1 H), 4.38-4.23
(m, 1 H), 4.24- 4.07 (m, 3 H), 3.80-3.67 (m, 3 H), 3.26-3.07 (m, 2
H), 2.62 (s, 3 H), 2.59-2.37 (m, 2 H), 2.38- 2.11 (m, 2 H), L 1.94
(s, 3 H), 1.25- 1.17 (m, 4 H), 0.97 (s, 9 H) ##STR00282## 183
(S)-2-(2-(3-(1-(1- acetylazetidin-3-yl) piperidin-4-yl)-1-
(difluoromethyl)-1H- pyrazolo[4,3-b]pyridin-5-
yl)-7-(4-chlorophenyl)-5- methylbenzo[d]thiazol-6-
yl)-2-(tert-butoxy)acetic acid 737.52 (M + H)+ .sup.1H NMR (400
MHz, Methanol- d.sub.4) .delta. 8.57 (dd, J = 8.9, 1.1 Hz, 1 H),
8.37 (d, J = 8.8 Hz, 1 H), 7.98- 7.64 (m, 3 H), 7.64-7.53 (m, 3 H),
5.24 (s, 1 H), 4.63-4.50 (m, 1 H), 4.50-4.38 (m, 1 H), 4.37- 4.23
(m, 1 H), 4.24-4.06 (m, 2 H), 3.84-3.56 (m, 3 H), 3.27- 3.06 (m, 2
H), 2.62 (s, 3 H), 2.59- 2.41 (m, 2 H), 2.39-2.11 (m, 2 H), 1.93
(s, 3 H), L 0.98 (s, 9 H) ##STR00283## 184
(S)-2-(tert-butoxy)-2-(7-(4- chlorophenyl)-5-methyl-2-
(1-methyl-3-(1-(1- methylazetidin-3-yl) piperidin-4-yl)-1H-
pyrazolo[4,3-b]pyridin- 5-yl)benzo[d]thiazol- 6-yl)acetic acid
673.54 (M + H)+ .sup.1H NMR (400 MHz, Methanol- d.sub.4) .delta.
8.40 (d, J = 8.9 Hz, 1 H), 8.12 (d, J = 8.9 Hz, 1 H), 7.88 (s, 1
H), 7.70 (dd, J = 9.3, 2.0 Hz, 1 H), 7.65- 7.53 (m, 3 H), 5.25 (s,
1 H), 4.48- 4.27 (m, 5 H), 4.09 (s, 3 H), 4.02- 3.84 (m, 1 H),
3.58-3.43 (m, 1 H), 3.02 (s, 3 H), 2.85-2.66 (m, 2 H), 2.62 (s, 3
H), 2.46-2.29 (m, 2 L H), 2.33-2.16 (m, 3 H), 0.98 (s, 9 H)
##STR00284## 185 (S)-2-(2-(3-(1-(1- acetylazetidin-3-yl)
piperidin-4-yl)-1-methyl- 1H-pyrazolo[4,3-b] pyridin-5-yl)-7-(4-
chlorophenyl)-5- methylbenzo[d]thiazol- 6-yl)-2-(tert-butoxy)acetic
acid 701.50 (M + H)+ .sup.1H NMR (400 MHz, Methanol- d.sub.4)
.delta. 8.42 (d, J = 8.9 Hz, 1 H), 8.15 (d, J = 8.9 Hz, 1 H), 7.88
(s, 1 H), 7.77-7.66 (m, 1 H), 7.66-7.49 (m, 3 H), 5.24 (s, 1 H),
4.65-4.50 (m, 1 H), 4.51- 4.38 (m, 1 H), 4.40-4.20 (m, 2 H),
4.22-4.10 (m, 2 H), 4.10 (s, 3 H), 3.84-3.52 (m, 2 H), 3.30- 3.08
(m, 2 H), 2.62 (s, 3 H), 2.61- 2.42 (m, 2 H), L 2.34-2.16 (m, 2 H),
1.94 (s, 3 H), 0.98 (s, 9 H) ##STR00285## 186
(S)-2-(tert-butoxy)-2-(7-(4- chlorophenyl)-2-(3-(1- ((1r,3r)-3-
hydroxycyclobutyl) piperidin-4-yl)-1-methyl- 1H-pyrazolo[4,3-b]
pyridin-5-yl)-5- methylbenzo[d]thiazol-6- yl)acetic acid 674.50 (M
+ H)+ .sup.1H NMR (400 MHz, Methanol- d.sub.4) .delta. 8.42 (d, J =
8.9 Hz, 1 H), 8.22- 8.07 (m, 1 H), 7.88 (s, 1 H), 7.72- 7.66 (m, 1
H), 7.66-7.50 (m, 3 H), 5.25 (s, 1 H), 4.49-4.33 (m, 1 H), 4.09 (s,
3 H), 4.01-3.86 (m, 2 H), 3.72-3.50 (m, 4 H), 3.14- 3.01 (m, 2 H),
2.63 (s, 3 H), 2.60- 2.43 (m, 3 H), 2.43-2.12 (m, 3 H), 0.98 (s, 9
H) L ##STR00286## 187 (S)-2-(tert-butoxy)-2-(7-(4-
chlorophenyl)-2-(3-(1- cyclopropylpiperidin-4-yl)-
1-methyl-1H-pyrazolo [4,3-b]pyridin-5-yl)-5-
methylbenzo[d]thiazol-6- yl)acetic acid 644.45 (M + H)+ .sup.1H NMR
(400 MHz, Methanol- d.sub.4) .delta. 8.39 (d, J = 8.9 Hz, 1 H),
8.12 (d, J =
9.0 Hz, 1 H), 7.87 (s, 1 H), 7.70 (d, J = 8.3 Hz, 1 H), 7.65- 5.24
(s, 1 H), 4.07 (s, 3 H), 3.87- 3.69 (m, 2 H), H), 3.53- 3.36 (m,
1H), 2.94- 2.73 (m, 1 H), 2.62 (s, 3 H), 2.55- 2.39 (m, 2 H), L
2.35-2.05 (m, 2 H), 1.07-0.98 (m, 4 H), 0.98 (s, 9 H) ##STR00287##
188 (S)-2-(tert-butoxy)-2-(7-(4- chlorophenyl)-2-(3-(1- ((1s,3s)-3-
hydroxycyclobutyl) piperidin-4-yl)-1-methyl-
1H-pyrazolo[4,3-b]pyridin- 5-yl)-5-methylbenzo[d]
thiazol-6-yl)acetic acid 674.63 (M + H)+ .sup.1H NMR (400 MHz,
Methanol- d.sub.4) .delta. 8.39 (d, J = (d, J = 8.9 Hz, 1 H), 7.87
(d, J = 0.9 Hz, 1 H), 7.69 (dt, J = 7.5, 1.9 Hz, 1 H), 7.65- 7.50
(m, 3 H), 5.24 (s, 1H) 4.15- 4.01 (m, 4 H), 3.69-3.50 (m, 2 H),
3.29-3.12 (m, 2 H), 3.06 (ddd, J = 17.0, 12.6, 2.9 Hz, 2 H),
2.84-2.67 (m, 2 H), 2.62 (s, 3 H), 2.47 (d, J = 14.4 L Hz, 2 H),
2.40- 1.98 (m, 4 H), 0.98 (s, 9 H) ##STR00288## 189
(S)-2-(2-(3-(1-(1- acetylazetidin-3-yl) piperidin-4-yl)-2-
(difluoromethyl)-2H- pyrazolo[4,3-b]pyridin-
5-yl)-7-(4-chlorophenyl)-5- methylbenzo[d]thiazol-6-
yl)-2-(tert-butoxy) acetic acid 737.82 (M + H)+ .sup.1H NMR (400
MHz, Methanol- d.sub.4) .delta. 8.46 (d, J = 9.4 Hz, 1 H), 8.27 (d,
J = 9.3 Hz, 1 H), 8.15-7.77 (m, 2 H), 7.77- 7.66 (m, 1 H), 7.61 (d,
J = 11.3 Hz, 3 H), 5.21 (s, 1 H), 4.67-4.50 (m, 1 H), 4.50- 4.37
(m, 1 H), 4.38-4.24 (m, 1 H), 4.24-4.09 (m, 2 H), 3.98- 3.83 (m, 1
H), 3.78 (dd, J = 29.3, 12.6 Hz, 2 H), 3.28-3.09 (m, 2 L H),
3.06-2.65 (m, 2 H), 2.64 (s, 3 H), 2.43-2.25 (m, 2 H), 2.04- 1.91
(m, 3 H), 0.98 (d, J = 1.4 Hz, 9 H) ##STR00289## 190
(S)-2-(tert-butoxy)-2-(7-(4- chlorophenyl)-2-(2-
(difluoromethyl)-3-(1-(1- (methoxycarbonyl)azetidin-
3-yl)piperidin-4-yl)-2H- pyrazolo[4,3-b]pyridin-5-
yl)-5-methylbenzo[d] thiazol-6-yl)acetic acid 753.57 (M + H)+
.sup.1H NMR (400 MHz, Methanol- d.sub.4) .delta. 8.46 (d, J = 9.2
Hz, 1 H), 8.26 (d, J = 9.3 Hz, 1 H), 8.16-7.77 (m, 2 H), 7.77- 7.67
(m, 1 H), 7.67-7.49 (m, 3 H), 5.21 (s, 1 H), 4.43-4.27 (m, 2 H),
4.28-4.07 (m, 2 H), 3.98- 3.79 (m, 2 H), 3.83-3.68 (m, 5 H),
3.25-3.08 (m, 2 H), 3.00- 2.83 (m, 1 H), 2.83-2.64 (m, 1 H), 2.64
(s, 3 H), 2.42-2.24 (m, 2 L H), 0.98 (s, 9 H) ##STR00290## 191
(S)-2-(tert-butoxy)-2-(7-(4- chlorophenyl)-2-(3-(1-(1-
(methoxycarbonyl)azetidin- 3-yl)piperidin-4-yl)-1-
(methyl-d3)-1H-pyrazolo [4,3-b]pyridin-5-yl)-5-
methylbenzo[d]thiazol-6- yl)acetic acid 720.56 (M + H)+ 1H NMR (400
MHz, Chloroform-d) .delta. 8.62 (d, J = 8.9 Hz, 1H), 7.97 (s, 1H),
7.93 (d, J = 8.9 Hz, 1H), 7.62- 7.43 (m, 4H), 5.18 (s, 1H), 4.33-
4.15 (m, 5H), 3.97-3.93 (m, 1H), 3.77-3.63 (m, 3H), 3.44 (t, J =
5.5 Hz, 1H), 2.86-2.75 (m, 3H), 2.62 (s, 3H), 2.28-2.18 (m, 1H),
2.05 (s, 3H), 0.98 (s, 9H). L ##STR00291## 192 (S)-2-(2-(3-(1-(1-
acetylazetidin-3-yl) piperidin-4-yl)-1-(methyl-
d3)-1H-pyrazolo[4,3-b] pyridin-5-yl)-7-(4- chlorophenyl)-5-
methylbenzo[d]thiazol- 6-yl)-2-(tert-butoxy)acetic acid 704.60 (M +
H)+ .sup.1H NMR (400 MHz, Methanol- d.sub.4) .delta. 8.43 (d, J =
8.4 Hz, 1H), 8.15 (d, J = 8.8 Hz, 1H), 7.89 (s, 1H), 7.71-7.66 (m,
1H), 7.65-7.53 (m, 3H), 5.24 (s, 1H), 4.62-4.23 (m, 3H), 4.21- 4.07
(m, 3H), 3.80-3.55 (m, 3H), 2.63 (s, 3H), 2.58-2.13 (m, 5H), 1.94
(s, 3H), 0.98 (s, 9H). L ##STR00292## 193
(S)-2-(tert-butoxy)-2-(7-(4- chlorophenyl)-2-(3-(1-((S)-
1-(methoxycarbonyl) pyrrolidin-3-yl)piperidin-4-
yl)-1-methyl-1H-pyrazolo [4,3-b]pyridin-5-yl)-5-
methylbenzo[d]thiazol-6- yl)acetic acid 731.58 (M + H)+ .sup.1H NMR
(400 MHz, Methanol- d.sub.4) .delta. 8.19 (d, J = 8.9 Hz, 1H), 7.91
(d, J = 8.9 Hz, 1H), 7.77 (s, 1H), 7.73-7.67 (m, 1H), 7.63-7.51 (m,
3H), 5.24 (s, 1H), 4.03-3.83 (m, 5H), 3.81- 3.39 (m, 10H),
3.39-3.18 (m, 1H), 2.61 (s, 3H), 2.56-2.06 (m, 6H), 0.97 (s, 9H). L
##STR00293## 194 (S)-2-(tert-butoxy)-2-(7-(4- chlorophenyl)-2-(1-
(difluoromethyl)-3-(1- (oxetan-3-yl)piperidin-4-
yl)-1H-pyrazolo[4,3-b] pyridin-5-yl)-5- methylbenzo[d]thiazol-6-
yl)acetic acid 696.43 (M + H)+ .sup.1H NMR (400 MHz, Methanol-
d.sub.4) .delta. 8.58 (d, J = 8.9, 0.9 Hz, 1H), 8.38 (d, J = 8.9
Hz, 1H), 7.99- 7.82 (m, 2H), 7.73-7.55 (m, 4H), 5.25 (s, 1H),
4.85-4.73 (m, 3H), 4.52-4.38 (m, 1H), 3.80- 3.58 (m, 4H), 3.24-3.08
(m, 3H), 2.67-2.51 (m, 4H), 2.35- 2.15 (m, 2H), 0.98 (s, 9H). L
##STR00294## 195 (S)-2-(tert-butoxy)-2-(7-(4- chlorophenyl)-2-(2-
(difluoromethyl)-3-(1- (oxetan-3-yl)piperidin-4-
yl)-2H-pyrazolo[4,3-b] pyridin-5-yl)-5- methylbenzo[d]thiazol-6-
yl)acetic acid 696.43 (M + H)+ .sup.1H NMR (400 MHz, Methanol-
d.sub.4) .delta. 8.46 (d, J = 9.3 Hz, 1H), 8.27 (d, J = 9.4 Hz,
1H), 8.14-7.80 (m, 2H), 7.74- 7.57 (m, 4H), 5.23 (s, 1H), 4.84-
4.75 (m, 1H), 4.53-4.35 (m, 1H), 3.96-3.81 (m, 2H), 3.69 (dd, J =
27.4, 12.4 Hz, 3H), 3.22-2.67 (m, 4H), 2.64 (s, 3H), 2.41-2.20 L
(m, 3H), 0.99 (d, J = 0.9 Hz, 9H). ##STR00295## 196
(S)-2-(tert-butoxy)-2-(7-(4- chlorophenyl)-5-methyl-2-
(1-methyl-3-(4- methylpiperazin-1-yl)-1H- pyrazolo[4,3-b]pyridin-5-
yl)benzo[d]thiazol-6-yl) acetic acid 619.3 (M + H)+ 1H NMR (400
MHz, Methanol- d4) .delta. 8.34 (d, J = 9.0 Hz, 1H), 7.98 (d, J =
9.0 Hz, 1H), 7.85 (s, 1H), 7.72-7.65 (m, 1H), 7.62-7.52 (m, 3H),
5.22 (s, 1H), 4.74 (s, 2H), 3.92 (s, 3H), 3.60 (s, 2H), 3.33 (s,
2H), 2.94 (s, 3H), 2.61 (s, 3H), 0.96 M (s, 9H). ##STR00296## 197
(S)-2-(tert-butoxy)-2-(7-(4- chlorophenyl)-2-(3-(4- ((1s,3s)-3-
hydroxycyclobutyl) piperazin-1-yl)-1-methyl-
1H-pyrazolo[4,3-b]pyridin- 5-yl)-5-methylbenzo
[d]thiazol-6-yl)acetic acid 676.37 (M + H)+ .sup.1H NMR (400 MHz,
Methanol- d.sub.4) .delta. 8.36 (d, J = 9.0 Hz, 1 H), 8.00 (d, J =
9.0 Hz, 1 H), 7.86 (s, 1 H), 7.68 (dd, J = 8.6, 2.2 Hz, 1 H), 7.64
5.22 (s, 1 H), 4.84- 4.66 (m, 3 H), 4.14-3.99 (m, 1 3.68-3.52 (m, 2
H), 3.41-3.33 (m, 2 H), 3.23- 3.02 (m, 2 H), 2.86-2.67 (m, 2 H),
2.61 (s, 3 H), 2.16-1.99 (m, 2 H), 0.96 (s, 9 H) M ##STR00297## 198
(S)-2-(tert-butoxy)-2-(7-(4- chlorophenyl)-2-(3-(4-(1,1-
dioxidothietan-3-yl) piperazin-1-yl)-1-methyl- 1H-pyrazolo
[4,3-b]pyridin-5-yl)-5- methylbenzo[d]thiazol-6- yl)acetic acid
709.10 (M + H)+ .sup.1H NMR (400 MHz, Methanol- d.sub.4) .delta.
8.33 (d, J = 9.0 Hz, 1 H), 7.95 (d, J = 9.0 Hz, 1 H), 7.85 (s, 1
H), 7.77-7.63 (m, 1 H), 7.64-7.44 (m, 3 H), 5.22 (s, 1 H),
4.43-4.12 (m, 4 H), 3.91 (s, 3 H), 3.92-3.83 (m, 4 H), 3.62- 3.45
(m, 1 H), 2.95-2.81 (m, 4 H), 2.61 (s, 3 H), 0.96 (s, 9 H) M
##STR00298## 199 (S)-2-(tert-butoxy)-2-(7-(4-
chlorophenyl)-2-(7-(1-(1- (methoxycarbonyl)
azetidin-3-yl)piperidin- 4-yl)-5-methyl- 5H-pyrrolo[2,3-b]pyrazin-
2-yl)-5-methylbenzo[d] thiazol-6-yl)acetic acid 717.57 (M + H)+
.sup.1H NMR (400 MHz, Methanol- d.sub.4) .delta. 9.21 (s, 1 H),
7.86 (s, 1 H), 7.74-7.63 (m, 2 H), 7.64-7.53 (m, 3 H), 5.24 (s, 1
H), 4.40-4.25 (m, 3 H), 4.26- 4.17 (m, 2 H), 4.18-4.07 (m, 1 H),
3.87 (s, 3 H), 3.73 (s, 3 H), 3.70- 3.58 (m, 2 H), 3.21-3.00 (m, 2
H), 2.63 (s, 3 H), 2.54-2.33 (m, 2 H), 2.22-2.00 (m, 2 H), 0.98 (s,
9 H) N ##STR00299## 200 (S)-2-(2-(7-(1-(1- acetylazetidin-3-yl)
piperidin-4-yl)-5-methyl- 5H-pyrrolo [2,3-b]pyrazin-2-yl)-
7-(4-chlorophenyl)-5- methylbenzo[d]thiazol-6-
yl)-2-(tert-butoxy)acetic acid 701.46 (M + H)+ .sup.1H NMR (400
MHz, Methanol- d.sub.4) .delta. 9.24 (s, 1 H), 7.88 (s, 1 H), 7.69
(d, J = 8.9 Hz, 2 H), 7.60 (t, J = 8.0 Hz, 3 H), 5.24 (s, 1 H),
4.64- 4.50 (m, 1 H), 4.50-4.38 (m, 1 H), 4.38-4.24 (m, 1 H), 4.22-
4.07 (m, 2 H), 3.90 (s, 3 H), 3.77- 3.59 (m, 2 H), 3.43-3.34 (m, 1
H), 3.26-3.04 (m, 2 H), 2.63 (s, 3 H), 2.55-2.37 (m, 2 H), 2.24-
2.00 (m, 2 H), N 1.94 (s, 3 H), 0.98 (s, 9 H) ##STR00300## 201
(S)-2-(tert-butoxy)-2-(7-(4- chlorophenyl)-2-(3-(1-
((R)-1-(methoxycarbonyl) pyrrolidin-3-yl)piperidin-
4-yl)-1-methyl-1H- pyrrolo[2,3-b]pyridin-5- yl)-5-methylbenzo
[d]thiazol-6-yl)acetic acid 703.3 (M + H)+ 1H NMR (400 MHz,
Methanol- d4) .delta. 8.75 (d, J = 1.7 Hz, 1H), 8.43- 8.36 (m, 1H),
7.75-7.65 (m, 2H), 7.55 (d, J = 9.5 Hz, 3H), 7.18 (s, 1H), 5.25 (s,
1H), 3.95 (s, 2H), 3.72 (s, 3H), 3.69 (s, 3H), 3.59 (d, J = 10.5
Hz, 3H), 3.44 (q, J = 9.7 Hz, 1H), 3.29- 3.02 (m, 3H), 2.57 (s,
3H), 2.48 (s, 1H), 2.21 (dd, J = 26.8, 14.4 Hz, 3H), 2.00 (d, J =
15.2 Hz, 2H), 0.95 (s, 9H). O ##STR00301## 202
(S)-2-(tert-butoxy)-2-(7-(4- chlorophenyl)-2-(3-(1-((S)-
1-(methoxycarbonyl) pyrrolidin-3-yl)piperidin- 4-yl)-1-methyl-1H-
pyrrolo[2,3-b]pyridin-5-yl)- 5-methylbenzo[d]thiazol- 6-yl)acetic
acid 703.3 (M + H)+ 1H NMR (400 MHz, Methanol- d4) .delta. 8.87 (d,
J = 1.8 Hz, 1H), 8.58- 8.51 (m, 1H), 7.79 (s, 1H), 7.72- 7.66 (m,
1H), 7.59 (d, J = 1.6 Hz, 1H), 7.57 (s, 2H), 7.30 (s, 1H), 5.26 (s,
1H), 3.97 (s, 2H), 3.84- 3.52 (m, 10H), 3.52-3.40 (m, 1H),
3.28-3.11 (m, 2H), 2.60 (s, 3H), 2.51 (s, 1H), 2.40-1.92 (m, 5H),
0.97 (s, 9H). O ##STR00302## 203 (S)-2-(tert-butoxy)-2-(7-(4-
chlorophenyl)-2-(3-(1-(1- (methoxycarbonyl)azetidin-
3-yl)piperidin-4-yl)-1- methyl-1H-pyrrolo[2,3-b] pyridin-5-yl)-5-
methylbenzo[d]thiazol-6- yl)acetic acid 716.3 (M + H)+ 1H NMR (400
MHz, Methanol- d4) .delta. 8.92 (d, J = 1.9 Hz, 1H), 8.60 (d, J =
2.0 Hz, 1H), 7.82 (s, 1H), 7.73-7.65 (m, 1H), 7.59 (d, J = 6.5 Hz,
3H), 7.35 (s, 1H), 5.25 (s, 1H), 4.45-4.07 (m, 6H), 3.85 (s, 3H),
3.72 (s, 3H), 3.67 (d, J = 6.8 Hz, 2H), 3.27- 3.03 (m, 3H), 2.61
(s, 3H), 2.35 (d, J = 15.0 Hz, 2H), 2.16-1.97 (m, 2H), 0.98 (s,
9H). O ##STR00303## 204 (S)-2-(2-(3-(1-(1- acetylazetidin-3-yl)
piperidin-4-yl)-1-methyl- 1H-pyrrolo[2,3-b]pyridin-5-
yl)-7-(4-chlorophenyl)-5- methylbenzo[d]thiazol-6-
yl)-2-(tert-butoxy)acetic acid 700.2 (M + H)+ 1H NMR (400 MHz,
Methanol- d4) .delta. 8.92 (s, 1H), 8.61 (s, 1H), 7.82 (s, 1H),
7.72 (m, 1H), 7.59 (m, 3H), 7.35 (s, 1H), 5.26 (s, 1H), 4.59 (t, J
= 8.9 Hz, 1H), 4.48 (dd, J = 10.5, 4.5 Hz, 1H), 4.34 (dd, J = 11.3,
7.8 Hz, 1H), 4.19 (m, 2H), 3.85 (s, 3H), 3.69 (m, 2H), 3.30 (s,
3H), 3.24 (m, 1H), 3.18 (m, 2H), 2.61 (s, 3H), 2.36 (d, J = 14.8 O
Hz, 2H), 2.09 (t, J = 13.1 Hz, 2H), 1.94 (s, 3H), 0.98 (s, 9H).
##STR00304## 205 (S)-2-(tert-butoxy)-2-(7-(4-
chlorophenyl)-5-methyl-2- (1-methyl-3-((R)-4-
oxohexahydropyrazino[2,1- c][1,4]oxazin-8(1H)-yl)-
1H-indazol-5-yl)benzo[d] thiazol-6-yl)acetic acid 674.25 (M + H)+
.sup.1H NMR (400 MHz, Methanol- d.sub.4) .delta. 8.46 (s, 1H), 7.99
(dd, J = 8.9, 1.6 Hz, 1H), 7.81 (s, 1H), 7.72- 7.67 (m, 1H),
7.63-7.46 (m, 4H), 5.25 (s, 1H), 4.64 (d, J = 13.1 Hz, 1H), 4.19-
4.12 (m, 3H), 4.03-3.87 (m, 6H), 3.71 (dd, J = 12.0, 7.3 Hz, 1H), D
3.18-3.06 (m, 1H), 3.05-2.83 (m, 2H), 2.61 (d, J = 0.8 Hz, 3H),
0.98 (s, 9H). ##STR00305## 206 (S)-2-(tert-butoxy)-2-(7-(4-
chlorophenyl)-2-(3-(4- ((1s,3s)-3- hydroxycyclobutyl)
piperazin-1-yl)-1-methyl- 1H-indazol-5-yl)-5-
methylbenzo[d]thiazol-6- yl)acetic acid 674.95 (M + H)+ .sup.1H NMR
(400 MHz, Methanol- d.sub.4) .delta. 8.42 (s, 1H), 8.06 (dd, J =
8.9, 1.6 Hz, 1H), 7.81 (s, 1H), 7.71- 7.67 (m, 1H), 7.63-7.53 (m,
4H), 5.25 (s, 1H), 4.23-4.03 (m, 3H), 3.94 (s, 3H), 3.75-3.50 (m,
4H), 3.31 (s, 5H), 2.87-2.75 (m, 2H), 2.61 (s, 3H), 2.19-2.06 (m,
2H), 0.98 (s, 9H). D ##STR00306## 207 (S)-2-(tert-butoxy)-2-(7-(4-
chlorophenyl)-5-methyl-2- (1-methyl-3-(4-(3- methyloxetan-3-yl)
piperazin-1-yl)-1H- indazol-5-yl)benzo[d] thiazol-6-yl)acetic acid
674.32 (M + H)+ .sup.1H NMR (400 MHz, Methanol- d.sub.4) .delta.
8.42 (s, 1H), 8.07 (dd, J = 8.9, 1.6 Hz, 1H), 7.80 (s, 1H), 7.71-
7.66 (m, 1H), 7.62-7.53 (m, 4H), 5.25 (s, 1H), 4.93 (d, J = 7.9 Hz,
2H), 4.57 (d, J = 7.9 Hz, 2H), 3.95 (s, 3H), 3.90- 3.56 (m, 4H),
3.52-3.45 (m, 4H), 2.61 (s, 3H), D 1.81 (s, 3H), 0.98 (s, 9H).
##STR00307## 208 (S)-2-(tert-butoxy)-2-(7-(4-
chlorophenyl)-2-(3-(1- ((R)-1-(methoxycarbonyl)
pyrrolidin-3-yl)piperidin-4- yl)-1-methyl-1H-pyrazolo
[4,3-b]pyridin-5-yl)-5- methylbenzo[d]thiazol-6- yl)acetic acid
731.58 (M + H)+ .sup.1H NMR (400 MHz, Methanol- d.sub.4) .delta.
8.38 (d, J = 8.9 Hz, 1H), 8.11 (d, J = 8.9 Hz, 1H), 7.86 (s, 1H),
7.72-7.66 (m, 1H), 7.64-7.54 (m, 3H), 5.24 (s, 1H), 4.07 (s, 3H),
4.02-3.91 (m, 2H), 3.82-3.34 (m, 11H), 2.62 (s, 3H), 2.57-1.99 (m,
6H), 0.98 (s, 9H). L ##STR00308##
Example 125
Compound Assays
Antiviral Assay in MT4 Cells
[0794] For the antiviral assay, 0.4 .mu.L of 189X test
concentration of 3-fold serially diluted compound in DMSO was added
to 40 .mu.L of cell growth medium (RPMI 1640, 10% FBS, 1%
Penicillin-Streptomycin, 1% L-Glutamine, 1% HEPES) in each well of
384-well plate (10 concentrations) in quadruplicate.
[0795] 1 mL Aliquots of MT4 cells were pre-infected for 3 hours at
37.degree. C. with 25 .mu.L of cell growth medium (mock-infected)
or a fresh 1:250 dilution of an HIV-IIIb (wildtype, IN.sub.T174I BT
, or IN T174I DE) concentrated ABI stock (0.004 m.o.i.). IN T174I
BT virus was derived from viral breakthrough (BT) assay as
described in Mulato, A.; Hansen, D.; Thielen, A.; Porter, D.;
Stepan, G.; White, K.; Daeumer, M.; Cihlar, T.; Yant, S. R. AIDS
Research and Human Retrovirues, July 2016, ahead of print.
doi:10.1089/aid.2016.0071. IN T1741 DE virus was derived from
serial passaging with dose escalation (DE) of test compound.
Infected and uninfected cells were diluted in cell growth media and
35 .mu.L (2000 cells) was added to each well of the assay
plates.
[0796] Assay plates were then maintained in a humidified, 5%
CO.sub.2 incubator at 37.degree. C. After 5 days of incubation, 25
.mu.l of 2.times. concentrated CellTiter-Glo.TM. Reagent (catalog
#G7573, Promega Biosciences, Inc., Madison, Wis.) was added to each
well of the assay plate. Cell lysis was carried out by incubating
at room temperature for 10 minutes and then chemiluminescence was
read using an Envision plate reader (PerkinElmer). EC.sub.50 values
were calculated as the compound concentration that caused a 50%
decrease in luminescence signal, a measure of HIV-1
replication.
TABLE-US-00002 T1741 T1741 Hum MS WT BT DE stability Compound EC50
EC50 EC50 t1/2 Structure # (nM) (nM) (nM) (min) ##STR00309## 181 1
12 34 ##STR00310## 182 2 27 59 ##STR00311## 179 3 28 108
##STR00312## 192 1 28 55 ##STR00313## 183 2 29 69 ##STR00314## 185
1 35 66 36 ##STR00315## 169 2 36 86 30 ##STR00316## 47 7 38 67
##STR00317## 173 2 45 89 72 ##STR00318## 177 3 47 185 ##STR00319##
22 23 48 108 ##STR00320## 208 2 54 206 ##STR00321## 172 5 54 118 56
##STR00322## 191 2 55 108 ##STR00323## 167 3 57 138 395
##STR00324## 170 2 57 112 32 ##STR00325## 180 4 64 212 ##STR00326##
48 8 70 165 ##STR00327## 50 4 74 276 ##STR00328## 49 4 79 286
##STR00329## 149 11 80 98 ##STR00330## 12 10 81 138 395
##STR00331## 35 4 84 238 ##STR00332## 176 3 85 214 ##STR00333## 11
8 85 166 395 ##STR00334## 193 3 87 265 ##STR00335## 200 1 90 241
##STR00336## 147 11 91 167 ##STR00337## 201 7 92 530 ##STR00338##
171 5 98 239 ##STR00339## 184 4 103 218 46 ##STR00340## 16 2 104
603 ##STR00341## 5 3 106 169 ##STR00342## 14 5 109 304 ##STR00343##
30 12 111 187 395 ##STR00344## 7 14 114 138 ##STR00345## 165 5 118
182 ##STR00346## 178 4 121 317 ##STR00347## 175 3 122 252 357
##STR00348## 130 12 122 232 395 ##STR00349## 21 4 124 239 198
##STR00350## 194 4 126 300 ##STR00351## 156 11 126 197 297
##STR00352## 26 4 129 270 281 ##STR00353## 31 12 138 236 395
##STR00354## 148 12 143 199 ##STR00355## 1 5 143 315 350
##STR00356## 199 4 149 770 ##STR00357## 162 5 149 272 ##STR00358##
27 4 154 245 250 ##STR00359## 202 7 157 680 ##STR00360## 153 11 159
217 ##STR00361## 45 17 174 287 ##STR00362## 152 23 175 210
##STR00363## 164 15 184 183 ##STR00364## 120 3 185 217 ##STR00365##
188 11 196 391 152 ##STR00366## 110 2 198 559 ##STR00367## 154 13
201 321 348 ##STR00368## 163 20 204 324 127 ##STR00369## 109 3 205
614 ##STR00370## 150 4 214 182 ##STR00371## 203 11 215 702
##STR00372## 174 11 219 587 ##STR00373## 37 22 223 405 ##STR00374##
168 11 230 456 395 ##STR00375## 9 9 237 511 250 ##STR00376## 151 16
237 231 ##STR00377## 17 8 238 786 282 ##STR00378## 204 15 255 636
##STR00379## 40 10 257 518 ##STR00380## 103 32 267 367 148
##STR00381## 10 10 275 303 215 ##STR00382## 6 4 283 577 395
##STR00383## 20 7 287 542 ##STR00384## 98 4 290 516 190
##STR00385## 128 4 292 511 242 ##STR00386## 38 8 293 349
##STR00387## 118 4 298 737 ##STR00388## 119 8 310 332 ##STR00389##
43 26 313 409 ##STR00390## 161 18 316 600 ##STR00391## 62 108 331
514 ##STR00392## 187 4 339 844 ##STR00393## 206 21 340 539
##STR00394## 74 10 349 587 199 ##STR00395## 46 17 352 716
##STR00396## 186 29 367 784 ##STR00397## 55 36 372 1070 395
##STR00398## 138 7 373 678 395 ##STR00399## 160 15 375 756
##STR00400## 207 4 380 693 395 ##STR00401## 135 10 399 1059 165
##STR00402## 125 8 400 715 263 ##STR00403## 25 10 404 806 255
##STR00404## 75 16 423 496 ##STR00405## 159 11 430 583 ##STR00406##
133 3 434 439 349 ##STR00407## 205 7 457 736 ##STR00408## 60 31 477
692 ##STR00409## 99 6 485 759 260 ##STR00410## 104 11 491 904 395
##STR00411## 129 5 509 696 ##STR00412## 76 16 510 906 ##STR00413##
126 8 551 540 395 ##STR00414## 72 7 553 1034 395 ##STR00415## 70 7
587 942 352 ##STR00416## 33 5 587 1016 ##STR00417## 32 11 591 1601
90 ##STR00418## 44 30 600 776 ##STR00419## 157 11 620 789
##STR00420## 108 6 630 1229 395 ##STR00421## 29 52 646 823
##STR00422## 39 13 651 1149 ##STR00423## 15 4 657 3071 170
##STR00424## 137 10 697 962 ##STR00425## 73 6 720 823 183
##STR00426## 65 4 752 2117 395 ##STR00427## 24 16 769 1094
##STR00428## 136 14 857 1698 ##STR00429## 106 29 864 3077 395
##STR00430## 113 5 871 1523
##STR00431## 59 8 883 1734 395 ##STR00432## 52 8 905 946 223
##STR00433## 155 13 922 1919 ##STR00434## 127 8 932 1702
##STR00435## 102 13 934 1271 ##STR00436## 197 18 936 2679 168
##STR00437## 92 14 938 1945 363 ##STR00438## 34 31 968 1173
##STR00439## 69 5 972 1154 343 ##STR00440## 23 99 987 356
##STR00441## 93 13 1008 3451 395 ##STR00442## 189 12 1023 1403
##STR00443## 2 7 1024 2583 109 ##STR00444## 198 9 1044 4618
##STR00445## 36 14 1078 3575 ##STR00446## 114 12 1085 2203
##STR00447## 8 13 1091 1334 ##STR00448## 132 25 1100 1684 395
##STR00449## 107 23 1113 2365 ##STR00450## 111 5 1151 2876
##STR00451## 68 5 1155 1602 395 ##STR00452## 134 13 1164 2244 89
##STR00453## 19 12 1166 2780 249 ##STR00454## 90 8 1178 1354 395
##STR00455## 117 27 1179 1686 ##STR00456## 13 10 1227 3128
##STR00457## 88 10 1242 1696 395 ##STR00458## 84 48 1250 1872 =0
##STR00459## 112 10 1250 2112 ##STR00460## 4 10 1268 1744 395
##STR00461## 158 11 1301 1670 ##STR00462## 85 57 1349 1166
##STR00463## 56 4 1386 2071 395 ##STR00464## 124 4 1440 3443 395
##STR00465## 122 14 1443 3813 269 ##STR00466## 123 11 1446 7088 96
##STR00467## 105 35 1464 2292 ##STR00468## 80 13 1512 2278 325
##STR00469## 142 12 1565 2331 ##STR00470## 145 12 1592 2168 129
##STR00471## 115 14 1599 2449 ##STR00472## 61 7 1607 2703 217
##STR00473## 91 11 1722 2440 ##STR00474## 146 31 1745 2215
##STR00475## 95 41 1748 11505 ##STR00476## 190 6 1765 2748
##STR00477## 28 73 1801 2258 ##STR00478## 144 10 1809 3273
##STR00479## 77 9 1810 3273 130 ##STR00480## 54 6 1829 3294 395
##STR00481## 100 10 1883 3587 194 ##STR00482## 58 9 1930 3092 395
##STR00483## 18 14 2154 4502 ##STR00484## 83 17 2231 2813
##STR00485## 79 7 2325 2183 395 ##STR00486## 86 15 2334 1995
##STR00487## 140 29 2369 2630 ##STR00488## 71 5 2469 2239 395
##STR00489## 78 32 2693 3194 ##STR00490## 94 38 2717 2519
##STR00491## 51 15 2725 3591 ##STR00492## 63 10 2796 13152 395
##STR00493## 166 11 2835 2141 ##STR00494## 64 11 2842 2624 395
##STR00495## 82 14 3088 3866 395 ##STR00496## 121 39 3481 2692
##STR00497## 141 24 3557 3930 ##STR00498## 116 40 3812 5192
##STR00499## 57 13 4263 4136 395 ##STR00500## 41 3828 4976 5308
##STR00501## 3 43 5714 5714 ##STR00502## 42 5039 5714 5714
##STR00503## 143 27 5775 5610 ##STR00504## 81 13 6593 6973
##STR00505## 97 150 6809 9186 ##STR00506## 139 88 7810 5777
##STR00507## 131 10 7946 3743 249 ##STR00508## 53 45 8909 57000
##STR00509## 96 61 10259 9207 ##STR00510## 89 107 57000 57000
##STR00511## 101 58 57000 57000 ##STR00512## 87 13 395 ##STR00513##
196 4 395 ##STR00514## 195 ##STR00515##
[0797] All references, including publications, patents, and patent
documents are incorporated by reference herein, as though
individually incorporated by reference. The invention has been
described with reference to various specific and preferred
embodiments and techniques. However, it should be understood that
many variations and modifications may be made while remaining
within the spirit and scope of the invention.
[0798] The use of the terms "a" and "an" and "the" and similar
references in the context of this disclosure (especially in the
context of the following claims) are to be construed to cover both
the singular and the plural, unless otherwise indicated herein or
clearly contradicted by context. All methods described herein can
be performed in any suitable order unless otherwise indicated
herein or otherwise clearly contradicted by context. The use of any
and all examples, or exemplary language (e.g., such as, preferred,
preferably) provided herein, is intended merely to further
illustrate the content of the disclosure and does not pose a
limitation on the scope of the claims. No language in the
specification should be construed as indicating any non-claimed
element as essential to the practice of the present disclosure.
[0799] Alternative embodiments of the claimed disclosure are
described herein, including the best mode known to the inventors
for practicing the claimed invention. Of these, variations of the
disclosed embodiments will become apparent to those of ordinary
skill in the art upon reading the foregoing disclosure. The
inventors expect skilled artisans to employ such variations as
appropriate (e.g., altering or combining features or embodiments),
and the inventors intend for the invention to be practiced
otherwise than as specifically described herein.
[0800] Accordingly, this invention includes all modifications and
equivalents of the subject matter recited in the claims appended
hereto as permitted by applicable law. Moreover, any combination of
the above described elements in all possible variations thereof is
encompassed by the invention unless otherwise indicated herein or
otherwise clearly contradicted by context.
[0801] The use of individual numerical values is stated as
approximations as though the values were preceded by the word
"about" or "approximately." Similarly, the numerical values in the
various ranges specified in this application, unless expressly
indicated otherwise, are stated as approximations as though the
minimum and maximum values within the stated ranges were both
preceded by the word "about" or "approximately." In this manner,
variations above and below the stated ranges can be used to achieve
substantially the same results as values within the ranges. As used
herein, the terms "about" and "approximately" when referring to a
numerical value shall have their plain and ordinary meanings to a
person of ordinary skill in the art to which the disclosed subject
matter is most closely related or the art relevant to the range or
element at issue. The amount of broadening from the strict
numerical boundary depends upon many factors. For example, some of
the factors which may be considered include the criticality of the
element and/or the effect a given amount of variation will have on
the performance of the claimed subject matter, as well as other
considerations known to those of skill in the art. As used herein,
the use of differing amounts of significant digits for different
numerical values is not meant to limit how the use of the words
"about" or "approximately" will serve to broaden a particular
numerical value or range. Thus, as a general matter, "about" or
"approximately" broaden the numerical value. Also, the disclosure
of ranges is intended as a continuous range including every value
between the minimum and maximum values plus the broadening of the
range afforded by the use of the term "about" or "approximately."
Thus, recitation of ranges of values herein are merely intended to
serve as a shorthand method of referring individually to each
separate value falling within the range, unless otherwise indicated
herein, and each separate value is incorporated into the
specification as if it were individually recited herein.
[0802] It is to be understood that any ranges, ratios and ranges of
ratios that can be formed by, or derived from, any of the data
disclosed herein represent further embodiments of the present
disclosure and are included as part of the disclosure as though
they were explicitly set forth. This includes ranges that can be
formed that do or do not include a finite upper and/or lower
boundary. Accordingly, a person of ordinary skill in the art most
closely related to a particular range, ratio or range of ratios
will appreciate that such values are unambiguously derivable from
the data presented herein.
* * * * *